01241000000000469000450099100020000070000020000270600020000470100020000609100090
00081300038000174210024000551510026000792300038001050350010001434800038001530300
02400191031000300215032000200218036000600220930000500226042000200231117000600233
08500030023920000020024206500090024412200030025304800140025604900250027004900280
02950490024003230490034003470490035003810480014004160480024004300490024004540490
02900478049003600507049003000543043006500573043006500638043006800703#1#0#i#1#200
80318#Revista Panamericana de Salud Pública#Rev Panam Salud Publica#Rev. panam. 
salud pública#Pan American Journal of Public Health#1020-4989#Organización Panam
ericana de la Salud#Rev Panam Salud Publica#23#2#20082#RPSP#1#other#nd#0#2008020
0#15#^les^hSumario#^les^cRPSP020^tArtículos#^les^cRPSP030^tInstantáneas#^les^cRP
SP060^tAnuncios#^les^cRPSP300^tOpinión y Análisis#^les^cRPSP050^tTemas de Actual
idad#^lpt^hSumário#^len^hTable of Contents#^len^cRPSP020^tArticles#^len^cRPSP060
^tAnnouncements#^len^cRPSP300^tOpinion and Analysis#^len^cRPSP050^tCurrent Topic
s#^les^tRev Panam Salud Publica^vv.23^nn.2^cWashington^mfeb.^a2008#^lpt^tRev Pan
am Salud Publica^vv.23^nn.2^cWashington^mfev.^a2008#^len^tRev Panam Salud Public
a^vvol.23^nno.2^cWashington^mFeb.^a2008##
00263000000000169000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640910009000660920007000750020007000827030
00400089#v23n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#o#1#1#article#1#20080
318#103124#01.htm#126##
04866000000000805000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000400084121000300088049000800091158000300099030002400102
03100030012603200020012906500090013101400090014003500100014901201000015901200860
02590100028003450100032003730100030004050100027004350100027004620100026004890100
03300515010002400548070006800572070007200640070013700712083133500849085000802184
08500330219208500180222508500480224308500240229108500200231508500480233508500210
23830831212024040850008036160850033036240850020036570850028036770850021037050850
02003726085003803746085002103784058005803805058008503863058002003948060001403968
11700060398207200030398811200090399111100200400011400090402011300240402900200070
4053#v23n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#h#2#1#article#1#oa#es#br1
.1#1#3.1#TAB#01#RPSP020#nd#Rev Panam Salud Publica#23#2#20080200#^f73^l77#1020-4
989#Estudio de resistencia a la rifampicina y la dapsona en tres pacientes con r
ecurrencia de lepra^les#Study of rifampin and dapsone resistance in three patien
ts with recurring leprosy^len#^rND^1A01^nElkin^sHernández#^rND^1A02^nNora^sCardo
na-Castro#^rND^1A01^nGerzaín^sRodríguez#^rND^1A01^nSonia^sVillegas#^rND^1A02^nCa
milo^sBeltrán#^rND^1A03^nMiyako^sKimura#^rND^1A03^nVaralakshmi D.^sVissa#^rND^1A
01^nYenny^sGómez#Universidad de La Sabana^iA01^1Facultad de Medicina^cChía^pColo
mbia#Instituto Colombiano de Medicina Tropical^iA02^1CES^cSabaneta^pColombia#Col
orado State University^iA03^1Department of Microbiology, Immunology, and Patholo
gy^cFort Collins^sColorado^pEstados Unidos de América#^les^aOBJETIVO: Detectar l
a presencia de cepas de Mycobacterium leprae resistentes a la rifampicina y la d
apsona en tres pacientes con recurrencia de lepra y sospecha clínica de resisten
cia antimicrobiana, mediante la aplicación de técnicas moleculares. MÉTODOS: Se 
realizó un estudio descriptivo retrospectivo en tres pacientes multibacilares de
l Sanatorio de Agua de Dios, Cundinamarca, Colombia, que habían presentado recid
ivas de lepra documentadas por su historia clínica, baciloscopia y biopsia. Se o
btuvieron biopsias de lesiones cutáneas que se procesaron para la extracción y p
urificación del ADN bacilar. Se amplificaron regiones de los genes rpoB y folP1 
asociadas con la resistencia antimicrobiana, mediante la reacción en cadena de l
a polimerasa "touch-down" y se secuenciaron los productos amplificados mediante 
el método de Sanger. RESULTADOS: Se detectó una mutación puntual en el nucleótid
o 1367 del gen rpoB en dos de las muestras estudiadas. No se encontró la mutació
n estudiada en el gen folP1 en ninguno de los tres pacientes. CONCLUSIONES: La m
utación identificada demostró la presencia de bacilos de M. leprae resistentes a
 la rifampicina en dos de los tres pacientes estudiados con recurrencia de la en
fermedad. No se detectó la mutación indicadora de resistencia a la dapsona en ni
nguno de los tres pacientes.#^dnd^i1#^tm^les^kMycobacterium leprae^i1#^tm^les^kl
epra^i1#^tm^les^kresistencia microbiana a las drogas^i1#^tm^les^krifampicina^i1#
^tm^les^kdapsona^i1#^tm^les^kreacción en cadena de la polimerasa^i1#^tm^les^kCol
ombia^i1#^len^aOBJECTIVE: To detect the presence of rifampin- and dapsone-resist
ant strains of Mycobacterium leprae in three patients with recurring leprosy and
 clinically-suspected antimicrobial resistance through molecular techniques. MET
HODS: A retrospective, descriptive study was conducted of three multibacillary p
atients at the "Agua de Dios" Sanitarium in Cundinamarca, Colombia, that present
ed leprosy relapses that were documented by medical history, bacilloscopy, and b
iopsy. Biopsies were taken of the skin lesions and the bacteria were subject to 
DNA extraction and purification. Regions of the rpoB and folP1 genes associated 
with antimicrobial resistance were amplified and subjected to touch-down polymer
ase chain reaction and the amplified products were sequenced using the Sanger me
thod. RESULTS: A punctual mutation was identified in nucleotide 1367 of the rpoB
 gene in two of the samples studied. This mutation was not found in the folP1 ge
ne of any of the three patients. CONCLUSIONS: The mutation identified showed str
ains of rifampin-resistant M. leprae in two of the three patients with recurring
 leprosy. Mutations that indicate dapsone-resistance were not detected in any of
 the three patients.#^dnd^i2#^tm^len^kMycobacterium leprae^i2#^tm^len^kleprosy^i
2#^tm^len^kdrug resistance^i2#^tm^len^krifampin^i2#^tm^len^kdapsone^i2#^tm^len^k
polymerase chain reaction^i2#^tm^len^kColombia^i2#Fondo Patrimonial Especial de 
La Universidad de La Sabana#Instituto Colombiano de Medicina Tropical del Instit
uto de Ciencias de la Salud^dCES#NIAID^dCSU-ICMT-NIH#RO1-AI5-37720#other#28#2007
0129#29 de enero de 2007#20071123#23 de noviembre de 2007#01.htm##
05088000000000805000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000400084121000300088049000800091158000300099030002400102
03100030012603200020012906500090013101400090014003500100014901201070015901200930
02660100028003590100032003870100030004190100027004490100027004760100026005030100
03300529010002400562070006800586070007200654070013700726083141200863085000802275
08500400228308500180232308500480234108500240238908500200241308500480243308500210
24810831287025020850008037890850040037970850020038370850028038570850021038850850
02003906085003803926085002103964058005803985058008504043058002004128060005604148
11700060420407200030421011200090421311100200422211400090424211300240425100200070
4275#v23n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#f#3#1#article#1#oa#es#br1
.1#1#3.1#TAB#01#RPSP020#nd#Rev Panam Salud Publica#23#2#20080200#^f73^l77#1020-4
989#<B>Estudio de resistencia a la rifampicina y la dapsona en tres pacientes co
n recurrencia de lepra</B>^les#<B>Study of rifampin and dapsone resistance in th
ree patients with recurring leprosy</B>^len#^rND^1A01^nElkin^sHernández#^rND^1A0
2^nNora^sCardona-Castro#^rND^1A01^nGerzaín^sRodríguez#^rND^1A01^nSonia^sVillegas
#^rND^1A02^nCamilo^sBeltrán#^rND^1A03^nMiyako^sKimura#^rND^1A03^nVaralakshmi D.^
sVissa#^rND^1A01^nYenny^sGómez#Universidad de La Sabana^iA01^1Facultad de Medici
na^cChía^pColombia#Instituto Colombiano de Medicina Tropical^iA02^1CES^cSabaneta
^pColombia#Colorado State University^iA03^1Department of Microbiology, Immunolog
y, and Pathology^cFort Collins^sColorado^pEstados Unidos de América#^les^a<B>OBJ
ETIVO:</B> Detectar la presencia de cepas de <I>Mycobacterium leprae</I> resiste
ntes a la rifampicina y la dapsona en tres pacientes con recurrencia de lepra y 
sospecha clínica de resistencia antimicrobiana, mediante la aplicación de técnic
as moleculares. <B>MÉTODOS: </B>Se realizó un estudio descriptivo retrospectivo 
en tres pacientes multibacilares del Sanatorio de Agua de Dios, Cundinamarca, Co
lombia, que habían presentado recidivas de lepra documentadas por su historia cl
ínica, baciloscopia y biopsia. Se obtuvieron biopsias de lesiones cutáneas que s
e procesaron para la extracción y purificación del ADN bacilar. Se amplificaron 
regiones de los genes <I>rpoB</I> y <I>folP1</I> asociadas con la resistencia an
timicrobiana, mediante la reacción en cadena de la polimerasa "<I>touch-down</I>
" y se secuenciaron los productos amplificados mediante el método de Sanger. <B>
RESULTADOS: </B>Se detectó una mutación puntual en el nucleótido 1367 del gen <I
>rpoB</I> en dos de las muestras estudiadas. No se encontró la mutación estudiad
a en el gen <I>folP1</I> en ninguno de los tres pacientes. <B>CONCLUSIONES: </B>
La mutación identificada demostró la presencia de bacilos de <I>M. leprae</I> re
sistentes a la rifampicina en dos de los tres pacientes estudiados con recurrenc
ia de la enfermedad. No se detectó la mutación indicadora de resistencia a la da
psona en ninguno de los tres pacientes.#^dnd^i1#^tm^les^k<I>Mycobacterium leprae
</I>^i1#^tm^les^klepra^i1#^tm^les^kresistencia microbiana a las drogas^i1#^tm^le
s^krifampicina^i1#^tm^les^kdapsona^i1#^tm^les^kreacción en cadena de la polimera
sa^i1#^tm^les^kColombia^i1#^len^a<B>OBJECTIVE:</B> To detect the presence of rif
ampin- and dapsone-resistant strains of <I>Mycobacterium leprae</I> in three pat
ients with recurring leprosy and clinically-suspected antimicrobial resistance t
hrough molecular techniques. <B>METHODS:</B> A retrospective, descriptive study 
was conducted of three multibacillary patients at the "Agua de Dios" Sanitarium 
in Cundinamarca, Colombia, that presented leprosy relapses that were documented 
by medical history, bacilloscopy, and biopsy. Biopsies were taken of the skin le
sions and the bacteria were subject to DNA extraction and purification. Regions 
of the <I>rpoB</I> and <I>folP1</I> genes associated with antimicrobial resistan
ce were amplified and subjected to touch-down polymerase chain reaction and the 
amplified products were sequenced using the Sanger method. <B>RESULTS:&nbsp;</B>
A punctual mutation was identified in nucleotide 1367 of the <I>rpoB</I> gene in
 two of the samples studied. This mutation was not found in the <I>folP1</I> gen
e of any of the three patients. <B>CONCLUSIONS: </B>The mutation identified show
ed strains of rifampin-resistant <I>M. leprae</I> in two of the three patients w
ith recurring leprosy. Mutations that indicate dapsone-resistance were not detec
ted in any of the three patients.#^dnd^i2#^tm^len^k<I>Mycobacterium leprae</I>^i
2#^tm^len^kleprosy^i2#^tm^len^kdrug resistance^i2#^tm^len^krifampin^i2#^tm^len^k
dapsone^i2#^tm^len^kpolymerase chain reaction^i2#^tm^len^kColombia^i2#Fondo Patr
imonial Especial de La Universidad de La Sabana#Instituto Colombiano de Medicina
 Tropical del Instituto de Ciencias de la Salud^dCES#NIAID^dCSU-ICMT-NIH#<FONT F
ACE="Verdana, Arial" SIZE=2>RO1-AI5-37720</FONT>#other#28#20070129#29 de enero d
e 2007#20071123#23 de noviembre de 2007#01.htm##
05002000000000829000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640640013000660710003000790400003000820010
00600085042000200091120000400093038000400097121000300101049000800104158000300112
03000260011503100030014103200020014406500090014601400090015503500100016401201000
01740120086002740100028003600100032003880100030004200100027004500100027004770100
02600504010003200530010002400562070007000586070007400656070013900730083133500869
08500080220408500330221208500180224508500480226308500240231108500200233508500480
23550850021024030831212024240850008036360850033036440850020036770850028036970850
02103725085002003746085003803766085002103804058005803825058008503883058002003968
06000140398811700060400207200030400811200090401111100200402011400090404011300240
4049002000704073008009204080#v23n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#l
#4#1#article#1#^mfeb.^a2008#oa#es#br1.1#1#3.1#tab#01#RPSP020#nd#Rev. panam. salu
d pública#23#2#20080200#^f73^l77#1020-4989#Estudio de resistencia a la rifampici
na y la dapsona en tres pacientes con recurrencia de lepra^les#Study of rifampin
 and dapsone resistance in three patients with recurring leprosy^len#^rND^1A01^n
Elkin^sHernández#^rND^1A02^nNora^sCardona-Castro#^rND^1A01^nGerzaín^sRodríguez#^
rND^1A01^nSonia^sVillegas#^rND^1A02^nCamilo^sBeltrán#^rND^1A03^nMiyako^sKimura#^
rND^1A03^nVaralakshmi D^sVissa#^rND^1A01^nYenny^sGómez#^iA01^1Universidad de La 
Sabana^2Facultad de Medicina^cChía^pColombia#^iA02^1Instituto Colombiano de Medi
cina Tropical^2CES^cSabaneta^pColombia#^iA03^1Colorado State University^2Departm
ent of Microbiology, Immunology, and Pathology^cFort Collins^sColorado^pEstados 
Unidos de América#^les^aOBJETIVO: Detectar la presencia de cepas de Mycobacteriu
m leprae resistentes a la rifampicina y la dapsona en tres pacientes con recurre
ncia de lepra y sospecha clínica de resistencia antimicrobiana, mediante la apli
cación de técnicas moleculares. MÉTODOS: Se realizó un estudio descriptivo retro
spectivo en tres pacientes multibacilares del Sanatorio de Agua de Dios, Cundina
marca, Colombia, que habían presentado recidivas de lepra documentadas por su hi
storia clínica, baciloscopia y biopsia. Se obtuvieron biopsias de lesiones cután
eas que se procesaron para la extracción y purificación del ADN bacilar. Se ampl
ificaron regiones de los genes rpoB y folP1 asociadas con la resistencia antimic
robiana, mediante la reacción en cadena de la polimerasa "touch-down" y se secue
nciaron los productos amplificados mediante el método de Sanger. RESULTADOS: Se 
detectó una mutación puntual en el nucleótido 1367 del gen rpoB en dos de las mu
estras estudiadas. No se encontró la mutación estudiada en el gen folP1 en ningu
no de los tres pacientes. CONCLUSIONES: La mutación identificada demostró la pre
sencia de bacilos de M. leprae resistentes a la rifampicina en dos de los tres p
acientes estudiados con recurrencia de la enfermedad. No se detectó la mutación 
indicadora de resistencia a la dapsona en ninguno de los tres pacientes.#^dnd^i1
#^tm^les^kMycobacterium leprae^i1#^tm^les^klepra^i1#^tm^les^kresistencia microbi
ana a las drogas^i1#^tm^les^krifampicina^i1#^tm^les^kdapsona^i1#^tm^les^kreacció
n en cadena de la polimerasa^i1#^tm^les^kColombia^i1#^len^aOBJECTIVE: To detect 
the presence of rifampin- and dapsone-resistant strains of Mycobacterium leprae 
in three patients with recurring leprosy and clinically-suspected antimicrobial 
resistance through molecular techniques. METHODS: A retrospective, descriptive s
tudy was conducted of three multibacillary patients at the "Agua de Dios" Sanita
rium in Cundinamarca, Colombia, that presented leprosy relapses that were docume
nted by medical history, bacilloscopy, and biopsy. Biopsies were taken of the sk
in lesions and the bacteria were subject to DNA extraction and purification. Reg
ions of the rpoB and folP1 genes associated with antimicrobial resistance were a
mplified and subjected to touch-down polymerase chain reaction and the amplified
 products were sequenced using the Sanger method. RESULTS: A punctual mutation w
as identified in nucleotide 1367 of the rpoB gene in two of the samples studied.
 This mutation was not found in the folP1 gene of any of the three patients. CON
CLUSIONS: The mutation identified showed strains of rifampin-resistant M. leprae
 in two of the three patients with recurring leprosy. Mutations that indicate da
psone-resistance were not detected in any of the three patients.#^dnd^i2#^tm^len
^kMycobacterium leprae^i2#^tm^len^kleprosy^i2#^tm^len^kdrug resistance^i2#^tm^le
n^krifampin^i2#^tm^len^kdapsone^i2#^tm^len^kpolymerase chain reaction^i2#^tm^len
^kColombia^i2#Fondo Patrimonial Especial de La Universidad de La Sabana#Institut
o Colombiano de Medicina Tropical del Instituto de Ciencias de la Salud^dCES#NIA
ID^dCSU-ICMT-NIH#RO1-AI5-37720#other#28#20070129#29 de enero de 2007#20071123#23
 de noviembre de 2007#01.htm#Internet^ihttp://www.scielosp.org/scielo.php?script
=sci_arttext&pid=S1020-49892008000200001##
00374000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704015400067002000700221#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#5#1#article#94#<p align="right"><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>INVESTIGACI&Oacute;N    ORIG
INAL</b> ORIGINAL RESEARCH</font></p>     ^cY#01.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704002200067002000700089#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#6#2#article#94#<p>&nbsp;</p>     ^cY#01.htm
##
00429000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704020900067002000700276#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#7#3#article#94#<p><font face="Verdana, Aria
l, Helvetica, sans-serif" size="4"><b><a name="top"></a>Estudio    de resistenci
a a la rifampicina y la dapsona en tres pacientes con recurrencia    de lepra</b
></font></p>     ^cY#01.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704002200067002000700089#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#8#4#article#94#<p>&nbsp;</p>     ^cY#01.htm
##
00394000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704017400067002000700241#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#9#5#article#94#<p><font face="Verdana, Aria
l, Helvetica, sans-serif" size="3"><b>Study of rifampin    and dapsone resistanc
e in three patients with recurring leprosy</b></font></p>     ^cY#01.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704002200068002000700090#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#10#6#article#94#<p>&nbsp;</p>     ^cY#01.ht
m##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704002200068002000700090#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#11#7#article#94#<p>&nbsp;</p>     ^cY#01.ht
m##
00617000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704039600068002000700464#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#12#8#article#94#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><b>Elkin Hern&aacute;ndez<sup>I</sup>;    No
ra Cardona-Castro<sup>II</sup>; Gerza&iacute;n Rodr&iacute;guez<sup>I</sup>;    
Sonia Villegas<sup>I</sup>; Camilo Beltr&aacute;n<sup>II</sup>; Miyako Kimura<su
p>III</sup>;    Varalakshmi D. Vissa<sup>III</sup>; Yenny G&oacute;mez<sup>I, <a
 href="#back">*</a></sup></b></font></p>     ^cY#01.htm##
00376000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704015500068002000700223#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#13#9#article#94#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><sup>I</sup>Universidad    de La Sabana, Fac
ultad de Medicina, Ch&iacute;a, Colombia    ^cY#01.htm##
00315000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704009300069002000700162#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#14#10#article#94#<br>   <sup>II</sup>Instit
uto Colombiano de Medicina Tropical-CES, Sabaneta, Colombia    ^cY#01.htm##
00404000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704018200069002000700251#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#15#11#article#94#<br>   <sup>III</sup>Color
ado State University, Department of Microbiology, Immunology,    and Pathology, 
Fort Collins, Colorado, Estados Unidos de Am&eacute;rica</font></p>     ^cY#01.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#16#12#article#94#<p>&nbsp;</p>     ^cY#01.h
tm##
00266000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704004400069002000700113#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#17#13#article#94#<p>&nbsp;</p> <hr size="1"
 noshade>     ^cY#01.htm##
00319000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704009700069002000700166#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#18#14#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>RESUMEN</b></font></p>     ^cY#01.htm##
00587000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704036500069002000700434#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#19#15#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Detectar la presencia d
e cepas de <i>Mycobacterium leprae</i> resistentes a    la rifampicina y la daps
ona en tres pacientes con recurrencia de lepra y sospecha    cl&iacute;nica de r
esistencia antimicrobiana, mediante la aplicaci&oacute;n    de t&eacute;cnicas m
oleculares.    ^cY#01.htm##
00945000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704072300069002000700792#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#20#16#article#94#<br>   <b>M&Eacute;TODOS: 
</b> Se realiz&oacute; un estudio descriptivo retrospectivo    en tres pacientes
 multibacilares del Sanatorio de Agua de Dios, Cundinamarca,    Colombia, que ha
b&iacute;an presentado recidivas de lepra documentadas por su    historia cl&iac
ute;nica, baciloscopia y biopsia. Se obtuvieron biopsias de lesiones    cut&aacu
te;neas que se procesaron para la extracci&oacute;n y purificaci&oacute;n    del
 ADN bacilar. Se amplificaron regiones de los genes <i>rpoB</i> y <i>folP1</i>  
  asociadas con la resistencia antimicrobiana, mediante la reacci&oacute;n en   
 cadena de la polimerasa "<i>touch-down</i>" y se secuenciaron los productos    
amplificados mediante el m&eacute;todo de Sanger.    ^cY#01.htm##
00500000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704027800069002000700347#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#21#17#article#94#<br>   <b>RESULTADOS: </b>
 Se detect&oacute; una mutaci&oacute;n puntual en el nucle&oacute;tido    1367 d
el gen <i>rpoB</i> en dos de las muestras estudiadas. No se encontr&oacute;    l
a mutaci&oacute;n estudiada en el gen <i>folP1</i> en ninguno de los tres pacien
tes.    ^cY#01.htm##
00590000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704036800069002000700437#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#22#18#article#94#<br>   <b>CONCLUSIONES: </
b> La mutaci&oacute;n identificada demostr&oacute; la presencia    de bacilos de
 <i>M. leprae</i> resistentes a la rifampicina en dos de los tres    pacientes e
studiados con recurrencia de la enfermedad. No se detect&oacute;    la mutaci&oa
cute;n indicadora de resistencia a la dapsona en ninguno de los    tres paciente
s.</font></p>     ^cY#01.htm##
00504000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704028200069002000700351#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#23#19#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Palabras clave:</b>    <i>Mycobacterium 
leprae,</i> lepra, resistencia microbiana a las drogas, rifampicina,    dapsona,
 reacci&oacute;n en cadena de la polimerasa, Colombia.</font></p> <hr size="1" n
oshade>     ^cY#01.htm##
00320000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704009800069002000700167#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#24#20#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     ^cY#01.htm##
00537000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704031500069002000700384#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#25#21#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>OBJECTIVE:</b>    To detect the presence
 of rifampin- and dapsone-resistant strains of <i>Mycobacterium    leprae</i> in
 three patients with recurring leprosy and clinically-suspected    antimicrobial
 resistance through molecular techniques.    ^cY#01.htm##
00847000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704062500069002000700694#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#26#22#article#94#<br>   <b>METHODS:</b> A r
etrospective, descriptive study was conducted of three multibacillary    patient
s at the "Agua de Dios" Sanitarium in Cundinamarca, Colombia, that presented    
leprosy relapses that were documented by medical history, bacilloscopy, and    b
iopsy. Biopsies were taken of the skin lesions and the bacteria were subject    
to DNA extraction and purification. Regions of the <i>rpoB</i> and <i>folP1</i> 
   genes associated with antimicrobial resistance were amplified and subjected  
  to touch-down polymerase chain reaction and the amplified products were sequen
ced    using the Sanger method.    ^cY#01.htm##
00455000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704023300069002000700302#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#27#23#article#94#<br>   <b>RESULTS:&nbsp;</
b>A punctual mutation was identified in nucleotide 1367 of    the <i>rpoB</i> ge
ne in two of the samples studied. This mutation was not found    in the <i>folP1
</i> gene of any of the three patients.    ^cY#01.htm##
00497000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704027500069002000700344#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#28#24#article#94#<br>   <b>CONCLUSIONS: </b
> The mutation identified showed strains of rifampin-resistant    <i>M. leprae</
i> in two of the three patients with recurring leprosy. Mutations    that indica
te dapsone-resistance were not detected in any of the three patients.</font></p>
     ^cY#01.htm##
00461000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704023900069002000700308#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#29#25#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Key words:</b>    <i>Mycobacterium lepra
e,</i> leprosy, drug resistance, rifampin, dapsone, polymerase    chain reaction
, Colombia.</font></p> <hr size="1" noshade>     ^cY#01.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#30#26#article#94#<p>&nbsp;</p>     ^cY#01.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#31#27#article#94#<p>&nbsp;</p>     ^cY#01.h
tm##
01610000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704138800069002000701457#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#32#28#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Hasta 1982, el    tratamiento de la lepra s
e bas&oacute; en la monoterapia con dapsona. La emergencia    de cepas de <i>Myc
obacterium leprae</i> resistentes a este antimicrobiano (1)    hizo que la Organ
izaci&oacute;n Mundial de la Salud (OMS) recomendara el uso    de la poliquimiot
erapia (PQT), que combina tres antibi&oacute;ticos: dapsona,    clofazimina y ri
fampicina (2). La base de la PQT es la rifampicina, ya que es    el componente c
on mayor actividad bactericida, incluso mayor que la de nuevos    antimicrobiano
s empleados espec&iacute;ficamente contra <i>M. leprae</i> (3,    4). La funci&o
acute;n principal de la dapsona y la clofazimina es garantizar    la eliminaci&o
acute;n de las poblaciones de <i>M. leprae</i> resistentes a la    rifampicina (
3). El uso de este esquema terap&eacute;utico ha permitido reducir    eficazment
e la prevalencia global de la enfermedad, aunque en los pa&iacute;ses    con may
or endemia, la incidencia ha permanecido estable (5) y se ha observado    una ma
yor frecuencia de la recurrencia de la enfermedad. Esta recurrencia se    ha con
statado en pacientes con lepra multibacilar que presentaban un alto &iacute;ndic
e    de infecci&oacute;n al inicio del tratamiento y que se siguieron durante va
rios    a&ntilde;os despu&eacute;s de terminada la PQT (6, 7).</font></p>     ^c
Y#01.htm##
00941000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704071900069002000700788#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#33#29#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Tambi&eacute;n    se ha documentado la pres
encia de cepas de <i>M. leprae</i> resistentes a los    antimicrobianos empleado
s en la PQT, entre ellos la rifampicina (8&#150;11).    Aunque esta modalidad te
rap&eacute;utica ha limitado la diseminaci&oacute;n    de la resistencia a la da
psona, se siguen notificando casos resistentes a este    medicamento, incluso en
 &aacute;reas donde la PQT se ha aplicado exitosamente    (8, 12, 13). Adem&aacu
te;s, se ha informado de posibles cepas de <i>M. leprae</i>    resistentes a m&u
acute;ltiples antimicrobianos, responsables de la recurrencia    en casos tratad
os con monoterapia y PQT (9, 11).</font></p>     ^cY#01.htm##
00581000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704035900069002000700428#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#34#30#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">La OMS ha planteado    la necesidad de vigi
lar la emergencia de la resistencia a los antimicrobianos,    principalmente a l
a rifampicina, ya que esto puede reducir significativamente    la eficacia del t
ratamiento y obstaculizar la erradicaci&oacute;n de la lepra    (10, 14).</font>
</p>     ^cY#01.htm##
01435000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704121300069002000701282#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#35#31#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">La prueba est&aacute;ndar    para determina
r la susceptibilidad antimicrobiana de <i>M. leprae</i> es la    t&eacute;cnica 
de la almohadilla plantar del rat&oacute;n, que adem&aacute;s    de costosa, dem
ora entre 6 y 12 meses en dar resultados y est&aacute; disponible    en pocos la
boratorios (1). Debido a estas limitaciones, se han desarrollado    diferentes t
&eacute;cnicas moleculares basadas en la detecci&oacute;n de mutaciones    puntu
ales en los genes <i>rpoB</i> y <i>folP1</i> de <i>M. leprae,</i> las cuales    
se utilizan como marcadores de resistencia a la rifampicina y la dapsona, con   
 una alta correlaci&oacute;n con la prueba est&aacute;ndar (8&#150;11, 15, 16). 
   Esto se basa en diversas investigaciones que han demostrado que esas mutacion
es    puntuales en los genes <i>rpoB</i> y <i>folP1</i> son las responsables de 
la    resistencia de <i>M. leprae</i> a la rifampicina y la dapsona, respectivam
ente    (8, 15, 16). Se ha podido predecir la resistencia antimicrobiana de algu
nos    aislamientos mediante diversa t&eacute;cnicas de biolog&iacute;a molecula
r que    detectan estas mutaciones (9&#150;11).</font></p>     ^cY#01.htm##
00990000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704076800069002000700837#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#36#32#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">En el municipio    de Agua de Dios, departa
mento de Cundinamarca, Colombia, donde funcion&oacute;    un sanatorio de reclus
i&oacute;n obligatoria para enfermos de lepra entre 1872    y 1961, se han prese
ntado casos de recurrencia de la enfermedad en los que han    concurrido factore
s de riesgo para la aparici&oacute;n de cepas resistentes    de <i>M. leprae</i>
 (17). El objetivo de este estudio fue detectar la presencia    de cepas de <i>M
. leprae</i> resistentes a la rifampicina y la dapsona en tres    pacientes de e
se municipio con recurrencia de lepra y sospecha cl&iacute;nica    de resistenci
a antimicrobiana, mediante la aplicaci&oacute;n de t&eacute;cnicas    moleculare
s.</font></p>     ^cY#01.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#37#33#article#94#<p>&nbsp;</p>     ^cY#01.h
tm##
00342000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704012000069002000700189#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#38#34#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>MATERIALES Y    M&Eacute;TODOS</b></font
></p>     ^cY#01.htm##
00321000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704009900069002000700168#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#39#35#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Pacientes</b></font></p>     ^cY#01.htm#
#
00996000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704077400069002000700843#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#40#36#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Se realiz&oacute;    un estudio descriptivo
 retrospectivo en tres pacientes del Sanatorio de Agua    de Dios, de Cundinamar
ca, Colombia, que presentaron de uno a tres episodios    de recurrencia de la en
fermedad, por lo que se sospechaba que estaban infectados    por una cepa resist
ente a antibi&oacute;ticos (17). Todos los pacientes hab&iacute;an    recibido m
onoterapia con dapsona por m&aacute;s de dos d&eacute;cadas, pero    de forma ir
regular, con dosis variables y no supervisadas, y los pacientes 1    y 2 hab&iac
ute;an recibido adem&aacute;s PQT administrada en iguales condiciones.    En el 
<a href="#cua1">cuadro 1</a> se muestran los datos principales de los    tres pa
cientes.</font></p>     ^cY#01.htm##
00257000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704003500069002000700104#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#41#37#article#94#<p><a name="cua1"></a></p>
     ^cY#01.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#42#38#article#94#<p>&nbsp;</p>     ^cY#01.h
tm##
00298000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704007600069002000700145#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#43#39#article#94#<p align="center"><img src
="/img/revistas/rpsp/v23n2/01q1.jpg"></p>     ^cY#01.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#44#40#article#94#<p>&nbsp;</p>     ^cY#01.h
tm##
00363000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704014100069002000700210#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#45#41#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Obtenci&oacute;n    y procesamiento de l
as muestras</b></font></p>     ^cY#01.htm##
01754000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704153200069002000701601#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#46#42#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">De cada paciente    con recurrencia &#151;d
ocumentada por su historia cl&iacute;nica, baciloscopia    y biopsia&#151; se to
m&oacute; una muestra de las lesiones cut&aacute;neas que    se conserv&oacute; 
en etanol al 70% (18). Esta muestra se utiliz&oacute; para    el an&aacute;lisis
 molecular de la cepa infectante mediante la reacci&oacute;n    en cadena de la 
polimerasa (RCP) en el Laboratorio del Grupo de Microbiolog&iacute;a    Molecula
r de la Universidad de La Sabana, Ch&iacute;a, Colombia. La extracci&oacute;n   
 y la purificaci&oacute;n del ADN bacilar se realizaron por los m&eacute;todos  
  de choque t&eacute;rmico (19) y digesti&oacute;n enzim&aacute;tica con protein
asa    K, respectivamente, con el estuche DNeasy<sup>&reg;</sup> Tissue (Qiagen 
GmbH,    Hilden, Alemania). Se estandariz&oacute; la t&eacute;cnica de RCP denom
inada    <i>touch-down</i> para amplificar regiones de los genes <i>rpoB</i> y <
i>folP1</i>    asociadas con la resistencia a la rifampicina y la dapsona, respe
ctivamente    (8&#150;11, 15, 16). Para el gen <i>rpoB</i> se utilizaron los ceb
adores descritos    previamente (15), que amplifican un fragmento de 394 pares d
e bases (pb), y    para el gen <i>folP1</i> se utilizaron los iniciadores 5'-CAG
GACGTCGAGGCGATCAC-3'    y 5'-TCCTCGTCAGCGGTCAAGTA-3', que amplifican un fragment
o de 389 pb. Se emplearon    las mismas concentraciones de reactivos y condicion
es del termociclador para    ambas reacciones.</font></p>     ^cY#01.htm##
01988000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704176600069002000701835#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#47#43#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">La RCP se realiz&oacute;    en un volumen f
inal de 25 &#181;L de soluci&oacute;n tamp&oacute;n de MgCl<sub>2</sub>    1,5 m
M que conten&iacute;a 1 pM de cada iniciador, 2 &#181;M de cada trifosfato    de
 desoxinucle&oacute;sido, 2,5 unidades (U) de polimerasa <i>Taq</i> (Promega,   
 Madison, Wisconsin, Estados Unidos de Am&eacute;rica) y 5 &#181;L de muestra.  
  Se emple&oacute; un termociclador iCycler (Bio-Rad, Hercules, California, Esta
dos    Unidos) con el siguiente programa: 5 min de desnaturalizaci&oacute;n inic
ial    a 95 &deg;C; 11 ciclos de 1 min de desnaturalizaci&oacute;n a 95 &deg;C, 
1 min    de anillamiento a 68 &deg;C (con una disminuci&oacute;n de 1&nbsp;&deg;
C por    cada ciclo hasta llegar a 58 &deg;C) y 2 min de extensi&oacute;n a 72 &
deg;C;    seguidos de 27 ciclos de 1 min de desnaturalizaci&oacute;n a 95 &deg;C
, 1 min    de anillamiento a 57 &deg;C y 2 min de extensi&oacute;n a 72 &deg;C; 
y un paso    final de extensi&oacute;n por 30 segundos a 72 &deg;C. Como control
 positivo    se emple&oacute; el ADN bacilar extra&iacute;do de una biopsia de p
iel de un    paciente con diagn&oacute;stico confirmado de lepra lepromatosa por
 historia    cl&iacute;nica, baciloscopia y biopsia. Como control negativo de la
 reacci&oacute;n    se us&oacute; agua ultrapura y ADN extra&iacute;do de una bi
opsia de piel de    un paciente con diagn&oacute;stico de cicatriz hipertr&oacut
e;fica, sin signos    ni antecedentes de lepra. Los productos de la RCP se verif
icaron por electroforesis    en gel de agarosa al 2% coloreado con 0,2 &#181;g/m
L de bromuro de etidio y    se visualizaron en un sistema fotodocumentador con l
uz ultravioleta (GelDoc    XR, Bio-Rad).</font></p>     ^cY#01.htm##
00343000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704012100069002000700190#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#48#44#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Secuenciaci&oacute;n    del ADN</b></fon
t></p>     ^cY#01.htm##
01227000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704100500069002000701074#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#49#45#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Se secuenci&oacute;    el producto de la am
plificaci&oacute;n mediante el m&eacute;todo de Sanger (20)    con un secuenciad
or autom&aacute;tico ABI Prism (Applied Biosystems, Foster    City, California, 
Estados Unidos). Los cromatogramas se editaron con el programa    Chromas v. 1.4
5 (Technelysium, Queensland, Australia) y el an&aacute;lisis bioinform&aacute;ti
co    se realiz&oacute; mediante el alineamiento local con el m&oacute;dulo Wate
r    del programa Emboss (21), usando como patr&oacute;n de comparaci&oacute;n l
as    secuencias de una cepa sensible a la dapsona y de otra sensible a la rifam
picina    (c&oacute;digos de acceso Z14314 y AB028656, respectivamente, en la ba
se de    datos GenBank). Se identific&oacute; la posici&oacute;n de los nucle&oa
cute;tidos    sustituidos mediante los tres sistemas de referencia descritos (15
, 22, 23)    y se compararon con las mutaciones publicadas (8&#150;11, 15, 16).<
/font></p>     ^cY#01.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#50#46#article#94#<p>&nbsp;</p>     ^cY#01.h
tm##
00322000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704010000069002000700169#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#51#47#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>RESULTADOS</b></font></p>     ^cY#01.htm
##
00398000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704017600069002000700245#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#52#48#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Genotipificaci&oacute;n    de los genes 
<i>rpoB</i> y <i>folP1</i> de <i>M. leprae</i></b></font></p>     ^cY#01.htm##
01186000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704096400069002000701033#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#53#49#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">En las muestras    de los pacientes 1 y 2 s
e detect&oacute; una mutaci&oacute;n puntual en el gen    <i>rpoB</i>, localizad
a en el nucle&oacute;tido 1367 (TCG <font face="Symbol">&reg;</font>    TTG), qu
e produce un cambio de serina por leucina en la posici&oacute;n 456    de la sec
uencia aminoac&iacute;dica, seg&uacute;n el sistema de numeraci&oacute;n    empl
eado en la base de datos Leproma (23) (<a href="/img/revistas/rpsp/v23n2/01q2.gi
f">cuadro    2</a>). No se observaron cambios en la secuencia del gen <i>rpoB</i
> de <i>M.    leprae</i> en el paciente 3, ni en la secuencia del gen <i>folP1</
i> en ninguna    de las tres muestras estudiadas. El control positivo empleado m
ostr&oacute;    ADN de <i>M. leprae</i> sin mutaciones en las regiones estudiada
s de los genes    <i>rpoB</i> y <i>folP1.</i> Los controles negativos no evidenc
iaron la presencia    del ADN bacilar.</font></p>     ^cY#01.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#54#50#article#94#<p>&nbsp;</p>     ^cY#01.h
tm##
00328000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704010600069002000700175#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#55#51#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>DISCUSI&Oacute;N</b></font></p>     ^cY#
01.htm##
00691000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704046900069002000700538#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#56#52#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">En este estudio    se demostr&oacute; por p
rimera vez la presencia de cepas de <i>M. leprae</i>    resistentes a la rifampi
cina en Colombia. Adem&aacute;s. A pesar de haberse    documentado en las histor
ias cl&iacute;nicas de los tres pacientes estudiados    el tratamiento inadecuad
o con dapsona, no se encontr&oacute; la mutaci&oacute;n    estudiada de resisten
cia a este medicamento.</font></p>     ^cY#01.htm##
01583000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704136100069002000701430#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#57#53#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">La t&eacute;cnica    empleada, basada en la
 RCP con secuenciaci&oacute;n del ADN bacilar amplificado    (24), es la m&aacut
e;s confiable para identificar mutaciones y en esta investigaci&oacute;n    perm
iti&oacute; detectar una mutaci&oacute;n en el gen <i>rpoB</i> en las cepas    d
e <i>M. leprae</i> que portaban los pacientes 1 y 2. Esta modificaci&oacute;n,  
  descrita inicialmente por Honor&eacute; y Cole (15), es espec&iacute;fica de  
  las cepas que poseen resistencia a la rifampicina y, como lo han confirmado   
 otros autores mediante la t&eacute;cnica de la almohadilla plantar del rat&oacu
te;n,    esta es la mutaci&oacute;n que se presenta con mayor frecuencia (24). L
os resultados    de los estudios moleculares concuerdan con los antecedentes y l
a evoluci&oacute;n    cl&iacute;nica de los pacientes: un tratamiento irregular 
y la recurrencia de    la enfermedad, condiciones asociadas con el desarrollo de
 la resistencia a antimicrobianos    y con la resistencia secundaria a la rifamp
icina (2, 9, 11, 24). El paciente    3 no hab&iacute;a recibido rifampicina, lo 
que es consecuente con el hecho de    que en las muestras de su biopsia no se de
tect&oacute; la mutaci&oacute;n en    el gen <i>rpoB</i>, propia de cepas con re
sistencia a ese antibi&oacute;tico.</font></p>     ^cY#01.htm##
01672000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704145000069002000701519#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#58#54#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">La detecci&oacute;n    de mutaciones puntua
les en el gen <i>folP1</i> ha sido identificada con una    alta frecuencia en la
s cepas de <i>M. leprae</i> que presentan resistencia alta    o intermedia a la 
dapsona (8, 12, 25, 26). A pesar de que estos tres pacientes    recibieron trata
miento con dapsona de manera prolongada e irregular, en sus    muestras no se de
tectaron mutaciones en la regi&oacute;n secuenciada del gen    <i>folP1</i>, lo 
cual podr&iacute;a indicar que a&uacute;n son sensibles a la    dapsona. No obst
ante, la evoluci&oacute;n cl&iacute;nica de estos pacientes    indica que presen
tan resistencia secundaria a la dapsona. Varias hip&oacute;tesis    podr&iacute;
an explicar este resultado: la presencia de bacilos con una baja    resistencia,
 no detectable mediante las t&eacute;cnicas moleculares, que no    se correlacio
na con las manifestaciones cl&iacute;nicas (8, 13, 25, 26); la    presencia de p
orinas y mecanismos de eflujo que permiten el transporte del medicamento    al e
xterior de la bacteria, como se ha descrito en otras micobacterias (27,    28); 
o que las muestras tuvieran una mezcla de bacilos sensibles y resistentes    en 
diferentes proporciones y que la amplificaci&oacute;n y secuenciaci&oacute;n    
del genotipo dominante correspondiera al de los bacilos sensibles a la dapsona, 
   como han sugerido otros autores (16, 25).</font></p>     ^cY#01.htm##
00883000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704066100069002000700730#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#59#55#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A pesar del reducido    n&uacute;mero de ca
sos estudiados, los presentes resultados permiten afirmar    que la metodolog&ia
cute;a molecular empleada puede ayudar a detectar tempranamente    una posible r
ecidiva. Esta metodolog&iacute;a permiti&oacute; estudiar sendas    regiones de 
los genes <i>rpoB</i> y <i>folP1</i> que contienen mutaciones asociadas    con l
a resistencia antimicrobiana. Sin embargo, existen otras regiones g&eacute;nicas
    que podr&iacute;an presentar mutaciones relacionadas con la resistencia a an
tibi&oacute;ticos    y que deben ser objeto de estudio.</font></p>     ^cY#01.ht
m##
00598000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704037600069002000700445#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#60#56#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Debido a la frecuencia    con que se ha obs
ervado la recidiva de lepra en pacientes tratados con monoterapia    de dapsona 
durante a&ntilde;os (17) es recomendable realizar un seguimiento    cl&iacute;ni
co y bacilosc&oacute;pico anual a fin de detectar tempranamente    las posibles 
recidivas.</font></p>     ^cY#01.htm##
00846000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704062400069002000700693#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#61#57#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Agradecimientos.</b>    El presente estu
dio recibi&oacute; financiamiento del Fondo Patrimonial Especial    de La Univer
sidad de La Sabana, Ch&iacute;a, Colombia, y del Instituto Colombiano    de Medi
cina Tropical del Instituto de Ciencias de la Salud (ICMT-CES) y el convenio    
CSU-ICMT-NIH/NIAID RO1-AI5-37720. Los autores agradecen al personal de salud    
del Sanatorio de Agua de Dios y a Tiberio Rodr&iacute;guez, auxiliar t&eacute;cn
ico    del Programa de Lepra, por su apoyo en la b&uacute;squeda de las historia
s cl&iacute;nicas.</font></p>     ^cY#01.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#62#58#article#94#<p>&nbsp;</p>     ^cY#01.h
tm##
00323000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704010100069002000700170#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#63#59#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>REFERENCIAS</b></font></p>     ^cY#01.ht
m##
00453000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704021700071002000700288#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#p#64#60#article#94#1#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;1.&nbsp;Ji    B. Rifamp
icin resistant leprosy: a review and a research proposal of a pilot    study. Le
pr Rev. 2002;73:2&#150;8.</font></p>     ^cY#01.htm##
00483000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704024700071002000700318#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#p#65#61#article#94#2#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;2.&nbsp;World    Health
 Organization Study Group. Chemotherapy of leprosy for control programmes.    Ge
neva: WHO; 1982. (WHO Technical Report Series No. 675).</font></p>     ^cY#01.ht
m##
00534000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704029800071002000700369#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#p#66#62#article#94#3#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;3.&nbsp;Ji    B, Perani
 EG, Petinom C, Grosset JH. Bactericidal activities of combinations    of new dr
ugs against <i>Mycobacterium leprae</i> in nude mice. Antimicrob Agents    Chemo
ther. 1996;40: 393&#150;9.</font></p>     ^cY#01.htm##
00601000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704036500071002000700436#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#p#67#63#article#94#4#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;4.&nbsp;Ji    B, Sow S,
 Perani E. Bactericidal activities of a single-dose combination of    ofloxacin 
plus minocycline, with or without rifampin, against <i>Mycobacterium    leprae</
i> in mice and in lepromatous patients. Antimicrob Agents Chemother.    1998;42:
1115&#150;20.</font></p>     ^cY#01.htm##
00474000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704023800071002000700309#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#p#68#64#article#94#5#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;5.&nbsp;Lockwood    D, 
Suneetha S. Leprosy: too complex a disease for a simple elimination paradigm.   
 Bull World Health Organ. 2005;83: 230&#150;5.</font></p>     ^cY#01.htm##
00511000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704027500071002000700346#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#p#69#65#article#94#6#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;6.&nbsp;Gelber    RH, B
alagon MVF, Cellona RV. The relapse rate in MB leprosy patients treated    with 
2 years of WHO-MDT is not low. Int J Lepr Other Mycobact Dis. 2004;72:493&#150;5
00.</font></p>     ^cY#01.htm##
00574000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704033800071002000700409#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#p#70#66#article#94#7#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;7.&nbsp;Cellona    RV, 
Balagon MVF, dela Cruz EC, Burgos JA, Abalos RM, Walsh GP, et al. Long-term    e
fficacy of 2-year WHO multiple-drug therapy (MDT) in multibacillary (MB) leprosy
    patients. Int J Lepr Other Mycobact Dis. 2003; 71:308&#150;19.</font></p>   
  ^cY#01.htm##
00567000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704033100071002000700402#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#p#71#67#article#94#8#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;8.&nbsp;Kai    M, Matsu
oka M, Nakata N, Maeda S, Gidoh M, Maeda Y, et al. Diaminodiphenylsulfone    res
istance of <i>Mycobacterium leprae</i> due to mutations in the dihydropteroate  
  synthase gene. FEMS Microbiol Lett. 1999;177: 231&#150;5.</font></p>     ^cY#0
1.htm##
00525000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704028900071002000700360#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#p#72#68#article#94#9#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;9.&nbsp;You    E, Kang 
T, Kim S, Lee S, Chae G. Mutations in genes related to drug resistance    in <i>
Mycobacterium leprae</i> isolates from leprosy patients in Korea. J Infect.    2
005;50:6&#150;11.</font></p>     ^cY#01.htm##
00557000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704032000072002000700392#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#p#73#69#article#94#10#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">10.&nbsp;Cambau    E, Bonnaf
ous P, Perani E, Sougakoff W, Ji B, Jarlier V. Molecular detection    of rifampi
n and ofloxacin resistance for patients who experience relapse of    multibacill
ary leprosy. Clin Infect Dis. 2002;34:39&#150;45.</font></p>     ^cY#01.htm##
00531000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704029400072002000700366#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#p#74#70#article#94#11#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">11.&nbsp;Maeda    S, Matsuok
a M, Nakata N, Kai M, Maeda Y, Hashimoto K, et al. Multidrug resistant    <i>Myc
obacterium leprae</i> from patients with leprosy. Antimicrob Agents Chemother.  
  2001; 45:3635&#150;9.</font></p>     ^cY#01.htm##
00585000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704034800072002000700420#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#p#75#71#article#94#12#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">12.&nbsp;Sekar    B, Elanges
waran N, Jayarama E, Rajendran M, Kumar S, Vijayaraghavan R, et al.    Drug susc
eptibility of <i>Mycobacterium leprae</i>: a retrospective analysis    of mouse 
foodpad inoculation results from 1993 to 1997. Lepr Rev. 2002;73:239&#150;44.</f
ont></p>     ^cY#01.htm##
00543000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704030600072002000700378#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#p#76#72#article#94#13#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">13.&nbsp;Dela Cruz    E, Cel
lona R, Balagon M, Villahermosa LG, Fajardo TT, Hablaos RM, et al. Primary    da
psone resistance in Cebu, the Philippines: cause for concern. Int J Lepr Other  
  Mycobact Dis. 1996;64:264&#150;7.</font></p>     ^cY#01.htm##
00696000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704045900072002000700531#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#p#77#73#article#94#14#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">14.&nbsp;World    Health Org
anization. Global strategy for further reducing the leprosy bur- den    and sust
aining leprosy control activities (plan period: 2006&#150;2010). Geneva:    WHO;
 2005. Hallado en: <a href="http://www.who.int/lep/resources/GlobalStrategy.pdf"
 target="_blank">http://www.who.int/lep/    resources/GlobalStrategy.pdf</a>. Ac
ceso el 17 de enero de 2008.</font></p>     ^cY#01.htm##
00480000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704024300072002000700315#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#p#78#74#article#94#15#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">15.&nbsp;Honor&eacute;    N,
 Cole ST. Molecular basis of rifampin resistance in <i>Mycobacterium leprae</i>.
    Antimicrob Agents Chemother. 1993;37:414&#150;8.</font></p>     ^cY#01.htm##
00517000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704028000072002000700352#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#p#79#75#article#94#16#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">16.&nbsp;Williams    DL, Spr
ing L, Harris E, Roche P, Gillis TP. Dihydropteroate synthase of <i>Mycobacteriu
m    leprae</i> and dapsone resistance. Antimicrob Agents Chemother. 2000;44:153
0&#150;7.</font></p>     ^cY#01.htm##
00508000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704027100072002000700343#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#p#80#76#article#94#17#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">17.&nbsp;Rodr&iacute;guez   
 G, Pinto R, Laverde C, Sarmiento M, Riveros A, Valderrama J, et al. Recidivas  
  postratamiento de la lepra multibacilar. Biom&eacute;dica. 2004;24:133&#150;9.
</font></p>     ^cY#01.htm##
00644000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704040700072002000700479#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#p#81#77#article#94#18#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">18.&nbsp;Torres    P, Camare
na JJ, G&oacute;mez JR, Nogueira JM, Gimeno V, Navarro JC, et al. Comparison    
of PCR mediated amplification of DNA and the classical methods for detection    
of <i>Mycobacterium leprae</i> in different types of clinical samples in leprosy
    patients and contacts. Lepr Rev. 2003;74:18&#150;30.</font></p>     ^cY#01.h
tm##
00491000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704025400072002000700326#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#p#82#78#article#94#19#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">19. Zhang ZQ, Ishaque    M. 
Evaluation of methods for isolation of DNA from slowly and rapidly growing    my
cobacteria. Int J Lepr Other Mycobact Dis. 1997;65:469&#150;76.</font></p>     ^
cY#01.htm##
00458000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704022100072002000700293#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#p#83#79#article#94#20#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">20.&nbsp;Sanger    F, Nickle
n S, Coulson AR. DNA sequencing with chain-terminating inhibitors.    Proc Natl 
Acad Sci. 1977;74:5463&#150;7.</font></p>     ^cY#01.htm##
00458000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704022100072002000700293#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#p#84#80#article#94#21#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">21.&nbsp;Rice P,    Longden 
I, Bleasby A. EMBOSS: the European molecular biology open software suite.    Tre
nds Genet. 2000;16:276&#150;7.</font></p>     ^cY#01.htm##
00511000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704027400072002000700346#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#p#85#81#article#94#22#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">22.&nbsp;Telenti    A, Imbod
en P, Marchesi F, Lowrie D, Cole S, Colston MJ, et al. Detection of    rifampici
n-resistance mutations in Mycobacterium tuberculosis. Lancet. 1993;341:647&#150;
50.</font></p>     ^cY#01.htm##
00447000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704021000072002000700282#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#p#86#82#article#94#23#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">23.&nbsp;Jones    L, Moszer 
I, Cole ST. Leproma: a <i>Mycobacterium leprae</i> genome browser.    Lepr Rev. 
2001;72:470&#150;7.</font></p>     ^cY#01.htm##
00458000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704022100072002000700293#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#p#87#83#article#94#24#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">24.&nbsp;Williams    D, Gill
is T. Molecular detection of drug resistance in <i>Mycobacterium leprae</i>.    
Lepr Rev. 2004;75:118&#150;30.</font></p>     ^cY#01.htm##
00546000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704030900072002000700381#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#p#88#84#article#94#25#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">25.&nbsp;Cambau    E, Cartha
gena L, Chauffour A, Ji B, Jarlier V. Dihydropteroate synthase mutations    in t
he <i>folP1</i> gene predict dapsone resistance in relapsed cases of leprosy.   
 Clin Infect Dis. 2006;42:238&#150;41.</font></p>     ^cY#01.htm##
00623000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704038600072002000700458#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#p#89#85#article#94#26#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">26.&nbsp;Guelpa-Lauras    CC
, Cartel JL, Constant-Desportes M, Millan J, Bobin P, Guidi C, et al. Primary   
 and secondary dapsone resistance of M. leprae in Martinique, Guadeloupe, New   
 Caledonia, Tahiti, Senegal, and Paris between 1980 and 1985. Int J Lepr Other  
  Mycobact Dis. 1987;55:672&#150;9.</font></p>     ^cY#01.htm##
00460000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704022300072002000700295#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#p#90#86#article#94#27#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">27.&nbsp;Niederweiss    M. M
ycobacterial porins&#151;new channel proteins in unique outer membranes.    Mol 
Microbiol. 2003;49:1167&#150;77.</font></p>     ^cY#01.htm##
00487000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704025000072002000700322#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#p#91#87#article#94#28#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">28.&nbsp;Li XZ,    Zhang L, 
Nikaido H. Efflux pump-mediated intrinsic drug resistance in Mycobacterium    sm
egmatis. Antimicrob Agents Chemother. 2004;48:2415&#150;23.</font></p>     ^cY#0
1.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#92#88#article#94#<p>&nbsp;</p>     ^cY#01.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#93#89#article#94#<p>&nbsp;</p>     ^cY#01.h
tm##
00339000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704011700069002000700186#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#94#90#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Manuscrito recibido    el 29 de enero de 20
07.    ^cY#01.htm##
00335000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704011300069002000700182#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#95#91#article#94#<br>   Aceptado para publi
caci&oacute;n, tras revisi&oacute;n, el 23 de noviembre de    2007.</font></p>  
   ^cY#01.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#96#92#article#94#<p>&nbsp;</p>     ^cY#01.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#97#93#article#94#<p>&nbsp;</p>     ^cY#01.h
tm##
00644000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704042200069002000700491#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\01.htm#S#p#98#94#article#94#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"> <a name="back"></a><a href="#top">*</a>   
 La correspondencia se debe dirigir a Yenny Milena G&oacute;mez, Universidad    
de La Sabana, Campus Universitario Puente del Com&uacute;n, Autopista Norte    k
m 21, Ch&iacute;a, Colombia. Correo electr&oacute;nico: <a href="mailto:yenny.go
mez1@unisabana.edu.co">yenny.gomez1@unisabana.edu.co</a></font></p>     ^cY#01.h
tm##
00497000000000265000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080003000651180002000680100012000700120084000820300
00900166065000900175064000500184031000300189014000400192865000900196002000700205
035001000212801000900222#v23n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#c#99#
1#article#28#1#^rND^sJi^nB#Rifampicin resistant leprosy: a review and a research
 proposal of a pilot study^len#Lepr Rev#20020000#2002#73#2-8#20080200#01.htm#030
5-7518#Lepr Rev##
00487000000000253000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690170038000710180051001090660
00700160062000400167065000900171064000500180025002800185061000400213865000900217
002000700226#v23n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#c#100#2#article#2
8#2#World Health Organization Study Group#Chemotherapy of leprosy for control pr
ogrammes^len#Geneva#WHO#19820000#1982#WHO Technical Report Series#675#20080200#0
1.htm##
00641000000000301000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100012000710100017000830100
01700100010001800117012009900135030002800234065000900262064000500271031000300276
014000600279865000900285002000700294035001000301801002800311#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\01.htm#S#c#101#3#article#28#3#^rND^sJi^nB#^rND^sPerani^nEG
#^rND^sPetinom^nC#^rND^sGrosset^nJH#Bactericidal activities of combinations of n
ew drugs against Mycobacterium leprae in nude mice^len#Antimicrob Agents Chemoth
er#19960000#1996#40#393-9#20080200#01.htm#0066-4804#Antimicrob Agents Chemother#
#
00688000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100012000710100013000830100
01600096012017900112030002800291065000900319064000500328031000300333014000800336
865000900344002000700353035001000360801002800370#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\01.htm#S#c#102#4#article#28#4#^rND^sJi^nB#^rND^sSow^nS#^rND^sPerani^nE
#Bactericidal activities of a single-dose combination of ofloxacin plus minocycl
ine, with or without rifampin, against Mycobacterium leprae in mice and in lepro
matous patients^len#Antimicrob Agents Chemother#19980000#1998#42#1115-20#2008020
0#01.htm#0066-4804#Antimicrob Agents Chemother##
00551000000000277000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100018000710100018000890120
06900107030002400176065000900200064000500209031000300214014000600217865000900223
002000700232035001000239801002400249#v23n2#v:\scielo\serial\rpsp\v23n2\markup\01
.htm#S#c#103#5#article#28#5#^rND^sLockwood^nD#^rND^sSuneetha^nS#Leprosy: too com
plex a disease for a simple elimination paradigm^len#Bull World Health Organ#200
50000#2005#83#230-5#20080200#01.htm#0042-9686#Bull World Health Organ##
00613000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100017000710100019000880100
01800107012008700125030003000212065000900242064000500251031000300256014000800259
865000900267002000700276035001000283801003000293#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\01.htm#S#c#104#6#article#28#6#^rND^sGelber^nRH#^rND^sBalagon^nMVF#^rND
^sCellona^nRV#The relapse rate in MB leprosy patients treated with 2 years of WH
O-MDT is not low^len#Int J Lepr Other Mycobact Dis#20040000#2004#72#493-500#2008
0200#01.htm#0148-916X#Int J Lepr Other Mycobact Dis##
00737000000000337000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100018000710100019000890100
02000108010001700128010001700145010001600162810000600178012010500184030003000289
06500090031906400050032803100030033301400070033686500090034300200070035203500100
0359801003000369#v23n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#c#105#7#artic
le#28#7#^rND^sCellona^nRV#^rND^sBalagon^nMVF#^rND^sdela Cruz^nEC#^rND^sBurgos^nJ
A#^rND^sAbalos^nRM#^rND^sWalsh^nGP#et al#Long-term efficacy of 2-year WHO multip
le-drug therapy (MDT) in multibacillary (MB) leprosy patients^len#Int J Lepr Oth
er Mycobact Dis#20030000#2003#71#308-19#20080200#01.htm#0148-916X#Int J Lepr Oth
er Mycobact Dis##
00713000000000337000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100013000710100018000840100
01600102010001500118010001500133010001500148810000600163012011600169030002000285
06500090030506400050031403100040031901400060032386500090032900200070033803500100
0345801002000355#v23n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#c#106#8#artic
le#28#8#^rND^sKai^nM#^rND^sMatsuoka^nM#^rND^sNakata^nN#^rND^sMaeda^nS#^rND^sGido
h^nM#^rND^sMaeda^nY#et al#Diaminodiphenylsulfone resistance of Mycobacterium lep
rae due to mutations in the dihydropteroate synthase gene^len#FEMS Microbiol Let
t#19990000#1999#177#231-5#20080200#01.htm#0378-1097#FEMS Microbiol Lett##
00632000000000313000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100013000710100014000840100
01300098010001300111010001400124012011400138030000900252065000900261064000500270
031000300275014000500278865000900283002000700292035001000299801000900309#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\01.htm#S#c#107#9#article#28#9#^rND^sYou^nE#^rN
D^sKang^nT#^rND^sKim^nS#^rND^sLee^nS#^rND^sChae^nG#Mutations in genes related to
 drug resistance in Mycobacterium leprae isolates from leprosy patients in Korea
^len#J Infect#20050000#2005#50#6-11#20080200#01.htm#0163-4453#J Infect##
00702000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100019000890100
01600108010001900124010001200143010001700155012012300172030001600295065000900311
06400050032003100030032501400060032886500090033400200070034303500100035080100160
0360#v23n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#c#108#10#article#28#10#^r
ND^sCambau^nE#^rND^sBonnafous^nP#^rND^sPerani^nE#^rND^sSougakoff^nW#^rND^sJi^nB#
^rND^sJarlier^nV#Molecular detection of rifampin and ofloxacin resistance for pa
tients who experience relapse of multibacillary leprosy^len#Clin Infect Dis#2002
0000#2002#34#39-45#20080200#01.htm#1058-4838#Clin Infect Dis##
00691000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100018000880100
01600106010001300122010001500135010001900150810000600169012007200175030002800247
06500090027506400050028403100030028901400070029286500090029900200070030803500100
0315801002800325#v23n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#c#109#11#arti
cle#28#11#^rND^sMaeda^nS#^rND^sMatsuoka^nM#^rND^sNakata^nN#^rND^sKai^nM#^rND^sMa
eda^nY#^rND^sHashimoto^nK#et al#Multidrug resistant Mycobacterium leprae from pa
tients with leprosy^len#Antimicrob Agents Chemother#20010000#2001#45#3635-9#2008
0200#01.htm#0066-4804#Antimicrob Agents Chemother##
00727000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100022000880100
01800110010001900128010001500147010002400162810000600186012012900192030000900321
06500090033006400050033903100030034401400070034786500090035400200070036303500100
0370801000900380#v23n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#c#110#12#arti
cle#28#12#^rND^sSekar^nB#^rND^sElangeswaran^nN#^rND^sJayarama^nE#^rND^sRajendran
^nM#^rND^sKumar^nS#^rND^sVijayaraghavan^nR#et al#Drug susceptibility of Mycobact
erium leprae: a retrospective analysis of mouse foodpad inoculation results from
 1993 to 1997^len#Lepr Rev#20020000#2002#73#239-44#20080200#01.htm#0305-7518#Lep
r Rev##
00713000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100017000920100
01700109010002300126010001800149010001800167810000600185012007500191030003000266
06500090029606400050030503100030031001400060031386500090031900200070032803500100
0335801003000345#v23n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#c#111#13#arti
cle#28#13#^rND^sDela Cruz^nE#^rND^sCellona^nR#^rND^sBalagon^nM#^rND^sVillahermos
a^nLG#^rND^sFajardo^nTT#^rND^sHablaos^nRM#et al#Primary dapsone resistance in Ce
bu, the Philippines: cause for concern^len#Int J Lepr Other Mycobact Dis#1996000
0#1996#64#264-7#20080200#01.htm#0148-916X#Int J Lepr Other Mycobact Dis##
00617000000000265000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700170026000730180129000990660
00700228062000400235065000900239064000500248037005300253110000900306109002000315
865000900335002000700344#v23n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#c#112
#14#article#28#14#World Health Organization#Global strategy for further reducing
 the leprosy bur- den and sustaining leprosy control activities (plan period: 20
06-2010)^len#Geneva#WHO#20050000#2005#http://www.who.int/lep/ resources/GlobalSt
rategy.pdf#20080117#17 de enero de 2008#20080200#01.htm##
00554000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100015000890120
06700104030002800171065000900199064000500208031000300213014000600216865000900222
002000700231035001000238801002800248#v23n2#v:\scielo\serial\rpsp\v23n2\markup\01
.htm#S#c#113#15#article#28#15#^rND^sHonoré^nN#^rND^sCole^nST#Molecular basis of 
rifampin resistance in Mycobacterium leprae^len#Antimicrob Agents Chemother#1993
0000#1993#37#414-8#20080200#01.htm#0066-4804#Antimicrob Agents Chemother##
00652000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100016000920100
01600108010001500124010001700139012007600156030002800232065000900260064000500269
031000300274014000700277865000900284002000700293035001000300801002800310#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\01.htm#S#c#114#16#article#28#16#^rND^sWilliams
^nDL#^rND^sSpring^nL#^rND^sHarris^nE#^rND^sRoche^nP#^rND^sGillis^nTP#Dihydropter
oate synthase of Mycobacterium leprae and dapsone resistance^len#Antimicrob Agen
ts Chemother#20000000#2000#44#1530-7#20080200#01.htm#0066-4804#Antimicrob Agents
 Chemother##
00647000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100015000920100
01700107010001900124010001700143010002000160810000600180012005400186030001000240
06500090025006400050025903100030026401400060026786500090027300200070028203500100
0289801001000299#v23n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#c#115#17#arti
cle#28#17#^rND^sRodríguez^nG#^rND^sPinto^nR#^rND^sLaverde^nC#^rND^sSarmiento^nM#
^rND^sRiveros^nA#^rND^sValderrama^nJ#et al#Recidivas postratamiento de la lepra 
multibacilar^les#Biomédica#20040000#2004#24#133-9#20080200#01.htm#0120-4157#Biom
édica##
00776000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100019000890100
01600108010001900124010001600143010001800159810000600177012018800183030000900371
06500090038006400050038903100030039401400060039786500090040300200070041203500100
0419801000900429#v23n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#c#116#18#arti
cle#28#18#^rND^sTorres^nP#^rND^sCamarena^nJJ#^rND^sGómez^nJR#^rND^sNogueira^nJM#
^rND^sGimeno^nV#^rND^sNavarro^nJC#et al#Comparison of PCR mediated amplification
 of DNA and the classical methods for detection of Mycobacterium leprae in diffe
rent types of clinical samples in leprosy patients and contacts^len#Lepr Rev#200
30000#2003#74#18-30#20080200#01.htm#0305-7518#Lepr Rev##
00586000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100017000890120
09200106030003000198065000900228064000500237031000300242014000700245865000900252
002000700261035001000268801003000278#v23n2#v:\scielo\serial\rpsp\v23n2\markup\01
.htm#S#c#117#19#article#28#19#^rND^sZhang^nZQ#^rND^sIshaque^nM#Evaluation of met
hods for isolation of DNA from slowly and rapidly growing mycobacteria^len#Int J
 Lepr Other Mycobact Dis#19970000#1997#65#469-76#20080200#01.htm#0148-916X#Int J
 Lepr Other Mycobact Dis##
00555000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100017000890100
01800106012005300124030001900177065000900196064000500205031000300210014000700213
865000900220002000700229035001000236801001900246#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\01.htm#S#c#118#20#article#28#20#^rND^sSanger^nF#^rND^sNicklen^nS#^rND^
sCoulson^nAR#DNA sequencing with chain-terminating inhibitors^len#Proc Natl Acad
 Sci#19770000#1977#74#5463-7#20080200#01.htm#0027-8424#Proc Natl Acad Sci##
00549000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100014000730100017000870100
01700104012006300121030001300184065000900197064000500206031000300211014000600214
865000900220002000700229035001000236801001300246#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\01.htm#S#c#119#21#article#28#21#^rND^sRice^nP#^rND^sLongden^nI#^rND^sB
leasby^nA#EMBOSS: the European molecular biology open software suite^len#Trends 
Genet#20000000#2000#16#276-7#20080200#01.htm#0168-9525#Trends genet##
00661000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100017000900100
01800107010001600125010001400141010001800155810000600173012007900179030000700258
06500090026506400050027403100040027901400070028386500090029000200070029903500100
0306801000700316#v23n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#c#120#22#arti
cle#28#22#^rND^sTelenti^nA#^rND^sImboden^nP#^rND^sMarchesi^nF#^rND^sLowrie^nD#^r
ND^sCole^nS#^rND^sColston^nMJ#et al#Detection of rifampicin-resistance mutations
 in Mycobacterium tuberculosis^len#Lancet#19930000#1993#341#647-50#20080200#01.h
tm#0099-5355#Lancet##
00527000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100016000880100
01500104012005100119030000900170065000900179064000500188031000300193014000600196
865000900202002000700211035001000218801000900228#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\01.htm#S#c#121#23#article#28#23#^rND^sJones^nL#^rND^sMoszer^nI#^rND^sC
ole^nST#Leproma: a Mycobacterium leprae genome browser^len#Lepr Rev#20010000#200
1#72#470-7#20080200#01.htm#0305-7518#Lepr Rev##
00520000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100016000910120
06700107030000900174065000900183064000500192031000300197014000700200865000900207
002000700216035001000223801000900233#v23n2#v:\scielo\serial\rpsp\v23n2\markup\01
.htm#S#c#122#24#article#28#24#^rND^sWilliams^nD#^rND^sGillis^nT#Molecular detect
ion of drug resistance in Mycobacterium leprae^len#Lepr Rev#20040000#2004#75#118
-30#20080200#01.htm#0305-7518#Lepr Rev##
00666000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100020000890100
01900109010001200128010001700140012011300157030001600270065000900286064000500295
031000300300014000700303865000900310002000700319035001000326801001600336#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\01.htm#S#c#123#25#article#28#25#^rND^sCambau^n
E#^rND^sCarthagena^nL#^rND^sChauffour^nA#^rND^sJi^nB#^rND^sJarlier^nV#Dihydropte
roate synthase mutations in the folP1 gene predict dapsone resistance in relapse
d cases of leprosy^len#Clin Infect Dis#20060000#2006#42#238-41#20080200#01.htm#1
058-4838#Clin Infect Dis##
00790000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100024000730100017000970100
02800114010001600142010001500158010001500173810000600188012014900194030003000343
06500090037306400050038203100030038701400060039086500090039600200070040503500100
0412801003000422#v23n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#c#124#26#arti
cle#28#26#^rND^sGuelpa-Lauras^nCC#^rND^sCartel^nJL#^rND^sConstant-Desportes^nM#^
rND^sMillan^nJ#^rND^sBobin^nP#^rND^sGuidi^nC#et al#Primary and secondary dapsone
 resistance of M. leprae in Martinique, Guadeloupe, New Caledonia, Tahiti, Seneg
al, and Paris between 1980 and 1985^len#Int J Lepr Other Mycobact Dis#19870000#1
987#55#672-9#20080200#01.htm#0148-916X#Int J Lepr Other Mycobact Dis##
00511000000000265000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100021000730120072000940300
01400166065000900180064000500189031000300194014000800197865000900205002000700214
035001000221801001400231#v23n2#v:\scielo\serial\rpsp\v23n2\markup\01.htm#S#c#125
#27#article#28#27#^rND^sNiederweiss^nM#Mycobacterial porins-new channel proteins
 in unique outer membranes^len#Mol Microbiol#20030000#2003#49#1167-77#20080200#0
1.htm#0950-382X#Mol Microbiol##
00593000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100013000730100015000860100
01700101012007800118030002800196065000900224064000500233031000300238014000800241
865000900249002000700258035001000265801002800275#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\01.htm#S#c#126#28#article#28#28#^rND^sLi^nXZ#^rND^sZhang^nL#^rND^sNika
ido^nH#Efflux pump-mediated intrinsic drug resistance in Mycobacterium smegmatis
^len#Antimicrob Agents Chemother#20040000#2004#48#2415-23#20080200#01.htm#0066-4
804#Antimicrob Agents Chemother##
00263000000000169000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640910009000660920007000750020007000827030
00400089#v23n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#o#1#1#article#1#20080
318#103127#02.htm#140##
05215000000000661000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000400084121000300088049000800091158000300099030002400102
03100030012603200020012906500090013101400090014003500100014901201140015901201130
02730100044003860100043004300100033004730700045005060700080005510700113006310831
67600744085000802420085002702428085003602455085002802491085003602519085001902555
08316820257408500080425608500260426408500350429008500290432508500340435408500190
43880580069044071170006044760720003044821120009044851110019044941140009045131130
02404522002000704546#v23n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#h#2#1#art
icle#1#oa#pt#br1.1#1#3.1#TAB#02#RPSP020#nd#Rev Panam Salud Publica#23#2#20080200
#^f78^l84#1020-4989#Prevalência de cárie não tratada na dentição decídua em área
s urbanas e rurais do Estado de São Paulo, Brasil^lpt#Prevalence of untreated ca
ries in deciduous teeth in urban and rural areas in the state of São Paulo, Braz
il^len#^rND^1A01^nTatiana Ribeiro de Campos^sMello#^rND^1A02^nJose Leopoldo Ferr
eira^sAntunes#^rND^1A03^nEliseu Alves^sWaldman#Universidade do Oeste de Santa Ca
tarina^iA01#Universidade de São Paulo^iA02^1Faculdade de Odontologia^cSão Paulo^
sSP^pBrasil#Universidade de São Paulo^iA03^1Faculdade de Saúde Pública^2Departam
ento de Epidemiologia^cSão Paulo^sSP^pBrasil#^lpt^aOBJETIVO: Descrever os difere
nciais urbano-rurais da prevalência de cárie dentária em crianças com dentição d
ecídua no Estado de São Paulo e identificar fatores associados. MÉTODOS: Partici
param do estudo 24 744 crianças de 5 a 7 anos examinadas no Levantamento Epidemi
ológico de Saúde Bucal do Estado de São Paulo. Utilizou-se a análise multinível 
para verificar se havia associação entre a prevalência de cárie não tratada e as
 características sociodemográficas das crianças examinadas ou os aspectos socioe
conômicos das cidades participantes. RESULTADOS: Ser negro ou pardo (razão de ch
ances, ou OR, ajustada = 1,27), estudar na área rural (OR ajustada = 1,88) e fre
qüentar a escola pública (OR ajustada = 3,41) foram identificados como determina
ntes individuais de chance mais elevada de apresentar um ou mais dentes decíduos
 com cárie não tratada. Ser do sexo feminino (OR ajustada = 0,83) foi identifica
do como fator de proteção para essa condição. Os coeficientes negativos obtidos 
para as variáveis independentes de segundo nível indicaram que o perfil de saúde
 bucal das cidades participantes se beneficiou de valores mais elevados de índic
e de desenvolvimento humano municipal (beta = -0,47) e da adição de flúor à rede
 de águas (beta = -0,32). CONCLUSÕES: A prevalência de cárie não tratada é influ
enciada por fatores sociodemográficos de ordem individual e contextual. O presen
te estudo apresenta informações epidemiológicas das áreas rurais do Estado de Sã
o Paulo, oferecendo subsídios para o planejamento estratégico e normativo das aç
ões de saúde bucal nos sistemas locais de saúde, com o intuito de contribuir par
a a promoção de eqüidade em saúde bucal.#^dnd^i1#^tm^lpt^kCárie dentária^i1#^tm^
lpt^kserviços de saúde bucal^i1#^tm^lpt^kpopulação rural^i1#^tm^lpt^kfatores soc
ioeconômicos^i1#^tm^lpt^kBrasil^i1#^len^aOBJECTIVES: To describe the prevalence 
of dental caries in children with deciduous teeth in urban and rural areas in th
e state of São Paulo, Brazil, and to identify associated factors. METHODS: The s
tudy included 24 744 children (5-7 years of age) examined as part of an epidemio
logical survey on oral health carried out in the state of São Paulo (Levantament
o Epidemiológico de Saúde Bucal do Estado de São Paulo). Multilevel analysis was
 used to investigate whether the prevalence of untreated caries was associated w
ith the sociodemographic characteristics of the children examined or with the so
cioeconomic aspects of the participating cities. RESULTS: Being black or brown (
adjusted odds ratio (OR) = 1.27), attending school in rural areas (adjusted OR =
 1.88), and attending public school (adjusted OR = 3.41) were identified as dete
rminants for an increased probability of presenting deciduous teeth with untreat
ed caries. Being a female (adjusted OR = 0.83) was identified as a protective fa
ctor. The negative coefficients obtained for second-level independent variables 
indicate that the oral health profile of the cities included in the study were p
ositively impacted by a higher municipal human development index (beta = -0.47) 
and fluoridated drinking water (beta = -0.32). CONCLUSIONS: The prevalence of un
treated caries is influenced by individual and sociodemographic factors. The pre
sent study provides epidemiological information concerning the rural areas in th
e state of São Paulo. This information is useful for strategic planning and for 
establishing guidelines for oral health actions in local health systems, thereby
 contributing to oral health equity.#^dnd^i2#^tm^len^kDental caries^i2#^tm^len^k
dental health services^i2#^tm^len^krural population^i2#^tm^len^ksocioeconomic fa
ctors^i2#^tm^len^kBrazil^i2#Conselho Nacional de Desenvolvimento Científico e Te
cnológico (CNPq)#other#29#20070308#8 de março de 2007#20070912#12 de septembro d
e 2007#02.htm##
05403000000000661000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000400084121000300088049000800091158000300099030002400102
03100030012603200020012906500090013101400090014003500100014901201210015901201200
02800100044004000100043004440100033004870700045005200700080005650700113006450831
75700758085000802515085002702523085003602550085002802586085003602614085001902650
08317750266908500080444408500260445208500350447808500290451308500340454208500190
45760580069045951170006046640720003046701120009046731110019046821140009047011130
02404710002000704734#v23n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#f#3#1#art
icle#1#oa#pt#br1.1#1#3.1#TAB#02#RPSP020#nd#Rev Panam Salud Publica#23#2#20080200
#^f78^l84#1020-4989#<B>Prevalência de cárie não tratada na dentição decídua em á
reas urbanas e rurais do Estado de São Paulo, Brasil</B>^lpt#<B>Prevalence of un
treated caries in deciduous teeth in urban and rural areas in the state of São P
aulo, Brazil</B>^len#^rND^1A01^nTatiana Ribeiro de Campos^sMello#^rND^1A02^nJose
 Leopoldo Ferreira^sAntunes#^rND^1A03^nEliseu Alves^sWaldman#Universidade do Oes
te de Santa Catarina^iA01#Universidade de São Paulo^iA02^1Faculdade de Odontolog
ia^cSão Paulo^sSP^pBrasil#Universidade de São Paulo^iA03^1Faculdade de Saúde Púb
lica^2Departamento de Epidemiologia^cSão Paulo^sSP^pBrasil#^lpt^a<B>OBJETIVO:</B
> Descrever os diferenciais urbano-rurais da prevalência de cárie dentária em cr
ianças com dentição decídua no Estado de São Paulo e identificar fatores associa
dos. <B>MÉTODOS:&nbsp;</B>Participaram do estudo 24 744 crianças de 5 a 7 anos e
xaminadas no Levantamento Epidemiológico de Saúde Bucal do Estado de São Paulo. 
Utilizou-se a análise multinível para verificar se havia associação entre a prev
alência de cárie não tratada e as características sociodemográficas das crianças
 examinadas ou os aspectos socioeconômicos das cidades participantes. <B>RESULTA
DOS:</B> Ser negro ou pardo (razão de chances, ou OR, ajustada = 1,27), estudar 
na área rural (OR ajustada = 1,88) e freqüentar a escola pública (OR ajustada = 
3,41) foram identificados como determinantes individuais de chance mais elevada 
de apresentar um ou mais dentes decíduos com cárie não tratada. Ser do sexo femi
nino (OR ajustada = 0,83) foi identificado como fator de proteção para essa cond
ição. Os coeficientes negativos obtidos para as variáveis independentes de segun
do nível indicaram que o perfil de saúde bucal das cidades participantes se bene
ficiou de valores mais elevados de índice de desenvolvimento humano municipal (<
FONT FACE="Symbol">b</FONT> = -0,47) e da adição de flúor à rede de águas (<FONT
 FACE="Symbol">b</FONT> = -0,32). <B>CONCLUSÕES:</B> A prevalência de cárie não 
tratada é influenciada por fatores sociodemográficos de ordem individual e conte
xtual. O presente estudo apresenta informações epidemiológicas das áreas rurais 
do Estado de São Paulo, oferecendo subsídios para o planejamento estratégico e n
ormativo das ações de saúde bucal nos sistemas locais de saúde, com o intuito de
 contribuir para a promoção de eqüidade em saúde bucal.#^dnd^i1#^tm^lpt^kCárie d
entária^i1#^tm^lpt^kserviços de saúde bucal^i1#^tm^lpt^kpopulação rural^i1#^tm^l
pt^kfatores socioeconômicos^i1#^tm^lpt^kBrasil^i1#^len^a<B>OBJECTIVES: </B>To de
scribe the prevalence of dental caries in children with deciduous teeth in urban
 and rural areas in the state of São Paulo, Brazil, and to identify associated f
actors. <B>METHODS:&nbsp;</B>The study included 24 744 children (5-7 years of ag
e) examined as part of an epidemiological survey on oral health carried out in t
he state of São Paulo (<I>Levantamento Epidemiológico de Saúde Bucal do Estado d
e São Paulo</I>). Multilevel analysis was used to investigate whether the preval
ence of untreated caries was associated with the sociodemographic characteristic
s of the children examined or with the socioeconomic aspects of the participatin
g cities. <B>RESULTS:&nbsp;</B>Being black or brown (adjusted odds ratio (OR) = 
1.27), attending school in rural areas (adjusted OR = 1.88), and attending publi
c school (adjusted OR = 3.41) were identified as determinants for an increased p
robability of presenting deciduous teeth with untreated caries. Being a female (
adjusted OR = 0.83) was identified as a protective factor. The negative coeffici
ents obtained for second-level independent variables indicate that the oral heal
th profile of the cities included in the study were positively impacted by a hig
her municipal human development index (<FONT FACE="Symbol">b</FONT> = -0.47) and
 fluoridated drinking water (<FONT FACE="Symbol">b</FONT> = -0.32). <B>CONCLUSIO
NS: </B>The prevalence of untreated caries is influenced by individual and socio
demographic factors. The present study provides epidemiological information conc
erning the rural areas in the state of São Paulo. This information is useful for
 strategic planning and for establishing guidelines for oral health actions in l
ocal health systems, thereby contributing to oral health equity.#^dnd^i2#^tm^len
^kDental caries^i2#^tm^len^kdental health services^i2#^tm^len^krural population^
i2#^tm^len^ksocioeconomic factors^i2#^tm^len^kBrazil^i2#Conselho Nacional de Des
envolvimento Científico e Tecnológico (CNPq)#other#29#20070308#8 de março de 200
7#20070912#12 de septembro de 2007#02.htm##
05352000000000685000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640640013000660710003000790400003000820010
00600085042000200091120000400093038000400097121000300101049000800104158000300112
03000260011503100030014103200020014406500090014601400090015503500100016401201140
01740120113002880100044004010100043004450100033004880700047005210700082005680700
11500650083167600765085000802441085002702449085003602476085002802512085003602540
08500190257608316820259508500080427708500260428508500350431108500290434608500340
43750850019044090580069044281170006044970720003045031120009045061110019045151140
00904534113002404543002000704567008009204574#v23n2#v:\scielo\serial\rpsp\v23n2\m
arkup\02.htm#S#l#4#1#article#1#^mfev.^a2008#oa#pt#br1.1#1#3.1#tab#02#RPSP020#nd#
Rev. panam. salud pública#23#2#20080200#^f78^l84#1020-4989#Prevalência de cárie 
não tratada na dentição decídua em áreas urbanas e rurais do Estado de São Paulo
, Brasil^lpt#Prevalence of untreated caries in deciduous teeth in urban and rura
l areas in the state of São Paulo, Brazil^len#^rND^1A01^nTatiana Ribeiro de Camp
os^sMello#^rND^1A02^nJose Leopoldo Ferreira^sAntunes#^rND^1A03^nEliseu Alves^sWa
ldman#^iA01^1Universidade do Oeste de Santa Catarina#^iA02^1Universidade de São 
Paulo^2Faculdade de Odontologia^cSão Paulo^sSP^pBrasil#^iA03^1Universidade de Sã
o Paulo^2Faculdade de Saúde Pública^3Departamento de Epidemiologia^cSão Paulo^sS
P^pBrasil#^lpt^aOBJETIVO: Descrever os diferenciais urbano-rurais da prevalência
 de cárie dentária em crianças com dentição decídua no Estado de São Paulo e ide
ntificar fatores associados. MÉTODOS: Participaram do estudo 24 744 crianças de 
5 a 7 anos examinadas no Levantamento Epidemiológico de Saúde Bucal do Estado de
 São Paulo. Utilizou-se a análise multinível para verificar se havia associação 
entre a prevalência de cárie não tratada e as características sociodemográficas 
das crianças examinadas ou os aspectos socioeconômicos das cidades participantes
. RESULTADOS: Ser negro ou pardo (razão de chances, ou OR, ajustada = 1,27), est
udar na área rural (OR ajustada = 1,88) e freqüentar a escola pública (OR ajusta
da = 3,41) foram identificados como determinantes individuais de chance mais ele
vada de apresentar um ou mais dentes decíduos com cárie não tratada. Ser do sexo
 feminino (OR ajustada = 0,83) foi identificado como fator de proteção para essa
 condição. Os coeficientes negativos obtidos para as variáveis independentes de 
segundo nível indicaram que o perfil de saúde bucal das cidades participantes se
 beneficiou de valores mais elevados de índice de desenvolvimento humano municip
al (beta = -0,47) e da adição de flúor à rede de águas (beta = -0,32). CONCLUSÕE
S: A prevalência de cárie não tratada é influenciada por fatores sociodemográfic
os de ordem individual e contextual. O presente estudo apresenta informações epi
demiológicas das áreas rurais do Estado de São Paulo, oferecendo subsídios para 
o planejamento estratégico e normativo das ações de saúde bucal nos sistemas loc
ais de saúde, com o intuito de contribuir para a promoção de eqüidade em saúde b
ucal.#^dnd^i1#^tm^lpt^kCárie dentária^i1#^tm^lpt^kserviços de saúde bucal^i1#^tm
^lpt^kpopulação rural^i1#^tm^lpt^kfatores socioeconômicos^i1#^tm^lpt^kBrasil^i1#
^len^aOBJECTIVES: To describe the prevalence of dental caries in children with d
eciduous teeth in urban and rural areas in the state of São Paulo, Brazil, and t
o identify associated factors. METHODS: The study included 24 744 children (5-7 
years of age) examined as part of an epidemiological survey on oral health carri
ed out in the state of São Paulo (Levantamento Epidemiológico de Saúde Bucal do 
Estado de São Paulo). Multilevel analysis was used to investigate whether the pr
evalence of untreated caries was associated with the sociodemographic characteri
stics of the children examined or with the socioeconomic aspects of the particip
ating cities. RESULTS: Being black or brown (adjusted odds ratio (OR) = 1.27), a
ttending school in rural areas (adjusted OR = 1.88), and attending public school
 (adjusted OR = 3.41) were identified as determinants for an increased probabili
ty of presenting deciduous teeth with untreated caries. Being a female (adjusted
 OR = 0.83) was identified as a protective factor. The negative coefficients obt
ained for second-level independent variables indicate that the oral health profi
le of the cities included in the study were positively impacted by a higher muni
cipal human development index (beta = -0.47) and fluoridated drinking water (bet
a = -0.32). CONCLUSIONS: The prevalence of untreated caries is influenced by ind
ividual and sociodemographic factors. The present study provides epidemiological
 information concerning the rural areas in the state of São Paulo. This informat
ion is useful for strategic planning and for establishing guidelines for oral he
alth actions in local health systems, thereby contributing to oral health equity
.#^dnd^i2#^tm^len^kDental caries^i2#^tm^len^kdental health services^i2#^tm^len^k
rural population^i2#^tm^len^ksocioeconomic factors^i2#^tm^len^kBrazil^i2#Conselh
o Nacional de Desenvolvimento Científico e Tecnológico (CNPq)#other#29#20070308#
8 de março de 2007#20070912#12 de septembro de 2007#02.htm#Internet^ihttp://www.
scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892008000200002##
00375000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704015400068002000700222#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#5#1#article#107#<p align="right"><font face
="Verdana, Arial, Helvetica, sans-serif" size="2"><b>INVESTIGACI&Oacute;N    ORI
GINAL</b> ORIGINAL RESEARCH</font></p>     ^cY#02.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704002200068002000700090#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#6#2#article#107#<p>&nbsp;</p>     ^cY#02.ht
m##
00499000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704027800068002000700346#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#7#3#article#107#<p><a name="top"></a><font 
face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Preval&ecirc;ncia    de
 c&aacute;rie n&atilde;o tratada na denti&ccedil;&atilde;o dec&iacute;dua    em 
&aacute;reas urbanas e rurais do Estado de S&atilde;o Paulo, Brasil</b></font></
p>     ^cY#02.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704002200068002000700090#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#8#4#article#107#<p>&nbsp;</p>     ^cY#02.ht
m##
00432000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704021100068002000700279#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#9#5#article#107#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="3"><b>Prevalence of    untreated caries in deci
duous teeth in urban and rural areas in the state of    S&atilde;o Paulo, Brazil
</b></font></p>     ^cY#02.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#10#6#article#107#<p>&nbsp;</p>     ^cY#02.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#11#7#article#107#<p>&nbsp;</p>     ^cY#02.h
tm##
00465000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704024300069002000700312#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#12#8#article#107#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Tatiana Ribeiro    de Campos Mello<sup>I
, <a href="#back">*</a></sup>; Jose Leopoldo Ferreira Antunes<sup>II</sup>;    E
liseu Alves Waldman<sup>III</sup></b></font></p>     ^cY#02.htm##
00391000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704016900069002000700238#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#13#9#article#107#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><sup>I</sup>Universidade    do Oeste de San
ta Catarina (UNOESC), Mestrado em Sa&uacute;de Coletiva    ^cY#02.htm##
00343000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704012000070002000700190#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#14#10#article#107#<br>   <sup>II</sup>Unive
rsidade de S&atilde;o Paulo, Faculdade de Odontologia, S&atilde;o    Paulo (SP),
 Brasil    ^cY#02.htm##
00403000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704018000070002000700250#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#15#11#article#107#<br>   <sup>III</sup>Univ
ersidade de S&atilde;o Paulo, Faculdade de Sa&uacute;de P&uacute;blica,    Depar
tamento de Epidemiologia, S&atilde;o Paulo (SP), Brasil</font></p>     ^cY#02.ht
m##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#16#12#article#107#<p>&nbsp;</p>     ^cY#02.
htm##
00267000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704004400070002000700114#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#17#13#article#107#<p>&nbsp;</p> <hr size="1
" noshade>     ^cY#02.htm##
00319000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009600070002000700166#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#18#14#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY#02.htm##
00537000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704031400070002000700384#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#19#15#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Descrever os diferenci
ais urbano-rurais da preval&ecirc;ncia de c&aacute;rie    dent&aacute;ria em cri
an&ccedil;as com denti&ccedil;&atilde;o dec&iacute;dua    no Estado de S&atilde;
o Paulo e identificar fatores associados.    ^cY#02.htm##
00750000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704052700070002000700597#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#20#16#article#107#<br>   <b>M&Eacute;TODOS:
&nbsp;</b>Participaram do estudo 24 744 crian&ccedil;as de    5 a 7 anos examina
das no Levantamento Epidemiol&oacute;gico de Sa&uacute;de    Bucal do Estado de 
S&atilde;o Paulo. Utilizou-se a an&aacute;lise multin&iacute;vel    para verific
ar se havia associa&ccedil;&atilde;o entre a preval&ecirc;ncia de    c&aacute;ri
e n&atilde;o tratada e as caracter&iacute;sticas sociodemogr&aacute;ficas    das
 crian&ccedil;as examinadas ou os aspectos socioecon&ocirc;micos das cidades    
participantes.    ^cY#02.htm##
01182000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704095900070002000701029#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#21#17#article#107#<br>   <b>RESULTADOS:</b>
 Ser negro ou pardo (raz&atilde;o de chances, ou OR, ajustada    = 1,27), estuda
r na &aacute;rea rural (OR ajustada = 1,88) e freq&uuml;entar    a escola p&uacu
te;blica (OR ajustada = 3,41) foram identificados como determinantes    individu
ais de chance mais elevada de apresentar um ou mais dentes dec&iacute;duos    co
m c&aacute;rie n&atilde;o tratada. Ser do sexo feminino (OR ajustada = 0,83)    
foi identificado como fator de prote&ccedil;&atilde;o para essa condi&ccedil;&at
ilde;o.    Os coeficientes negativos obtidos para as vari&aacute;veis independen
tes de    segundo n&iacute;vel indicaram que o perfil de sa&uacute;de bucal das 
cidades    participantes se beneficiou de valores mais elevados de &iacute;ndice
 de desenvolvimento    humano municipal (<font face="Symbol">b</font> = &#150;0,
47) e da adi&ccedil;&atilde;o    de fl&uacute;or &agrave; rede de &aacute;guas (
<font face="Symbol">b</font>    = &#150;0,32).    ^cY#02.htm##
00833000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704061000070002000700680#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#22#18#article#107#<br>   <b>CONCLUS&Otilde;
ES:</b> A preval&ecirc;ncia de c&aacute;rie n&atilde;o tratada    &eacute; influ
enciada por fatores sociodemogr&aacute;ficos de ordem individual    e contextual
. O presente estudo apresenta informa&ccedil;&otilde;es epidemiol&oacute;gicas  
  das &aacute;reas rurais do Estado de S&atilde;o Paulo, oferecendo subs&iacute;
dios    para o planejamento estrat&eacute;gico e normativo das a&ccedil;&otilde;
es de    sa&uacute;de bucal nos sistemas locais de sa&uacute;de, com o intuito d
e contribuir    para a promo&ccedil;&atilde;o de eq&uuml;idade em sa&uacute;de b
ucal.</font></p>     ^cY#02.htm##
00496000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704027300070002000700343#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#23#19#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Palavras-chave:    </b> C&aacute;rie de
nt&aacute;ria, servi&ccedil;os de sa&uacute;de bucal, popula&ccedil;&atilde;o   
 rural, fatores socioecon&ocirc;micos, Brasil.</font></p> <hr size="1" noshade> 
    ^cY#02.htm##
00321000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009800070002000700168#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#24#20#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     ^cY#02.htm#
#
00502000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704027900070002000700349#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#25#21#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>OBJECTIVES:    </b> To describe the pre
valence of dental caries in children with deciduous    teeth in urban and rural 
areas in the state of S&atilde;o Paulo, Brazil, and    to identify associated fa
ctors.    ^cY#02.htm##
00770000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704054700070002000700617#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#26#22#article#107#<br>   <b>METHODS:&nbsp;<
/b>The study included 24 744 children (5&#150;7 years of age)    examined as par
t of an epidemiological survey on oral health carried out in    the state of S&a
tilde;o Paulo (<i>Levantamento Epidemiol&oacute;gico de Sa&uacute;de    Bucal do
 Estado de S&atilde;o Paulo</i>). Multilevel analysis was used to investigate   
 whether the prevalence of untreated caries was associated with the sociodemogra
phic    characteristics of the children examined or with the socioeconomic aspec
ts of    the participating cities.    ^cY#02.htm##
00969000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704074600070002000700816#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#27#23#article#107#<br>   <b>RESULTS:&nbsp;<
/b>Being black or brown (adjusted odds ratio (OR) = 1.27),    attending school i
n rural areas (adjusted OR = 1.88), and attending public school    (adjusted OR 
= 3.41) were identified as determinants for an increased probability    of prese
nting deciduous teeth with untreated caries. Being a female (adjusted    OR = 0.
83) was identified as a protective factor. The negative coefficients    obtained
 for second-level independent variables indicate that the oral health    profile
 of the cities included in the study were positively impacted by a higher    mun
icipal human development index (<font face="Symbol">b</font> = &#150;0.47)    an
d fluoridated drinking water (<font face="Symbol">b</font> = &#150;0.32).    ^cY
#02.htm##
00666000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704044300070002000700513#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#28#24#article#107#<br>   <b>CONCLUSIONS: </
b> The prevalence of untreated caries is influenced by individual    and sociode
mographic factors. The present study provides epidemiological information    con
cerning the rural areas in the state of S&atilde;o Paulo. This information    is
 useful for strategic planning and for establishing guidelines for oral health  
  actions in local health systems, thereby contributing to oral health equity.</
font></p>     ^cY#02.htm##
00439000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704021600070002000700286#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#29#25#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Key words:</b>    Dental caries, dental
 health services, rural population, socioeconomic factors,    Brazil.</font></p>
 <hr size="1" noshade>     ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#30#26#article#107#<p>&nbsp;</p>     ^cY#02.
htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#31#27#article#107#<p>&nbsp;</p>     ^cY#02.
htm##
01265000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704104200070002000701112#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#32#28#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Nos &uacute;ltimos    anos, os levantament
os epidemiol&oacute;gicos de sa&uacute;de bucal t&ecirc;m    mostrado uma tend&e
circ;ncia ao decl&iacute;nio na preval&ecirc;ncia de c&aacute;rie    em muitos p
a&iacute;ses do mundo. Em escolares brasileiros, a fluora&ccedil;&atilde;o    da
 &aacute;gua de abastecimento p&uacute;blico, a adi&ccedil;&atilde;o de fl&uacut
e;or    aos dentifr&iacute;cios e a descentraliza&ccedil;&atilde;o do sistema de
 sa&uacute;de    foram os fatores apontados como associados a esse decl&iacute;n
io (1). Entretanto,    a redu&ccedil;&atilde;o da preval&ecirc;ncia de c&aacute;
rie dent&aacute;ria    foi acompanhada pelo fen&ocirc;meno conhecido como polari
za&ccedil;&atilde;o    da doen&ccedil;a, caracterizado pela concentra&ccedil;&at
ilde;o de &iacute;ndices    de c&aacute;rie mais elevados em grupos populacionai
s mais submetidos &agrave;    priva&ccedil;&atilde;o material dentro de um mesmo
 pa&iacute;s ou regi&atilde;o    (2).</font></p>     ^cY#02.htm##
01565000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704134200070002000701412#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#33#29#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">S&atilde;o escassos    os estudos de preva
l&ecirc;ncia de c&aacute;rie dent&aacute;ria em popula&ccedil;&otilde;es    resi
dentes em &aacute;reas rurais; al&eacute;m disso, esses estudos geralmente    tr
atam apenas dos indicadores de c&aacute;rie em dentes permanentes. Em uma    pro
v&iacute;ncia rural no sudoeste de Zimb&aacute;bue, na &Aacute;frica, a preval&e
circ;ncia    de c&aacute;rie aos 5 e 6 anos foi de 25,2%, com &iacute;ndice de d
entes cariados,    com extra&ccedil;&atilde;o indicada e obturados (ceod) de 0,6
. Os autores atribu&iacute;ram    essa preval&ecirc;ncia, considerada baixa, a d
ois fatores: 1) aproximadamente    40% das escolas inclu&iacute;das no estudo ti
nham acesso a &aacute;gua com concentra&ccedil;&atilde;o    de fl&uacute;or de 0
,8 ppm, n&iacute;vel considerado ideal para pa&iacute;ses    tropicais; e 2) a p
rov&iacute;ncia estudada era pouco urbanizada, tendo os seus    moradores h&aacu
te;bitos alimentares tradicionais, considerados mais saud&aacute;veis    (3). No
 contexto brasileiro, por sua vez, a preval&ecirc;ncia de necessidade    de trat
amento odontol&oacute;gico em crian&ccedil;as com denti&ccedil;&atilde;o    dec&
iacute;dua foi de 70% em &aacute;reas rurais brasileiras no per&iacute;odo    de
 2002 a 2003 (4).</font></p>     ^cY#02.htm##
00829000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704060600070002000700676#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#34#30#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">No Estado de S&atilde;o    Paulo, as &aacu
te;reas rurais apresentam indicadores de renda, escolaridade    e saneamento pio
res do que as &aacute;reas urbanas. A propor&ccedil;&atilde;o    de pessoas anal
fabetas com 15 anos ou mais na &aacute;rea urbana representa    quase o dobro do
s valores encontrados na &aacute;rea rural (5). Com piores condi&ccedil;&otilde;
es    socioecon&ocirc;micas, as &aacute;reas rurais podem configurar um p&oacute
;lo    de concentra&ccedil;&atilde;o para os agravos &agrave; sa&uacute;de bucal
.</font></p>     ^cY#02.htm##
00721000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704049800070002000700568#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#35#31#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O presente estudo    teve por objetivo des
crever poss&iacute;veis diferenciais urbano-rurais e identificar    fatores asso
ciados &agrave; preval&ecirc;ncia de c&aacute;rie dent&aacute;ria    em crian&cc
edil;as com denti&ccedil;&atilde;o dec&iacute;dua no Estado de S&atilde;o    Pau
lo, fornecendo subs&iacute;dios para o planejamento de a&ccedil;&otilde;es    pr
eventivas e assistenciais do sistema de sa&uacute;de.</font></p>     ^cY#02.htm#
#
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#36#32#article#107#<p>&nbsp;</p>     ^cY#02.
htm##
00342000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704011900070002000700189#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#37#33#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>MATERIAIS E    M&Eacute;TODOS</b></font
></p>     ^cY#02.htm##
01191000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704096800070002000701038#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#38#34#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Os dados utilizados    neste estudo foram 
obtidos do banco de dados disponibilizado pelo Levantamento    Epidemiol&oacute;
gico de Sa&uacute;de Bucal realizado por meio de conv&ecirc;nio    de coopera&cc
edil;&atilde;o t&eacute;cnica entre a Secretaria de Estado de Sa&uacute;de    (S
ES) e a Faculdade de Sa&uacute;de P&uacute;blica da Universidade de S&atilde;o  
  Paulo (FSP-USP) de outubro de 1997 a outubro de 1999 (6). No total, 89 114 pes
soas    foram examinadas de acordo com as normas da Organiza&ccedil;&atilde;o Mu
ndial    da Sa&uacute;de (OMS) (7). Para o estudo da denti&ccedil;&atilde;o dec&
iacute;dua,    todas as crian&ccedil;as da faixa et&aacute;ria de 5 a 7 anos sel
ecionadas e    que efetivamente participaram do Levantamento Epidemiol&oacute;gi
co de Sa&uacute;de    Bucal (6) foram inclu&iacute;das neste estudo, totalizando
 uma amostra global    de 25 012 escolares.</font></p>     ^cY#02.htm##
01696000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704147300070002000701543#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#39#35#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Para avaliar a    preval&ecirc;ncia e a se
veridade do ataque de c&aacute;rie de acordo com as    recomenda&ccedil;&otilde;
es da OMS, o levantamento utilizou o &iacute;ndice    ceod. Esse &iacute;ndice c
ontabiliza os dentes dec&iacute;duos de algum modo    afetados por c&aacute;rie 
(cariados, extra&iacute;dos ou restaurados) (7). Com    base nessas informa&cced
il;&otilde;es, foi poss&iacute;vel estimar a preval&ecirc;ncia    de c&aacute;ri
e n&atilde;o tratada. Para avalia&ccedil;&otilde;es em n&iacute;vel    individua
l, a vari&aacute;vel &eacute; definida pela manifesta&ccedil;&atilde;o    de ao 
menos um dente dec&iacute;duo com c&aacute;rie n&atilde;o tratada (isto    &eacu
te;, o componente "c" do &iacute;ndice ceod <u>&gt;</u> 1); e para avalia&ccedil
;&otilde;es    em n&iacute;vel agregado, a vari&aacute;vel &eacute; definida pel
a propor&ccedil;&atilde;o    de crian&ccedil;as apresentando essa condi&ccedil;&
atilde;o em cada &aacute;rea.    Assim definida, a vari&aacute;vel congrega info
rma&ccedil;&otilde;es sobre a    preval&ecirc;ncia de c&aacute;rie e a falta de 
acesso a tratamento odontol&oacute;gico,    e &eacute; especialmente interessant
e para avalia&ccedil;&otilde;es em crian&ccedil;as,    em fun&ccedil;&atilde;o d
e uma relativamente baixa incorpora&ccedil;&atilde;o    de tratamentos de restau
ra&ccedil;&atilde;o na denti&ccedil;&atilde;o dec&iacute;dua    (8).</font></p> 
    ^cY#02.htm##
02009000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704178600070002000701856#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#40#36#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Para estimar a    associa&ccedil;&atilde;o
 em n&iacute;vel individual, as crian&ccedil;as foram    examinadas em termos de
 sexo, cor da pele e localiza&ccedil;&atilde;o e tipo    de escola. A classifica
&ccedil;&atilde;o por cor da pele, definida pelo cirurgi&atilde;o-dentista    qu
e efetuou o exame bucal, foi estudada em duas categorias: negros (isto &eacute;,
    crian&ccedil;as de descend&ecirc;ncia africana, incluindo as que foram class
ificadas    como pardas) e n&atilde;o negros (isto &eacute;, crian&ccedil;as bra
ncas de    descend&ecirc;ncia europ&eacute;ia). A amostra continha um pequeno n&
uacute;mero    de crian&ccedil;as amarelas (0,69%), isto &eacute;, de descend&ec
irc;ncia asi&aacute;tica,    que n&atilde;o foram inclu&iacute;das no estudo. Ne
nhuma crian&ccedil;a da amostra    foi classificada em outra categoria de cor da
 pele. A localiza&ccedil;&atilde;o    da escola diz respeito &agrave; &aacute;re
a urbana ou rural, e o tipo se refere    ao car&aacute;ter p&uacute;blico ou pri
vado. Os estudos de epidemiologia da    sa&uacute;de bucal t&ecirc;m presumido q
ue as crian&ccedil;as matriculadas em    estabelecimentos privados de ensino no 
contexto brasileiro apresentam melhores    condi&ccedil;&otilde;es socioecon&oci
rc;micas do que as crian&ccedil;as das    escolas p&uacute;blicas, que s&atilde;
o gratuitas (9, 10). Para 0,38% das crian&ccedil;as,    n&atilde;o foi informado
 o tipo de escola, e essas crian&ccedil;as tamb&eacute;m    foram exclu&iacute;d
as do estudo. Com a exclus&atilde;o dos escolares de descend&ecirc;ncia    asi&a
acute;tica e daqueles sem informa&ccedil;&atilde;o quanto ao tipo de escola,    
a popula&ccedil;&atilde;o de estudo incluiu 24 744 escolares.</font></p>     ^cY
#02.htm##
01274000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704105100070002000701121#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#41#37#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">As caracter&iacute;sticas    socioecon&oci
rc;micas de cada munic&iacute;pio participante na amostra foram    obtidas atrav
&eacute;s do &Iacute;ndice de Desenvolvimento Humano Municipal    (IDH-M), dispo
nibilizado pelo escrit&oacute;rio regional no Brasil do Programa    das Na&ccedi
l;&otilde;es Unidas para o Desenvolvimento (PNUD). O IDH-M &eacute;    medido at
rav&eacute;s de indicadores de educa&ccedil;&atilde;o (taxa de alfabetiza&ccedil
;&atilde;o    de pessoas acima de 15 anos de idade e taxa bruta de freq&uuml;&ec
irc;ncia &agrave;    escola), longevidade (expectativa de vida ao nascer) e rend
a (renda municipal    <i>per capita</i>). O levantamento epidemiol&oacute;gico (
6) forneceu dados    sobre a presen&ccedil;a ou n&atilde;o de fl&uacute;or na &a
acute;gua de abastecimento    p&uacute;blico. Essas vari&aacute;veis foram utili
zadas para avaliar a associa&ccedil;&atilde;o    em n&iacute;vel agregado, ou se
ja, das cidades participantes do levantamento.</font></p>     ^cY#02.htm##
00339000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704011600070002000700186#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#42#38#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>An&aacute;lise    de dados</b></font></
p>     ^cY#02.htm##
00562000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704033900070002000700409#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#43#39#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">As vari&aacute;veis    do estudo foram org
anizadas em um banco de dados informatizado e a an&aacute;lise    estat&iacute;s
tica foi efetuada atrav&eacute;s dos programas Epi Info 6.04d    2001 e <i>Stati
stical Package for the Social Sciences</i> (SPSS) 8.0.</font></p>     ^cY#02.htm
##
01317000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704109400070002000701164#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#44#40#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Na primeira etapa,    foram obtidos os ind
icadores globais de sa&uacute;de bucal do Estado de S&atilde;o    Paulo, segundo
 a estratifica&ccedil;&atilde;o urbano-rural. Ap&oacute;s o c&aacute;lculo    do
s &iacute;ndices apresentados anteriormente, os diferenciais entre esses dois   
 segmentos foram estimados atrav&eacute;s da raz&atilde;o desses indicadores,   
 ou seja, o indicador de preval&ecirc;ncia do grupo 1 (rural) em rela&ccedil;&at
ilde;o    ao grupo 2 (urbano). Atrav&eacute;s dessa raz&atilde;o, obteve-se um i
ndicador    do diferencial entre essas &aacute;reas. O indicador de c&aacute;rie
 n&atilde;o    tratada (c <u>&gt;</u> 1) foi utilizado como vari&aacute;vel depe
ndente para    cada estrato (urbano e rural). As raz&otilde;es de chances (<i>od
ds ratio</i>,    OR) foram calculadas de acordo com as caracter&iacute;sticas so
ciodemogr&aacute;ficas    das crian&ccedil;as. Num primeiro momento, tamb&eacute
;m foram calculadas OR    n&atilde;o ajustadas para as demais vari&aacute;veis d
o estudo.</font></p>     ^cY#02.htm##
01210000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704098700070002000701057#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#45#41#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Empregou-se a an&aacute;lise    multin&iac
ute;vel para o posterior ajuste de determinantes individuais e contextuais    qu
e podem interferir no agravo &agrave; sa&uacute;de bucal estudado com controle  
  de colinearidade para as vari&aacute;veis independentes em cada n&iacute;vel  
  da an&aacute;lise. A avalia&ccedil;&atilde;o da qualidade do ajuste do modelo 
   empregou o teste -2 log-probabilidade. A an&aacute;lise multin&iacute;vel uti
lizou    o esquema de efeitos fixos/intersec&ccedil;&atilde;o rand&ocirc;mica (1
1) para    ajustar os indicadores de sa&uacute;de bucal estudados &agrave;s vari
&aacute;veis    independentes das crian&ccedil;as examinadas (primeiro n&iacute;
vel) e das cidades    participantes (segundo n&iacute;vel). O teste de raz&atild
e;o de probabilidade    (<i>likelihood ratio</i>) foi utilizado para comparar a 
qualidade de ajuste    dos diferentes modelos delineados (12).</font></p>     ^c
Y#02.htm##
01450000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704122700070002000701297#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#46#42#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">No primeiro n&iacute;vel,    uma an&aacute
;lise multivariada de regress&atilde;o log&iacute;stica convencional    compreen
dendo todas as crian&ccedil;as examinadas permitiu avaliar o efeito    das carac
ter&iacute;sticas sociodemogr&aacute;ficas sobre a condi&ccedil;&atilde;o    con
siderada. No segundo n&iacute;vel, uma an&aacute;lise multivariada de regress&at
ilde;o    log&iacute;stica convencional foi executada para cada cidade. Essas eq
ua&ccedil;&otilde;es    tiveram seus coeficientes fixados para coincidir com os 
previamente determinados    pela equa&ccedil;&atilde;o, compreendendo o banco de
 dados completo, pois este    modelo n&atilde;o admite varia&ccedil;&atilde;o de
 segundo n&iacute;vel nos    efeitos das vari&aacute;veis independentes de prime
iro n&iacute;vel. Desse modo,    toda a varia&ccedil;&atilde;o de segundo n&iacu
te;vel foi atribu&iacute;da &agrave;    intersec&ccedil;&atilde;o, e uma an&aacu
te;lise de regress&atilde;o linear avaliou    a varia&ccedil;&atilde;o da inters
ec&ccedil;&atilde;o. Uma indica&ccedil;&atilde;o    esquem&aacute;tica desse pro
cedimento anal&iacute;tico foi descrita na literatura    (13).</font></p>     ^c
Y#02.htm##
00633000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704041000070002000700480#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#47#43#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O protocolo da    pesquisa foi aprovado pe
lo Comit&ecirc; de &Eacute;tica em Pesquisa da Faculdade    de Sa&uacute;de P&ua
cute;blica da Universidade de S&atilde;o Paulo (parecer    no. 1096, 2005), auto
rizando o acesso &agrave;s fichas originais dos exames    dent&aacute;rios das c
rian&ccedil;as participantes do levantamento.</font></p>     ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#48#44#article#107#<p>&nbsp;</p>     ^cY#02.
htm##
00323000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010000070002000700170#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#49#45#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>RESULTADOS</b></font></p>     ^cY#02.ht
m##
00945000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704072200070002000700792#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#50#46#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">As crian&ccedil;as    de &aacute;reas rura
is do Estado de S&atilde;o Paulo apresentaram indicadores    de experi&ecirc;nci
a de c&aacute;rie e de acesso a tratamento odontol&oacute;gico    na denti&ccedi
l;&atilde;o dec&iacute;dua piores do que as crian&ccedil;as de    &aacute;reas u
rbanas (<i>P</i> &lt; 0,01). Na &aacute;rea rural, apenas 19,55%    das crian&cc
edil;as examinadas estavam livres de c&aacute;rie e o &iacute;ndice    de cuidad
o foi de 21,20%, resultados significativamente mais baixos do que daqueles    ob
tidos para o grupo de crian&ccedil;as de &aacute;reas urbanas (<i>P</i> &lt;    
0,01) (<a href="#tab1">tabela 1</a>).</font></p>     ^cY#02.htm##
00258000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003500070002000700105#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#51#47#article#107#<p><a name="tab1"></a></p
>     ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#52#48#article#107#<p>&nbsp;</p>     ^cY#02.
htm##
00299000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007600070002000700146#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#53#49#article#107#<p align="center"><img sr
c="/img/revistas/rpsp/v23n2/02t1.gif"></p>     ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#54#50#article#107#<p>&nbsp;</p>     ^cY#02.
htm##
01153000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704093000070002000701000#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#55#51#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Foram analisadas    as condi&ccedil;&otild
e;es sociodemogr&aacute;ficas que poderiam estar associadas    &agrave; preval&e
circ;ncia de c&aacute;rie n&atilde;o tratada na denti&ccedil;&atilde;o    dec&ia
cute;dua. Apresentaram maior preval&ecirc;ncia de c&aacute;rie as crian&ccedil;a
s    negras e pardas (em rela&ccedil;&atilde;o &agrave;s brancas) e as crian&cce
dil;as    matriculadas em escolas p&uacute;blicas (em rela&ccedil;&atilde;o &agr
ave;s    matriculadas em escolas privadas), tanto em &aacute;reas urbanas como r
urais.    Ser do sexo feminino associou-se a menor preval&ecirc;ncia de cavidade
 de c&aacute;rie    n&atilde;o tratada nas duas &aacute;reas estudadas, mas essa
 associa&ccedil;&atilde;o    mostrou-se lim&iacute;trofe para a &aacute;rea rura
l (IC95%: 0,68 a 1,02) (<a href="/img/revistas/rpsp/v23n2/02t2.gif">tabela    2<
/a>).</font></p>     ^cY#02.htm##
02210000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704198700070002000702057#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#56#52#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O modelo multin&iacute;vel    de an&aacute
;lise multivariada de regress&atilde;o log&iacute;stica ajustou    as vari&aacut
e;veis explicativas para a preval&ecirc;ncia de c&aacute;rie n&atilde;o    trata
da na denti&ccedil;&atilde;o dec&iacute;dua (<a href="#tab3">tabela 3</a>).    A
s vari&aacute;veis, independentemente das demais, que se mostraram associadas   
 &agrave; c&aacute;rie dent&aacute;ria n&atilde;o tratada em dentes dec&iacute;d
uos    foram: ser negro ou pardo (OR ajustada = 1,27), estudar na &aacute;rea ru
ral    (OR ajustada = 1,88) e em escola p&uacute;blica (OR ajustada = 3,41) e se
r do    sexo feminino (OR ajustada = 0,83). A idade foi inclu&iacute;da no model
o como    fator de ajuste porque a amostra reunia crian&ccedil;as de 5 a 7 anos 
e as crian&ccedil;as    com idade mais elevada apresentaram maior chance de c&aa
cute;rie n&atilde;o    tratada (<i>P</i> &lt; 0,001). Os coeficientes negativos 
obtidos para as vari&aacute;veis    independentes do segundo n&iacute;vel indica
ram que o perfil de sa&uacute;de    bucal das cidades participantes se beneficio
u de valores mais elevados de IDH-M    (<font face="Symbol">b </font>= &#150;0,4
7) e da adi&ccedil;&atilde;o de fl&uacute;or    &agrave; rede de &aacute;guas (<
font face="Symbol">b </font>= &#150;0,32). Assim,    essas condi&ccedil;&otilde;
es foram reconhecidas como determinantes contextuais    da preval&ecirc;ncia de 
c&aacute;rie n&atilde;o tratada na denti&ccedil;&atilde;o    dec&iacute;dua no E
stado de S&atilde;o Paulo. Como o modelo completo apresentou    medida de qualid
ade do ajuste (&#150;2 log-probabilidade) significativamente    menos elevada do
 que a medida correspondente para o primeiro n&iacute;vel, considerou-se    o mo
delo final (compreendendo todo o conjunto de vari&aacute;veis explicativas)    c
omo sendo o mais efetivo para explicar a varia&ccedil;&atilde;o da condi&ccedil;
&atilde;o    estudada.</font></p>     ^cY#02.htm##
00258000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003500070002000700105#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#57#53#article#107#<p><a name="tab3"></a></p
>     ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#58#54#article#107#<p>&nbsp;</p>     ^cY#02.
htm##
00299000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007600070002000700146#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#59#55#article#107#<p align="center"><img sr
c="/img/revistas/rpsp/v23n2/02t3.gif"></p>     ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#60#56#article#107#<p>&nbsp;</p>     ^cY#02.
htm##
00329000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010600070002000700176#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#61#57#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>DISCUSS&Atilde;O</b></font></p>     ^cY
#02.htm##
01607000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704138400070002000701454#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#62#58#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Neste estudo, foram    analisados dados se
cund&aacute;rios de c&aacute;rie dent&aacute;ria provenientes    originalmente d
o banco de dados gerado pelo Levantamento Epidemiol&oacute;gico    de Sa&uacute;
de Bucal: Estado de S&atilde;o Paulo, 1998 (6). Esse levantamento    foi o mais 
abrangente j&aacute; realizado no Estado no que diz respeito ao n&uacute;mero   
 de pessoas examinadas, o que representa um importante diferencial para o estudo
    de desigualdades de sa&uacute;de bucal em &aacute;reas urbanas e rurais. Ape
sar    de um levantamento epidemiol&oacute;gico de sa&uacute;de bucal mais recen
te    (2002 e 2003) ter indicado o decl&iacute;nio da experi&ecirc;ncia de c&aac
ute;rie    em escolares brasileiros (14), os indicadores epidemiol&oacute;gicos 
da doen&ccedil;a    continuam associados a fatores contextuais de desenvolviment
o social (13), o    que motivou a an&aacute;lise comparativa da preval&ecirc;nci
a de c&aacute;rie    em popula&ccedil;&otilde;es urbanas e rurais. Espera-se com
 isso ter valorizado    o esfor&ccedil;o despendido na realiza&ccedil;&atilde;o 
desse extenso levantamento    epidemiol&oacute;gico e suprido, ao menos em parte
, a escassez de trabalhos    avaliando as condi&ccedil;&otilde;es de sa&uacute;d
e bucal das popula&ccedil;&otilde;es    rurais brasileiras.</font></p>     ^cY#0
2.htm##
01634000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704141100070002000701481#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#63#59#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">De acordo com o    relat&oacute;rio final 
do Levantamento Epidemiol&oacute;gico de Sa&uacute;de    Bucal de 1998 (6), as i
nforma&ccedil;&otilde;es obtidas permitem estratificar    a amostra segundo a lo
calidade onde se encontra a escola (urbana ou rural).    No entanto, o delineame
nto da amostra n&atilde;o foi programado para garantir    a infer&ecirc;ncia pro
babil&iacute;stica de resultados relativos a essa estratifica&ccedil;&atilde;o. 
   Al&eacute;m disso, a classifica&ccedil;&atilde;o dos escolares como sendo de 
   &aacute;rea urbana ou rural refere-se &agrave; localiza&ccedil;&atilde;o da  
  escola que freq&uuml;entavam e, nesse sentido, essa informa&ccedil;&atilde;o  
  n&atilde;o reflete obrigatoriamente a &aacute;rea de resid&ecirc;ncia. Tamb&ea
cute;m    n&atilde;o podem ser inferidas informa&ccedil;&otilde;es para as &aacu
te;reas    rurais que n&atilde;o participaram do levantamento. Apesar dessas lim
ita&ccedil;&otilde;es,    o elevado n&uacute;mero de indiv&iacute;duos examinado
s, combinado com a dispers&atilde;o    dos pontos de coleta dos dados, tanto no 
Estado como em cada cidade, encorajou    os autores a explorar as diferen&ccedil
;as na experi&ecirc;ncia de c&aacute;rie    e sua associa&ccedil;&atilde;o com o
s indicadores de desenvolvimento social    em &aacute;reas urbanas e rurais do E
stado.</font></p>     ^cY#02.htm##
01818000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704159500070002000701665#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#64#60#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A m&eacute;dia    de 4,64 do &iacute;ndice
 ceod observada para a &aacute;rea rural do Estado reflete    um n&iacute;vel el
evado de preval&ecirc;ncia de c&aacute;rie, de acordo com    a escala proposta p
ela OMS (15), ao passo que as crian&ccedil;as residentes    em &aacute;reas urba
nas apresentaram melhores indicadores de sa&uacute;de bucal.    Um pior perfil d
e sa&uacute;de bucal para crian&ccedil;as em &aacute;reas rurais    tamb&eacute;
m foi registrado para Itapetininga (S&atilde;o Paulo) (16), Ita&uacute;na    (Mi
nas Gerais) (17) e em pa&iacute;ses africanos (18, 19). Al&eacute;m disso,    es
se resultado &eacute; consistente com o que foi encontrado na an&aacute;lise    
dos dados do levantamento epidemiol&oacute;gico "Condi&ccedil;&otilde;es de    S
a&uacute;de Bucal da Popula&ccedil;&atilde;o Brasileira 2002&#150; 03", tamb&eac
ute;m    conhecido como SB-Brasil 2003, realizado em diferentes regi&otilde;es b
rasileiras    (4). Naquele estudo, as discrep&acirc;ncias urbano-rurais foram ai
nda mais intensas    nas regi&otilde;es Norte e Nordeste em compara&ccedil;&atil
de;o com as regi&otilde;es    Sul e Sudeste, sugerindo que a desigualdade no per
fil epidemiol&oacute;gico    da c&aacute;rie foi mais marcante nas regi&otilde;e
s mais submetidas &agrave;    priva&ccedil;&atilde;o material. Situa&ccedil;&ati
lde;o oposta, entretanto,    foi observada em estudos realizados em &aacute;reas
 rurais africanas consideradas    isoladas e mantenedoras de h&aacute;bitos alim
entares tradicionais (18, 19).</font></p>     ^cY#02.htm##
01254000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704103100070002000701101#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#65#61#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A baixa incorpora&ccedil;&atilde;o    de t
ratamento odontol&oacute;gico restaurador para as crian&ccedil;as tanto    em &a
acute;reas urbanas como rurais pode refletir fatores culturais e a falta    de c
onhecimento dos pais sobre a import&acirc;ncia da denti&ccedil;&atilde;o    dec&
iacute;dua (20, 21). Por&eacute;m, a situa&ccedil;&atilde;o &eacute; ainda    ma
is preocupante nas &aacute;reas rurais do Estado, visto que o componente c    (c
ariado) &eacute; respons&aacute;vel por 75% do valor do &iacute;ndice ceod.    N
o continente africano, os pais que moravam em &aacute;reas rurais nunca haviam  
  informado os filhos quanto &agrave; import&acirc;ncia de visitar o cirurgi&ati
lde;o-dentista,    pois, naquela comunidade carente, havia-se priorizado o enfre
ntamento de outras    condi&ccedil;&otilde;es, como a situa&ccedil;&atilde;o soc
ial de extrema mis&eacute;ria    e a elevada preval&ecirc;ncia de desnutri&ccedi
l;&atilde;o infantil (18).</font></p>     ^cY#02.htm##
00936000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704071300070002000700783#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#66#62#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Utilizando o indiv&iacute;duo    como unid
ade de an&aacute;lise, observou-se que, em &aacute;reas rurais do Estado,    n&a
tilde;o houve diferen&ccedil;a entre os sexos para a preval&ecirc;ncia de    c&a
acute;rie n&atilde;o tratada, em observa&ccedil;&atilde;o semelhante &agrave;   
 efetuada na &aacute;rea rural de Ita&uacute;na, Estado de Minas Gerais (17).   
 Apesar da aus&ecirc;ncia de disparidade entre os sexos para essa condi&ccedil;&
atilde;o,    reitera-se que isso foi verificado em um contexto de baixo acesso a
 tratamento    odontol&oacute;gico tanto para meninos como para meninas de &aacu
te;reas rurais    do Estado.</font></p>     ^cY#02.htm##
00908000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704068500070002000700755#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#67#63#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Tamb&eacute;m foi    observada uma preval&
ecirc;ncia de c&aacute;rie n&atilde;o tratada desigual    na compara&ccedil;&ati
lde;o entre as crian&ccedil;as brancas e as negras ou    pardas. Essa observa&cc
edil;&atilde;o representa uma indica&ccedil;&atilde;o    adicional de desigualda
de sociodemogr&aacute;fica afetando essa condi&ccedil;&atilde;o.    Estudos ante
riores sobre o tema atribuem essas diferen&ccedil;as &agrave; discrepante    ins
er&ccedil;&atilde;o socioecon&ocirc;mica desses segmentos da popula&ccedil;&atil
de;o    e ao grau distinto de acesso a bens e servi&ccedil;os no Brasil (2, 22).
</font></p>     ^cY#02.htm##
01185000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704096200070002000701032#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#68#64#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Tanto em &aacute;reas    urbanas como rura
is do Estado, os estudantes de escolas p&uacute;blicas apresentaram    maior pre
val&ecirc;ncia de c&aacute;rie n&atilde;o tratada em rela&ccedil;&atilde;o    ao
s estudantes de escolas particulares. Isso pode ser explicado pelo fato de    qu
e freq&uuml;entar a escola p&uacute;blica pode ser um marcador de n&iacute;vel  
  socioecon&ocirc;mico mais baixo. No contexto brasileiro, os estudantes de esco
las    p&uacute;blicas t&ecirc;m mais chance de ter pais com n&iacute;vel de ins
tru&ccedil;&atilde;o    mais baixo e menor renda <i>per capita</i> do que os est
udantes de escolas particulares    (23). Tamb&eacute;m j&aacute; foi observado q
ue pessoas com maior grau de educa&ccedil;&atilde;o    formal tendem a escovar o
s seus dentes mais vezes, e que os seus filhos adotam    h&aacute;bitos bucais s
aud&aacute;veis mais facilmente (24).</font></p>     ^cY#02.htm##
01440000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704121700070002000701287#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#69#65#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A an&aacute;lise    de regress&atilde;o lo
g&iacute;stica multivariada indicou que todas as vari&aacute;veis    sociodemogr
&aacute;ficas descritas anteriormente se mantiveram associadas com    a preval&e
circ;ncia de c&aacute;rie n&atilde;o tratada. O modelo multin&iacute;vel    expl
icativo de preval&ecirc;ncia de c&aacute;rie n&atilde;o tratada permitiu    indi
car o IDH-M e o acesso &agrave; &aacute;gua fluoretada como sendo condi&ccedil;&
otilde;es    contextuais significativamente associadas a essa condi&ccedil;&atil
de;o, ap&oacute;s    ajuste para as caracter&iacute;sticas sociodemogr&aacute;fi
cas dos escolares    examinados. Observou-se uma correla&ccedil;&atilde;o negati
va entre a preval&ecirc;ncia    de c&aacute;rie n&atilde;o tratada e essas vari&
aacute;veis. A associa&ccedil;&atilde;o    contextual entre as condi&ccedil;&oti
lde;es de sa&uacute;de e as condi&ccedil;&otilde;es    socioecon&ocirc;micas est
&aacute; bem estabelecida na literatura mundial, e    sugere para a denti&ccedil
;&atilde;o dec&iacute;dua os mesmos determinantes    da experi&ecirc;ncia de c&a
acute;rie da denti&ccedil;&atilde;o permanente (25).</font></p>     ^cY#02.htm##
02080000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704185700070002000701927#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#70#66#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Estudos no contexto    internacional sobre
 o fl&uacute;or t&ecirc;m indicado que esse recurso, al&eacute;m    de contribui
r para a redu&ccedil;&atilde;o de preval&ecirc;ncia da c&aacute;rie,    seria ef
etivo para reduzir a desigualdade da distribui&ccedil;&atilde;o da c&aacute;rie 
   (26, 27). N&atilde;o obstante, essa considera&ccedil;&atilde;o &eacute; limit
ada    pelo contexto brasileiro, em fun&ccedil;&atilde;o dos intensos contrastes
 na    implementa&ccedil;&atilde;o da medida. Muitos munic&iacute;pios n&atilde;
o efetuam    a adi&ccedil;&atilde;o de fl&uacute;or &agrave; &aacute;gua de abas
tecimento    p&uacute;blico, e muitos dos que o fazem apresentam ponder&aacute;v
el propor&ccedil;&atilde;o    de domic&iacute;lios n&atilde;o ligados &agrave; r
ede de &aacute;guas. Essa    observa&ccedil;&atilde;o sugere que a &aacute;gua f
luoretada n&atilde;o vem    beneficiando a popula&ccedil;&atilde;o de modo homog
&ecirc;neo (28) e que h&aacute;    espa&ccedil;o para uma redu&ccedil;&atilde;o 
ainda mais intensa dos indicadores    epidemiol&oacute;gicos da c&aacute;rie no 
Pa&iacute;s atrav&eacute;s da implementa&ccedil;&atilde;o    desse recurso nas c
idades que ainda n&atilde;o o oferecem e atrav&eacute;s da    amplia&ccedil;&ati
lde;o de cobertura do sistema de abastecimento de &aacute;gua    para as cidades
 que j&aacute; disponibilizam o benef&iacute;cio. Em Ita&uacute;na,    Estado de
 Minas Gerais, apenas 28,3% das fam&iacute;lias de &aacute;reas rurais    utiliz
avam a &aacute;gua tratada fornecida pelo sistema de abastecimento de    &aacute
;gua e esgoto local (17). Em &aacute;reas rurais que apresentam concentra&ccedil
;&atilde;o    natural desse &iacute;on na &aacute;gua, as condi&ccedil;&otilde;e
s de sa&uacute;de    bucal s&atilde;o melhores (29).</font></p>     ^cY#02.htm##
01113000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704089000070002000700960#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#71#67#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">As diferen&ccedil;as    na distribui&ccedi
l;&atilde;o dos agravos &agrave; sa&uacute;de bucal em indiv&iacute;duos    e po
pula&ccedil;&otilde;es com caracter&iacute;sticas sociais, econ&ocirc;micas    e
 demogr&aacute;ficas distintas encontradas neste estudo s&atilde;o consistentes 
   com outros achados relatados na literatura. Por&eacute;m, s&atilde;o escassos
    os estudos estimando a preval&ecirc;ncia das principais doen&ccedil;as bucai
s    em popula&ccedil;&otilde;es rurais, o que dificulta o planejamento das inte
rven&ccedil;&otilde;es    em sa&uacute;de. A inexist&ecirc;ncia de informa&ccedi
l;&otilde;es anteriores    sobre essa condi&ccedil;&atilde;o na popula&ccedil;&a
tilde;o rural do Estado    impede a avalia&ccedil;&atilde;o de tend&ecirc;ncias 
na distribui&ccedil;&atilde;o    dos agravos.</font></p>     ^cY#02.htm##
00977000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704075400070002000700824#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#72#68#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O presente estudo    apresenta informa&cce
dil;&otilde;es epidemiol&oacute;gicas das &aacute;reas    rurais do Estado, ofer
ecendo subs&iacute;dios para o planejamento de interven&ccedil;&otilde;es    de 
sa&uacute;de bucal nos sistemas locais de sa&uacute;de, com o intuito de    cont
ribuir para a promo&ccedil;&atilde;o de eq&uuml;idade em sa&uacute;de. O    moni
toramento cont&iacute;nuo da experi&ecirc;ncia de c&aacute;rie no Pa&iacute;s   
 pode instruir o direcionamento de recursos adicionais para as &aacute;reas com 
   maiores necessidades, contribuindo, desse modo, para a implementa&ccedil;&ati
lde;o    de um servi&ccedil;o de sa&uacute;de socialmente apropriado.</font></p>
     ^cY#02.htm##
00442000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704021900070002000700289#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#73#69#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Agradecimentos.</b>    Projeto financia
do pelo Conselho Nacional de Desenvolvimento Cient&iacute;fico    e Tecnol&oacut
e;gico (CNPq).</font></p>     ^cY#02.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#74#70#article#107#<p>&nbsp;</p>     ^cY#02.
htm##
00330000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010700070002000700177#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#75#71#article#107#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>REFER&Ecirc;NCIAS</b></font></p>     ^c
Y#02.htm##
00547000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704031000072002000700382#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#p#76#72#article#107#1#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;1. Narvai    PC, Fraz&
atilde;o P, Castellanos RA. Decl&iacute;nio na experi&ecirc;ncia de    c&aacute;
rie em dentes permanentes de escolares brasileiros no final do s&eacute;culo    
XX. Odontol Soc. 1999;1(1/2):25&#150;9.</font></p>     ^cY#02.htm##
00539000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704030200072002000700374#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#p#77#73#article#107#2#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;2. Antunes    JLF, Fra
z&atilde;o P, Narvai PC, Bispo CM, Pegoretti T. Spatial analysis to    identify 
differentials in dental needs by area-based measures. Community Dent    Oral Epi
demiol. 2002;30(2):133&#150;42.</font></p>     ^cY#02.htm##
00532000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704029500072002000700367#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#p#78#74#article#107#3#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;3. Sathananthan    K, 
Vos T, Bango G. Dental caries, fluoride levels and oral hygiene practices    of 
school children in Matebeleland South, Zimbabwe. Community Dent Oral Epidemiol. 
   1996;24(1):21&#150;4.</font></p>     ^cY#02.htm##
00558000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704032100072002000700393#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#p#79#75#article#107#4#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;4. Antunes    JLF, Per
es MA, Mello TRC. Determinantes individuais e contextuais da necessidade    de t
ratamento odontol&oacute;gico na denti&ccedil;&atilde;o dec&iacute;dua no    Bra
sil. Cienc Saude Coletiva. 2006; 11(1):79&#150;87.</font></p>     ^cY#02.htm##
00680000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704044300072002000700515#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#p#80#76#article#107#5#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;5. Brasil,    Minist&e
acute;rio da Sa&uacute;de, Funda&ccedil;&atilde;o Nacional da Sa&uacute;de,    D
ATASUS. Indicadores socioecon&ocirc;micos. Dispon&iacute;vel em: <a href="http:/
/tabnet.datasus.gov.br/cgi/tabcgi.exe?idb2006/b01.def" target="_blank">http://ta
bnet.datasus.gov.br/cgi/tabcgi.exe?idb2006/b01.def</a>    Acessado em 20 de jane
iro de 2008.</font></p>     ^cY#02.htm##
00632000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704039500072002000700467#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#p#81#77#article#107#6#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;6. Universidade    de 
S&atilde;o Paulo, Faculdade de Sa&uacute;de P&uacute;blica, N&uacute;cleo    de 
Estudos e Pesquisas de Sistemas de Sa&uacute;de. Levantamento epidemiol&oacute;g
ico    em sa&uacute;de bucal: Estado de S&atilde;o Paulo, 1998. S&atilde;o Paulo
: Universidade    de S&atilde;o Paulo; 1999.</font></p>     ^cY#02.htm##
00424000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704018700072002000700259#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#p#82#78#article#107#7#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;7. World    Health Org
anization. Oral health surveys: basic methods. 4ª ed. Genebra: WHO;    1997.</fo
nt></p>     ^cY#02.htm##
00654000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704041700072002000700489#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#p#83#79#article#107#8#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;8. Peres    MA, Latorr
e MRDO, Sheiham A, Peres KGA, Barros FC, Hernandez PG, et al. Determinantes    s
ociais e biol&oacute;gicos da c&aacute;rie dent&aacute;ria em crian&ccedil;as   
 de 6 anos de idade: um estudo transversal aninhado numa coorte de nascidos vivo
s    no Sul do Brasil. Rev Bras Epidemiol. 2003;6(4):293&#150;304.</font></p>   
  ^cY#02.htm##
00595000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704035800072002000700430#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#p#84#80#article#107#9#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;9. Peres    MA, Narvai
 PC, Calvo MCM. Preval&ecirc;ncia de c&aacute;rie dent&aacute;ria    em crian&cc
edil;as aos doze anos de idade, em localidades do Estado de S&atilde;o    Paulo,
 Brasil, per&iacute;odo 1990&#150;1995. Rev Saude Publica. 1997;31(6):    594&#1
50;600.</font></p>     ^cY#02.htm##
00539000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704030100073002000700374#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#p#85#81#article#107#10#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">10. Traebert JL,    Peres M
A, Galesso ER, Zabot NE, Mercenes W. Preval&ecirc;ncia e severidade da    c&aacu
te;rie dent&aacute;ria em escolares de seis a doze anos de idade. Rev    Saude P
ublica. 2001;35(3): 283&#150;8.</font></p>     ^cY#02.htm##
00469000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704023100073002000700304#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#p#86#82#article#107#11#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">11. Snijders TAB,    Bosker
 RJ. Multilevel analysis: an introduction to basic and advanced multilevel    mo
deling. Londres: Sage Publications; 2003.</font></p>     ^cY#02.htm##
00458000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704022000073002000700293#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#p#87#83#article#107#12#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">12. Johnson RA,    Wichern 
DW. Applied multivariate statistical analysis. Upper Saddle River, Nova    J&eac
ute;rsei: Prentice Hall; 1998.</font></p>     ^cY#02.htm##
00506000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704026800073002000700341#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#p#88#84#article#107#13#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">13. Antunes JLF,    Peres M
A, Mello TRC, Waldman EA. Multilevel assessment of determinants of dental    car
ies experience in Brazil. Community Dent Oral Epidemiol. 2006;34: 146&#150;52.</
font></p>     ^cY#02.htm##
00585000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704034700073002000700420#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#p#89#85#article#107#14#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">14. Narvai PC,    Fraz&atil
de;o P, Roncalli AG, Antunes JLF. C&aacute;rie dent&aacute;ria no Brasil:    dec
l&iacute;nio, polariza&ccedil;&atilde;o, iniq&uuml;idade e exclus&atilde;o    so
cial. Rev Panam Salud Publica/Pan Am J Public Health. 2006;19(6):385&#150;93.</f
ont></p>     ^cY#02.htm##
00551000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704031300073002000700386#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#p#90#86#article#107#15#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">15. Petersen PE.    The wor
ld oral health report 2003: continuous improvement of oral health in    the 21st
 century&#151;the approach of the WHO Global Oral Health Programme.    Community
 Dent Oral Epidemiol. 2003;31(1):3&#150;24.</font></p>     ^cY#02.htm##
00529000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704029100073002000700364#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#p#91#87#article#107#16#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">16. Mello TRC,    Antunes J
LF. Preval&ecirc;ncia de c&aacute;rie dent&aacute;ria em escolares    da regi&at
ilde;o rural de Itapetininga, S&atilde;o Paulo, Brasil. Cad Saude    Publica. 20
04;20(3):829&#150;35.</font></p>     ^cY#02.htm##
00532000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704029400073002000700367#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#p#92#88#article#107#17#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">17. Abreu MHNG,    Pordeus 
IA, Modena CM. C&aacute;rie dent&aacute;ria entre escolares do meio    rural de 
Ita&uacute;na (MG), Brasil. Rev Panam Salud Publica/Pan Am J Public    Health. 2
004;16(50): 334&#150;43.</font></p>     ^cY#02.htm##
00507000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704026900073002000700342#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#p#93#89#article#107#18#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">18. Brindle R,    Wilkinson
 D, Harrison A, Connoly C, Cleaton-Jones P. Oral heath in Hlabisa,    KwaZulu/Na
tal: a rural school and community based survey. Int Dent J. 2000;50:13&#150;20.<
/font></p>     ^cY#02.htm##
00498000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704026000073002000700333#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#p#94#90#article#107#19#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">19. Blay D, Astrom    NA, H
augejorden O. Oral hygiene and sugar consumption among urban and rural    adoles
cents in Ghana. Community Dent Oral Epidemiol. 2000;28(6):443&#150;50.</font></p
>     ^cY#02.htm##
00613000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704037500073002000700448#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#p#95#91#article#107#20#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">20. Peres MA, Peres    KG, 
Antunes JLF, Junqueira SR, Fraz&atilde;o P, Narvai PC. The association between  
  socioeconomic development at the town level and the distribution of dental car
ies    in Brazilian children. Rev Panam Salud Publica/Pan Am J Public Health. 20
03;14(3):    149&#150;57.</font></p>     ^cY#02.htm##
00566000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704032800073002000700401#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#p#96#92#article#107#21#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">21. Pine CM, Adair    PM, B
urnside G, Nicoll AD, Gillett A, Borges-Yanez SA, et al. Barriers to the    trea
tment of childhood caries perceived by dentists working in different countries. 
   Community Dental Health. 2004;21(1 Suppl): 112&#150;20.</font></p>     ^cY#02
.htm##
00557000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704031900073002000700392#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#p#97#93#article#107#22#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">22. Antunes JLF,    Pegoret
ti T, Andrade FP, Junqueira SR, Fraz&atilde;o P, Narvai PC. Ethnic disparities  
  in the prevalence of dental caries and restorative dental treatment in Brazili
an    children. Int Dent J. 2003;53(1):7&#150;12.</font></p>     ^cY#02.htm##
00505000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704026700073002000700340#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#p#98#94#article#107#23#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">23. Maltz M, Silva    BB. R
ela&ccedil;&atilde;o entre c&aacute;rie, gengivite, fluorose e n&iacute;veis    
socioecon&ocirc;micos em escolares. Rev Saude Publica. 2001;32(2):170&#150;6.</f
ont></p>     ^cY#02.htm##
00539000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704030100073002000700374#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#p#99#95#article#107#24#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">24. Baldani MH,    Narvai P
C, Antunes JLF. C&aacute;rie dent&aacute;ria e condi&ccedil;&otilde;es    s&oacu
te;cio-econ&ocirc;micas no Estado do Paran&aacute;, Brasil, 1996. Cad    Saude P
ublica. 2002;18(3):755&#150;63.</font></p>     ^cY#02.htm##
00554000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000300071704031500074002000700389#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#p#100#96#article#107#25#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Frias AC, Antunes    J
LF, Junqueira SR, Narvai PC. Determinantes individuais e contextuais da preval&e
circ;ncia    de c&aacute;rie dent&aacute;ria n&atilde;o tratada no Brasil. Rev P
anam Salud    Publica 2007; 22(4): 279&#150;85</font></p>     ^cY#02.htm##
00567000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000300071704032800074002000700402#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#p#101#97#article#107#26#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Jones CM, Taylor    GO
, Whittle JG, Evans D, Trotter DP. Water fluoridation, tooth decay in 5 year    
olds and social deprivation measured by the Jarman score: analysis of data from 
   British dental surveys. BMJ. 1997;315(7107): 514&#150;7.</font></p>     ^cY#0
2.htm##
00416000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000300071704017700074002000700251#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#p#102#98#article#107#27#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Burt BA. Fluoridation 
   and social equity. J Public Health Dent. 2002;62(4):195&#150;200.</font></p> 
    ^cY#02.htm##
00551000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000300071704031200074002000700386#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#p#103#99#article#107#28#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Peres MA, Antunes    J
LF, Peres KG. Is water fluoridation effective in reducing inequalities in dental
    caries distribution in developing countries? Recent findings from Brazil. So
z    Preventiv Med. 2006;51(5):302&#150;10.</font></p>     ^cY#02.htm##
00559000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704031900075002000700394#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#p#104#100#article#107#29#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">29. Sampaio FC,    Hossai
n NA, Von der Fehr FR, Ameberg P. Dental caries and sugar intake of children    
from rural areas with different water fluoride levels in Paraiba, Brazil. Commun
ity    Dent Oral Epidemiol. 2000;28(4):307&#150;13.</font></p>     ^cY#02.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#105#101#article#107#<p>&nbsp;</p>     ^cY#0
2.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#106#102#article#107#<p>&nbsp;</p>     ^cY#0
2.htm##
00348000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704012300072002000700195#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#107#103#article#107#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Manuscrito recebido    em 8 de mar&ccedi
l;o de 2007.    ^cY#02.htm##
00312000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704008700072002000700159#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#108#104#article#107#<br>   Aceito em vers&a
tilde;o revisada em 12 de septembro de 2007.</font></p>     ^cY#02.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#109#105#article#107#<p>&nbsp;</p>     ^cY#0
2.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#110#106#article#107#<p>&nbsp;</p>     ^cY#0
2.htm##
00670000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704044500072002000700517#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\02.htm#S#p#111#107#article#107#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#top">*</a> 
   Correspond&ecirc;ncia: Rua Jos&eacute; Firmo Bernade 1591, Bairro Flor da Ser
ra,    CEP 89600-000, Joa&ccedil;aba, SC, Brasil. Fone: +55-49-3551.2112; fax: +
55-49-3551.2004;    e-mail: <a href="mailto:tatmello@usp.br">tatmello@usp.br</a>
, <a href="mailto:tatiana.mello@unoesc.edu.br">tatiana.mello@unoesc.    edu.br</
a></font></p>     ^cY#02.htm##
00577000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100017000710100016000880100
02200104012010600126030001200232710000200244065000900246064000500255031000200260
032000400262014000500266865000900271002000700280#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\02.htm#S#c#112#1#article#29#1#^rND^sNarvai^nPC#^rND^sFrazão^nP#^rND^sC
astellanos^nRA#Declínio na experiência de cárie em dentes permanentes de escolar
es brasileiros no final do século XX^lpt#Odontol Soc#2#19990000#1999#1#1/2#25-9#
20080200#02.htm##
00682000000000325000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100019000710100016000900100
01700106010001600123010001900139012008600158030003000244065000900274064000500283
03100030028803200020029101400070029386500090030000200070030903500100031680100300
0326#v23n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#c#113#2#article#29#2#^rND
^sAntunes^nJLF#^rND^sFrazão^nP#^rND^sNarvai^nPC#^rND^sBispo^nCM#^rND^sPegoretti^
nT#Spatial analysis to identify differentials in dental needs by area-based meas
ures^len#Community Dent Oral Epidemiol#20020000#2002#30#2#133-42#20080200#02.htm
#0301-5661#Community Dent Oral Epidemiol##
00600000000000265000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100022000710100013000930100
01500106012011300121030003000234065000900264064000500273865000900278002000700287
035001000294801003000304#v23n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#c#114
#3#article#29#3#^rND^sSathananthan^nK#^rND^sVos^nT#^rND^sBango^nG#Dental caries,
 fluoride levels and oral hygiene practices of school children in Matebeleland S
outh, Zimbabwe^len#Community Dent Oral Epidemiol#19960000#1996#20080200#02.htm#0
301-5661#Community Dent Oral Epidemiol##
00593000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100019000710100016000900100
01700106012011600123030002100239710000200260065000900262064000500271031000300276
032000200279014000600281865000900287002000700296#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\02.htm#S#c#115#4#article#29#4#^rND^sAntunes^nJLF#^rND^sPeres^nMA#^rND^
sMello^nTRC#Determinantes individuais e contextuais da necessidade de tratamento
 odontológico na dentição decídua no Brasil^lpt#Cienc Saude Coletiva#2#20060000#
2006#11#1#79-87#20080200#02.htm##
00493000000000217000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690170065000710180032001360370
06000168110000900228109002200237865000900259002000700268#v23n2#v:\scielo\serial\
rpsp\v23n2\markup\02.htm#S#c#116#5#article#29#5#Brasil^dMinistério da Saúde, Fun
dação Nacional da Saúde, DATASUS#Indicadores socioeconômicos^lpt#http://tabnet.d
atasus.gov.br/cgi/tabcgi.exe?idb2006/b01.def#20080120#20 de janeiro de 2008#2008
0200#02.htm##
00547000000000229000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690170106000710180074001770660
01000251062002600261065000900287064000500296865000900301002000700310#v23n2#v:\sc
ielo\serial\rpsp\v23n2\markup\02.htm#S#c#117#6#article#29#6#Universidade de São 
Paulo^dFaculdade de Saúde Pública, Núcleo de Estudos e Pesquisas de Sistemas de 
Saúde#Levantamento epidemiológico em saúde bucal: Estado de São Paulo, 1998^lpt#
São Paulo#Universidade de São Paulo#19990000#1999#20080200#02.htm##
00368000000000205000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690170026000710180039000970630
00200136066000800138865000900146002000700155#v23n2#v:\scielo\serial\rpsp\v23n2\m
arkup\02.htm#S#c#118#7#article#29#7#World Health Organization#Oral health survey
s: basic methods^len#4#Genebra#20080200#02.htm##
00752000000000337000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100016000710100020000870100
01700107010001700124010001700141010002000158810000600178012016700184030001900351
71000020037006500090037206400050038103100020038603200020038801400080039086500090
0398002000700407#v23n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#c#119#8#artic
le#29#8#^rND^sPeres^nMA#^rND^sLatorre^nMRDO#^rND^sSheiham^nA#^rND^sPeres^nKGA#^r
ND^sBarros^nFC#^rND^sHernandez^nPG#et al#Determinantes sociais e biológicos da c
árie dentária em crianças de 6 anos de idade: um estudo transversal aninhado num
a coorte de nascidos vivos no Sul do Brasil^lpt#Rev Bras Epidemiol#2#20030000#20
03#6#4#293-304#20080200#02.htm##
00647000000000301000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100016000710100017000870100
01700104012013500121030001800256065000900274064000500283031000300288032000200291
014000800293865000900301002000700310035001000317801001800327#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\02.htm#S#c#120#9#article#29#9#^rND^sPeres^nMA#^rND^sNarvai
^nPC#^rND^sCalvo^nMCM#Prevalência de cárie dentária em crianças aos doze anos de
 idade, em localidades do Estado de São Paulo, Brasil, período 1990-1995^lpt#Rev
 Saude Publica#19970000#1997#31#6#594-600#20080200#02.htm#0034-8910#Rev Saude Pu
blica##
00662000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100016000920100
01800108010001600126010001800142012008900160030001800249065000900267064000500276
03100030028103200020028401400060028686500090029200200070030103500100030880100180
0318#v23n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#c#121#10#article#29#10#^r
ND^sTraebert^nJL#^rND^sPeres^nMA#^rND^sGalesso^nER#^rND^sZabot^nNE#^rND^sMercene
s^nW#Prevalência e severidade da cárie dentária em escolares de seis a doze anos
 de idade^lpt#Rev Saude Publica#20010000#2001#35#3#283-8#20080200#02.htm#0034-89
10#Rev Saude Publica##
00491000000000241000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700160020000730160017000930180
08300110066000800193062001800201065000900219064000500228865000900233002000700242
#v23n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#c#122#11#article#29#11#^rND^s
Snijders^nTAB#^rND^sBosker^nRJ#Multilevel analysis: an introduction to basic and
 advanced multilevel modeling^len#Londres#Sage Publications#20030000#2003#200802
00#02.htm##
00473000000000241000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700160018000730160018000910180
04600109066003200155062001400187065000900201064000500210865000900215002000700224
#v23n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#c#123#12#article#29#12#^rND^s
Johnson^nRA#^rND^sWichern^nDW#Applied multivariate statistical analysis^len#Uppe
r Saddle River^eNova Jérsei#Prentice Hall#19980000#1998#20080200#02.htm##
00635000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100016000920100
01700108010001800125012008000143030003000223065000900253064000500262031000300267
014000700270865000900277002000700286035001000293801003000303#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\02.htm#S#c#124#13#article#29#13#^rND^sAntunes^nJLF#^rND^sP
eres^nMA#^rND^sMello^nTRC#^rND^sWaldman^nEA#Multilevel assessment of determinant
s of dental caries experience in Brazil^len#Community Dent Oral Epidemiol#200600
00#2006#34#146-52#20080200#02.htm#0301-5661#Community Dent Oral Epidemiol##
00619000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100016000900100
01900106010001900125012008200144030004700226710000200273065000900275064000500284
031000300289032000200292014000700294865000900301002000700310#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\02.htm#S#c#125#14#article#29#14#^rND^sNarvai^nPC#^rND^sFra
zão^nP#^rND^sRoncalli^nAG#^rND^sAntunes^nJLF#Cárie dentária no Brasil: declínio,
 polarização, iniqüidade e exclusão social^lpt#Rev Panam Salud Publica/Pan Am J 
Public Health#2#20060000#2006#19#6#385-93#20080200#02.htm##
00630000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730120150000920300
03000242065000900272064000500281031000300286032000200289014000500291865000900296
002000700305035001000312801003000322#v23n2#v:\scielo\serial\rpsp\v23n2\markup\02
.htm#S#c#126#15#article#29#15#^rND^sPetersen^nPE#The world oral health report 20
03: continuous improvement of oral health in the 21st century-the approach of th
e WHO Global Oral Health Programme^len#Community Dent Oral Epidemiol#20030000#20
03#31#1#3-24#20080200#02.htm#0301-5661#Community Dent Oral Epidemiol##
00585000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100019000900120
09800109030001800207065000900225064000500234031000300239032000200242014000700244
865000900251002000700260035001000267801001800277#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\02.htm#S#c#127#16#article#29#16#^rND^sMello^nTRC#^rND^sAntunes^nJLF#Pr
evalência de cárie dentária em escolares da região rural de Itapetininga, São Pa
ulo, Brasil^lpt#Cad Saude Publica#20040000#2004#20#3#829-35#20080200#02.htm#0102
-311X#Cad Saude Publica##
00580000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100018000910100
01700109012007200126030004700198710000200245065000900247064000500256031000300261
032000300264014000700267865000900274002000700283#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\02.htm#S#c#128#17#article#29#17#^rND^sAbreu^nMHNG#^rND^sPordeus^nIA#^r
ND^sModena^nCM#Cárie dentária entre escolares do meio rural de Itaúna (MG), Bras
il^lpt#Rev Panam Salud Publica/Pan Am J Public Health#2#20040000#2004#16#50#334-
43#20080200#02.htm##
00636000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100019000900100
01800109010001700127010002300144012008400167030001100251065000900262064000500271
031000300276014000600279865000900285002000700294035001000301801001100311#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\02.htm#S#c#129#18#article#29#18#^rND^sBrindle^
nR#^rND^sWilkinson^nD#^rND^sHarrison^nA#^rND^sConnoly^nC#^rND^sCleaton-Jones^nP#
Oral heath in Hlabisa, KwaZulu/Natal: a rural school and community based survey^
len#Int Dent J#20000000#2000#50#13-20#20080200#02.htm#0020-6539#Int Dent J##
00621000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100014000730100017000870100
02100104012008200125030003000207065000900237064000500246031000300251032000200254
014000700256865000900263002000700272035001000279801003000289#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\02.htm#S#c#130#19#article#29#19#^rND^sBlay^nD#^rND^sAstrom
^nNA#^rND^sHaugejorden^nO#Oral hygiene and sugar consumption among urban and rur
al adolescents in Ghana^len#Community Dent Oral Epidemiol#20000000#2000#28#6#443
-50#20080200#02.htm#0301-5661#Community Dent Oral Epidemiol##
00726000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100016000890100
01900105010002000124010001600144010001700160012013200177030004700309710000200356
06500090035806400050036703100030037203200020037501400070037786500090038400200070
0393#v23n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#c#131#20#article#29#20#^r
ND^sPeres^nMA#^rND^sPeres^nKG#^rND^sAntunes^nJLF#^rND^sJunqueira^nSR#^rND^sFrazã
o^nP#^rND^sNarvai^nPC#The association between socioeconomic development at the t
own level and the distribution of dental caries in Brazilian children^len#Rev Pa
nam Salud Publica/Pan Am J Public Health#2#20030000#2003#14#3#149-57#20080200#02
.htm##
00740000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100016000880100
01800104010001700122010001700139010002300156810000600179012010300185030002400288
06500090031206400050032103100030032603200040032901400070033386500090034000200070
0349035001000356801002400366#v23n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#c
#132#21#article#29#21#^rND^sPine^nCM#^rND^sAdair^nPM#^rND^sBurnside^nG#^rND^sNic
oll^nAD#^rND^sGillett^nA#^rND^sBorges-Yanez^nSA#et al#Barriers to the treatment 
of childhood caries perceived by dentists working in different countries^len#Com
munity Dental Health#20040000#2004#21#^s1#112-20#20080200#02.htm#0265-539X#Commu
nity Dental Health##
00705000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100019000920100
01800111010002000129010001600149010001700165012011300182030001100295065000900306
06400050031503100030032003200020032301400050032586500090033000200070033903500100
0346801001100356#v23n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#c#133#22#arti
cle#29#22#^rND^sAntunes^nJLF#^rND^sPegoretti^nT#^rND^sAndrade^nFP#^rND^sJunqueir
a^nSR#^rND^sFrazão^nP#^rND^sNarvai^nPC#Ethnic disparities in the prevalence of d
ental caries and restorative dental treatment in Brazilian children^len#Int Dent
 J#20030000#2003#53#1#7-12#20080200#02.htm#0020-6539#Int Dent J##
00564000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100016000880120
08300104030001800187065000900205064000500214031000300219032000200222014000600224
865000900230002000700239035001000246801001800256#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\02.htm#S#c#134#23#article#29#23#^rND^sMaltz^nM#^rND^sSilva^nBB#Relação
 entre cárie, gengivite, fluorose e níveis socioeconômicos em escolares^lpt#Rev 
Saude Publica#20010000#2001#32#2#170-6#20080200#02.htm#0034-8910#Rev Saude Publi
ca##
00599000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100017000910100
01900108012008200127030001800209065000900227064000500236031000300241032000200244
014000700246865000900253002000700262035001000269801001800279#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\02.htm#S#c#135#24#article#29#24#^rND^sBaldani^nMH#^rND^sNa
rvai^nPC#^rND^sAntunes^nJLF#Cárie dentária e condições sócio-econômicas no Estad
o do Paraná, Brasil, 1996^lpt#Cad Saude Publica#20020000#2002#18#3#755-63#200802
00#02.htm#0102-311X#Cad Saude Publica##
00658000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100019000890100
02000108010001700128012009900145030002400244065000900268064000500277031000300282
032000200285014000700287865000900294002000700303035001000310801002400320#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\02.htm#S#c#136#25#article#29#25#^rND^sFrias^nA
C#^rND^sAntunes^nJLF#^rND^sJunqueira^nSR#^rND^sNarvai^nPC#Determinantes individu
ais e contextuais da prevalência de cárie dentária não tratada no Brasil^lpt#Rev
 Panam Salud Publica#20070000#2007#22#4#279-85#20080200#02.htm#1020-4989#Rev Pan
am Salud Publica##
00695000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100017000890100
01800106010001500124010001800139012014900157030000400306065000900310064000500319
03100040032403200050032801400060033386500090033900200070034803500100035580100040
0365#v23n2#v:\scielo\serial\rpsp\v23n2\markup\02.htm#S#c#137#26#article#29#26#^r
ND^sJones^nCM#^rND^sTaylor^nGO#^rND^sWhittle^nJG#^rND^sEvans^nD#^rND^sTrotter^nD
P#Water fluoridation, tooth decay in 5 year olds and social deprivation measured
 by the Jarman score: analysis of data from British dental surveys^len#BMJ#19970
000#1997#315#7107#514-7#20080200#02.htm#0959-8138#BMJ##
00496000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730120035000880300
02100123065000900144064000500153031000300158032000200161014000800163865000900171
002000700180035001000187801002100197#v23n2#v:\scielo\serial\rpsp\v23n2\markup\02
.htm#S#c#138#27#article#29#27#^rND^sBurt^nBA#Fluoridation and social equity^len#
J Public Health Dent#20020000#2002#62#4#195-200#20080200#02.htm#0022-4006#J Publ
ic Health Dent##
00621000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100019000890100
01600108012014500124030001800269710000200287065000900289064000500298031000300303
032000200306014000700308865000900315002000700324#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\02.htm#S#c#139#28#article#29#28#^rND^sPeres^nMA#^rND^sAntunes^nJLF#^rN
D^sPeres^nKG#Is water fluoridation effective in reducing inequalities in dental 
caries distribution in developing countries?: Recent findings from Brazil^len#So
z Preventiv Med#2#20060000#2006#51#5#302-10#20080200#02.htm##
00695000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100018000910100
02300109010001700132012012000149030003000269065000900299064000500308031000300313
032000200316014000700318865000900325002000700334035001000341801003000351#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\02.htm#S#c#140#29#article#29#29#^rND^sSampaio^
nFC#^rND^sHossain^nNA#^rND^sVon der Fehr^nFR#^rND^sAmeberg^nP#Dental caries and 
sugar intake of children from rural areas with different water fluoride levels i
n Paraiba, Brazil^len#Community Dent Oral Epidemiol#20000000#2000#28#4#307-13#20
080200#02.htm#0301-5661#Community Dent Oral Epidemiol##
00263000000000169000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640910009000660920007000750020007000827030
00400089#v23n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#o#1#1#article#1#20080
318#103132#03.htm#169##
04849000000000697000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000400084121000300088049000800091158000300099030002400102
03100030012603200020012906500090013101400090014003500100014901201260015901201390
02850100030004240100027004540100030004810100030005110100029005410100036005700100
02900606070009200635070007900727070011000806070007800916083125300994085000802247
08500300225508500330228508500210231808500200233908500200235908315850237908500080
39640850030039720850033040020850028040350850020040631170006040830720003040891120
00904092111001704101114000904118113001704127002000704144#v23n2#v:\scielo\serial\
rpsp\v23n2\markup\03.htm#S#h#2#1#article#1#oa#en#br1.1#1#3.1#TAB#03#RPSP020#nd#R
ev Panam Salud Publica#23#2#20080200#^f85^l91#1020-4989#The burden of gestationa
l diabetes mellitus in Jamaican women with a family history of autosomal dominan
t type 2 diabetes^len#La carga de la diabetes mellitus gestacional en mujeres de
 Jamaica con antecedentes familiares de diabetes autosómica dominante tipo 2^les
#^rND^1A01^nRachael R.^sIrving#^rND^1A01^nJames L.^sMills#^rND^1A02^nEric G.^sCh
oo-Kang#^rND^1A01^nErrol Y.^sMorrison#^rND^1A03^nSantosh^sKulkarni#^rND^1A04^nRo
semarie^sWright-Pascoe#^rND^1A01^nWayne^sMclaughlin#University of the West Indie
s^iA01^1Department of Basic Medical Sciences^cKingston^pJamaica#University of th
e West Indies^iA02^1Department of Pathology^cKingston^pJamaica#University of the
 West Indies^iA03^1Department of Gynaecology, Obstetrics and Child Health^cKings
ton^pJamaica#University of the West Indies^iA04^1Department of Medicine^cKingsto
n^pJamaica#^len^aOBJECTIVES: To determine if Jamaican women of African descent w
ith a family history of early onset autosomal dominant type 2 diabetes have grea
ter odds of developing gestational diabetes mellitus (GDM) than those without a 
family history of the disease. METHODS: A comparative study was conducted of two
 groups of pregnant Jamaican women: the first with a family history of early ons
et autosomal dominant type 2 diabetes; the second with no history of the disease
. Incidence, odds for developing GDM, and metabolic profiles in first and second
 trimesters were assessed using SPSS 11.5 (SPSS Inc., Chicago, Illinois, United 
States). RESULTS: The incidence of GDM was 12.0 % in women with a family history
 of early onset autosomal dominant type 2 diabetes and 1.5% in women without a f
amily history of the disease (P < 0.05). Women with a family history were nine t
imes more likely to develop GDM than those without a family history of diabetes 
(95% confidence interval: 5.00-16.38, P < 0.0001). CONCLUSION: Family history of
 early onset autosomal dominant type 2 diabetes appears to increase susceptibili
ty to GDM in Jamaican women. Pregnant women of any age with family history of ea
rly onset autosomal type 2 diabetes should be screened for GDM.#^dnd^i1#^tm^len^
kDiabetes mellitus^i1#^tm^len^kdiabetes gestational^i1#^tm^len^kgenetics^i1#^tm^
len^kmedical^i1#^tm^len^kJamaica^i1#^les^aOBJETIVOS: Determinar si las mujeres j
amaicanas de ascendencia africana con antecedentes familiares de inicio temprano
 de diabetes autosómica dominante tipo 2 tienen mayor probabilidad de desarrolla
r diabetes mellitus gestacional (DMG) que las que no tienen esos antecedentes fa
miliares. MÉTODOS: Se realizó un estudio comparativo con dos grupos de mujeres j
amaicanas embarazadas: el primero con mujeres que tenían antecedentes familiares
 de inicio temprano de diabetes autosómica dominante tipo 2 y el segundo con muj
eres sin antecedentes familiares de esa enfermedad. Se empleó el programa SPSS v
. 11.5 (SPSS Inc., Chicago, Illinois, Estados Unidos de América) para analizar l
os resultados y calcular la incidencia, la probabilidad de desarrollar DMG y los
 perfiles metabólicos en el primer y el segundo trimestres de gestación. RESULTA
DOS: La incidencia de DMG fue de 12,0% en las mujeres con antecedentes familiare
s de inicio temprano de diabetes autosómica dominante tipo 2 y de 1,5% en las mu
jeres sin antecedentes familiares de esa enfermedad (P < 0,05). Las mujeres del 
primer grupo tuvieron nueve veces más probabilidades de desarrollar DMG que las 
del segundo grupo (intervalo de confianza de 95%: 5,00 a 16,38; P < 0,0001). CON
CLUSIÓN: Los antecedentes familiares de inicio temprano de diabetes autosómica d
ominante tipo 2 aumentaron la predisposición a sufrir DMG en mujeres jamaicanas.
 Las mujeres embarazadas con antecedentes familiares de inicio temprano de diabe
tes autosómica tipo 2 deben someterse a pruebas de tamizaje para DMG, independie
ntemente de su edad.#^dnd^i2#^tm^les^kDiabetes mellitus^i2#^tm^les^kdiabetes ges
tacional^i2#^tm^les^kgenética médica^i2#^tm^les^kJamaica^i2#other#42#20061125#25
 November 2006#20071123#23 November 2007#03.htm##
04965000000000697000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000400084121000300088049000800091158000300099030002400102
03100030012603200020012906500090013101400090014003500100014901201330015901201460
02920100030004380100027004680100030004950100030005250100029005550100036005840100
02900620070009200649070007900741070011000820070007800930083130201008085000802310
08500300231808500330234808500210238108500200240208500200242208316380244208500080
40800850030040880850033041180850028041510850020041791170006041990720003042051120
00904208111001704217114000904234113001704243002000704260#v23n2#v:\scielo\serial\
rpsp\v23n2\markup\03.htm#S#f#3#1#article#1#oa#en#br1.1#1#3.1#TAB#03#RPSP020#nd#R
ev Panam Salud Publica#23#2#20080200#^f85^l91#1020-4989#<B>The burden of gestati
onal diabetes mellitus in Jamaican women with a family history of autosomal domi
nant type 2 diabetes</B>^len#<B>La carga de la diabetes mellitus gestacional en 
mujeres de Jamaica con antecedentes familiares de diabetes autosómica dominante 
tipo 2</B>^les#^rND^1A01^nRachael R.^sIrving#^rND^1A01^nJames L.^sMills#^rND^1A0
2^nEric G.^sChoo-Kang#^rND^1A01^nErrol Y.^sMorrison#^rND^1A03^nSantosh^sKulkarni
#^rND^1A04^nRosemarie^sWright-Pascoe#^rND^1A01^nWayne^sMclaughlin#University of 
the West Indies^iA01^1Department of Basic Medical Sciences^cKingston^pJamaica#Un
iversity of the West Indies^iA02^1Department of Pathology^cKingston^pJamaica#Uni
versity of the West Indies^iA03^1Department of Gynaecology, Obstetrics and Child
 Health^cKingston^pJamaica#University of the West Indies^iA04^1Department of Med
icine^cKingston^pJamaica#^len^a<B>OBJECTIVES:</B>&nbsp;To determine if Jamaican 
women of African descent with a family history of early onset autosomal dominant
 type 2 diabetes have greater odds of developing gestational diabetes mellitus (
GDM) than those without a family history of the disease. <B>METHODS:</B>&nbsp;A 
comparative study was conducted of two groups of pregnant Jamaican women: the fi
rst with a family history of early onset autosomal dominant type 2 diabetes; the
 second with no history of the disease. Incidence, odds for developing GDM, and 
metabolic profiles in first and second trimesters were assessed using SPSS 11.5 
(SPSS Inc., Chicago, Illinois, United States). <B>RESULTS: </B>The incidence of 
GDM was 12.0 % in women with a family history of early onset autosomal dominant 
type 2 diabetes and 1.5% in women without a family history of the disease (P &lt
; 0.05). Women with a family history were nine times more likely to develop GDM 
than those without a family history of diabetes (95% confidence interval: 5.00-1
6.38, P &lt; 0.0001). <B>CONCLUSION:</B>&nbsp;Family history of early onset auto
somal dominant type 2 diabetes appears to increase susceptibility to GDM in Jama
ican women. Pregnant women of any age with family history of early onset autosom
al type 2 diabetes should be screened for GDM.#^dnd^i1#^tm^len^kDiabetes mellitu
s^i1#^tm^len^kdiabetes gestational^i1#^tm^len^kgenetics^i1#^tm^len^kmedical^i1#^
tm^len^kJamaica^i1#^les^a<B>OBJETIVOS:</B> Determinar si las mujeres jamaicanas 
de ascendencia africana con antecedentes familiares de inicio temprano de diabet
es autosómica dominante tipo 2 tienen mayor probabilidad de desarrollar diabetes
 mellitus gestacional (DMG) que las que no tienen esos antecedentes familiares. 
<B>MÉTODOS: </B>Se realizó un estudio comparativo con dos grupos de mujeres jama
icanas embarazadas: el primero con mujeres que tenían antecedentes familiares de
 inicio temprano de diabetes autosómica dominante tipo 2 y el segundo con mujere
s sin antecedentes familiares de esa enfermedad. Se empleó el programa SPSS v. 1
1.5 (SPSS Inc., Chicago, Illinois, Estados Unidos de América) para analizar los 
resultados y calcular la incidencia, la probabilidad de desarrollar DMG y los pe
rfiles metabólicos en el primer y el segundo trimestres de gestación. <B>RESULTA
DOS: </B>La incidencia de DMG fue de 12,0% en las mujeres con antecedentes famil
iares de inicio temprano de diabetes autosómica dominante tipo 2 y de 1,5% en la
s mujeres sin antecedentes familiares de esa enfermedad (<I>P</I> &lt; 0,05). La
s mujeres del primer grupo tuvieron nueve veces más probabilidades de desarrolla
r DMG que las del segundo grupo (intervalo de confianza de 95%: 5,00 a 16,38; <I
>P</I> &lt; 0,0001). <B>CONCLUSIÓN:</B>&nbsp;Los antecedentes familiares de inic
io temprano de diabetes autosómica dominante tipo 2 aumentaron la predisposición
 a sufrir DMG en mujeres jamaicanas. Las mujeres embarazadas con antecedentes fa
miliares de inicio temprano de diabetes autosómica tipo 2 deben someterse a prue
bas de tamizaje para DMG, independientemente de su edad.#^dnd^i2#^tm^les^kDiabet
es mellitus^i2#^tm^les^kdiabetes gestacional^i2#^tm^les^kgenética médica^i2#^tm^
les^kJamaica^i2#other#42#20061125#25 November 2006#20071123#23 November 2007#03.
htm##
05035000000000721000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640640013000660710003000790400003000820010
00600085042000200091120000400093038000400097121000300101049000800104158000300112
03000260011503100030014103200020014406500090014601400090015503500100016401201260
01740120139003000100029004390100026004680100029004940100029005230100029005520100
03600581010002900617070009400646070008100740070011200821070008000933083127401013
08500080228708500300229508500330232508500210235808500200237908500200239908316150
24190850008040340850030040420850033040720850028041050850020041331170006041530720
00304159112000904162111001704171114000904188113001704197002000704214008009204221
#v23n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#l#4#1#article#1#^mFeb.^a2008#
oa#en#br1.1#1#3.1#tab#03#RPSP020#nd#Rev. panam. salud pública#23#2#20080200#^f85
^l91#1020-4989#The burden of gestational diabetes mellitus in Jamaican women wit
h a family history of autosomal dominant type 2 diabetes^len#La carga de la diab
etes mellitus gestacional en mujeres de Jamaica con antecedentes familiares de d
iabetes autosómica dominante tipo 2^les#^rND^1A01^nRachael R^sIrving#^rND^1A01^n
James L^sMills#^rND^1A02^nEric G^sChoo-Kang#^rND^1A01^nErrol Y^sMorrison#^rND^1A
03^nSantosh^sKulkarni#^rND^1A04^nRosemarie^sWright-Pascoe#^rND^1A01^nWayne^sMcla
ughlin#^iA01^1University of the West Indies^2Department of Basic Medical Science
s^cKingston^pJamaica#^iA02^1University of the West Indies^2Department of Patholo
gy^cKingston^pJamaica#^iA03^1University of the West Indies^2Department of Gynaec
ology, Obstetrics and Child Health^cKingston^pJamaica#^iA04^1University of the W
est Indies^2Department of Medicine^cKingston^pJamaica#^len^aOBJECTIVES: To deter
mine if Jamaican women of African descent with a family history of early onset a
utosomal dominant type 2 diabetes have greater odds of developing gestational di
abetes mellitus (GDM) than those without a family history of the disease. METHOD
S: A comparative study was conducted of two groups of pregnant Jamaican women: t
he first with a family history of early onset autosomal dominant type 2 diabetes
; the second with no history of the disease. Incidence, odds for developing GDM,
 and metabolic profiles in first and second trimesters were assessed using SPSS 
11.5 (SPSS Inc., Chicago, Illinois, United States). RESULTS: The incidence of GD
M was 12.0  percent in women with a family history of early onset autosomal domi
nant type 2 diabetes and 1.5 percent in women without a family history of the di
sease (P < 0.05). Women with a family history were nine times more likely to dev
elop GDM than those without a family history of diabetes (95 percent confidence 
interval: 5.00-16.38, P < 0.0001). CONCLUSION: Family history of early onset aut
osomal dominant type 2 diabetes appears to increase susceptibility to GDM in Jam
aican women. Pregnant women of any age with family history of early onset autoso
mal type 2 diabetes should be screened for GDM.#^dnd^i1#^tm^len^kDiabetes mellit
us^i1#^tm^len^kdiabetes gestational^i1#^tm^len^kgenetics^i1#^tm^len^kmedical^i1#
^tm^len^kJamaica^i1#^les^aOBJETIVOS: Determinar si las mujeres jamaicanas de asc
endencia africana con antecedentes familiares de inicio temprano de diabetes aut
osómica dominante tipo 2 tienen mayor probabilidad de desarrollar diabetes melli
tus gestacional (DMG) que las que no tienen esos antecedentes familiares. MÉTODO
S: Se realizó un estudio comparativo con dos grupos de mujeres jamaicanas embara
zadas: el primero con mujeres que tenían antecedentes familiares de inicio tempr
ano de diabetes autosómica dominante tipo 2 y el segundo con mujeres sin anteced
entes familiares de esa enfermedad. Se empleó el programa SPSS v. 11.5 (SPSS Inc
., Chicago, Illinois, Estados Unidos de América) para analizar los resultados y 
calcular la incidencia, la probabilidad de desarrollar DMG y los perfiles metabó
licos en el primer y el segundo trimestres de gestación. RESULTADOS: La incidenc
ia de DMG fue de 12,0 por ciento en las mujeres con antecedentes familiares de i
nicio temprano de diabetes autosómica dominante tipo 2 y de 1,5 por ciento en la
s mujeres sin antecedentes familiares de esa enfermedad (P < 0,05). Las mujeres 
del primer grupo tuvieron nueve veces más probabilidades de desarrollar DMG que 
las del segundo grupo (intervalo de confianza de 95 por ciento: 5,00 a 16,38; P 
< 0,0001). CONCLUSIÓN: Los antecedentes familiares de inicio temprano de diabete
s autosómica dominante tipo 2 aumentaron la predisposición a sufrir DMG en mujer
es jamaicanas. Las mujeres embarazadas con antecedentes familiares de inicio tem
prano de diabetes autosómica tipo 2 deben someterse a pruebas de tamizaje para D
MG, independientemente de su edad.#^dnd^i2#^tm^les^kDiabetes mellitus^i2#^tm^les
^kdiabetes gestacional^i2#^tm^les^kgenética médica^i2#^tm^les^kJamaica^i2#other#
42#20061125#25 November 2006#20071123#23 November 2007#03.htm#Internet^ihttp://w
ww.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892008000200003##
00375000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704015400068002000700222#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#5#1#article#123#<p align="right"><font face
="Verdana, Arial, Helvetica, sans-serif" size="2"><b>INVESTIGACI&Oacute;N    ORI
GINAL</b> ORIGINAL RESEARCH</font></p>     ^cY#03.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704002200068002000700090#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#6#2#article#123#<p>&nbsp;</p>     ^cY#03.ht
m##
00456000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704023500068002000700303#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#7#3#article#123#<p><a name="top"></a><font 
face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>The    burden of gestat
ional diabetes mellitus in Jamaican women with a family history    of autosomal 
dominant type 2 diabetes</b></font></p>     ^cY#03.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704002200068002000700090#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#8#4#article#123#<p>&nbsp;</p>     ^cY#03.ht
m##
00458000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704023700068002000700305#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#9#5#article#123#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="3"><b>La carga de    la diabetes mellitus gesta
cional en mujeres de Jamaica con antecedentes familiares    de diabetes autos&oa
cute;mica dominante tipo 2</b></font></p>     ^cY#03.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#10#6#article#123#<p>&nbsp;</p>     ^cY#03.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#11#7#article#123#<p>&nbsp;</p>     ^cY#03.h
tm##
00564000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704034200069002000700411#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#12#8#article#123#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Rachael R. Irving<sup>I,    <a href="#ba
ck">*</a></sup>; James L. Mills<sup>I</sup>; Eric G. Choo-Kang<sup>II</sup>;    
Errol Y. Morrison<sup>I</sup>; Santosh Kulkarni<sup>III</sup>; Rosemarie Wright-
Pascoe<sup>IV</sup>;    Wayne Mclaughlin<sup>I</sup></b></font></p>     ^cY#03.h
tm##
00394000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704017200069002000700241#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#13#9#article#123#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><sup>I</sup>Department    of Basic Medical 
Sciences, University of the West Indies, Kingston, Jamaica    ^cY#03.htm##
00327000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010400070002000700174#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#14#10#article#123#<br>   <sup>II</sup>Depar
tment of Pathology, University of the West Indies, Kingston,    Jamaica    ^cY#0
3.htm##
00359000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704013600070002000700206#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#15#11#article#123#<br>   <sup>III</sup>Depa
rtment of Gynaecology, Obstetrics and Child Health, University    of the West In
dies, Kingston, Jamaica    ^cY#03.htm##
00338000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704011500070002000700185#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#16#12#article#123#<br>   <sup>IV</sup>Depar
tment of Medicine, University of the West Indies, Kingston,    Jamaica</font></p
>     ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#17#13#article#123#<p>&nbsp;</p>     ^cY#03.
htm##
00267000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704004400070002000700114#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#18#14#article#123#<p>&nbsp;</p> <hr size="1
" noshade>     ^cY#03.htm##
00321000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009800070002000700168#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#19#15#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     ^cY#03.htm#
#
00568000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704034500070002000700415#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#20#16#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>OBJECTIVES:</b>&nbsp;To    determine if
 Jamaican women of African descent with a family history of early    onset autos
omal dominant type 2 diabetes have greater odds of developing gestational    dia
betes mellitus (GDM) than those without a family history of the disease.    ^cY#
03.htm##
00639000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704041600070002000700486#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#21#17#article#123#<br>   <b>METHODS:</b>&nb
sp;A comparative study was conducted of two groups of pregnant    Jamaican women
: the first with a family history of early onset autosomal dominant    type 2 di
abetes; the second with no history of the disease. Incidence, odds    for develo
ping GDM, and metabolic profiles in first and second trimesters were    assessed
 using SPSS 11.5 (SPSS Inc., Chicago, Illinois, United States).    ^cY#03.htm##
00630000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704040700070002000700477#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#22#18#article#123#<br>   <b>RESULTS: </b> T
he incidence of GDM was 12.0 % in women with a family history    of early onset 
autosomal dominant type 2 diabetes and 1.5% in women without    a family history
 of the disease (P &lt; 0.05). Women with a family history were    nine times mo
re likely to develop GDM than those without a family history of    diabetes (95%
 confidence interval: 5.00&#150;16.38, P &lt; 0.0001).    ^cY#03.htm##
00523000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704030000070002000700370#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#23#19#article#123#<br>   <b>CONCLUSION:</b>
&nbsp;Family history of early onset autosomal dominant type    2 diabetes appear
s to increase susceptibility to GDM in Jamaican women. Pregnant    women of any 
age with family history of early onset autosomal type 2 diabetes    should be sc
reened for GDM.</font></p>     ^cY#03.htm##
00417000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704019400070002000700264#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#24#20#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Key words:</b>    Diabetes mellitus; di
abetes gestational; genetics, medical; Jamaica.</font></p> <hr size="1" noshade>
     ^cY#03.htm##
00320000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009700070002000700167#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#25#21#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>RESUMEN</b></font></p>     ^cY#03.htm##
00607000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704038400070002000700454#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#26#22#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>OBJETIVOS:</b>    Determinar si las muj
eres jamaicanas de ascendencia africana con antecedentes    familiares de inicio
 temprano de diabetes autos&oacute;mica dominante tipo 2    tienen mayor probabi
lidad de desarrollar diabetes mellitus gestacional (DMG)    que las que no tiene
n esos antecedentes familiares.    ^cY#03.htm##
00865000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704064200070002000700712#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#27#23#article#123#<br>   <b>M&Eacute;TODOS:
 </b> Se realiz&oacute; un estudio comparativo con dos grupos    de mujeres jama
icanas embarazadas: el primero con mujeres que ten&iacute;an    antecedentes fam
iliares de inicio temprano de diabetes autos&oacute;mica dominante    tipo 2 y e
l segundo con mujeres sin antecedentes familiares de esa enfermedad.    Se emple
&oacute; el programa SPSS v. 11.5 (SPSS Inc., Chicago, Illinois, Estados    Unid
os de Am&eacute;rica) para analizar los resultados y calcular la incidencia,    
la probabilidad de desarrollar DMG y los perfiles metab&oacute;licos en el prime
r    y el segundo trimestres de gestaci&oacute;n.    ^cY#03.htm##
00698000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704047500070002000700545#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#28#24#article#123#<br>   <b>RESULTADOS: </b
> La incidencia de DMG fue de 12,0% en las mujeres con antecedentes    familiare
s de inicio temprano de diabetes autos&oacute;mica dominante tipo 2    y de 1,5%
 en las mujeres sin antecedentes familiares de esa enfermedad (<i>P</i>    &lt; 
0,05). Las mujeres del primer grupo tuvieron nueve veces m&aacute;s probabilidad
es    de desarrollar DMG que las del segundo grupo (intervalo de confianza de 95
%:    5,00 a 16,38; <i>P</i> &lt; 0,0001).    ^cY#03.htm##
00645000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704042200070002000700492#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#29#25#article#123#<br>   <b>CONCLUSI&Oacute
;N:</b>&nbsp;Los antecedentes familiares de inicio temprano    de diabetes autos
&oacute;mica dominante tipo 2 aumentaron la predisposici&oacute;n    a sufrir DM
G en mujeres jamaicanas. Las mujeres embarazadas con antecedentes    familiares 
de inicio temprano de diabetes autos&oacute;mica tipo 2 deben someterse    a pru
ebas de tamizaje para DMG, independientemente de su edad.</font></p>     ^cY#03.
htm##
00438000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704021500070002000700285#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#30#26#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Palabras clave:    </b> Diabetes mellit
us, diabetes gestacional, gen&eacute;tica m&eacute;dica,    Jamaica.</font></p> 
<hr size="1" noshade>     ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#31#27#article#123#<p>&nbsp;</p>     ^cY#03.
htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#32#28#article#123#<p>&nbsp;</p>     ^cY#03.
htm##
01730000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704150700070002000701577#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#33#29#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Atypical diabetes    seen as an autosomal 
dominant transmitted disorder is an emerging epidemic among    African Americans
 (1). Families with early onset autosomal dominant type 2 diabetes    can be def
ined as those with two or more first-degree relatives with type 2    diabetes di
agnosed before age 35 years, three or more generations affected by    diabetes, 
and diabetes inherited in an autosomal dominant fashion (2). <font face="Symbol"
>b</font>    cell dysfunction is a common feature of autosomal dominant diabetes
 (2&#150;3).    A distinct form of early onset autosomal dominant type 2 diabete
s is called    Maturity Onset Diabetes of Youth (MODY) and is characterized by a
 pure insulin    secretory defect, rather than impairment of insulin sensitivity
 as is seen in    common early onset autosomal dominant type 2 diabetes (2&#150;
3). MODY is mainly    a disease of Caucasians (3). Genetic defects in six genes 
are known to cause    MODY: the hepatocyte nuclear factor-4<font face="Symbol">a
</font>: HNF-4<font face="Symbol">a</font>/(MODY1);    glucokinase: GCK/(MODY2);
 the hepatocyte nuclear factor-1<font face="Symbol">a</font>:    HNF-1<font face
="Symbol">a</font>/(MODY3); insulin promoter factor-1: IPFl/    (MODY4); hepatoc
yte nuclear factor-1<font face="Symbol">b</font>: HNF-1<font face="Symbol">b</fo
nt>/(MODY5);    and transcriptional factor, neurogenic differentiation1: Neuro-D
1/(MODY 6) (3&#150;5).</font></p>     ^cY#03.htm##
01385000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704116200070002000701232#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#34#30#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Family history    is one of the determinin
g factors of early onset autosomal dominant type 2 diabetes    and is also seen 
in the reports of GDM around the globe (6&#150;8). In population    surveys, the
 prevalence of the disease among relatives of patients with diabetes    has been
 reported as being 4&#150;10 times greater than in controls (9). In    addition,
 emerging data is increasingly showing an association between ethnicity    and t
ype 2 diabetes (1). There is an increasing presence of early onset type    2 dia
betes not linked to MODY 1&#150;6 in African Americans, this type of diabetes   
 is often termed atypical (1). Like GDM, this type of diabetes is frequently    
characterized by failure of the <font face="Symbol">b</font> cells to compensate
    for insulin resistance (2, 10). Ethnicity, family history of diabetes, and <
font face="Symbol">b</font>    cells failure in compensating for insulin resista
nce are therefore common factors    implicated in the pathophysiology of both GD
M and early onset autosomal dominant    type 2 diabetes worldwide (2, 7, 10).</f
ont></p>     ^cY#03.htm##
00758000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704053500070002000700605#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#35#31#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">We postulated that    Jamaican women of Af
rican descent with a family history of early onset autosomal    dominant type 2 
diabetes would have greater odds of developing GDM. We therefore    conducted a 
prospective study evaluating the odds for and incidence of GDM in    pre-gravid 
women with and without a family history of atypical diabetes. The    metabolic p
rofiles of these women during the first and second trimesters have    also been 
described.</font></p>     ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#36#32#article#123#<p>&nbsp;</p>     ^cY#03.
htm##
00336000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704011300070002000700183#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#37#33#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>MATERIAL AND    METHODS</b></font></p> 
    ^cY#03.htm##
01380000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704115700070002000701227#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#38#34#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A total of 698    pregnant Jamaican women 
with a family history of early onset autosomal dominant    type 2 diabetes were 
identified from March 2000&#150;September 2003 at the Antenatal    Clinic at the
 University Hospital of the West Indies. Early onset autosomal    dominant type 
2 diabetes was defined as having a family history of diabetes    in multi-genera
tions, at least two first degree relatives diagnosed with type    2 diabetes bef
ore 35 years of age, and diabetes only on the maternal or paternal    side of th
e family (2). In addition, 1 000 pregnant women without a family history    of d
iabetes were identified at the same clinic during the same time period.    The i
nvestigation of both groups of women was carried out simultaneously so    that t
he odds for developing GDM and incidence of GDM could be compared. The    study 
received approval from the Faculty of Medical Sciences of the University    of t
he West Indies and Ethics Committee of the University Hospital of the West    In
dies. Written, informed consent was also obtained from each participant.</font><
/p>     ^cY#03.htm##
00328000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010500070002000700175#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#39#35#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Data collection</b></font></p>     ^cY#
03.htm##
01097000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704087400070002000700944#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#40#36#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Information was    collected from the prob
and and family members that included age, sex, ancestral    origin of parents an
d grandparents, and, if applicable, age at time of diabetes    diagnosis and typ
e of diabetes. Body Mass Index (BMI) was calculated at approximately    six week
s of gestation by measuring the expectant woman's weight and height.    A standa
rd stadiometer was used for measurements. BMI was classified according    to the
 Institute of Medicine (Washington, DC, United States of America) calculations  
  for weight and weight-gain during pregnancy (11). This calculation was correla
ted    with the self-reported BMI before pregnancy. Systolic and diastolic blood
 pressure    measurements were obtained by using a standard sphygmomanometer whi
le the patient    was seated.</font></p>     ^cY#03.htm##
01217000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704099400070002000701064#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#41#37#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">All participants    were screened at nine 
weeks of gestation for glucose intolerance using the 50    g glucose O'Sullivan 
Test (12). Those with screening values greater than 7.8    mmol/L were then subj
ected to a 75-g Oral Glucose Tolerance Test (OGTT) (13).    GDM is usually detec
ted in the second trimester; however since the prevalence    of diabetes in Jama
ica is high and can pre-date the pregnancy (14), it is important    to screen fo
r diabetes early in the first trimester (nine weeks). Fasting plasma    glucose 
is used to eliminate women being classified as GDM whose diabetes might    likel
y antedate their pregnancy (15). Baseline samples were also taken at nine    wee
ks for insulin, glucagon, cortisol glucose, triglyceride, and total and HDL    c
holesterol. The O'Sullivan Test was repeated at 24&#150;27 weeks of gestation   
 on participants with normal O'Sullivan test results or OGTT results.</font></p>
     ^cY#03.htm##
02686000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704246300070002000702533#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#42#38#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The diagnosis of    GDM was based on the W
orld Health Organization's OGTT criteria (13) because    the revised criteria do
 not affect the prevalence of GDM (16). Fasting samples    were repeated at 24&#
150;27 weeks of gestation on all participants. The O'Sullivan    test was repeat
ed at 32 weeks of gestation on participants with normal O'Sullivan    or OGTT re
sults. <font face="Symbol">b</font> cell function and insulin resistance    were
 calculated from fasting insulin and glucose values using the Homeostasis    Mod
el Assessment method as this is less invasive, less expensive, and easy to    us
e (17). Women with family history of early onset autosomal dominant type 2    di
abetes who were diagnosed with GDM were screened, along with two affected    fam
ily members, for sequence variants in the MODY genes by polymerase chain    reac
tion single strand conformation polymorphism (PCR-SSCP) analysis (18). Genomic  
  DNA was prepared from peripheral blood by phenol-chloroform extraction. A geno
me    scan was performed by means of PCR and automated fragment analysis. Each i
ndividual    was genotyped for approximately 425 microsatellite markers with mea
n distance    between markers of &lt; 10 cm. Failure rate averaged across all ma
rkers was    &lt; 3%. Mutations in glucokinase, HNF-1<font face="Symbol">a</font
>, HNF-1<font face="Symbol">b</font>,    HNF-4<font face="Symbol">a</font>, IPF-
1, and Neuro-D1 genes linked with early    onset autosomal type 2 diabetes were 
searched for by means of a double gradient,    denaturing gradient gel electroph
oresis. This was followed by direct sequencing    of the products of the PCR tha
t were amplified from the exons, flanking introns    and minimal promoters of gl
ucokinase, HNF-1<font face="Symbol">a</font>, HNF-1<font face="Symbol">b</font>,
    HNF-4<font face="Symbol">a</font>, IPF-1, and Neuro-D1 genes. Finally linkag
e    with markers D7S2846 and D7S1818 flanking the glucokinase locus, D12S395 fl
anking    the HNF-1<font face="Symbol">a</font> locus, D20S478, D20S481 flanking
 the HNF-4<font face="Symbol">a</font>    locus, D17S1293 flanking the HNF-1<fon
t face="Symbol">b</font> locus, and D2S1391    flanking the Neuro-D1 locus were 
excluded in the families by parametric linkage    analysis with logarithmic scor
es ranging from &#150;0.10 to &#150;10.80 and    no significant evidence of link
age heterogeneity.</font></p>     ^cY#03.htm##
00336000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704011300070002000700183#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#43#39#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Statistical    analysis</b></font></p> 
    ^cY#03.htm##
01630000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704140700070002000701477#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#44#40#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Statistics were    computed using SPSS 11.
5 (SPSS Inc., Chicago, Illinois, United States). Frequency    tables and accompa
nying histograms were produced and examined with related descriptive    statisti
cs (means, medians, modes, and standard deviations for all 1 968 participants   
 in the first trimester/nine weeks and the 99 diagnosed with diabetes and the   
 1 599 without diabetes in the second trimester/24&#150;27 weeks). This informat
ion    along with the Kolmogorov-Smirnov one-sample test were used to assess the
 variables    approximation to normality. Such results were used to determine wh
ether a parametric    or non-parametric test should be used for comparison of me
ans and medians. The    Mann Whitney U-test was used to compare median differenc
es based on having or    not having a family history of diabetes; while the inde
pendent group t-test    was used to compare mean differences of these two groups
. Data are generally    presented as mean &plusmn; SD; however, because imbalanc
ed sample sizes of women    with GDM may affected validity of comparison, mean a
nd median results are reported    by group. Using binary logistic regression, od
d ratios for getting GDM were    derived employing the predicator variables: fam
ily history, age, BMI, insulin    resistance, hypertension, and cholesterol leve
l.</font></p>     ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#45#41#article#123#<p>&nbsp;</p>     ^cY#03.
htm##
00320000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009700070002000700167#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#46#42#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>RESULTS</b></font></p>     ^cY#03.htm##
00356000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704013300070002000700203#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#47#43#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Metabolic profile    in the first trime
ster</b></font></p>     ^cY#03.htm##
01528000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704130500070002000701375#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#48#44#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Based on the OGTT    WHO criteria (13), no
 woman was diagnosed with GDM in the first trimester/first    nine weeks of gest
ation. The metabolic profiles of participants at nine weeks    of gestation are 
shown in <a href="#tab1">Table 1</a>. The women with a family    history of earl
y onset autosomal dominant type 2 diabetes had lower insulin    levels (10.0 &pl
usmn; 4.6 versus 11.1 &plusmn; 7.4, <i>P</i> &lt; 0.05), lower    <font face="Sy
mbol">b</font> cell function (95.0 &plusmn; 24.8 versus 105.6    &plusmn; 30.7%,
 <i>P</i> &lt; 0.05), and were less insulin resistant (2.5 &plusmn;    1.4 versu
s 2.7 &plusmn; 1.2, <i>P</i> &lt; 0.05), but had higher triglyceride    levels (
1.7 &plusmn; 0.8 versus 1.3 &plusmn; 0.3 mmol/L, <i>P</i> &lt; 0.04)    than wom
en without a family history of diabetes. Elevated triglyceride levels    (1.7 &p
lusmn; 0.8 mmol/L) (19) were noted in women with a family history of    early on
set autosomal dominant type 2 diabetes. No significant differences in    age, BM
I , glucose, cortisol, glucagon, total cholesterol, HDL, or systolic    and dias
tolic blood pressures were noted between women with a family history    of early
 onset autosomal dominant type 2 diabetes and those without.</font></p>     ^cY#
03.htm##
00258000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003500070002000700105#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#49#45#article#123#<p><a name="tab1"></a></p
>     ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#50#46#article#123#<p>&nbsp;</p>     ^cY#03.
htm##
00299000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007600070002000700146#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#51#47#article#123#<p align="center"><img sr
c="/img/revistas/rpsp/v23n2/03t1.gif"></p>     ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#52#48#article#123#<p>&nbsp;</p>     ^cY#03.
htm##
00375000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704015200070002000700222#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#53#49#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Metabolic profile    of women with GDM 
in the second trimester</b></font></p>     ^cY#03.htm##
02455000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704223200070002000702302#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#54#50#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Of the 698 women    with a family history 
of early onset autosomal dominant type 2 diabetes, 84    (12.0%) were diagnosed 
with GDM at 24&#150;27 weeks (second trimester) of pregnancy,    while of the 1 
000 women without a family history of diabetes, 15 (1.5%) were    diagnosed with
 GDM (<a href="#tab2">Table 2</a>). Women with a family history    of early onse
t autosomal type 2 diabetes were younger (26.4 &plusmn; 4.3 versus    32.2 &plus
mn; 4.1 years, <i>P</i> &lt; 0.02) and had a significantly lower BMI    (24.8 &p
lusmn; 4.6 versus 26.6 &plusmn; 5.1 kg/m<sup>2</sup> <i>P</i> &lt; 0.04)    at s
ix weeks of gestation than did GDM women without family history of diabetes.    
All of the following were significantly lower in GDM women with a family history
    of early onset autosomal type 2 diabetes than in GDM women without a family 
   history of diabetes: fasting glucose (6.1 &plusmn; 1.3 versus 7.1 &plusmn; 2.
0    mmol/L, <i>P</i> &lt; 0.05); postprandial glucose (8.5 &plusmn; 2.1 versus 
10.8    &plusmn; 3.4 mmol/L, <i>P</i> &lt; 0.03); fasting insulin (10.9 &plusmn;
 2.9    versus 19.0 &plusmn; 7.9 mU/L); postprandial insulin (14.2 &plusmn; 2.2 
versus    32.4 &plusmn; 6.5 mU/L, <i>P</i> &lt; 0.0001); HDL (1.2 &plusmn; 0.3 v
ersus    1.7 &plusmn; 0.3 mmol/L, <i>P</i> &lt; 0.05); total cholesterol (4.5 &p
lusmn;    1.2 versus 5.6 &plusmn; 0.5 mmol/L, <i>P</i> &lt; 0.05); insulin resis
tance    (2.9 &plusmn; 0.7 versus 5.7 &plusmn; 1.2); cell function (83.4 &plusmn
; 14.1    versus 100.4 &plusmn; 24.1%, <i>P</i> &lt; 0.03); systolic blood press
ure (120.1    &plusmn; 6.8 versus 126.9 &plusmn; 8.9 mmHg, <i>P</i> &lt; 0.04); 
and diastolic    blood pressure (80.0 &plusmn; 5.0 versus 85.3 &plusmn; 7.4 mmHg
, <i>P</i> &lt;    0.05). The blood pressures were within normal range (systolic
: 120.1 &plusmn;    6.8 mmHg; diastolic: 80.0 &plusmn; 5.0 mmHg) (19) in women w
ith a family history    of early onset autosomal dominant type 2, however trigly
ceride levels were elevated    and significantly higher (1.7 &plusmn; 0.8 versus
 1.1 &plusmn; 0.1 mmol/L, <i>P</i>    &lt; 0.05) than that of GDM women with no 
family history of diabetes.</font></p>     ^cY#03.htm##
00258000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003500070002000700105#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#55#51#article#123#<p><a name="tab2"></a></p
>     ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#56#52#article#123#<p>&nbsp;</p>     ^cY#03.
htm##
00299000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007600070002000700146#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#57#53#article#123#<p align="center"><img sr
c="/img/revistas/rpsp/v23n2/03t2.gif"></p>     ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#58#54#article#123#<p>&nbsp;</p>     ^cY#03.
htm##
00369000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704014600070002000700216#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#59#55#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Metabolic profile    without GDM in the
 second trimester</b></font></p>     ^cY#03.htm##
01393000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704117000070002000701240#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#60#56#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">There were two    groups of "normal" (i.e.
, negative for GDM) women, those with a family history    of early onset autosom
al dominant type 2 diabetes and those with no history    of the disease (<a href
="#tab3">Table 3</a>). The 614 normal women with a family    history of the dise
ase had elevated triglyceride levels (1.7 &plusmn; 0.8 mmol/L)    (19). Between 
the normal group with a family history and the normal group with    no history, 
there were the following significant differences: insulin levels    (10.4 &plusm
n; 4.8 versus 12.0 &plusmn; 7.3 mU/L, <i>P</i> &lt; 0.05); , cell    function (9
8.9 &plusmn; 24.2 versus 109.7 &plusmn; 30.4%, <i>P</i> &lt; 0.04);    and insul
in resistance (2.6 &plusmn; 1.1 versus 3.0 &plusmn; 1.6, <i>P</i> &lt;    0.05).
 There were no significant differences between the two groups in glucose,    glu
cagon, cortisol, HDL, total cholesterol, or systolic and diastolic blood    pres
sure levels at 24&#150;27 weeks of gestation. Women from both groups who    had 
normal glucose tolerance at 24&#150;27 weeks remained normal throughout    pregn
ancy.</font></p>     ^cY#03.htm##
00258000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003500070002000700105#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#61#57#article#123#<p><a name="tab3"></a></p
>     ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#62#58#article#123#<p>&nbsp;</p>     ^cY#03.
htm##
00299000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007600070002000700146#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#63#59#article#123#<p align="center"><img sr
c="/img/revistas/rpsp/v23n2/03t3.gif"></p>     ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#64#60#article#123#<p>&nbsp;</p>     ^cY#03.
htm##
00357000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704013400070002000700204#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#65#61#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Family history    and odds of developin
g GDM</b></font></p>     ^cY#03.htm##
00824000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704060100070002000700671#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#66#62#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The odds of developing    GDM for Jamaican
 women with a family history of early onset autosomal dominant    type 2 diabete
s is nine times that of those without a family history of the    disease (95% co
nfidence interval: 5.00&#150; 16.38, <i>P</i> &lt; 0.0001). Mutation    screen- 
ing via SSCP (18), sequencing (2), and linkage analysis was negative    for the 
six known MODY genes (HNF-4<font face="Symbol">a</font>, GCK, HNF-1<font face="S
ymbol">a</font>,    IPF-1, HNF-1<font face="Symbol">b</font>, and Neuro-D1).</fo
nt></p>     ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#67#63#article#123#<p>&nbsp;</p>     ^cY#03.
htm##
00323000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010000070002000700170#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#68#64#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>DISCUSSION</b></font></p>     ^cY#03.ht
m##
00804000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704058100070002000700651#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#69#65#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The main ethnic    groups in Jamaica are N
egro/Black (90.5%), mixed/ Negro (7.3%), and East Indian    (1.3%); other racial
 groups are less than 1% (20). Marked variations in GDM    prevalence among diff
erent racial/ethnic groups have been documented, with higher    prevalence among
 Native-Americans, Asians, and African-Americans (8, 21, 22).    GDM incidence u
sually ranges from 3%&#150;5%, and although an incidence rate    higher than 11%
 is rare, up to 14.3% has been reported (6, 21&#150;24).</font></p>     ^cY#03.h
tm##
02190000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704196700070002000702037#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#70#66#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">In this study,    GDM incidence among Jama
ican women with a family history of early onset type    2 diabetes that segregat
es with autosomal dominant inheritance was 12.0%. This    high incidence of GDM 
is rare and has been reported in only a few populations    worldwide, such as am
ong the Cree Indians (12.8%) in Quebec, Canada; the Aboriginal    Indians (11.5%
) in Saskatoon District, Canada; and the Zuni Indians (14.3%)    in New Mexico, 
United States. The women in these populations were overweight    prior to pregna
ncy, older, and more hypertensive (21&#150;23), thus showing    features consist
ent with the metabolic syndrome (19) that has been linked to    GDM (22&#150;24)
. The Jamaicans with a family history of early onset autosomal    dominant type 
2 diabetes who developed GDM were normotensive, younger (26.4    &plusmn; 4.3 ye
ars), and had normal pregnancy BMI at 24&#150;27 weeks of gestation    (24.8 &pl
usmn; 4.6 kg/m<sup>2</sup>) suggesting that underlying factors, such    as genet
ic and intrauterine, may have taken more prominent roles in the pathophysiology 
   of GDM in this population. At 24&#150;27 weeks of gestation, these women had 
   a mean fasting glucose value of 6.1 mmol/L and a mean insulin value of 10.9  
  mU/L manifesting 1.79 mU/L of insulin for each mmol/L of glucose in the basal 
   state. When these women were challenged with glucose, their mean postprandial
    glucose value at 2 hours was 8.5 mmol/L with insulin at 14.2 mU/L thus manif
esting    1.67 mU/L of insulin for each mmol/L of glucose; the insulin resistanc
e at this    stage was 2.9. This clearly is suggestive of the<font face="Symbol"
> b </font>cell    dysfunction in the face of insulin resistance in pregnancy. D
etailed metabolic    studies have revealed abnormalities in glucose-mediated ins
ulin secretion in    some forms of early onset autosomal dominant diabetes (3, 5
).</font></p>     ^cY#03.htm##
01501000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704127800070002000701348#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#71#67#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">At 24&#150;27 weeks    of gestation, norma
l pregnant women with a family history of early onset autosomal    dominant type
 2 diabetes had a mean fasting glucose value of 5.6 mmol/L and    insulin of 10.
4 mU/L, thus showing 1.85 mU/L of insulin for each mmol/L of glucose    in the s
econd trimester. <font face="Symbol">b</font> cell function was at 98.9%    and 
insulin resistance was 2.6. It seems possible therefore, that there is a    thre
shold of insulin sensitivity above which the development of GDM is very    unlik
ely and there is also a stage in the development of GDM too late to protect    <
font face="Symbol">b</font> cells by reducing insulin resistance. The ability   
 of the pancreatic <font face="Symbol">b</font>-cell to compensate for prevailin
g    insulin sensitivity (i.e., <font face="Symbol">b</font>-cell compensation) 
is    highly heritable (25, 26). Although <font face="Symbol">b</font> cell dysf
unction    is associated with MODY (3), mutation screening of the women and fami
ly members    with early onset autosomal dominant type 2 diabetes for the MODY g
enes 1&#150;6    ruled out <font face="Symbol">b</font> cell defects associated 
with MODY as    the cause of GDM.</font></p>     ^cY#03.htm##
01057000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704083400070002000700904#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#72#68#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Chronic autoimmunity    directed at <font 
face="Symbol">b</font> cells is one mechanism that may contribute    to <font fa
ce="Symbol">b</font> cell failure in GDM, perhaps even in the absence    of chro
nic insulin resistance. However, evidence for such autoimmunity is present    in
 only a small minority of patients (27&#150;29). The frequency of anti-islet    
cell and anti-GAD antibodies in GDM parallels ethnic trends in the prevalence   
 of type 1 diabetes outside of pregnancy (10). The prevalence of type 1 diabetes
    in Jamaicans is low, at about 2.5 per 10 000 (30). We therefore do not belie
ve    the 12% incidence of GDM in the women with a family history of early onset
 autosomal    dominant type 2 diabetes is due to autoimmune diabetes.</font></p>
     ^cY#03.htm##
01286000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704106300070002000701133#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#73#69#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The hypertriglyceridemia    seen in both n
ormal women and those with GDM who had a family history of early    onset autoso
mal dominant type 2 diabetes may be due to defective lipolysis of    very low de
nsity lipoprotein triglyceride (VLDL-TG) (31, 32). A large number    of mutation
s in lipoprotein lipase (LPL) have been identified (33) and these    can cause h
ypertriglyceridemia. However, it is doubtful that most cases of endogenous    hy
pertriglyceridemia can be explained by mutations in LPL, which appear to be    r
elatively rare. Another attractive suggestion for defective lipolysis of VLDL-TG
    has recently been proposed. This is an overproduction of apolipoprotein (apo
)    CIII. This apolipoprotein inhibits the function of LPL (34). The hepatic sy
nthesis    of apo CIII apparently is insulin responsive (35); in the presence of
 insulin    resistance, apo CIII may be over-expressed, which can inhibit lipoly
sis of plasma    VLDL-TG and lead to hypertriglyceridemia.</font></p>     ^cY#03
.htm##
02109000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704188600070002000701956#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#74#70#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Risk factors for    GDM include age and ob
esity (21&#150;23). In our study, 1.5% of women with no    family history of dia
betes developed GDM. These women were overweight at 24&#150;27    weeks of gesta
tion, over 30 years of age, and hypertensive with elevated total    cholesterol 
and high insulin resistance. This subset of women without family    history of d
iabetes who developed GDM had many of the features of the metabolic    syndrome,
 associated with increased incidence of GDM (19, 21&#150;23). In the    face of 
increasing insulin resistance in the second trimester, appropriate hyperinsuline
mia    occurred. The fasting glucose value was 7.1 mmol/L and insulin 19.0 mU/L.
 They    manifested 2.71 mU/L of insulin for each mmol/L of glucose in the basal
 state.    With a glucose challenge, the mean postprandial glucose value was 10.
8 mmol/L    and the insulin 32.4 mU/L thus showing 2.99 mU/L of insulin for each
 mmol/L    of glucose. <font face="Symbol">b</font> cell function was 100.4%. Ro
bust plasticity    of <font face="Symbol">b</font> cell function in time of insu
lin resistance    is the hallmark of normal glucose regulation during pregnancy 
(10). The myriad    of obesity, age, high blood pressure, and elevated total cho
lesterol in these    women are markers of increased insulin resistance (19) to w
hich the insulin    resistance of pregnancy was additive. This exaggerated resis
tance to insulin    and ability to suppress glucose production and stimulate glu
cose uptake resulted    in hyperglycemia in pregnancy. During the fasting state 
in GDM, severe insulin    resistance is characterized by an overproduction of gl
ucose by the liver; while    in the fed state, severe insulin resistance is char
acterized by a decrease in    insulin-mediated glucose uptake by the muscle (36)
.</font></p>     ^cY#03.htm##
01517000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704129400070002000701364#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#75#71#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Although family    history is a risk facto
r for GDM (3, 6, 7, 37), not much is known about its    genetics. Allele frequen
cies of candidate genes in women with GDM and controls    have not documented an
y specificity for phenotypic sub-classification (10, 38).    Variants that diffe
red in frequency between GDM and controls have been identified    in genes codin
g for the (a) islet specific promoter of glucokinase, said to    be important fo
r glucose sensing by the <font face="Symbol">b</font> cells;    (b) Calpain 10, 
a gene associated with type 2 diabetes in some ethnic groups;    and (c) the sul
fonylurea receptor-1 that is involved in glucose-stimulated secretion    (39&#15
0; 41). Several studies have also evaluated a series of <i>a priori</i>    candi
date genes for a role in early-onset type 2 diabetes (42). Sequence variants    
have been identified in genes such as HNF-3<font face="Symbol">b</font>, NeuroD4
,    Neurogenin-3, HNF-6, and GLUT-2; however, none of these have been conclusiv
ely    shown to predispose to type 2 diabetes or GDM (40). Therefore, GDM appear
s to    be multifaceted and may be caused by both genetic and environmental fact
ors    that characterize other types of diabetes.</font></p>     ^cY#03.htm##
00815000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704059200070002000700662#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#76#72#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The environmental    factors that cause GD
M in Jamaican women with a family history of early onset    autosomal dominant t
ype 2 diabetes may be absent after delivery, thus with a    usual incidence rate
 of 12%, GDM presents a unique opportunity to investigate    the early pathogene
sis of the disease. Because of the increased suceptibility    to GDM that Jamaic
an women with a family history of early onset type 2 diabetes    have at any age
, it is important that they be screened for GDM early in pregnancy.</font></p>  
   ^cY#03.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#77#73#article#123#<p>&nbsp;</p>     ^cY#03.
htm##
00323000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010000070002000700170#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#78#74#article#123#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>REFERENCES</b></font></p>     ^cY#03.ht
m##
00463000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704022600072002000700298#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#79#75#article#123#1#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;1.&nbsp;Rosenbloom    
A, Joe J, Young R, Winter W. Emerging epidemic of type diabetes in youth. Diabet
es    Care. 1999;22(2):345&#150;54.</font></p>     ^cY#03.htm##
00552000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704031500072002000700387#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#80#76#article#123#2#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;2.&nbsp;Doria    A, Ya
ng Y, Malecki M. Phenotypic characteristics of early-onset autosomal-dominant   
 type 2 diabetes unlinked to known maturity-onset diabetes on the young (MODY)  
  genes. Diabetes Care. 1999;22:253&#150;26.</font></p>     ^cY#03.htm##
00619000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704038200072002000700454#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#81#77#article#123#3#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;3.&nbsp;Hattersley    
AT, Ellard S, Shepherd M, Fray-ling TM, Bulman M, Ballantyne L, et al. Phenotype
&#151;genotype    relationships in maturity-onset diabetes of the young. In Mats
chinsky FM, Magnusson    MA (eds). Molecular Pathogenesis of MODYs. Frontiers Di
abetes. Basel: Karger,    2000.</font></p>     ^cY#03.htm##
00530000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704029300072002000700365#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#82#78#article#123#4#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;4.&nbsp;Kim    S, Ma X
, Weremowicz S, Ercolino T, Powers C, Mlynarski W, et al. Identification    of a
 locus for maturity-onset diabetes of the young on chromosome 8p23. Diabetes.   
 2004;3: 1375&#150;84.</font></p>     ^cY#03.htm##
00504000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704026700072002000700339#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#83#79#article#123#5#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;5.&nbsp;Fajans    SS, 
Bell GI and Polonsky KS. Molecular mechanisms and clinical pathophysiology    of
 maturity-onset diabetes of the young. New Engl J Med. 2001;345:971&#150;80.</fo
nt></p>     ^cY#03.htm##
00491000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704025400072002000700326#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#84#80#article#123#6#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;6.&nbsp;Coustan    DR,
 Nelson C, Carpenter MW. Maternal age and screening for gestational diabetes.   
 A population-based study. Obstet Gynecol. 1989;73:557&#150;61.</font></p>     ^
cY#03.htm##
00489000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704025200072002000700324#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#85#81#article#123#7#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;7.&nbsp;Wein    P, Bei
scher N. Gestational diabetes. In twin pregnancy: prevalence and long    term im
plications. Aust NZ J Obstet Gynaecol. 1992;32(4):325&#150;7.</font></p>     ^cY
#03.htm##
00517000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704028000072002000700352#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#86#82#article#123#8#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;8.&nbsp;Nahum    GG, H
uffaker BJ. Racial differences in oral glucose screening tests. Establishing    
race-specific criteria for abnormality in pregnancy. Obstet Gynecol. 1993;81:517
&#150;22.</font></p>     ^cY#03.htm##
00561000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704032400072002000700396#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#87#83#article#123#9#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;9.&nbsp;Groop    L, Fo
rsblom C, Lehtovirta M, Tuorm T, Karanko S, Nissen M, et al. Metabolic    conseq
uences of a family history of NIDDM (the Botnia study): evidence of sex-specific
    parental effects. Diabetes. 1996;45:1585&#150;93.</font></p>     ^cY#03.htm#
#
00428000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704019000073002000700263#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#88#84#article#123#10#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">10.&nbsp;Buchanon    T and 
Xiang A. Gestational diabetes mellitus. J Clin Invest. 2005;115(3): 485&#150;91.
</font></p>     ^cY#03.htm##
00737000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704049900073002000700572#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#89#85#article#123#11#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">11.&nbsp;Institute    of Me
dicine. Nutrition during pregnancy, weight gain and nutrient supplements.    Rep
ort of the Subcommittee on Nutritional Status and Weight Gain during Pregnancy, 
   Subcommittee on Dietary Intake and Nutrient Supplements During Pregnancy, Com
mittee    on Nutritional Status During Pregnancy and Lactation, Food and Nutriti
on Board.    Washington, DC. National Academy Press. 1990:1&#150;233.</font></p>
     ^cY#03.htm##
00445000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704020700073002000700280#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#90#86#article#123#12#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">12.&nbsp;O'Sullivan    JB, 
Mahan CM. Criteria for the glucose tolerance test in pregnancy. Diabetes.    196
4;13:278&#150;85.</font></p>     ^cY#03.htm##
00448000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704021000073002000700283#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#91#87#article#123#13#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">13.&nbsp;World    Health Or
ganization. Diabetes mellitus, report of a WHO Study Group. Geneva:    WHO 1985.
 Tech Rep. Ser. 727.</font></p>     ^cY#03.htm##
00478000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704024000073002000700313#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#92#88#article#123#14#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">14.&nbsp;Ragoobirsingh    D
, Lewis Fuller G, Morrison. The Jamaican diabetes survey. A protocol for the    
Caribbean. Diabetes Care. 1995;18(9): 1277&#150;9.</font></p>     ^cY#03.htm##
00528000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704029000073002000700363#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#93#89#article#123#15#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">15.&nbsp;Sacks    D, Chen W
, Wolde-Tsadik G, Buchanon T. Fasting plasma glucose test at first    pre-natal 
visit as a screen for gestational diabetes. Obstetrics &amp; Gynaecology.    200
3;101:1197&#150;203.</font></p>     ^cY#03.htm##
00479000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704024100073002000700314#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#94#90#article#123#16#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">16.&nbsp;Ko G,    Tam WH, C
hen JC, Rogers M. Prevalence of gestational diabetes mellitus in Hong    Kong ba
sed on 1998 criteria. Diabetic Medicine. 2002;19:80</font></p>     ^cY#03.htm##
00570000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704033200073002000700405#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#95#91#article#123#17#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">17.&nbsp;Matthews    D, Hos
ker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis Model Assessment.
    Insulin resistance and<font face="Symbol"> b </font>cell function from gluco
se    concentrations in man. Diabetologia. 1985;28:412&#150;9.</font></p>     ^c
Y#03.htm##
00506000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704026800073002000700341#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#96#92#article#123#18#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">18.&nbsp;Fulton    RE, Sala
sek ML, DuTeau NM, Black WC. SSCP analysis of cDNA markers provides    a dense l
inkage map of the <i>Aedes Aegypti</i> genome. Genetics. 2001;158:715&#150;26.</
font></p>     ^cY#03.htm##
00465000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704022700073002000700300#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#97#93#article#123#19#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">19.&nbsp;Ford E,    Giles W
, Mokdad A. Increasing prevalence of the metabolic syndrome amongst US    adults
. Diabetes Care. 2004;27:2444&#150;9.</font></p>     ^cY#03.htm##
00482000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704024400073002000700317#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#98#94#article#123#20#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">20.&nbsp;United    Nations.
 International convention on the elimination of all forms of racial    discrimin
ation. Geneva: United Nations; 2001. CERD/ C/383/Add.1</font></p>     ^cY#03.htm
##
00550000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704031200073002000700385#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#99#95#article#123#21#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">21.&nbsp;Benjamin    E, Win
ters D, Mayfield J, Gohdes D. Diabetes in pregnancy in Zuni Indian women.    Pre
valence and subsequent development of clinical diabetes after gestational    dia
betes. Diabetes Care. 2002;25:487&#150;93.</font></p>     ^cY#03.htm##
00534000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000300071704029500074002000700369#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#100#96#article#123#22#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">22.&nbsp;Rodriques    E, R
obinson E, Gray-Donald S. Prevalence of gestational diabetes mellitus among    J
ames Bay Cree women in Northern Quebec. Canadian Medical Association Journal.   
 1999;160(2):1293&#150;97.</font></p>     ^cY#03.htm##
00575000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000300071704033600074002000700410#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#101#97#article#123#23#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">23.&nbsp;Dyck R,    Klomp 
H,Tan L, Turnell R , Boctor M. A comparison of rates, risk factors, and    outco
mes of gestational diabetes between Aboriginal and Non-Aboriginal women    in th
e Saskatoon Health District. Diabetes Care. 2002;16(9):1231&#150;5.</font></p>  
   ^cY#03.htm##
00529000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000300071704029000074002000700364#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#102#98#article#123#24#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">24.&nbsp;Dabelea    D, Sne
ll-Bergeon J, Hartsfield C, Kischoff K, Hamman R, Mc Duffie R. Increasing    pre
valence of gestational diabetes over time and by birth cohort. Diabetes Care.   
 2005;28:579&#150;84.</font></p>     ^cY#03.htm##
00643000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000300071704040400074002000700478#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#103#99#article#123#25#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">25.&nbsp;Watanabe    RM, V
alle T, Hauser ER, Ghosh S, Eriksson J, Kohtamaki K, et al. Familiarity    of qu
antitative metabolic traits in Finnish families with non-insulin-dependent    di
abetes mellitus. Finland-United States investigation of NIDDM genetics (FUSION) 
   study investigators. Hum Hered. 1990;49:159&#150;68.</font></p>     ^cY#03.ht
m##
00586000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704034600075002000700421#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#104#100#article#123#26#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">26.&nbsp;Poulsen    P, Le
vin K, Petersen I, Christensen K, Beck-Nielsen H, Vaag A. Heritability    of ins
ulin secretion, peripheral and hepatic insulin action, and intracellular    gluc
ose partitioning in young and old Danish twins. Diabetes. 2005;54:275&#150;83.</
font></p>     ^cY#03.htm##
00503000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704026300075002000700338#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#105#101#article#123#27#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">27.&nbsp;Catalano    OM, 
Tyzbir ED, Sims EA. Incidence and significance of islet cell antibodies    in wo
men with previous gestational diabetes. Diabetes Care. 1990;13:478&#150;82.</fon
t></p>     ^cY#03.htm##
00588000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704034800075002000700423#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#106#102#article#123#28#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">28.&nbsp;Mauricio    D, C
orcoy RM, Codina M, Balsells M, Puig-Domingo M, Pou Jm, et al. Islet cell    ant
ibodies identify a subset of gestational diabetic women with higher risk    of d
eveloping diabetes shortly after pregnancy. Diab Nutr Metab. 1992;5:237&#150;41.
</font></p>     ^cY#03.htm##
00586000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704034600075002000700421#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#107#103#article#123#29#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">29.&nbsp;Damm P,    Kuhl 
C, Buschard K, Jakobsen BK, Svejgaard A, Sodoyez-Goffaux F, et al. Prevalence   
 and predictive value of women with islet cell antibodies and insulin autoantibo
dies    in women with gestational diabetes. Diabetic Med. 1994;11:558&#150;63.</
font></p>     ^cY#03.htm##
00476000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704023600075002000700311#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#108#104#article#123#30#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">30.&nbsp;Barcelo    A and
 Rajpathak S. Incidence and prevalence of diabetes mellitus in the Americas.    
Rev Panam Salud Publica. 2001;10(5): 301&#150;8.</font></p>     ^cY#03.htm##
00602000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704036200075002000700437#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#109#105#article#123#31#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">31.&nbsp;Boberg    J, Car
lson LA, Freyschuss U, Lassers BW, Wahlqvist ML. Sphlanchic secretion    rates o
f plasma triglycerides and total and Splanchnic turnover of plasma free    fatty
 acids in men with normo- and hypertriglyceridaemia. Eur J Clin Invest.    1992;
9:454&#150;66.</font></p>     ^cY#03.htm##
00540000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704030000075002000700375#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#110#106#article#123#32#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">32.&nbsp;Dunn FL,    Grun
dy SM, Bilheimer DW, Havel RJ, Raskin P. Impaired catabolism of very low-density
    lipoprotein-triglyceride in a family with primary hypertriglyceridaemia. Met
abolism.    1985;34:316&#150;24.</font></p>     ^cY#03.htm##
00492000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704025200075002000700327#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#111#107#article#123#33#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">33.&nbsp;Lalouel    JM, W
ilson DE, Iverius P. Lipoprotein lipase and hepatic triglyceride lipase.    Mole
cular and genetic aspects. Curr Opin Lipidol. 1992;3:86&#150;95.</font></p>     
^cY#03.htm##
00673000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704043300075002000700508#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#112#108#article#123#34#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">34.&nbsp;Aalto-Setala    
K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, Zechner R, et al. Mechanism of   
 hypertriglyceridaemia in human apolipoprotein (apo) CIII transgenic mice. Dimin
ished    very low density lipoprotein fractional catabolic rate associated with 
increased    apo CIII reduced apo E on particles. J Clin Invest. 1992;9:889&#150
;900.</font></p>     ^cY#03.htm##
00585000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704034500075002000700420#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#113#109#article#123#35#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">35.&nbsp;Dammerman    M, 
Sandkuijl LA, Halaas JL, Chung W, Breslow JL. An apolipoprotein CIII haplotype  
  protective against hypertriglyceridaemia is specified by promoter and 3' untra
nslated    region polymorphisms. Proc Natl Acad Sci USA. 1993;90:4562&#150;6.</f
ont></p>     ^cY#03.htm##
00414000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704017400075002000700249#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#114#110#article#123#36#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">36.&nbsp;Langer    O. Man
agement of gestational diabetes. Clin Perinatol.1993;20:1&#150;15.</font></p>   
  ^cY#03.htm##
00489000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704024900075002000700324#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#115#111#article#123#37#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">37.&nbsp;Super    DM, Ede
lberg SC, Philipson EH, Hertz RH, Kachan SC. Diagnosis of gestational    diabete
s in early pregnancy. Diabetes Care. 1991; 14(4):288&#150;94.</font></p>     ^cY
#03.htm##
00544000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704030400075002000700379#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#116#112#article#123#38#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">38.&nbsp;Shaat    N,Ekelu
nd M, Lernmark A,Ivarsson S, Almgren P, Berntorp K, et al. Association    of the
 E23K polymorphism in the KCNJ11 gene with gestational diabetes mellitus.    Dia
betologia. 2005;48(12):2544&#150;51.</font></p>     ^cY#03.htm##
00642000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704040200075002000700477#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#117#113#article#123#39#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">39.&nbsp;Zaidi    FK,Ware
ham NJ, McCarthy MI, Holdstock J, Kalloo-Hosein H, Krook A, et al. Homozygosity 
   for a common polymorphism in the islet-specific promoter of the glucokinase  
  gene is associated with a reduced early insulin response to oral glucose in   
 pregnant women. Diabet Medicine. 1997;14:228&#150;34.</font></p>     ^cY#03.htm
##
00535000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704029500075002000700370#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#118#114#article#123#40#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">40.&nbsp;Leipold    H, Kn
ofler M, Gruber C, Haslinger P, Bancer-Todesca D, Worda C.Calpain-10 haplotype  
  combination and association with gestational diabetes mellitus. Obstet Gynecol
.    2004;103:1235&#150;40.</font></p>     ^cY#03.htm##
00606000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704036600075002000700441#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#119#115#article#123#41#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">41.&nbsp;Rissanen    J, M
arkkanen A, Karkkainen P, Pihlajamaki J, Kekalainen P, Mykkanen L, et al.    Sul
fonylurea receptor 1 gene variants are associated with gestational diabetes    a
nd type 2 diabetes but not with altered secretion of insulin. Diabetes Care.    
2000;23:70&#150;3.</font></p>     ^cY#03.htm##
00572000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704033200075002000700407#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#p#120#116#article#123#42#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">42.&nbsp;Frayling    TM, 
Lindgren CM, Chevre JC, Menzel S, Wishart M, Benmezroua Y, et al. A genome-wide 
   scan in families with maturity onset diabetes of the young: evidence for furt
her    genetic heterogeneity. Diabetes. 2003; 52(3):872&#150;81.</font></p>     
^cY#03.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#121#117#article#123#<p>&nbsp;</p>     ^cY#0
3.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#122#118#article#123#<p>&nbsp;</p>     ^cY#0
3.htm##
00339000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704011400072002000700186#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#123#119#article#123#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Manuscript received    on 25 November 20
06.    ^cY#03.htm##
00313000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704008800072002000700160#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#124#120#article#123#<br>   Revised version 
accepted for publication on 23 November 2007.</font></p>     ^cY#03.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#125#121#article#123#<p>&nbsp;</p>     ^cY#0
3.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#126#122#article#123#<p>&nbsp;</p>     ^cY#0
3.htm##
00625000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704040000072002000700472#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\03.htm#S#p#127#123#article#123#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#top">*</a> 
   Send correspondence to: Rachael Irving, Department of Basic Medical Sciences,
    University of the West Indies, Mona, Kingston, Jamaica; telephone: 876-92722
90;    fax: 876-9775233; email: <a href="mailto:rachael.irving@uwimona.edu.jm">r
achael.irving@uwimona.    edu.jm.</a></font></p>     ^cY#03.htm##
00577000000000313000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100020000710100013000910100
01500104010001600119012004800135030001400183065000900197064000500206031000300211
032000200214014000700216865000900223002000700232035001000239801001400249#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\03.htm#S#c#128#1#article#42#1#^rND^sRosenbloom
^nA#^rND^sJoe^nJ#^rND^sYoung^nR#^rND^sWinter^nW#Emerging epidemic of type diabet
es in youth^len#Diabetes Care#19990000#1999#22#2#345-54#20080200#03.htm#0149-599
2#Diabetes Care##
00634000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100015000710100014000860100
01700100012014900117030001400266065000900280064000500289031000300294014000700297
865000900304002000700313035001000320801001400330#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\03.htm#S#c#129#2#article#42#2#^rND^sDoria^nA#^rND^sYang^nY#^rND^sMalec
ki^nM#Phenotypic characteristics of early-onset autosomal-dominant type 2 diabet
es unlinked to known maturity-onset diabetes on the young (MODY) genes^len#Diabe
tes Care#19990000#1999#22#253-26#20080200#03.htm#0149-5992#Diabetes Care##
00744000000000337000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100021000710100016000920100
01800108010002000126010001600146010002000162810000600182012007700188016002200265
01600200028701800560030706600060036306200070036906500090037606400050038586500090
0390002000700399#v23n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#c#130#3#artic
le#42#3#^rND^sHattersley^nAT#^rND^sEllard^nS#^rND^sShepherd^nM#^rND^sFray-ling^n
TM#^rND^sBulman^nM#^rND^sBallantyne^nL#et al#Phenotype-genotype relationships in
 maturity-onset diabetes of the young^len#^rED^sMatschinsky^nFM#^rED^sMagnusson^
nMA#Molecular Pathogenesis of MODYs: Frontiers Diabetes^len#Basel#Karger#2000000
0#2000#20080200#03.htm##
00671000000000337000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100013000710100012000840100
02000096010001800116010001600134010001900150810000600169012009000175030000900265
06500090027406400050028303100020028801400080029086500090029800200070030703500100
0314801000900324#v23n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#c#131#4#artic
le#42#4#^rND^sKim^nS#^rND^sMa^nX#^rND^sWeremowicz^nS#^rND^sErcolino^nT#^rND^sPow
ers^nC#^rND^sMlynarski^nW#et al#Identification of a locus for maturity-onset dia
betes of the young on chromosome 8p23^len#Diabetes#20040000#2004#3#1375-84#20080
200#03.htm#0012-1797#Diabetes##
00552000000000277000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100017000710100015000880100
01900103012009400122030001500216710000200231065000900233064000500242031000400247
014000700251865000900258002000700267#v23n2#v:\scielo\serial\rpsp\v23n2\markup\03
.htm#S#c#132#5#article#42#5#^rND^sFajans^nSS#^rND^sBell^nGI#^rND^sPolonsky^nKS#M
olecular mechanisms and clinical pathophysiology of maturity-onset diabetes of t
he young^len#New Engl J Med#2#20010000#2001#345#971-80#20080200#03.htm##
00577000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100018000710100016000890100
02000105012008200125030001500207065000900222064000500231031000300236014000700239
865000900246002000700255035001000262801001500272#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\03.htm#S#c#133#6#article#42#6#^rND^sCoustan^nDR#^rND^sNelson^nC#^rND^s
Carpenter^nMW#Maternal age and screening for gestational diabetes: A population-
based study^len#Obstet Gynecol#19890000#1989#73#557-61#20080200#03.htm#0029-7844
#Obstet Gynecol##
00533000000000277000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100014000710100018000850120
08300103030002600186710000200212065000900214064000500223031000300228032000200231
014000600233865000900239002000700248#v23n2#v:\scielo\serial\rpsp\v23n2\markup\03
.htm#S#c#134#7#article#42#7#^rND^sWein^nP#^rND^sBeischer^nN#Gestational diabetes
. In twin pregnancy: prevalence and long term implications^len#Aust NZ J Obstet 
Gynaecol#2#19920000#1992#32#4#325-7#20080200#03.htm##
00585000000000277000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100016000710100019000870120
12100106030001500227065000900242064000500251031000300256014000700259865000900266
002000700275035001000282801001500292#v23n2#v:\scielo\serial\rpsp\v23n2\markup\03
.htm#S#c#135#8#article#42#8#^rND^sNahum^nGG#^rND^sHuffaker^nBJ#Racial difference
s in oral glucose screening tests: Establishing race-specific criteria for abnor
mality in pregnancy^len#Obstet Gynecol#19930000#1993#81#517-22#20080200#03.htm#0
029-7844#Obstet Gynecol##
00703000000000337000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100015000710100018000860100
02000104010001500124010001700139010001600156810000600172012011800178030000900296
06500090030506400050031403100030031901400080032286500090033000200070033903500100
0346801000900356#v23n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#c#136#9#artic
le#42#9#^rND^sGroop^nL#^rND^sForsblom^nC#^rND^sLehtovirta^nM#^rND^sTuorm^nT#^rND
^sKaranko^nS#^rND^sNissen^nM#et al#Metabolic consequences of a family history of
 NIDDM (the Botnia study): evidence of sex-specific parental effects^len#Diabete
s#19960000#1996#45#1585-93#20080200#03.htm#0012-1797#Diabetes##
00511000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100015000910120
03400106030001400140065000900154064000500163031000400168032000200172014000700174
865000900181002000700190035001000197801001400207#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\03.htm#S#c#137#10#article#42#10#^rND^sBuchanon^nT#^rND^sXiang^nA#Gesta
tional diabetes mellitus^len#J Clin Invest#20050000#2005#115#3#485-91#20080200#0
3.htm#0021-9738#J Clin Invest##
00724000000000253000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700170022000730180069000950620
23200164066001500396062002300411065000900434064000500443014000600448865000900454
002000700463#v23n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#c#138#11#article#
42#11#Institute of Medicine#Nutrition during pregnancy, weight gain and nutrient
 supplements^len#Subcommittee on Nutritional Status and Weight Gain during Pregn
ancy, Subcommittee on Dietary Intake and Nutrient Supplements During Pregnancy, 
Committee on Nutritional Status During Pregnancy and Lactation, Food and Nutriti
on Board#Washington^eDC#National Academy Press#19900000#1990#1-233#20080200#03.h
tm##
00513000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100021000730100016000940120
05700110030000900167065000900176064000500185031000300190014000700193865000900200
002000700209035001000216801000900226#v23n2#v:\scielo\serial\rpsp\v23n2\markup\03
.htm#S#c#139#12#article#42#12#^rND^sO'Sullivan^nJB#^rND^sMahan^nCM#Criteria for 
the glucose tolerance test in pregnancy^len#Diabetes#19640000#1964#13#278-85#200
80200#03.htm#0012-1797#Diabetes##
00463000000000253000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700170026000730180051000990660
00700150062000400157065000900161064000500170025001400175031000400189865000900193
002000700202#v23n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#c#140#13#article#
42#13#World Health Organization#Diabetes mellitus, report of a WHO Study Group^l
en#Geneva#WHO#19850000#1985#Tech Rep. Ser#727#20080200#03.htm##
00578000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100023000730100022000960100
01500118012006300133030001400196065000900210064000500219031000300224032000200227
014000700229865000900236002000700245035001000252801001400262#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\03.htm#S#c#141#14#article#42#14#^rND^sRagoobirsingh^nD#^rN
D^sLewis Fuller^nG#^rND^sMorrison#The Jamaican diabetes survey: A protocol for t
he Caribbean^len#Diabetes Care#19950000#1995#18#9#1277-9#20080200#03.htm#0149-59
92#Diabetes Care##
00596000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100014000880100
02200102010001800124012009400142030002500236710000200261065000900263064000500272
031000400277014000900281865000900290002000700299#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\03.htm#S#c#142#15#article#42#15#^rND^sSacks^nD#^rND^sChen^nW#^rND^sWol
de-Tsadik^nG#^rND^sBuchanon^nT#Fasting plasma glucose test at first pre-natal vi
sit as a screen for gestational diabetes^len#Obstetrics & Gynaecology#2#20030000
#2003#101#1197-203#20080200#03.htm##
00598000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100012000730100014000850100
01500099010001600114012008400130030001800214065000900232064000500241031000300246
020000300249865000900252002000700261035001000268801001800278#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\03.htm#S#c#143#16#article#42#16#^rND^sKo^nG#^rND^sTam^nWH#
^rND^sChen^nJC#^rND^sRogers^nM#Prevalence of gestational diabetes mellitus in Ho
ng Kong based on 1998 criteria^len#Diabetic Medicine#20020000#2002#19#80#2008020
0#03.htm#0742-3071#Diabetic Medicine##
00685000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100016000910100
01800107010001600125010001800141010001600159012010900175030001300284065000900297
06400050030603100030031101400060031486500090032000200070032903500100033680100130
0346#v23n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#c#144#17#article#42#17#^r
ND^sMatthews^nD#^rND^sHosker^nJ#^rND^sRudenski^nA#^rND^sNaylor^nB#^rND^sTreacher
^nD#^rND^sTurner^nR#Homeostasis Model Assessment: Insulin resistance andbetacell
 function from glucose concentrations in man^len#Diabetologia#19850000#1985#28#4
12-9#20080200#03.htm#0012-186X#Diabetologia##
00603000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100018000900100
01700108010001600125012009100141030000900232065000900241064000500250031000400255
014000700259865000900266002000700275035001000282801000900292#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\03.htm#S#c#145#18#article#42#18#^rND^sFulton^nRE#^rND^sSal
asek^nML#^rND^sDuTeau^nNM#^rND^sBlack^nWC#SSCP analysis of cDNA markers provides
 a dense linkage map of the Aedes Aegypti genome^len#Genetics#20010000#2001#158#
715-26#20080200#03.htm#0016-6731#Genetics##
00556000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100014000730100015000870100
01600102012007000118030001400188065000900202064000500211031000300216014000700219
865000900226002000700235035001000242801001400252#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\03.htm#S#c#146#19#article#42#19#^rND^sFord^nE#^rND^sGiles^nW#^rND^sMok
dad^nA#Increasing prevalence of the metabolic syndrome amongst US adults^len#Dia
betes Care#20040000#2004#27#2444-9#20080200#03.htm#0149-5992#Diabetes Care##
00486000000000241000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700170015000730180086000880660
00700174062001500181065000900196064000500205061001800210865000900228002000700237
#v23n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#c#147#20#article#42#20#United
 Nations#International convention on the elimination of all forms of racial disc
rimination^len#Geneva#United Nations#20010000#2001#CERD/ C/383/Add.1#20080200#03
.htm##
00656000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100017000910100
01800108010001600126012013400142030001400276065000900290064000500299031000300304
014000700307865000900314002000700323035001000330801001400340#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\03.htm#S#c#148#21#article#42#21#^rND^sBenjamin^nE#^rND^sWi
nters^nD#^rND^sMayfield^nJ#^rND^sGohdes^nD#Diabetes in pregnancy in Zuni Indian 
women: Prevalence and subsequent development of clinical diabetes after gestatio
nal diabetes^len#Diabetes Care#20020000#2002#25#487-93#20080200#03.htm#0149-5992
#Diabetes Care##
00655000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100018000920100
02100110012009400131030003700225065000900262064000500271031000400276032000200280
014000800282865000900290002000700299035001000306801003700316#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\03.htm#S#c#149#22#article#42#22#^rND^sRodriques^nE#^rND^sR
obinson^nE#^rND^sGray-Donald^nS#Prevalence of gestational diabetes mellitus amon
g James Bay Cree women in Northern Quebec^len#Canadian Medical Association Journ
al#19990000#1999#160#2#1293-97#20080200#03.htm#0008-4409#CANADIAN MEDICAL ASSOCI
ATION JOURNAL##
00709000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100014000730100015000870100
01300102010001700115010001600132012015500148030001400303065000900317064000500326
03100030033103200020033401400070033686500090034300200070035203500100035980100140
0369#v23n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#c#150#23#article#42#23#^r
ND^sDyck^nR#^rND^sKlomp^nH#^rND^sTan^nL#^rND^sTurnell^nR#^rND^sBoctor^nM#A compa
rison of rates, risk factors, and outcomes of gestational diabetes between Abori
ginal and Non-Aboriginal women in the Saskatoon Health District^len#Diabetes Car
e#20020000#2002#16#9#1231-5#20080200#03.htm#0149-5992#Diabetes Care##
00670000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100023000900100
02000113010001800133010001600151010001900167012008000186030001400266065000900280
06400050028903100030029401400070029786500090030400200070031303500100032080100140
0330#v23n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#c#151#24#article#42#24#^r
ND^sDabelea^nD#^rND^sSnell-Bergeon^nJ#^rND^sHartsfield^nC#^rND^sKischoff^nK#^rND
^sHamman^nR#^rND^sMc Duffie^nR#Increasing prevalence of gestational diabetes ove
r time and by birth cohort^len#Diabetes Care#20050000#2005#28#579-84#20080200#03
.htm#0149-5992#Diabetes Care##
00788000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100015000920100
01700107010001500124010001800139010001900157810000600176012019800182030001000380
06500090039006400050039903100030040401400070040786500090041400200070042303500100
0430801001000440#v23n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#c#152#25#arti
cle#42#25#^rND^sWatanabe^nRM#^rND^sValle^nT#^rND^sHauser^nER#^rND^sGhosh^nS#^rND
^sEriksson^nJ#^rND^sKohtamaki^nK#et al#Familiarity of quantitative metabolic tra
its in Finnish families with non-insulin-dependent diabetes mellitus: Finland-Un
ited States investigation of NIDDM genetics (FUSION) study investigators^len#Hum
 Hered#19900000#1990#49#159-68#20080200#03.htm#0001-5652#Hum Hered##
00721000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100015000900100
01800105010002100123010002200144010001400166012014700180030000900327065000900336
06400050034503100030035001400070035386500090036000200070036903500100037680100090
0386#v23n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#c#153#26#article#42#26#^r
ND^sPoulsen^nP#^rND^sLevin^nK#^rND^sPetersen^nI#^rND^sChristensen^nK#^rND^sBeck-
Nielsen^nH#^rND^sVaag^nA#Heritability of insulin secretion, peripheral and hepat
ic insulin action, and intracellular glucose partitioning in young and old Danis
h twins^len#Diabetes#20050000#2005#54#275-83#20080200#03.htm#0012-1797#Diabetes#
#
00592000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100017000920100
01500109012010000124030001400224065000900238064000500247031000300252014000700255
865000900262002000700271035001000278801001400288#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\03.htm#S#c#154#27#article#42#27#^rND^sCatalano^nOM#^rND^sTyzbir^nED#^r
ND^sSims^nEA#Incidence and significance of islet cell antibodies in women with p
revious gestational diabetes^len#Diabetes Care#19900000#1990#13#478-82#20080200#
03.htm#0149-5992#Diabetes Care##
00705000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100017000910100
01600108010001800124010002200142010001400164810000600178012013800184030001600322
71000020033806500090034006400050034903100020035401400070035686500090036300200070
0372#v23n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#c#155#28#article#42#28#^r
ND^sMauricio^nD#^rND^sCorcoy^nRM#^rND^sCodina^nM#^rND^sBalsells^nM#^rND^sPuig-Do
mingo^nM#^rND^sPou^nJm#et al#Islet cell antibodies identify a subset of gestatio
nal diabetic women with higher risk of developing diabetes shortly after pregnan
cy^len#Diab Nutr Metab#2#19920000#1992#5#237-41#20080200#03.htm##
00736000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100014000730100014000870100
01800101010001900119010001900138010002500157810000600182012013400188030001300322
06500090033506400050034403100030034901400070035286500090035900200070036803500100
0375801001300385#v23n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#c#156#29#arti
cle#42#29#^rND^sDamm^nP#^rND^sKuhl^nC#^rND^sBuschard^nK#^rND^sJakobsen^nBK#^rND^
sSvejgaard^nA#^rND^sSodoyez-Goffaux^nF#et al#Prevalence and predictive value of 
women with islet cell antibodies and insulin autoantibodies in women with gestat
ional diabetes^len#Diabetic Med#19940000#1994#11#558-63#20080200#03.htm#0742-307
1#Diabetic med##
00564000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100019000900120
06600109030002400175065000900199064000500208031000300213032000200216014000600218
865000900224002000700233035001000240801002400250#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\03.htm#S#c#157#30#article#42#30#^rND^sBarcelo^nA#^rND^sRajpathak^nS#In
cidence and prevalence of diabetes mellitus in the Americas^len#Rev Panam Salud 
Publica#20010000#2001#10#5#301-8#20080200#03.htm#1020-4989#Rev Panam Salud Publi
ca##
00725000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100018000890100
02000107010001800127010002000145012016100165030001800326065000900344064000500353
031000200358014000700360865000900367002000700376035001000383801001800393#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\03.htm#S#c#158#31#article#42#31#^rND^sBoberg^n
J#^rND^sCarlson^nLA#^rND^sFreyschuss^nU#^rND^sLassers^nBW#^rND^sWahlqvist^nML#Sp
hlanchic secretion rates of plasma triglycerides and total and Splanchnic turnov
er of plasma free fatty acids in men with normo- and hypertriglyceridaemia^len#E
ur J Clin Invest#19920000#1992#9#454-66#20080200#03.htm#0014-2972#Eur J Clin Inv
est##
00659000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100017000880100
02000105010001600125010001600141012011600157030001100273065000900284064000500293
031000300298014000700301865000900308002000700317035001000324801001100334#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\03.htm#S#c#159#32#article#42#32#^rND^sDunn^nFL
#^rND^sGrundy^nSM#^rND^sBilheimer^nDW#^rND^sHavel^nRJ#^rND^sRaskin^nP#Impaired c
atabolism of very low-density lipoprotein-triglyceride in a family with primary 
hypertriglyceridaemia^len#Metabolism#19850000#1985#34#316-24#20080200#03.htm#002
6-0495#Metabolism##
00585000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100017000910100
01700108012008600125030001800211065000900229064000500238031000200243014000600245
865000900251002000700260035001000267801001800277#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\03.htm#S#c#160#33#article#42#33#^rND^sLalouel^nJM#^rND^sWilson^nDE#^rN
D^sIverius^nP#Lipoprotein lipase and hepatic triglyceride lipase: Molecular and 
genetic aspects^len#Curr Opin Lipidol#19920000#1992#3#86-95#20080200#03.htm#0957
-9672#Curr Opin Lipidol##
00821000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100022000730100017000950100
01400112010002200126010001500148010001700163810000600180012021900186030001400405
06500090041906400050042803100020043301400080043586500090044300200070045203500100
0459801001400469#v23n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#c#161#34#arti
cle#42#34#^rND^sAalto-Setala^nK#^rND^sFisher^nEA#^rND^sChen^nX#^rND^sChajek-Shau
l^nT#^rND^sHayek^nT#^rND^sZechner^nR#et al#Mechanism of hypertriglyceridaemia in
 human apolipoprotein (apo) CIII transgenic mice. Diminished very low density li
poprotein fractional catabolic rate associated with increased apo CIII reduced a
po E on particles^len#J Clin Invest#19920000#1992#9#889-900#20080200#03.htm#0021
-9738#J Clin Invest##
00716000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100020000920100
01700112010001500129010001800144012014400162030002300306065000900329064000500338
031000300343014000700346865000900353002000700362035001000369801002300379#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\03.htm#S#c#162#35#article#42#35#^rND^sDammerma
n^nM#^rND^sSandkuijl^nLA#^rND^sHalaas^nJL#^rND^sChung^nW#^rND^sBreslow^nJL#An ap
olipoprotein CIII haplotype protective against hypertriglyceridaemia is specifie
d by promoter and 3' untranslated region polymorphisms^len#Proc Natl Acad Sci US
A#19930000#1993#90#4562-6#20080200#03.htm#0027-8424#Proc Natl Acad Sci USA##
00472000000000265000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730120039000890300
01500128065000900143064000500152031000300157014000500160865000900165002000700174
035001000181801001500191#v23n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#c#163
#36#article#42#36#^rND^sLanger^nO#Management of gestational diabetes^len#Clin Pe
rinatol#19930000#1993#20#1-15#20080200#03.htm#0095-5108#Clin Perinatol##
00624000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100019000890100
02000108010001600128010001700144012005700161030001400218065000900232064000500241
03100030024603200020024901400070025186500090025800200070026703500100027480100140
0284#v23n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#c#164#37#article#42#37#^r
ND^sSuper^nDM#^rND^sEdelberg^nSC#^rND^sPhilipson^nEH#^rND^sHertz^nRH#^rND^sKacha
n^nSC#Diagnosis of gestational diabetes in early pregnancy^len#Diabetes Care#199
10000#1991#14#4#288-94#20080200#03.htm#0149-5992#Diabetes Care##
00707000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100017000880100
01800105010001800123010001700141010001800158810000600176012009500182030001300277
06500090029006400050029903100030030403200030030701400080031086500090031800200070
0327035001000334801001300344#v23n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#c
#165#38#article#42#38#^rND^sShaat^nN#^rND^sEkelund^nM#^rND^sLernmark^nA#^rND^sIv
arsson^nS#^rND^sAlmgren^nP#^rND^sBerntorp^nK#et al#Association of the E23K polym
orphism in the KCNJ11 gene with gestational diabetes mellitus^len#Diabetologia#2
0050000#2005#48#12#2544-51#20080200#03.htm#0012-186X#Diabetologia##
00757000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100018000890100
01900107010001900126010002300145010001500168810000600183012018400189030001600373
71000020038906500090039106400050040003100030040501400070040886500090041500200070
0424#v23n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#c#166#39#article#42#39#^r
ND^sZaidi^nFK#^rND^sWareham^nNJ#^rND^sMcCarthy^nMI#^rND^sHoldstock^nJ#^rND^sKall
oo-Hosein^nH#^rND^sKrook^nA#et al#Homozygosity for a common polymorphism in the 
islet-specific promoter of the glucokinase gene is associated with a reduced ear
ly insulin response to oral glucose in pregnant women^len#Diabet Medicine#2#1997
0000#1997#14#228-34#20080200#03.htm##
00677000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100017000900100
01600107010001900123010002400142010001500166012008800181030001500269065000900284
06400050029303100040029801400080030286500090031000200070031903500100032680100150
0336#v23n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#c#167#40#article#42#40#^r
ND^sLeipold^nH#^rND^sKnofler^nM#^rND^sGruber^nC#^rND^sHaslinger^nP#^rND^sBancer-
Todesca^nD#^rND^sWorda^nC#Calpain-10 haplotype combination and association with 
gestational diabetes mellitus^len#Obstet Gynecol#20040000#2004#103#1235-40#20080
200#03.htm#0029-7844#Obstet Gynecol##
00754000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100019000910100
02000110010002100130010002000151010001800171810000600189012014500195030001400340
06500090035406400050036303100030036801400050037186500090037600200070038503500100
0392801001400402#v23n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#c#168#41#arti
cle#42#41#^rND^sRissanen^nJ#^rND^sMarkkanen^nA#^rND^sKarkkainen^nP#^rND^sPihlaja
maki^nJ#^rND^sKekalainen^nP#^rND^sMykkanen^nL#et al#Sulfonylurea receptor 1 gene
 variants are associated with gestational diabetes and type 2 diabetes but not w
ith altered secretion of insulin^len#Diabetes Care#20000000#2000#23#70-3#2008020
0#03.htm#0149-5992#Diabetes Care##
00728000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100019000920100
01700111010001600128010001700144010002000161810000600181012012100187030000900308
06500090031706400050032603100030033103200020033401400070033686500090034300200070
0352035001000359801000900369#v23n2#v:\scielo\serial\rpsp\v23n2\markup\03.htm#S#c
#169#42#article#42#42#^rND^sFrayling^nTM#^rND^sLindgren^nCM#^rND^sChevre^nJC#^rN
D^sMenzel^nS#^rND^sWishart^nM#^rND^sBenmezroua^nY#et al#A genome-wide scan in fa
milies with maturity onset diabetes of the young: evidence for further genetic h
eterogeneity^len#Diabetes#20030000#2003#52#3#872-81#20080200#03.htm#0012-1797#Di
abetes##
00263000000000169000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640910009000660920007000750020007000827030
00400089#v23n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#o#1#1#article#1#20080
318#103136#04.htm#191##
04488000000000637000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000400084121000300088049000800091158000300099030002400102
03100030012603200020012906500090013101400100014003500100015001200600016001200610
02200100041002810100027003220100038003490100043003870700126004300700110005560831
43800666085000802104085002202112085002202134085002202156085001902178083144902197
08500080364608500380365408500230369208500230371508500190373805800290375711700060
3786072000303792112000903795111001303804114000903817113001703826002000703843#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#h#2#1#article#1#oa#en#br1.1#1#3.1
#TAB#04#RPSP020#nd#Rev Panam Salud Publica#23#2#20080200#^f92^l100#1020-4989#Rot
avirus morbidity and mortality in children in Brazil^len#Morbilidad y mortalidad
 por rotavirus en niños en Brasil^les#^rND^1A01^nAna Marli Christovam^sSartori#^
rND^1A02^nJoice^sValentim#^rND^1A02^nPatrícia Coelho de^sSoárez#^rND^1A02^nHille
gonda Maria Dutilh^sNovaes#Universidade de São Paulo^iA01^1Faculdade de Medicina
^2Hospital das Clínicas^3Clínica de Moléstias Infecciosas e Parasitárias#Univers
idade de São Paulo^iA02^1Faculdade de Medicina^2Departamento de Medicina Prevent
iva^cSao Paulo^pBrasil#^len^aOBJECTIVE: To study the epidemiology of rotavirus a
nd estimate rotavirus-associated morbidity and mortality in children < 5 years o
f age in Brazil in 2004 before introducing the rotavirus vaccine in Brazil's Nat
ional Immunization Program (Programa Nacional de Imunizações, PNI). METHODS: To 
estimate rotavirus morbidity, published studies (1999-2006) addressing incidence
 of acute diarrhea among children < 5 years of age and frequency of rotavirus in
fection among children with diarrhea in Brazil were reviewed. Diarrhea episodes 
were divided into three categories of severity by level of care: mild cases requ
iring only home-based care; moderate cases requiring a visit to an outpatient he
althcare facility; and severe cases requiring hospitalization. To estimate rotav
irus mortality, information on the number of registered deaths from diarrhea in 
children < 5 years of age was obtained from the Mortality Information System (Si
stema de Informação sobre Mortalidade, SIM) of Brazil's public healthcare system
 (Sistema Único de Saúde, SUS) and the proportion of deaths due to rotavirus was
 calculated. RESULTS: Rotavirus infections were estimated to cause 3 525 053 epi
sodes of diarrhea, 655 853 visits to outpatient healthcare facilities, 92 453 ho
spitalizations, and 850 deaths of children < 5 years of age each year in Brazil.
 CONCLUSION: Rotavirus infections are an important cause of child morbidity and 
mortality in Brazil.#^dnd^i1#^tm^len^kRotavirus^i1#^tm^len^kmortality^i1#^tm^len
^kmorbidity^i1#^tm^len^kBrazil^i1#^les^aOBJETIVOS: Analizar la epidemiología del
 rotavirus y estimar la morbilidad y la mortalidad asociadas con las infecciones
 por rotavirus en niños < 5 años de edad en Brasil en 2004, antes de incluir la 
vacuna contra el rotavirus en el Programa Nacional de Inmunizaciones (PNI). MÉTO
DOS: Para estimar la morbilidad por rotavirus se revisaron los estudios publicad
os (1999-2006) que abordaban la incidencia de diarrea aguda en niños < 5 años de
 edad y la frecuencia de las infecciones por rotavirus en niños con diarrea en B
rasil. Los casos de diarrea se dividieron en tres categorías de gravedad según e
l nivel de atención que requirieron: casos leves que solo requirieron atención d
omiciliaria, casos moderados que requirieron la visita a un servicio ambulatorio
 de salud y casos graves que requirieron hospitalización. Para estimar la mortal
idad por rotavirus se utilizó el número de muertes registradas por diarrea en ni
ños de < 5 años, según el Sistema de Información sobre Mortalidad (SIM) del Sist
ema Único de Salud (SUS) de Brasil, y se calculó la proporción de muertes causad
as por este virus. RESULTADOS: Se estimó que las infecciones por rotavirus causa
n anualmente 3 525 053 casos de diarrea, 655 853 visitas a servicios ambulatorio
s de salud, 92 453 hospitalizaciones y 850 muertes en niños < 5 años de edad en 
Brasil. CONCLUSIONES: Las infecciones por rotavirus constituyen una importante c
ausa de morbilidad y mortalidad en Brasil.#^dnd^i2#^tm^les^kInfecciones por rota
virus^i2#^tm^les^kmorbilidad^i2#^tm^les^kmortalidad^i2#^tm^les^kBrasil^i2#Brazil
ian Ministry of Health#other#49#20070612#12 June 2007#20071120#20 November 2007#
04.htm##
04679000000000637000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000400084121000300088049000800091158000300099030002400102
03100030012603200020012906500090013101400100014003500100015001200670016001200680
02270100041002950100027003360100038003630100043004010700126004440700110005700831
54700680085000802227085002202235085002202257085002202279085001902301083151702320
08500080383708500380384508500230388308500230390608500190392905800290394811700060
3977072000303983112000903986111001303995114000904008113001704017002000704034#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#f#3#1#article#1#oa#en#br1.1#1#3.1
#TAB#04#RPSP020#nd#Rev Panam Salud Publica#23#2#20080200#^f92^l100#1020-4989#<B>
Rotavirus morbidity and mortality in children in Brazil</B>^len#<B>Morbilidad y 
mortalidad por rotavirus en niños en Brasil</B>^les#^rND^1A01^nAna Marli Christo
vam^sSartori#^rND^1A02^nJoice^sValentim#^rND^1A02^nPatrícia Coelho de^sSoárez#^r
ND^1A02^nHillegonda Maria Dutilh^sNovaes#Universidade de São Paulo^iA01^1Faculda
de de Medicina^2Hospital das Clínicas^3Clínica de Moléstias Infecciosas e Parasi
tárias#Universidade de São Paulo^iA02^1Faculdade de Medicina^2Departamento de Me
dicina Preventiva^cSao Paulo^pBrasil#^len^a<B>OBJECTIVE:</B>&nbsp;To study the e
pidemiology of rotavirus and estimate rotavirus-associated morbidity and mortali
ty in children <U>&lt;</U> 5 years of age in Brazil in 2004 before introducing t
he rotavirus vaccine in Brazil's National Immunization Program (<I>Programa Naci
onal de Imunizações</I>, PNI). <B>METHODS:</B>&nbsp;To estimate rotavirus morbid
ity, published studies (1999-2006) addressing incidence of acute diarrhea among 
children <U>&lt;</U> 5 years of age and frequency of rotavirus infection among c
hildren with diarrhea in Brazil were reviewed. Diarrhea episodes were divided in
to three categories of severity by level of care: mild cases requiring only home
-based care; moderate cases requiring a visit to an outpatient healthcare facili
ty; and severe cases requiring hospitalization. To estimate rotavirus mortality,
 information on the number of registered deaths from diarrhea in children <U>&lt
;</U> 5 years of age was obtained from the Mortality Information System (<I>Sist
ema de Informação sobre Mortalidade</I>, SIM) of Brazil's public healthcare syst
em (<I>Sistema Único de Saúde</I>, SUS) and the proportion of deaths due to rota
virus was calculated. <B>RESULTS:</B>&nbsp;Rotavirus infections were estimated t
o cause 3 525 053 episodes of diarrhea, 655 853 visits to outpatient healthcare 
facilities, 92 453 hospitalizations, and 850 deaths of children <U>&lt;</U> 5 ye
ars of age each year in Brazil. <B>CONCLUSION:</B>&nbsp;Rotavirus infections are
 an important cause of child morbidity and mortality in Brazil.#^dnd^i1#^tm^len^
kRotavirus^i1#^tm^len^kmortality^i1#^tm^len^kmorbidity^i1#^tm^len^kBrazil^i1#^le
s^a<B>OBJETIVOS:</B> Analizar la epidemiología del rotavirus y estimar la morbil
idad y la mortalidad asociadas con las infecciones por rotavirus en niños <U>&lt
;</U> 5 años de edad en Brasil en 2004, antes de incluir la vacuna contra el rot
avirus en el Programa Nacional de Inmunizaciones (PNI). <B>MÉTODOS: </B>Para est
imar la morbilidad por rotavirus se revisaron los estudios publicados (1999-2006
) que abordaban la incidencia de diarrea aguda en niños <U>&lt;</U> 5 años de ed
ad y la frecuencia de las infecciones por rotavirus en niños con diarrea en Bras
il. Los casos de diarrea se dividieron en tres categorías de gravedad según el n
ivel de atención que requirieron: casos leves que solo requirieron atención domi
ciliaria, casos moderados que requirieron la visita a un servicio ambulatorio de
 salud y casos graves que requirieron hospitalización. Para estimar la mortalida
d por rotavirus se utilizó el número de muertes registradas por diarrea en niños
 de <U>&lt;</U> 5 años, según el Sistema de Información sobre Mortalidad (SIM) d
el Sistema Único de Salud (SUS) de Brasil, y se calculó la proporción de muertes
 causadas por este virus. <B>RESULTADOS: </B>Se estimó que las infecciones por r
otavirus causan anualmente 3 525 053 casos de diarrea, 655 853 visitas a servici
os ambulatorios de salud, 92 453 hospitalizaciones y 850 muertes en niños <U>&lt
;</U> 5 años de edad en Brasil. <B>CONCLUSIONES: </B>Las infecciones por rotavir
us constituyen una importante causa de morbilidad y mortalidad en Brasil.#^dnd^i
2#^tm^les^kInfecciones por rotavirus^i2#^tm^les^kmorbilidad^i2#^tm^les^kmortalid
ad^i2#^tm^les^kBrasil^i2#Brazilian Ministry of Health#other#49#20070612#12 June 
2007#20071120#20 November 2007#04.htm##
04642000000000661000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640640013000660710003000790400003000820010
00600085042000200091120000400093038000400097121000300101049000800104158000300112
03000260011503100030014103200020014406500090014601400100015503500100016501200600
01750120061002350100041002960100027003370100038003640100043004020700147004450700
11200592083143800704085000802142085002202150085002202172085002202194085001902216
08314490223508500080368408500380369208500230373008500230375308500190377605800290
37951170006038240720003038301120009038331110013038421140009038551130017038640020
00703881008009203888#v23n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#l#4#1#art
icle#1#^mFeb.^a2008#oa#en#br1.1#1#3.1#tab#04#RPSP020#nd#Rev. panam. salud públic
a#23#2#20080200#^f92^l100#1020-4989#Rotavirus morbidity and mortality in childre
n in Brazil^len#Morbilidad y mortalidad por rotavirus en niños en Brasil^les#^rN
D^1A01^nAna Marli Christovam^sSartori#^rND^1A02^nJoice^sValentim#^rND^1A02^nPatr
ícia Coelho de^sSoárez#^rND^1A02^nHillegonda Maria Dutilh^sNovaes#^iA01^1Univers
idade de São Paulo^2Faculdade de Medicina^3Hospital das Clínicas. Clínica de Mol
éstias Infecciosas e Parasitárias^cSao Paulo^pBrasil#^iA02^1Universidade de São 
Paulo^2Faculdade de Medicina^3Departamento de Medicina Preventiva^cSao Paulo^pBr
asil#^len^aOBJECTIVE: To study the epidemiology of rotavirus and estimate rotavi
rus-associated morbidity and mortality in children < 5 years of age in Brazil in
 2004 before introducing the rotavirus vaccine in Brazil's National Immunization
 Program (Programa Nacional de Imunizações, PNI). METHODS: To estimate rotavirus
 morbidity, published studies (1999-2006) addressing incidence of acute diarrhea
 among children < 5 years of age and frequency of rotavirus infection among chil
dren with diarrhea in Brazil were reviewed. Diarrhea episodes were divided into 
three categories of severity by level of care: mild cases requiring only home-ba
sed care; moderate cases requiring a visit to an outpatient healthcare facility;
 and severe cases requiring hospitalization. To estimate rotavirus mortality, in
formation on the number of registered deaths from diarrhea in children < 5 years
 of age was obtained from the Mortality Information System (Sistema de Informaçã
o sobre Mortalidade, SIM) of Brazil's public healthcare system (Sistema Único de
 Saúde, SUS) and the proportion of deaths due to rotavirus was calculated. RESUL
TS: Rotavirus infections were estimated to cause 3 525 053 episodes of diarrhea,
 655 853 visits to outpatient healthcare facilities, 92 453 hospitalizations, an
d 850 deaths of children < 5 years of age each year in Brazil. CONCLUSION: Rotav
irus infections are an important cause of child morbidity and mortality in Brazi
l.#^dnd^i1#^tm^len^kRotavirus^i1#^tm^len^kmortality^i1#^tm^len^kmorbidity^i1#^tm
^len^kBrazil^i1#^les^aOBJETIVOS: Analizar la epidemiología del rotavirus y estim
ar la morbilidad y la mortalidad asociadas con las infecciones por rotavirus en 
niños < 5 años de edad en Brasil en 2004, antes de incluir la vacuna contra el r
otavirus en el Programa Nacional de Inmunizaciones (PNI). MÉTODOS: Para estimar 
la morbilidad por rotavirus se revisaron los estudios publicados (1999-2006) que
 abordaban la incidencia de diarrea aguda en niños < 5 años de edad y la frecuen
cia de las infecciones por rotavirus en niños con diarrea en Brasil. Los casos d
e diarrea se dividieron en tres categorías de gravedad según el nivel de atenció
n que requirieron: casos leves que solo requirieron atención domiciliaria, casos
 moderados que requirieron la visita a un servicio ambulatorio de salud y casos 
graves que requirieron hospitalización. Para estimar la mortalidad por rotavirus
 se utilizó el número de muertes registradas por diarrea en niños de < 5 años, s
egún el Sistema de Información sobre Mortalidad (SIM) del Sistema Único de Salud
 (SUS) de Brasil, y se calculó la proporción de muertes causadas por este virus.
 RESULTADOS: Se estimó que las infecciones por rotavirus causan anualmente 3 525
 053 casos de diarrea, 655 853 visitas a servicios ambulatorios de salud, 92 453
 hospitalizaciones y 850 muertes en niños < 5 años de edad en Brasil. CONCLUSION
ES: Las infecciones por rotavirus constituyen una importante causa de morbilidad
 y mortalidad en Brasil.#^dnd^i2#^tm^les^kInfecciones por rotavirus^i2#^tm^les^k
morbilidad^i2#^tm^les^kmortalidad^i2#^tm^les^kBrasil^i2#Brazilian Ministry of He
alth#other#49#20070612#12 June 2007#20071120#20 November 2007#04.htm#Internet^ih
ttp://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892008000200004
##
00375000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704015400068002000700222#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#5#1#article#138#<p align="right"><font face
="Verdana, Arial, Helvetica, sans-serif" size="2"><b>INVESTIGACI&Oacute;N    ORI
GINAL</b> ORIGINAL RESEARCH</font></p>     ^cY#04.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704002200068002000700090#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#6#2#article#138#<p>&nbsp;</p>     ^cY#04.ht
m##
00387000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704016600068002000700234#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#7#3#article#138#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="4"><b><a name="top"></a>Rotavirus    morbidity 
and mortality in children in Brazil</b></font></p>     ^cY#04.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704002200068002000700090#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#8#4#article#138#<p>&nbsp;</p>     ^cY#04.ht
m##
00377000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704015600068002000700224#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#9#5#article#138#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="3"><b>Morbilidad y    mortalidad por rotavirus 
en ni&ntilde;os en Brasil</b></font></p>     ^cY#04.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#10#6#article#138#<p>&nbsp;</p>     ^cY#04.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#11#7#article#138#<p>&nbsp;</p>     ^cY#04.h
tm##
00509000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704028700069002000700356#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#12#8#article#138#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Ana Marli Christovam    Sartori<sup>I, <
a href="#back">*</a></sup>; Joice Valentim<sup>II</sup>; Patr&iacute;cia    Coel
ho de So&aacute;rez<sup>II</sup>; Hillegonda Maria Dutilh Novaes<sup>II</sup></b
></font></p>     ^cY#04.htm##
00489000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704026700069002000700336#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#13#9#article#138#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><sup>I</sup>Cl&iacute;nica    de Mol&eacute
;stias Infecciosas e Parasit&aacute;rias, Hospital das Cl&iacute;nicas    da Fac
uldade de Medicina da Universidade de S&atilde;o Paulo, Sao Paulo, Brasil    ^cY
#04.htm##
00379000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704015600070002000700226#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#14#10#article#138#<br>   <sup>II</sup>Depar
tamento de Medicina Preventiva, Faculdade de Medicina da Universidade    de S&at
ilde;o Paulo, Sao Paulo, Brasil</font></p>     ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#15#11#article#138#<p>&nbsp;</p>     ^cY#04.
htm##
00267000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704004400070002000700114#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#16#12#article#138#<p>&nbsp;</p> <hr size="1
" noshade>     ^cY#04.htm##
00321000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009800070002000700168#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#17#13#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     ^cY#04.htm#
#
00627000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704040400070002000700474#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#18#14#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>OBJECTIVE:</b>&nbsp;To    study the epi
demiology of rotavirus and estimate rotavirus-associated morbidity    and mortal
ity in children <u>&lt;</u> 5 years of age in Brazil in 2004 before    introduci
ng the rotavirus vaccine in Brazil's National Immunization Program    (<i>Progra
ma Nacional de Imuniza&ccedil;&otilde;es</i>, PNI).    ^cY#04.htm##
01174000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704095100070002000701021#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#19#15#article#138#<br>   <b>METHODS:</b>&nb
sp;To estimate rotavirus morbidity, published studies (1999&#150;2006)    addres
sing incidence of acute diarrhea among children <u>&lt;</u> 5 years of    age an
d frequency of rotavirus infection among children with diarrhea in Brazil    wer
e reviewed. Diarrhea episodes were divided into three categories of severity    
by level of care: mild cases requiring only home-based care; moderate cases    r
equiring a visit to an outpatient healthcare facility; and severe cases requirin
g    hospitalization. To estimate rotavirus mortality, information on the number
    of registered deaths from diarrhea in children <u>&lt;</u> 5 years of age wa
s    obtained from the Mortality Information System (<i>Sistema de Informa&ccedi
l;&atilde;o    sobre Mortalidade</i>, SIM) of Brazil's public healthcare system 
(<i>Sistema    &Uacute;nico de Sa&uacute;de</i>, SUS) and the proportion of deat
hs due to rotavirus    was calculated.    ^cY#04.htm##
00496000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704027300070002000700343#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#20#16#article#138#<br>   <b>RESULTS:</b>&nb
sp;Rotavirus infections were estimated to cause 3 525 053    episodes of diarrhe
a, 655 853 visits to outpatient healthcare facilities, 92    453 hospitalization
s, and 850 deaths of children <u>&lt;</u> 5 years of age    each year in Brazil.
    ^cY#04.htm##
00364000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704014100070002000700211#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#21#17#article#138#<br>   <b>CONCLUSION:</b>
&nbsp;Rotavirus infections are an important cause of child    morbidity and mort
ality in Brazil.</font></p>     ^cY#04.htm##
00389000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704016600070002000700236#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#22#18#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Key words:</b>    Rotavirus, mortality,
 morbidity, Brazil.</font></p> <hr size="1" noshade>     ^cY#04.htm##
00320000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009700070002000700167#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#23#19#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>RESUMEN</b></font></p>     ^cY#04.htm##
00619000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704039600070002000700466#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#24#20#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>OBJETIVOS:</b>    Analizar la epidemiol
og&iacute;a del rotavirus y estimar la morbilidad y la    mortalidad asociadas c
on las infecciones por rotavirus en ni&ntilde;os <u>&lt;</u>    5 a&ntilde;os de
 edad en Brasil en 2004, antes de incluir la vacuna contra el    rotavirus en el
 Programa Nacional de Inmunizaciones (PNI).    ^cY#04.htm##
01255000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704103200070002000701102#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#25#21#article#138#<br>   <b>M&Eacute;TODOS:
 </b> Para estimar la morbilidad por rotavirus se revisaron    los estudios publ
icados (1999&#150;2006) que abordaban la incidencia de diarrea    aguda en ni&nt
ilde;os <u>&lt;</u> 5 a&ntilde;os de edad y la frecuencia de las    infecciones 
por rotavirus en ni&ntilde;os con diarrea en Brasil. Los casos de    diarrea se 
dividieron en tres categor&iacute;as de gravedad seg&uacute;n el    nivel de ate
nci&oacute;n que requirieron: casos leves que solo requirieron atenci&oacute;n  
  domiciliaria, casos moderados que requirieron la visita a un servicio ambulato
rio    de salud y casos graves que requirieron hospitalizaci&oacute;n. Para esti
mar    la mortalidad por rotavirus se utiliz&oacute; el n&uacute;mero de muertes
 registradas    por diarrea en ni&ntilde;os de <u>&lt;</u> 5 a&ntilde;os, seg&ua
cute;n el Sistema    de Informaci&oacute;n sobre Mortalidad (SIM) del Sistema &U
acute;nico de Salud    (SUS) de Brasil, y se calcul&oacute; la proporci&oacute;n
 de muertes causadas    por este virus.    ^cY#04.htm##
00514000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704029100070002000700361#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#26#22#article#138#<br>   <b>RESULTADOS: </b
> Se estim&oacute; que las infecciones por rotavirus causan    anualmente 3 525 
053 casos de diarrea, 655 853 visitas a servicios ambulatorios    de salud, 92 4
53 hospitalizaciones y 850 muertes en ni&ntilde;os <u>&lt;</u>    5 a&ntilde;os 
de edad en Brasil.    ^cY#04.htm##
00375000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704015200070002000700222#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#27#23#article#138#<br>   <b>CONCLUSIONES: <
/b> Las infecciones por rotavirus constituyen una importante    causa de morbili
dad y mortalidad en Brasil.</font></p>     ^cY#04.htm##
00413000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704019000070002000700260#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#28#24#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Palabras clave:    </b> Infecciones por
 rotavirus, morbilidad, mortalidad, Brasil.</font></p> <hr size="1" noshade>    
 ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#29#25#article#138#<p>&nbsp;</p>     ^cY#04.
htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#30#26#article#138#<p>&nbsp;</p>     ^cY#04.
htm##
02167000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704194400070002000702014#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#31#27#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Diarrhea-associated    morbidity and morta
lity remains a significant problem among children in developing    countries. Fo
r the past several decades, efforts have been made worldwide to    combat this u
biquitous health problem. In Brazil, as in many other countries,    morbidity an
d mortality due to diarrheal disease decreased sharply in the 1970s    (1&#150;3
). Improvements in potable water supply and household sanitation are    consider
ed to have had a very important role (2&#150;3). By the 1980s, the decrease    i
n severe diarrhea and mortality was also influenced by the increasing use of    
oral rehydration therapy (ORT), the promotion of breast-feeding, and improvement
    in children's nutritional status (2&#150;4). Despite these achievements, reg
ional    and socioeconomic differences in diarrhea morbidity and mortality persi
sted    into the 1990s, even though access to healthcare services improved count
rywide    and the use of ORT did not vary significantly across different regions
 (3&#150;4).    In Southeast Brazil, which has better average socioeconomic cond
itions than    other parts of the country, the sharp reduction in mortality due 
to diarrhea    was accompanied by changes in seasonal patterns (5&#150;6). Analy
sis of the    temporal patterns of hospitalization and deaths from diarrhea amon
g children    <u>&lt;</u> 5 years of age in the Southeastern state of Rio de Jan
eiro from    1995 to 1998 revealed winter rather than summer peaks, suggesting v
iruses are    the predominant etiologic agents of severe diarrhea (5&#150;6). Di
arrhea caused    by bacteria and parasites, which are transmitted mainly through
 contaminated    food or water, is more prevalent during the summer, as opposed 
to diarrhea caused    by rotavirus infection, which is spread from person-to-per
son and is more frequent    in the cold and dry season (7).</font></p>     ^cY#0
4.htm##
01008000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704078500070002000700855#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#32#28#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Rotavirus is the    most common cause of s
evere diarrhea among children, with an estimated 111 million    diarrhea episode
s, 25 million outpatient healthcare facility visits, 2 million    hospitalizatio
ns, and 440 000 deaths among children <u>&lt;</u> 5 years worldwide    attributa
ble to the disease each year (8). By 5 years of age, nearly all children    will
 have had an episode of rotavirus gastroenteritis. While the incidence of    rot
avirus infections does not differ significantly between developing and industria
lized    countries, most deaths occur in underdeveloped countries, where infecti
on seems    to occur earlier in life and a broad diversity of rotavirus strains 
are observed    (8).</font></p>     ^cY#04.htm##
01280000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704105700070002000701127#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#33#29#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The similar incidence    of rotavirus infe
ctions in both industrialized and developing countries suggests    that it can n
ot be controlled through improved water supply and sanitation alone    (7). Ther
efore, to prevent severe rotavirus-associated disease and deaths, the    univers
al use of rotavirus vaccine has been recommended (9). Two new live oral    vacci
nes have recently been made available commercially&#151;a monovalent attenuated 
   G1P&#91;8&#93; human rotavirus vaccine (10) and a pentavalent human-bovine re
assortant    rotavirus vaccine containing human serotypes G1, G2, G3, G4, and P&
#91;8&#93;    (11). Both products have demonstrated efficacy against severe rota
virus-associated    disease and a reassuring safety profile in phase 3 trials (1
0&#150;11). The    accelerated introduction of rotavirus vaccine in national imm
unization programs,    particularly in developing countries, is considered a pri
ority by the World    Health Organization (WHO) (9).</font></p>     ^cY#04.htm##
00804000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704058100070002000700651#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#34#30#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The sentinel surveillance    system for di
arrheal disease, proposed by the Brazilian Ministry of Health (MOH)    in 1994 a
nd currently active in around 80% of municipalities, has identified    an increa
sing number of outbreaks and provided a great deal of information about    rotav
irus infection in different regions of Brazil. Knowledge of the epidemiology    
of rotaviruses in the country as a whole remains limited, however, due to the   
 lack of population-based national studies (12&#150;13).</font></p>     ^cY#04.h
tm##
00704000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704048100070002000700551#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#35#31#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The main objectives    of this study were 
to understand the epidemiology of rotavirus infection in    Brazil in the pre-va
ccine era and to estimate rotavirus-associated disease and    death in children 
<u>&lt;</u> 5 years of age in order to provide data for a    baseline epidemiolo
gical diagnosis that may be useful for cost-effectiveness    studies as well as 
rotavirus vaccine impact monitoring.</font></p>     ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#36#32#article#138#<p>&nbsp;</p>     ^cY#04.
htm##
00337000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704011400070002000700184#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#37#33#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>MATERIALS AND    METHODS</b></font></p>
     ^cY#04.htm##
00336000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704011300070002000700183#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#38#34#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Selection of    studies</b></font></p> 
    ^cY#04.htm##
00776000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704055300070002000700623#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#39#35#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">To identify studies    of diarrhea episode
s among children <u>&lt;</u> 5 years of age in Brazil, a    computer search of s
cientific literature was conducted in PubMed and LILACS    (Latin American and C
aribbean Literature on Health Sciences) databases using    the keywords "diarrhe
a" and "Brazil" simultaneously. Cross-sectional surveys    and longitudinal comm
unity-based cohort studies published in Portuguese and    English between 1999 a
nd March 2006 were selected.</font></p>     ^cY#04.htm##
00500000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704027700070002000700347#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#40#36#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">For studies that    included results on di
arrhea prevalence but not estimated annual incidence,    the 2-week prevalence r
ate was converted to a 2-week incidence rate as described    below (14):</font><
/p>     ^cY#04.htm##
00299000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007600070002000700146#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#41#37#article#138#<p align="center"><img sr
c="/img/revistas/rpsp/v23n2/04s1.gif"></p>     ^cY#04.htm##
00376000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704015300070002000700223#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#42#38#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The average duration    of a diarrhea epis
ode was estimated as 3 days.</font></p>     ^cY#04.htm##
00519000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704029600070002000700366#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#43#39#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The 2-week diarrhea    incidence rate was 
then multiplied by 26 (the number of 2-week periods in a    year) (14) to estima
te annual incidence of diarrhea (per child). Correction    for seasonality was n
ot applied.</font></p>     ^cY#04.htm##
01221000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704099800070002000701068#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#44#40#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">National administrative    data were also 
collected on hospitalization of children <u>&lt;</u> 5 years    of age for diarr
hea<a name="top1"></a><a href="#back1"><sup>1</sup></a> by the    public healthc
are system (<i>Sistema &Uacute;nico de Sa&uacute;de</i>, SUS)    in 2004, based 
on registration records from the SUS Hospital Information System    (<i>Sistema 
de Informa&ccedil;&otilde;es Hospitalares</i>, SIH) (15), and number    of death
s of children <u>&lt;</u> 5 years of age from diarrhea in 2003 (the    last year
 for which definitive data were available), based on registration records    fro
m the national public health database (<i>Departamento de Inform&aacute;tica    
do Sistema &Uacute;nico de Sa&uacute;de</i>, DATASUS) Mortality Information    S
ystem (<i>Sistema de Informa&ccedil;&atilde;o sobre Mortalidade</i>, SIM) (16). 
   These data are freely available and in the public domain (15&#150;16).</font>
</p>     ^cY#04.htm##
01352000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704112900070002000701199#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#45#41#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">To identify studies    of frequency of rot
avirus disease among children <u>&lt;</u> 5 years of age    with diarrhea in Bra
zil, a computer search of scientific literature was conducted    in PubMed and L
ILACS using the keywords "rotavirus" and "Brazil" simultaneously.    Community-b
ased and healthcare services studies published in Portuguese and    English betw
een 1999 and March 2006 were selected. The review included studies    that laste
d at least 12 consecutive months and observed at least 100 children.    All meth
ods of rotavirus detection (enzyme-linked immunosorbent assay &#91;ELISA&#93;;  
  polyacrylamide gel electrophoresis &#91;PAGE&#93;; latex tests; and passive   
 hemagglutination) were considered. Letters and editorials as well as studies   
 limited to circulating rotavirus strains (i.e., the distribution and prevalence
    of G and P serotypes &#91;17&#93;) were excluded. The studies were grouped a
nd    analyzed by healthcare setting&#151;hospital, outpatient or mixed (outpati
ent    + hospital) facility, and home-based.</font></p>     ^cY#04.htm##
00368000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704014500070002000700215#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#46#42#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Estimates of    rotavirus-associated di
sease and deaths</b></font></p>     ^cY#04.htm##
01057000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704083400070002000700904#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#47#43#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">To estimate the    impact of rotavirus-ass
ociated diarrhea among children <u>&lt;</u> 5 years of    age in Brazil, a model
 used by Parashar et al. (8) was adopted. The population    of Brazilian childre
n <u>&lt;</u> 5 years of age in 2004 (18) was multiplied    by the estimated ann
ual incidence of diarrhea. These episodes of diarrhea were    then sorted into t
hree categories of severity by level of care: mild cases requiring    only home-
based care, moderate cases requiring care in outpatient healthcare    facilities
, and severe cases requiring hospitalization. Next, the total number    of episo
des in each category was multiplied by the estimated proportion attributable    
to rotavirus to yield the number of rotavirus cases in each category.</font></p>
     ^cY#04.htm##
00699000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704047600070002000700546#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#48#44#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">To estimate annual    incidence of rotavir
us-associated diarrhea per child, the number of reported    episodes of mild, mo
derate, and severe diarrhea was divided by the estimated    number of children u
nder 5 in the 2004 cohort (18). These annual incidence figures    were then mult
iplied by 5 in order to estimate the 5-year cumulative incidence    of rotavirus
-associated diarrhea per child.</font></p>     ^cY#04.htm##
00563000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704034000070002000700410#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#49#45#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">To estimate the    number of deaths from r
otavirus-associated diarrhea in Brazil, the number of    deaths of children <u>&
lt;</u> 5 years of age from diarrhea in 2003 (16) was    multiplied by the propo
rtion of rotavirus among children with severe diarrhea.</font></p>     ^cY#04.ht
m##
00776000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704055300070002000700623#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#50#46#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The risk of dying    from rotavirus by age
 5 was then calculated by dividing the number of births    in Brazil in 2004 (3 
210 361) (<i>Instituto Brasileiro de Geografia e Estat&iacute;stica</i>,    IBGE
) by the number of estimated rotavirus-associated deaths in the cohort of    chi
ldren under 5 in 1 year (assuming the number of events in a birth cohort    foll
owed for 5 years is similar to the number of events in a cohort of children    u
nder 5 followed for 1 year).</font></p>     ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#51#47#article#138#<p>&nbsp;</p>     ^cY#04.
htm##
00320000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009700070002000700167#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#52#48#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>RESULTS</b></font></p>     ^cY#04.htm##
00388000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704016500070002000700235#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#53#49#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Incidence of    diarrhea episodes among
 children <u>&lt;</u> 5 years of age</b></font></p>     ^cY#04.htm##
01884000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704166100070002000701731#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#54#50#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Five surveys and    five prospective longi
tudinal studies of diarrhea episodes in children <u>&lt;</u>    5 years of age i
n Brazil were identified (<a href="/img/revistas/rpsp/v23n2/04t1.gif">Table    1
</a>) (4; 19&#150;27). Most involved local or regional communities, and one    l
ongitudinal study lasted less than 12 consecutive months (23). There were signif
icant    regional differences in the incidence of diarrhea in children <u>&lt;</
u> 5    years of age in Brazil (<a href="/img/revistas/rpsp/v23n2/04t1.gif">Tabl
e 1</a>),    ranging from 1.04 episodes per child per year in the city of S&atil
de;o Paulo    in Southeast Brazil (26) to 5.55 among children living in househol
ds without    proper sanitation in Salvador (Bahia state) in Northeast Brazil (2
1). The results    of a national cross-sectional survey conducted in 1996 that e
stimated the incidence    of diarrhea in children <u>&lt;</u> 5 years of age at 
3.1 episodes per child    per year countrywide (4.06 for the Northeast region an
d 2.48 for the rest of    the country) (4) was adopted to calculate the number o
f diarrhea episodes. The    proportions of mild, moderate, and severe episodes w
ere calculated based on    a community-based study conducted in Salvador in whic
h the proportion of children    with diarrhea who required an outpatient healthc
are facility visit was 11.6%    and the proportion of children who required hosp
italization was 0.7% (22). In    a community-based study conducted in S&atilde;o
 Paulo, the proportion of children    with diarrhea who required hospitalization
 was 0.76% (26).</font></p>     ^cY#04.htm##
00772000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704054900070002000700619#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#55#51#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Multiplying the    estimated population of
 children <u>&lt;</u> 5 years of age in Brazil in 2004    (14 590 732 &#91;18&#9
3;) by estimated incidence of diarrhea (3.1) resulted    in 45 231 269 episodes 
of diarrhea distributed across the three categories of    severity by level of c
are: hospitalizations (0.7%, or 316 619 episodes); care    at outpatient health-
 care facilities (11.6%, or 5 246 827 episodes); and home-based    care (87.7%, 
or 39 667 823 episodes).</font></p>     ^cY#04.htm##
01351000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704112800070002000701198#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#56#52#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The estimate of    316 619 hospitalization
s compared well with the national administrative data:    In 2004, 259 669 child
ren <u>&lt;</u> 5 years of age were hospitalized in the    public healthcare sys
tem due to diarrhea, based on SIH/SUS registration records    (15). Children in 
their first year of life accounted for 98 703 (37.8%) of these    hospitalizatio
ns. Because SIH registries only include events occurring in the    public health
care system, this number (259 669) was adjusted to include the    private sector
. Data from a national household survey (<i>Pesquisa Nacional    por Amostra de 
Domic&iacute;lios</i>, PNAD) conducted in 2003 indicated the    public healthcar
e system was responsible for 77% of all hospitalizations of    children under 5 
in Brazil, whereas the private sector was responsible for 23%    (28). Taking in
to account the participation of the private sector, based on    administrative d
ata, an estimated total of 337 232 children <u>&lt;</u> 5 years    of age were h
ospitalized for diarrhea in Brazil in 2004.</font></p>     ^cY#04.htm##
00377000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704015400070002000700224#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#57#53#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Frequency of    rotavirus detection amo
ng children with diarrhea</b></font></p>     ^cY#04.htm##
01476000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704125300070002000701323#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#58#54#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Fifteen studies    that met the criteria f
or inclusion were identified, eight of them involving    hospitalized children a
nd nine involving children treated at outpatient healthcare    facilities or mix
ed (outpatient + hospital) facilities. The frequency of rotavirus    detection a
mong children <u>&lt;</u> 5 years of age hospitalized for diarrhea    in Brazil 
ranged from 15% to 36.7%, with a median of 29.2% (<a href="/img/revistas/rpsp/v2
3n2/04t2.gif">Table    2</a>) (29&#150;36). Among children <u>&lt;</u> 5 years o
f age with diarrhea    seen at outpatient healthcare facilities, the frequency o
f rotavirus detection    ranged from 3.8% to 23%, with a median of 12.5% (<a hre
f="/img/revistas/rpsp/v23n2/04t3.gif">Table    3</a>) (32&#150;33; 36&#150;41). 
Only two community-based studies reported the    frequency of rotavirus detectio
n. In one of them, involving children &lt; 3    years of age with diarrhea in Fo
rtaleza (Cear&aacute; state), rotavirus was    detected in 6% (12 out of 199 cas
es) (19). In the other, which included children    &lt; 4 years of age with diar
rhea in Salvador, rotavirus infections were found    in 7.9% (11 out of 139 case
s) (23).</font></p>     ^cY#04.htm##
00367000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704014400070002000700214#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#59#55#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Estimates of    rotavirus-associated di
arrhea episodes</b></font></p>     ^cY#04.htm##
01366000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704114300070002000701213#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#60#56#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The estimated number    of diarrhea episod
es attributable to rotavirus in each of the three categories    of severity by l
evel of care (hospital, outpatient healthcare facilities, and    home-based) and
 the estimated total number of rotavirus-associated diarrhea    episodes in chil
dren <u>&lt;</u> 5 years of age in Brazil are shown in <a href="#tab4">Table    
4</a>. In the base-case analysis, the incidence of rotavirus-associated diarrhea
    was estimated using the median rates of rotavirus detection in each category
.    The incidence of rotavirus-associated diarrhea in "best-case" and "worst-ca
se"    scenarios was also calculated, using the frequency of rotavirus infection
 according    to the lowest and highest rates of rotavirus detection in the revi
ewed studies    (<a href="#tab4">Table 4</a>). In the base-case analysis, among 
children <i>&lt;</i>    5 years of age, an estimated 3 525 053 diarrhea episodes
, 655 853 visits to    outpatient healthcare facilities, and 92 453 hospitalizat
ions related to rotavirus    occurred each year in Brazil.</font></p>     ^cY#04
.htm##
00258000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003500070002000700105#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#61#57#article#138#<p><a name="tab4"></a></p
>     ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#62#58#article#138#<p>&nbsp;</p>     ^cY#04.
htm##
00299000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007600070002000700146#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#63#59#article#138#<p align="center"><img sr
c="/img/revistas/rpsp/v23n2/04t4.gif"></p>     ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#64#60#article#138#<p>&nbsp;</p>     ^cY#04.
htm##
00634000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704041100070002000700481#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#65#61#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The estimated incidence    of rotavirus- a
ssociated diarrhea among children &lt; 5 years of age is 0.242    episodes per c
hild per year (base-case analysis), with a low-case to high-case    range from 0
.18 to 0.306. The 5-year cumulative incidence of rotavirus-associated    diarrhe
a is presented in <a href="#tab5">Table 5</a>.</font></p>     ^cY#04.htm##
00258000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003500070002000700105#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#66#62#article#138#<p><a name="tab5"></a></p
>     ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#67#63#article#138#<p>&nbsp;</p>     ^cY#04.
htm##
00299000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007600070002000700146#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#68#64#article#138#<p align="center"><img sr
c="/img/revistas/rpsp/v23n2/04t5.gif"></p>     ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#69#65#article#138#<p>&nbsp;</p>     ^cY#04.
htm##
00370000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704014700070002000700217#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#70#66#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Estimates of    deaths from rotavirus-a
ssociated diarrhea</b></font></p>     ^cY#04.htm##
00538000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704031500070002000700385#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#71#67#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">There were 2 913    deaths from diarrhea&#
151;4.3% of all deaths (67 846) of children <u>&lt;</u>    5 years of age in Bra
zil in 2003 (16). Children in their first year of life    accounted for most of 
these deaths (2 387 or 81.9%).</font></p>     ^cY#04.htm##
00648000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704042500070002000700495#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#72#68#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Multiplying the    number of diarrhea deat
hs by the proportion of rotavirus detection in children    hospitalized for diar
rhea (median, 29.2%; minimum, 15%; and maximum, 36.7%)    resulted in an estimat
ed 850 (minimum, 437; maximum, 1 069) deaths of children    <u>&lt;</u> 5 years 
of age from rotavirus-associated diarrhea in Brazil in 2003.</font></p>     ^cY#
04.htm##
00418000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704019500070002000700265#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#73#69#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The risk of dying    from rotavirus-associ
ated diarrhea by age 5 is presented in <a href="#tab5">Table    5</a>.</font></p
>     ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#74#70#article#138#<p>&nbsp;</p>     ^cY#04.
htm##
00323000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010000070002000700170#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#75#71#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>DISCUSSION</b></font></p>     ^cY#04.ht
m##
00972000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704074900070002000700819#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#76#72#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Estimates of the    impact of rotavirus-as
sociated diarrhea in childhood in Brazil in the pre-vaccine    era were calculat
ed using national data from published research and from the    SIH/SIM (SUS Hosp
ital and Mortality Information Systems). These estimates indicated    rotavirus 
infections are an important factor in morbidity and mortality among    Brazilian
 children <u>&lt;</u> 5 years of age, causing 3 525 053 episodes of    diarrhea,
 655 853 visits to outpatient healthcare facilities, 92 453 hospitalizations,   
 and 850 deaths per year, using base-case estimates, or 1.2 episodes of rotaviru
s-associated    diarrhea per child in the first 5 years of life.</font></p>     
^cY#04.htm##
00588000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704036500070002000700435#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#77#73#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">It should be noted    that these estimates
 reflect the situation a decade ago, when most of the studies    included in thi
s review were conducted. To incorporate parameter uncertainties    in the study 
estimates, additional "best-case" and "worst-case" scenarios were    calculated.
</font></p>     ^cY#04.htm##
01995000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704177200070002000701842#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#78#74#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Another limitation    of this study is the
 fact that most of the literature reviewed involved selected    populations that
 may not be representative of the entire country. The estimated    proportions o
f diarrhea episodes distributed across the three categories of    severity by le
vel of care&#151;home-based care (87.7%), a visit to an outpatient    healthcare
 facility (11.6%), or hospitalization (0.7%)&#151;were based on only    two loca
l studies. While there are still significant regional differences in    diarrhea
 morbidity in Brazil, healthcare access, particularly for primary care    and ho
spital care for acute conditions for children <u>&lt;</u> 5 years old,    is not
 significantly different and is of an acceptable quality in urban areas    count
rywide (3). One interesting finding is that the proportions of diarrhea    episo
des by level of care observed in Brazilian studies were similar to those    foun
d in a Chilean study involving <u>&lt;</u> 11-month-old infants and 1- to    4-y
ear-old children. These study results, respectively, were as follows: 88.2%    a
nd 91.9% of diarrhea episodes required only home-based care, 10.3% and 7.9%    r
equired an outpatient healthcare facility visit, and 1.5% and 0.2% required    h
ospitalization (8). There are no official data on the number of visits to outpat
ient    healthcare facilities due to diarrhea in Brazil, but the number of hospi
tal    registrations for diarrhea, as per the SUS Hospital Information System, p
rovided    an essential reference point that strengthened this study's estimates
, with    the two independent approaches used to calculate hospitalizations for 
diarrhea    providing nearly identical numbers.</font></p>     ^cY#04.htm##
01749000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704152600070002000701596#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#79#75#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Although rotavirus    is most frequently d
etected in Brazilian children with severe diarrhea, great    variations were obs
erved in the proportions of rotavirus detection across different    studies&#151
;from 15% to 36.7% (median 29.2%) in hospitalized children, and    from 3.8% to 
23% (median 12.5%) in children cared for in outpatient healthcare    facilities.
 A high degree of variation in rotavirus detection has also been    observed in 
other studies conducted in South America (42&#150;48) (<a href="/img/revistas/rp
sp/v23n2/04t6.gif">Table    6</a>). This variation could be due to the differenc
e in age groups across the    study populations, which included children under 2
 years in Peru (48); children    under 3 in Argentina, Chile, and Venezuela (44)
; and children under 5 in Venezuela    (45) and El Salvador (46). It may also re
flect differences in the sensitivity    of the assays used across studies and/or
 geographic and temporal differences    in the prevalence of the various etiolog
ic agents&#151;i.e., competing pathogens&#151;of    diarrheal disease. In a revi
ew of severe diarrhea in childhood, Parashar et    al. (7) observed a 17% increa
se in the rate of rotavirus among children hospitalized    for diarrhea&#151;fro
m 22% (low-case scenario, 17%; high-case scenario, 28%)    in studies published 
between 1986 and 1999 to 39% (low-case scenario, 29%; high-case    scenario, 45%
) in studies published from 2000 to 2004.</font></p>     ^cY#04.htm##
01027000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704080400070002000700874#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#80#76#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">This study's estimates    for rotavirus-as
sociated diarrhea for the 2004 Brazilian birth cohort's first    5 years of life
 compared reasonably well with those from other studies (49),    whose calculati
ons indicated 712 249 visits to a healthcare facility (very close    to this stu
dy's base-case scenario estimate of 655 853) and 120 513 hospitalizations    (ve
ry close to this study's high-case scenario estimate of 116 199) due to rotaviru
s-associated    diarrhea. However, other studies' estimates of rotavirus-associa
ted deaths (2    475) seems overestimated, considering there were 2 913 deaths a
mong children    under 5 from all causes of diarrhea in 2003, according to SUS M
ortality Information    System records.</font></p>     ^cY#04.htm##
00954000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704073100070002000700801#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#81#77#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The risk of dying    from rotavirus-associ
ated diarrhea by age 5 estimated in this study (1 in 3    777) is smaller than t
hat estimated by Parashar et al. (1 in 1 152) for the    "upper-middle-income" c
ategory of country economies defined by the World Bank    (8), which includes Br
azil. Parashar et al. (8) estimated the proportion of    deaths among children u
nder 5 attributable to diarrhea for this group of countries    at 9%, whereas th
e 2 913 deaths attributed to diarrhea among children under    5 in Brazil in 200
3, as per national health database (DATASUS) mortality records,    represent 4.3
% of all deaths of children in that age group.</font></p>     ^cY#04.htm##
00941000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704071800070002000700788#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#82#78#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Since March 2006,    the monovalent human 
attenuated rotavirus vaccine has been included in Brazil's    National Immunizat
ion Program, recommended for administration to all children    at 2 and 4 months
 of age. The main objective of this immunization program is    to prevent hospit
alizations and deaths from severe rotavirus-associated disease.    This study's 
estimates of rotavirus- associated morbidity and mortality among    Brazilian ch
ildren <u>&lt;</u> 5 years of age in the pre-vaccine era may serve    as a basel
ine to monitor the impact of the rotavirus vaccine's introduction    in routine 
childhood immunization in Brazil.</font></p>     ^cY#04.htm##
00520000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704029700070002000700367#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#83#79#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Acknowledgment</b>.    This study is pa
rt of a project evaluating the economic impact of introducing    new vaccines in
to Brazil's National Immunization Program, supported by the Brazilian    Ministr
y of Health.</font></p>     ^cY#04.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#84#80#article#138#<p>&nbsp;</p>     ^cY#04.
htm##
00323000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010000070002000700170#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#85#81#article#138#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>REFERENCES</b></font></p>     ^cY#04.ht
m##
00466000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704022900072002000700301#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#86#82#article#138#1#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;1.&nbsp;Ahmad    OB, L
opez AD, Inoue M. The decline in child mortality: a reappraisal. Bull World    H
ealth Organ. 2000;78(10):1175&#150;91.</font></p>     ^cY#04.htm##
00573000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704033600072002000700408#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#87#83#article#138#2#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;2.&nbsp;Fuchs    SC, V
ictora CG, Fachel J. Modelo hierarquizado: uma proposta de modelagem aplicada   
 &agrave; investiga&ccedil;&atilde;o de fatores de risco para diarr&eacute;ia   
 grave. Rev Sa&uacute;de P&uacute;blica. 1996; 30(2):168&#150;78.</font></p>    
 ^cY#04.htm##
00495000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704025800072002000700330#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#88#84#article#138#3#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;3.&nbsp;Victora    CG.
 Interven&ccedil;&otilde;es para reduzir a mortalidade infantil pr&eacute;-escol
ar    e materna no Brasil. Rev Bras Epidemiol. 2001;4(1):3&#150;69.</font></p>  
   ^cY#04.htm##
00503000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704026600072002000700338#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#89#85#article#138#4#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;4.&nbsp;Sastry    N, B
urgard S. The prevalence of diarrheal disease among Brazilian children:    trend
s and differentials from 1986 to 1996. Soc Sci Med. 2005;60(5):923&#150;35.</fon
t></p>     ^cY#04.htm##
00567000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704033000072002000700402#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#90#86#article#138#5#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;5.&nbsp;Kale    PL, Fe
rnandes C, Nobre FF. Padr&atilde;o temporal das interna&ccedil;&otilde;es    e &
oacute;bitos por diarr&eacute;ia em crian&ccedil;as, 1995 a 1998, Rio de    Jane
iro. Rev Sa&uacute;de P&uacute;blica. 2004;38(1):30&#150;7.</font></p>     ^cY#0
4.htm##
00522000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704028500072002000700357#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#91#87#article#138#6#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;6.&nbsp;Kale    PL, An
dreozzi VL, Nobre FF. Time series analysis of deaths due to diarrhoea    in chil
dren in Rio de Janeiro, Brazil, 1980&#150;1998. J Health Popul Nutr.    2004;22(
1):27&#150;33.</font></p>     ^cY#04.htm##
00466000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704022900072002000700301#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#92#88#article#138#7#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;7.&nbsp;Parashar    UD
, Gibson CJ, Bresee JS, Glass RI. Rotavirus and severe childhood diarrhea.    Em
erg Infect Dis. 2006;12(2):304&#150;6.</font></p>     ^cY#04.htm##
00506000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704026900072002000700341#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#93#89#article#138#8#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;8.&nbsp;Parashar    UD
, Hummemman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths    cau
sed by rotavirus disease in children. Emerg Infect Dis. 2003;9(5):565&#150;72.</
font></p>     ^cY#04.htm##
00463000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704022600072002000700298#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#94#90#article#138#9#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;9.&nbsp;World    Healt
h Organization. Rotavirus vaccines &#91;Position Paper&#93;. Wkly Epidemiol    R
ec. 2007 Aug 10;82(32):285&#150;95.</font></p>     ^cY#04.htm##
00572000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704033400073002000700407#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#95#91#article#138#10#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">10.&nbsp;Ruiz-Pal&aacute;ci
os    GM, P&eacute;rez Schael I, Vel&aacute;squez FR, Abate H, Breuer T, Clemens
 SC,    et al. Safety and efficacy of an attenuated vaccine against severe rotav
irus    gastroenteritis. New Engl J Med. 2006;354(1):11&#150;22.</font></p>     
^cY#04.htm##
00546000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704030800073002000700381#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#96#92#article#138#11#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">11.&nbsp;Vesikari    T, Mat
son DO, Dennehy P, Van Damme P, Santosharn M, Rodriguez Z, et al. Safety    and 
efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.    N
ew Engl J Med. 2006;354(1):23&#150;33.</font></p>     ^cY#04.htm##
00740000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704050200073002000700575#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#97#93#article#138#12#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">12.&nbsp;Brasil,    Secreta
ria de Estado da Sa&uacute;de de S&atilde;o Paulo, Coordenadoria de Controle    
de Doen&ccedil;as, Centro de Vigil&acirc;ncia Epidemiol&oacute;gica "Prof. Alexa
ndre    Vranjac," Divis&atilde;o de Imuniza&ccedil;&atilde;o e Divis&atilde;o de
 Doen&ccedil;as    de Transmiss&atilde;o H&iacute;drica e Alimentar. Vacina cont
ra rotavirus. Rev    Sa&uacute;de P&uacute;blica. 2006;40(2):355&#150;8.</font><
/p>     ^cY#04.htm##
00834000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704059600073002000700669#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#98#94#article#138#13#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">13.&nbsp;Brasil,    Minist&
eacute;rio da Sa&uacute;de, Doen&ccedil;a Diarr&eacute;ica por Rotav&iacute;rus.
    Vigil&acirc;ncia epidemiol&oacute;gica e preven&ccedil;&atilde;o pela Vacina
    Oral de Rotavirus Humano-VORH &#91;Informe T&eacute;cnico&#93;. 1 March 2006
.    Available from: <a href="http://portal.saude.gov.br/portal/arquivos/pdf/inf
orme_rotavirus_02_03_2006.pdf" target="_blank">http://portal.saude.    gov.br/po
rtal/arquivos/pdf/informe_ rotavirus_02_03_2006.pdf</a>. Accessed 19    November
 2006.</font></p>     ^cY#04.htm##
00705000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704046700073002000700540#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#99#95#article#138#14#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">14.&nbsp;World    Health Or
ganization. Converting 2-week diarrhoea prevalence to 2-week incidence    and es
timating annual incidence rate from 2-week incidence &#91;Appendix&#93;.    Avai
lable from: <a href="http://whqlibdoc.who.int/hq/1994/who_CDR_94_8_annexes_r_v.p
df" target="_blank">http://whqlibdoc.who.int/hq/1994/    who_CDR_94_8_annexes_r_
v.pdf</a>. Accessed 15 November 2007.</font></p>     ^cY#04.htm##
00755000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000300071704051600074002000700590#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#100#96#article#138#15#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">15.&nbsp;Brasil,    Minist
&eacute;rio da Sa&uacute;de, Departamento de Inform&aacute;tica do Sistema    &U
acute;nico de Sa&uacute;de (DATASUS), Informa&ccedil;&otilde;es de Saude:    Mor
bidade Hospitalar do SUS &#91;Internet site&#93;. Available from: <a href="http:
//tabnet.datasus.gov.br/cgi/tabcgi.exe?sih/cnv/mruf.def" target="_blank">http://
tabnet.datasus.gov.br/cgi/    tabcgi.exe?sih/cnv/mruf.def</a>. Accessed 9 Januar
y 2006.</font></p>     ^cY#04.htm##
00740000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000300071704050100074002000700575#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#101#97#article#138#16#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">16.&nbsp;Brasil,    Minist
&eacute;rio da Sa&uacute;de, Departamento de Inform&aacute;tica do Sistema    &U
acute;nico de Sa&uacute;de (DATASUS), Informa&ccedil;&otilde;es de Saude:    Mor
talidade &#91;Internet site&#93;. Available from: <a href="http://tabnet.datasus
.gov.br/cgi/tabcgi.exe?sih/cnv/mruf.def" target="_blank">http://tabnet.datasus.g
ov.br/cgi/tabcgi.exe?sim/    cnv/obtuf.def</a>. Accessed 9 January 2006.</font><
/p>     ^cY#04.htm##
00515000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000300071704027600074002000700350#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#102#98#article#138#17#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">17.&nbsp;Castello    AA, A
rvay ML, Glass RI, Gentsch J. Rotavirus strain surveillance in Latin America:   
 a review of the last nine years. Pediatr Infect Dis J. 2004;23(suppl 10):S168&#
150;72.</font></p>     ^cY#04.htm##
00544000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000300071704030500074002000700379#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#103#99#article#138#18#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">18.&nbsp;Brasil,    Instit
uto Brasileiro de Geografia e Estat&iacute;stica &#91;Internet site&#93;.    Ava
ilable from: <a href="http://www.ibge.gov.br" target="_blank">http://www.ibge.go
v.br</a>.    Accessed November 2005.</font></p>     ^cY#04.htm##
00628000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704038800075002000700463#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#104#100#article#138#19#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">19.&nbsp;Lima AA,    Moor
e SR, Barboza Jr MS, Soares AM, Schleupner MA, Newman RD, et al. Persistent    d
iarrhea signals a critical period of increased diarrhea burdens and nutritional 
   shortfalls: a prospective cohort study among children in Northeastern Brazil.
    J Infect Dis. 2000;181:1643&#150;51.</font></p>     ^cY#04.htm##
00582000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704034200075002000700417#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#105#101#article#138#20#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">20.&nbsp;Moore    SR, Lim
a AA, Shorling JB, Barboza Jr MS, Soares AS, Guerrant RL. Changes over    time i
n the epidemiology of diarrhea and malnutrition among children in an urban    Br
azilian shantytown, 1989 to 1996. Int J Infect Dis. 2000;4(4):179&#150;86.</font
></p>     ^cY#04.htm##
00518000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704027800075002000700353#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#106#102#article#138#21#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">21.&nbsp;Moraes    LR, Ca
ncio JA, Cairncross S, Huttly S. Impact of drainage and sewerage on diarrhoea   
 in poor urban areas in Salvador, Brazil. Trans R Soc Trop Med Hyg. 2003;97(2):1
53&#150;8.</font></p>     ^cY#04.htm##
00552000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704031200075002000700387#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#107#103#article#138#22#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">22.&nbsp;Strina    A, Cai
rncross S, Prado MS, Teles CA, Barreto ML. Childhood diarrhoea symptoms,    mana
gement and duration: observations from a longitudinal community study. Trans    
R Soc Trop Med Hyg. 2005;99(6): 407&#150;16.</font></p>     ^cY#04.htm##
00565000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704032500075002000700400#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#108#104#article#138#23#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">23.&nbsp;Barreto    ML, M
ilroy CA, Strina A, Prado MS, Leite JP, Ramos EA, et al. Community-based    moni
toring of diarrhea in urban Brazilian children: incidence and associated    path
ogens. Trans R Soc Trop Med Hyg. 2006;100(3):234&#150;42.</font></p>     ^cY#04.
htm##
00651000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704041100075002000700486#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#109#105#article#138#24#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">24.&nbsp;V&aacute;zquez  
  ML, Mosquera M, Cuevas LE, Gonz&aacute;lez ES, Veras IC, Luz EO, et al. Incid&
ecirc;ncia    e fatores de risco de diarr&eacute;ia e infec&ccedil;&otilde;es re
spirat&oacute;rias    agudas em comunidades urbanas de Pernambuco, Brasil. Cad. 
Sa&uacute;de P&uacute;blica    (Rio J). 1999;15(1):163&#150;71.</font></p>     ^
cY#04.htm##
00504000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704026400075002000700339#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#110#106#article#138#25#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">25.&nbsp;Escuder    MM, d
a Silva NN, Pereira JC, Puccini RF, Herrman AA. Assessing morbidity in    the pa
ediatric community. Rev Sa&uacute;de P&uacute;blica. 1999;33(4):349&#150;57.</fo
nt></p>     ^cY#04.htm##
00557000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704031700075002000700392#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#111#107#article#138#26#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">26.&nbsp;Ben&iacute;cio  
  MH, Monteiro CA. Tend&ecirc;ncia secular da doen&ccedil;a diarr&eacute;ica na 
   inf&acirc;ncia na cidade de S&atilde;o Paulo (1985&#150;1996). Rev Sa&uacute;
de    P&uacute;blica. 2000;34(6 supl):83&#150;90.</font></p>     ^cY#04.htm##
00451000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704021100075002000700286#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#112#108#article#138#27#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">27.&nbsp;Vieira    GO, Si
lva LR, Vieira TO. Child feeding and diarrhea morbidity. J Pediatr (Rio    J). 2
003; 79(5):449&#150;54.</font></p>     ^cY#04.htm##
00847000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704060700075002000700682#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#113#109#article#138#28#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">28.&nbsp;Brasil,    Insti
tuto Brasileiro de Geografia e Estat&iacute;stica, Pesquisa Nacional por    Amos
tra de Domic&iacute;lios-PNAD 2003 &#91;Internet site&#93;. Acesso e utiliza&cce
dil;&atilde;o    de servi&ccedil;os de sa&uacute;de 2003. Available from: <a hre
f="http://www.ibge.gov.br/home/estatistica/populacao/trabalhoerendimento/pnad200
3/coeficiente_brasil.shtm" target="_blank">http://www.ibge.gov.br/home/estatisti
ca/populacao/trabalhoerendimento/    pnad2003/coeficiente_brasil.shtm</a>. Acces
sed 3 January 2007.</font></p>     ^cY#04.htm##
00585000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704034500075002000700420#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#114#110#article#138#29#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">29.&nbsp;Ara&uacute;jo   
 IT, Fialho AM, de Assis RM, Rocha M, Galv&atilde;o M, Cruz CM, et al. Rotavirus
    strain diversity in Rio de Janeiro, Brazil: characterization of VP4 and VP7 
   genotypes in hospitalized children. J Trop Pediatr. 2002;48(4):214&#150;8.</f
ont></p>     ^cY#04.htm##
00593000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704035300075002000700428#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#115#111#article#138#30#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">30.&nbsp;Domingues    AL,
 Da Silva Vaz MG, Moreno M, C&acirc;mara FP. Molecular epidemiology of group    
A rotavirus causing acute diarrhea in infants and young children hospitalised   
 in Rio de Janeiro, Brazil, 1995&#150;1996. Braz J Infect Dis. 2000;4(3):119&#15
0;25.</font></p>     ^cY#04.htm##
00593000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704035300075002000700428#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#116#112#article#138#31#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">31.&nbsp;Gusm&atilde;o   
 RH, Mascarenhas JD, Gabbay IB, Lins-Lainson Z, Ramos FL, Monteiro TA, et al.   
 Rotavirus subgroups, G serotypes, and electrophoretypes in cases of nosocomial 
   infantile diarrhea in Bel&eacute;m, Brazil. J Trop Pediatr. 1999; 45(2):81&#1
50;6.</font></p>     ^cY#04.htm##
00588000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704034800075002000700423#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#117#113#article#138#32#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">32.&nbsp;Cardoso    DD, S
oares CM, Dias e Souza MB, de Azevedo MDS, Martins RM, Queiroz DA, et al.    Epi
demiological features of rotavirus infection in Goi&acirc;nia, Goi&aacute;s,    
Brazil, from 1986 to 2000. Mem Inst Oswaldo Cruz (Rio J). 2003; 98(1):25&#150;9.
</font></p>     ^cY#04.htm##
00555000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704031500075002000700390#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#118#114#article#138#33#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">33.&nbsp;da Rosa    e Sil
va ML, Carvalho IP, Gouvea V. 1998&#150;1999 rotavirus seasons in Juiz    de For
a, Minas Gerais, Brazil: detection of an unusual G3P&#91;4&#93; epidemic    stra
in. J Clin Microbiol. 2002; 40(8):2837&#150;42.</font></p>     ^cY#04.htm##
00647000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704040700075002000700482#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#119#115#article#138#34#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">34.&nbsp;Santos    N, Vol
ot&atilde;o EM, Soares CC, Campos GS, Sardi SI, Hoshino Y. Predominance    of ro
tavirus genotype G9 during the 1999, 2000 and 2002 seasons among hospitalized   
 children in the city of Salvador, Bahia, Brazil: implications for future vaccin
e    strategies. J Clin Microbiol. 2005; 43(8):4064&#150;9.</font></p>     ^cY#0
4.htm##
00598000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704035800075002000700433#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#120#116#article#138#35#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">35.&nbsp;Luz CR,    Masca
renhas JD, Gabbay YB, Motta AR, Lima TV, Soares LS, et al. Rotavirus serotypes  
  and electropherotypes identified among hospitalised children in S&atilde;o Lui
s,    Maranh&atilde;o, Brazil. Rev Inst Med Trop S&atilde;o Paulo. 2005;47(5):28
7&#150;93.</font></p>     ^cY#04.htm##
00562000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704032200075002000700397#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#121#117#article#138#36#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">36.&nbsp;Carmona    RC, T
imenetsky Mdo C, da Silva FF, Granato CF. Characterization of rotavirus    strai
ns from hospitalized and outpatient children with acute diarrhoea in S&atilde;o 
   Paulo, Brazil. J Med Virol. 2004;74(1):166&#150;72.</font></p>     ^cY#04.htm
##
00624000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704038400075002000700459#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#122#118#article#138#37#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">37.&nbsp;Volot&atilde;o  
  EM, Soares CC, Maranh&atilde;o AG, Rocha LN, Hoshino Y, Santos N. Rotavirus   
 surveillance in the city of Rio de Janeiro-Brazil during 2000&#150;2004: detect
ion    of unusual strains with G8P&#91;4&#93; or G10P&#91;9&#93; specificities. 
J Med    Virol. 2006;78:263&#150;72.</font></p>     ^cY#04.htm##
00533000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704029300075002000700368#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#123#119#article#138#38#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">38.&nbsp;Fernandes    JV,
 Fonseca SM, Azevedo JC, Maranh&atilde;o HS, Fonseca MH, Dantas MT, et al.    Ro
tavirus detection in feces of children with acute diarrhea. J Pediatr (Rio    J)
. 2000;76(4): 300&#150;4.</font></p>     ^cY#04.htm##
00560000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704032000075002000700395#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#124#120#article#138#39#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">39.&nbsp;Soares    CC, Vo
lot&atilde;o EM, Albuquerque MC, da Silva FM, de Carvalho TR, Nozawa CM,    et a
l. Prevalence of enteric adenoviruses among children with diarrhea in four    Br
azilian cities. J Clin Virol. 2002;23(3):171&#150;7.</font></p>     ^cY#04.htm##
00510000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704027000075002000700345#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#125#121#article#138#40#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">40.&nbsp;Bittencourt    J
A, Arbo E, Malysz AS, Oravec R, Dias C. Seasonal and age distribution of rotavir
us    infection in Porto Alegre, Brazil. Braz J Infect Dis. 2000;4(6):279&#150;8
3.</font></p>     ^cY#04.htm##
00596000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704035600075002000700431#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#126#122#article#138#41#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">41.&nbsp;Santos    N, Vol
ot&atilde;o EM, Soares CC, Albuquerque MC, da Silva FM, de Carvalho TR,    et al
. Rotavirus strains bearing genotype G9 or P&#91;9&#93; recovered from    Brazil
ian children with diarrhea from 1997 to 1999. J Clin Microbiol. 2001;39(3):1157&
#150;60.</font></p>     ^cY#04.htm##
00546000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704030600075002000700381#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#127#123#article#138#42#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">42.&nbsp;Kane EM,    Turc
ios RM, Arvay ML, Garcia S, Bresee JS, Glass RI. The epidemiology of rotavirus  
  diarrhea in Latin America. Anticipating rotavirus vaccine. Rev Panam Salud P&u
acute;blica.    2004;16(6):371&#150;7.</font></p>     ^cY#04.htm##
00567000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704032700075002000700402#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#128#124#article#138#43#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">43.&nbsp;G&oacute;mez    
JA, Nates S, De Castagnaro NR, Espul C, Borsa A, Glass RI. Anticipating rotaviru
s    vaccines: review of epidemiologic studies of rotavirus diarrhea in Argentin
a.    Rev Panam Salud P&uacute;blica. 1998;3(2):69&#150;78.</font></p>     ^cY#0
4.htm##
00590000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704035000075002000700425#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#129#125#article#138#44#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">44.&nbsp;O'Ryan    M, Per
ez-Schael I, Mamani N, Pena A, Salinas B, Gonzalez G, et al. Rotavirus-associate
d    medical visits and hospitalizations in South America: a prospective study a
t    three large sentinel hospitals. Pediatr Infect Dis J. 2001;20(7):685&#150;9
3.</font></p>     ^cY#04.htm##
00575000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704033500075002000700410#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#130#126#article#138#45#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">45.&nbsp;Salinas    B, Go
nzalez G, Gonzalez R, Escalona M, Materan M, Schael IP. Epidemiologic and    cli
nical characteristics of rotavirus disease during five years of surveillance    
in Venezuela. Pediatr Infect Dis J. 2004;23(suppl 10): S161&#150;7.</font></p>  
   ^cY#04.htm##
00581000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704034100075002000700416#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#131#127#article#138#46#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">46.&nbsp;Guardado    JA, 
Clar&aacute; WA, Turcios RM, Fuentes RA, Valencia D, Sandoval, R, et al.    Rota
virus in El Salvador: an outbreak, surveillance and estimates of disease    burd
en, 2000&#150;2002. Pediatr Infect Dis J. 2004;23(suppl 10):S156&#150;60.</font>
</p>     ^cY#04.htm##
00565000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704032500075002000700400#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#132#128#article#138#47#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">47.&nbsp;Ehrenkranz    P,
 Lanata CF, Penny ME, Salazar-Lindo E, Glass RI. Rotavirus diarrhea disease    b
urden in Peru: the need for a rotavirus vaccine and its potential cost savings. 
   Rev Panam Salud P&uacute;blica. 2001;10(4):240&#150;8.</font></p>     ^cY#04.
htm##
00637000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704039700075002000700472#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#133#129#article#138#48#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">48.&nbsp;Pan American    
Health Organization, Family and Community Health Area, Immunization Unit. Region
al    Meeting on the Implementation of Rotavirus Epidemiological Surveillance: g
enerating    information for decision-making. &#91;Final Report&#93;. Washington
, D.C.: PAHO;    2003. (PAHO/IM/2003&#150;00005).</font></p>     ^cY#04.htm##
00584000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704034400075002000700419#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#p#134#130#article#138#49#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">49.&nbsp;Rheigans    RD, 
Constenla D, Antil L, Innis BL, Breuer T. Economic and health burden of    rotav
irus gastroenteritis for the 2003 birth cohort in eight Latin American    and Ca
ribbean countries. Rev Panam Salud P&uacute;blica. 2007; 21(4):192&#150;204.</fo
nt></p>     ^cY#04.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#135#131#article#138#<p>&nbsp;</p>     ^cY#0
4.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#136#132#article#138#<p>&nbsp;</p>     ^cY#0
4.htm##
00335000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704011000072002000700182#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#137#133#article#138#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Manuscript received    on 12 June 2007. 
   ^cY#04.htm##
00313000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704008800072002000700160#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#138#134#article#138#<br>   Revised version 
accepted for publication on 20 November 2007.</font></p>     ^cY#04.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#139#135#article#138#<p>&nbsp;</p>     ^cY#0
4.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#140#136#article#138#<p>&nbsp;</p>     ^cY#0
4.htm##
00822000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704059700072002000700669#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#141#137#article#138#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#top">*</a> 
   Send correspondence and requests for reprints to: Ana Marli C. Sartori, Cl&ia
cute;nica    de Mol&eacute;stias Infecciosas e Parasit&aacute;rias, Hospital das
 Cl&iacute;nicas    da Faculdade de Medicina da Universidade de S&atilde;o Paulo
, Av. Dr. En&eacute;as    de Carvalho Aguiar, 455, 4o andar, sala 4028 Cerqueira
 Cesar, Sao Paulo 05403-000,    Brasil; telephone: +55 (11) 3069 7517; fax: +55 
(11) 3069 7508; e-mail: <a href="mailto:anasartori@gmail.com">anasartori@gmail.c
om</a>    ^cY#04.htm##
00440000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704021500072002000700287#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\04.htm#S#p#142#138#article#138#<br>   <a name="back1">
</a><a href="#top1">1</a> As per Who International Statistical    Classification
 of Diseases and Related Health Problems 10th Revision (ICD-10)    disease codes
 A00 to A09.</font></p>     ^cY#04.htm##
00572000000000301000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100016000710100016000870100
01500103012005000118030002400168065000900192064000500201031000300206032000300209
014000800212865000900220002000700229035001000236801002400246#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\04.htm#S#c#143#1#article#49#1#^rND^sAhmad^nOB#^rND^sLopez^
nAD#^rND^sInoue^nM#The decline in child mortality: a reappraisal^len#Bull World 
Health Organ#20000000#2000#78#10#1175-91#20080200#04.htm#0042-9686#Bull World He
alth Organ##
00589000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100016000710100018000870100
01600105012011600121030001800237710000200255065000900257064000500266031000300271
032000200274014000700276865000900283002000700292#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\04.htm#S#c#144#2#article#49#2#^rND^sFuchs^nSC#^rND^sVictora^nCG#^rND^s
Fachel^nJ#Modelo hierarquizado: uma proposta de modelagem aplicada à investigaçã
o de fatores de risco para diarréia grave^lpt#Rev Saúde Pública#2#19960000#1996#
30#2#168-78#20080200#04.htm##
00500000000000265000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100018000710120085000890300
01900174710000200193065000900195064000500204031000200209032000200211014000500213
865000900218002000700227#v23n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c#145
#3#article#49#3#^rND^sVictora^nCG#Intervenções para reduzir a mortalidade infant
il pré-escolar e materna no Brasil^lpt#Rev Bras Epidemiol#2#20010000#2001#4#1#3-
69#20080200#04.htm##
00579000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100016000710100017000870120
10900104030001200213065000900225064000500234031000300239032000200242014000700244
865000900251002000700260035001000267801001200277#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\04.htm#S#c#146#4#article#49#4#^rND^sSastry^nN#^rND^sBurgard^nS#The pre
valence of diarrheal disease among Brazilian children: trends and differentials 
from 1986 to 1996^len#Soc Sci Med#20050000#2005#60#5#923-35#20080200#04.htm#0037
-7856#Soc Sci Med##
00570000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100015000710100019000860100
01600105012009900121030001800220710000200238065000900240064000500249031000300254
032000200257014000500259865000900264002000700273#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\04.htm#S#c#147#5#article#49#5#^rND^sKale^nPL#^rND^sFernandes^nC#^rND^s
Nobre^nFF#Padrão temporal das internações e óbitos por diarréia em crianças, 199
5 a 1998, Rio de Janeiro^lpt#Rev Saúde Pública#2#20040000#2004#38#1#30-7#2008020
0#04.htm##
00576000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100015000710100020000860100
01600106012010100122030002000223710000200243065000900245064000500254031000300259
032000200262014000600264865000900270002000700279#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\04.htm#S#c#148#6#article#49#6#^rND^sKale^nPL#^rND^sAndreozzi^nVL#^rND^
sNobre^nFF#Time series analysis of deaths due to diarrhoea in children in Rio de
 Janeiro, Brazil, 1980-1998^len#J Health Popul Nutr#2#20040000#2004#22#1#27-33#2
0080200#04.htm##
00547000000000301000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100019000710100017000900100
01700107010001600124012004400140030001800184710000200202065000900204064000500213
031000300218032000200221014000600223865000900229002000700238#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\04.htm#S#c#149#7#article#49#7#^rND^sParashar^nUD#^rND^sGib
son^nCJ#^rND^sBresee^nJS#^rND^sGlass^nRI#Rotavirus and severe childhood diarrhea
^len#Emerg Infect Dis.#2#20060000#2006#12#2#304-6#20080200#04.htm##
00641000000000325000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100019000710100020000900100
01700110010001700127010001600144012007000160030001700230065000900247064000500256
03100020026103200020026301400070026586500090027200200070028103500100028880100170
0298#v23n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c#150#8#article#49#8#^rND
^sParashar^nUD#^rND^sHummemman^nEG#^rND^sBresee^nJS#^rND^sMiller^nMA#^rND^sGlass
^nRI#Global illness and deaths caused by rotavirus disease in children^len#Emerg
 Infect Dis#20030000#2003#9#5#565-72#20080200#04.htm#1080-6040#Emerg Infect Dis#
#
00524000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690110026000710120039000970300
01900136065000900155064000500164061000700169031000300176032000300179014000700182
865000900189002000700198035001000205801001900215#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\04.htm#S#c#151#9#article#49#9#World Health Organization#Rotavirus vacc
ines: Position Paper^len#Wkly Epidemiol Rec#20070000#2007#Aug 10#82#32#285-95#20
080200#04.htm#0049-8114#Wkly Epidemiol Rec##
00681000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100024000730100022000970100
02000119010001500139010001600154010001800170810000600188012009000194030001500284
71000020029906500090030106400050031003100040031503200020031901400060032186500090
0327002000700336#v23n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c#152#10#arti
cle#49#10#^rND^sRuiz-Palácios^nGM#^rND^sPérez Schael^nI#^rND^sVelásquez^nFR#^rND
^sAbate^nH#^rND^sBreuer^nT#^rND^sClemens^nSC#et al#Safety and efficacy of an att
enuated vaccine against severe rotavirus gastroenteritis^len#New Engl J Med#2#20
060000#2006#354#1#11-22#20080200#04.htm##
00676000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100017000910100
01700108010001900125010002000144010001900164810000600183012009000189030001500279
71000020029406500090029606400050030503100040031003200020031401400060031686500090
0322002000700331#v23n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c#153#11#arti
cle#49#11#^rND^sVesikari^nT#^rND^sMatson^nDO#^rND^sDennehy^nP#^rND^sVan Damme^nP
#^rND^sSantosharn^nM#^rND^sRodriguez^nZ#et al#Safety and efficacy of a pentavale
nt human-bovine (WC3) reassortant rotavirus vaccine^len#New Engl J Med#2#2006000
0#2006#354#1#23-33#20080200#04.htm##
00659000000000265000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700110231000730120028003040300
01800332710000200350065000900352064000500361031000300366032000200369014000600371
865000900377002000700386#v23n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c#154
#12#article#49#12#Brasil^dSecretaria de Estado da Saúde de São Paulo, Coordenado
ria de Controle de Doenças, Centro de Vigilância Epidemiológica "Prof. Alexandre
 Vranjac," Divisão de Imunização e Divisão de Doenças de Transmissão Hídrica e A
limentar#Vacina contra rotavirus^lpt#Rev Saúde Pública#2#20060000#2006#40#2#355-
8#20080200#04.htm##
00633000000000253000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700170028000730180116001010610
01600217065000900233064001300242037008200255110000900337109001700346865000900363
002000700372#v23n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c#155#13#article#
49#13#Brasil^dMinistério da Saúde#Doença Diarréica por Rotavírus: Vigilância epi
demiológica e prevenção pela Vacina Oral de Rotavirus Humano-VORH^lpt#Informe Té
cnico#20060301#1 March 2006#http://portal.saude. gov.br/portal/arquivos/pdf/info
rme_ rotavirus_02_03_2006.pdf#20061119#19 November 2006#20080200#04.htm##
00565000000000229000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700170026000730180122000990610
00900221037006300230110000900293109001700302865000900319002000700328#v23n2#v:\sc
ielo\serial\rpsp\v23n2\markup\04.htm#S#c#156#14#article#49#14#World Health Organ
ization#Converting 2-week diarrhoea prevalence to 2-week incidence and estimatin
g annual incidence rate from 2-week incidence^len#Appendix#http://whqlibdoc.who.
int/hq/1994/ who_CDR_94_8_annexes_r_v.pdf#20071115#15 November 2007#20080200#04.
htm##
00566000000000229000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700170093000730180054001660610
01400220037006200234110000900296109001500305865000900320002000700329#v23n2#v:\sc
ielo\serial\rpsp\v23n2\markup\04.htm#S#c#157#15#article#49#15#Brasil^dMinistério
 da Saúde, Departamento de Informática do Sistema Único de Saúde (DATASUS)#Infor
mações de Saude: Morbidade Hospitalar do SUS^lpt#Internet site#http://tabnet.dat
asus.gov.br/cgi/ tabcgi.exe?sih/cnv/mruf.def#20060109#9 January 2006#20080200#04
.htm##
00551000000000229000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700170093000730180038001660610
01400204037006300218110000900281109001500290865000900305002000700314#v23n2#v:\sc
ielo\serial\rpsp\v23n2\markup\04.htm#S#c#158#16#article#49#16#Brasil^dMinistério
 da Saúde, Departamento de Informática do Sistema Único de Saúde (DATASUS)#Infor
mações de Saude: Mortalidade^lpt#Internet site#http://tabnet.datasus.gov.br/cgi/
tabcgi.exe?sim/ cnv/obtuf.def#20060109#9 January 2006#20080200#04.htm##
00637000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100016000920100
01600108010001700124012008400141030002100225065000900246064000500255031000300260
032000500263014000800268865000900276002000700285035001000292801002100302#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c#159#17#article#49#17#^rND^sCastello
^nAA#^rND^sArvay^nML#^rND^sGlass^nRI#^rND^sGentsch^nJ#Rotavirus strain surveilla
nce in Latin America: a review of the last nine years^len#Pediatr Infect Dis J#2
0040000#2004#23#^s10#S168-72#20080200#04.htm#0891-3668#Pediatr Infect Dis J##
00423000000000217000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700170056000730610014001290370
02300143110000900166109001400175865000900189002000700198#v23n2#v:\scielo\serial\
rpsp\v23n2\markup\04.htm#S#c#160#18#article#49#18#Brasil^dInstituto Brasileiro d
e Geografia e Estatística#Internet site#http://www.ibge.gov.br#20051100#November
 2005#20080200#04.htm##
00775000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100016000880100
02100104010001700125010002100142010001700163810000600180012017300186030001300359
06500090037206400050038103100040038601400080039086500090039800200070040703500100
0414801001300424#v23n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c#161#19#arti
cle#49#19#^rND^sLima^nAA#^rND^sMoore^nSR#^rND^sBarboza Jr^nMS#^rND^sSoares^nAM#^
rND^sSchleupner^nMA#^rND^sNewman^nRD#et al#Persistent diarrhea signals a critica
l period of increased diarrhea burdens and nutritional shortfalls: a prospective
 cohort study among children in Northeastern Brazil^len#J Infect Dis#20000000#20
00#181#1643-51#20080200#04.htm#0022-1899#J Infect Dis##
00736000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100015000890100
01900104010002100123010001700144010001900161012013300180030001700313065000900330
06400050033903100020034403200020034601400070034886500090035500200070036403500100
0371801001700381#v23n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c#162#20#arti
cle#49#20#^rND^sMoore^nSR#^rND^sLima^nAA#^rND^sShorling^nJB#^rND^sBarboza Jr^nMS
#^rND^sSoares^nAS#^rND^sGuerrant^nRL#Changes over time in the epidemiology of di
arrhea and malnutrition among children in an urban Brazilian shantytown, 1989 to
 1996^len#Int J Infect Dis#20000000#2000#4#4#179-86#20080200#04.htm#1201-9712#In
t J Infect Dis##
00647000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100017000900100
02000107010001600127012008900143030002500232065000900257064000500266031000300271
032000200274014000600276865000900282002000700291035001000298801002500308#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c#163#21#article#49#21#^rND^sMoraes^n
LR#^rND^sCancio^nJA#^rND^sCairncross^nS#^rND^sHuttly^nS#Impact of drainage and s
ewerage on diarrhoea in poor urban areas in Salvador, Brazil^len#Trans R Soc Tro
p Med Hyg#20030000#2003#97#2#153-8#20080200#04.htm#0035-9203#Trans R Soc Trop Me
d Hyg##
00695000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100020000890100
01600109010001600125010001800141012010800159030002500267065000900292064000500301
03100030030603200020030901400070031186500090031800200070032703500100033480100250
0344#v23n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c#164#22#article#49#22#^r
ND^sStrina^nA#^rND^sCairncross^nS#^rND^sPrado^nMS#^rND^sTeles^nCA#^rND^sBarreto^
nML#Childhood diarrhoea symptoms, management and duration: observations from a l
ongitudinal community study^len#Trans R Soc Trop Med Hyg#20050000#2005#99#6#407-
16#20080200#04.htm#0035-9203#Trans R Soc Trop Med Hyg##
00738000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100017000910100
01600108010001600124010001600140010001600156810000600172012010700178030002500285
06500090031006400050031903100040032403200020032801400070033086500090033700200070
0346035001000353801002500363#v23n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c
#165#23#article#49#23#^rND^sBarreto^nML#^rND^sMilroy^nCA#^rND^sStrina^nA#^rND^sP
rado^nMS#^rND^sLeite^nJP#^rND^sRamos^nEA#et al#Community-based monitoring of dia
rrhea in urban Brazilian children: incidence and associated pathogens^len#Trans 
R Soc Trop Med Hyg#20060000#2006#100#3#234-42#20080200#04.htm#0035-9203#Trans R 
Soc Trop Med Hyg##
00714000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100018000910100
01700109010001900126010001600145010001400161810000600175012012400181030002700305
71000020033206500090033406400050034303100030034803200020035101400070035386500090
0360002000700369#v23n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c#166#24#arti
cle#49#24#^rND^sVázquez^nML#^rND^sMosquera^nM#^rND^sCuevas^nLE#^rND^sGonzález^nE
S#^rND^sVeras^nIC#^rND^sLuz^nEO#et al#Incidência e fatores de risco de diarréia 
e infecções respiratórias agudas em comunidades urbanas de Pernambuco, Brasil^lp
t#Cad. Saúde Pública (Rio J)#2#19990000#1999#15#1#163-71#20080200#04.htm##
00592000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100019000910100
01800110010001800128010001800146012005200164030001800216710000200234065000900236
064000500245031000300250032000200253014000700255865000900262002000700271#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c#167#25#article#49#25#^rND^sEscuder^
nMM#^rND^sda Silva^nNN#^rND^sPereira^nJC#^rND^sPuccini^nRF#^rND^sHerrman^nAA#Ass
essing morbidity in the paediatric community^len#Rev Saúde Pública#2#19990000#19
99#33#4#349-57#20080200#04.htm##
00540000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100019000910120
08900110030001800199710000200217065000900219064000500228031000300233032000400236
014000600240865000900246002000700255#v23n2#v:\scielo\serial\rpsp\v23n2\markup\04
.htm#S#c#168#26#article#49#26#^rND^sBenício^nMH#^rND^sMonteiro^nCA#Tendência sec
ular da doença diarréica na infância na cidade de São Paulo (1985-1996)^lpt#Rev 
Saúde Pública#2#20000000#2000#34#^s6#83-90#20080200#04.htm##
00554000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100016000900100
01700106012004100123030001800164065000900182064000500191031000300196032000200199
014000700201865000900208002000700217035001000224801001800234#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\04.htm#S#c#169#27#article#49#27#^rND^sVieira^nGO#^rND^sSil
va^nLR#^rND^sVieira^nTO#Child feeding and diarrhea morbidity^len#J Pediatr (Rio 
J)#20030000#2003#79#5#449-54#20080200#04.htm#0021-7557#J Pediatr (Rio J)##
00622000000000229000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700170111000730610014001840180
05000198037010400248110000900352109001500361865000900376002000700385#v23n2#v:\sc
ielo\serial\rpsp\v23n2\markup\04.htm#S#c#170#28#article#49#28#Brasil^dInstituto 
Brasileiro de Geografia e Estatística, Pesquisa Nacional por Amostra de Domicíli
os-PNAD 2003#Internet site#Acesso e utilização de serviços de saúde 2003^lpt#htt
p://www.ibge.gov.br/home/estatistica/populacao/trabalhoerendimento/ pnad2003/coe
ficiente_brasil.shtm#20070103#3 January 2007#20080200#04.htm##
00734000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100017000900100
01900107010001500126010001600141010001500157810000600172012012500178030001500303
06500090031806400050032703100030033203200020033501400060033786500090034300200070
0352035001000359801001500369#v23n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c
#171#29#article#49#29#^rND^sAraújo^nIT#^rND^sFialho^nAM#^rND^sde Assis^nRM#^rND^
sRocha^nM#^rND^sGalvão^nM#^rND^sCruz^nCM#et al#Rotavirus strain diversity in Rio
 de Janeiro, Brazil: characterization of VP4 and VP7 genotypes in hospitalized c
hildren^len#J Trop Pediatr#20020000#2002#48#4#214-8#20080200#04.htm#0142-6338#J 
Trop Pediatr##
00724000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100020000730100023000930100
01600116010001700132012015100149030001800300065000900318064000500327031000200332
032000200334014000700336865000900343002000700352035001000359801004100369#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c#172#30#article#49#30#^rND^sDomingue
s^nAL#^rND^sDa Silva Vaz^nMG#^rND^sMoreno^nM#^rND^sCâmara^nFP#Molecular epidemio
logy of group A rotavirus causing acute diarrhea in infants and young children h
ospitalised in Rio de Janeiro, Brazil, 1995-1996^len#Braz J Infect Dis#20000000#
2000#4#3#119-25#20080200#04.htm#1413-8670#Brazilian Journal of Infectious Diseas
es##
00741000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100022000900100
01700112010002200129010001600151010001900167810000600186012011900192030001500311
06500090032606400050033503100030034003200020034301400050034586500090035000200070
0359035001000366801001500376#v23n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c
#173#31#article#49#31#^rND^sGusmão^nRH#^rND^sMascarenhas^nJD#^rND^sGabbay^nIB#^r
ND^sLins-Lainson^nZ#^rND^sRamos^nFL#^rND^sMonteiro^nTA#et al#Rotavirus subgroups
, G serotypes, and electrophoretypes in cases of nosocomial infantile diarrhea i
n Belém, Brazil^len#J Trop Pediatr#19990000#1999#45#2#81-6#20080200#04.htm#0142-
6338#J Trop Pediatr##
00702000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100017000910100
02300108010002200131010001800153010001800171810000600189012009700195030003000292
71000020032206500090032406400050033303100030033803100020034101400050034386500090
0348002000700357#v23n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c#174#32#arti
cle#49#32#^rND^sCardoso^nDD#^rND^sSoares^nCM#^rND^sDias e Souza^nMB#^rND^sde Aze
vedo^nMDS#^rND^sMartins^nRM#^rND^sQueiroz^nDA#et al#Epidemiological features of 
rotavirus infection in Goiânia, Goiás, Brazil, from 1986 to 2000^len#Mem Inst Os
waldo Cruz (Rio J)#2#20030000#2003#98#1#25-9#20080200#04.htm##
00641000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100026000730100019000990100
01600118012011800134030001700252065000900269064000500278031000300283032000200286
014000800288865000900296002000700305035001000312801001700322#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\04.htm#S#c#175#33#article#49#33#^rND^sda Rosa e Silva^nML#
^rND^sCarvalho^nIP#^rND^sGouvea^nV#1998-1999 rotavirus seasons in Juiz de Fora, 
Minas Gerais, Brazil: detection of an unusual G3P[4] epidemic strain^len#J Clin 
Microbiol#20020000#2002#40#8#2837-42#20080200#04.htm#0095-1137#J Clin Microbiol#
#
00790000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100018000890100
01700107010001700124010001600141010001700157012019200174030001700366065000900383
06400050039203100030039703200020040001400070040286500090040900200070041803500100
0425801001700435#v23n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c#176#34#arti
cle#49#34#^rND^sSantos^nN#^rND^sVolotão^nEM#^rND^sSoares^nCC#^rND^sCampos^nGS#^r
ND^sSardi^nSI#^rND^sHoshino^nY#Predominance of rotavirus genotype G9 during the 
1999, 2000 and 2002 seasons among hospitalized children in the city of Salvador,
 Bahia, Brazil: implications for future vaccine strategies^len#J Clin Microbiol#
20050000#2005#43#8#4064-9#20080200#04.htm#0095-1137#J Clin Microbiol##
00753000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100014000730100022000870100
01700109010001600126010001500142010001700157810000600174012011500180030002800295
06500090032306400050033203100030033703200020034001400070034286500090034900200070
0358035001000365801002800375#v23n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c
#177#35#article#49#35#^rND^sLuz^nCR#^rND^sMascarenhas^nJD#^rND^sGabbay^nYB#^rND^
sMotta^nAR#^rND^sLima^nTV#^rND^sSoares^nLS#et al#Rotavirus serotypes and electro
pherotypes identified among hospitalised children in São Luis, Maranhão, Brazil^
len#Rev Inst Med Trop São Paulo#20050000#2005#47#5#287-93#20080200#04.htm#0036-4
665#Rev Inst Med Trop São Paulo##
00668000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100024000910100
01900115010001800134012012600152030001200278065000900290064000500299031000300304
032000200307014000700309865000900316002000700325035001000332801001200342#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c#178#36#article#49#36#^rND^sCarmona^
nRC#^rND^sTimenetsky Mdo^nC#^rND^sda Silva^nFF#^rND^sGranato^nCF#Characterizatio
n of rotavirus strains from hospitalized and outpatient children with acute diar
rhoea in São Paulo, Brazil^len#J Med Virol#20040000#2004#74#1#166-72#20080200#04
.htm#0146-6615#J Med Virol##
00724000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100017000910100
01900108010001600127010001700143010001600160012014800176030001200324065000900336
06400050034503100030035001400070035386500090036000200070036903500100037680100120
0386#v23n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c#179#37#article#49#37#^r
ND^sVolotão^nEM#^rND^sSoares^nCC#^rND^sMaranhão^nAG#^rND^sRocha^nLN#^rND^sHoshin
o^nY#^rND^sSantos^nN#Rotavirus surveillance in the city of Rio de Janeiro-Brazil
 during 2000-2004: detection of unusual strains with G8P[4] or G10P[9] specifici
ties^len#J Med Virol#20060000#2006#78#263-72#20080200#04.htm#0146-6615#J Med Vir
ol##
00691000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100020000730100018000930100
01800111010001900129010001800148010001700166810000600183012006500189030001800254
06500090027206400050028103100030028603200020028901400060029186500090029700200070
0306035001000313801001800323#v23n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c
#180#38#article#49#38#^rND^sFernandes^nJV#^rND^sFonseca^nSM#^rND^sAzevedo^nJC#^r
ND^sMaranhão^nHS#^rND^sFonseca^nMH#^rND^sDantas^nMT#et al#Rotavirus detection in
 feces of children with acute diarrhea^len#J Pediatr (Rio J)#20000000#2000#76#4#
300-4#20080200#04.htm#0021-7557#J Pediatr (Rio J)##
00714000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100018000900100
02200108010001900130010002200149010001700171810000600188012009300194030001300287
06500090030006400050030903100030031403200020031701400060031986500090032500200070
0334035001000341801001300351#v23n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c
#181#39#article#49#39#^rND^sSoares^nCC#^rND^sVolotão^nEM#^rND^sAlbuquerque^nMC#^
rND^sda Silva^nFM#^rND^sde Carvalho^nTR#^rND^sNozawa^nCM#et al#Prevalence of ent
eric adenoviruses among children with diarrhea in four Brazilian cities^len#J Cl
in Virol#20020000#2002#23#3#171-7#20080200#04.htm#0928-0197#J Clin Virol##
00673000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100022000730100014000950100
01700109010001600126010001400142012008100156030001800237065000900255064000500264
03100020026903200020027101400070027386500090028000200070028903500100029680100410
0306#v23n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c#182#40#article#49#40#^r
ND^sBittencourt^nJA#^rND^sArbo^nE#^rND^sMalysz^nAS#^rND^sOravec^nR#^rND^sDias^nC
#Seasonal and age distribution of rotavirus infection in Porto Alegre, Brazil^le
n#Braz J Infect Dis#20000000#2000#4#6#279-83#20080200#04.htm#1413-8670#Brazilian
 Journal of Infectious Diseases##
00746000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100018000890100
01700107010002200124010001900146010002200165810000600187012011600193030001700309
06500090032606400050033503100030034003200020034301400080034586500090035300200070
0362035001000369801001700379#v23n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c
#183#41#article#49#41#^rND^sSantos^nN#^rND^sVolotão^nEM#^rND^sSoares^nCC#^rND^sA
lbuquerque^nMC#^rND^sda Silva^nFM#^rND^sde Carvalho^nTR#et al#Rotavirus strains 
bearing genotype G9 or P[9] recovered from Brazilian children with diarrhea from
 1997 to 1999^len#J Clin Microbiol#20010000#2001#39#3#1157-60#20080200#04.htm#00
95-1137#J Clin Microbiol##
00656000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100018000880100
01600106010001600122010001700138010001600155012009200171030002400263710000200287
06500090028906400050029803100030030303200020030601400060030886500090031400200070
0323#v23n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c#184#42#article#49#42#^r
ND^sKane^nEM#^rND^sTurcios^nRM#^rND^sArvay^nML#^rND^sGarcia^nS#^rND^sBresee^nJS#
^rND^sGlass^nRI#The epidemiology of rotavirus diarrhea in Latin America: Anticip
ating rotavirus vaccine^len#Rev Panam Salud Pública#2#20040000#2004#16#6#371-7#2
0080200#04.htm##
00670000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100015000890100
02400104010001500128010001500143010001600158012010400174030002400278710000200302
06500090030406400050031303100020031803100020032001400060032286500090032800200070
0337#v23n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c#185#43#article#49#43#^r
ND^sGómez^nJA#^rND^sNates^nS#^rND^sDe Castagnaro^nNR#^rND^sEspul^nC#^rND^sBorsa^
nA#^rND^sGlass^nRI#Anticipating rotavirus vaccines: review of epidemiologic stud
ies of rotavirus diarrhea in Argentina^len#Rev Panam Salud Pública#2#19980000#19
98#3#2#69-78#20080200#04.htm##
00759000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100022000890100
01600111010001400127010001700141010001800158810000600176012013300182030002100315
06500090033606400050034503100030035003200020035301400070035586500090036200200070
0371035001000378801002100388#v23n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c
#186#44#article#49#44#^rND^sO'Ryan^nM#^rND^sPerez-Schael^nI#^rND^sMamani^nN#^rND
^sPena^nA#^rND^sSalinas^nB#^rND^sGonzalez^nG#et al#Rotavirus-associated medical 
visits and hospitalizations in South America: a prospective study at three large
 sentinel hospitals^len#Pediatr Infect Dis J#20010000#2001#20#7#685-93#20080200#
04.htm#0891-3668#Pediatr Infect Dis J##
00728000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100018000900100
01800108010001800126010001700144010001700161012011500178030002100293065000900314
06400050032303100030032803200050033101400070033686500090034300200070035203500100
0359801002100369#v23n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c#187#45#arti
cle#49#45#^rND^sSalinas^nB#^rND^sGonzalez^nG#^rND^sGonzalez^nR#^rND^sEscalona^nM
#^rND^sMateran^nM#^rND^sSchael^nIP#Epidemiologic and clinical characteristics of
 rotavirus disease during five years of surveillance in Venezuela^len#Pediatr In
fect Dis J#20040000#2004#23#^s10#S161-7#20080200#04.htm#0891-3668#Pediatr Infect
 Dis J##
00733000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100016000920100
01800108010001800126010001800144010001800162810000600180012009900186030002100285
06500090030606400050031503100030032003200050032301400080032886500090033600200070
0345035001000352801002100362#v23n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c
#188#46#article#49#46#^rND^sGuardado^nJA#^rND^sClará^nWA#^rND^sTurcios^nRM#^rND^
sFuentes^nRA#^rND^sValencia^nD#^rND^sSandoval^nR#et al#Rotavirus in El Salvador:
 an outbreak, surveillance and estimates of disease burden, 2000-2002^len#Pediat
r Infect Dis J#20040000#2004#23#^s10#S156-60#20080200#04.htm#0891-3668#Pediatr I
nfect Dis J##
00657000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100020000730100017000930100
01600110010002300126010001600149012011100165030002400276710000200300065000900302
064000500311031000300316032000200319014000600321865000900327002000700336#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c#189#47#article#49#47#^rND^sEhrenkra
nz^nP#^rND^sLanata^nCF#^rND^sPenny^nME#^rND^sSalazar-Lindo^nE#^rND^sGlass^nRI#Ro
tavirus diarrhea disease burden in Peru: the need for a rotavirus vaccine and it
s potential cost savings^len#Rev Panam Salud Pública#2#20010000#2001#10#4#240-8#
20080200#04.htm##
00626000000000253000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700170086000730180129001590610
01300288066001700301062000500318065000900323064000500332061001900337865000900356
002000700365#v23n2#v:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c#190#48#article#
49#48#Pan American Health Organization^dFamily and Community Health Area, Immuni
zation Unit#Regional Meeting on the Implementation of Rotavirus Epidemiological 
Surveillance: generating information for decision-making^len#Final Report#Washin
gton^eD.C.#PAHO#20030000#2003#PAHO/IM/2003-00005#20080200#04.htm##
00675000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100019000920100
01500111010001600126010001600142012013400158030002400292710000200316065000900318
064000500327031000300332032000200335014000800337865000900345002000700354#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\04.htm#S#c#191#49#article#49#49#^rND^sRheigans
^nRD#^rND^sConstenla^nD#^rND^sAntil^nL#^rND^sInnis^nBL#^rND^sBreuer^nT#Economic 
and health burden of rotavirus gastroenteritis for the 2003 birth cohort in eigh
t Latin American and Caribbean countries^len#Rev Panam Salud Pública#2#20070000#
2007#21#4#192-204#20080200#04.htm##
00263000000000169000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640910009000660920007000750020007000827030
00400089#v23n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#o#1#1#article#1#20080
318#103140#05.htm#167##
04440000000000625000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000500084038000400089121000300093049000800096158000300104
03000240010703100030013103200020013406500090013601400110014503500100015601200720
01660120086002380100043003240100035003670100035004020700103004370700117005400831
51100657085000802168085001802176085002502194085001902219085001902238083138802257
08500080364508500190365308500260367208500190369808500190371711700060373607200030
3742112000903745111002403754114000903778113002003787002000703807#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#h#2#1#article#1#oa#es#br1.1#1#3.1#ILUS#TAB#05
#RPSP020#nd#Rev Panam Salud Publica#23#2#20080200#^f101^l108#1020-4989#Modelo es
tructural predictor de la salud mental y física en mujeres^les#A structural equa
tion model for predictors of mental and physical health in women^len#^rND^1A01^n
Mónica Teresa González^sRamírez#^rND^1A01^nRené Landero^sHernández#^rND^1A02^nMi
guel Ángel Ruiz^sDíaz#Universidad Autónoma de Nuevo León^iA01^1Facultad de Psico
logía^2Cuerpo Académico en Psicología Social#Universidad Autónoma de Madrid^iA02
^1Facultad de Psicología^2Departamento de Psicología Social y Metodología^pEspañ
a#^les^aOBJETIVO: Valorar la capacidad predictora del estrés, el apoyo social y 
la autoestima respecto de la salud mental y física del individuo mediante ecuaci
ones estructurales, integrando modelos parciales estimados anteriormente, lo que
 permite simplificar los efectos entre las variables. MÉTODOS: La muestra estudi
ada abarcó 283 mujeres con hijos. Todas las participantes residían en el municip
io de General Escobedo, estado de Nuevo León, México. Las encuestas se realizaro
n en el segundo semestre de 2003, en los domicilios, utilizando cuestionarios de
 autoevaluación para valorar cada una de las variables incluidas en el modelo. C
ada participante respondió a los cuestionarios en una sola sesión. Los resultado
s se analizaron con el programa AMOS 5.0, empleando el método de máxima verosimi
litud, comúnmente utilizado en los modelos de ecuaciones estructurales. RESULTAD
OS: Los resultados obtenidos indican un ajuste aceptable en el modelo propuesto 
(ji2/gl = 3,03, GFI (índice de bondad del ajuste) = 0,894, AGFI (índice de bonda
d del ajuste corregido) = 0,848, RMSEA (error de aproximación cuadrático medio) 
= 0,08, IFI (índice de ajuste incremental) = 0,910). La varianza explicada es de
l 31,9% respecto del estrés, del 27,4% respecto de la salud física y del 72,1% r
especto de la salud mental. CONCLUSIONES: El apoyo social y la autoestima son pr
edictores del estrés; la edad y el estrés, predictores de la salud física; y el 
estrés, la autoestima y la salud física, predictores de la salud mental.#^dnd^i1
#^tm^les^kSalud^i1#^tm^les^ksalud mental^i1#^tm^les^kestrés^i1#^tm^les^kMéxico^i
1#^len^aOBJECTIVE: To measure the extent to which stress, social support, and se
lf-esteem are predictors of an individual's mental and physical health. Structur
al equations were integrated with previously-estimated partial models, which sim
plify the relationships among variables. METHODS: The study sample included 283 
women with children. All of the participants resided in the municipality of Gene
ral Escobedo, state of Nuevo León, Mexico. The surveys were carried out in the s
econd semester of 2003, in the participants homes, using self-evaluation questio
nnaires to measure each of the variables included in the model. Each participant
 completed the questionnaire in one sitting. Results were analyzed with AMOS 5.0
, employing the maximum likelihood method, often utilized in structural equation
 models. RESULTS: The results indicate an acceptable adjustment in the proposed 
model: (chi2/gl = 3.03, goodness of fit (GFI) = 0.894, adjusted goodness of fit 
(AGFI) = 0.848, root mean square error of approximation (RMSEA) = 0.08, incremen
tal fit index (IFI) = 0.910). Variances were 31.9% with regard to stress, 27.4% 
with regard to physical health, and 72.1% with regard to mental health. CONCLUSI
ONS: Social support and self-esteem are predictors of stress; age and stress are
 predictors of physical health; and stress, self-esteem, and physical health are
 predictors of mental health.#^dnd^i2#^tm^len^kHealth^i2#^tm^len^kmental health^
i2#^tm^len^kstress^i2#^tm^len^kMexico^i2#other#34#20061122#22 de noviembre de 20
06#20070802#2 de agosto de 2007#05.htm##
04590000000000625000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000500084038000400089121000300093049000800096158000300104
03000240010703100030013103200020013406500090013601400110014503500100015601200790
01660120093002450100043003380100035003810100035004160700103004510700117005540831
57600671085000802247085001802255085002502273085001902298085001902317083145902336
08500080379508500190380308500260382208500190384808500190386711700060388607200030
3892112000903895111002403904114000903928113002003937002000703957#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#f#3#1#article#1#oa#es#br1.1#1#3.1#ILUS#TAB#05
#RPSP020#nd#Rev Panam Salud Publica#23#2#20080200#^f101^l108#1020-4989#<B>Modelo
 estructural predictor de la salud mental y física en mujeres</B>^les#<B>A struc
tural equation model for predictors of mental and physical health in women</B>^l
en#^rND^1A01^nMónica Teresa González^sRamírez#^rND^1A01^nRené Landero^sHernández
#^rND^1A02^nMiguel Ángel Ruiz^sDíaz#Universidad Autónoma de Nuevo León^iA01^1Fac
ultad de Psicología^2Cuerpo Académico en Psicología Social#Universidad Autónoma 
de Madrid^iA02^1Facultad de Psicología^2Departamento de Psicología Social y Meto
dología^pEspaña#^les^a<B>OBJETIVO:</B> Valorar la capacidad predictora del estré
s, el apoyo social y la autoestima respecto de la salud mental y física del indi
viduo mediante ecuaciones estructurales, integrando modelos parciales estimados 
anteriormente, lo que permite simplificar los efectos entre las variables. <B>MÉ
TODOS:</B> La muestra estudiada abarcó 283 mujeres con hijos. Todas las particip
antes residían en el municipio de General Escobedo, estado de Nuevo León, México
. Las encuestas se realizaron en el segundo semestre de 2003, en los domicilios,
 utilizando cuestionarios de autoevaluación para valorar cada una de las variabl
es incluidas en el modelo. Cada participante respondió a los cuestionarios en un
a sola sesión. Los resultados se analizaron con el programa AMOS 5.0, empleando 
el método de máxima verosimilitud, comúnmente utilizado en los modelos de ecuaci
ones estructurales. <B>RESULTADOS: </B>Los resultados obtenidos indican un ajust
e aceptable en el modelo propuesto (<FONT FACE="Symbol">c</FONT><SUP>2</SUP>/gl 
= 3,03, GFI (índice de bondad del ajuste) = 0,894, AGFI (índice de bondad del aj
uste corregido) = 0,848, RMSEA (error de aproximación cuadrático medio) = 0,08, 
IFI (índice de ajuste incremental) = 0,910). La varianza explicada es del 31,9% 
respecto del estrés, del 27,4% respecto de la salud física y del 72,1% respecto 
de la salud mental. <B>CONCLUSIONES: </B>El apoyo social y la autoestima son pre
dictores del estrés; la edad y el estrés, predictores de la salud física; y el e
strés, la autoestima y la salud física, predictores de la salud mental.#^dnd^i1#
^tm^les^kSalud^i1#^tm^les^ksalud mental^i1#^tm^les^kestrés^i1#^tm^les^kMéxico^i1
#^len^a<B>OBJECTIVE:</B> To measure the extent to which stress, social support, 
and self-esteem are predictors of an individual's mental and physical health. St
ructural equations were integrated with previously-estimated partial models, whi
ch simplify the relationships among variables. <B>METHODS:</B> The study sample 
included 283 women with children. All of the participants resided in the municip
ality of General Escobedo, state of Nuevo León, Mexico. The surveys were carried
 out in the second semester of 2003, in the participants homes, using self-evalu
ation questionnaires to measure each of the variables included in the model. Eac
h participant completed the questionnaire in one sitting. Results were analyzed 
with AMOS 5.0, employing the maximum likelihood method, often utilized in struct
ural equation models. <B>RESULTS: </B>The results indicate an acceptable adjustm
ent in the proposed model: (<FONT FACE="Symbol">c</FONT><I><SUP>2</I></SUP>/gl =
 3.03, goodness of fit (GFI) = 0.894, adjusted goodness of fit (AGFI) = 0.848, r
oot mean square error of approximation (RMSEA) = 0.08, incremental fit index (IF
I) = 0.910). Variances were 31.9% with regard to stress, 27.4% with regard to ph
ysical health, and 72.1% with regard to mental health. <B>CONCLUSIONS: </B>Socia
l support and self-esteem are predictors of stress; age and stress are predictor
s of physical health; and stress, self-esteem, and physical health are predictor
s of mental health.#^dnd^i2#^tm^len^kHealth^i2#^tm^len^kmental health^i2#^tm^len
^kstress^i2#^tm^len^kMexico^i2#other#34#20061122#22 de noviembre de 2006#2007080
2#2 de agosto de 2007#05.htm##
04626000000000649000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640640013000660710003000790400003000820010
00600085042000200091120000400093038000500097038000400102121000300106049000800109
15800030011703000260012003100030014603200020014906500090015101400110016003500100
01710120072001810120086002530100043003390100035003820100035004170700105004520700
11900557083154100676085000802217085001802225085002502243085001902268085001902287
08314090230608500080371508500190372308500260374208500190376808500190378711700060
38060720003038121120009038151110024038241140009038481130020038570020007038770080
09203884#v23n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#l#4#1#article#1#^mfeb
.^a2008#oa#es#br1.1#1#3.1#ilus#tab#05#RPSP020#nd#Rev. panam. salud pública#23#2#
20080200#^f101^l108#1020-4989#Modelo estructural predictor de la salud mental y 
física en mujeres^les#A structural equation model for predictors of mental and p
hysical health in women^len#^rND^1A01^nMónica Teresa González^sRamírez#^rND^1A01
^nRené Landero^sHernández#^rND^1A02^nMiguel Ángel Ruiz^sDíaz#^iA01^1Universidad 
Autónoma de Nuevo León^2Facultad de Psicología^3Cuerpo Académico en Psicología S
ocial#^iA02^1Universidad Autónoma de Madrid^2Facultad de Psicología^3Departament
o de Psicología Social y Metodología^pEspaña#^les^aOBJETIVO: Valorar la capacida
d predictora del estrés, el apoyo social y la autoestima respecto de la salud me
ntal y física del individuo mediante ecuaciones estructurales, integrando modelo
s parciales estimados anteriormente, lo que permite simplificar los efectos entr
e las variables. MÉTODOS: La muestra estudiada abarcó 283 mujeres con hijos. Tod
as las participantes residían en el municipio de General Escobedo, estado de Nue
vo León, México. Las encuestas se realizaron en el segundo semestre de 2003, en 
los domicilios, utilizando cuestionarios de autoevaluación para valorar cada una
 de las variables incluidas en el modelo. Cada participante respondió a los cues
tionarios en una sola sesión. Los resultados se analizaron con el programa AMOS 
5.0, empleando el método de máxima verosimilitud, comúnmente utilizado en los mo
delos de ecuaciones estructurales. RESULTADOS: Los resultados obtenidos indican 
un ajuste aceptable en el modelo propuesto (ji2/gl = 3,03, GFI (índice de bondad
 del ajuste) = 0,894, AGFI (índice de bondad del ajuste corregido) = 0,848, RMSE
A (error de aproximación cuadrático medio) = 0,08, IFI (índice de ajuste increme
ntal) = 0,910). La varianza explicada es del 31,9 por ciento respecto del estrés
, del 27,4 por ciento respecto de la salud física y del 72,1 por ciento respecto
 de la salud mental. CONCLUSIONES: El apoyo social y la autoestima son predictor
es del estrés; la edad y el estrés, predictores de la salud física; y el estrés,
 la autoestima y la salud física, predictores de la salud mental.#^dnd^i1#^tm^le
s^kSalud^i1#^tm^les^ksalud mental^i1#^tm^les^kestrés^i1#^tm^les^kMéxico^i1#^len^
aOBJECTIVE: To measure the extent to which stress, social support, and self-este
em are predictors of an individual's mental and physical health. Structural equa
tions were integrated with previously-estimated partial models, which simplify t
he relationships among variables. METHODS: The study sample included 283 women w
ith children. All of the participants resided in the municipality of General Esc
obedo, state of Nuevo León, Mexico. The surveys were carried out in the second s
emester of 2003, in the participants homes, using self-evaluation questionnaires
 to measure each of the variables included in the model. Each participant comple
ted the questionnaire in one sitting. Results were analyzed with AMOS 5.0, emplo
ying the maximum likelihood method, often utilized in structural equation models
. RESULTS: The results indicate an acceptable adjustment in the proposed model: 
(chi2/gl = 3.03, goodness of fit (GFI) = 0.894, adjusted goodness of fit (AGFI) 
= 0.848, root mean square error of approximation (RMSEA) = 0.08, incremental fit
 index (IFI) = 0.910). Variances were 31.9 percent with regard to stress, 27.4 p
ercent with regard to physical health, and 72.1 percent with regard to mental he
alth. CONCLUSIONS: Social support and self-esteem are predictors of stress; age 
and stress are predictors of physical health; and stress, self-esteem, and physi
cal health are predictors of mental health.#^dnd^i2#^tm^len^kHealth^i2#^tm^len^k
mental health^i2#^tm^len^kstress^i2#^tm^len^kMexico^i2#other#34#20061122#22 de n
oviembre de 2006#20070802#2 de agosto de 2007#05.htm#Internet^ihttp://www.scielo
sp.org/scielo.php?script=sci_arttext&pid=S1020-49892008000200005##
00375000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704015400068002000700222#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#5#1#article#129#<p align="right"><font face
="Verdana, Arial, Helvetica, sans-serif" size="2"><b>INVESTIGACI&Oacute;N    ORI
GINAL</b> ORIGINAL RESEARCH</font></p>     ^cY#05.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704002200068002000700090#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#6#2#article#129#<p>&nbsp;</p>     ^cY#05.ht
m##
00406000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704018500068002000700253#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#7#3#article#129#<p><a name="top"></a><font 
face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Modelo    estructural p
redictor de la salud mental y f&iacute;sica en mujeres</b></font></p>     ^cY#05
.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704002200068002000700090#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#8#4#article#129#<p>&nbsp;</p>     ^cY#05.ht
m##
00395000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704017400068002000700242#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#9#5#article#129#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="3"><b>A structural    equation model for predic
tors of mental and physical health in women</b></font></p>     ^cY#05.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#10#6#article#129#<p>&nbsp;</p>     ^cY#05.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#11#7#article#129#<p>&nbsp;</p>     ^cY#05.h
tm##
00505000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704028300069002000700352#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#12#8#article#129#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>M&oacute;nica    Teresa Gonz&aacute;lez 
Ram&iacute;rez<sup>I, <a href="#back">*</a></sup>; Ren&eacute;    Landero Hern&a
acute;ndez<sup>I</sup>; Miguel &Aacute;ngel Ruiz D&iacute;az<sup>II</sup></b></f
ont></p>     ^cY#05.htm##
00444000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704022200069002000700291#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#13#9#article#129#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"> <sup>I</sup>Cuerpo    Acad&eacute;mico en 
Psicolog&iacute;a Social, Facultad de Psicolog&iacute;a,    Universidad Aut&oacu
te;noma de Nuevo Le&oacute;n    ^cY#05.htm##
00412000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704018900070002000700259#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#14#10#article#129#<br>   <sup>II</sup>Depar
tamento de Psicolog&iacute;a Social y Metodolog&iacute;a,    Facultad de Psicolo
g&iacute;a, Universidad Aut&oacute;noma de Madrid, Espa&ntilde;a</font></p>     
^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#15#11#article#129#<p>&nbsp;</p>     ^cY#05.
htm##
00267000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704004400070002000700114#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#16#12#article#129#<p>&nbsp;</p> <hr size="1
" noshade>     ^cY#05.htm##
00320000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009700070002000700167#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#17#13#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>RESUMEN</b></font></p>     ^cY#05.htm##
00612000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704038900070002000700459#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#18#14#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Valorar la capacidad p
redictora del estr&eacute;s, el apoyo social y la autoestima    respecto de la s
alud mental y f&iacute;sica del individuo mediante ecuaciones    estructurales, 
integrando modelos parciales estimados anteriormente, lo que    permite simplifi
car los efectos entre las variables.    ^cY#05.htm##
00920000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704069700070002000700767#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#19#15#article#129#<br>   <b>M&Eacute;TODOS:
</b> La muestra estudiada abarc&oacute; 283 mujeres con hijos.    Todas las part
icipantes resid&iacute;an en el municipio de General Escobedo,    estado de Nuev
o Le&oacute;n, M&eacute;xico. Las encuestas se realizaron en el    segundo semes
tre de 2003, en los domicilios, utilizando cuestionarios de autoevaluaci&oacute;
n    para valorar cada una de las variables incluidas en el modelo. Cada partici
pante    respondi&oacute; a los cuestionarios en una sola sesi&oacute;n. Los res
ultados    se analizaron con el programa AMOS 5.0, empleando el m&eacute;todo de
 m&aacute;xima    verosimilitud, com&uacute;nmente utilizado en los modelos de e
cuaciones estructurales.    ^cY#05.htm##
00785000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704056200070002000700632#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#20#16#article#129#<br>   <b>RESULTADOS: </b
> Los resultados obtenidos indican un ajuste aceptable en    el modelo propuesto
 (<font face="Symbol">c</font><sup>2</sup>/gl = 3,03, GFI    (&iacute;ndice de b
ondad del ajuste) = 0,894, AGFI (&iacute;ndice de bondad    del ajuste corregido
) = 0,848, RMSEA (error de aproximaci&oacute;n cuadr&aacute;tico    medio) = 0,0
8, IFI (&iacute;ndice de ajuste incremental) = 0,910). La varianza    explicada 
es del 31,9% respecto del estr&eacute;s, del 27,4% respecto de la    salud f&iac
ute;sica y del 72,1% respecto de la salud mental.    ^cY#05.htm##
00503000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704028000070002000700350#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#21#17#article#129#<br>   <b>CONCLUSIONES: <
/b> El apoyo social y la autoestima son predictores del estr&eacute;s;    la eda
d y el estr&eacute;s, predictores de la salud f&iacute;sica; y el estr&eacute;s,
    la autoestima y la salud f&iacute;sica, predictores de la salud mental.</fon
t></p>     ^cY#05.htm##
00405000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704018200070002000700252#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#22#18#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Palabras clave:    </b> Salud, salud me
ntal, estr&eacute;s, M&eacute;xico.</font></p> <hr size="1" noshade>     ^cY#05.
htm##
00321000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009800070002000700168#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#23#19#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     ^cY#05.htm#
#
00585000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704036200070002000700432#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#24#20#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>OBJECTIVE:</b>    To measure the extent
 to which stress, social support, and self-esteem are predictors    of an indivi
dual's mental and physical health. Structural equations were integrated    with 
previously-estimated partial models, which simplify the relationships among    v
ariables.    ^cY#05.htm##
00797000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704057400070002000700644#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#25#21#article#129#<br>   <b>METHODS:</b> Th
e study sample included 283 women with children. All of the    participants resi
ded in the municipality of General Escobedo, state of Nuevo    Le&oacute;n, Mexi
co. The surveys were carried out in the second semester of    2003, in the parti
cipants homes, using self-evaluation questionnaires to measure    each of the va
riables included in the model. Each participant completed the    questionnaire i
n one sitting. Results were analyzed with AMOS 5.0, employing    the maximum lik
elihood method, often utilized in structural equation models.    ^cY#05.htm##
00686000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704046300070002000700533#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#26#22#article#129#<br>   <b>RESULTS: </b> T
he results indicate an acceptable adjustment in the proposed    model: (<font fa
ce="Symbol">c</font><i><sup>2</sup></i>/gl = 3.03, goodness    of fit (GFI) = 0.
894, adjusted goodness of fit (AGFI) = 0.848, root mean square    error of appro
ximation (RMSEA) = 0.08, incremental fit index (IFI) = 0.910).    Variances were
 31.9% with regard to stress, 27.4% with regard to physical health,    and 72.1%
 with regard to mental health.    ^cY#05.htm##
00461000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704023800070002000700308#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#27#23#article#129#<br>   <b>CONCLUSIONS: </
b> Social support and self-esteem are predictors of stress;    age and stress ar
e predictors of physical health; and stress, self-esteem, and    physical health
 are predictors of mental health.</font></p>     ^cY#05.htm##
00387000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704016400070002000700234#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#28#24#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Key words:</b>    Health, mental health
, stress, Mexico.</font></p> <hr size="1" noshade>     ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#29#25#article#129#<p>&nbsp;</p>     ^cY#05.
htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#30#26#article#129#<p>&nbsp;</p>     ^cY#05.
htm##
00947000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704072400070002000700794#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#31#27#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Desde hace algunos    a&ntilde;os, los inv
estigadores proporcionan pruebas de que los factores psicol&oacute;gicos,    con
ductuales y ambientales influyen en las distintas esferas de la salud del    ind
ividuo. Espec&iacute;ficamente, el estr&eacute;s constituye un importante    fac
tor de riesgo de alteraci&oacute;n de la salud f&iacute;sica y mental. El    est
r&eacute;s puede alterar la salud precipitando la aparici&oacute;n de un    tras
torno, afectando el curso de una enfermedad, generando nuevas fuentes de    estr
&eacute;s, produciendo malestar f&iacute;sico y ps&iacute;quico, y reduciendo   
 el bienestar y la calidad de vida (1).</font></p>     ^cY#05.htm##
01651000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704142800070002000701498#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#32#28#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">La relaci&oacute;n    entre el estr&eacute
;s y la enfermedad puede analizarse considerando el estr&eacute;s    como un age
nte causal o coadyuvante del desarrollo de la enfermedad, o bien,    considerand
o la enfermedad como un acontecimiento generador de estr&eacute;s,    es decir, 
como un estresor (2). El estr&eacute;s puede tener efectos directos    e indirec
tos en la salud. Los efectos indirectos se relacionan con los estilos    de vida
 o las respuestas de afrontamiento nocivas, tales como fumar, usar drogas    o h
acer poco ejercicio (1); adem&aacute;s, las personas con alto grado de estr&eacu
te;s    tienden a presentar comportamientos que aumentan la probabilidad de enfe
rmarse    o tener accidentes (2). Los efectos directos son el producto de cambio
s neuroendocrinos,    inmunol&oacute;gicos o emocionales (1). En un metaan&aacut
e;lisis de m&aacute;s    de 300 art&iacute;culos emp&iacute;ricos se concluy&oac
ute; que el estr&eacute;s    altera realmente la inmunidad (3). Adem&aacute;s, c
uando se percibe un estresor,    los &oacute;rganos estimulados por tejidos nerv
iosos reciben un exceso de hormonas    del estr&eacute;s, las cuales estimulan l
a funci&oacute;n del &oacute;rgano    e incrementan su tasa metab&oacute;lica; c
uando los &oacute;rganos no tienen    la oportunidad de relajarse, se pueden pro
ducir disfunciones (4).</font></p>     ^cY#05.htm##
00619000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704039600070002000700466#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#33#29#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Adem&aacute;s del    estr&eacute;s, existe
n otras variables psicosociales asociadas al estado de    salud, tales como el n
ivel educativo (escolaridad) (5). Asimismo, se ha referido    que la baja autoes
tima se relaciona con los trastornos psicol&oacute;gicos (6),    y el apoyo soci
al, con el estado de salud (7).</font></p>     ^cY#05.htm##
01059000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704083600070002000700906#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#34#30#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Por otro lado,    se ha encontrado una cor
relaci&oacute;n entre el estr&eacute;s y determinadas    variables sociodemogr&a
acute;ficas y psicosociales, como la escolaridad (8),    el apoyo social (9, 10)
 y la autoestima (11). En M&eacute;xico, se hall&oacute;    una correlaci&oacute
;n negativa significativa entre el estr&eacute;s y la autoestima    (coeficiente
 de correlaci&oacute;n &#91;<i>r</i>&#93;&nbsp;=&nbsp;&#150;0,28)    y entre el 
estr&eacute;s y el apoyo social (<i>r</i>&nbsp;=&nbsp;&#150;0,20),    y una corr
elaci&oacute;n negativa d&eacute;bil entre el estr&eacute;s y la escolaridad    
(<i>r</i>&nbsp;=&nbsp;&#150;0,13), entendiendo por esc.olaridad el n&uacute;mero
    de a&ntilde;os terminados dentro del sistema educativo formal (12).</font></
p>     ^cY#05.htm##
00829000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704060600070002000700676#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#35#31#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">En cuanto a las    diferencias relacionada
s con el sexo, algunas investigaciones indican que las    mujeres pueden ser psi
col&oacute;gicamente m&aacute;s susceptibles a los efectos    estresantes cotidi
anos que los hombres (13). Asimismo, se ha encontrado que    los roles sociales 
femeninos est&aacute;n asociados con mayor grado de estr&eacute;s    que los mas
culinos (14). De manera similar, entre estudiantes universitarios,    se ha hall
ado mayor grado de estr&eacute;s entre las mujeres que entre los varones    (15)
.</font></p>     ^cY#05.htm##
01378000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704115500070002000701225#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#36#32#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">En un estudio anterior    (16) se integrar
on las variables estr&eacute;s, apoyo social, autoestima y estado    de salud me
ntal y f&iacute;sica en un conjunto de tres modelos independientes,    mediante 
regresi&oacute;n m&uacute;ltiple, utilizando como variable dependiente    el est
r&eacute;s, la salud mental y la salud f&iacute;sica, respectivamente.    En el 
primer modelo, la autoestima y el apoyo social explicaron 31,2% de la    varianz
a del estr&eacute;s. En el segundo modelo, la edad y el estr&eacute;s    explica
ron 26,9% de la varianza de la salud f&iacute;sica. En el tercer modelo,    el e
str&eacute;s, la autoestima, la edad y la escolaridad explicaron 46,1% de    la 
varianza de la salud mental. Los coeficientes de regresi&oacute;n obtenidos    c
on estos tres modelos parciales pueden consultarse en la primera columna del    
<a href="#cua3">cuadro&nbsp;3</a>. Como referencia, otros autores (17) han elabo
rado    modelos capaces de explicar 44% de la varianza de la salud mental a part
ir de    las situaciones estresantes, la autoestima y el apoyo social.</font></p
>     ^cY#05.htm##
00258000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003500070002000700105#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#37#33#article#129#<p><a name="cua1"></a></p
>     ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#38#34#article#129#<p>&nbsp;</p>     ^cY#05.
htm##
00299000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007600070002000700146#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#39#35#article#129#<p align="center"><img sr
c="/img/revistas/rpsp/v23n2/05q1.gif"></p>     ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#40#36#article#129#<p>&nbsp;</p>     ^cY#05.
htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#41#37#article#129#<p>&nbsp;</p>     ^cY#05.
htm##
00380000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704015700070002000700227#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#42#38#article#129#<p align="center"><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><a href="/img/revistas/rpsp
/v23n2/05q2.gif">Cuadro    2</a></font></p>     ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#43#39#article#129#<p>&nbsp;</p>     ^cY#05.
htm##
00258000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003500070002000700105#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#44#40#article#129#<p><a name="cua3"></a></p
>     ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#45#41#article#129#<p>&nbsp;</p>     ^cY#05.
htm##
00299000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007600070002000700146#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#46#42#article#129#<p align="center"><img sr
c="/img/revistas/rpsp/v23n2/05q3.gif"></p>     ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#47#43#article#129#<p>&nbsp;</p>     ^cY#05.
htm##
00724000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704050100070002000700571#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#48#44#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Respecto a la escolaridad,    se ha detect
ado una correlaci&oacute;n significativa y positiva con la salud,    tanto f&iac
ute;sica como mental (5). Sin embargo, en nuestro estudio original    (16), la e
scolaridad apenas aporta informaci&oacute;n al modelo de salud mental;    adem&a
acute;s la correlaci&oacute;n directa no es significativa, por lo cual    consid
eramos que podr&iacute;a ser excluida del modelo global.</font></p>     ^cY#05.h
tm##
00910000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704068700070002000700757#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#49#45#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Para poder integrar    los tres modelos pa
rciales de regresi&oacute;n, se propuso el modelo predictor    de salud presenta
do en la <a href="#fig1">figura&nbsp;1</a> (16), en el que    se representan los
 datos obtenidos a trav&eacute;s de las regresiones m&uacute;ltiples    realizad
as de manera independiente. El objetivo del presente trabajo fue estimar    medi
ante ecuaciones estructurales un modelo global integrado que incluyera los    mo
delos parciales y permitiera simplificar los efectos entre las distintas variabl
es,    y proponer un modelo simplificado si el modelo estimado lo permit&iacute;
a.</font></p>     ^cY#05.htm##
00258000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704003500070002000700105#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#50#46#article#129#<p><a name="fig1"></a></p
>     ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#51#47#article#129#<p>&nbsp;</p>     ^cY#05.
htm##
00299000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007600070002000700146#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#52#48#article#129#<p align="center"><img sr
c="/img/revistas/rpsp/v23n2/05f1.gif"></p>     ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#53#49#article#129#<p>&nbsp;</p>     ^cY#05.
htm##
00343000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704012000070002000700190#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#54#50#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>MATERIALES Y    M&Eacute;TODOS</b></fon
t></p>     ^cY#05.htm##
00394000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704017100070002000700241#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#55#51#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">El presente estudio    se llev&oacute; a c
abo seg&uacute;n un dise&ntilde;o transversal.</font></p>     ^cY#05.htm##
00326000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010300070002000700173#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#56#52#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Participantes</b></font></p>     ^cY#05
.htm##
01506000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704128300070002000701353#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#57#53#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">La estimaci&oacute;n    del modelo de ecua
ciones estructurales (SEM) se realiz&oacute; con la muestra    del estudio origi
nal (16), formada por 283 mujeres seleccionadas por conveniencia.    Se trabaj&o
acute; exclusivamente con mujeres debido a cuestiones de presupuesto    del trab
ajo de campo y de acceso a los sujetos, puesto que las entrevistas se    realiza
ron en los domicilios y, en esas circunstancias, era m&aacute;s probable    enco
ntrar mujeres que hombres. Los criterios de inclusi&oacute;n fueron los    sigui
entes: mujeres de poblaci&oacute;n general con hijos, de cualquier estado    civ
il, que estuvieran en sus casas en el momento en que se realiz&oacute; la    enc
uesta y aceptaran responder a &eacute;sta en su totalidad. Todas las participant
es    se seleccionaron en la misma zona urbana (municipio de General Escobedo, e
stado    de Nuevo Le&oacute;n, M&eacute;xico), lo que permiti&oacute; homogeneiz
ar su    nivel socioecon&oacute;mico (nivel medio bajo); este criterio y el de s
elecci&oacute;n    de mujeres con hijos se fijaron para obtener una muestra de e
studio homog&eacute;nea    y controlar estas variables. Las encuestas se realiza
ron en el segundo semestre    de 2003.</font></p>     ^cY#05.htm##
00882000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704065900070002000700729#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#58#54#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Considerando las    diferencias en el grad
o y los efectos del estr&eacute;s seg&uacute;n el sexo    (13, 14), la muestra e
studiada present&oacute; un sesgo de selecci&oacute;n,    puesto que estaba form
ada solamente por mujeres con hijos, de entre 18 y 59    a&ntilde;os. Este sesgo
 constituye una limitaci&oacute;n para generalizar los    resultados obtenidos, 
debido especialmente a la posibilidad de una excesiva    homogeneidad de la mues
tra, dado que cabe suponer que el grado de estr&eacute;s    de esta subpoblaci&o
acute;n es superior al de la poblaci&oacute;n general.</font></p>     ^cY#05.htm
##
00642000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704041900070002000700489#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#59#55#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">La edad media de    las mujeres de la mues
tra era 38,7 a&ntilde;os (desviaci&oacute;n est&aacute;ndar:    8,4&nbsp;a&ntild
e;os) y su nivel de escolaridad medio, 10,7 a&ntilde;os dentro    del sistema ed
ucativo formal. El n&uacute;mero medio de hijos era dos y el n&uacute;mero    me
dio de personas que viv&iacute;an en el hogar, cuatro.</font></p>     ^cY#05.htm
##
00325000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010200070002000700172#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#60#56#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Instrumentos</b></font></p>     ^cY#05.
htm##
00417000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704019400070002000700264#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#61#57#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Se utilizaron las    siguientes escalas:</
font></p> <ol>   <font face="Verdana, Arial, Helvetica, sans-serif" size="2">   
     ^cY#05.htm##
00999000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704077600070002000700846#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#62#58#article#129#<li>PSS (<i>Perceived Str
ess Scale</i>, escala de estr&eacute;s percibido):      esta escala se dise&ntil
de;&oacute; en ingl&eacute;s para medir el grado en      que las situaciones de 
la vida se eval&uacute;an como estresantes (18) y se      adapt&oacute; luego al
 espa&ntilde;ol (19). Consta de 14 &iacute;tems que      permiten evaluar el gra
do en que las personas encuentran que su vida es impredecible,      incontrolabl
e o est&aacute; sobrecargada (18). Estos tres aspectos se han      confirmado re
petidamente como componentes centrales del estr&eacute;s (19).      Cada &iacute
;tem se asocia a una puntuaci&oacute;n comprendida entre 0 ("nunca")      y 4 ("
muy a menudo"). Cuanto mayor es la puntuaci&oacute;n, mayor es el estr&eacute;s 
     percibido.</li>       ^cY#05.htm##
00912000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704068900070002000700759#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#63#59#article#129#<li>ISEL (<i>Interpersona
l Support Evaluation List&#150;General Population</i>,      cuestionario de eval
uaci&oacute;n del apoyo interpersonal del familiar o cuidador):      esta escala
 consta de 40 &iacute;tems (20) con cuatro opciones de respuesta      que van de
sde "definitivamente falso" (puntuaci&oacute;n = 0) hasta "definitivamente      
verdadero" (puntuaci&oacute;n = 3). En su versi&oacute;n en ingl&eacute;s      (
21), la consistencia interna, valorada a trav&eacute;s del coeficiente <font fac
e="Symbol">a</font>      de Cronbach, fue de 0,88. Las propiedades psicom&eacute
;tricas de la versi&oacute;n      en espa&ntilde;ol (22) a&uacute;n no se han es
tudiado.</li>       ^cY#05.htm##
00890000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704066700070002000700737#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#64#60#article#129#<li>Inventario de autoest
ima de Coopersmith, versi&oacute;n para adultos: este      cuestionario consta d
e 25 &iacute;tems con dos opciones de respuesta, "s&iacute;"      y "no". En una
 muestra de 411 sujetos de la ciudad de M&eacute;xico, la consistencia      inte
rna, valorada a trav&eacute;s del coeficiente <font face="Symbol">a</font>      
de Cronbach, fue de 0,81 (11). En el presente estudio, se modificaron las      o
pciones de respuesta para adaptarlo a una escala de tipo Likert con cuatro      
categor&iacute;as de respuesta, desde "definitivamente no" (puntuaci&oacute;n   
   = 1) hasta "definitivamente s&iacute;" (puntuaci&oacute;n = 4).</li>       ^c
Y#05.htm##
01378000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704115500070002000701225#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#65#61#article#129#<li>MOS SF-36 <i>(Medical
 Outcomes Study 36-Item Short Form Health Survey,</i>      cuestionario abreviad
o de 36 &iacute;tems sobre la salud derivado del estudio      de los resultados 
m&eacute;dicos<i>)</i> (23): esta escala eval&uacute;a la      percepci&oacute;n
 del estado de salud en poblaciones adultas (mayores de 16      a&ntilde;os), re
specto a la calidad de vida. Consta de 36 &iacute;tems que      exploran ocho as
pectos del estado de salud: funci&oacute;n f&iacute;sica,      funci&oacute;n so
cial, limitaciones del rol: problemas f&iacute;sicos, limitaciones      del rol:
 problemas emocionales, salud mental, vitalidad, dolor y percepci&oacute;n      
de la salud general. Estas ocho categor&iacute;as se reagrupan te&oacute;ricamen
te      en dos dimensiones de segundo orden: salud mental y salud f&iacute;sica.
 En      el presente estudio se emplearon estas dos escalas. En un estudio reali
zado      en M&eacute;xico con 257 personas (24), la consistencia interna, valor
ada      a trav&eacute;s del coeficiente <font face="Symbol">a</font> de Cronbac
h,      vari&oacute; entre 0,56 y 0,84 seg&uacute;n la subescala.</li>   </font>
      ^cY#05.htm##
00237000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704001400070002000700084#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#66#62#article#129#</ol>     ^cY#05.htm##
00326000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010300070002000700173#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#67#63#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Procedimiento</b></font></p>     ^cY#05
.htm##
02793000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704257000070002000702640#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#68#64#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Antes de realizar    los an&aacute;lisis p
ara estimar el modelo, se calcul&oacute; el coeficiente    <font face="Symbol">a
</font> de Cronbach para verificar la confiabilidad de    cada una de las escala
s utilizadas. Para estimar un modelo global que pronosticara    salud f&iacute;s
ica y salud mental, se trabaj&oacute; con modelos SEM, utilizando    el programa
 AMOS 5.0. Estos modelos presentan diversas ventajas con respecto    a los model
os de regresi&oacute;n lineal ordinaria. En primer lugar, permiten    la utiliza
ci&oacute;n de variables latentes en la propia especificaci&oacute;n    del mode
lo. Estas variables representan el constructo de inter&eacute;s, libre    del ef
ecto de los errores de medici&oacute;n, de manera similar al modelo de    factor
 com&uacute;n del an&aacute;lisis factorial. Al modelar la relaci&oacute;n    en
tre las variables latentes, los efectos estimados carecen tambi&eacute;n de    l
a influencia del error de medici&oacute;n. En segundo lugar, los modelos SEM    
permiten tener en cuenta la existencia de correlaciones entre los t&eacute;rmino
s    de error del modelo, y por ende considerar f&aacute;cilmente la colinealida
d    entre las variables predictoras, lo que no es posible hacer en los modelos 
de    regresi&oacute;n, en los que la colinealidad interfiere en la estimaci&oac
ute;n    de los pesos de regresi&oacute;n. Por &uacute;ltimo, los modelos SEM pe
rmiten    concatenar el efecto de diversas variables &#151;de manera que una var
iable    dependiente puede convertirse a su vez en variable predictora de otra v
ariable&#151;    y estimar todos los efectos de manera simult&aacute;nea, en lug
ar de hacerlo    por fases. Por todas estas razones, estos modelos se utilizan c
ada vez m&aacute;s    en la investigaci&oacute;n en ciencias sociales y de la sa
lud, en particular,    para la estimaci&oacute;n de modelos explicativos de la c
alidad de vida relacionada    con la salud (25, 26) y la satisfacci&oacute;n con
 el tratamiento (27, 28).    En el presente estudio, la utilizaci&oacute;n de mo
delos SEM permiti&oacute;    contrastar el modelo te&oacute;rico que se presenta
 en la <a href="#fig1">figura&nbsp;1</a>,    integrando en una &uacute;nica esti
maci&oacute;n los resultados obtenidos hasta    la fecha mediante modelos parcia
les. Adem&aacute;s, permiti&oacute; valorar    adecuadamente el efecto multivari
ante de unas variables sobre otras, sin que    las estimaciones se vieran afecta
das por los posibles efectos de colinealidad.</font></p>     ^cY#05.htm##
01383000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704116000070002000701230#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#69#65#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Para poder utilizar    este m&eacute;todo,
 es necesario formular previamente un modelo te&oacute;rico    que especifique d
e manera expl&iacute;cita el efecto de unas variables sobre    otras (29). Por e
sta raz&oacute;n los modelos SEM se denominan modelos confirmatorios.    Una vez
 especificado el modelo, se estiman los coeficientes de regresi&oacute;n    a pa
rtir de la matriz emp&iacute;rica de varianzas-covarianzas entre las variables  
  observables. Los coeficientes obtenidos son aquellos que mejor reproducen las 
   covarianzas existentes entre las variables y sus correspondientes varianzas. 
   La bondad del modelo se valora desde dos puntos de vista. En primer lugar, se
    verifica que los coeficientes estimados sean significativos, es decir, debe 
   poder concluirse que su valor es distinto de cero en la poblaci&oacute;n. En 
   segundo lugar, se valora el grado de coincidencia entre la matriz de varianza
s-covarianzas    original y la matriz reproducida a partir de los par&aacute;met
ros estimados    mediante diversos estad&iacute;sticos de bondad de ajuste.</fon
t></p>     ^cY#05.htm##
01797000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704157400070002000701644#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#70#66#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">El m&eacute;todo    de estimaci&oacute;n e
mpleado fue el de m&aacute;xima verosimilitud, com&uacute;nmente    utilizado en
 los modelos SEM (29, 30). Este m&eacute;todo supone normalidad,    y a pesar de
 que con frecuencia este supuesto no se cumple, es robusto respecto    de este i
ncumplimiento (30). La bondad del ajuste del modelo se evalu&oacute;    a trav&e
acute;s del estad&iacute;stico <font face="Symbol">c</font><i><sup>2</sup></i>, 
   la raz&oacute;n entre <font face="Symbol">c</font><i><sup>2</sup></i> y el n&
uacute;mero    de grados de libertad (<font face="Symbol">c</font><i><sup>2</sup
></i>/gl) &#151;cuyo    valor debe ser menor de 3 para indicar un ajuste adecuad
o&#151;, los &iacute;ndices    GFI (<i>Goodness of Fit Index,</i> &iacute;ndice 
de bondad del ajuste), AGFI    (<i>Adjusted Goodness of Fit Index,</i> &iacute;n
dice de bondad de ajuste corregido),    NFI (<i>Normed Fit Index,</i> &iacute;nd
ice de ajuste normalizado), TLI (<i>Tucker-Lewis    Index,</i> coeficiente de Tu
cker y Lewis), CFI (<i>Comparative Fit Index,</i>    &iacute;ndice de ajuste com
parativo) e IFI (<i>Incremental Fit Index,</i> &iacute;ndice    de ajuste increm
ental) &#151;cuyos valores deben ser cercanos a 1&#151; y los    &iacute;ndices 
RMR (<i>Root Mean Square Residual,</i> residuo cuadr&aacute;tico    medio) y RMS
EA (<i>Root Mean Square Error of Approximation,</i> error de aproximaci&oacute;n
    cuadr&aacute;tico medio) &#151;cuyos valores deben ser menores de 0,05&#151;
    (30).</font></p>     ^cY#05.htm##
01107000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704088400070002000700954#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#71#67#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">El primer modelo    estimado fue la r&eacu
te;plica del modelo de la <a href="#fig1">figura&nbsp;1</a>.    Como especificac
iones adicionales se incluyeron en la estimaci&oacute;n las    correlaciones ent
re las variables ex&oacute;genas, integradas ahora en un &uacute;nico    modelo.
 Por el contrario, en el modelo no se calcula directamente la correlaci&oacute;n
    entre las variables end&oacute;genas, aunque dicho valor se deduce de la mat
riz    muestral de varianzas-covarianzas. Tras una primera estimaci&oacute;n, se
 eliminaron    los coeficientes que no resultaron significativos, fijando su val
or en cero,    dado que de hecho, dichas restricciones no deber&iacute;an deteri
orar el ajuste    global del modelo, ni reducir la capacidad explicativa respect
o de las variables    end&oacute;genas.</font></p>     ^cY#05.htm##
01247000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704102400070002000701094#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#72#68#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Los diferentes    modelos alternativos se 
compararon seg&uacute;n se describe a continuaci&oacute;n.    En primer lugar, s
e estim&oacute; el modelo completo con todas las variables    de inter&eacute;s.
 El ajuste de este modelo se considera el modelo basal de    comparaci&oacute;n 
para otros modelos m&aacute;s simples que se puedan proponer.    Cuando se elimi
nan efectos no significativos del modelo, se compara el ajuste    del modelo sim
plificado con el del modelo completo. Si la eliminaci&oacute;n    de los coefici
entes no significativos es pertinente, el ajuste del modelo simplificado    debe
 ser al menos tan bueno como el del modelo basal. Si el ajuste del modelo    sim
plificado es mejor, la diferencia entre los valores de <font face="Symbol">c</fo
nt><i><sup>2</sup></i>    de ambos modelos ser&aacute; significativa (con un n&u
acute;mero de grados de    libertad igual a la diferencia de grados de libertad 
entre los modelos).</font></p>     ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#73#69#article#129#<p>&nbsp;</p>     ^cY#05.
htm##
00323000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010000070002000700170#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#74#70#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>RESULTADOS</b></font></p>     ^cY#05.ht
m##
01369000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704114600070002000701216#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#75#71#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">En el <a href="#cua1">cuadro    1</a> se p
resentan los resultados de la verificaci&oacute;n de la consistencia    interna 
de cada una de las escalas utilizadas. Todos los valores del coeficiente    <fon
t face="Symbol">a</font> de Cronbach fueron adecuados. En cuanto a los modelos  
  estructurales, en el primer modelo estimado (<a href="/img/revistas/rpsp/v23n2
/05f2.gif">figura    2</a>), los predictores explican 76,6% de la varianza de la
 salud mental y 27,5%    de la varianza de la salud f&iacute;sica. La raz&oacute
;n <font face="Symbol">c</font><sup>2</sup>/gl    y los indicadores de ajuste se
 consideran adecuados (<a href="/img/revistas/rpsp/v23n2/05q2.gif">cuadro    2</
a>). Sin embargo, con un nivel de significaci&oacute;n de 5%, el efecto de    la
 salud mental sobre la salud f&iacute;sica (<i>P</i> = 0,953) y el de la edad   
 sobre la salud mental (<i>P</i> = 0,930) no son significativos. Tampoco resulta
    significativa la correlaci&oacute;n d&eacute;bil y negativa (<i>r</i> = &#15
0;0,04)    entre la edad y el apoyo social (<i>P</i> = 0,54).</font></p>     ^cY
#05.htm##
01471000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704124800070002000701318#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#76#72#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A partir de las    correcciones sucesivas 
derivadas del modelo anterior, se estim&oacute; el modelo&nbsp;2,    donde todos
 los coeficientes son significativos. Este modelo explica 76,6% de    la varianz
a de la salud mental y 28,4% de la varianza de la salud f&iacute;sica.    La raz
&oacute;n <font face="Symbol">c</font><i><sup>2</sup></i>/gl y los &iacute;ndice
s    de ajuste se consideran adecuados (<a href="/img/revistas/rpsp/v23n2/05q2.g
if">cuadro    2</a>). Sin embargo, el coeficiente relativo al efecto de la escol
aridad sobre    la salud mental es &#150;0,18. En primer lugar, resulta de dif&i
acute;cil justificaci&oacute;n    te&oacute;rica el hecho de que el incremento e
n el nivel escolar de los sujetos    pueda tener un efecto negativo sobre la sal
ud mental. En segundo lugar, este    efecto apenas representa una explicaci&oacu
te;n de 3% de la varianza de la variable    dependiente. Adem&aacute;s, dicha va
riable queda aislada en el modelo, sin influencia    sobre la variable mediadora
 del estr&eacute;s, ni sobre la salud f&iacute;sica.    Por estos motivos, se co
nsider&oacute; pertinente estimar el modelo sin incluir    la variable escolarid
ad.</font></p>     ^cY#05.htm##
01176000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704095300070002000701023#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#77#73#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">En el modelo&nbsp;3,    el efecto de escol
aridad sobre la salud mental se consider&oacute; nulo y se    conserv&oacute; la
 correlaci&oacute;n con las variables ex&oacute;genas, con    la &uacute;nica fi
nalidad de valorar la p&eacute;rdida de ajuste. Posteriormente    se estim&oacut
e; el modelo final, cuya soluci&oacute;n estandarizada se presenta    en la <a h
ref="/img/revistas/rpsp/v23n2/05f3.gif">figura&nbsp;3</a>. En este    modelo, to
dos los coeficientes estimados son significativos y su signo coincide    con los
 planteamientos te&oacute;ricos del modelo. La varianza explicada por    los pre
dictores de salud mental es de 72,1% y por los de salud f&iacute;sica,    de 27,
4%. La raz&oacute;n <font face="Symbol">c</font><i><sup>2</sup></i>/gl    y los 
indicadores de ajuste se consideran adecuados (<a href="/img/revistas/rpsp/v23n2
/05q2.gif">cuadro    2</a>).</font></p>     ^cY#05.htm##
00600000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704037700070002000700447#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#78#74#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Puede observarse    que en el modelo final
 existe un efecto de la salud f&iacute;sica sobre la salud    mental (<font face
="Symbol">b</font>&nbsp;=&nbsp;0,52). Adem&aacute;s, el coeficiente    de la cor
relaci&oacute;n reproducida por el modelo entre ambas variables end&oacute;genas
    es 0,73.</font></p>     ^cY#05.htm##
00447000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704022400070002000700294#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#79#75#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">En el <a href="/img/revistas/rpsp/v23n2/05
q2.gif">cuadro    2</a> se comparan los cuatro modelos estimados mediante ecuaci
ones estructurales.</font></p>     ^cY#05.htm##
00750000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704052700070002000700597#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#80#76#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">La diferencia de    <font face="Symbol">c<
/font><i><sup>2</sup></i> entre el modelo&nbsp; 1 y el    modelo 2 no es signifi
cativa; por el contrario, la diferencia entre el modelo    2 y el 3 es significa
tiva, lo que indica una p&eacute;rdida de ajuste del modelo&nbsp;3,    justifica
ble solamente desde el plano te&oacute;rico. El modelo final no es    comparable
 en t&eacute;rminos de modelos anidados, pero su bondad de ajuste    es evaluabl
e.</font></p>     ^cY#05.htm##
01932000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704170900070002000701779#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#81#77#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">En el <a href="#cua3">cuadro&nbsp;3</a>   
 se comparan los coeficientes de regresi&oacute;n, tomando como base el modelo  
  original (<a href="#fig1">figura&nbsp;1</a>) e incluyendo datos del modelo fin
al    estimado mediante ecuaciones estructurales. Se proporcionan los valores de
 los    coeficientes estandarizados y no estandarizados. Puede observarse que en
 la    mayor&iacute;a de los casos, los valores de los coeficientes estandarizad
os    son muy similares a los del modelo original; los valores que m&aacute;s se
 apartan    de los de este modelo son los relativos a los efectos del estr&eacut
e;s y de    la edad sobre la salud mental. Se compararon los coeficientes no est
andarizados    del modelo final con los intervalos de confianza de 95 % de los c
oeficientes    no estandarizados del modelo original. Como se observa en el <a h
ref="#cua3">cuadro&nbsp;3</a>,    s&oacute;lo el valor correspondiente al efecto
 de la autoestima sobre el estr&eacute;s    se halla dentro del intervalo calcul
ado. Los dem&aacute;s valores de los pesos    de regresi&oacute;n no se encuentr
an dentro del intervalo de confianza de los    coeficientes obtenidos mediante r
egresi&oacute;n m&uacute;ltiple; esto puede    deberse a las diferencias entre l
as t&eacute;cnicas de estimaci&oacute;n (regresi&oacute;n    m&uacute;ltiple o m
odelo SEM), a que en el modelo original se integran resultados    obtenidos de m
anera aislada en cada submodelo parcial de regresi&oacute;n y    a que en el m&e
acute;todo SEM se incluyen correlaciones entre las variables    ex&oacute;genas 
que permiten tener en cuenta la colinealidad de los predictores.</font></p>     
^cY#05.htm##
01167000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704094400070002000701014#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#82#78#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Al comparar las    varianzas explicadas (<
a href="#cua3">cuadro&nbsp;3</a>), se observa que en    el caso del estr&eacute;
s y de la salud f&iacute;sica, los valores calculados    mediante ecuaciones est
ructurales en el modelo final son muy similares a los    obtenidos por regresi&o
acute;n m&uacute;ltiple en el modelo original. En cambio,    en el caso de la sa
lud mental, se observa un aumento considerable de la varianza    explicada, de 4
6,1% en el modelo original a 72,1% en el modelo final. En el    modelo final no 
se incluyen como predictores del estado de salud mental la edad    y la escolari
dad. Por otro lado, se agrega la salud f&iacute;sica como un predictor    import
ante de la salud mental; esta variable influye en el incremento de la    varianz
a explicada, con un efecto de 0,52 (<a href="/img/revistas/rpsp/v23n2/05f3.gif">
figura&nbsp;3</a>).</font></p>     ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#83#79#article#129#<p>&nbsp;</p>     ^cY#05.
htm##
00329000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010600070002000700176#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#84#80#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>DISCUSI&Oacute;N</b></font></p>     ^cY
#05.htm##
01399000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704117600070002000701246#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#85#81#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">La idea central    de la definici&oacute;n
 transaccional del estr&eacute;s de Lazarus y Folkman    (31) es el concepto de 
evaluaci&oacute;n cognitiva <i>(cognitive appraisal)</i>;    la evaluaci&oacute;
n que hace el sujeto de su medio ambiente y de s&iacute;    mismo influye en la 
percepci&oacute;n de una situaci&oacute;n como estresante    o no estresante. As
&iacute;, para que un sujeto considere determinada situaci&oacute;n    como estr
esante debe evaluarse a s&iacute; mismo como incapaz de hacerle frente.    El ap
oyo social es un factor sociocultural relacionado con el estr&eacute;s,    que a
dem&aacute;s se ha identificado como una variable amortiguadora del estr&eacute;
s    (32). El apoyo social percibido se incluye en la evaluaci&oacute;n del medi
o    ambiente (33). Tanto la evaluaci&oacute;n de s&iacute; mismo (autoestima) c
omo    la evaluaci&oacute;n del medio ambiente (apoyo social) forman parte de la
 evaluaci&oacute;n    cognitiva (31). Mediante el modelo elaborado se encontr&oa
cute; que, en conjunto,    estas variables explican 31,9% de la varianza del est
r&eacute;s.</font></p>     ^cY#05.htm##
00800000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704057700070002000700647#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#86#82#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Como se mencion&oacute;    en la introducc
i&oacute;n, el efecto del estr&eacute;s en la salud ha sido objeto    de estudio
 en los &uacute;ltimos a&ntilde;os. La otra variable incluida como    predictora
 de la salud f&iacute;sica es la edad. Ambas variables influyen de    manera neg
ativa: cuanto mayores son el estr&eacute;s y la edad, peor es la salud    f&iacu
te;sica. La varianza de la salud f&iacute;sica explicada por estas dos    variab
les es de 27,4%, con mayor efecto del estr&eacute;s.</font></p>     ^cY#05.htm##
00799000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704057600070002000700646#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#87#83#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Con el modelo elaborado    se enfatiza que
 el estr&eacute;s tambi&eacute;n afecta a la salud mental. El    papel central d
e esta variable en la salud mental ya ha sido considerado en    trabajos anterio
res (17). En el modelo final, el estr&eacute;s, la autoestima    y la salud f&ia
cute;sica explican 72,1% de la varianza de la salud mental, lo    que indica que
 la salud mental no puede ser reducida a un solo factor o causa;    la salud men
tal de las mujeres no es una excepci&oacute;n (34).</font></p>     ^cY#05.htm##
01110000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704088700070002000700957#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#88#84#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">La correlaci&oacute;n    entre la salud me
ntal y la salud f&iacute;sica en las variables desprovistas    de error (puntuac
iones entre las variables latentes) es sensiblemente superior    (<i>r</i>&nbsp;
=&nbsp;0,727) a la encontrada originalmente entre las mediciones    de dichas va
riables en el estudio original (<i>r</i>&nbsp;=&nbsp;0,596). El    modelo final 
permite representar dicha relaci&oacute;n en t&eacute;rminos de    un efecto de 
la salud f&iacute;sica sobre la salud mental. La relaci&oacute;n    estrecha de 
la salud f&iacute;sica y la mental nos lleva a recomendar que todo    programa p
reventivo incluya ambos elementos, considerando que una atenci&oacute;n    y una
 prevenci&oacute;n deficientes tendr&aacute;n repercusiones en diversos    aspec
tos de la calidad de vida de las personas.</font></p>     ^cY#05.htm##
01430000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704120700070002000701277#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#89#85#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Aunque el estudio    realizado cuenta con 
limitaciones en el tama&ntilde;o muestral y el m&eacute;todo    de muestro, se c
onfirma que el apoyo social y la autoestima son predictores    del estr&eacute;s
. Asimismo, se concluye que la escolaridad puede excluirse    del modelo predict
or. La edad tiene una relaci&oacute;n inversa con la salud    f&iacute;sica. El 
estr&eacute;s percibido tiene un efecto negativo en el estado    de salud f&iacu
te;sica; se recomienda confirmar este efecto utilizando, adem&aacute;s    de una
 medida autoevualuada del estr&eacute;s, una medida fisiol&oacute;gica,    como 
la concentraci&oacute;n plasm&aacute;tica de cortisol. La autoestima se    relac
iona directamente con la salud mental, aunque la relaci&oacute;n encontrada    n
o es muy fuerte. El estr&eacute;s tiene un papel central en la salud mental,    
con una relaci&oacute;n inversa entre estas variables. Por &uacute;ltimo, la    
salud f&iacute;sica tiene mayor efecto sobre la salud mental que las variables  
  consideradas en el estudio original (16), lo cual ocasiona un incremento en   
 la varianza explicada de la salud mental.</font></p>     ^cY#05.htm##
00691000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704046800070002000700538#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#90#86#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Cabe se&ntilde;alar    que las conclusione
s acerca del modelo pueden variar al evaluar otros sujetos    y, por lo tanto, n
o pueden ser definitivas ni generalizables. Asimismo, se recomienda    confirmar
 el modelo presentado, utilizando otros indicadores (escalas) para    las difere
ntes variables, adem&aacute;s de extender estas comparaciones a una    muestra q
ue incluya ambos sexos.</font></p>     ^cY#05.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#91#87#article#129#<p>&nbsp;</p>     ^cY#05.
htm##
00324000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010100070002000700171#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#92#88#article#129#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>REFERENCIAS</b></font></p>     ^cY#05.h
tm##
00397000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704016000072002000700232#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#93#89#article#129#1#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;1. Sand&iacute;n    B.
 Estr&eacute;s psicosocial. Madrid: Klinik; 1999.</font></p>     ^cY#05.htm##
00427000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704019000072002000700262#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#94#90#article#129#2#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;2. Rodr&iacute;guez   
 J. Psicolog&iacute;a social de la salud. Espa&ntilde;a: S&iacute;ntesis; 2001.<
/font></p>     ^cY#05.htm##
00493000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704025600072002000700328#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#95#91#article#129#3#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;3. Segerstrom    S, Mi
ller G. Psychological Stress and the Human Immune System: A meta-analytic    stu
dy of 30 years of inquiry. Psychol Bull. 2004;130(4):601&#150;30.</font></p>    
 ^cY#05.htm##
00489000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704025200072002000700324#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#96#92#article#129#4#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;4. Wimbush    F, Nelso
n M. Stress, psychosomatic illness and health. En Hill V, ed. Handbook    of str
ess, coping and health. Londres: Sage; 2000. Pp. 143&#150;74.</font></p>     ^cY
#05.htm##
00488000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704025100072002000700323#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#97#93#article#129#5#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;5. Ettner    S, Grzywa
cs J. Socioeconomic status and health among Californians: an examination    of m
ultiple pathways. Am J Public Health. 2003;93(3):441&#150;4.</font></p>     ^cY#
05.htm##
00437000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704020000072002000700272#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#98#94#article#129#6#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;6. Montt    MA, Ulloa 
F. Autoestima y salud mental en los adolescentes. Salud Mental. 1996;    19(3):3
0&#150;5.</font></p>     ^cY#05.htm##
00438000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704020100072002000700273#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#99#95#article#129#7#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><i>&nbsp;</i>7.    Gracia E.
 El apoyo social en la intervenci&oacute;n comunitaria. Barcelona:    Paid&oacut
e;s; 1997.</font></p>     ^cY#05.htm##
00415000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000200071704017700073002000700250#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#100#96#article#129#8#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;8. Ivancevich    JM, 
Matteson MT. Estr&eacute;s y trabajo. M&eacute;xico: Trillas; 1989.</font></p>  
   ^cY#05.htm##
00551000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000200071704031300073002000700386#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#101#97#article#129#9#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;9. Gonz&aacute;lez   
 MT, Landero R. El papel del es- tr&eacute;s y otras variables en la salud. En: 
   Contreras A, Oblitas L, eds. Terapia Cognitivo Conductual. Colombia: Psicom  
  Editores; 2005. Libro electr&oacute;nico.</font></p>     ^cY#05.htm##
00508000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000300071704026900074002000700343#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#102#98#article#129#10#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Sarason I.    El papel
 de las relaciones &iacute;ntimas en los resultados de salud. En Buend&iacute;a 
   J ed. Familia y psicolog&iacute;a de la salud. Madrid: Pir&aacute;mide; 1999.
</font></p>     ^cY#05.htm##
00540000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000300071704030100074002000700375#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#103#99#article#129#11#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Lara CM, Verduzco    M
, Acevedo M, Cort&eacute;s J. Validez y confiabilidad del inventario de autoesti
ma    de Coopersmith para adultos en poblaci&oacute;n mexicana. Rev Latinoam Psi
col.    1993; 25(2):247&#150;55.</font></p>     ^cY#05.htm##
00464000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704022400075002000700299#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#104#100#article#129#12#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Landero R,    Gonz&aa
cute;lez MT. Determinantes psicosociales del estr&eacute;s en amas de    casa. P
sicol Salud. 2002;12(2):279&#150;88.</font></p>     ^cY#05.htm##
00478000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704023800075002000700313#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#105#101#article#129#13#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Cronkite R,    Moos R
. The role of predisposing and moderating factors in the stress-illness    relat
ionship. J Health Soc Behav. 1984;25: 372&#150;93.</font></p>     ^cY#05.htm##
00490000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704025000075002000700325#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#106#102#article#129#14#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Golding J.    Divisio
n of household labor, strain, and depressive symptoms among Mexican-American    
and non-Hispanic Whites. Psychol Women Q. 1990;14:103&#150;17.</font></p>     ^c
Y#05.htm##
00434000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704019400075002000700269#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#107#103#article#129#15#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Hudson S, O'Regan    
J. Stress and the graduate psychology student. J Clin Psychol. 1994; 50(6):973&#
150;7.</font></p>     ^cY#05.htm##
00471000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704023100075002000700306#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#108#104#article#129#16#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Landero R,    Gonz&aa
cute;lez MT. Variables psicosociales como predictoras de la salud en    mujeres.
 Rev Psicol Social. 2004;19(3):255&#150;64.</font></p>     ^cY#05.htm##
00491000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704025100075002000700326#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#109#105#article#129#17#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">17. S&aacute;nchez    E, 
Garrido A, &Aacute;lvaro JL. Un modelo psicosociol&oacute;gico para el estudio  
  de la salud mental. Rev Psicol Social. 2003;18(1):17&#150;33.</font></p>     ^
cY#05.htm##
00446000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704020600075002000700281#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#110#106#article#129#18#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Cohen S, Kamarak    T
, Mermelstein R. A Global Measure of Perceived Stress. J Health Soc Behav.    19
83;24:385&#150;96.</font></p>     ^cY#05.htm##
00536000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704029600075002000700371#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#111#107#article#129#19#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Remor E, Carrobles   
 J. Versi&oacute;n Espa&ntilde;ola de la escala de estr&eacute;s percibido (PSS-
14):    Estudio psicom&eacute;trico en una muestra VIH+. Ansiedad y estr&eacute;
s. 2001;7(2-3):195&#150;201.</font></p>     ^cY#05.htm##
00464000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704022400075002000700299#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#112#108#article#129#20#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Cohen S, Hoberman    
H. Positive events and social supports as buffers of life change stress. J Appl 
   Soc Psychol. 1983;13:99&#150;125.</font></p>     ^cY#05.htm##
00448000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704020800075002000700283#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#113#109#article#129#21#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Heitzmann CA,    Kapl
an RM. Assessment of methods for measuring social support. Health Psychol.    19
88;7(1):75&#150;109.</font></p>     ^cY#05.htm##
00667000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704042700075002000700502#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#114#110#article#129#22#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Remor E. Cuestionario
    para la evaluaci&oacute;n del apoyo interpersonal-familiar/cuidador. &#91;Si
tio    en Internet&#93; Carnegie Mellon, Department of Psychology. Hallado en: <
a href="http://www.psy.cmu.edu/%7Escohen/ISEL40spanish.html" target="_blank">htt
p://www.psy.cmu.edu/~scohen/ISEL40spanish.html</a>.    Acceso el 22 marzo 2002.<
/font></p>     ^cY#05.htm##
00491000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704025100075002000700326#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#115#111#article#129#23#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Ware J, Snow    K, Ko
sinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide.    Bost
on, MA: New England Medical Center, The Health Institute: 1993.</font></p>     ^
cY#05.htm##
00562000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704032200075002000700397#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#116#112#article#129#24#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Z&uacute;&ntilde;iga 
   M, Carrillo-Jim&eacute;nez G, Fos P, Gandek B, Medina-Moreno M. Evaluaci&oacu
te;n    del estado de salud con la encuesta SF-36: resultados preliminares en M&
eacute;xico.    Salud Publica Mex. 1999;41:110&#150;8.</font></p>     ^cY#05.htm
##
00586000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704034600075002000700421#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#117#113#article#129#25#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Pathak DS,    Chisolm
 DJ, Weis, KA (2005). Functional Assessment in Migraine (FAIM) Questionnaire:   
 Development of an instrument based upon the WHO's International Classification 
   of Functioning, Disability, and Health. Val Health. 2005;8(5):591&#150;600.</
font></p>     ^cY#05.htm##
00420000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704018000075002000700255#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#118#114#article#129#26#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Reed PJ, Moore    D. 
SF-36 as a predictor of health states. Val Health. 2000;3(3):202&#150;7.</font><
/p>     ^cY#05.htm##
00571000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704033100075002000700406#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#119#115#article#129#27#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Atkinson MJ,    Kumar
 R, Cappelleri JC, Hass SL. Hierarchical construct validity of the "Treatment   
 Satisfaction Questionnaire for Medication" (TSQM Version II) among outpatient  
  pharmacy consumers. Val Health. 2005;8(Suppl. 1):S9&#150;S24.</font></p>     ^
cY#05.htm##
00556000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704031600075002000700391#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#120#116#article#129#28#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Ruiz MA, Pardo    A, 
Rejas J, Soto, Villasante F, Aranguren JL. Development and validation of    the 
"Treatment Satisfaction with Medicines Questionnaire" (SATMED Q)<sup>&copy;</sup
>.    Value Health. En preparaci&oacute;n, 2008.</font></p>     ^cY#05.htm##
00430000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704019000075002000700265#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#121#117#article#129#29#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">29. Ruiz M. Introducci&oa
cute;n    a los modelos de ecuaciones estructurales. Madrid: Ediciones UNED; 200
0.</font></p>     ^cY#05.htm##
00550000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704031000075002000700385#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#122#118#article#129#30#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">30. Schermelleh-Engel    
K, Moosbrugger H, M&uuml;ller H. Evaluating the fit of Structural Equation Model
s:    Tests of significance and descriptive goodness-of-fit measures. Methods Ps
ychol    Res Online. 2003;8(2):23&#150;74.</font></p>     ^cY#05.htm##
00408000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704016800075002000700243#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#123#119#article#129#31#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">31. Lazarus R,    Folkman
 S. Stress, coping and adaptation. New York: Springer; 1984.</font></p>     ^cY#
05.htm##
00467000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704022700075002000700302#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#124#120#article#129#32#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">32. Cohen S. Psychosocial
    models of the role of social support in the etiology of physical diseases. H
ealth    Psicol. 1988;7(3):269&#150;97.</font></p>     ^cY#05.htm##
00499000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704025900075002000700334#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#125#121#article#129#33#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">33. Gonz&aacute;lez    MT
, Landero R. S&iacute;ntomas psicosom&aacute;ticos y teor&iacute;a transaccional
    del estr&eacute;s. Ansiedad y estr&eacute;s. 2006;12(1):45&#150;61.</font></
p>     ^cY#05.htm##
00649000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704040900075002000700484#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#p#126#122#article#129#34#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">34. World Health    Organ
ization. Women's men-tal health: An evidence based review. 2000. &#91;Sitio    e
n Internet&#93; World Health Organization. Hallado en: <a href="http://whqlibdoc
.who.int/hq/2000/WHO_MSD_MDP_00.1.pdf" target="_blank">http://whqlibdoc.who.int/
hq/2000/WHO_MSD_MDP_00.1.pdf</a>.    Acceso el 28 enero 2006.</font></p>     ^cY
#05.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#127#123#article#129#<p>&nbsp;</p>     ^cY#0
5.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#128#124#article#129#<p>&nbsp;</p>     ^cY#0
5.htm##
00346000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704012100072002000700193#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#129#125#article#129#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Manuscrito recibido    el 22 de noviembr
e de 2006.    ^cY#05.htm##
00331000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704010600072002000700178#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#130#126#article#129#<br>   Aceptado para pu
blicaci&oacute;n, tras revisi&oacute;n, el 2 de agosto de 2007.</font></p>     ^
cY#05.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#131#127#article#129#<p>&nbsp;</p>     ^cY#0
5.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#132#128#article#129#<p>&nbsp;</p>     ^cY#0
5.htm##
00819000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704059400072002000700666#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\05.htm#S#p#133#129#article#129#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#top">*</a> 
   La correspondencia debe dirigirse a M&oacute;nica Teresa Gonz&aacute;lez Ram&
iacute;rez,    Universidad Aut&oacute;noma de Nuevo Le&oacute;n, Facultad de Psi
colog&iacute;a,    Cuerpo Acad&eacute;mico en Psicolog&iacute;a Social, Mutualis
mo 110, Colonia    Mitras Centro, Monterrey, Nuevo Le&oacute;n, CP 64460, M&eacu
te;xico; tel.:    +52 (81) 8333 8233, fax: +52 (81) 8333 8222, correo electr&oac
ute;nico: <a href="mailto:monygzz77@yahoo.com">monygzz77@yahoo.com</a>.</font></
p>     ^cY#05.htm##
00384000000000229000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690160016000710180023000870660
00700110062000700117065000900124064000500133865000900138002000700147#v23n2#v:\sc
ielo\serial\rpsp\v23n2\markup\05.htm#S#c#134#1#article#34#1#^rND^sSandín^nB#Estr
és psicosocial^les#Madrid#Klinik#19990000#1999#20080200#05.htm##
00400000000000229000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690160019000710180034000900670
00700124062000900131065000900140064000500149865000900154002000700163#v23n2#v:\sc
ielo\serial\rpsp\v23n2\markup\05.htm#S#c#135#2#article#34#2#^rND^sRodríguez^nJ#P
sicología social de la salud^les#España#Síntesis#20010000#2001#20080200#05.htm##
00575000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100020000710100016000910120
09900107030001300206065000900219064000500228031000400233032000200237014000700239
865000900246002000700255035001000262801001300272#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\05.htm#S#c#136#3#article#34#3#^rND^sSegerstrom^nS#^rND^sMiller^nG#Psyc
hological Stress and the Human Immune System: A meta-analytic study of 30 years 
of inquiry^len#Psychol Bull#20040000#2004#130#4#601-30#20080200#05.htm#0033-2909
#Psychol Bull##
00533000000000277000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100017000710100016000880120
04500104016001400149018004200163066000800205062000500213065000900218064000500227
014000700232865000900239002000700248#v23n2#v:\scielo\serial\rpsp\v23n2\markup\05
.htm#S#c#137#4#article#34#4#^rND^sWimbush^nF#^rND^sNelson^nM#Stress, psychosomat
ic illness and health^len#^rED^sHill^nV#Handbook of stress, coping and health^le
n#Londres#Sage#20000000#2000#143-74#20080200#05.htm##
00576000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100016000710100018000870120
09200105030001900197065000900216064000500225031000300230032000200233014000600235
865000900241002000700250035001000257801001900267#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\05.htm#S#c#138#5#article#34#5#^rND^sEttner^nS#^rND^sGrzywacs^nJ#Socioe
conomic status and health among Californians: an examination of multiple pathway
s^len#Am J Public Health#20030000#2003#93#3#441-4#20080200#05.htm#0090-0036#Am J
 Public Health##
00518000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100016000710100015000870120
05000102030001300152065000900165064000500174031000300179032000200182014000500184
865000900189002000700198035001000205801001300215#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\05.htm#S#c#139#6#article#34#6#^rND^sMontt^nMA#^rND^sUlloa^nF#Autoestim
a y salud mental en los adolescentes^len#Salud Mental#19960000#1996#19#3#30-5#20
080200#05.htm#0185-3325#Salud mental##
00415000000000229000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690160016000710180051000870660
01000138062000700148065000900155064000500164865000900169002000700178#v23n2#v:\sc
ielo\serial\rpsp\v23n2\markup\05.htm#S#c#140#7#article#34#7#^rND^sGracia^nE#El a
poyo social en la intervención comunitaria^les#Barcelona#Paidós#19970000#1997#20
080200#05.htm##
00419000000000241000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690160021000710160019000920180
02100111067000700132062000800139065000900147064000500156865000900161002000700170
#v23n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#c#141#8#article#34#8#^rND^sIv
ancevich^nJM#^rND^sMatteson^nMT#Estrés y trabajo^les#México#Trillas#19890000#198
9#20080200#05.htm##
00595000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100019000710100017000900120
05600107016001900163016001700182018003300199067000900232062001600241065000900257
064000500266061001800271865000900289002000700298#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\05.htm#S#c#142#9#article#34#9#^rND^sGonzález^nMT#^rND^sLandero^nR#El p
apel del es- trés y otras variables en la salud^les#^rED^sContreras^nA#^rED^sObl
itas^nL#Terapia Cognitivo Conductual^les#Colombia#Psicom Editores#20050000#2005#
Libro electrónico#20080200#05.htm##
00510000000000253000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730120066000900160
01700156018003700173066000700210062000900217065000900226064000500235865000900240
002000700249#v23n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#c#143#10#article#
34#10#^rND^sSarason^nI#El papel de las relaciones íntimas en los resultados de s
alud^les#^rED^sBuendía^nJ#Familia y psicología de la salud^les#Madrid#Pirámide#1
9990000#1999#20080200#05.htm##
00652000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100018000880100
01700106010001600123012010700139030002000246065000900266064000500275031000300280
032000200283014000700285865000900292002000700301035001000308801002000318#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\05.htm#S#c#144#11#article#34#11#^rND^sLara^nCM
#^rND^sVerduzco^nM#^rND^sAcevedo^nM#^rND^sCortés^nJ#Validez y confiabilidad del 
inventario de autoestima de Coopersmith para adultos en población mexicana^les#R
ev Latinoam Psicol#19930000#1993#25#2#247-55#20080200#05.htm#0120-0534#Rev Latin
oam Psicol##
00503000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100019000900120
05900109030001300168710000200181065000900183064000500192031000300197032000200200
014000700202865000900209002000700218#v23n2#v:\scielo\serial\rpsp\v23n2\markup\05
.htm#S#c#145#12#article#34#12#^rND^sLandero^nR#^rND^sGonzález^nMT#Determinantes 
psicosociales del estrés en amas de casa^les#Psicol Salud#2#20020000#2002#12#2#2
79-88#20080200#05.htm##
00558000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100014000910120
08700105030001900192065000900211064000500220031000300225014000700228865000900235
002000700244035001000251801001900261#v23n2#v:\scielo\serial\rpsp\v23n2\markup\05
.htm#S#c#146#13#article#34#13#^rND^sCronkite^nR#^rND^sMoos^nR#The role of predis
posing and moderating factors in the stress-illness relationship^len#J Health So
c Behav#19840000#1984#25#372-93#20080200#05.htm#0022-1465#J Health Soc Behav##
00550000000000265000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730120112000900300
01600202065000900218064000500227031000300232014000700235865000900242002000700251
035001000258801001600268#v23n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#c#147
#14#article#34#14#^rND^sGolding^nJ#Division of household labor, strain, and depr
essive symptoms among Mexican-American and non-Hispanic Whites^len#Psychol Women
 Q#19900000#1990#14#103-17#20080200#05.htm#0361-6843#Psychol Women Q##
00524000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100017000890120
04700106030001500153065000900168064000500177031000300182032000200185014000600187
865000900193002000700202035001000209801001500219#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\05.htm#S#c#148#15#article#34#15#^rND^sHudson^nS#^rND^sO'Regan^nJ#Stres
s and the graduate psychology student^len#J Clin Psychol#19940000#1994#50#6#973-
7#20080200#05.htm#0021-9762#J Clin Psychol##
00517000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100019000900120
06800109030001800177710000200195065000900197064000500206031000300211032000200214
014000700216865000900223002000700232#v23n2#v:\scielo\serial\rpsp\v23n2\markup\05
.htm#S#c#149#16#article#34#16#^rND^sLandero^nR#^rND^sGonzález^nMT#Variables psic
osociales como predictoras de la salud en mujeres^les#Rev Psicol Social#2#200400
00#2004#19#3#255-64#20080200#05.htm##
00541000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100017000900100
01700107012006600124030001800190710000200208065000900210064000500219031000300224
032000200227014000600229865000900235002000700244#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\05.htm#S#c#150#17#article#34#17#^rND^sSánchez^nE#^rND^sGarrido^nA#^rND
^sÁlvaro^nJL#Un modelo psicosociológico para el estudio de la salud mental^les#R
ev Psicol Social#2#20030000#2003#18#1#17-33#20080200#05.htm##
00545000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100017000880100
02100105012004100126030001900167065000900186064000500195031000300200014000700203
865000900210002000700219035001000226801001900236#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\05.htm#S#c#151#18#article#34#18#^rND^sCohen^nS#^rND^sKamarak^nT#^rND^s
Mermelstein^nR#A Global Measure of Perceived Stress^len#J Health Soc Behav#19830
000#1983#24#385-96#20080200#05.htm#0022-1465#J Health Soc Behav##
00554000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100019000880120
10500107030001800212710000200230065000900232064000500241031000200246032000400248
014000800252865000900260002000700269#v23n2#v:\scielo\serial\rpsp\v23n2\markup\05
.htm#S#c#152#19#article#34#19#^rND^sRemor^nE#^rND^sCarrobles^nJ#Versión Española
 de la escala de estrés percibido (PSS-14): Estudio psicométrico en una muestra 
VIH+^les#Ansiedad y estrés#2#20010000#2001#7#2-3#195-201#20080200#05.htm##
00545000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100018000880120
07300106030001900179065000900198064000500207031000300212014000700215865000900222
002000700231035001000238801001900248#v23n2#v:\scielo\serial\rpsp\v23n2\markup\05
.htm#S#c#153#20#article#34#20#^rND^sCohen^nS#^rND^sHoberman^nH#Positive events a
nd social supports as buffers of life change stress^len#J Appl Soc Psychol#19830
000#1983#13#99-125#20080200#05.htm#0021-9029#J Appl Soc Psychol##
00536000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100020000730100017000930120
05500110030001500165065000900180064000500189031000200194032000200196014000700198
865000900205002000700214035001000221801001500231#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\05.htm#S#c#154#21#article#34#21#^rND^sHeitzmann^nCA#^rND^sKaplan^nRM#A
ssessment of methods for measuring social support^len#Health Psychol#19880000#19
88#7#1#75-109#20080200#05.htm#0278-6133#Health Psychol##
00568000000000253000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700160015000730180078000880610
01800166061001600184062002500200037005000225110000900275109001400284865000900298
002000700307#v23n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#c#155#22#article#
34#22#^rND^sRemor^nE#Cuestionario para la evaluación del apoyo interpersonal-fam
iliar/cuidador^len#Sitio en Internet#Carnegie Mellon#Department of Psychology#ht
tp://www.psy.cmu.edu/~scohen/ISEL40spanish.html#20020322#22 marzo 2002#20080200#
05.htm##
00558000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700160014000730160014000870160
01800101016001600119018005600135066001100191062002700202062002100229065000900250
064000500259865000900264002000700273#v23n2#v:\scielo\serial\rpsp\v23n2\markup\05
.htm#S#c#156#23#article#34#23#^rND^sWare^nJ#^rND^sSnow^nK#^rND^sKosinski^nM#^rND
^sGandek^nB#SF-36 Health Survey Manual and Interpretation Guide^len#Boston^eMA#N
ew England Medical Center#The Health Institute#19930000#1993#20080200#05.htm##
00658000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100026000890100
01300115010001600128010002300144012009200167030001800259065000900277064000500286
031000300291014000600294865000900300002000700309035001000316801001800326#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\05.htm#S#c#157#24#article#34#24#^rND^sZúñiga^n
M#^rND^sCarrillo-Jiménez^nG#^rND^sFos^nP#^rND^sGandek^nB#^rND^sMedina-Moreno^nM#
Evaluación del estado de salud con la encuesta SF-36: resultados preliminares en
 México^les#Salud Publica Mex#19990000#1999#41#110-8#20080200#05.htm#0036-3634#S
alud Publica Mex##
00684000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100018000900100
01500108065000900123064000500132012017800137030001100315710000200326065000900328
064000500337031000200342032000200344014000800346865000900354002000700363#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\05.htm#S#c#158#25#article#34#25#^rND^sPathak^n
DS#^rND^sChisolm^nDJ#^rND^sWeis^nKA#20050000#2005#Functional Assessment in Migra
ine (FAIM) Questionnaire: Development of an instrument based upon the WHO's Inte
rnational Classification of Functioning, Disability, and Health^len#Val Health#2
#20050000#2005#8#5#591-600#20080200#05.htm##
00476000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100015000880120
04200103030001100145710000200156065000900158064000500167031000200172032000200174
014000600176865000900182002000700191#v23n2#v:\scielo\serial\rpsp\v23n2\markup\05
.htm#S#c#159#26#article#34#26#^rND^sReed^nPJ#^rND^sMoore^nD#SF-36 as a predictor
 of health states^len#Val Health#2#20000000#2000#3#3#202-7#20080200#05.htm##
00652000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100015000920100
02100107010001500128012015100143030001100294710000200305065000900307064000500316
031000200321032000400323014000700327865000900334002000700343#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\05.htm#S#c#160#27#article#34#27#^rND^sAtkinson^nMJ#^rND^sK
umar^nR#^rND^sCappelleri^nJC#^rND^sHass^nSL#Hierarchical construct validity of t
he "Treatment Satisfaction Questionnaire for Medication" (TSQM Version II) among
 outpatient pharmacy consumers^len#Val Health#2#20050000#2005#8#^s1#S9-S24#20080
200#05.htm##
00604000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700160015000730160015000880160
01500103016002600118016002000144018010400164062001300268061001500281065000900296
064000500305865000900310002000700319#v23n2#v:\scielo\serial\rpsp\v23n2\markup\05
.htm#S#c#161#28#article#34#28#^rND^sRuiz^nMA#^rND^sPardo^nA#^rND^sRejas^nJ#^rND^
sSoto, Villasante^nF#^rND^sAranguren^nJL#Development and validation of the "Trea
tment Satisfaction with Medicines Questionnaire" (SATMED Q)©^len#Value Health#En
 preparación#20080000#2008#20080200#05.htm##
00428000000000229000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700160014000730180059000870660
00700146062001500153065000900168064000500177865000900182002000700191#v23n2#v:\sc
ielo\serial\rpsp\v23n2\markup\05.htm#S#c#162#29#article#34#29#^rND^sRuiz^nM#Intr
oducción a los modelos de ecuaciones estructurales^les#Madrid#Ediciones UNED#200
00000#2000#20080200#05.htm##
00613000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100027000730100021001000100
01600121012011700137030002700254710000200281065000900283064000500292031000200297
032000200299014000600301865000900307002000700316#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\05.htm#S#c#163#30#article#34#30#^rND^sSchermelleh-Engel^nK#^rND^sMoosb
rugger^nH#^rND^sMüller^nH#Evaluating the fit of Structural Equation Models: Test
s of significance and descriptive goodness-of-fit measures^len#Methods Psychol R
es Online#2#20030000#2003#8#2#23-74#20080200#05.htm##
00431000000000241000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700160017000730160017000900180
03400107066000900141062000900150065000900159064000500168865000900173002000700182
#v23n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#c#164#31#article#34#31#^rND^s
Lazarus^nR#^rND^sFolkman^nS#Stress, coping and adaptation^len#New York#Springer#
19840000#1984#20080200#05.htm##
00502000000000265000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730120091000880300
01400179710000200193065000900195064000500204031000200209031000200211014000700213
865000900220002000700229#v23n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#c#165
#32#article#34#32#^rND^sCohen^nS#Psychosocial models of the role of social suppo
rt in the etiology of physical diseases^len#Health Psicol#2#19880000#1988#7#3#26
9-97#20080200#05.htm##
00510000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100017000920120
06200109030001800171710000200189065000900191064000500200031000300205032000200208
014000600210865000900216002000700225#v23n2#v:\scielo\serial\rpsp\v23n2\markup\05
.htm#S#c#166#33#article#34#33#^rND^sGonzález^nMT#^rND^sLandero^nR#Síntomas psico
somáticos y teoría transaccional del estrés^les#Ansiedad y estrés#2#20060000#200
6#12#1#45-61#20080200#05.htm##
00569000000000265000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700170026000730180053000990650
00900152064000500161061001800166062002600184037005400210110000900264109001400273
865000900287002000700296#v23n2#v:\scielo\serial\rpsp\v23n2\markup\05.htm#S#c#167
#34#article#34#34#World Health Organization#Women's men-tal health: An evidence 
based review^len#20000000#2000#Sitio en Internet#World Health Organization#http:
//whqlibdoc.who.int/hq/2000/WHO_MSD_MDP_00.1.pdf#20060128#28 enero 2006#20080200
#05.htm##
00263000000000169000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640910009000660920007000750020007000827030
00400089#v23n2#v:\scielo\serial\rpsp\v23n2\markup\06.htm#S#o#1#1#article#1#20080
318#103143#06.htm#144##
05066000000000625000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000400084121000300088049000800091158000300099030002400102
03100030012603200020012906500090013101400110014003500100015101201110016101201070
02720100046003790700054004250831769004790850008022480850033022560850030022890850
02602319085005902345085002202404085002102426083171802447085000804165085003304173
08500280420608500260423408500590426008500230431908500210434211700060436307200030
4369112000904372111002304381114000904404113002004413002000704433#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#h#2#1#article#1#oa#pt#br1.1#1#3.1#TAB#06#RPSP
020#nd#Rev Panam Salud Publica#23#2#20080200#^f109^l115#1020-4989#Validação da v
ersão em português europeu de questionário de avaliação funcional multidimension
al de idosos^lpt#Validation of the European Portuguese version of the Older Amer
icans Resources and Services instrument^len#^rND^1A01^nRogério Manuel Clemente^s
Rodrigues#Escola Superior de Enfermagem^iA01^cCoimbra^pPortugal#^lpt^aOBJETIVO: 
Validar a versão em português europeu do Older Americans Resources and Services,
 um instrumento para avaliar de forma multidimensional a qualidade de vida dos i
dosos. MÉTODO: O estudo, autorizado pelos autores da versão original em inglês, 
começou com a tradução e a adaptação cultural do questionário para a língua port
uguesa. A versão resultante foi validada por peritos e aplicada a 302 idosos (14
7 residentes em lares e 155 freqüentadores de centros de dia) na região centro d
e Portugal (distritos de Aveiro, Castelo Branco, Coimbra, Leiria, Guarda e Viseu
). Depois disso, foi feito o estudo psicométrico global do instrumento (coerênci
a interna, validade da construção da versão em português europeu, validade de cr
itério e reprodutibilidade). A amostra foi aleatória e estratificada por idade, 
gênero e tipo de apoio institucional. RESULTADOS: A coerência interna (alfa de C
ronbach) para as cinco escalas de avaliação funcional do instrumento situou-se e
ntre 0,64 e 0,91. Para a validade de critério, os valores relativamente baixos d
a correlação de Pearson (< 0,700) obtidos na correlação com o Medical Outcomes S
tudy 36-Item Short-Form General Health Survey demonstram a dificuldade em dispor
, na avaliação em saúde, de medidas de critério com as quais novos instrumentos 
possam ser comparados. No estudo da reprodutibilidade, os valores da correlação 
de Pearson situaram-se entre 0,859 e 1,000. CONCLUSÕES: O instrumento de avaliaç
ão da qualidade de vida para idosos resultante deste trabalho - o Questionário d
e Avaliação Funcional Multidimensional de Idosos - é útil para levantar informaç
ões significativas que auxiliem a centrar as intervenções comunitárias e a promo
ver estratégias de intervenção mais adequadas a esse grupo populacional.#^dnd^i1
#^tm^lpt^kAvaliação geriátrica^i1#^tm^lpt^kqualidade de vida^i1#^tm^lpt^ksaúde p
ública^i1#^tm^lpt^kOlder Americans Resources and Services Program^i1#^tm^lpt^kva
lidação^i1#^tm^lpt^kPortugal^i1#^len^aOBJECTIVE: To validate the European Portug
uese version of the Older Americans Resources and Services (OARS) instrument, us
ed for the multidimensional evaluation of the quality of life of the elderly. ME
THOD: The study was authorized by the authors of the original English version. F
irst, the questionnaire was translated into European Portuguese and culturally a
dapted. The resulting version was then validated by experts and administered to 
302 elderly persons (147 living in nursing homes and 155 at day care centers) in
 the central region of Portugal (districts of Aveiro, Castelo Branco, Coimbra, L
eiria, Guarda, and Viseu). Subsequently, a global psychometric study was conduct
ed on the instrument, evaluating internal coherence, validity of construction, c
riterion validity, and reproducibility. The sample was randomly selected and str
atified by age, sex, and type of institutional support. RESULTS: The internal co
herence (Cronbach's alpha) was between 0.64 and 0.91 for each of the five functi
onal assessment scales included in the instrument. For criterion validity, the r
elatively low Pearson correlation values obtained (< 0.700) through the Medical 
Outcomes Study 36-Item Short-Form General Health Survey reflect the challenges a
ssociated with establishing a criterion by which new health evaluation instrumen
ts might be compared. Pearson's correlation for reproducibility was between 0.85
9 and 1.0 for all the scales. CONCLUSIONS: The European-Portuguese version of th
e OARS (Questionário de Avaliação Funcional Multidimensional de Idosos) is usefu
l for collecting valid information that can help focus community interventions a
nd promote strategies that specifically target this population group.#^dnd^i2#^t
m^len^kGeriatric assessment^i2#^tm^len^kquality of life^i2#^tm^len^kpublic healt
h^i2#^tm^len^kOlder Americans Resources and Services Program^i2#^tm^len^kvalidat
ion^i2#^tm^len^kPortugal^i2#other#23#20061119#19 de novembro de 2006#20070720#20
 de julho de 2007#06.htm##
05183000000000625000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000400084121000300088049000800091158000300099030002400102
03100030012603200020012906500090013101400110014003500100015101201180016101201140
02790100046003930700054004390831819004930850008023120850033023200850030023530850
02602383085005902409085002202468085002102490083177102511085000804282085003304290
08500280432308500260435108500590437708500230443608500210445911700060448007200030
4486112000904489111002304498114000904521113002004530002000704550#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#f#3#1#article#1#oa#pt#br1.1#1#3.1#TAB#06#RPSP
020#nd#Rev Panam Salud Publica#23#2#20080200#^f109^l115#1020-4989#<B>Validação d
a versão em português europeu de questionário de avaliação funcional multidimens
ional de idosos</B>^lpt#<B>Validation of the European Portuguese version of the 
Older Americans Resources and Services instrument</B>^len#^rND^1A01^nRogério Man
uel Clemente^sRodrigues#Escola Superior de Enfermagem^iA01^cCoimbra^pPortugal#^l
pt^a<B>OBJETIVO:</B> Validar a versão em português europeu do <I>Older Americans
 Resources and Services</I>, um instrumento para avaliar de forma multidimension
al a qualidade de vida dos idosos. <B>MÉTODO:</B>&nbsp;O estudo, autorizado pelo
s autores da versão original em inglês, começou com a tradução e a adaptação cul
tural do questionário para a língua portuguesa. A versão resultante foi validada
 por peritos e aplicada a 302 idosos (147 residentes em lares e 155 freqüentador
es de centros de dia) na região centro de Portugal (distritos de Aveiro, Castelo
 Branco, Coimbra, Leiria, Guarda e Viseu). Depois disso, foi feito o estudo psic
ométrico global do instrumento (coerência interna, validade da construção da ver
são em português europeu, validade de critério e reprodutibilidade). A amostra f
oi aleatória e estratificada por idade, gênero e tipo de apoio institucional. <B
>RESULTADOS: </B>A coerência interna (alfa de Cronbach) para as cinco escalas de
 avaliação funcional do instrumento situou-se entre 0,64 e 0,91. Para a validade
 de critério, os valores relativamente baixos da correlação de Pearson (&lt; 0,7
00) obtidos na correlação com o <I>Medical Outcomes Study 36-Item Short-Form Gen
eral Health Survey</I> demonstram a dificuldade em dispor, na avaliação em saúde
, de medidas de critério com as quais novos instrumentos possam ser comparados. 
No estudo da reprodutibilidade, os valores da correlação de Pearson situaram-se 
entre 0,859 e 1,000. <B>CONCLUSÕES: </B>O instrumento de avaliação da qualidade 
de vida para idosos resultante deste trabalho - o Questionário de Avaliação Func
ional Multidimensional de Idosos - é útil para levantar informações significativ
as que auxiliem a centrar as intervenções comunitárias e a promover estratégias 
de intervenção mais adequadas a esse grupo populacional.#^dnd^i1#^tm^lpt^kAvalia
ção geriátrica^i1#^tm^lpt^kqualidade de vida^i1#^tm^lpt^ksaúde pública^i1#^tm^lp
t^kOlder Americans Resources and Services Program^i1#^tm^lpt^kvalidação^i1#^tm^l
pt^kPortugal^i1#^len^a<B>OBJECTIVE:</B> To validate the European Portuguese vers
ion of the Older Americans Resources and Services (OARS) instrument, used for th
e multidimensional evaluation of the quality of life of the elderly. <B>METHOD:<
/B>&nbsp;The study was authorized by the authors of the original English version
. First, the questionnaire was translated into European Portuguese and culturall
y adapted. The resulting version was then validated by experts and administered 
to 302 elderly persons (147 living in nursing homes and 155 at day care centers)
 in the central region of Portugal (districts of Aveiro, Castelo Branco, Coimbra
, Leiria, Guarda, and Viseu). Subsequently, a global psychometric study was cond
ucted on the instrument, evaluating internal coherence, validity of construction
, criterion validity, and reproducibility. The sample was randomly selected and 
stratified by age, sex, and type of institutional support. <B>RESULTS:</B>&nbsp;
The internal coherence (Cronbach's alpha) was between 0.64 and 0.91 for each of 
the five functional assessment scales included in the instrument. For criterion 
validity, the relatively low Pearson correlation values obtained (&lt; 0.700) th
rough the Medical Outcomes Study 36-Item Short-Form General Health Survey reflec
t the challenges associated with establishing a criterion by which new health ev
aluation instruments might be compared. Pearson's correlation for reproducibilit
y was between 0.859 and 1.0 for all the scales. <B>CONCLUSIONS:</B>&nbsp;The Eur
opean-Portuguese version of the OARS (<I>Questionário de Avaliação Funcional Mul
tidimensional de Idosos)</I> is useful for collecting valid information that can
 help focus community interventions and promote strategies that specifically tar
get this population group.#^dnd^i2#^tm^len^kGeriatric assessment^i2#^tm^len^kqua
lity of life^i2#^tm^len^kpublic health^i2#^tm^len^kOlder Americans Resources and
 Services Program^i2#^tm^len^kvalidation^i2#^tm^len^kPortugal^i2#other#23#200611
19#19 de novembro de 2006#20070720#20 de julho de 2007#06.htm##
05199000000000649000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640640013000660710003000790400003000820010
00600085042000200091120000400093038000400097121000300101049000800104158000300112
03000260011503100030014103200020014406500090014601400110015503500100016601201110
01760120107002870100046003940700056004400831769004960850008022650850033022730850
03002306085002602336085005902362085002202421085002102443083171802464085000804182
08500330419008500280422308500260425108500590427708500230433608500210435911700060
43800720003043861120009043891110023043981140009044211130020044300020007044500080
09204457#v23n2#v:\scielo\serial\rpsp\v23n2\markup\06.htm#S#l#4#1#article#1#^mfev
.^a2008#oa#pt#br1.1#1#3.1#tab#06#RPSP020#nd#Rev. panam. salud pública#23#2#20080
200#^f109^l115#1020-4989#Validação da versão em português europeu de questionári
o de avaliação funcional multidimensional de idosos^lpt#Validation of the Europe
an Portuguese version of the Older Americans Resources and Services instrument^l
en#^rND^1A01^nRogério Manuel Clemente^sRodrigues#^iA01^1Escola Superior de Enfer
magem^cCoimbra^pPortugal#^lpt^aOBJETIVO: Validar a versão em português europeu d
o Older Americans Resources and Services, um instrumento para avaliar de forma m
ultidimensional a qualidade de vida dos idosos. MÉTODO: O estudo, autorizado pel
os autores da versão original em inglês, começou com a tradução e a adaptação cu
ltural do questionário para a língua portuguesa. A versão resultante foi validad
a por peritos e aplicada a 302 idosos (147 residentes em lares e 155 freqüentado
res de centros de dia) na região centro de Portugal (distritos de Aveiro, Castel
o Branco, Coimbra, Leiria, Guarda e Viseu). Depois disso, foi feito o estudo psi
cométrico global do instrumento (coerência interna, validade da construção da ve
rsão em português europeu, validade de critério e reprodutibilidade). A amostra 
foi aleatória e estratificada por idade, gênero e tipo de apoio institucional. R
ESULTADOS: A coerência interna (alfa de Cronbach) para as cinco escalas de avali
ação funcional do instrumento situou-se entre 0,64 e 0,91. Para a validade de cr
itério, os valores relativamente baixos da correlação de Pearson (< 0,700) obtid
os na correlação com o Medical Outcomes Study 36-Item Short-Form General Health 
Survey demonstram a dificuldade em dispor, na avaliação em saúde, de medidas de 
critério com as quais novos instrumentos possam ser comparados. No estudo da rep
rodutibilidade, os valores da correlação de Pearson situaram-se entre 0,859 e 1,
000. CONCLUSÕES: O instrumento de avaliação da qualidade de vida para idosos res
ultante deste trabalho - o Questionário de Avaliação Funcional Multidimensional 
de Idosos - é útil para levantar informações significativas que auxiliem a centr
ar as intervenções comunitárias e a promover estratégias de intervenção mais ade
quadas a esse grupo populacional.#^dnd^i1#^tm^lpt^kAvaliação geriátrica^i1#^tm^l
pt^kqualidade de vida^i1#^tm^lpt^ksaúde pública^i1#^tm^lpt^kOlder Americans Reso
urces and Services Program^i1#^tm^lpt^kvalidação^i1#^tm^lpt^kPortugal^i1#^len^aO
BJECTIVE: To validate the European Portuguese version of the Older Americans Res
ources and Services (OARS) instrument, used for the multidimensional evaluation 
of the quality of life of the elderly. METHOD: The study was authorized by the a
uthors of the original English version. First, the questionnaire was translated 
into European Portuguese and culturally adapted. The resulting version was then 
validated by experts and administered to 302 elderly persons (147 living in nurs
ing homes and 155 at day care centers) in the central region of Portugal (distri
cts of Aveiro, Castelo Branco, Coimbra, Leiria, Guarda, and Viseu). Subsequently
, a global psychometric study was conducted on the instrument, evaluating intern
al coherence, validity of construction, criterion validity, and reproducibility.
 The sample was randomly selected and stratified by age, sex, and type of instit
utional support. RESULTS: The internal coherence (Cronbach's alpha) was between 
0.64 and 0.91 for each of the five functional assessment scales included in the 
instrument. For criterion validity, the relatively low Pearson correlation value
s obtained (< 0.700) through the Medical Outcomes Study 36-Item Short-Form Gener
al Health Survey reflect the challenges associated with establishing a criterion
 by which new health evaluation instruments might be compared. Pearson's correla
tion for reproducibility was between 0.859 and 1.0 for all the scales. CONCLUSIO
NS: The European-Portuguese version of the OARS (Questionário de Avaliação Funci
onal Multidimensional de Idosos) is useful for collecting valid information that
 can help focus community interventions and promote strategies that specifically
 target this population group.#^dnd^i2#^tm^len^kGeriatric assessment^i2#^tm^len^
kquality of life^i2#^tm^len^kpublic health^i2#^tm^len^kOlder Americans Resources
 and Services Program^i2#^tm^len^kvalidation^i2#^tm^len^kPortugal^i2#other#23#20
061119#19 de novembro de 2006#20070720#20 de julho de 2007#06.htm#Internet^ihttp
://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892008000200006##
00375000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704015400068002000700222#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#5#1#article#117#<p align="right"><font face
="Verdana, Arial, Helvetica, sans-serif" size="2"><b>INVESTIGACI&Oacute;N    ORI
GINAL</b> ORIGINAL RESEARCH</font></p>     ^cY#06.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704002200068002000700090#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#6#2#article#117#<p>&nbsp;</p>     ^cY#06.ht
m##
00489000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704026800068002000700336#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#7#3#article#117#<p><a name="top"></a><font 
face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Valida&ccedil;&atilde;o
    da vers&atilde;o em portugu&ecirc;s europeu de question&aacute;rio de avalia
&ccedil;&atilde;o    funcional multidimensional de idosos</b></font></p>     ^cY
#06.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704002200068002000700090#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#8#4#article#117#<p>&nbsp;</p>     ^cY#06.ht
m##
00419000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704019800068002000700266#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#9#5#article#117#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="3"><b>Validation of    the European Portuguese 
version of the Older Americans Resources and Services    instrument</b></font></
p>     ^cY#06.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#10#6#article#117#<p>&nbsp;</p>     ^cY#06.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#11#7#article#117#<p>&nbsp;</p>     ^cY#06.h
tm##
00387000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704016500069002000700234#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#12#8#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Rog&eacute;rio    Manuel Clemente Rodrig
ues<a href="#back"><sup>*</sup></a></b></font></p>     ^cY#06.htm##
00356000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704013400069002000700203#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#13#9#article#117#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Escola Superior    de Enfermagem, Coimbra, 
Portugal</font></p>     ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#14#10#article#117#<p>&nbsp;</p>     ^cY#06.
htm##
00267000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704004400070002000700114#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#15#11#article#117#<p>&nbsp;</p> <hr size="1
" noshade>     ^cY#06.htm##
00319000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009600070002000700166#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#16#12#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY#06.htm##
00506000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704028300070002000700353#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#17#13#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Validar a vers&atilde;
o em portugu&ecirc;s europeu do <i>Older Americans Resources    and Services</i>
, um instrumento para avaliar de forma multidimensional a qualidade    de vida d
os idosos.    ^cY#06.htm##
01098000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704087500070002000700945#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#18#14#article#117#<br>   <b>M&Eacute;TODO:<
/b>&nbsp;O estudo, autorizado pelos autores da vers&atilde;o    original em ingl
&ecirc;s, come&ccedil;ou com a tradu&ccedil;&atilde;o e a adapta&ccedil;&atilde;
o    cultural do question&aacute;rio para a l&iacute;ngua portuguesa. A vers&ati
lde;o    resultante foi validada por peritos e aplicada a 302 idosos (147 reside
ntes    em lares e 155 freq&uuml;entadores de centros de dia) na regi&atilde;o c
entro    de Portugal (distritos de Aveiro, Castelo Branco, Coimbra, Leiria, Guar
da e    Viseu). Depois disso, foi feito o estudo psicom&eacute;trico global do i
nstrumento    (coer&ecirc;ncia interna, validade da constru&ccedil;&atilde;o da 
vers&atilde;o    em portugu&ecirc;s europeu, validade de crit&eacute;rio e repro
dutibilidade).    A amostra foi aleat&oacute;ria e estratificada por idade, g&ec
irc;nero e tipo    de apoio institucional.    ^cY#06.htm##
00942000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704071900070002000700789#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#19#15#article#117#<br>   <b>RESULTADOS: </b
> A coer&ecirc;ncia interna (alfa de Cronbach) para as cinco    escalas de avali
a&ccedil;&atilde;o funcional do instrumento situou-se entre    0,64 e 0,91. Para
 a validade de crit&eacute;rio, os valores relativamente baixos    da correla&cc
edil;&atilde;o de Pearson (&lt; 0,700) obtidos na correla&ccedil;&atilde;o    co
m o <i>Medical Outcomes Study 36-Item Short-Form General Health Survey</i>    de
monstram a dificuldade em dispor, na avalia&ccedil;&atilde;o em sa&uacute;de,   
 de medidas de crit&eacute;rio com as quais novos instrumentos possam ser compar
ados.    No estudo da reprodutibilidade, os valores da correla&ccedil;&atilde;o 
de Pearson    situaram-se entre 0,859 e 1,000.    ^cY#06.htm##
00743000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704052000070002000700590#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#20#16#article#117#<br>   <b>CONCLUS&Otilde;
ES: </b> O instrumento de avalia&ccedil;&atilde;o da qualidade    de vida para i
dosos resultante deste trabalho &#151; o Question&aacute;rio de    Avalia&ccedil
;&atilde;o Funcional Multidimensional de Idosos &#151; &eacute;    &uacute;til p
ara levantar informa&ccedil;&otilde;es significativas que auxiliem    a centrar 
as interven&ccedil;&otilde;es comunit&aacute;rias e a promover estrat&eacute;gia
s    de interven&ccedil;&atilde;o mais adequadas a esse grupo populacional.</fon
t></p>     ^cY#06.htm##
00534000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704031100070002000700381#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#21#17#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Palavras-chave:    </b> Avalia&ccedil;&
atilde;o geri&aacute;trica, qualidade de vida, sa&uacute;de    p&uacute;blica, O
lder Americans Resources and Services Program, valida&ccedil;&atilde;o,    Portu
gal.</font></p> <hr size="1" noshade>     ^cY#06.htm##
00321000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009800070002000700168#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#22#18#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     ^cY#06.htm#
#
00509000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704028600070002000700356#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#23#19#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>OBJECTIVE:</b>    To validate the Europ
ean Portuguese version of the Older Americans Resources    and Services (OARS) i
nstrument, used for the multidimensional evaluation of    the quality of life of
 the elderly.    ^cY#06.htm##
00974000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704075100070002000700821#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#24#20#article#117#<br>   <b>METHOD:</b>&nbs
p;The study was authorized by the authors of the original    English version. Fi
rst, the questionnaire was translated into European Portuguese    and culturally
 adapted. The resulting version was then validated by experts    and administere
d to 302 elderly persons (147 living in nursing homes and 155    at day care cen
ters) in the central region of Portugal (districts of Aveiro,    Castelo Branco,
 Coimbra, Leiria, Guarda, and Viseu). Subsequently, a global    psychometric stu
dy was conducted on the instrument, evaluating internal coherence,    validity o
f construction, criterion validity, and reproducibility. The sample    was rando
mly selected and stratified by age, sex, and type of institutional    support.  
  ^cY#06.htm##
00804000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704058100070002000700651#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#25#21#article#117#<br>   <b>RESULTS:</b>&nb
sp;The internal coherence (Cronbach's alpha) was between 0.64    and 0.91 for ea
ch of the five functional assessment scales included in the instrument.    For c
riterion validity, the relatively low Pearson correlation values obtained    (&l
t; 0.700) through the Medical Outcomes Study 36-Item Short-Form General Health  
  Survey reflect the challenges associated with establishing a criterion by whic
h    new health evaluation instruments might be compared. Pearson's correlation 
for    reproducibility was between 0.859 and 1.0 for all the scales.    ^cY#06.h
tm##
00578000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704035500070002000700425#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#26#22#article#117#<br>   <b>CONCLUSIONS:</b
>&nbsp;The European-Portuguese version of the OARS (<i>Question&aacute;rio    de
 Avalia&ccedil;&atilde;o Funcional Multidimensional de Idosos)</i> is useful    
for collecting valid information that can help focus community interventions    
and promote strategies that specifically target this population group.</font></p
>     ^cY#06.htm##
00475000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704025200070002000700322#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#27#23#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Key words:</b>    Geriatric assessment,
 quality of life, public health, Older Americans Resources    and Services Progr
am, validation, Portugal.</font></p> <hr size="1" noshade>     ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#28#24#article#117#<p>&nbsp;</p>     ^cY#06.
htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#29#25#article#117#<p>&nbsp;</p>     ^cY#06.
htm##
01149000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704092600070002000700996#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#30#26#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O <i>Older Americans    Resources and Serv
ices Program</i> (OARS) &#151; um programa de recursos e servi&ccedil;os    para
 idosos &#151; &eacute; o resultado dos trabalhos desenvolvidos, desde 1972,    
na universidade Duke, nos Estados Unidos da Am&eacute;rica (1). A metodologia   
 OARS foi desenvolvida para avaliar a capacidade funcional em cinco &aacute;reas
    fundamentais para a qualidade de vida do idoso: recursos sociais, recursos e
con&ocirc;micos,    sa&uacute;de mental, sa&uacute;de f&iacute;sica e atividades
 de vida di&aacute;ria.    Mede, ainda, a utiliza&ccedil;&atilde;o e a necessida
de percebida de v&aacute;rios    tipos de servi&ccedil;os, o que permite a avali
a&ccedil;&atilde;o de programas    de interven&ccedil;&atilde;o e a tomada de de
cis&otilde;es fundamentadas sobre    o impacto de recursos e servi&ccedil;os (1)
.</font></p>     ^cY#06.htm##
00901000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704067800070002000700748#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#31#27#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Os idosos est&atilde;o    sujeitos a uma m
ultiplicidade de diagn&oacute;sticos de sa&uacute;de nos quais    os aspectos f&
iacute;sicos, mentais e sociais est&atilde;o fortemente interligados.    Portant
o, as medidas de avalia&ccedil;&atilde;o multidimensionais s&atilde;o    as mais
 apropriadas para essa popula&ccedil;&atilde;o. De igual modo, as medidas    de 
capacidade funcional que avaliam o grau de independ&ecirc;ncia apesar da    doen
&ccedil;a, das limita&ccedil;&otilde;es f&iacute;sicas ou mentais e do apoio    
social s&atilde;o indicadores &uacute;teis para quem cuida de idosos (2).</font>
</p>     ^cY#06.htm##
00882000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704065900070002000700729#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#32#28#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Al&eacute;m disso,    a revolu&ccedil;&ati
lde;o demogr&aacute;fica em curso, com o aumento crescente    da popula&ccedil;&
atilde;o idosa, exige uma nova abordagem desse grupo et&aacute;rio    (3), passa
ndo de um modelo centrado na doen&ccedil;a para um modelo centrado    nas necess
idades das pessoas com incapacidades ou em risco de incapacidade (4).    Em fun&
ccedil;&atilde;o dessas novas solicita&ccedil;&otilde;es, as interven&ccedil;&ot
ilde;es    comunit&aacute;rias tender&atilde;o a ser ajustadas &agrave;s necessi
dades e    &agrave; procura de servi&ccedil;os (5, 6).</font></p>     ^cY#06.htm
##
00402000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704017900070002000700249#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#33#29#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Partindo desses    pressupostos, o modelo 
conceitual do OARS inclui tr&ecirc;s elementos:</font></p> <ul>       ^cY#06.htm
##
00446000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704022300070002000700293#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#34#30#article#117#<li><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">avalia&ccedil;&atilde;o      da capacidad
e funcional, de forma a agrupar indiv&iacute;duos com id&ecirc;ntica      capaci
dade funcional;</font></li>       ^cY#06.htm##
00502000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704027900070002000700349#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#35#31#article#117#<li><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">avalia&ccedil;&atilde;o      do uso e da 
necessidade de servi&ccedil;os, tendo em conta a diferencia&ccedil;&atilde;o    
  desses aspectos, definindo o seu uso atual e a necessidade percebida;</font></
li>       ^cY#06.htm##
00439000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704021600070002000700286#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#36#32#article#117#<li><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">avalia&ccedil;&atilde;o      de alternati
vas de servi&ccedil;os a implementar em fun&ccedil;&atilde;o da      capacidade 
funcional.</font></li>     ^cY#06.htm##
00237000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704001400070002000700084#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#37#33#article#117#</ul>     ^cY#06.htm##
00636000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704041300070002000700483#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#38#34#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O instrumento desenvolvido    para operaci
onalizar esse modelo conceitual, o question&aacute;rio OARS, &eacute;    uma das
 ferramentas mais importantes atualmente dispon&iacute;veis para a avalia&ccedil
;&atilde;o    de idosos (2). O presente estudo teve como objetivo validar a vers
&atilde;o    em portugu&ecirc;s europeu do OARS.</font></p>     ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#39#35#article#117#<p>&nbsp;</p>     ^cY#06.
htm##
00342000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704011900070002000700189#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#40#36#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>MATERIAIS E    M&Eacute;TODOS</b></font
></p>     ^cY#06.htm##
00490000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704026700070002000700337#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#41#37#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O estudo, autorizado    pelos autores do i
nstrumento original, come&ccedil;ou com a tradu&ccedil;&atilde;o    e a adapta&c
cedil;&atilde;o cultural do OARS para portugu&ecirc;s europeu.</font></p>     ^c
Y#06.htm##
01502000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704127900070002000701349#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#42#38#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O OARS &eacute;    dividido em duas partes
: a parte A (<i>Multidimensional Functional Assessment    Questionnaire</i>, ou 
OARS-MFAQ) permite a avalia&ccedil;&atilde;o funcional    multidimensional (&aac
ute;reas de recursos sociais e econ&ocirc;micos, sa&uacute;de    mental, sa&uacu
te;de f&iacute;sica e atividades de vida di&aacute;ria). A parte    B (<i>Servic
es Assessment Questionnaire</i>) avalia a utiliza&ccedil;&atilde;o    e a necess
idade percebida de servi&ccedil;os (7). As duas partes podem ser utilizadas    e
m conjunto ou separadamente. Para relacionar a informa&ccedil;&atilde;o de    am
bas as partes, estas devem ser administradas ao mesmo tempo, j&aacute; que    al
guns itens da parte B se relacionam diretamente com a parte A (utiliza&ccedil;&a
tilde;o    de consultas m&eacute;dicas, por exemplo). No entanto, &eacute; poss&
iacute;vel    a utiliza&ccedil;&atilde;o apenas das quest&otilde;es espec&iacute
;ficas de    cada &aacute;rea, como demonstra a valida&ccedil;&atilde;o da vers&
atilde;o    brasileira, em que s&oacute; foram aplicadas as quest&otilde;es refe
rentes &agrave;    &aacute;rea de sa&uacute;de mental (8). No presente estudo, a
mbas as partes    foram validadas.</font></p>     ^cY#06.htm##
00366000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704014300070002000700213#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#43#39#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Avalia&ccedil;&atilde;o    funcional mu
ltidimensional</b></font></p>     ^cY#06.htm##
01216000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704099300070002000701063#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#44#40#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A parte A do OARS    avalia cada uma das c
inco &aacute;reas funcionais e permite uma classifica&ccedil;&atilde;o    em esc
alas que posicionam os idosos avaliados segundo as suas incapacidades    em cada
 &aacute;rea. &Eacute; constitu&iacute;da por 101 perguntas (j&aacute;    que um
a entre 102 quest&otilde;es se refere &agrave; parte B), das quais 70    s&atild
e;o dirigidas ao idoso (quest&otilde;es 1 a 70), 10 s&atilde;o sobre    o idoso,
 mas s&atilde;o respondidas por um informante (quest&otilde;es 72 a    82), e 14
 s&atilde;o sobre o idoso, mas s&atilde;o respondidas pelo entrevistador    (que
st&otilde;es 83 a 96). Cada uma das cinco escalas funcionais apresenta pontua&cc
edil;&atilde;o    de 1 a 6 (quest&otilde;es 97 a 101). A incapacidade global &ea
cute; determinada    a partir do somat&oacute;rio das pontua&ccedil;&otilde;es d
e incapacidade em    cada uma das &aacute;reas (quest&atilde;o 102).</font></p> 
    ^cY#06.htm##
01055000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704083200070002000700902#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#45#41#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A aplica&ccedil;&atilde;o    da parte A &e
acute; iniciada com um question&aacute;rio preliminar, o <i>Short    Portable Me
ntal Status Questionnaire</i> (SPMSQ). De forma r&aacute;pida, em    10 quest&ot
ilde;es, o SPMSQ avalia o d&eacute;ficit da fun&ccedil;&atilde;o    cognitiva do
 avaliado, permitindo definir se est&aacute; apto para continuar    a responder 
o question&aacute;rio ou se &eacute; necess&aacute;rio obter as    respostas de 
um informante qualificado. Mais de quatro erros no SPMSQ indicam    que o entrev
istado n&atilde;o pode prestar informa&ccedil;&otilde;es. Nesse    caso, o infor
mante deve responder a todas as quest&otilde;es, com exce&ccedil;&atilde;o    da
s consideradas subjetivas, que questionam sentimentos dos sujeitos.</font></p>  
   ^cY#06.htm##
00835000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704061200070002000700682#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#46#42#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Quanto &agrave;    avalia&ccedil;&atilde;o
 dos recursos sociais, esta &eacute; centrada na quantidade    e adequa&ccedil;&
atilde;o da intera&ccedil;&atilde;o social e na disponibilidade    de ajuda em c
aso de doen&ccedil;a ou incapacidade. &Eacute; composta por nove    quest&otilde
;es (quest&otilde;es 6 a 14) sobre estado civil, composi&ccedil;&atilde;o    do 
agregado familiar, rela&ccedil;&otilde;es sociais, exist&ecirc;ncia de confident
e    e sentimento de solid&atilde;o e auto-avalia&ccedil;&atilde;o de recursos s
ociais.</font></p>     ^cY#06.htm##
01307000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704108400070002000701154#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#47#43#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A avalia&ccedil;&atilde;o    dos recursos 
econ&ocirc;micos dirige-se aos rendimentos e &agrave; auto-avalia&ccedil;&atilde
;o    da sua adequa&ccedil;&atilde;o &agrave;s necessidades. &Eacute; composta p
or    16 quest&otilde;es (quest&otilde;es 15 a 30) sobre a atual situa&ccedil;&a
tilde;o    laboral, a ocupa&ccedil;&atilde;o principal e a ocupa&ccedil;&atilde;
o principal    do c&ocirc;njuge, a origem e o valor dos rendimentos, o n&uacute;
mero de pessoas    dependentes desses rendimentos, habita&ccedil;&atilde;o, a re
la&ccedil;&atilde;o    rendimentos/gastos, a necessidade de ajuda econ&ocirc;mic
a ou o aumento de rendimentos,    a necessidade de ajuda econ&ocirc;mica para co
mpra de alimentos, a disponibilidade    de seguro de sa&uacute;de, a compara&cce
dil;&atilde;o da situa&ccedil;&atilde;o    econ&ocirc;mica com a de pessoas da m
esma idade, auto-avalia&ccedil;&atilde;o    de recursos econ&ocirc;micos, a poss
ibilidade de comprar pequenos extras e a    perspectiva de rendimentos futuros.<
/font></p>     ^cY#06.htm##
00797000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704057400070002000700644#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#48#44#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A avalia&ccedil;&atilde;o    da sa&uacute;
de mental inclui os resultados do SPMSQ aplicado no in&iacute;cio    da parte A 
(9), uma avalia&ccedil;&atilde;o da satisfa&ccedil;&atilde;o com    a vida, sint
omas psiqui&aacute;tricos (10) (<i>Short Psychiatric Evaluation    Schedule,</i>
 ou SPES, composto por 15 itens), auto-avalia&ccedil;&atilde;o    da sa&uacute;d
e mental atual e auto-avalia&ccedil;&atilde;o, por compara&ccedil;&atilde;o,    
do estado atual com o existente h&aacute; 5 anos.</font></p>     ^cY#06.htm##
01399000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704117600070002000701246#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#49#45#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A avalia&ccedil;&atilde;o    da sa&uacute;
de f&iacute;sica inclui 19 quest&otilde;es (quest&otilde;es 37    a 55) sobre co
nsultas m&eacute;dicas nos &uacute;ltimos 6 meses, dias de incapacidade    f&iac
ute;sica nos &uacute;ltimos 6 meses, dias de hospitaliza&ccedil;&atilde;o    nos
 &uacute;ltimos 6 meses, dias de interna&ccedil;&atilde;o noutra institui&ccedil
;&atilde;o    de sa&uacute;de nos &uacute;ltimos 6 meses, necessidade percebida 
de consultas    m&eacute;dicas, uso de medicamentos com receita no &uacute;ltimo
 m&ecirc;s,    doen&ccedil;as atuais e sua interfer&ecirc;ncia nas atividades di
&aacute;rias,    incapacidades f&iacute;sicas, d&eacute;ficit visual e auditivo,
 uso e necessidade    de dispositivos de apoio e pr&oacute;teses, problemas pelo
 consumo de &aacute;lcool,    pr&aacute;tica de atividades f&iacute;sicas ou de 
esportes cansativos, auto-avalia&ccedil;&atilde;o    da sa&uacute;de f&iacute;si
ca, compara&ccedil;&atilde;o do estado atual com    o existente h&aacute; 5 anos
 e interfer&ecirc;ncia dos problemas de sa&uacute;de    nas atividades di&aacute
;rias (11).</font></p>     ^cY#06.htm##
00899000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704067600070002000700746#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#50#46#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A &aacute;rea de    atividades de vida di&
aacute;ria (AVD) inclui 15 quest&otilde;es (quest&otilde;es    56 a 70) sobre a 
capacidade para AVD instrumentais (telefonar, utilizar meios    de transporte, f
azer compras, preparar refei&ccedil;&otilde;es, fazer as tarefas    de casa, tom
ar os medicamentos, lidar com o dinheiro) e AVD f&iacute;sicas (comer,    vestir
-se e despir-se, cuidar da apar&ecirc;ncia, andar, levantar-se e deitar    na ca
ma, tomar banho ou ducha, manter contin&ecirc;ncia de esf&iacute;ncteres)    e s
obre a exist&ecirc;ncia de algu&eacute;m dispon&iacute;vel para ajudar.</font></
p>     ^cY#06.htm##
01259000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704103600070002000701106#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#51#47#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Ao completar o    question&aacute;rio, o e
ntrevistador emite um ju&iacute;zo quantitativo em fun&ccedil;&atilde;o    dos p
ar&acirc;metros definidos para cada uma das cinco &aacute;reas. Essa avalia&cced
il;&atilde;o    final, com a atribui&ccedil;&atilde;o de uma pontua&ccedil;&atil
de;o de incapacidade    funcional (PIF), permite enquadrar o sujeito no conjunto
 de caracter&iacute;sticas    predefinidas para cada &aacute;rea, classificando-
o com base em toda a informa&ccedil;&atilde;o    recolhida ao longo da entrevist
a. Essa classifica&ccedil;&atilde;o &eacute;    facilitada pelo conjunto de ques
t&otilde;es dirigidas ao entrevistador (quest&otilde;es    83 a 96). Assim, para
 cada escala, a capacidade funcional do idoso pode ser    classificada na catego
ria 1 (muito bom), 2 (bom), 3 (ligeiramente insatisfat&oacute;rio),    4 (modera
damente insatisfat&oacute;rio), 5 (fortemente insatisfat&oacute;rio)    e 6 (tot
almente insatisfat&oacute;rio).</font></p>     ^cY#06.htm##
00890000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704066700070002000700737#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#52#48#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Os perfis funcionais    caracterizam grupo
s funcionalmente equivalentes. Considera-se que todas as pessoas    com um mesmo
 perfil t&ecirc;m id&ecirc;nticas incapacidades e, portanto, um    funcionamento
 similar (7). A combina&ccedil;&atilde;o da capacidade satisfat&oacute;ria    co
m a capacidade insatisfat&oacute;ria, aplicada &agrave;s cinco &aacute;reas,    
resulta em 32 poss&iacute;veis combina&ccedil;&otilde;es ou perfis funcionais,  
  que v&atilde;o desde capacidade satisfat&oacute;ria em todas as &aacute;reas  
  a capacidade insatisfat&oacute;ria em todas as &aacute;reas.</font></p>     ^c
Y#06.htm##
00383000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704016000070002000700230#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#53#49#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Utiliza&ccedil;&atilde;o    e necessida
de percebida de servi&ccedil;os</b></font></p>     ^cY#06.htm##
01143000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704092000070002000700990#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#54#50#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A parte B, o grupo    de quest&otilde;es 7
1.1 a 71.19, avalia 19 servi&ccedil;os distribu&iacute;dos    em seis categorias
: servi&ccedil;os gerais de apoio; servi&ccedil;os sociais    e recreativos; ser
vi&ccedil;os de sa&uacute;de; servi&ccedil;os de apoio econ&ocirc;mico;    servi
&ccedil;os de apoio, avalia&ccedil;&atilde;o e coordena&ccedil;&atilde;o;    e s
ervi&ccedil;os n&atilde;o classificados (7). Avalia-se a utiliza&ccedil;&atilde;
o    atual (nos &uacute;ltimos 6 meses), a freq&uuml;&ecirc;ncia com que s&atild
e;o    utilizados e a necessidade percebida. Aos 19 servi&ccedil;os s&atilde;o a
inda    adicionados quatro servi&ccedil;os j&aacute; inseridos na parte A do que
stion&aacute;rio    (consultas m&eacute;dicas, dispositivos de apoio e pr&oacute
;teses, ajuda econ&ocirc;mica    em geral e ajuda para a compra de comida).</fon
t></p>     ^cY#06.htm##
00412000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704018900070002000700259#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#55#51#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Valida&ccedil;&atilde;o    da vers&atil
de;o em portugu&ecirc;s europeu e estudo psicom&eacute;trico</b></font></p>     
^cY#06.htm##
01466000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704124300070002000701313#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#56#52#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A vers&atilde;o    original do question&aa
cute;rio OARS foi traduzida para portugu&ecirc;s europeu.    Posteriormente retr
overtida, considerou-se, nos pontos de desacordo, a opini&atilde;o    de um conj
unto de tr&ecirc;s ju&iacute;zes (portugueses com conhecimento da    l&iacute;ng
ua inglesa, experi&ecirc;ncia na utiliza&ccedil;&atilde;o de escalas    de medi&
ccedil;&atilde;o em sa&uacute;de e experi&ecirc;ncia profissional em    cuidados
 de sa&uacute;de prim&aacute;rios e cuidados a idosos). Ap&oacute;s    altera&cc
edil;&otilde;es pontuais sugeridas, a escala, denominada Question&aacute;rio    
de Avalia&ccedil;&atilde;o Funcional Multidimensional de Idosos (QAFMI), foi    
considerada como apta a ser utilizada. Na elabora&ccedil;&atilde;o desta vers&at
ilde;o    foram mantidas todas as caracter&iacute;sticas da vers&atilde;o origin
al. No    question&aacute;rio, cada conjunto de perguntas &eacute; precedido por
 uma nota    introdut&oacute;ria que situa o respondente quanto ao tema que ser&
aacute; abordado    e &agrave; forma como deve fornecer a resposta. N&atilde;o h
&aacute; limite    de tempo para elaborar ou selecionar a resposta pretendida.</
font></p>     ^cY#06.htm##
00837000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704061400070002000700684#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#57#53#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O QAFMI foi aplicado    a 302 idosos (estu
do psicom&eacute;trico) com apoio institucional (amostra aleat&oacute;ria    e e
stratificada por idade, g&ecirc;nero e tipo de apoio institucional) na regi&atil
de;o    centro de Portugal (distritos de Aveiro, Castelo Branco, Coimbra, Leiria
, Guarda    e Viseu). Dos 302 idosos, 155 freq&uuml;entavam centros de dia e 147
 moravam    em lares para idosos. A coleta de informa&ccedil;&atilde;o foi autor
izada pelas    institui&ccedil;&otilde;es e teve o consentimento expresso dos in
quiridos.</font></p>     ^cY#06.htm##
00532000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704030900070002000700379#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#58#54#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Para o estudo do    question&aacute;rio, f
oram avaliadas a coer&ecirc;ncia interna, a validade da    constru&ccedil;&atild
e;o da vers&atilde;o em portugu&ecirc;s europeu, a validade    de crit&eacute;ri
o e a reprodutibilidade.</font></p>     ^cY#06.htm##
00880000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704065700070002000700727#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#59#55#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Para comprovar    a exist&ecirc;ncia de co
er&ecirc;ncia interna e a validade de constru&ccedil;&atilde;o    da adapta&cced
il;&atilde;o da vers&atilde;o portuguesa foi realizada a an&aacute;lise    fator
ial (alfa de Cronbach) dos itens subjetivos, agrupando-os tal como na vers&atild
e;o    original. Essa t&eacute;cnica de an&aacute;lise permite demonstrar a rela
&ccedil;&atilde;o    das diferentes dimens&otilde;es com um conjunto de vari&aac
ute;veis que lhe    est&atilde;o subjacentes (12). Um alfa de Cronbach superior 
a 0,80 indica uma    boa consist&ecirc;ncia interna.</font></p>     ^cY#06.htm##
00698000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704047500070002000700545#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#60#56#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Uma dificuldade    para avaliar a validade
 de crit&eacute;rio reside no fato de n&atilde;o existirem,    para a maioria da
s medidas utilizadas em ci&ecirc;ncias sociais, vari&aacute;veis    de crit&eacu
te;rio significativas (12). Ainda, algumas das medidas com o estatuto    de padr
&atilde;o apresentam, quando examinadas com detalhe, menor confiabilidade    e v
alidade que as desejadas (13).</font></p>     ^cY#06.htm##
01424000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704120100070002000701271#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#61#57#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O presente estudo    adotou como medida de
 crit&eacute;rio um instrumento multidimensional, o <i>Medical    Outcomes Study
 36-Item Short-Form General Health Survey</i> (MOS SF-36), utilizado    para ava
liar a qualidade de vida. Utiliza os conceitos de fun&ccedil;&atilde;o    f&iacu
te;sica, desempenho f&iacute;sico, desempenho emocional, dor f&iacute;sica,    s
a&uacute;de mental, fun&ccedil;&atilde;o social, vitalidade e sa&uacute;de    em
 geral. No seu conjunto, esses conceitos constituem dois componentes: f&iacute;s
ico    e mental (12). &Eacute; considerado como um dos question&aacute;rios de a
valia&ccedil;&atilde;o,    para a popula&ccedil;&atilde;o em geral, com melhores
 perspectivas de aplica&ccedil;&atilde;o    no campo da sa&uacute;de. Estudos de
 confiabilidade e de validade realizados    com idosos (14) demonstram a sua cap
acidade de avalia&ccedil;&atilde;o tamb&eacute;m    com este grupo et&aacute;rio
. Para a compara&ccedil;&atilde;o entre o OARS e    o MOS SF-36 utilizou-se a co
rrela&ccedil;&atilde;o de Pearson, sendo considerada    boa uma correla&ccedil;&
atilde;o com valor superior a 0,700.</font></p>     ^cY#06.htm##
01287000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704106400070002000701134#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#62#58#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A reprodutibilidade    do instrumento, ou 
verifica&ccedil;&atilde;o da estabilidade dos resultados    no tempo (15), foi a
valiada atrav&eacute;s do m&eacute;todo do teste repetido    (teste-reteste). Pa
ra o estudo da reprodutibilidade foram selecionados 30 indiv&iacute;duos    em c
entros de dia, a quem foi aplicado o question&aacute;rio na sua totalidade,    e
m dois momentos, com intervalo de 1 semana. Esse intervalo de tempo foi selecion
ado    (13) porque no espa&ccedil;o de 1 semana n&atilde;o ocorrem fen&ocirc;men
os    capazes de alterar a percep&ccedil;&atilde;o de uma popula&ccedil;&atilde;
o    sobre o conjunto de &aacute;reas a avaliar, al&eacute;m de ser tempo sufici
ente    para que as quest&otilde;es anteriormente formuladas e as respostas forn
ecidas    n&atilde;o sejam lembradas. Os pr&oacute;prios indiv&iacute;duos inqui
ridos    n&atilde;o sabiam que, 1 semana ap&oacute;s a primeira entrevista, seri
am novamente    confrontados com as mesmas quest&otilde;es.</font></p>     ^cY#0
6.htm##
01230000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704100700070002000701077#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#63#59#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">O estudo incidiu    sobre as quest&otilde;
es consideradas chave pelos autores do instrumento original.    Essas quest&otil
de;es s&atilde;o as referentes aos valores atribu&iacute;dos    pelo entrevistad
or nas escalas de classifica&ccedil;&atilde;o final (quest&atilde;o    97 a 101)
 e sobre a auto-avalia&ccedil;&atilde;o dos sujeitos nas &aacute;reas    de recu
rsos sociais, recursos econ&ocirc;micos, sa&uacute;de mental e sa&uacute;de    f
&iacute;sica (n&atilde;o existe nenhuma pergunta de auto-avalia&ccedil;&atilde;o
    para a &aacute;rea de AVD). Essas quest&otilde;es foram selecionadas pelo fa
to    de as escalas de classifica&ccedil;&atilde;o final funcionarem como resumo
 de    toda a avalia&ccedil;&atilde;o efetuada pelo entrevistador e pela possibi
lidade    de avaliar a persist&ecirc;ncia das respostas a quest&otilde;es subjet
ivas como    s&atilde;o a auto-avalia&ccedil;&atilde;o nas &aacute;reas referida
s.</font></p>     ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#64#60#article#117#<p>&nbsp;</p>     ^cY#06.
htm##
00323000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010000070002000700170#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#65#61#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>RESULTADOS</b></font></p>     ^cY#06.ht
m##
00720000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704049700070002000700567#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#66#62#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Na <a href="/img/revistas/rpsp/v23n2/06t1.
gif">tabela    1</a> s&atilde;o apresentados os resultados da an&aacute;lise de 
Cronbach para    os fatores integrados em cada escala, comparando os resultados 
obtidos &agrave;queles    da vers&atilde;o original norte-americana (OARS-MFAQ) 
e da vers&atilde;o espanhola    (OARS-MFAQ-VE). Para a vers&atilde;o original n&
atilde;o dispomos do valor global    de cada escala.</font></p>     ^cY#06.htm##
00861000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704063800070002000700708#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#67#63#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Na escala de recursos    sociais, o valor 
global obtido (0,64) &eacute; inferior ao da vers&atilde;o    espanhola. Os fato
res de intera&ccedil;&atilde;o e confian&ccedil;a apresentam    valores comparat
ivos mais elevados, 0,63 e 0,80 respectivamente, sendo o fator    sentimentos o 
mais baixo das tr&ecirc;s vers&otilde;es. Tomando como refer&ecirc;ncia    um al
fa de 0,80 como indicativo de bons resultados de coer&ecirc;ncia interna,    e c
onsiderando somente as escalas globais, observa-se um valor inferior para    a e
scala global de recursos sociais.</font></p>     ^cY#06.htm##
00878000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704065500070002000700725#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#68#64#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Na escala de recursos    econ&ocirc;micos,
 o alfa global obtido (0,89) &eacute; mais elevado do que nas    outras vers&oti
lde;es. Na escala de sa&uacute;de mental o valor global (0,83)    &eacute; infer
ior ao da vers&atilde;o espanhola. Os fatores de satisfa&ccedil;&atilde;o    com
 a vida e os transtornos do sono apresentam os alfas mais elevados das tr&ecirc;
s    vers&otilde;es (0,81). Os fatores de energia (0,65) e de paran&oacute;ia (0
,51)    s&atilde;o comparativamente mais baixos, com o fator de paran&oacute;ia 
muito    pr&oacute;ximo da vers&atilde;o original.</font></p>     ^cY#06.htm##
00905000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704068200070002000700752#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#69#65#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Na escala de sa&uacute;de    f&iacute;sica
, o estudo do fator de auto-percep&ccedil;&atilde;o de sa&uacute;de    f&iacute;
sica apresenta o valor mais elevado das tr&ecirc;s vers&otilde;es (0,85).    Na 
escala de atividades de vida di&aacute;ria o valor global obtido (0,91) &eacute;
    inferior ao da vers&atilde;o espanhola. O fator instrumental (0,89) &eacute;
    ligeiramente superior ao da vers&atilde;o original, mas inferior ao da vers&
atilde;o    espanhola. O fator f&iacute;sico (0,82) &eacute; inferior ao das out
ras vers&otilde;es,    mas muito pr&oacute;ximo ao da vers&atilde;o original.</f
ont></p>     ^cY#06.htm##
00746000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704052300070002000700593#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#70#66#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A aplica&ccedil;&atilde;o    da vers&atild
e;o em portugu&ecirc;s europeu mostra os valores globais mais elevados    na esc
ala de recursos econ&ocirc;micos e sa&uacute;de f&iacute;sica, n&atilde;o    apr
esentando as outras vers&otilde;es valores muito distintos. Numa an&aacute;lise 
   geral das cinco escalas, e apesar das diferen&ccedil;as acima analisadas, a  
  tend&ecirc;ncia &eacute; de acompanhar os valores das outras vers&otilde;es.</
font></p>     ^cY#06.htm##
01071000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704084800070002000700918#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#71#67#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Em geral, os resultados    indicam que as 
tr&ecirc;s vers&otilde;es est&atilde;o medindo os mesmos fen&ocirc;menos.    Os 
dados de que atualmente dispomos ainda n&atilde;o nos permitem uma explica&ccedi
l;&atilde;o    satisfat&oacute;ria para os mais baixos valores observados em alg
umas dimens&otilde;es    (mesmo quando comuns &agrave;s tr&ecirc;s vers&otilde;e
s, como nos fatores intera&ccedil;&atilde;o    e paran&oacute;ia), ou para as di
feren&ccedil;as entre as tr&ecirc;s vers&otilde;es    (de que s&atilde;o exemplo
s os fatores confian&ccedil;a e sentimentos), apesar    de os peritos estarem de
 acordo quanto ao conte&uacute;do, a formula&ccedil;&atilde;o,    a pertin&ecirc
;ncia e o agrupamento das quest&otilde;es que constituem estas    dimens&otilde;
es.</font></p>     ^cY#06.htm##
00343000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704012000070002000700190#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#72#68#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Validade de    crit&eacute;rio</b></fon
t></p>     ^cY#06.htm##
01207000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704098400070002000701054#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#73#69#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Os dados acerca    da validade de crit&eac
ute;rio foram obtidos a partir da mesma popula&ccedil;&atilde;o    e no primeiro
 momento em que foi utilizado o QAFMI para o estudo da reprodutibilidade    (tes
te-reteste), gerando a matriz da correla&ccedil;&atilde;o de Pearson apresentada
    na <a href="/img/revistas/rpsp/v23n2/06t2.gif">tabela 2</a>. Para o MOS SF-3
6    foram utilizados todos os oito conceitos, e para o QAFMI foram selecionadas
    as classifica&ccedil;&otilde;es finais (PIF) em cada uma das &aacute;reas av
aliadas    (recursos sociais, recursos econ&ocirc;micos, sa&uacute;de mental, sa
&uacute;de    f&iacute;sica e AVD) e a auto-avalia&ccedil;&atilde;o efetuada pel
os respondentes    nas &aacute;reas de recursos sociais (quest&atilde;o 14), rec
ursos econ&ocirc;micos    (quest&atilde;o 28), sa&uacute;de mental (quest&atilde
;o 35) e sa&uacute;de    f&iacute;sica (quest&atilde;o 53).</font></p>     ^cY#0
6.htm##
01055000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704083200070002000700902#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#74#70#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Os resultados mostram    que os valores ma
is elevados se encontram na correla&ccedil;&atilde;o da dor    f&iacute;sica (0,
620), da sa&uacute;de em geral (0,655) e da vitalidade (0,677)    com a auto-ava
lia&ccedil;&atilde;o da sa&uacute;de f&iacute;sica. A fun&ccedil;&atilde;o    f&
iacute;sica (&#150;0,569) e a sa&uacute;de mental (&#150;0,600) tamb&eacute;m   
 se correlacionam com a PIF na &aacute;rea de AVD. A vitalidade (&#150;0,591)   
 e a sa&uacute;de mental (&#150;0,611) correlacionam-se com a PIF na &aacute;rea
    de sa&uacute;de mental. Esses resultados (com valores inferiores a 0,700 tom
ados    como refer&ecirc;ncia) refor&ccedil;am a dificuldade j&aacute; apontada 
de encontrar    vari&aacute;veis de crit&eacute;rio significativas.</font></p>  
   ^cY#06.htm##
00330000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010700070002000700177#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#75#71#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Reprodutibilidade</b></font></p>     ^c
Y#06.htm##
01002000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704077900070002000700849#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#76#72#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Verifica-se que,    para as escalas de cla
ssifica&ccedil;&atilde;o de sa&uacute;de f&iacute;sica    (1,000) e de desempenh
o de atividades da vida di&aacute;ria (1,000), n&atilde;o    existiram diferen&c
cedil;as de avalia&ccedil;&atilde;o nos dois momentos, como    demonstram os val
ores obtidos (<a href="/img/revistas/rpsp/v23n2/06t3.gif">tabela    3</a>). Quan
to &agrave;s escalas de classifica&ccedil;&atilde;o de recursos    sociais (0,96
2), recursos econ&ocirc;micos (0,964) e sa&uacute;de mental (0,979),    os valor
es obtidos s&atilde;o elevados, permitindo afirmar uma id&ecirc;ntica    avalia&
ccedil;&atilde;o pelo entrevistador, do mesmo indiv&iacute;duo, nos dois    dife
rentes tempos.</font></p>     ^cY#06.htm##
00520000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704029700070002000700367#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#77#73#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Dos resultados    obtidos verifica-se, par
a todas as perguntas selecionadas, que as respostas    n&atilde;o foram influenc
iadas pelo intervalo de tempo decorrido entre a primeira    e segunda medi&ccedi
l;&atilde;o.</font></p>     ^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#78#74#article#117#<p>&nbsp;</p>     ^cY#06.
htm##
00329000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010600070002000700176#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#79#75#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>DISCUSS&Atilde;O</b></font></p>     ^cY
#06.htm##
01125000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704090200070002000700972#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#80#76#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A partir deste    estudo, ficou dispon&iac
ute;vel um instrumento de avalia&ccedil;&atilde;o da    qualidade de vida para i
dosos falantes de portugu&ecirc;s europeu que pode fornecer    informa&ccedil;&o
tilde;es significativas para centrar as interven&ccedil;&otilde;es    comunit&aa
cute;rias e promover mais adequadas estrat&eacute;gias de interven&ccedil;&atild
e;o    nesse grupo populacional (16). A aplica&ccedil;&atilde;o do QAFMI em outr
os    pa&iacute;ses de l&iacute;ngua portuguesa, como o Brasil, exigir&aacute; u
m    estudo das particularidades de vocabul&aacute;rio, j&aacute; que o estudo a
qui    apresentado se refere ao portugu&ecirc;s escrito e falado em Portugal. A 
vers&atilde;o    do OARS em portugu&ecirc;s europeu pode ser solicitada, sem enc
argos, atrav&eacute;s    do e-mail do autor deste artigo.</font></p>     ^cY#06.
htm##
01140000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704091700070002000700987#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#81#77#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">S&atilde;o v&aacute;rias    as considera&c
cedil;&otilde;es acerca do processo de valida&ccedil;&atilde;o    do OARS. Uma v
antagem desse instrumento &eacute; que as quest&otilde;es s&atilde;o    fechadas
, o que torna compar&aacute;veis as respostas &agrave; mesma quest&atilde;o,    
com menos variabilidade. As quest&otilde;es s&atilde;o de mais f&aacute;cil    r
esposta e de mais f&aacute;cil an&aacute;lise, codifica&ccedil;&atilde;o e    in
formatiza&ccedil;&atilde;o. O foco central na elabora&ccedil;&atilde;o dessas   
 quest&otilde;es &eacute; garantir a qualidade da informa&ccedil;&atilde;o verba
l    atrav&eacute;s da compreens&atilde;o da natureza do comportamento pergunta/
    resposta, que reflete aquilo que o respondente pensa que o investigador quer
    saber e que pretende fazer com a informa&ccedil;&atilde;o fornecida.</font><
/p>     ^cY#06.htm##
00711000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704048800070002000700558#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#82#78#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Considera-se o    per&iacute;odo de 1 ano 
como o limite aceit&aacute;vel para a mem&oacute;ria    sobre acontecimentos com
 relev&acirc;ncia para os respondentes, e 30 dias o    limite cred&iacute;vel pa
ra assuntos pouco relevantes (17). Neste question&aacute;rio,    o limite m&aacu
te;ximo de apelo &agrave; mem&oacute;ria &eacute; de 6 meses,    e o per&iacute;
odo m&iacute;nimo reporta-se a 1 m&ecirc;s.</font></p>     ^cY#06.htm##
01002000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704077900070002000700849#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#83#79#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Para o estudo da    confiabilidade de um i
nstrumento, &eacute; necess&aacute;ria aten&ccedil;&atilde;o    &agrave; coer&ec
irc;ncia interna, reprodutibilidade e concord&acirc;ncia entre    observadores. 
Ainda n&atilde;o foi poss&iacute;vel o estudo da concord&acirc;ncia    entre obs
ervadores para a vers&atilde;o em portugu&ecirc;s europeu, j&aacute;    que nos 
estudos efetuados (18&#150;20) apenas se dispunha do autor para a realiza&ccedil
;&atilde;o    das entrevistas. Entretanto, a informa&ccedil;&atilde;o dispon&iac
ute;vel nesse    campo (7, 13) demonstra que os resultados das avalia&ccedil;&ot
ilde;es nas diferentes    &aacute;reas n&atilde;o s&atilde;o influenciados pelo 
entrevistador.</font></p>     ^cY#06.htm##
01586000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704136300070002000701433#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#84#80#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Quanto &agrave;    validade do instrumento
 de medida (que inclui a validade de conte&uacute;do,    constru&ccedil;&atilde;
o e crit&eacute;rio), esta representa a capacidade para    medir o que nos propo
mos. Um instrumento pode ser v&aacute;lido para o efeito    que levou ao seu des
envolvimento, mas n&atilde;o adequado para algo semelhante    ou n&atilde;o equi
valente. A validade deve ser analisada em fun&ccedil;&atilde;o    do contexto da
 utiliza&ccedil;&atilde;o pr&aacute;tica a dar ao instrumento    (15). Tendo par
tido de um instrumento j&aacute; validado em contextos sociais    e culturais, q
uer distintos, quer pr&oacute;ximos dos nossos, e com estudos    profundos da va
lidade de conte&uacute;do e validade de constru&ccedil;&atilde;o,    a nossa ate
n&ccedil;&atilde;o centrou-se na avalia&ccedil;&atilde;o da validade    de crit&
eacute;rio, estudando a correla&ccedil;&atilde;o de algumas das vari&aacute;veis
    mais significativas com outra medida multidimensional do campo da sa&uacute;
de,    n&atilde;o espec&iacute;fica para determinado grupo et&aacute;rio ou pato
logia.    Esses procedimentos levaram em conta as recomenda&ccedil;&otilde;es ge
n&eacute;ricas    para estudos de valida&ccedil;&atilde;o de instrumentos de med
i&ccedil;&atilde;o    em sa&uacute;de.</font></p>     ^cY#06.htm##
00767000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704054400070002000700614#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#85#81#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Por outro lado,    n&atilde;o existem proc
edimentos padronizados para demonstrar a validade de    conte&uacute;do, sendo q
ue no campo da sa&uacute;de esta tarefa &eacute; ainda    mais dif&iacute;cil. A
 necessidade de um consenso quanto aos dom&iacute;nios    a incluir no estudo de
 cada dimens&atilde;o torna aconselh&aacute;vel a exist&ecirc;ncia    de um n&ua
cute;mero representativo de ju&iacute;zes capazes de propor e selecionar    os m
ais significativos.</font></p>     ^cY#06.htm##
01210000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704098700070002000701057#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#86#82#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A validade de constru&ccedil;&atilde;o    
pretende demonstrar que a constru&ccedil;&atilde;o do instrumento foi baseada   
 em paradigmas te&oacute;ricos com verdadeira correspond&ecirc;ncia &agrave;s   
 observa&ccedil;&otilde;es. &Eacute; dividida em validade convergente (requer   
 correla&ccedil;&atilde;o com vari&aacute;veis relacionadas) e validade discrimi
nante    (requer que n&atilde;o haja correla&ccedil;&atilde;o com vari&aacute;ve
is n&atilde;o    relacionadas) (12, 13). Pretende-se saber se um instrumento med
e realmente aquilo    que se pretende medir. O modelo de desenvolvimento do OARS
 foi feito por uma    equipe multidisciplinar e baseado na adapta&ccedil;&atilde
;o de algumas escalas    j&aacute; existentes, criando as condi&ccedil;&otilde;e
s para um consenso entre    t&eacute;cnicos de diversas &aacute;reas que se trad
uz por boas condi&ccedil;&otilde;es    de validade (1, 7, 21).</font></p>     ^c
Y#06.htm##
01102000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704087900070002000700949#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#87#83#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">A adapta&ccedil;&atilde;o    de instrument
os de medi&ccedil;&atilde;o em sa&uacute;de j&aacute; desenvolvidos    e validad
os para diferentes contextos sociais e culturais &eacute; uma alternativa    &ag
rave; cria&ccedil;&atilde;o de novas formas de avalia&ccedil;&atilde;o (12).    
A tradu&ccedil;&atilde;o do OARS da sua vers&atilde;o original para outras l&iac
ute;nguas    tem-se mostrado uma tarefa n&atilde;o isenta de alguma complexidade
, mas que    se torna simplificada (apesar da sua extens&atilde;o) pela linguage
m acess&iacute;vel    do instrumento. Essa caracter&iacute;stica &eacute; aponta
da como facilitadora    da sua divulga&ccedil;&atilde;o noutros pa&iacute;ses (1
5), comprovada pelas    vers&otilde;es existentes em diversas l&iacute;nguas, in
cluindo as latinas (8,    13, 21).</font></p>     ^cY#06.htm##
01653000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704143000070002000701500#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#88#84#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Os resultados do    estudo psicom&eacute;t
rico efetuado com a aplica&ccedil;&atilde;o do OARS na    sua vers&atilde;o port
uguesa pretendem demonstrar que essa vers&atilde;o &eacute;    equivalente &agra
ve; vers&atilde;o original do instrumento. A an&aacute;lise    psicom&eacute;tri
ca de um instrumento de medida, definindo a sua qualidade,    compreende o estud
o da confiabilidade e validade (22). Existem dois conceitos    independentes no 
estudo da confiabilidade. Por um lado, a exist&ecirc;ncia de    coer&ecirc;ncia 
interna, implicando homogeneidade do conte&uacute;do, e a n&atilde;o    exist&ec
irc;ncia de erro aleat&oacute;rio. O segundo conceito diz respeito &agrave;    r
eprodutibilidade, ou capacidade de obter uma mesma resposta em tempos diferentes
    (reprodutibilidade teste-reteste) (12). Quanto &agrave; consist&ecirc;ncia i
nterna,    e comparativamente &agrave;s outras vers&otilde;es apresentadas (nort
e-americana    e espanhola), os resultados s&atilde;o bons, e em linha com os ob
tidos por essas    vers&otilde;es. Quanto &agrave; reprodutibilidade, os resulta
dos obtidos neste    estudo s&atilde;o excelentes, com algumas classifica&ccedil
;&otilde;es e auto-avalia&ccedil;&otilde;es    a coincidir totalmente (1,000), s
endo o valor mais baixo 0,859, como indica    a <a href="/img/revistas/rpsp/v23n
2/06t3.gif">tabela 3</a>.</font></p>     ^cY#06.htm##
00892000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704066900070002000700739#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#89#85#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Em resumo, pode-se    dizer que, pela meto
dologia, pela qualidade e pelo volume de informa&ccedil;&atilde;o    coletada, o
 QAFMI pode desempenhar um importante papel no estudo dessa popula&ccedil;&atild
e;o,    identificando problemas e orientando interven&ccedil;&otilde;es (23). A 
an&aacute;lise    dos dados indica que podemos considerar a vers&atilde;o em por
tugu&ecirc;s europeu    uma vers&atilde;o equivalente &agrave; original, com res
ultados do estudo psicom&eacute;trico    id&ecirc;nticos &agrave; vers&atilde;o 
original e a outras vers&otilde;es em    l&iacute;nguas latinas.</font></p>     
^cY#06.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#90#86#article#117#<p>&nbsp;</p>     ^cY#06.
htm##
00330000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010700070002000700177#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#91#87#article#117#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>REFER&Ecirc;NCIAS</b></font></p>     ^c
Y#06.htm##
00504000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704026700072002000700339#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\06.htm#S#p#92#88#article#117#1#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;1. Fillenbaum    GG, S
myer MA. The development, validity, and reliability of the OARS Multidimensional
    Functional Assessment Questionnaire. J Gerontol. 1981;36(4):428&#150;34.</fo
nt></p>     ^cY#06.htm##
00469000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704023200072002000700304#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\06.htm#S#p#93#89#article#117#2#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;2. George    LK, Fille
nbaum GG. OARS methodology. A decade of experience in geriatric assessment.    J
 Am Geriatr Soc. 1985;33(9): 607&#150;15.</font></p>     ^cY#06.htm##
00497000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704026000072002000700332#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\06.htm#S#p#94#90#article#117#3#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;3. Kane RL.    The pub
lic health paradigm. Em: Hickey T, Speers MA, Prohaska TR, eds. Public    health
 and aging. Baltimore: Johns Hopkins University; 1997. Pp. 3&#150;16.</font></p>
     ^cY#06.htm##
00572000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704033500072002000700407#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\06.htm#S#p#95#91#article#117#4#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;4. Kutza    EA. Implic
ations of an aging society for the organization and evaluation of    public heal
th services. Em: Hickey T, Speers MA, Prohaska TR, eds. Public health    and agi
ng. Baltimore: Johns Hopkins University; 1997. Pp. 293&#150;307.</font></p>     
^cY#06.htm##
00489000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704025200072002000700324#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\06.htm#S#p#96#92#article#117#5#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;5. Wacker    RR, Rober
to KA, Piper LE. Community resources for older adults: programs and    services 
in an era of change. 2nd ed. Thousand Oaks: Pine Forge; 2002.</font></p>     ^cY
#06.htm##
00437000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704020000072002000700272#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\06.htm#S#p#97#93#article#117#6#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;6. Cox CB.    Communit
y care for an aging society: issues, policies, and services. New York:    Spring
er; 2005.</font></p>     ^cY#06.htm##
00499000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704026200072002000700334#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\06.htm#S#p#98#94#article#117#7#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;7. Fillenbaum    GG. M
ultidimensional functional assessment of older adults. The Duke Older Americans 
   Resources and Services Procedures. Hilldale: Lawrence Erlbaum; 1988.</font></
p>     ^cY#06.htm##
00534000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704029700072002000700369#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\06.htm#S#p#99#95#article#117#8#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;8. Blay SL,    Ramos L
R, Mari Jde J. Validity of a Brazilian Version of the Older Americans    Resourc
es and Services (OARS) Mental Health Screening Questionnaire. J Am Geriatr    So
c. 1988;36(8):687&#150;92.</font></p>     ^cY#06.htm##
00448000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000200071704021000073002000700283#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\06.htm#S#p#100#96#article#117#9#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;9. Liang    J, Levin 
JS, Krause NM. Dimensions of the OARS mental health measures. J Gerontol.    198
9;44(5):127&#150;38.</font></p>     ^cY#06.htm##
00507000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000300071704026800074002000700342#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\06.htm#S#p#101#97#article#117#10#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Gatz M, Pedersen    NL
, Harris J. Measurement characteristics of the mental health scale from the    O
ARS. Older Americans Resources and Services. J Gerontol. 1987;42(3):332&#150;5.<
/font></p>     ^cY#06.htm##
00435000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000300071704019600074002000700270#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\06.htm#S#p#102#98#article#117#11#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Whitlaw NA,    Liang J
. The structure of the OARS physical health measures. Med Care. 1991;29(4):332&#
150;47.</font></p>     ^cY#06.htm##
00651000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000300071704041200074002000700486#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\06.htm#S#p#103#99#article#117#12#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Ferreira PL,    Marque
s FB. Avalia&ccedil;&atilde;o psicom&eacute;trica e adapta&ccedil;&atilde;o    c
ultural e ling&uuml;&iacute;stica de instrumentos de medi&ccedil;&atilde;o    em
 sa&uacute;de: princ&iacute;pios metodol&oacute;gicos gerais. Coimbra: Centro   
 de Estudos e Investiga&ccedil;&atilde;o em Sa&uacute;de; 1998.</font></p>     ^
cY#06.htm##
00498000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704025800075002000700333#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\06.htm#S#p#104#100#article#117#13#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Pati&ntilde;o    PE. 
Valoraci&oacute;n multidimensional de la tercera edad en el municipio de    Vigo
. Santiago de Compostela: Universidad de Santiago de Compostela; 1994.</font></p
>     ^cY#06.htm##
00509000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704026900075002000700344#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\06.htm#S#p#105#101#article#117#14#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Stadnyk K,    Calder 
J, Rockwood K. Testing the measurement properties of the Short Form-36    Health
 Survey in a frail elderly population. J Clin Epidemiol. 1998;51(10):827&#150;35
.</font></p>     ^cY#06.htm##
00452000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704021200075002000700287#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\06.htm#S#p#106#102#article#117#15#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Wilkin D, Hallam    L
, Dogget MA. Measures of need and outcome for primary health care. New York:    
Oxford University; 1994.</font></p>     ^cY#06.htm##
00457000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704021700075002000700292#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\06.htm#S#p#107#103#article#117#16#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Ferreira PL,    Rodri
gues RMC, Nogueira DMS. Avalia&ccedil;&atilde;o multidimensional em idosos.    C
oimbra: Mar da Palavra; 2006.</font></p>     ^cY#06.htm##
00482000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704024200075002000700317#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\06.htm#S#p#108#104#article#117#17#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Foddy W. Como    perg
untar: teoria e pr&aacute;tica da constru&ccedil;&atilde;o de perguntas    em en
trevistas e question&aacute;rios. Oeiras: Celta; 1996.</font></p>     ^cY#06.htm
##
00535000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704029500075002000700370#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\06.htm#S#p#109#105#article#117#18#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Rodrigues RMC.    Ava
lia&ccedil;&atilde;o funcional multidimensional de idosos: estudo das incapacida
des    funcionais e utiliza&ccedil;&atilde;o de servi&ccedil;os. Coimbra: Univer
sidade    de Coimbra; 1999.</font></p>     ^cY#06.htm##
00602000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704036200075002000700437#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\06.htm#S#p#110#106#article#117#19#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Nogueira DMS.    Aval
ia&ccedil;&atilde;o multidimensional de idosos. Estudo de uma popula&ccedil;&ati
lde;o    idosa n&atilde;o institucionalizada: caracteriza&ccedil;&atilde;o das i
ncapacidades    funcionais e utiliza&ccedil;&atilde;o de servi&ccedil;os. Lisboa
: ISCTE; 2003.</font></p>     ^cY#06.htm##
00491000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704025100075002000700326#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\06.htm#S#p#111#107#article#117#20#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Silva SMDT.    Avalia
&ccedil;&atilde;o multidimensional dos idosos inscritos no Centro de Sa&uacute;d
e    de Vale de Cambra. Coimbra: Universidade de Coimbra; 2005.</font></p>     ^
cY#06.htm##
00577000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704033700075002000700412#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\06.htm#S#p#112#108#article#117#21#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Fibla GG, Pati&ntilde
;o    PE, Dom&iacute;nguez AC. Versi&oacute;n espa&ntilde;ola del OARS Multidime
nsional    Functional Assessment Questionnaire: adaptaci&oacute;n transcultural 
y medida    de la validez. Atencion Primaria. 1996;17(8):486&#150;95.</font></p>
     ^cY#06.htm##
00476000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704023600075002000700311#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\06.htm#S#p#113#109#article#117#22#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Streiner DL,    Norma
n GR. Health measurement scales. A practical guide to their development    and u
se. 2ª ed. Nova Iorque: Oxford University; 1995.</font></p>     ^cY#06.htm##
00612000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704037200075002000700447#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\06.htm#S#p#114#110#article#117#23#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Van Hook MP,    Berkm
an B, Dunkle R. Assessment tools for general health care settings: Prime-MD,    
OARS, and SF-36. Primary care evaluation of mental health disorders. Older Ameri
cans    Resources and Services Questionnaire; Short Form-36. Health Soc Work. 19
96;    21(3):230&#150;4.</font></p>     ^cY#06.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#115#111#article#117#<p>&nbsp;</p>     ^cY#0
6.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#116#112#article#117#<p>&nbsp;</p>     ^cY#0
6.htm##
00345000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704012000072002000700192#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#117#113#article#117#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">Manuscrito recebido    em 19 de novembro
 de 2006.    ^cY#06.htm##
00308000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704008300072002000700155#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#118#114#article#117#<br>   Aceito em vers&a
tilde;o revisada em 20 de julho de 2007.</font></p>     ^cY#06.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#119#115#article#117#<p>&nbsp;</p>     ^cY#0
6.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#120#116#article#117#<p>&nbsp;</p>     ^cY#0
6.htm##
00573000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704034800072002000700420#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\06.htm#S#p#121#117#article#117#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#top">*</a> 
   Correspond&ecirc;ncia: Rua Central 6-A, Esp&iacute;rito Santo das Touregas 30
40/144,    Coimbra, Portugal. E-mail: <a href="mailto:rogerio@esenfc.pt">rogerio
@esenfc.pt</a>,    <a href="mailto:rmcr@sapo.pt">rmcr@sapo.pt</a></font></p>    
 ^cY#06.htm##
00584000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100021000710100016000920120
11200108030001100220065000900231064000500240031000300245032000200248014000700250
865000900257002000700266035001000273801001100283#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\06.htm#S#c#122#1#article#23#1#^rND^sFillenbaum^nGG#^rND^sSmyer^nMA#The
 development, validity, and reliability of the OARS Multidimensional Functional 
Assessment Questionnaire^len#J Gerontol#19810000#1981#36#4#428-34#20080200#06.ht
m#0022-1422#J Gerontol##
00554000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100017000710100021000880120
06900109030001700178065000900195064000500204031000300209032000200212014000700214
865000900221002000700230035001000237801001700247#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\06.htm#S#c#123#2#article#23#2#^rND^sGeorge^nLK#^rND^sFillenbaum^nGG#OA
RS methodology: A decade of experience in geriatric assessment^len#J Am Geriatr 
Soc#19850000#1985#33#9#607-15#20080200#06.htm#0002-8614#J Am Geriatr Soc##
00557000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100015000710120031000860160
01600117016001700133016001900150018002800169066001000197062002500207065000900232
064000500241014000500246865000900251002000700260#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\06.htm#S#c#124#3#article#23#3#^rND^sKane^nRL#The public health paradig
m^len#^rED^sHickey^nT#^rED^sSpeers^nMA#^rED^sProhaska^nTR#Public health and agin
g^len#Baltimore#Johns Hopkins University#19970000#1997#3-16#20080200#06.htm##
00629000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100016000710120099000870160
01600186016001700202016001900219018002800238066001000266062002500276065000900301
064000500310014000800315865000900323002000700332#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\06.htm#S#c#125#4#article#23#4#^rND^sKutza^nEA#Implications of an aging
 society for the organization and evaluation of public health services^len#^rED^
sHickey^nT#^rED^sSpeers^nMA#^rED^sProhaska^nTR#Public health and aging^len#Balti
more#Johns Hopkins University#19970000#1997#293-307#20080200#06.htm##
00529000000000265000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690160017000710160018000880160
01600106018008400122063000200206066001400208062001100222065000900233064000500242
865000900247002000700256#v23n2#v:\scielo\serial\rpsp\v23n2\markup\06.htm#S#c#126
#5#article#23#5#^rND^sWacker^nRR#^rND^sRoberto^nKA#^rND^sPiper^nLE#Community res
ources for older adults: programs and services in an era of change^len#2#Thousan
d Oaks#Pine Forge#20020000#2002#20080200#06.htm##
00435000000000229000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690160014000710180072000850660
00900157062000900166065000900175064000500184865000900189002000700198#v23n2#v:\sc
ielo\serial\rpsp\v23n2\markup\06.htm#S#c#127#6#article#23#6#^rND^sCox^nCB#Commun
ity care for an aging society: issues, policies, and services^len#New York#Sprin
ger#20050000#2005#20080200#06.htm##
00497000000000229000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690160021000710180119000920660
00900211062001700220065000900237064000500246865000900251002000700260#v23n2#v:\sc
ielo\serial\rpsp\v23n2\markup\06.htm#S#c#128#7#article#23#7#^rND^sFillenbaum^nGG
#Multidimensional functional assessment of older adults: The Duke Older American
s Resources and Services Procedures^len#Hilldale#Lawrence Erlbaum#19880000#1988#
20080200#06.htm##
00635000000000301000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100015000710100016000860100
01800102012012700120030001700247065000900264064000500273031000300278032000200281
014000700283865000900290002000700299035001000306801001700316#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\06.htm#S#c#129#8#article#23#8#^rND^sBlay^nSL#^rND^sRamos^n
LR#^rND^sMari Jde^nJ#Validity of a Brazilian Version of the Older Americans Reso
urces and Services (OARS) Mental Health Screening Questionnaire^len#J Am Geriatr
 Soc#19880000#1988#36#8#687-92#20080200#06.htm#0002-8614#J Am Geriatr Soc##
00545000000000301000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100015000710100016000860100
01700102012005000119030001100169065000900180064000500189031000300194032000200197
014000700199865000900206002000700215035001000222801001100232#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\06.htm#S#c#130#9#article#23#9#^rND^sLiang^nJ#^rND^sLevin^n
JS#^rND^sKrause^nNM#Dimensions of the OARS mental health measures^len#J Gerontol
#19890000#1989#44#5#127-38#20080200#06.htm#0022-1422#J Gerontol##
00610000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100014000730100019000870100
01600106012011300122030001100235065000900246064000500255031000300260032000200263
014000600265865000900271002000700280035001000287801001100297#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\06.htm#S#c#131#10#article#23#10#^rND^sGatz^nM#^rND^sPeders
en^nNL#^rND^sHarris^nJ#Measurement characteristics of the mental health scale fr
om the OARS: Older Americans Resources and Services^len#J Gerontol#19870000#1987
#42#3#332-5#20080200#06.htm#0022-1422#J Gerontol##
00521000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100015000910120
05500106030000900161065000900170064000500179031000300184032000200187014000700189
865000900196002000700205035001000212801000900222#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\06.htm#S#c#132#11#article#23#11#^rND^sWhitlaw^nNA#^rND^sLiang^nJ#The s
tructure of the OARS physical health measures^len#Med Care#19910000#1991#29#4#33
2-47#20080200#06.htm#0025-7079#Med Care##
00563000000000241000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700160019000730160018000920180
13100110066000800241062004200249065000900291064000500300865000900305002000700314
#v23n2#v:\scielo\serial\rpsp\v23n2\markup\06.htm#S#c#133#12#article#23#12#^rND^s
Ferreira^nPL#^rND^sMarques^nFB#Avaliação psicométrica e adaptação cultural e lin
güística de instrumentos de medição em saúde: princípios metodológicos gerais^le
n#Coimbra#Centro de Estudos e Investigação em Saúde#19980000#1998#20080200#06.ht
m##
00486000000000229000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700160017000730180075000900660
02300165062003800188065000900226064000500235865000900240002000700249#v23n2#v:\sc
ielo\serial\rpsp\v23n2\markup\06.htm#S#c#134#13#article#23#13#^rND^sPatiño^nPE#V
aloración multidimensional de la tercera edad en el municipio de Vigo^les#Santia
go de Compostela#Universidad de Santiago de Compostela#19940000#1994#20080200#06
.htm##
00617000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100016000900100
01800106012010400124030001700228065000900245064000500254031000300259032000300262
014000700265865000900272002000700281035001000288801001700298#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\06.htm#S#c#135#14#article#23#14#^rND^sStadnyk^nK#^rND^sCal
der^nJ#^rND^sRockwood^nK#Testing the measurement properties of the Short Form-36
 Health Survey in a frail elderly population^len#J Clin Epidemiol#19980000#1998#
51#10#827-35#20080200#06.htm#0895-4356#J Clin Epidemiol##
00490000000000253000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700160016000730160016000890160
01700105018005700122066000900179062001800188065000900206064000500215865000900220
002000700229#v23n2#v:\scielo\serial\rpsp\v23n2\markup\06.htm#S#c#136#15#article#
23#15#^rND^sWilkin^nD#^rND^sHallam^nL#^rND^sDogget^nMA#Measures of need and outc
ome for primary health care^len#New York#Oxford University#19940000#1994#2008020
0#06.htm##
00481000000000253000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700160019000730160021000920160
02000113018004100133066000800174062001500182065000900197064000500206865000900211
002000700220#v23n2#v:\scielo\serial\rpsp\v23n2\markup\06.htm#S#c#137#16#article#
23#16#^rND^sFerreira^nPL#^rND^sRodrigues^nRMC#^rND^sNogueira^nDMS#Avaliação mult
idimensional em idosos^lpt#Coimbra#Mar da Palavra#20060000#2006#20080200#06.htm#
#
00456000000000229000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700160015000730180095000880660
00700183062000600190065000900196064000500205865000900210002000700219#v23n2#v:\sc
ielo\serial\rpsp\v23n2\markup\06.htm#S#c#138#17#article#23#17#^rND^sFoddy^nW#Com
o perguntar: teoria e prática da construção de perguntas em entrevistas e questi
onários^lpt#Oeiras#Celta#19960000#1996#20080200#06.htm##
00499000000000229000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700160021000730180113000940660
00800207062002400215065000900239064000500248865000900253002000700262#v23n2#v:\sc
ielo\serial\rpsp\v23n2\markup\06.htm#S#c#139#18#article#23#18#^rND^sRodrigues^nR
MC#Avaliação funcional multidimensional de idosos: estudo das incapacidades func
ionais e utilização de serviços^lpt#Coimbra#Universidade de Coimbra#19990000#199
9#20080200#06.htm##
00531000000000229000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700160020000730180165000930660
00700258062000600265065000900271064000500280865000900285002000700294#v23n2#v:\sc
ielo\serial\rpsp\v23n2\markup\06.htm#S#c#140#19#article#23#19#^rND^sNogueira^nDM
S#Avaliação multidimensional de idosos. Estudo de uma população idosa não instit
ucionalizada: caracterização das incapacidades funcionais e utilização de serviç
os^lpt#Lisboa#ISCTE#20030000#2003#20080200#06.htm##
00472000000000229000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700160018000730180089000910660
00800180062002400188065000900212064000500221865000900226002000700235#v23n2#v:\sc
ielo\serial\rpsp\v23n2\markup\06.htm#S#c#141#20#article#23#20#^rND^sSilva^nSMDT#
Avaliação multidimensional dos idosos inscritos no Centro de Saúde de Vale de Ca
mbra^lpt#Coimbra#Universidade de Coimbra#20050000#2005#20080200#06.htm##
00648000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100017000890100
02000106012013200126030001800258065000900276064000500285031000300290032000200293
014000700295865000900302002000700311035001000318801001800328#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\06.htm#S#c#142#21#article#23#21#^rND^sFibla^nGG#^rND^sPati
ño^nPE#^rND^sDomínguez^nAC#Versión española del OARS Multidimensional Functional
 Assessment Questionnaire: adaptación transcultural y medida de la validez^les#A
tencion Primaria#19960000#1996#17#8#486-95#20080200#06.htm#0212-6567#ATENCION PR
IMARIA##
00503000000000253000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700160019000730160017000920180
07800109063000200187066001200189062001800201065000900219064000500228865000900233
002000700242#v23n2#v:\scielo\serial\rpsp\v23n2\markup\06.htm#S#c#143#22#article#
23#22#^rND^sStreiner^nDL#^rND^sNorman^nGR#Health measurement scales: A practical
 guide to their development and use^len#2#Nova Iorque#Oxford University#19950000
#1995#20080200#06.htm##
00712000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100017000920100
01600109012020200125030001600327065000900343064000500352031000300357032000200360
014000600362865000900368002000700377035001000384801001600394#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\06.htm#S#c#144#23#article#23#23#^rND^sVan Hook^nMP#^rND^sB
erkman^nB#^rND^sDunkle^nR#Assessment tools for general health care settings: Pri
me-MD, OARS, and SF-36. Primary care evaluation of mental health disorders. Olde
r Americans Resources and Services Questionnaire; Short Form-36^len#Health Soc W
ork#19960000#1996#21#3#230-4#20080200#06.htm#0360-7283#Health Soc Work##
00262000000000169000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640910009000660920007000750020007000827030
00300089#v23n2#v:\scielo\serial\rpsp\v23n2\markup\07.htm#S#o#1#1#article#1#20080
318#103144#07.htm#62##
03848000000000625000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000500084121000300089049000800092158000300100030002400103
03100030012703200020013006500090013201400110014103500100015201200930016201201450
02550100026004000100025004260100028004510100025004790100030005040700085005340700
05800619083095800677085000801635085003701643085002201680085002201702083128101724
08500080300508500480301308500210306108500220308205800510310411700060315507200020
3161112000903163111001803172114000903190113001603199002000703215#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#h#2#1#article#1#oa#en#br1.1#1#3.1#ILUS#07#RPS
P020#nd#Rev Panam Salud Publica#23#2#20080200#^f116^l118#1020-4989#Validation of
 a job aid to rule out pregnancy among family planning clients in Nicaragua^len#
Validación de una lista de verificación para descartar el embarazo en mujeres qu
e solicitan servicios de planificación familiar en Nicaragua^les#^rND^1A01^nJohn
^sStanback#^rND^1A01^nKavita^sNanda#^rND^1A02^nYolanda^sRamirez#^rND^1A01^nWes^s
Rountree#^rND^1A01^nSandra B.^sCameron#Family Health International^iA01^1Health 
Services Research^pUnited States of America#Hospital 'Bertha Calderón Roque'^iA0
2^cManagua^pNicaragua#^len^aIn Latin America, one of the most common barriers to
 family planning access is denial of services to women who present at clinics in
 the absence of menses. Where pregnancy tests are unavailable, many providers fe
ar that nonmenstruating women may be pregnant and, worrying about possible harm 
to the fetus, require the woman to await the onset of menses before initiating a
 contraceptive method. In 2005, during a randomized trial of oral contraceptive 
users in Nicaragua, we assessed a job aid endorsed by the World Health Organizat
ion to help providers exclude pregnancy among family planning clients. Among 263
 new, nonmenstruating clients, the job aid ruled out pregnancy for 60% of the wo
men. Only 1% of the women were pregnant, and no woman identified by the job aid 
as "not pregnant" was pregnant. Provider fears that nonmenstruating clients are 
pregnant are usually misplaced, while fears that hormonal methods can harm fetus
es are exaggerated.#^dnd^i1#^tm^len^kFamily planning services^i1#^tm^len^kpregna
ncy^i1#^tm^len^kNicaragua^i1#^les^aEn América Latina, uno de los obstáculos más 
frecuentes para acceder a los servicios de planificación familiar es la negativa
 a atender a las mujeres que se presentan en las clínicas sin menstruación. Cuan
do no hay pruebas de embarazo disponibles, muchos profesionales piensan que las 
mujeres sin menstruación visible pueden estar embarazadas y por temor a ocasiona
r algún daño al feto les exigen esperar hasta el inicio de la menstruación para 
comenzar con algún método anticonceptivo. En 2005, durante un ensayo aleatorizad
o con usuarias de anticonceptivos orales en Nicaragua, se evaluó una lista de ve
rificación avalada por la Organización Mundial de la Salud para ayudar a los pro
fesionales sanitarios a descartar el embarazo en las mujeres que solicitan servi
cios de planificación familiar. Este procedimiento permitió descartar el embaraz
o en 60% de las 263 mujeres sin menstruación que solicitaban por primera vez ese
 servicio. Solamente 1% de las mujeres estaban embarazadas y ninguna de las iden
tificadas por este procedimiento como "no embarazada" lo estaba. El temor de los
 profesionales de la salud de que las mujeres sin menstruación estén embarazadas
 es frecuentemente infundado y los temores de que los métodos hormonales puedan 
dañar al feto son exagerados.#^dnd^i2#^tm^les^kServicios de planificación famili
ar^i2#^tm^les^kembarazo^i2#^tm^les^kNicaragua^i2#United States Agency for Intern
ational Development#other#7#20070918#18 September 2007#20080111#11 January 2008#
07.htm##
03862000000000625000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000500084121000300089049000800092158000300100030002400103
03100030012703200020013006500090013201400110014103500100015201201000016201201520
02620100026004140100025004400100028004650100025004930100030005180700085005480700
05800633083095800691085000801649085003701657085002201694085002201716083128101738
08500080301908500480302708500210307508500220309605800510311811700060316907200020
3175112000903177111001803186114000903204113001603213002000703229#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#f#3#1#article#1#oa#en#br1.1#1#3.1#ILUS#07#RPS
P020#nd#Rev Panam Salud Publica#23#2#20080200#^f116^l118#1020-4989#<B>Validation
 of a job aid to rule out pregnancy among family planning clients in Nicaragua</
B>^len#<B>Validación de una lista de verificación para descartar el embarazo en 
mujeres que solicitan servicios de planificación familiar en Nicaragua</B>^les#^
rND^1A01^nJohn^sStanback#^rND^1A01^nKavita^sNanda#^rND^1A02^nYolanda^sRamirez#^r
ND^1A01^nWes^sRountree#^rND^1A01^nSandra B.^sCameron#Family Health International
^iA01^1Health Services Research^pUnited States of America#Hospital 'Bertha Calde
rón Roque'^iA02^cManagua^pNicaragua#^len^aIn Latin America, one of the most comm
on barriers to family planning access is denial of services to women who present
 at clinics in the absence of menses. Where pregnancy tests are unavailable, man
y providers fear that nonmenstruating women may be pregnant and, worrying about 
possible harm to the fetus, require the woman to await the onset of menses befor
e initiating a contraceptive method. In 2005, during a randomized trial of oral 
contraceptive users in Nicaragua, we assessed a job aid endorsed by the World He
alth Organization to help providers exclude pregnancy among family planning clie
nts. Among 263 new, nonmenstruating clients, the job aid ruled out pregnancy for
 60% of the women. Only 1% of the women were pregnant, and no woman identified b
y the job aid as "not pregnant" was pregnant. Provider fears that nonmenstruatin
g clients are pregnant are usually misplaced, while fears that hormonal methods 
can harm fetuses are exaggerated.#^dnd^i1#^tm^len^kFamily planning services^i1#^
tm^len^kpregnancy^i1#^tm^len^kNicaragua^i1#^les^aEn América Latina, uno de los o
bstáculos más frecuentes para acceder a los servicios de planificación familiar 
es la negativa a atender a las mujeres que se presentan en las clínicas sin mens
truación. Cuando no hay pruebas de embarazo disponibles, muchos profesionales pi
ensan que las mujeres sin menstruación visible pueden estar embarazadas y por te
mor a ocasionar algún daño al feto les exigen esperar hasta el inicio de la mens
truación para comenzar con algún método anticonceptivo. En 2005, durante un ensa
yo aleatorizado con usuarias de anticonceptivos orales en Nicaragua, se evaluó u
na lista de verificación avalada por la Organización Mundial de la Salud para ay
udar a los profesionales sanitarios a descartar el embarazo en las mujeres que s
olicitan servicios de planificación familiar. Este procedimiento permitió descar
tar el embarazo en 60% de las 263 mujeres sin menstruación que solicitaban por p
rimera vez ese servicio. Solamente 1% de las mujeres estaban embarazadas y ningu
na de las identificadas por este procedimiento como "no embarazada" lo estaba. E
l temor de los profesionales de la salud de que las mujeres sin menstruación est
én embarazadas es frecuentemente infundado y los temores de que los métodos horm
onales puedan dañar al feto son exagerados.#^dnd^i2#^tm^les^kServicios de planif
icación familiar^i2#^tm^les^kembarazo^i2#^tm^les^kNicaragua^i2#United States Age
ncy for International Development#other#7#20070918#18 September 2007#20080111#11
 January 2008#07.htm##
04016000000000649000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640640013000660710003000790400003000820010
00600085042000200091120000400093038000500097121000300102049000800105158000300113
03000260011603100030014203200020014506500090014701400110015603500100016701200930
01770120145002700100026004150100025004410100028004660100025004940100029005190700
08700548070006000635083097200695085000801667085003701675085002201712085002201734
08313010175608500080305708500480306508500210311308500220313405800510315611700060
32070720002032131120009032151110018032241140009032421130016032510020007032670080
09203274#v23n2#v:\scielo\serial\rpsp\v23n2\markup\07.htm#S#l#4#1#article#1#^mFeb
.^a2008#oa#en#br1.1#1#3.1#ilus#07#RPSP020#nd#Rev. panam. salud pública#23#2#2008
0200#^f116^l118#1020-4989#Validation of a job aid to rule out pregnancy among fa
mily planning clients in Nicaragua^len#Validación de una lista de verificación p
ara descartar el embarazo en mujeres que solicitan servicios de planificación fa
miliar en Nicaragua^les#^rND^1A01^nJohn^sStanback#^rND^1A01^nKavita^sNanda#^rND^
1A02^nYolanda^sRamirez#^rND^1A01^nWes^sRountree#^rND^1A01^nSandra B^sCameron#^iA
01^1Family Health International^2Health Services Research^pUnited States of Amer
ica#^iA02^1Hospital 'Bertha Calderón Roque'^cManagua^pNicaragua#^len^aIn Latin A
merica, one of the most common barriers to family planning access is denial of s
ervices to women who present at clinics in the absence of menses. Where pregnanc
y tests are unavailable, many providers fear that nonmenstruating women may be p
regnant and, worrying about possible harm to the fetus, require the woman to awa
it the onset of menses before initiating a contraceptive method. In 2005, during
 a randomized trial of oral contraceptive users in Nicaragua, we assessed a job 
aid endorsed by the World Health Organization to help providers exclude pregnanc
y among family planning clients. Among 263 new, nonmenstruating clients, the job
 aid ruled out pregnancy for 60 percent of the women. Only 1 percent of the wome
n were pregnant, and no woman identified by the job aid as "not pregnant" was pr
egnant. Provider fears that nonmenstruating clients are pregnant are usually mis
placed, while fears that hormonal methods can harm fetuses are exaggerated.#^dnd
^i1#^tm^len^kFamily planning services^i1#^tm^len^kpregnancy^i1#^tm^len^kNicaragu
a^i1#^les^aEn América Latina, uno de los obstáculos más frecuentes para acceder 
a los servicios de planificación familiar es la negativa a atender a las mujeres
 que se presentan en las clínicas sin menstruación. Cuando no hay pruebas de emb
arazo disponibles, muchos profesionales piensan que las mujeres sin menstruación
 visible pueden estar embarazadas y por temor a ocasionar algún daño al feto les
 exigen esperar hasta el inicio de la menstruación para comenzar con algún métod
o anticonceptivo. En 2005, durante un ensayo aleatorizado con usuarias de antico
nceptivos orales en Nicaragua, se evaluó una lista de verificación avalada por l
a Organización Mundial de la Salud para ayudar a los profesionales sanitarios a 
descartar el embarazo en las mujeres que solicitan servicios de planificación fa
miliar. Este procedimiento permitió descartar el embarazo en 60 por ciento de la
s 263 mujeres sin menstruación que solicitaban por primera vez ese servicio. Sol
amente 1 por ciento de las mujeres estaban embarazadas y ninguna de las identifi
cadas por este procedimiento como "no embarazada" lo estaba. El temor de los pro
fesionales de la salud de que las mujeres sin menstruación estén embarazadas es 
frecuentemente infundado y los temores de que los métodos hormonales puedan daña
r al feto son exagerados.#^dnd^i2#^tm^les^kServicios de planificación familiar^i
2#^tm^les^kembarazo^i2#^tm^les^kNicaragua^i2#United States Agency for Internatio
nal Development#other#7#20070918#18 September 2007#20080111#11 January 2008#07.h
tm#Internet^ihttp://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-498
92008000200007##
00372000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704015200067002000700219#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#5#1#article#51#<p align="right"><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>COMUNICACI&Oacute;N    BREVE
</b> SHORT COMMUNICATION</font></p>     ^cY#07.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704002200067002000700089#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#6#2#article#51#<p>&nbsp;</p>     ^cY#07.htm
##
00419000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704019900067002000700266#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#7#3#article#51#<p><a name="top"></a><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Validation    of a job a
id to rule out pregnancy among family planning clients in Nicaragua</b></font></
p>     ^cY#07.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704002200067002000700089#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#8#4#article#51#<p>&nbsp;</p>     ^cY#07.htm
##
00477000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704025700067002000700324#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#9#5#article#51#<p><font face="Verdana, Aria
l, Helvetica, sans-serif" size="3"><b>Validaci&oacute;n    de una lista de verif
icaci&oacute;n para descartar el embarazo en mujeres que    solicitan servicios 
de planificaci&oacute;n familiar en Nicaragua</b></font></p>     ^cY#07.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704002200068002000700090#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#10#6#article#51#<p>&nbsp;</p>     ^cY#07.ht
m##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704002200068002000700090#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#11#7#article#51#<p>&nbsp;</p>     ^cY#07.ht
m##
00478000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704025700068002000700325#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#12#8#article#51#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><b>John Stanback<sup>I, <a href="#back">*</a
></sup>;    Kavita Nanda<sup>I</sup>; Yolanda Ramirez<sup>II</sup>; Wes Rountree
<sup>I</sup>;    Sandra B. Cameron<sup>I</sup></b></font></p>     ^cY#07.htm##
00437000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704021600068002000700284#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#13#9#article#51#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><sup>I</sup>Family    Health International, 
Health Services Research, PO Box 13950, Research Triangle    Park 27709, NC, Uni
ted States of America    ^cY#07.htm##
00321000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704009900069002000700168#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#14#10#article#51#<br>   <sup>II</sup>Hospit
al "Bertha Calder&oacute;n Roque", Managua, Nicaragua</font></p>     ^cY#07.htm#
#
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#15#11#article#51#<p>&nbsp;</p>     ^cY#07.h
tm##
00266000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704004400069002000700113#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#16#12#article#51#<p>&nbsp;</p> <hr size="1"
 noshade>     ^cY#07.htm##
00320000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704009800069002000700167#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#17#13#article#51#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     ^cY#07.htm##
01292000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704107000069002000701139#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#18#14#article#51#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In Latin America,    one of the most common
 barriers to family planning access is denial of services    to women who presen
t at clinics in the absence of menses. Where pregnancy tests    are unavailable,
 many providers fear that nonmenstruating women may be pregnant    and, worrying
 about possible harm to the fetus, require the woman to await the    onset of me
nses before initiating a contraceptive method. In 2005, during a    randomized t
rial of oral contraceptive users in Nicaragua, we assessed a job    aid endorsed
 by the World Health Organization to help providers exclude pregnancy    among f
amily planning clients. Among 263 new, nonmenstruating clients, the job    aid r
uled out pregnancy for 60% of the women. Only 1% of the women were pregnant,    
and no woman identified by the job aid as "not pregnant" was pregnant. Provider 
   fears that nonmenstruating clients are pregnant are usually misplaced, while 
   fears that hormonal methods can harm fetuses are exaggerated.</font></p>     
^cY#07.htm##
00395000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704017300069002000700242#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#19#15#article#51#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Key words:</b>    Family planning servic
es, pregnancy, Nicaragua.</font></p> <hr size="1" noshade>     ^cY#07.htm##
00319000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704009700069002000700166#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#20#16#article#51#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>RESUMEN</b></font></p>     ^cY#07.htm##
01787000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704156500069002000701634#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#21#17#article#51#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">En Am&eacute;rica    Latina, uno de los obs
t&aacute;culos m&aacute;s frecuentes para acceder a los    servicios de planific
aci&oacute;n familiar es la negativa a atender a las mujeres    que se presentan
 en las cl&iacute;nicas sin menstruaci&oacute;n. Cuando no hay    pruebas de emb
arazo disponibles, muchos profesionales piensan que las mujeres    sin menstruac
i&oacute;n visible pueden estar embarazadas y por temor a ocasionar    alg&uacut
e;n da&ntilde;o al feto les exigen esperar hasta el inicio de la menstruaci&oacu
te;n    para comenzar con alg&uacute;n m&eacute;todo anticonceptivo. En 2005, du
rante    un ensayo aleatorizado con usuarias de anticonceptivos orales en Nicara
gua,    se evalu&oacute; una lista de verificaci&oacute;n avalada por la Organiz
aci&oacute;n    Mundial de la Salud para ayudar a los profesionales sanitarios a
 descartar el    embarazo en las mujeres que solicitan servicios de planificaci&
oacute;n familiar.    Este procedimiento permiti&oacute; descartar el embarazo e
n 60% de las 263 mujeres    sin menstruaci&oacute;n que solicitaban por primera 
vez ese servicio. Solamente    1% de las mujeres estaban embarazadas y ninguna d
e las identificadas por este    procedimiento como "no embarazada" lo estaba. El
 temor de los profesionales    de la salud de que las mujeres sin menstruaci&oac
ute;n est&eacute;n embarazadas    es frecuentemente infundado y los temores de q
ue los m&eacute;todos hormonales    puedan da&ntilde;ar al feto son exagerados.<
/font></p>     ^cY#07.htm##
00418000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704019600069002000700265#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#22#18#article#51#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Palabras clave:    </b> Servicios de pla
nificaci&oacute;n familiar, embarazo, Nicaragua.</font></p> <hr size="1" noshade
>     ^cY#07.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#23#19#article#51#<p>&nbsp;</p>     ^cY#07.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#24#20#article#51#<p>&nbsp;</p>     ^cY#07.h
tm##
01085000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704086300069002000700932#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#25#21#article#51#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Denial of contraception    to nonmenstruati
ng women is a common barrier to family planning services in    many parts of the
 world, particularly where pregnancy tests are unavailable    or unaffordable (1
). In a recent study in Guatemala, for example, 16% of all    new family plannin
g clients were denied services because of the absence of menses    (2). Behind t
he problem of menstruation requirements lie provider fears that    contraception
 can harm an unrecognized pregnancy. This fear is legitimate in    the case of t
he intrauterine device but is exaggerated in the case of hormonal    methods. Ac
cording to the World Health Organization (WHO), there is good evidence    that h
ormonal methods will not harm a fetus if they are accidentally initiated    duri
ng pregnancy (3).</font></p>     ^cY#07.htm##
01021000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704079900069002000700868#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#26#22#article#51#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Sending family    planning clients home wit
hout a contraceptive method is rarely necessary. An    algorithm for excluding p
regnancy was developed in the early 1990s and now is    included in many interna
tional guidance documents, including consensus recommendations    published by W
HO (4). The algorithm consists of six criteria, meeting any one    of which is s
ufficient to be "reasonably certain that the woman is not pregnant."    A job ai
d (<a href="#fig1">Figure 1</a>) based on the WHO criteria was developed    in t
he late 1990s; it was found to be very effective in Kenyan and Egyptian    famil
y planning clinics, primarily because very few new clients (~1%) presented    fo
r services while pregnant (5, 6).</font></p>     ^cY#07.htm##
00257000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704003500069002000700104#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#27#23#article#51#<p><a name="fig1"></a></p>
     ^cY#07.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#28#24#article#51#<p>&nbsp;</p>     ^cY#07.h
tm##
00298000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704007600069002000700145#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#29#25#article#51#<p align="center"><img src
="/img/revistas/rpsp/v23n2/07f1.gif"></p>     ^cY#07.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#30#26#article#51#<p>&nbsp;</p>     ^cY#07.h
tm##
01034000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704081200069002000700881#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#31#27#article#51#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The job aid consists    of six questions re
lated to most recent birth, duration and frequency of breast-feeding,    last me
nstrual period, abortion or miscarriage, sexual relations, and current    contra
ception. If the woman answers "yes" to any of the questions and is free    of si
gns or symptoms of pregnancy, it can be assumed she is not pregnant. Although   
 the job aid&#151;often called the "pregnancy checklist"&#151;has been introduce
d    in several forms to Latin America and even shown in research in Guatemala (
2)    to reduce family planning denial rates by almost 90%, it has never been va
lidated    in the region and shown to be effective at ruling out pregnancy among
 women    normally at risk for service denial.</font></p>     ^cY#07.htm##
01311000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704108900069002000701158#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#32#28#article#51#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">We assessed the    job aid during admission
 screening for a randomized trial comparing two approaches    to provision of or
al contraceptives. The trial, conducted&nbsp;with the Asociaci&oacute;n    Pro-B
ienestar de la Familia Nicarag&uuml;ense (PROFAMILIA) in Managua, Nicaragua,    
in 2005, has been described elsewhere (7). To test the validity of the job aid, 
   we administered it and followed up with a commercial dipstick urine pregnancy
    test to 263 new, nonmenstruating family planning clients desiring oral contr
aception    (<a href="#tab1">Table 1</a>). The checklist ruled out pregnancy for
 60% of    the women, somewhat less than the 88% and 83% specificity found in Ke
nya and    Egypt, respectively. This lower specificity was likely due to the nat
ure of    the ongoing clinical trial, which excluded postpartum clients for whom
 pregnancy    might have been easily ruled out by lactational infecundability. T
he earlier    assessments in Kenya and Egypt included many such postpartum clien
ts.</font></p>     ^cY#07.htm##
00257000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704003500069002000700104#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#33#29#article#51#<p><a name="tab1"></a></p>
     ^cY#07.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#34#30#article#51#<p>&nbsp;</p>     ^cY#07.h
tm##
00298000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704007600069002000700145#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#35#31#article#51#<p align="center"><img src
="/img/revistas/rpsp/v23n2/07t1.gif"></p>     ^cY#07.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#36#32#article#51#<p>&nbsp;</p>     ^cY#07.h
tm##
00631000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704040900069002000700478#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#37#33#article#51#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Interestingly,    the pregnancy test detect
ed pregnancies in 1% of women, the same prevalence    found in Kenya and Egypt. 
With the dipstick pregnancy test as the reference    standard, the sensitivity o
f the job aid was 100%; the positive predictive value    was 3%, and the negativ
e predictive value of the job aid was 100%.</font></p>     ^cY#07.htm##
01224000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704100200069002000701071#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#38#34#article#51#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">One weakness of    the study was its limite
d sample size, which, because of the rarity of pregnancy,    resulted in an unst
able estimate for the job aid's sensitivity. However, we    contend that the rel
evant statistic for family planning programs is the job    aid's high (and stabl
e) negative predictive value (100%). No woman identified    by the job aid as "n
ot pregnant" was pregnant. Given the rarity of pregnancy    documented among new
, nonmenstruating family planning clients in Nicaragua and    elsewhere, provide
rs should stop the practice of routinely denying services    to nonmenstruating 
clients. Instead, they should make efforts to ensure that    every new family pl
anning client leaves the clinic with an effective method.    Widespread use of t
his job aid, with recourse to pregnancy tests when necessary,    could reduce a 
serious barrier to contraceptive access in many Latin American    countries.</fo
nt></p>     ^cY#07.htm##
00428000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704020600069002000700275#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#39#35#article#51#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Acknowledgment.</b>    Funding for this 
study was provided by the United States Agency for International    Development.
</font></p>     ^cY#07.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#40#36#article#51#<p>&nbsp;</p>     ^cY#07.h
tm##
00322000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704010000069002000700169#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#41#37#article#51#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>REFERENCES</b></font></p>     ^cY#07.htm
##
00447000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704021100071002000700282#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\07.htm#S#p#42#38#article#51#1#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">1. Shelton JD,    Angle MA, J
acobstein RA. Medical barriers to access to family planning. Lancet.    1992;340
(8831):1334&#150;5.</font></p>     ^cY#07.htm##
00543000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704030700071002000700378#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\07.htm#S#p#43#39#article#51#2#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">2. Stanback J,    Diabate F, 
Dieng T, de Morales TD, Cummings S, Traor&eacute; M. Ruling out pregnancy    amo
ng family planning clients: the impact of a checklist in three countries.    Stu
d Fam Plann. 2005;36(4):311&#150;5.</font></p>     ^cY#07.htm##
00588000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704035200071002000700423#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\07.htm#S#p#44#40#article#51#3#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">3. World Health    Organizati
on, Department of Reproductive Health and Research, and Johns Hopkins    Bloombe
rg School of Public Health/ Center for Communications Programs. Family    planni
ng: a global handbook for providers. Geneva and Baltimore: WHO and CCP;    2007.
</font></p>     ^cY#07.htm##
00430000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704019400071002000700265#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\07.htm#S#p#45#41#article#51#4#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">4. World Health    Organizati
on. Selected practice recommendations for contraceptive use. Geneva:    WHO; 200
4.</font></p>     ^cY#07.htm##
00501000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704026500071002000700336#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\07.htm#S#p#46#42#article#51#5#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">5. Stanback J,    Qureshi Z, 
Sekadde-Kigondu C, Gonzalez B, Nutley T. Checklist for ruling out    pregnancy a
mong family-planning clients in primary care. Lancet. 1999;354(9178):566.</font>
</p>     ^cY#07.htm##
00499000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704026300071002000700334#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\07.htm#S#p#47#43#article#51#6#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">6. Hassan EO, Stanback    J, 
Eldamanhoury H. Validation of the pregnancy checklist in selected Egyptian    fa
mily planning centers. Cairo: Egyptian Fertility Care Foundation; 2005.</font></
p>     ^cY#07.htm##
00579000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704034300071002000700414#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\07.htm#S#p#48#44#article#51#7#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">7. Nanda K, Stanback    J, Ro
untree RW, Cameron SB. Randomized trial of 'quick start' versus advance    provi
sion of oral contraceptive pills in Nicaragua. Annual Conference of the    Ameri
can College of Obstetrics and Gynecology. Obstet Gynecol. 2006;107:50S.</font></
p>     ^cY#07.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#49#45#article#51#<p>&nbsp;</p>     ^cY#07.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#50#46#article#51#<p>&nbsp;</p>     ^cY#07.h
tm##
00334000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704011200069002000700181#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#51#47#article#51#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Manuscript received    18 September 2007.  
  ^cY#07.htm##
00309000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704008700069002000700156#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#52#48#article#51#<br>   Revised version acc
epted for publication on 11 January 2008.</font></p>     ^cY#07.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#53#49#article#51#<p>&nbsp;</p>     ^cY#07.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#54#50#article#51#<p>&nbsp;</p>     ^cY#07.h
tm##
00653000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704043100069002000700500#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\07.htm#S#p#55#51#article#51#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#top">*</a>    
Send correspondence and reprint requests to: John Stanback, Family Health Intern
ational,    Health Services Research, PO Box 13950, Research Triangle Park 27709
, NC, United    States of America; telephone (919) 544-7040; fax (919) 544-7261;
 e-mail: <a href="mailto:jstanback@fhi.org">jstanback@fhi.org</a></font></p>    
 ^cY#07.htm##
00546000000000301000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080002000651180002000670100018000690100016000870100
02100103012005000124030000700174065000900181064000500190031000400195032000500199
014000700204865000900211002000700220035001000227801000700237#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\07.htm#S#c#56#1#article#7#1#^rND^sShelton^nJD#^rND^sAngle^
nMA#^rND^sJacobstein^nRA#Medical barriers to access to family planning^len#Lance
t#19920000#1992#340#8831#1334-5#20080200#07.htm#0099-5355#Lancet##
00694000000000337000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080002000651180002000670100018000690100017000870100
01500104010002100119010001800140010001600158012010100174030001500275065000900290
06400050029903100030030403200020030701400060030986500090031500200070032403500100
0331801001500341#v23n2#v:\scielo\serial\rpsp\v23n2\markup\07.htm#S#c#57#2#articl
e#7#2#^rND^sStanback^nJ#^rND^sDiabate^nF#^rND^sDieng^nT#^rND^sde Morales^nTD#^rN
D^sCummings^nS#^rND^sTraoré^nM#Ruling out pregnancy among family planning client
s: the impact of a checklist in three countries^len#Stud Fam Plann#20050000#2005
#36#4#311-5#20080200#07.htm#0039-3665#Stud Fam Plann##
00594000000000253000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080002000651180002000670170163000690180053002320660
00700285066001000292062000400302062000400306065000900310064000500319865000900324
002000700333#v23n2#v:\scielo\serial\rpsp\v23n2\markup\07.htm#S#c#58#3#article#7#
3#World Health Organization^dDepartment of Reproductive Health and Research, and
 Johns Hopkins Bloomberg School of Public Health/ Center for Communications Prog
rams#Family planning: a global handbook for providers^len#Geneva#Baltimore#WHO#C
CP#20070000#2007#20080200#07.htm##
00426000000000229000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080002000651180002000670170026000690180060000950660
00700155062000400162065000900166064000500175865000900180002000700189#v23n2#v:\sc
ielo\serial\rpsp\v23n2\markup\07.htm#S#c#59#4#article#7#4#World Health Organizat
ion#Selected practice recommendations for contraceptive use^len#Geneva#WHO#20040
000#2004#20080200#07.htm##
00641000000000325000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080002000651180002000670100018000690100017000870100
02500104010001800129010001600147012008500163030000700248065000900255064000500264
03100040026903200050027302000040027886500090028200200070029103500100029880100070
0308#v23n2#v:\scielo\serial\rpsp\v23n2\markup\07.htm#S#c#60#5#article#7#5#^rND^s
Stanback^nJ#^rND^sQureshi^nZ#^rND^sSekadde-Kigondu^nC#^rND^sGonzalez^nB#^rND^sNu
tley^nT#Checklist for ruling out pregnancy among family-planning clients in prim
ary care^len#Lancet#19990000#1999#354#9178#566#20080200#07.htm#0099-5355#Lancet#
#
00538000000000253000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080002000651180002000670160017000690160018000860160
02200104018008700126066000600213062003500219065000900254064000500263865000900268
002000700277#v23n2#v:\scielo\serial\rpsp\v23n2\markup\07.htm#S#c#61#6#article#7#
6#^rND^sHassan^nEO#^rND^sStanback^nJ#^rND^sEldamanhoury^nH#Validation of the pre
gnancy checklist in selected Egyptian family planning centers^len#Cairo#Egyptian
 Fertility Care Foundation#20050000#2005#20080200#07.htm##
00695000000000301000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080002000651180002000670100015000690100018000840100
01900102010001800121012017600139030001500315065000900330064000500339031000400344
020000400348865000900352002000700361035001000368801001500378#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\07.htm#S#c#62#7#article#7#7#^rND^sNanda^nK#^rND^sStanback^
nJ#^rND^sRountree^nRW#^rND^sCameron^nSB#Randomized trial of 'quick start' versus
 advance provision of oral contraceptive pills in Nicaragua: Annual Conference o
f the American College of Obstetrics and Gynecology^len#Obstet Gynecol#20060000#
2006#107#50S#20080200#07.htm#0029-7844#Obstet Gynecol##
00263000000000169000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640910009000660920007000750020007000827030
00400089#v23n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#o#1#1#article#1#20080
318#114749#08.htm#119##
02819000000000529000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000500084121000300089049000800092158000300100030002400103
03100030012703200020013006500090013201400110014103500100015201200990016201201130
02610100038003740100027004120100034004390100026004730100030004990700139005290700
16200668070015300830083116500983085000802148085004202156085002302198085003302221
085001902254117000602273072000302279002000702282#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\08.htm#S#h#2#1#article#1#oa#en#br1.1#1#3.1#ILUS#08#RPSP300#nd#Rev Pana
m Salud Publica#23#2#20080200#^f119^l124#1020-4989#Cardiovascular disease survei
llance in Mexicans and Mexican Americans: a tale of two countries^len#Enfermedad
 cardiovascular en mexicanos y estadounidenses de ascendencia mexicana: una hist
oria de dos países^les#^rND^1A01^nRamón Angel^sDurazo-Arvizu#^rND^1A02^nSimon^sB
arquera#^rND^1A03^nMariana^sLazo-Elizondo#^rND^1A03^nManuel^sFranco#^rND^1A01^nR
ichard S.^sCooper#University Stritch School of Medicine^iA01^1Department of Prev
entive Medicine and Epidemiology, Loyola^cIllinois^pUnited States of America#Ins
tituto Nacional de Salud PúblicaDepartamento de Enfermedades Crónicas y Dieta^iA
02^1Departamento de Enfermedades Crónicas y Dieta^cCuernavaca^sMorelos^pMéxico#J
ohn Hopkins University^iA03^1Johns Hopkins Bloomberg School of Public Health^2De
partment of Epidemiology^cBaltimore^sMaryland^pUnited States of America#^les^aLa
 migración a gran escala que tiene lugar actualmente de México a los Estados Uni
dos de América origina nuevos retos para la salud pública. Se deben diseñar polí
ticas de salud bien fundamentadas que aborden los problemas emergentes de salud 
en los estadounidenses de origen mexicano y otras subpoblaciones de los Estados 
Unidos. En este artículo se describe un enfoque que permite analizar la carga de
 las enfermedades cardiovasculares (ECV), tanto en mexicanos como en estadounide
nses de ascendencia mexicana (en el contexto de la sociedad que acaban de abando
nar). Estos datos se analizan también en el contexto de otras poblaciones de asc
endencia hispanoamericana. La caracterización rigurosa de la población migrante 
mexicana permitirá explicar el estado de salud de los estadounidenses de ascende
ncia mexicana. De manera similar, la copiosa experiencia en salud pública acumul
ada en los Estados Unidos puede ser útil en la lucha para controlar las ECV en M
éxico. El primer paso lógico puede ser alinear los sistemas existentes de datos 
de los dos países y describir los patrones fundamentales del desenlace y las sit
uaciones de riesgo de la enfermedad.#^dnd^i1#^tm^les^kenfermedades cardiovascula
res^i1#^tm^les^kvigilancia^i1#^tm^les^kmexicanos americanos^i1#^tm^les^kMéxico^i
1#other#28#08.htm##
02847000000000529000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000500084121000300089049000800092158000300100030002400103
03100030012703200020013006500090013201400110014103500100015201201130016201201270
02750100038004020100027004400100034004670100026005010100030005270700139005570700
16200696070015300858083116501011085000802176085004202184085002302226085003302249
085001902282117000602301072000302307002000702310#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\08.htm#S#f#3#1#article#1#oa#en#br1.1#1#3.1#ILUS#08#RPSP300#nd#Rev Pana
m Salud Publica#23#2#20080200#^f119^l124#1020-4989#<B>Cardiovascular disease sur
veillance in Mexicans and Mexican Americans</B>: <B>a tale of two countries</B>^
len#<B>Enfermedad cardiovascular en mexicanos y estadounidenses de ascendencia m
exicana</B>: <B>una historia de dos países</B>^les#^rND^1A01^nRamón Angel^sDuraz
o-Arvizu#^rND^1A02^nSimon^sBarquera#^rND^1A03^nMariana^sLazo-Elizondo#^rND^1A03^
nManuel^sFranco#^rND^1A01^nRichard S.^sCooper#University Stritch School of Medic
ine^iA01^1Department of Preventive Medicine and Epidemiology, Loyola^cIllinois^p
United States of America#Instituto Nacional de Salud PúblicaDepartamento de Enfe
rmedades Crónicas y Dieta^iA02^1Departamento de Enfermedades Crónicas y Dieta^cC
uernavaca^sMorelos^pMéxico#John Hopkins University^iA03^1Johns Hopkins Bloomberg
 School of Public Health^2Department of Epidemiology^cBaltimore^sMaryland^pUnite
d States of America#^les^aLa migración a gran escala que tiene lugar actualmente
 de México a los Estados Unidos de América origina nuevos retos para la salud pú
blica. Se deben diseñar políticas de salud bien fundamentadas que aborden los pr
oblemas emergentes de salud en los estadounidenses de origen mexicano y otras su
bpoblaciones de los Estados Unidos. En este artículo se describe un enfoque que 
permite analizar la carga de las enfermedades cardiovasculares (ECV), tanto en m
exicanos como en estadounidenses de ascendencia mexicana (en el contexto de la s
ociedad que acaban de abandonar). Estos datos se analizan también en el contexto
 de otras poblaciones de ascendencia hispanoamericana. La caracterización riguro
sa de la población migrante mexicana permitirá explicar el estado de salud de lo
s estadounidenses de ascendencia mexicana. De manera similar, la copiosa experie
ncia en salud pública acumulada en los Estados Unidos puede ser útil en la lucha
 para controlar las ECV en México. El primer paso lógico puede ser alinear los s
istemas existentes de datos de los dos países y describir los patrones fundament
ales del desenlace y las situaciones de riesgo de la enfermedad.#^dnd^i1#^tm^les
^kenfermedades cardiovasculares^i1#^tm^les^kvigilancia^i1#^tm^les^kmexicanos ame
ricanos^i1#^tm^les^kMéxico^i1#other#28#08.htm##
02955000000000553000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640640013000660710003000790400003000820010
00600085042000200091120000400093038000500097121000300102049000800105158000300113
03000260011603100030014203200020014506500090014701400110015603500100016701200990
01770120113002760100038003890100027004270100034004540100026004880100029005140700
14100543070016400684070015500848083116501003085000802168085004202176085002302218
085003302241085001902274117000602293072000302299002000702302008009202309#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\08.htm#S#l#4#1#article#1#^mFeb.^a2008#oa#en#br
1.1#1#3.1#ilus#08#RPSP300#nd#Rev. panam. salud pública#23#2#20080200#^f119^l124#
1020-4989#Cardiovascular disease surveillance in Mexicans and Mexican Americans:
 a tale of two countries^len#Enfermedad cardiovascular en mexicanos y estadounid
enses de ascendencia mexicana: una historia de dos países^les#^rND^1A01^nRamón A
ngel^sDurazo-Arvizu#^rND^1A02^nSimon^sBarquera#^rND^1A03^nMariana^sLazo-Elizondo
#^rND^1A03^nManuel^sFranco#^rND^1A01^nRichard S^sCooper#^iA01^1University Stritc
h School of Medicine^2Department of Preventive Medicine and Epidemiology, Loyola
^cIllinois^pUnited States of America#^iA02^1Instituto Nacional de Salud PúblicaD
epartamento de Enfermedades Crónicas y Dieta^2Departamento de Enfermedades Cróni
cas y Dieta^cCuernavaca^sMorelos^pMéxico#^iA03^1John Hopkins University^2Johns H
opkins Bloomberg School of Public Health^3Department of Epidemiology^cBaltimore^
sMaryland^pUnited States of America#^les^aLa migración a gran escala que tiene l
ugar actualmente de México a los Estados Unidos de América origina nuevos retos 
para la salud pública. Se deben diseñar políticas de salud bien fundamentadas qu
e aborden los problemas emergentes de salud en los estadounidenses de origen mex
icano y otras subpoblaciones de los Estados Unidos. En este artículo se describe
 un enfoque que permite analizar la carga de las enfermedades cardiovasculares (
ECV), tanto en mexicanos como en estadounidenses de ascendencia mexicana (en el 
contexto de la sociedad que acaban de abandonar). Estos datos se analizan tambié
n en el contexto de otras poblaciones de ascendencia hispanoamericana. La caract
erización rigurosa de la población migrante mexicana permitirá explicar el estad
o de salud de los estadounidenses de ascendencia mexicana. De manera similar, la
 copiosa experiencia en salud pública acumulada en los Estados Unidos puede ser 
útil en la lucha para controlar las ECV en México. El primer paso lógico puede s
er alinear los sistemas existentes de datos de los dos países y describir los pa
trones fundamentales del desenlace y las situaciones de riesgo de la enfermedad.
#^dnd^i1#^tm^les^kenfermedades cardiovasculares^i1#^tm^les^kvigilancia^i1#^tm^le
s^kmexicanos americanos^i1#^tm^les^kMéxico^i1#other#28#08.htm#Internet^ihttp://w
ww.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892008000200008##
00380000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704016000067002000700227#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#5#1#article#87#<p align="right"><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>OPINI&Oacute;N    Y AN&Aacut
e;LISIS</b> OPINION AND ANALYSIS</font></p>     ^cY#08.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704002200067002000700089#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#6#2#article#87#<p>&nbsp;</p>     ^cY#08.htm
##
00425000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704020500067002000700272#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#7#3#article#87#<p><a name="top"></a><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Cardiovascular    diseas
e surveillance in Mexicans and Mexican Americans: a tale of two countries</b></f
ont></p>     ^cY#08.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704002200067002000700089#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#8#4#article#87#<p>&nbsp;</p>     ^cY#08.htm
##
00431000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704021100067002000700278#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#9#5#article#87#<p><font face="Verdana, Aria
l, Helvetica, sans-serif" size="3"><b>Enfermedad cardiovascular    en mexicanos 
y estadounidenses de ascendencia mexicana: una historia de dos    pa&iacute;ses<
/b></font></p>     ^cY#08.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704002200068002000700090#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#10#6#article#87#<p>&nbsp;</p>     ^cY#08.ht
m##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704002200068002000700090#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#11#7#article#87#<p>&nbsp;</p>     ^cY#08.ht
m##
00513000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704029200068002000700360#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#12#8#article#87#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><b>Ram&oacute;n    Angel Durazo-Arvizu<sup>I
, <a href="#back">*</a></sup>; Simon Barquera<sup>II</sup>;    Mariana Lazo-Eliz
ondo<sup>III</sup>; Manuel Franco<sup>III</sup>; Richard S.    Cooper<sup>I</sup
></b></font></p>     ^cY#08.htm##
00451000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704023000068002000700298#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#13#9#article#87#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><sup>I</sup>Department    of Preventive Medi
cine and Epidemiology, Loyola University Stritch School of    Medicine, Maywood,
 Illinois, United States of America    ^cY#08.htm##
00385000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704016300069002000700232#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#14#10#article#87#<br>   <sup>II</sup>Depart
amento de Enfermedades Cr&oacute;nicas y Dieta, Instituto    Nacional de Salud P
&uacute;blica, Cuernavaca, Morelos, M&eacute;xico    ^cY#08.htm##
00416000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704019400069002000700263#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#15#11#article#87#<br>   <sup>III</sup>Depar
tment of Epidemiology, Johns Hopkins Bloomberg School of    Public Health, John 
Hopkins University, Baltimore, Maryland, United States of    America</font></p> 
    ^cY#08.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#16#12#article#87#<p>&nbsp;</p>     ^cY#08.h
tm##
00266000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704004400069002000700113#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#17#13#article#87#<p>&nbsp;</p> <hr size="1"
 noshade>     ^cY#08.htm##
00413000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704019100069002000700260#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#18#14#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Key words:</b>    cardiovascular disease
s, surveillance, Mexican Americans, Mexico.</font></p> <hr size="1" noshade>    
 ^cY#08.htm##
00320000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704009800069002000700167#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#19#15#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>SINOPSIS</b></font></p>     ^cY#08.htm##
01623000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704140100069002000701470#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#20#16#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">La migraci&oacute;n    a gran escala que ti
ene lugar actualmente de M&eacute;xico a los Estados Unidos    de Am&eacute;rica
 origina nuevos retos para la salud p&uacute;blica. Se deben    dise&ntilde;ar p
ol&iacute;ticas de salud bien fundamentadas que aborden los    problemas emergen
tes de salud en los estadounidenses de origen mexicano y otras    subpoblaciones
 de los Estados Unidos. En este art&iacute;culo se describe un    enfoque que pe
rmite analizar la carga de las enfermedades cardiovasculares (ECV),    tanto en 
mexicanos como en estadounidenses de ascendencia mexicana (en el contexto    de 
la sociedad que acaban de abandonar). Estos datos se analizan tambi&eacute;n    
en el contexto de otras poblaciones de ascendencia hispanoamericana. La caracter
izaci&oacute;n    rigurosa de la poblaci&oacute;n migrante mexicana permitir&aac
ute; explicar    el estado de salud de los estadounidenses de ascendencia mexica
na. De manera    similar, la copiosa experiencia en salud p&uacute;blica acumula
da en los Estados    Unidos puede ser &uacute;til en la lucha para controlar las
 ECV en M&eacute;xico.    El primer paso l&oacute;gico puede ser alinear los sis
temas existentes de datos    de los dos pa&iacute;ses y describir los patrones f
undamentales del desenlace    y las situaciones de riesgo de la enfermedad.</fon
t></p>     ^cY#08.htm##
00432000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704021000069002000700279#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#21#17#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Palabras clave:</b>    enfermedades card
iovasculares, vigilancia, mexicanos americanos, M&eacute;xico.</font></p> <hr si
ze="1" noshade>     ^cY#08.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#22#18#article#87#<p>&nbsp;</p>     ^cY#08.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#23#19#article#87#<p>&nbsp;</p>     ^cY#08.h
tm##
01266000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704104400069002000701113#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#24#20#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Throughout its    history, the United State
s has consistently received large numbers of immigrants    from around the world
. Most early immigration originated in Europe, but the    more recent influx has
 been dominated by people from Asia and Latin America    (1). In the year 2002, 
the number of people of Hispanic origin in the United    States reached over 37 
million (2). The vast majority of this U.S. subpopulation    are of Mexican desc
ent (66.9%), with smaller proportions represented by Central    and South Americ
ans (14.3%), Puerto Ricans (8.6%), Cubans (3.7%), and other    Hispanics (6.5%) 
(2). In March 2003, it was estimated that 53.3% of the 33.5    million immigrant
s in the United States were born in Latin America. Two-thirds    of those born i
n Latin America are from Mexico and Central America. Foreign-born    Mexicans in
 the United States currently number 11.9 million (2, 3), 13.6% of    whom entere
d the country since the year 2000 (3).</font></p>     ^cY#08.htm##
01137000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704091500069002000700984#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#25#21#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The rapid growth    of the Hispanic populat
ion in the United States has enormous implications for    public health. Taken t
ogether with substantial migration from Asia, the arrival    of over 350 000 peo
ple per year from Mexico (4, 5) requires revision of the    current framework us
ed in health-related population research. In the most concrete    terms, nationa
l health statistics data must now be presented with at least two    additional c
olumns for Hispanics and Asians. Embedded in the transition to surveillance    f
or additional racial/ethnic subgroups is a series of complex technical and    co
nceptual challenges. Most prominently, there is an urgent need to understand    
the significance of the markedly reduced mortality from cardiovascular disease  
  (CVD) among Mexican Americans that is reported by official sources.</font></p>
     ^cY#08.htm##
01103000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704088100069002000700950#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#26#22#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Surprisingly, limited    effort has been ma
de to understand the evolving health status of this immigrant    population with
in the context of their country of origin. In the absence of    highly selective
 migration, the health status of recent Mexican immigrants should    closely res
emble that of Mexicans. Due to a substantial investment in surveillance    syste
ms over the last decade, nationally representative data are now available    fro
m Mexico. It should be possible, therefore, to describe an integrated approach  
  to understanding the burden of CVD among Mexicans and Mexican Americans by com
paring    results from these national data sources. These data should also be co
mpared    to data on other Hispanic subpopulations in the United States, and the
ir respective    country of origin.</font></p>     ^cY#08.htm##
00335000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704011300069002000700182#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#27#23#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Surveillance    for CVD</b></font></p>  
   ^cY#08.htm##
00805000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704058300069002000700652#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#28#24#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Surveillance&#151;monitoring    and reporti
ng on major health conditions&#151;is a core function of public health    care s
ystems, and developed countries have well-established frameworks for carrying   
 it out. Surveillance for CVD, however, presents an unusual set of challenges   
 (6). It requires three main components: (1) tracking of national CVD mortality,
    (2) monitoring of risk factors, and (3) assessment of the availability and i
mpact    of public health interventions and medical care.</font></p>     ^cY#08.
htm##
00835000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704061300069002000700682#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#29#25#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Mortality</b>.    Cause-specific mortali
ty trends have become the most widely used public health    indicator for explai
ning changes in CVD epidemiology. Despite the potential    risk of skewed result
s from inconsistent death certificate coding, these data    are often the only r
ealistic option for true national surveillance of CVD. Other    measures of CVD 
disease occurrence, such as prevalence and incidence, are difficult    to estima
te accurately within a population because of a high proportion of undiagnosed   
 cases.</font></p>     ^cY#08.htm##
00877000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704065500069002000700724#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#30#26#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Risk factors</b>.    Surveys based on re
presentative samples provide the best source of data for    monitoring and evalu
ation of CVD risk factors. Efficient methods exist for obtaining    systematic p
opulation-wide prevalence rates and global CVD risk estimates based    on recurr
ing surveys such as the National Health Survey (<i>Encuesta Nacional    de Salud
</i>, ENSA) in Mexico (7) and the National Health and Nutrition Examination    S
urvey (NHANES) in the United States (8). These data can also be used to guide   
 public policy and directly inform interventions.</font></p>     ^cY#08.htm##
00972000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704075000069002000700819#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#31#27#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Public health    interventions and medic
al care</b>. Major advances are occurring in CVD clinical    care. Therefore, in
 order to be maximally informative, CVD surveillance must    provide information
 on CVD risk factor detection and control rates as well as    treatment and care
 (e.g., distribution of surgical and catheter-based interventions).    While tre
atment and control rates of hypertension, for example, can be determined    from
 national population surveys, monitoring uptake of hospital-based medical    car
e requires an additional system component for collecting data on individual    p
atients as the frequency of use of cardiac procedures increases.</font></p>     
^cY#08.htm##
00703000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704048100069002000700550#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#32#28#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Over the past several    decades, all three
 components described above have been incorporated in population    sampling for
 European surveillance, known collectively as MONICA (multinational    MONItorin
g of trends and determinants in CArdiovascular disease). Only limited    use has
 been made of this approach in the United States, however, and no similar    stu
dies have been conducted in Mexico.</font></p>     ^cY#08.htm##
00336000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704011400069002000700183#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#33#29#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Secular trends    in CVD</b></font></p> 
    ^cY#08.htm##
01602000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704138000069002000701449#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#34#30#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">CVD rates are changing    rapidly in both i
ndustrialized and nonindustrialized countries. The United States,    Canada, Aus
tralia, and most of Western Europe have all experienced declines    in stroke mo
rtality since vital statistics were first recorded in the early    20<sup>th</su
p> century. National data on coronary (ischemic) heart disease    (CHD) became a
vailable in the United States through changes in death certificate    coding in 
the period after World War II. Steep increases in mortality due to    CHD were t
hen observed until 1968, when CHD mortality began to drop sharply    (9). A simi
lar decline in CHD was subsequently described in most industrialized    countrie
s, including Australia, Canada, and much of Western Europe (10). Since    1968, 
age-adjusted mortality from stroke has declined almost 75% in the United    Stat
es, while CHD has dropped by 60% (11). It is estimated that approximately    one
-third to one-half of this decline is directly related to lower levels of    ris
k factors (12&#150;14). Much of the remaining effect is attributed to better    
clinical care and tertiary prevention. Achieving reductions in CVD mortality    
similar to those in the United States is now one of the most important public   
 health challenges facing nonindustrialized countries.</font></p>     ^cY#08.htm
##
01201000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704097900069002000701048#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#35#31#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">While effective    data systems have been d
eveloped in most industrialized countries, little is    known about the national
 CVD burden or its related trends in middle-income and    poor countries (15). N
umerous articles have focused on the growing CVD epidemic    in these countries,
 highlighting the difficulties in implementing effective    control strategies w
hen medical care infrastructure is weak. A prerequisite    for effective control
, however, is adequate surveillance. It is unlikely that    substantive, sustain
able reductions in the CVD burden will be achieved without    better surveillanc
e tools to guide national CVD control strategies, most of    which are based on 
the experiences of industrialized countries. The framework    for applying these
 tools, which correlate trends in risk factors with disease    outcomes, has bee
n used to great advantage in many countries (16, 17).</font></p>     ^cY#08.htm#
#
00715000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704049300069002000700562#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#36#32#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Designed to enable    similar reductions in
 the CVD burden among Mexicans and Mexican Americans, the    proposals below inc
lude suggested lines of research to help define CVD surveillance    in these pop
ulations, as well as some general demographic and mortality information    about
 the population of Mexican descent to help clarify the nature of the ongoing    
migration between Mexico and the United States.</font></p>     ^cY#08.htm##
00372000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704015000069002000700219#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#37#33#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Measuring CVD    burden among Mexicans a
nd Mexican Americans</b></font></p>     ^cY#08.htm##
00919000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704069700069002000700766#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#38#34#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Mexico has a robust    public health system
 with a high-quality vital registration system; a complex    medical care system
; and recurrent, nationally representative surveys of risk    factors. However, 
attempts to characterize the CVD epidemic for surveillance    purposes, includin
g collection of CVD mortality statistics and surveys of CVD    risk factors, hav
e been limited. At present, substantial work is needed to define    the validity
 and consistency of death records and to construct trend lines for    major vasc
ular conditions, including heart disease, stroke, and the emerging    epidemic o
f diabetes.</font></p>     ^cY#08.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#39#35#article#87#<p>&nbsp;</p>     ^cY#08.h
tm##
00319000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704009700069002000700166#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#40#36#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>METHODS</b></font></p>     ^cY#08.htm##
01602000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704138000069002000701449#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#41#37#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Vital statistics    from Mexico, the United
 States, Puerto Rico, and Cuba were obtained for 5-year    incremental age group
s and used to calculate age-adjusted mortality rates from    cardiovascular dise
ase and diabetes in the various countries. Mortality rates    are presented per 
100 000 population, adjusted to the adult (20&#150;84-year)    U.S. population i
n the year 2000 to facilitate comparisons across time and countries.    Direct s
tandardization was applied in all cases (18). Standardization is necessary,    g
iven that over 69% of the adult Mexican population is young (20&#150;44 years   
 old), compared to 51% in the United States, according to the 2000 census in    
the respective countries. In addition, 17.7% of adults in the United States    a
re over the age of 65, whereas only 8.3% in Mexico belong to this age group.    
Based on disease codes from the 10<sup>th</sup> revision of the World Health    
Organization (WHO) International Statistical Classification of Diseases and    R
elated Health Problems (ICD-10), mortality is reported for total cardiovascular 
   disease (CVD; ICD I00&#150;I99), including total heart disease (HD; ICD I05&#
150;I52),    coronary heart disease (CHD; ICD I20&#150;I25), and stroke (ICD I60
&#150;I69),    as well as diabetes (ICD E10&#150;E14).</font></p>     ^cY#08.htm
##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#42#38#article#87#<p>&nbsp;</p>     ^cY#08.h
tm##
00319000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704009700069002000700166#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#43#39#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>RESULTS</b></font></p>     ^cY#08.htm##
01040000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704081800069002000700887#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#44#40#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The estimated CVD    and diabetes mortality
 rates are shown in <a href="/img/revistas/rpsp/v23n2/08t1.gif">Table    1</a>, 
based on vital statistics records from Mexico, the United States, Puerto    Rico
, and Cuba. These figures indicate that in comparison to the general population 
   of the United States, mortality from heart disease in Mexico in the year 2000
    was 27% lower (174 vs. 239 per 100 000, respectively), whereas stroke was 33
%    higher (68 vs. 51 per 100 000, respectively). Surprisingly, mortality from 
diabetes    in Mexico for the year 2000 was reported to be almost fivefold highe
r than in    the United States (138 vs. 28 per 100 000, respectively) and is cur
rently listed    as the leading cause of death (19).</font></p>     ^cY#08.htm##
01300000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704107800069002000701147#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#45#41#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a href="/img/revistas/rpsp/v23n2/08t2.gif"
>Table    2</a> depicts estimated mortality from CVD in the various U.S. subpopu
lations    and in Mexican, Cuban, and Puerto Rican populations. Among men and wo
men in    the United States, Mexican Americans have lower mortality rates from t
otal cardiovascular    disease&#151;including total heart disease and coronary h
eart disease&#151;than    non-Hispanic whites, African Americans, and Puerto Ric
an Americans, but higher    rates for each of these disease categories than Cuba
n Americans. Stroke rates    among Mexican Americans are lower than those for Af
rican Americans, but higher    than those for any of the other ethnic groups con
sidered. In addition, women    in Mexico have higher rates for total cardiovascu
lar disease, heart disease,    and coronary heart disease than Puerto Rican wome
n, whereas (with the exception    of stroke) the opposite is observed among men.
 Stroke rates are lower among    Puerto Ricans than Cubans and Mexicans.</font><
/p>     ^cY#08.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#46#42#article#87#<p>&nbsp;</p>     ^cY#08.h
tm##
00322000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704010000069002000700169#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#47#43#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>CONCLUSION</b></font></p>     ^cY#08.htm
##
02210000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704198800069002000702057#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#48#44#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In aggregate, Hispanics    are the largest 
minority population in the United States, and two-thirds of    this subpopulatio
n are Mexican Americans. Despite considerable debate, the CVD    burden in this 
population has not been adequately described. At present, it    is crucial to ob
tain reliable information about current levels of CVD and trends.    Routine vit
al statistics data as well as cohort studies based on national samples    demons
trate that Hispanic Americans have total mortality rate ratios of approximately 
   0.65 relative to whites (20&#150;23). However, local studies from Texas sugge
st    Hispanic Americans have higher CVD rates than non-Hispanic whites (24, 25)
.    As noted, mortality reports from Mexico suggest lower rates of coronary hea
rt    disease but greater mortality from stroke and diabetes compared to the tot
al    U.S. population. Because there is usually a one-generation time lag before
 migrant    populations lose the mortality structure of their country of origin,
 these data    raise questions about the validity of Mexican American vital stat
istics in the    United States. Assuming that&#151;with more consistent death ce
rtificate coding&#151;stroke    can be considered a "sentinel condition," and th
at the vital records comparison    between the United States and Mexico in <a hr
ef="/img/revistas/rpsp/v23n2/08t1.gif">Table    1</a> is valid, then the reporte
d rates for stroke among Mexican Americans shown    in <a href="/img/revistas/rp
sp/v23n2/08t2.gif">Table 2</a> are underestimated    by almost 22% (53 vs. 68 pe
r 100 000). In this regard, the comparability of    the counting systems used to
 estimate numerators (i.e., deaths) and denominators    (i.e., population) needs
 to be carefully considered. In order to develop an    effective CVD control str
ategy, better surveillance methods will need to be    implemented for the Mexica
n American population.</font></p>     ^cY#08.htm##
00794000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704057200069002000700641#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#49#45#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The most striking    feature of the United 
States&#150;Mexico comparison is the markedly higher mortality    ascribed to di
abetes in Mexico. These data need to be analyzed within the context    of risk f
actor prevalence rates from the population surveys that document lower    diabet
es prevalence in Mexico. While these higher mortality rates could reflect,    in
 part, lower levels of medical attention, the discrepancy between prevalence    
and recorded death rates needs to be explored.</font></p>     ^cY#08.htm##
00329000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704010700069002000700176#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#50#46#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Future directions</b></font></p>     ^cY
#08.htm##
02352000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704213000069002000702199#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#51#47#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Much of the public    health literature in 
the United States concerning the health status of Latin    American immigrants o
ver the past several decades has been organized around    the concept of the "Hi
spanic paradox." This concept grew out of the observation    that despite a limi
ted educational background and low occupational status, the    health experience
 of Spanish-speaking immigrants has been quite favorable relative    to the majo
rity population. This so-called paradox should be viewed with caution,    howeve
r, as it is apparent that the framework used to define it stems from culturally 
   specific expectations from within the United States, where "low socioeconomic
    status" is viewed as a powerful and independent negative force determining h
ealth    experiences. In addition, myriad different cultural practices exist amo
ng populations    labeled as "Hispanic" in the United States, many of which may 
have either positive    or negative influences on health. Therefore, many questi
ons have been raised    regarding the validity of the "Hispanic paradox" (24, 26
, 27). Other approaches    for gathering and analyzing data need to be undertake
n, however, before this    concept is totally dismissed. A suggested alternative
 approach would focus on    the populations of the various countries of origin. 
Based on the U.S. census    for the year 2000 (28), the Hispanic population can 
be divided into five main    categories: (1) Mexican Americans (59.3%), by far t
he largest group, accounting    for more than one-third of a million new U.S. im
migrants per year; (2) Cuban    Americans (3.5%), an established U.S. subpopulat
ion with limited ongoing migration;    (3) Puerto Rican Americans (9.7%)&#151;de
spite U.S. citizenship, this group    remains distinct from the majority U.S. po
pulation due to its ongoing bidirectional    migration and retention of Latin Am
erican culture; (4) Central Americans (5.1%),    including many persons seeking 
high-wage employment; and (5) South Americans    (4.0%) and other Hispanics (18.
3%).</font></p>     ^cY#08.htm##
01206000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704098400069002000701053#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#52#48#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">It should be noted    that various mechanis
ms rooted in the nature of the economic transitions occurring    in specific sou
rce countries as a result of globalization could affect CVD patterns    in the r
espective country population. Many societies recently articulated by    the glob
al economy exhibit patterns of disease risk that are the inverse of    those fou
nd in mature capitalist countries (e.g., in Mexico, persons with lower    educat
ional level are less likely to smoke cigarettes, which is the inverse    of the 
situation in the United States). Therefore, understanding of CVD patterns    amo
ng Mexican Americans will be greatly enhanced by taking account of experiences  
  in both the United States and Mexico, as well as the current large-scale migra
tion    between the two countries, and by abandoning the use of the category "Hi
spanic,"    which aggregates dissimilar population groups.</font></p>     ^cY#08
.htm##
01163000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704094100069002000701010#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#53#49#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Much can be learned    by viewing the healt
h status of Mexican Americans as the extension and natural    evolution of the e
xperience in Mexico. A rigorous characterization of the Mexican    migrant popul
ation will shed light on their health status and disease burden.    Likewise, U.
S. public health data extrapolated from CVD monitoring to guide    CVD intervent
ion strategies could also be applied to CVD control strategies    in Mexico. A f
irst logical step toward integrating the knowledge base from Mexico    would be 
to align existing data systems in the two countries and to describe    the under
lying patterns of disease outcomes and risk status. The feasibility    and effec
tiveness of the U.S. control strategy could then be evaluated within    the Mexi
can context. To initiate this process, the following lines of research    are su
ggested:</font></p> <ul>       ^cY#08.htm##
00415000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704019300069002000700262#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#54#50#article#87#<li><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Describe the      health-related character
istics of those migrating from Mexico to the United      States;</font></li>    
   ^cY#08.htm##
00457000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704023500069002000700304#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#55#51#article#87#<li><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Describe the      epidemiology of CVD in M
exico, using the country's robust national data sets,      which allow for ongoi
ng surveillance of trends;</font></li>       ^cY#08.htm##
00452000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704023000069002000700299#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#56#52#article#87#<li><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Use the knowledge      gained from studies
 in Mexico to shed light on the transitional health status      observed among M
exican Americans; and</font></li>       ^cY#08.htm##
00569000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704034700069002000700416#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#57#53#article#87#<li><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Use the information      generated by the 
lines of research suggested above to identify challenges      and opportunities 
that might be useful in defining new policy initiatives      to improve cardiova
scular health among populations on both sides of the border.</font></li>     ^cY
#08.htm##
00236000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704001400069002000700083#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#58#54#article#87#</ul>     ^cY#08.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#59#55#article#87#<p>&nbsp;</p>     ^cY#08.h
tm##
00322000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704010000069002000700169#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#60#56#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>REFERENCES</b></font></p>     ^cY#08.htm
##
00449000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704021300071002000700284#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#p#61#57#article#87#1#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;1.&nbsp;Taylor    Bell 
M. Immigration: a megatrends backgrounder. Lexington (KY): The Council    of Sta
te Governments; 2004.</font></p>     ^cY#08.htm##
00503000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704026700071002000700338#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#p#62#58#article#87#2#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;2.&nbsp;Ramirez    RR, 
de la Cruz GP. The Hispanic population in the United States: March 2002.    Curr
ent Population Reports, P20&#150;545. Washington: U.S. Census Bureau; 2003.</fon
t></p>     ^cY#08.htm##
00485000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704024900071002000700320#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#p#63#59#article#87#3#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;3.&nbsp;Larsen    LJ. T
he foreign-born population in the United States: 2003. Current Population    Rep
orts, P20&#150;551. Washington: U.S. Census Bureau; 2004.</font></p>     ^cY#08.
htm##
00488000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704025200071002000700323#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#p#64#60#article#87#4#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;4.&nbsp;L&oacute;pez   
 DA. Migraci&oacute;n en M&eacute;xico: datos de 1990 al 2000. Notas Revista    
de Informaci&oacute;n y An&aacute;lysis. 2002;19:45&#150;51.</font></p>     ^cY#
08.htm##
00613000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704037700071002000700448#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#p#65#61#article#87#5#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;5.&nbsp;L&oacute;pez   
 DA. Migraci&oacute;n de mexicanos desde y hacia Estados Unidos de Am&eacute;ric
a:    estad&iacute;sticas, problem&aacute;ticas y retos. Bolet&iacute;n de los S
istemas    Nacionales Estad&iacute;stico y de Informaci&oacute;n Geogr&aacute;fi
ca. 2004;1(2):21&#150;38.</font></p>     ^cY#08.htm##
00472000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704023600071002000700307#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#p#66#62#article#87#6#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;6.&nbsp;Labarthe    DR.
 Epidemiology and prevention of cardiovascular diseases: a global challenge.    
Gaithersburg (MD): Aspen Publications; 1998.</font></p>     ^cY#08.htm##
00556000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704032000071002000700391#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#p#67#63#article#87#7#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;7.&nbsp;Olaiz    G, Roj
as R, Barquera S, Shamah T, Aguilar C, Cravioto P. Encuesta Nacional de    Salud
 2000. Tomo 2: La salud de los adultos. Cuernavaca, Morelos, M&eacute;xico:    I
nstituto Nacional de Salud P&uacute;blica; 2003.</font></p>     ^cY#08.htm##
00583000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704034700071002000700418#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#p#68#64#article#87#8#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;8.&nbsp;U.S.    Departm
ent of Health and Human Services, Centers for Disease Control and Prevention,   
 National Center for Health Statistics. National Health and Nutrition Examinatio
n    Survey (NHANES) 1999&#150; 2004. Hyattsville (MD): US-DHHS-NCHS; 2005.</fon
t></p>     ^cY#08.htm##
00524000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704028800071002000700359#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#p#69#65#article#87#9#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">&nbsp;9.&nbsp;Levi    F, Lucc
hini F, Negri E, La Vecchia C. Trends in mortality from cardiovascular    and ce
rebrovascular diseases in Europe and other areas of the world. Heart.    2002;88
(2):119&#150;24.</font></p>     ^cY#08.htm##
00492000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704025500072002000700327#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#p#70#66#article#87#10#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">10.&nbsp;Cooper    R, Stamle
r J, Dyer A, Garside D. The decline in mortality from coronary heart    disease,
 U.S.A., 1968&#150;1975. J Chronic Dis. 1978;31(12):709&#150;20.</font></p>     
^cY#08.htm##
00649000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704041200072002000700484#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#p#71#67#article#87#11#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">11.&nbsp;Cooper    R, Cutler
 J, Desvigne-Nickens P, Fortmann SP, Fiedman L, Havlik R, et al. Trends    and d
isparities in coronary heart disease, stroke, and other cardiovascular    diseas
es in the United States: findings of the National Conference on Cardiovascular  
  Disease Prevention. Circulation. 2000;102(25):3137&#150;47.</font></p>     ^cY
#08.htm##
00585000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704034800072002000700420#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#p#72#68#article#87#12#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">12.&nbsp;Goldman    L, Phill
ips KA, Coxson P, Goldman PA, Williams L, Hunink MG, et al. The effect    of ris
k factor reductions between 1981 and 1990 on coronary heart disease incidence,  
  prevalence, mortality and cost. J Am Coll Cardiol. 2001;38(4):1012&#150;17.</f
ont></p>     ^cY#08.htm##
00547000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704031000072002000700382#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#p#73#69#article#87#13#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">13.&nbsp;Taylor    R, Dobson
 A, Mirzaei M. Contribution of changes in risk factors to the decline    of coro
nary heart disease mortality in Australia over three decades. Eur J Cardiovasc  
  Prev Rehabil. 2006; 13(5):760&#150;8.</font></p>     ^cY#08.htm##
00502000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704026500072002000700337#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#p#74#70#article#87#14#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">14.&nbsp;Soltero    I, Liu K
, Cooper R, Stamler J, Garside D. Trends in mortality from cerebrovascular    di
seases in the United States, 1960 to 1975. Stroke. 1978;9(6): 549&#150;58.</font
></p>     ^cY#08.htm##
00560000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704032300072002000700395#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#p#75#71#article#87#15#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">15.&nbsp;Yusuf    S, Reddy S
, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part    I: genera
l considerations, the epidemiologic transition, risk factors, and impact    of u
rbanization. Circulation. 2001;104(22):2746&#150;53.</font></p>     ^cY#08.htm##
00571000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704033400072002000700406#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#p#76#72#article#87#16#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">16.&nbsp;Cheng    Y, Chen KJ
, Wang CJ, Chan SH, Chang WC, Chen JH. Secular trends in coronary    heart disea
se mortality, hospitalization rates, and major cardiovascular risk    factors in
 Taiwan, 1971&#150;2001. Int J Cardiol. 2005;100(1):47&#150;52.</font></p>     ^
cY#08.htm##
00548000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704031100072002000700383#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#p#77#73#article#87#17#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">17.&nbsp;Laatikainen    T, C
ritchley J, Vartiainen E, Salomaa V, Ketonen M, Capewell S. Explaining the    de
cline in coronary heart disease mortality in Finland between 1982 and 1997.    A
m J Epidemiol. 2005; 162(8):764&#150;73.</font></p>     ^cY#08.htm##
00428000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704019100072002000700263#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#p#78#74#article#87#18#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">18.&nbsp;Pagano    M, Gauvre
au K. Principles of biostatistics. 2nd ed. Pacific Grove (CA): Duxbury;    2000.
</font></p>     ^cY#08.htm##
00530000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704029300072002000700365#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#p#79#75#article#87#19#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">19.&nbsp;M&eacute;xico,    S
ecretar&iacute;a de Salud. Estad&iacute;sticas de mortalidad en M&eacute;xico:  
  muertes registradas en el a&ntilde;o 2003. Salud P&uacute;blica M&eacute;x.   
 2005;47:171&#150;187.</font></p>     ^cY#08.htm##
00532000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704029500072002000700367#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#p#80#76#article#87#20#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">20.&nbsp;Liao Y,    Cooper R
S, Cao G, Durazo-Arvizu R, Kaufman JS, Luke A, et al. Mortality patterns    amon
g adult Hispanics: findings from the NHIS, 1986 to 1990. Am J Public Health.    
1998;88(2): 227&#150;32.</font></p>     ^cY#08.htm##
00597000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704036000072002000700432#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#p#81#77#article#87#21#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">21.&nbsp;Liao Y,    Cooper R
S, Cao G, Kaufman JS, Long AE, McGee DL. Mortality from coronary heart    diseas
e and cardiovascular disease among adult U.S. Hispanics: findings from    the Na
tional Health Interview Survey (1986 to 1994). J Am Coll Cardiol. 1997;30(5):120
0&#150;5.</font></p>     ^cY#08.htm##
00513000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704027600072002000700348#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#p#82#78#article#87#22#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">22.&nbsp;Swenson    CJ, Trep
ka MJ, Rewers MJ, Scarbro S, Hiatt WR, Hamman RF. Cardiovascular disease    mort
ality in Hispanics and non-Hispanic whites. Am J Epidemiol. 2002;156(10):919&#15
0;28.</font></p>     ^cY#08.htm##
00518000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704028100072002000700353#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#p#83#79#article#87#23#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">23.&nbsp;Thomas    AJ, Eberl
y LE, Neaton JD, Smith GD. Latino risk-adjusted mortality in the men    screened
 for the Multiple Risk Factor Intervention Trial. Am J Epidemiol. 2005;162(6):56
9&#150;78.</font></p>     ^cY#08.htm##
00631000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704039400072002000700466#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#p#84#80#article#87#24#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">24.&nbsp;Hunt KJ,    Resende
z RG, Williams K, Haffner SM, Stern MP, Hazuda HP. All-cause and cardiovascular 
   mortality among Mexican-American and non-Hispanic White older participants in
    the San Antonio Heart Study&#151;evidence against the "Hispanic paradox." Am
    J Epidemiol. 2003;158(11):1048&#150;57.</font></p>     ^cY#08.htm##
00575000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704033800072002000700410#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#p#85#81#article#87#25#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">25.&nbsp;Pandey    DK, Labar
the DR, Goff DC, Chan W, Nichaman MZ. Community-wide coronary heart    disease m
ortality in Mexican Americans equals or exceeds that in non-Hispanic    whites: 
the Corpus Christi Heart Project. Am J Med. 2001; 110(2):81&#150;7.</font></p>  
   ^cY#08.htm##
00486000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704024900072002000700321#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#p#86#82#article#87#26#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">26.&nbsp;Lerman-Garber    I,
 Villa AR, Caballero E. Diabetes and cardiovascular disease: is there a true    
Hispanic paradox? Rev Invest Clin. 2004;56(3):282&#150;96.</font></p>     ^cY#08
.htm##
00519000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704028200072002000700354#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#p#87#83#article#87#27#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">27.&nbsp;Smith    DP, Bradsh
aw BS. Rethinking the Hispanic paradox: death rates and life expectancy    for U
S non-Hispanic white and Hispanic populations. Am J Public Health. 2006;96(9):16
86&#150;92.</font></p>     ^cY#08.htm##
00478000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704024100072002000700313#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#p#88#84#article#87#28#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">28.&nbsp;Ramirez    RR. We t
he People: Hispanics in the United States: CENSR-18. (Census 2000 Special    Rep
ort). Washington: U.S. Bureau of the Census; 2004.</font></p>     ^cY#08.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#89#85#article#87#<p>&nbsp;</p>     ^cY#08.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#90#86#article#87#<p>&nbsp;</p>     ^cY#08.h
tm##
00749000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704052700069002000700596#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\08.htm#S#p#91#87#article#87#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#top">*</a>    
Send correspondence and reprint requests to: Ram&oacute;n Angel Durazo-Arvizu,  
  Associate Professor, Department of Preventive Medicine and Epidemiology, Loyol
a    University Stritch School of Medicine, 2160 S. First Avenue, Building 105, 
Maywood,    IL 60153, United States of America; telephone: (708) 327-9007; fax: 
(708) 327-9009;    e-mail: <a href="mailto:rdurazo@lumc.edu">rdurazo@lumc.edu</a
></font></p>     ^cY#08.htm##
00441000000000229000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080003000651180002000680160021000700180043000910660
01400134062003300148065000900181064000500190865000900195002000700204#v23n2#v:\sc
ielo\serial\rpsp\v23n2\markup\08.htm#S#c#92#1#article#28#1#^rND^sTaylor Bell^nM#
Immigration: a megatrends backgrounder^len#Lexington^eKY#The Council of State Go
vernments#20040000#2004#20080200#08.htm##
00532000000000265000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080003000651180002000680160018000700160021000880180
06100109025002700170014000800197066001700205062001400222065000900236064000500245
865000900250002000700259#v23n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#c#93#
2#article#28#2#^rND^sRamirez^nRR#^rND^sde la Cruz^nGP#The Hispanic population in
 the United States: March 2002^len#Current Population Reports#P20-545#Washington
^eU.S.#Census Bureau#20030000#2003#20080200#08.htm##
00496000000000253000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080003000651180002000680160017000700180059000870250
02700146014000800173066001700181062001400198065000900212064000500221865000900226
002000700235#v23n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#c#94#3#article#28
#3#^rND^sLarsen^nLJ#The foreign-born population in the United States: 2003^len#C
urrent Population Reports#P20-551#Washington^eU.S.#Census Bureau#20040000#2004#2
0080200#08.htm##
00468000000000253000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080003000651180002000680100016000700120047000860300
04000133710000200173065000900175064000500184031000300189014000600192865000900198
002000700207#v23n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#c#95#4#article#28
#4#^rND^sLópez^nDA#Migración en México: datos de 1990 al 2000^les#Notas Revista 
de Información y Análysis#2#20020000#2002#19#45-51#20080200#08.htm##
00573000000000265000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080003000651180002000680100016000700120104000860300
07500190710000200265065000900267064000500276031000200281032000200283014000600285
865000900291002000700300#v23n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#c#96#
5#article#28#5#^rND^sLópez^nDA#Migración de mexicanos desde y hacia Estados Unid
os de América: estadísticas, problemáticas y retos^les#Boletín de los Sistemas N
acionales Estadístico y de Información Geográfica#2#20040000#2004#1#2#21-38#2008
0200#08.htm##
00464000000000229000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080003000651180002000680160019000700180079000890660
01700168062001900185065000900204064000500213865000900218002000700227#v23n2#v:\sc
ielo\serial\rpsp\v23n2\markup\08.htm#S#c#97#6#article#28#6#^rND^sLabarthe^nDR#Ep
idemiology and prevention of cardiovascular diseases: a global challenge^len#Gai
thersburg^eMD#Aspen Publications#19980000#1998#20080200#08.htm##
00633000000000301000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080003000651180002000680160015000700160015000850160
01800100016001600118016001700134016001800151018006900169066002000238067000700258
062003600265065000900301064000500310865000900315002000700324#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\08.htm#S#c#98#7#article#28#7#^rND^sOlaiz^nG#^rND^sRojas^nR
#^rND^sBarquera^nS#^rND^sShamah^nT#^rND^sAguilar^nC#^rND^sCravioto^nP#Encuesta N
acional de Salud 2000. Tomo 2: La salud de los adultos^les#Cuernavaca^eMorelos#M
éxico#Instituto Nacional de Salud Pública#20030000#2003#20080200#08.htm##
00560000000000229000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080003000651180002000680170128000700180073001980660
01600271062001300287065000900300064000500309865000900314002000700323#v23n2#v:\sc
ielo\serial\rpsp\v23n2\markup\08.htm#S#c#99#8#article#28#8#U.S. Department of He
alth and Human Services^dCenters for Disease Control and Prevention, National Ce
nter for Health Statistics#National Health and Nutrition Examination Survey (NHA
NES) 1999- 2004^len#Hyattsville^eMD#US-DHHS-NCHS#20050000#2005#20080200#08.htm##
00628000000000313000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100014000710100018000850100
01500103010002000118012011200138030000600250065000900256064000500265031000300270
032000200273014000700275865000900282002000700291035001000298801000600308#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\08.htm#S#c#100#9#article#28#9#^rND^sLevi^nF#^r
ND^sLucchini^nF#^rND^sNegri^nE#^rND^sLa Vecchia^nC#Trends in mortality from card
iovascular and cerebrovascular diseases in Europe and other areas of the world^l
en#Heart#20020000#2002#88#2#119-24#20080200#08.htm#1355-6037#Heart##
00608000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100017000890100
01400106010001700120012007600137030001400213065000900227064000500236031000300241
032000300244014000700247865000900254002000700263035001000270801001400280#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\08.htm#S#c#101#10#article#28#10#^rND^sCooper^n
R#^rND^sStamler^nJ#^rND^sDyer^nA#^rND^sGarside^nD#The decline in mortality from 
coronary heart disease, U.S.A., 1968-1975^len#J Chronic Dis#19780000#1978#31#12#
709-20#20080200#08.htm#0021-9681#J Chronic Dis##
00809000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100016000890100
02600105010001900131010001700150010001600167810000600183012019100189030001200380
06500090039206400050040103100040040603200030041001400080041386500090042100200070
0430035001000437801001200447#v23n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#c
#102#11#article#28#11#^rND^sCooper^nR#^rND^sCutler^nJ#^rND^sDesvigne-Nickens^nP#
^rND^sFortmann^nSP#^rND^sFiedman^nL#^rND^sHavlik^nR#et al#Trends and disparities
 in coronary heart disease, stroke, and other cardiovascular diseases in the Uni
ted States: findings of the National Conference on Cardiovascular Disease Preven
tion^len#Circulation#20000000#2000#102#25#3137-47#20080200#08.htm#0009-7322#Circ
ulation##
00754000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100019000900100
01600109010001800125010001800143010001700161810000600178012013100184030001800315
06500090033306400050034203100030034703200020035001400080035286500090036000200070
0369035001000376801001800386#v23n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#c
#103#12#article#28#12#^rND^sGoldman^nL#^rND^sPhillips^nKA#^rND^sCoxson^nP#^rND^s
Goldman^nPA#^rND^sWilliams^nL#^rND^sHunink^nMG#et al#The effect of risk factor r
eductions between 1981 and 1990 on coronary heart disease incidence, prevalence,
 mortality and cost^len#J Am Coll Cardiol#20010000#2001#38#4#1012-17#20080200#08
.htm#0735-1097#J Am Coll Cardiol##
00612000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100016000890100
01700105012012700122030003000249710000200279065000900281064000500290031000300295
032000200298014000600300865000900306002000700315#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\08.htm#S#c#104#13#article#28#13#^rND^sTaylor^nR#^rND^sDobson^nA#^rND^s
Mirzaei^nM#Contribution of changes in risk factors to the decline of coronary he
art disease mortality in Australia over three decades^len#Eur J Cardiovasc Prev 
Rehabil#2#20060000#2006#13#5#760-8#20080200#08.htm##
00633000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100013000900100
01600103010001700119010001700136012008900153030000700242065000900249064000500258
03100020026303200020026501400070026786500090027400200070028303500100029080100070
0300#v23n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#c#105#14#article#28#14#^r
ND^sSoltero^nI#^rND^sLiu^nK#^rND^sCooper^nR#^rND^sStamler^nJ#^rND^sGarside^nD#Tr
ends in mortality from cerebrovascular diseases in the United States, 1960 to 19
75^len#Stroke#19780000#1978#9#6#549-58#20080200#08.htm#0039-2499#Stroke##
00676000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100015000880100
01600103010001500119012014900134030001200283065000900295064000500304031000400309
032000300313014000800316865000900324002000700333035001000340801001200350#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\08.htm#S#c#106#15#article#28#15#^rND^sYusuf^nS
#^rND^sReddy^nS#^rND^sOunpuu^nS#^rND^sAnand^nS#Global burden of cardiovascular d
iseases: part I: general considerations, the epidemiologic transition, risk fact
ors, and impact of urbanization^len#Circulation#20010000#2001#104#22#2746-53#200
80200#08.htm#0009-7322#Circulation##
00720000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100015000880100
01500103010001500118010001600133010001500149012013800164030001400302065000900316
06400050032503100040033003200020033401400060033686500090034200200070035103500100
0358801001400368#v23n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#c#107#16#arti
cle#28#16#^rND^sCheng^nY#^rND^sChen^nKJ#^rND^sWang^nCJ#^rND^sChan^nSH#^rND^sChan
g^nWC#^rND^sChen^nJH#Secular trends in coronary heart disease mortality, hospita
lization rates, and major cardiovascular risk factors in Taiwan, 1971-2001^len#I
nt J Cardiol#20050000#2005#100#1#47-52#20080200#08.htm#0167-5273#Int J Cardiol##
00702000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100021000730100019000940100
02000113010001700133010001700150010001800167012009600185030001500281065000900296
06400050030503100040031003200020031401400070031686500090032300200070033203500100
0339801001500349#v23n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#c#108#17#arti
cle#28#17#^rND^sLaatikainen^nT#^rND^sCritchley^nJ#^rND^sVartiainen^nE#^rND^sSalo
maa^nV#^rND^sKetonen^nM#^rND^sCapewell^nS#Explaining the decline in coronary hea
rt disease mortality in Finland between 1982 and 1997^len#Am J Epidemiol#2005000
0#2005#162#8#764-73#20080200#08.htm#0002-9262#Am J Epidemiol##
00451000000000253000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700160016000730160018000890180
03200107063000200139066001800141062000800159065000900167064000500176865000900181
002000700190#v23n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#c#109#18#article#
28#18#^rND^sPagano^nM#^rND^sGauvreau^nK#Principles of biostatistics^len#2#Pacifi
c Grove^eCA#Duxbury#20000000#2000#20080200#08.htm##
00531000000000265000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700110028000730120077001010300
01800178065000900196064000500205031000300210014000800213865000900221002000700230
035001000237801001800247#v23n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#c#110
#19#article#28#19#México^dSecretaría de Salud#Estadísticas de mortalidad en Méxi
co: muertes registradas en el año 2003^les#Salud Pública Méx#20050000#2005#47#17
1-187#20080200#08.htm#0036-3634#Salud pública Méx##
00701000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100014000730100017000870100
01300104010002300117010001800140010001400158810000600172012008300178030001900261
06500090028006400050028903100030029403200020029701400070029986500090030600200070
0315035001000322801001900332#v23n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#c
#111#20#article#28#20#^rND^sLiao^nY#^rND^sCooper^nRS#^rND^sCao^nG#^rND^sDurazo-A
rvizu^nR#^rND^sKaufman^nJS#^rND^sLuke^nA#et al#Mortality patterns among adult Hi
spanics: findings from the NHIS, 1986 to 1990^len#Am J Public Health#19980000#19
98#88#2#227-32#20080200#08.htm#0090-0036#Am J Public Health##
00755000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100014000730100017000870100
01300104010001800117010001500135010001600150012016300166030001800329065000900347
06400050035603100030036103200020036401400070036686500090037300200070038203500100
0389801001800399#v23n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#c#112#21#arti
cle#28#21#^rND^sLiao^nY#^rND^sCooper^nRS#^rND^sCao^nG#^rND^sKaufman^nJS#^rND^sLo
ng^nAE#^rND^sMcGee^nDL#Mortality from coronary heart disease and cardiovascular 
disease among adult U.S. Hispanics: findings from the National Health Interview 
Survey (1986 to 1994)^len#J Am Coll Cardiol#19970000#1997#30#5#1200-5#20080200#0
8.htm#0735-1097#J Am Coll Cardiol##
00671000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100017000910100
01700108010001700125010001600142010001700158012007400175030001500249065000900264
06400050027303100040027803200030028201400070028586500090029200200070030103500100
0308801001500318#v23n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#c#113#22#arti
cle#28#22#^rND^sSwenson^nCJ#^rND^sTrepka^nMJ#^rND^sRewers^nMJ#^rND^sScarbro^nS#^
rND^sHiatt^nWR#^rND^sHamman^nRF#Cardiovascular disease mortality in Hispanics an
d non-Hispanic whites^len#Am J Epidemiol#20020000#2002#156#10#919-28#20080200#08
.htm#0002-9262#Am J Epidemiol##
00640000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100017000900100
01700107010001600124012010300140030001500243065000900258064000500267031000400272
032000200276014000700278865000900285002000700294035001000301801001500311#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\08.htm#S#c#114#23#article#28#23#^rND^sThomas^n
AJ#^rND^sEberly^nLE#^rND^sNeaton^nJD#^rND^sSmith^nGD#Latino risk-adjusted mortal
ity in the men screened for the Multiple Risk Factor Intervention Trial^len#Am J
 Epidemiol#20050000#2005#162#6#569-78#20080200#08.htm#0002-9262#Am J Epidemiol##
00779000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100019000880100
01800107010001800125010001600143010001700159012018000176030001500356065000900371
06400050038003100040038503200030038901400080039286500090040000200070040903500100
0416801001500426#v23n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#c#115#24#arti
cle#28#24#^rND^sHunt^nKJ#^rND^sResendez^nRG#^rND^sWilliams^nK#^rND^sHaffner^nSM#
^rND^sStern^nMP#^rND^sHazuda^nHP#All-cause and cardiovascular mortality among Me
xican-American and non-Hispanic White older participants in the San Antonio Hear
t Study-evidence against the "Hispanic paradox."^len#Am J Epidemiol#20030000#200
3#158#11#1048-57#20080200#08.htm#0002-9262#Am J Epidemiol##
00705000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100019000900100
01500109010001400124010001900138012015300157030000900310065000900319064000500328
03100040033303200020033701400050033986500090034400200070035303500100036080100090
0370#v23n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#c#116#25#article#28#25#^r
ND^sPandey^nDK#^rND^sLabarthe^nDR#^rND^sGoff^nDC#^rND^sChan^nW#^rND^sNichaman^nM
Z#Community-wide coronary heart disease mortality in Mexican Americans equals or
 exceeds that in non-Hispanic whites: the Corpus Christi Heart Project^len#Am J 
Med#20010000#2001#110#2#81-7#20080200#08.htm#0002-9343#Am J Med##
00592000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100023000730100016000960100
01900112012007500131030001600206065000900222064000500231031000300236032000200239
014000700241865000900248002000700257035001000264801001600274#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\08.htm#S#c#117#26#article#28#26#^rND^sLerman-Garber^nI#^rN
D^sVilla^nAR#^rND^sCaballero^nE#Diabetes and cardiovascular disease: is there a 
true Hispanic paradox?^len#Rev Invest Clin#20040000#2004#56#3#282-96#20080200#08
.htm#0034-8376#Rev Invest Clin##
00609000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100019000890120
12000108030001900228065000900247064000500256031000300261032000200264014000800266
865000900274002000700283035001000290801001900300#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\08.htm#S#c#118#27#article#28#27#^rND^sSmith^nDP#^rND^sBradshaw^nBS#Ret
hinking the Hispanic paradox: death rates and life expectancy for US non-Hispani
c white and Hispanic populations^len#Am J Public Health#20060000#2006#96#9#1686-
92#20080200#08.htm#0090-0036#Am J Public Health##
00487000000000241000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700160018000730180060000910250
02700151066001100178062002600189065000900215064000500224865000900229002000700238
#v23n2#v:\scielo\serial\rpsp\v23n2\markup\08.htm#S#c#119#28#article#28#28#^rND^s
Ramirez^nRR#We the People: Hispanics in the United States: CENSR-18^len#Census 2
000 Special Report#Washington#U.S. Bureau of the Census#20040000#2004#20080200#0
8.htm##
00259000000000169000450000400060000070200420000670500020004870600020005070000020
00527010002000547090005000567080002000610910009000630920007000720020007000797030
00300086#v23n2#v:\scielo\serial\rpsp\v23n2\markup\09.htm#S#o#1#1#text#1#20080318
#103149#09.htm#15##
00603000000000337000450000400060000070200420000670500020004870600020005070000020
00527010002000547090005000567080002000610710003000630400003000660010006000690420
00200075120000400077038000300081121000300084049000800087158000300095030002400098
03100030012203200020012506500090012701400110013603500100014712300020015701200990
0159002000700258#v23n2#v:\scielo\serial\rpsp\v23n2\markup\09.htm#S#h#2#1#text#1#
sc#es#br1.1#1#3.1#ND#09#RPSP030#nd#Rev Panam Salud Publica#23#2#20080200#^f125^l
125#1020-4989#1#Prevalencia de parasitismo intestinal en niños quechuas de zonas
 rurales montañosas de Ecuador^les#09.htm##
00610000000000337000450000400060000070200420000670500020004870600020005070000020
00527010002000547090005000567080002000610710003000630400003000660010006000690420
00200075120000400077038000300081121000300084049000800087158000300095030002400098
03100030012203200020012506500090012701400110013603500100014712300020015701201060
0159002000700265#v23n2#v:\scielo\serial\rpsp\v23n2\markup\09.htm#S#f#3#1#text#1#
sc#es#br1.1#1#3.1#ND#09#RPSP030#nd#Rev Panam Salud Publica#23#2#20080200#^f125^l
125#1020-4989#1#<B>Prevalencia de parasitismo intestinal en niños quechuas de zo
nas rurales montañosas de Ecuador</B>^les#09.htm##
00719000000000349000450000400060000070200420000670500020004870600020005070000020
00527010002000547090005000567080002000610640013000630710003000760400003000790010
00600082042000200088120000400090121000300094049000800097158000300105030002600108
03100030013403200020013706500090013901400110014803500100015912300020016901200990
0171002000700270008009200277#v23n2#v:\scielo\serial\rpsp\v23n2\markup\09.htm#S#l
#4#1#text#1#^mfeb.^a2008#sc#es#br1.1#1#3.1#09#RPSP030#nd#Rev. panam. salud públi
ca#23#2#20080200#^f125^l125#1020-4989#1#Prevalencia de parasitismo intestinal en
 niños quechuas de zonas rurales montañosas de Ecuador^les#09.htm#Internet^ihttp
://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892008000200009##
00340000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704012300064002000700187#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\09.htm#S#p#5#1#text#11#<p align="right"><font face="Ve
rdana, Arial, Helvetica, sans-serif" size="2"><b>INSTANT&Aacute;NEAS</b></font><
/p>     ^cY#09.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704002200064002000700086#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\09.htm#S#p#6#2#text#11#<p>&nbsp;</p>     ^cY#09.htm##
00421000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704020400064002000700268#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\09.htm#S#p#7#3#text#11#<p><font face="Verdana, Arial, 
Helvetica, sans-serif" size="4"><b>Prevalencia    de parasitismo intestinal en n
i&ntilde;os quechuas de zonas rurales monta&ntilde;osas    de Ecuador</b></font>
</p>     ^cY#09.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704002200064002000700086#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\09.htm#S#p#8#4#text#11#<p>&nbsp;</p>     ^cY#09.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704002200064002000700086#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\09.htm#S#p#9#5#text#11#<p>&nbsp;</p>     ^cY#09.htm##
00550000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000500057708000300062704033200065002000700397#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\09.htm#S#p#10#6#text#11#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2">Diversos estudios    epidemiol&oacute;gicos abo
rdan el tema de la prevalencia del parasitismo intestinal    en Ecuador y otros 
pa&iacute;ses de Am&eacute;rica del Sur, pero pocos han estudiado    el parasiti
smo en ni&ntilde;os preescolares quechuas.</font></p>     ^cY#09.htm##
01401000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000500057708000300062704118300065002000701248#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\09.htm#S#p#11#7#text#11#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2">En este trabajo    se determin&oacute; la preva
lencia de varias infecciones parasitarias en ni&ntilde;os    peque&ntilde;os de 
comunidades rurales quechuas que viven en las monta&ntilde;as    de la provincia
 de Chimborazo, en la regi&oacute;n central de Ecuador. Adem&aacute;s,    se ana
liz&oacute; la relaci&oacute;n entre algunas variables sanitarias (el    uso de 
letrinas, la disponibilidad de m&eacute;todos adecuados de almacenamiento    y t
ratamiento de agua y la aplicaci&oacute;n de proyectos comunitarios para    prot
eger las fuentes de agua potable) y las enfermedades y la prevalencia de    para
sitismo infantil. Se busc&oacute; una gran variedad de par&aacute;sitos,    la m
ayor&iacute;a de ellos pat&oacute;genos, que se transmiten por diversas    v&iac
ute;as, como el agua, los alimentos, el suelo y las heces fecales. Se analiz&oac
ute;    el nivel de acceso de estas comunidades al agua potable, al agua necesar
ia para    su higiene y a sistemas sanitarios de eliminaci&oacute;n de los desec
hos fecales,    ya que todos estos factores pueden incidir en el nivel de infest
aci&oacute;n.</font></p>     ^cY#09.htm##
01744000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000500057708000300062704152600065002000701591#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\09.htm#S#p#12#8#text#11#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2">Se analizaron muestras    de heces fecales de 1
12 (75,2%) de los 149 ni&ntilde;os residentes en las comunidades    con proyecto
s de higienizaci&oacute;n y protecci&oacute;n del agua potable y    de 91 (63,2%
) de los 144 ni&ntilde;os de las comunidades sin ese tipo de proyectos.    En ge
neral, 85,7% de las muestras presentaban al menos uno de los 10 par&aacute;sitos
    estudiados y 63,4% conten&iacute;an dos o m&aacute;s especies de par&aacute;
sitos.    La prevalencia general fue de 57,1% de <i>Entomoeba histolytica</i> o 
<i>Entomoeba    dispar</i>, 35,5% de <i>Ascaris lumbricoides</i>, 34,0% de <i>Es
cherichia coli</i>,    21,1% de <i>Giardia intestinalis</i> (<i>lamblia</i>), 11
,3% de <i>Hymenolepis    nana</i>, 8,9% de <i>Cryptosporidium parvum</i>, 1,7% d
e <i>Chilomastix mesnili</i>,    1,0% de <i>Hymenolepis diminuta</i>, 0,7% de <i
>Strongyloides stercoralis</i>    y 0,5% de <i>Trichuris trichiura</i>. Se encon
traron protozoos en 78,3% de las    muestras y helmintos en 42,4%. No se encontr
aron diferencias significativas    entre el n&uacute;mero de casos informados de
 enfermedades (diarrea, fiebre,    infecciones respiratorias, v&oacute;mitos y o
tras) seg&uacute;n los par&aacute;sitos    detectados, excepto un ligero increme
nto en el n&uacute;mero informado de diarreas    en el mes anterior en los ni&nt
ilde;os con infecci&oacute;n por <i>E. histolytica</i>    o <i>E. dispar</i> (65
,2% contra 49,6%; <i>P</i> = 0,032).</font></p>     ^cY#09.htm##
01293000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000500057708000300062704107500065002000701140#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\09.htm#S#p#13#9#text#11#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2">La prevalencia    de par&aacute;sitos intestina
les aument&oacute; con la edad. En comparaci&oacute;n    con los otros ni&ntilde
;os, los de mayor edad (48&#150;60 meses) presentaron    una mayor probabilidad 
de tener al menos uno de los 10 par&aacute;sito estudiados    (<i>P</i> &lt; 0,0
01) o m&aacute;s de uno de ellos (<i>P</i> = 0,002) que el    resto. Esta tenden
cia fue significativa en los casos de <i>E. histolytica</i>    o <i>E. dispar</i
> (<i>P</i> &lt; 0,001) y <i>E. coli</i> (<i>P</i> = 0,030).    La tendencia fue
 de menor significaci&oacute;n para <i>H. nana</i> (<i>P</i>    = 0,068) y <i>G.
 intestinalis</i> (<i>P</i> = 0,070) y no fue significativa    para <i>A. lumbri
coides</i> (<i>P</i> = 0,386) y <i>C. parvum</i> (<i>P</i>    = 0,407). Los ni&n
tilde;os de menor edad (12-23 meses) tuvieron una probabilidad    significativam
ente mayor que los otros grupos de presentar diarreas en la semana    y el mes p
revios (<i>P</i> = 0,013 y <i>P</i> &lt; 0,001, respectivamente).</font></p>    
 ^cY#09.htm##
00866000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704064700066002000700713#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\09.htm#S#p#14#10#text#11#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">No se encontraron    diferencias significativa
s en la prevalencia de par&aacute;sitos intestinales    o diarrea y la participa
ci&oacute;n en proyectos comunitarios de agua potable.    El almacenamiento y el
 tratamiento del agua, el uso habitual de letrinas y la    participaci&oacute;n 
en proyectos comunitarios de agua potable no mostraron    una asociaci&oacute;n 
fuerte con la prevalencia de par&aacute;sitos intestinales.    El suelo sucio fu
e un factor de riesgo de la infecci&oacute;n con <i>E. histolytica</i>    o <i>E
. dispar</i> y <i>G. intestinalis</i>.</font></p>     ^cY#09.htm##
00966000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704074700066002000700813#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\09.htm#S#p#15#11#text#11#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">Estos resultados    indican que la instalaci&o
acute;n de fuentes limpias de agua potable y la disponibilidad    de instalacion
es sanitarias no garantizan por s&iacute; solas cambios significativos    en la 
conducta higi&eacute;nica y las pr&aacute;cticas sanitarias de la comunidad,    
por lo que es importante complementar estas intervenciones con un componente    
educativo-sanitario si se desea reducir la diarrea y el parasitismo intestinal  
  en estas comunidades. (Jacobsen KH, Ribeiro PS, Quist BK, Rydbeck BV. Prevalen
ce    of intestinal parasites in young Quichua children in the highlands of rura
l    Ecuador. J Health Pop Nutr. 2007;25(4):399&#150;405.)</font></p>     ^cY#09
.htm##
00259000000000169000450000400060000070200420000670500020004870600020005070000020
00527010002000547090005000567080002000610910009000630920007000720020007000797030
00300086#v23n2#v:\scielo\serial\rpsp\v23n2\markup\10.htm#S#o#1#1#text#1#20080318
#103149#10.htm#15##
00642000000000337000450000400060000070200420000670500020004870600020005070000020
00527010002000547090005000567080002000610710003000630400003000660010006000690420
00200075120000400077038000300081121000300084049000800087158000300095030002400098
03100030012203200020012506500090012701400110013603500100014712300020015701201380
0159002000700297#v23n2#v:\scielo\serial\rpsp\v23n2\markup\10.htm#S#h#2#1#text#1#
sc#es#br1.1#1#3.1#ND#10#RPSP030#nd#Rev Panam Salud Publica#23#2#20080200#^f125^l
126#1020-4989#1#Costos de la detección, el diagnóstico y la clasificación del cá
ncer de próstata en países industrializados: una referencia necesaria^les#10.htm
##
00656000000000337000450000400060000070200420000670500020004870600020005070000020
00527010002000547090005000567080002000610710003000630400003000660010006000690420
00200075120000400077038000300081121000300084049000800087158000300095030002400098
03100030012203200020012506500090012701400110013603500100014712300020015701201520
0159002000700311#v23n2#v:\scielo\serial\rpsp\v23n2\markup\10.htm#S#f#3#1#text#1#
sc#es#br1.1#1#3.1#ND#10#RPSP030#nd#Rev Panam Salud Publica#23#2#20080200#^f125^l
126#1020-4989#1#<B>Costos de la detección, el diagnóstico y la clasificación del
 cáncer de próstata en países industrializados</B>: <B>una referencia necesaria<
/B>^les#10.htm##
00758000000000349000450000400060000070200420000670500020004870600020005070000020
00527010002000547090005000567080002000610640013000630710003000760400003000790010
00600082042000200088120000400090121000300094049000800097158000300105030002600108
03100030013403200020013706500090013901400110014803500100015912300020016901201380
0171002000700309008009200316#v23n2#v:\scielo\serial\rpsp\v23n2\markup\10.htm#S#l
#4#1#text#1#^mfeb.^a2008#sc#es#br1.1#1#3.1#10#RPSP030#nd#Rev. panam. salud públi
ca#23#2#20080200#^f125^l126#1020-4989#1#Costos de la detección, el diagnóstico y
 la clasificación del cáncer de próstata en países industrializados: una referen
cia necesaria^les#10.htm#Internet^ihttp://www.scielosp.org/scielo.php?script=sci
_arttext&pid=S1020-49892008000200010##
00340000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704012300064002000700187#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\10.htm#S#p#5#1#text#11#<p align="right"><font face="Ve
rdana, Arial, Helvetica, sans-serif" size="2"><b>INSTANT&Aacute;NEAS</b></font><
/p>     ^cY#10.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704002200064002000700086#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\10.htm#S#p#6#2#text#11#<p>&nbsp;</p>     ^cY#10.htm##
00488000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704027100064002000700335#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\10.htm#S#p#7#3#text#11#<p><font face="Verdana, Arial, 
Helvetica, sans-serif" size="4"><b>Costos de la    detecci&oacute;n, el diagn&oa
cute;stico y la clasificaci&oacute;n del c&aacute;ncer    de pr&oacute;stata en 
pa&iacute;ses industrializados: una referencia necesaria</b></font></p>     ^cY#
10.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704002200064002000700086#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\10.htm#S#p#8#4#text#11#<p>&nbsp;</p>     ^cY#10.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704002200064002000700086#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\10.htm#S#p#9#5#text#11#<p>&nbsp;</p>     ^cY#10.htm##
01207000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000500057708000300062704098900065002000701054#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\10.htm#S#p#10#6#text#11#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2">Debido a que en    ning&uacute;n pa&iacute;s se
 cuenta con los recursos suficientes para cubrir    todas las necesidades sanita
rias, se hace imprescindible comprender los elementos    que inciden en las esti
maciones del costo de las enfermedades, de modo que se    pueda disponer de la i
nformaci&oacute;n adecuada para decidir si se debe invertir    o no, por ejemplo
, en sistemas y programas de detecci&oacute;n precoz de esas    enfermedades. Es
to es particularmente importante en el caso del c&aacute;ncer    de pr&oacute;st
ata, no solamente por ser el segundo tipo de c&aacute;ncer m&aacute;s    frecuen
te en hombres, sino por los beneficios que pueden ofrecer su detecci&oacute;n   
 precoz y su oportuno tratamiento. No obstante, la efectividad de la detecci&oac
ute;n    temprana en la reducci&oacute;n de la mortalidad asociada con el c&aacu
te;ncer    de pr&oacute;stata es a&uacute;n tema de debate.</font></p>     ^cY#1
0.htm##
00742000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000500057708000300062704052400065002000700589#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\10.htm#S#p#11#7#text#11#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2">Existen diversas    estimaciones de los costos 
asociados con la detecci&oacute;n, el diagn&oacute;stico    y la clasificaci&oac
ute;n del c&aacute;ncer de pr&oacute;stata. Sin embargo,    a&uacute;n se descon
ocen los costos en recursos &#151;el tiempo de trabajo del    m&eacute;dico, los
 an&aacute;lisis de laboratorio, el tiempo que el paciente    debe ausentarse de
l trabajo, entre otros&#151; a tomar en cuenta para estas    estimaciones.</font
></p>     ^cY#10.htm##
00642000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000500057708000300062704042400065002000700489#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\10.htm#S#p#12#8#text#11#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2">En este trabajo    se analizaron los costos de 
los recursos empleados en la detecci&oacute;n, el    diagn&oacute;stico y la cla
sificaci&oacute;n por etapas del c&aacute;ncer de    pr&oacute;stata en los Esta
dos Unidos de Am&eacute;rica y en qu&eacute; medida    esos costos difieren de l
os publicados en otros pa&iacute;ses industrializados.</font></p>     ^cY#10.htm
##
01183000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000500057708000300062704096500065002000701030#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\10.htm#S#p#13#9#text#11#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2">Para ello se buscaron    los art&iacute;culos e
 informes sobre el c&aacute;ncer de pr&oacute;stata publicados    entre enero de
 1980 y diciembre de 2003 e indizados en las bases de datos electr&oacute;nicas 
   MEDLINE, EMBASE y CINAHL. Se seleccionaron los art&iacute;culos publicados en
    ingl&eacute;s, disponibles en texto completo, que contuvieran los datos sobr
e    los costos de los recursos o los datos necesarios para estimar el costo de 
la    detecci&oacute;n, el diagn&oacute;stico y la clasificaci&oacute;n de las e
tapas    de c&aacute;ncer de pr&oacute;stata. Se seleccionaron solamente los est
udios    realizados en pa&iacute;ses con econom&iacute;a de mercado consolidada.
 Para    agrupar y analizar los datos obtenidos se utilizaron procedimientos est
ad&iacute;sticos    descriptivos, valores medios ponderados y el m&eacute;todo d
e simulaci&oacute;n    Monte Carlo.</font></p>     ^cY#10.htm##
01357000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704113800066002000701204#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\10.htm#S#p#14#10#text#11#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">De los 262 estudios    analizados, 28 cumpl&ia
cute;an con los criterios de selecci&oacute;n (15 eran    de los Estados Unidos 
y 13 de otros pa&iacute;ses industrializados). En los    estudios realizados en 
los Estados Unidos se observ&oacute; que el costo inicial    combinado de los re
cursos para la detecci&oacute;n mediante el ant&iacute;geno    prost&aacute;tico
 espec&iacute;fico fue de US$ 37,23 y para la detecci&oacute;n    mediante el ex
amen rectal digital, de US$ 31,77. En los estudios realizados    en otros pa&iac
ute;ses industrializados, el costo inicial combinado de los recursos    para la 
detecci&oacute;n mediante el ant&iacute;geno prost&aacute;tico espec&iacute;fico
    fue de US$ 30,92 y de US$ 33,54 para la detecci&oacute;n mediante el examen 
   rectal digital. Se observ&oacute; una gran variaci&oacute;n en los costos de 
   los recursos vinculados a los procedimientos de diagn&oacute;stico y de clasi
ficaci&oacute;n    por etapas, tanto dentro de los Estados Unidos como en los ot
ros pa&iacute;ses    industrializados analizados.</font></p>     ^cY#10.htm##
01098000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704087900066002000700945#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\10.htm#S#p#15#11#text#11#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">Este estudio puede    ser de gran utilidad par
a las autoridades sanitarias de otros pa&iacute;ses    de la Regi&oacute;n de la
s Am&eacute;ricas, ya que por primera vez se ofrece    un valor de base que pued
e emplearse como referencia al trazar pol&iacute;ticas    sanitarias relacionada
s con el tamizaje &#151;masivo o selectivo&#151; de c&aacute;ncer    de pr&oacut
e;stata, siempre que se adapte a las condiciones locales. (Ekwueme    DU, Stroud
 LA, Chen Y. Cost analysis of screening for, diagnosing, and staging    prostate
 cancer based on a systematic review of published studies. Prev Chronic    Dis. 
2007;4(4). Hallado en <a href="http://www.cdc.gov/pcd/issues/2007/oct/06_0051.ht
m" target="_blank">http://www.cdc.gov/pcd/issues/2007/    oct/06_0051.htm</a>. A
cceso el 24 de enero de 2008.)</font></p>     ^cY#10.htm##
00259000000000169000450000400060000070200420000670500020004870600020005070000020
00527010002000547090005000567080002000610910009000630920007000720020007000797030
00300086#v23n2#v:\scielo\serial\rpsp\v23n2\markup\11.htm#S#o#1#1#text#1#20080318
#103151#11.htm#15##
00595000000000337000450000400060000070200420000670500020004870600020005070000020
00527010002000547090005000567080002000610710003000630400003000660010006000690420
00200075120000400077038000300081121000300084049000800087158000300095030002400098
03100030012203200020012506500090012701400110013603500100014712300020015701200910
0159002000700250#v23n2#v:\scielo\serial\rpsp\v23n2\markup\11.htm#S#h#2#1#text#1#
sc#es#br1.1#1#3.1#ND#11#RPSP030#nd#Rev Panam Salud Publica#23#2#20080200#^f126^l
127#1020-4989#1#Influencia de dos métodos de cálculo de las inequidades en salud
: estudio en 22 países^les#11.htm##
00609000000000337000450000400060000070200420000670500020004870600020005070000020
00527010002000547090005000567080002000610710003000630400003000660010006000690420
00200075120000400077038000300081121000300084049000800087158000300095030002400098
03100030012203200020012506500090012701400110013603500100014712300020015701201050
0159002000700264#v23n2#v:\scielo\serial\rpsp\v23n2\markup\11.htm#S#f#3#1#text#1#
sc#es#br1.1#1#3.1#ND#11#RPSP030#nd#Rev Panam Salud Publica#23#2#20080200#^f126^l
127#1020-4989#1#<B>Influencia de dos métodos de cálculo de las inequidades en sa
lud</B>: <B>estudio en 22 países</B>^les#11.htm##
00711000000000349000450000400060000070200420000670500020004870600020005070000020
00527010002000547090005000567080002000610640013000630710003000760400003000790010
00600082042000200088120000400090121000300094049000800097158000300105030002600108
03100030013403200020013706500090013901400110014803500100015912300020016901200910
0171002000700262008009200269#v23n2#v:\scielo\serial\rpsp\v23n2\markup\11.htm#S#l
#4#1#text#1#^mfeb.^a2008#sc#es#br1.1#1#3.1#11#RPSP030#nd#Rev. panam. salud públi
ca#23#2#20080200#^f126^l127#1020-4989#1#Influencia de dos métodos de cálculo de 
las inequidades en salud: estudio en 22 países^les#11.htm#Internet^ihttp://www.s
cielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892008000200011##
00340000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704012300064002000700187#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\11.htm#S#p#5#1#text#11#<p align="right"><font face="Ve
rdana, Arial, Helvetica, sans-serif" size="2"><b>INSTANT&Aacute;NEAS</b></font><
/p>     ^cY#11.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704002200064002000700086#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\11.htm#S#p#6#2#text#11#<p>&nbsp;</p>     ^cY#11.htm##
00420000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704020300064002000700267#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\11.htm#S#p#7#3#text#11#<p><font face="Verdana, Arial, 
Helvetica, sans-serif" size="4"><b>Influencia de    dos m&eacute;todos de c&aacu
te;lculo de las inequidades en salud: estudio en    22 pa&iacute;ses</b></font><
/p>     ^cY#11.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704002200064002000700086#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\11.htm#S#p#8#4#text#11#<p>&nbsp;</p>     ^cY#11.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704002200064002000700086#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\11.htm#S#p#9#5#text#11#<p>&nbsp;</p>     ^cY#11.htm##
00891000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000500057708000300062704067300065002000700738#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\11.htm#S#p#10#6#text#11#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2">El efecto negativo    de las inequidades socioe
con&oacute;micas sobre la salud contin&uacute;a siendo    un tema prioritario en
 las agendas de las autoridades sanitarias de la mayor&iacute;a    de los pa&iac
ute;ses. Para los gobiernos y la comunidad internacional es importante    y dese
able poder medir y comparar la magnitud de las inequidades en salud &#151;ya    
sea entre diferentes pa&iacute;ses o entre diferentes zonas o grupos de un mismo
    pa&iacute;s&#151;, as&iacute; como evaluar la magnitud de los cambios ocurri
dos    en esas inequidades en un per&iacute;odo de tiempo dado.</font></p>     ^
cY#11.htm##
01160000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000500057708000300062704094200065002000701007#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\11.htm#S#p#11#7#text#11#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2">Aunque existen    muchas formas de evaluar el n
ivel de las inequidades en salud, las mediciones    m&aacute;s empleadas son la 
raz&oacute;n de las tasas y la diferencia de las    tasas. Estas mediciones se b
asan en la comparaci&oacute;n (ya sea mediante la    raz&oacute;n o la diferenci
a) de las tasas de mortalidad en relaci&oacute;n    con la posici&oacute;n socio
econ&oacute;mica. Para ello se comparan los valores    de mortalidad correspondi
entes al segmento de mejor situaci&oacute;n socioecon&oacute;mica    (por lo gen
eral el 20% superior) con la mortalidad correspondiente al segmento    de peor s
ituaci&oacute;n socioecon&oacute;mica (por lo general el 20% inferior).    A pes
ar de que estas mediciones no toman en cuenta toda la informaci&oacute;n    disp
onible, son las m&aacute;s frecuentemente utilizadas por su sencillez y    f&aac
ute;cil uso.</font></p>     ^cY#11.htm##
00893000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000500057708000300062704067500065002000700740#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\11.htm#S#p#12#8#text#11#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2">En este trabajo    se emple&oacute; informaci&o
acute;n p&uacute;blica para analizar los niveles    y las tendencias de la inequ
idad en salud a partir de los datos de mortalidad    en menores de 5 a&ntilde;os
 de 22 pa&iacute;ses clasificados como de ingresos    bajos y mediano-bajos que 
aplicaron dos encuestas de poblaci&oacute;n y salud    entre 1991 y 2001. Se ana
lizaron once pa&iacute;ses de &Aacute;frica, seis de    Asia y cinco de Am&eacut
e;rica Latina (Colombia, Guatemala, Hait&iacute;, Nicaragua    y Per&uacute;), q
ue en su conjunto representan 27% de la poblaci&oacute;n mundial.</font></p>    
 ^cY#11.htm##
01323000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000500057708000300062704110500065002000701170#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\11.htm#S#p#13#9#text#11#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2">Se observ&oacute;    que en ocasiones, la posic
i&oacute;n relativa de los pa&iacute;ses seg&uacute;n    su nivel de inequidad e
n un momento determinado vari&oacute; en dependencia    de la medici&oacute;n em
pleada, ya fuera la raz&oacute;n o la diferencia de    las tasas (coeficiente de
 correlaci&oacute;n de rangos de Spearman = 0,49).    De manera similar, la posi
ci&oacute;n relativa de los pa&iacute;ses seg&uacute;n    la magnitud y la direc
ci&oacute;n de los cambios en los niveles de inequidad    en el per&iacute;odo d
e tiempo analizado vari&oacute; tambi&eacute;n en dependencia    del tipo de med
ici&oacute;n empleada. De gran importancia desde el punto de    vista de la elab
oraci&oacute;n de pol&iacute;ticas result&oacute; el hecho de    que la direcci&
oacute;n de la tendencia observada mostr&oacute; un cambio de    signo (de aumen
to de la inequidad a la reducci&oacute;n) en cinco de los pa&iacute;ses    (Indi
a, Namibia, Nepal, Per&uacute; y Vietnam) cuando se emplearon las dos mediciones
    estudiadas.</font></p>     ^cY#11.htm##
01218000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704099900066002000701065#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\11.htm#S#p#14#10#text#11#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">Esta es la primera    comparaci&oacute;n siste
m&aacute;tica del uso de diferentes mediciones de la    inequidad en salud, con 
herramientas estandarizadas, en un considerable n&uacute;mero    de pa&iacute;se
s. El empleo indistinto de la raz&oacute;n de las tasas o de    la diferencia de
 las tasas para medir la tendencia de los cambios en el nivel    de inequidad ge
ner&oacute; diferencias sustanciales en el orden relativo que    ocuparon los pa
&iacute;ses analizados, tanto por la magnitud como por la direcci&oacute;n    de
 los cambios. Estos resultados no se vieron afectados por factores de confusi&oa
cute;n    &#151;como el dise&ntilde;o del estudio, los m&eacute;todos de obtenci
&oacute;n    de los datos y los indicadores socioecon&oacute;micos, entre otros&
#151; y tienen    importantes implicaciones para la elaboraci&oacute;n de pol&ia
cute;ticas, la    atenci&oacute;n sanitaria y la investigaci&oacute;n.</font></p
>     ^cY#11.htm##
01068000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704084900066002000700915#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\11.htm#S#p#15#11#text#11#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">A pesar de que    no es posible hacer una reco
mendaci&oacute;n categ&oacute;rica sobre las ventajas    de medir la inequidad c
on m&eacute;todos absolutos o relativos para comparar    el efecto de las inequi
dades socioecon&oacute;micas en la salud, al analizar    las inequidades y discu
tir las tasas se debe tomar en cuenta el m&eacute;todo    de medici&oacute;n uti
lizado, ya sea la raz&oacute;n de las tasas o la diferencia    de las tasas, y e
l tipo de escala empleada, ya sea absoluta o relativa. (Moser    K, Frost C, Leo
n DA. Comparing health inequalities across time and place&#151;rate    ratios an
d rate differences lead to different conclusions: analysis of cross-sectional   
 data from 22 countries 1991&#150;2001. Int J Epidemiol. 2007; 36:1285&#150;91.)
</font></p>     ^cY#11.htm##
00259000000000169000450000400060000070200420000670500020004870600020005070000020
00527010002000547090005000567080002000610910009000630920007000720020007000797030
00300086#v23n2#v:\scielo\serial\rpsp\v23n2\markup\12.htm#S#o#1#1#text#1#20080318
#103151#12.htm#15##
00615000000000337000450000400060000070200420000670500020004870600020005070000020
00527010002000547090005000567080002000610710003000630400003000660010006000690420
00200075120000400077038000300081121000300084049000800087158000300095030002400098
03100030012203200020012506500090012701400110013603500100014712300020015701201110
0159002000700270#v23n2#v:\scielo\serial\rpsp\v23n2\markup\12.htm#S#h#2#1#text#1#
sc#es#br1.1#1#3.1#ND#12#RPSP030#nd#Rev Panam Salud Publica#23#2#20080200#^f127^l
128#1020-4989#1#Estudio del Millón de Mujeres establece relación entre varios ti
pos de cáncer y el índice de masa corporal^les#12.htm##
00622000000000337000450000400060000070200420000670500020004870600020005070000020
00527010002000547090005000567080002000610710003000630400003000660010006000690420
00200075120000400077038000300081121000300084049000800087158000300095030002400098
03100030012203200020012506500090012701400110013603500100014712300020015701201180
0159002000700277#v23n2#v:\scielo\serial\rpsp\v23n2\markup\12.htm#S#f#3#1#text#1#
sc#es#br1.1#1#3.1#ND#12#RPSP030#nd#Rev Panam Salud Publica#23#2#20080200#^f127^l
128#1020-4989#1#<B>Estudio del Millón de Mujeres establece relación entre varios
 tipos de cáncer y el índice de masa corporal</B>^les#12.htm##
00731000000000349000450000400060000070200420000670500020004870600020005070000020
00527010002000547090005000567080002000610640013000630710003000760400003000790010
00600082042000200088120000400090121000300094049000800097158000300105030002600108
03100030013403200020013706500090013901400110014803500100015912300020016901201110
0171002000700282008009200289#v23n2#v:\scielo\serial\rpsp\v23n2\markup\12.htm#S#l
#4#1#text#1#^mfeb.^a2008#sc#es#br1.1#1#3.1#12#RPSP030#nd#Rev. panam. salud públi
ca#23#2#20080200#^f127^l128#1020-4989#1#Estudio del Millón de Mujeres establece 
relación entre varios tipos de cáncer y el índice de masa corporal^les#12.htm#In
ternet^ihttp://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892008
000200012##
00340000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704012300064002000700187#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\12.htm#S#p#5#1#text#11#<p align="right"><font face="Ve
rdana, Arial, Helvetica, sans-serif" size="2"><b>INSTANT&Aacute;NEAS</b></font><
/p>     ^cY#12.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704002200064002000700086#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\12.htm#S#p#6#2#text#11#<p>&nbsp;</p>     ^cY#12.htm##
00447000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704023000064002000700294#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\12.htm#S#p#7#3#text#11#<p><font face="Verdana, Arial, 
Helvetica, sans-serif" size="4"><b>Estudio del    Mill&oacute;n de Mujeres estab
lece relaci&oacute;n entre varios tipos de c&aacute;ncer    y el &iacute;ndice d
e masa corporal</b></font></p>     ^cY#12.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704002200064002000700086#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\12.htm#S#p#8#4#text#11#<p>&nbsp;</p>     ^cY#12.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704002200064002000700086#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\12.htm#S#p#9#5#text#11#<p>&nbsp;</p>     ^cY#12.htm##
00859000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000500057708000300062704064100065002000700706#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\12.htm#S#p#10#6#text#11#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2">La prevalencia    de la obesidad ha aumentado e
n el mundo. A pesar de que est&aacute; ampliamente    aceptado que el &iacute;nd
ice de masa corporal (IMC) est&aacute; asociado directamente    con el adenocarc
inoma de es&oacute;fago, el c&aacute;ncer colorrectal, de endometrio    y de ri&
ntilde;&oacute;n en la poblaci&oacute;n general, y con el c&aacute;ncer    de ma
ma en mujeres posmenop&aacute;usica, no se tienen datos exactos sobre la    magn
itud de este efecto y el papel que desempe&ntilde;a el IMC en el desarrollo    d
e otros tipos de c&aacute;ncer.</font></p>     ^cY#12.htm##
00855000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000500057708000300062704063700065002000700702#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\12.htm#S#p#11#7#text#11#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2">En este trabajo    se investig&oacute; la relac
i&oacute;n entre la incidencia de y la mortalidad    por 17 tipos/ubicaciones de
 c&aacute;ncer y el IMC en las participantes en el    denominado Estudio del Mil
l&oacute;n de Mujeres. Como parte de este estudio    prospectivo de cohorte se r
ealiz&oacute; el seguimiento de 1,3 millones de mujeres    de 50&#150;64 a&ntild
e;os de edad del Reino Unido entre 1996 y 2001. El tiempo    promedio de seguimi
ento fue de 5,4 a&ntilde;os para la incidencia de c&aacute;ncer    y de 7,0 a&nt
ilde;os para la mortalidad.</font></p>     ^cY#12.htm##
01807000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000500057708000300062704158900065002000701654#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\12.htm#S#p#12#8#text#11#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2">En el per&iacute;odo    de seguimiento se diagn
osticaron 45 037 casos de c&aacute;ncer y ocurrieron    17 203 muertes por esta 
causa. Se encontr&oacute; una asociaci&oacute;n significativa    entre el aument
o del IMC y el incremento en la incidencia de c&aacute;ncer en    10 de las 17 u
bicaciones espec&iacute;ficas o tipos de c&aacute;ncer estudiados:    c&aacute;n
cer de endometrio (tendencia del riesgo relativo por 10 unidades &#91;tRR<sub>10
</sub>&#93;    = 2,89; intervalo de confianza de 95% &#91;IC95%&#93;: 2,62 a 3,1
8), adenocarcinoma    de es&oacute;fago (tRR<sub>10</sub> = 2,38; IC95%: 1,59 a 
3,56), c&aacute;ncer    de ri&ntilde;&oacute;n (tRR<sub>10</sub> = 1,53; IC95%: 
1,27 a 1,84), leucemia    (tRR<sub>10</sub> = 1,50; IC95%: 1,23 a 1,83), mieloma
s m&uacute;ltiples (tRR<sub>10</sub>    = 1,31; IC95%: 1,04 a 1,65), c&aacute;nc
er de p&aacute;ncreas (tRR<sub>10</sub>    = 1,24; IC95%: 1,03 a 1,48), linfoma 
no Hodgkin (tRR<sub>10</sub> = 1,17; IC95%:    1,03 a 1,34), c&aacute;ncer de ov
ario (tRR<sub>10</sub> = 1,14; IC95%: 1,03    a 1,27), todos los tipos de c&aacu
te;ncer (tRR<sub>10</sub> = 1,12; IC95%: 1,09    a 1,14), c&aacute;ncer de mama 
en mujeres posmenop&aacute;usicas (tRR<sub>10</sub>    = 1,40; IC95%: 1,31 a 1,4
9) y c&aacute;ncer colorrectal en mujeres premenop&aacute;usicas    (tRR<sub>10<
/sub> = 1,61; IC95%: 1,05 a 2,48). La asociaci&oacute;n entre el    IMC y la mor
talidad por c&aacute;ncer sigui&oacute; un patr&oacute;n similar    al descrito 
para la incidencia.</font></p>     ^cY#12.htm##
01194000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000500057708000300062704097600065002000701041#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\12.htm#S#p#13#9#text#11#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2">El riesgo de c&aacute;ncer    de mama en mujere
s premenop&aacute;usicas disminuy&oacute; a medida que aumentaba    el IMC y aum
ent&oacute; con el IMC en las posmenop&aacute;usicas que no hab&iacute;an    rec
ibido tratamiento de sustituci&oacute;n hormonal. Estos datos demuestran    que 
el estado de la mujer con relaci&oacute;n a la menopausia constituye un    facto
r clave en la relaci&oacute;n entre el IMC y el riesgo de c&aacute;ncer    en mu
jeres, no solamente para los tipos de c&aacute;ncer relacionados con las    horm
onas, como el c&aacute;ncer de mama y de endometrio, sino tambi&eacute;n    en o
tros tipos frecuentes de c&aacute;ncer sin relaci&oacute;n conocida con    las h
ormonas. El efecto del IMC sobre el riesgo de melanomas malignos y c&aacute;ncer
    colorrectal, de mama y de endometrio difiere significativamente seg&uacute;n
    el estatus menop&aacute;usico de la mujer.</font></p>     ^cY#12.htm##
01352000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704113300066002000701199#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\12.htm#S#p#14#10#text#11#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">A pesar de la dificultad    para lograr los es
timados correspondientes a las mujeres que no han llegado    a la menopausia con
 los datos disponibles, se concluy&oacute; que la proporci&oacute;n    de casos 
de c&aacute;ncer atribuibles al sobrepeso en mujeres premenop&aacute;usicas    d
el Reino Unido puede ser menor que en mujeres posmenop&aacute;usicas, debido    
a la relaci&oacute;n inversa observada en mujeres premenop&aacute;usicas entre  
  el IMC y el riesgo de c&aacute;ncer de mama, el m&aacute;s frecuente en estas 
   mujeres. Seg&uacute;n los resultados y los estimados actuales del IMC en las 
   mujeres del Reino Unido, se estim&oacute; que 5% de todos los casos de c&aacu
te;ncer    en mujeres posmenop&aacute;usicas de ese pa&iacute;s est&aacute;n aso
ciados    con el sobrepeso o la obesidad (IMC <u>&gt;</u> 25) y que 4% est&aacut
e;n asociados    con la obesidad (IMC <u>&gt;</u> 30). En el caso del c&aacute;n
cer de endometrio    y del adenocarcinoma de es&oacute;fago, el IMC representa e
l principal factor    de riesgo modificable.</font></p>     ^cY#12.htm##
00985000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704076600066002000700832#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\12.htm#S#p#15#11#text#11#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">Estos resultados    constituyen la primera evi
dencia cient&iacute;fica de la asociaci&oacute;n entre    el IMC y muchos de est
os tipos de c&aacute;ncer y el gran tama&ntilde;o de la    muestra le aporta una
 considerable robustez a estas conclusiones. En la Regi&oacute;n    de las Am&ea
cute;ricas, donde el sobrepeso y la obesidad constituyen un grave    y creciente
 problema, estos resultados deben tomarse muy en cuenta, tanto por    los especi
alistas como por las autoridades de salud. (Reeves GK, Pirie K, Beral    V, Gree
n J, Spencer E, Bull D. Cancer incidence and mortality in relation to    body ma
ss index in the Million Women Study: cohort study. Br Med J. 2007; 335:1134.)</f
ont></p>     ^cY#12.htm##
00259000000000169000450000400060000070200420000670500020004870600020005070000020
00527010002000547090005000567080002000610910009000630920007000720020007000797030
00300086#v23n2#v:\scielo\serial\rpsp\v23n2\markup\13.htm#S#o#1#1#text#1#20080318
#103152#13.htm#15##
00589000000000337000450000400060000070200420000670500020004870600020005070000020
00527010002000547090005000567080002000610710003000630400003000660010006000690420
00200075120000400077038000300081121000300084049000800087158000300095030002400098
03100030012203200020012506500090012701400110013603500100014712300020015701200850
0159002000700244#v23n2#v:\scielo\serial\rpsp\v23n2\markup\13.htm#S#h#2#1#text#1#
sc#es#br1.1#1#3.1#ND#13#RPSP030#nd#Rev Panam Salud Publica#23#2#20080200#^f128^l
128#1020-4989#1#Exposición al cadmio e hipertensión arterial en adultos fumadore
s y no fumadores^les#13.htm##
00596000000000337000450000400060000070200420000670500020004870600020005070000020
00527010002000547090005000567080002000610710003000630400003000660010006000690420
00200075120000400077038000300081121000300084049000800087158000300095030002400098
03100030012203200020012506500090012701400110013603500100014712300020015701200920
0159002000700251#v23n2#v:\scielo\serial\rpsp\v23n2\markup\13.htm#S#f#3#1#text#1#
sc#es#br1.1#1#3.1#ND#13#RPSP030#nd#Rev Panam Salud Publica#23#2#20080200#^f128^l
128#1020-4989#1#<B>Exposición al cadmio e hipertensión arterial en adultos fumad
ores y no fumadores</B>^les#13.htm##
00705000000000349000450000400060000070200420000670500020004870600020005070000020
00527010002000547090005000567080002000610640013000630710003000760400003000790010
00600082042000200088120000400090121000300094049000800097158000300105030002600108
03100030013403200020013706500090013901400110014803500100015912300020016901200850
0171002000700256008009200263#v23n2#v:\scielo\serial\rpsp\v23n2\markup\13.htm#S#l
#4#1#text#1#^mfeb.^a2008#sc#es#br1.1#1#3.1#13#RPSP030#nd#Rev. panam. salud públi
ca#23#2#20080200#^f128^l128#1020-4989#1#Exposición al cadmio e hipertensión arte
rial en adultos fumadores y no fumadores^les#13.htm#Internet^ihttp://www.scielos
p.org/scielo.php?script=sci_arttext&pid=S1020-49892008000200013##
00340000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704012300064002000700187#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\13.htm#S#p#5#1#text#11#<p align="right"><font face="Ve
rdana, Arial, Helvetica, sans-serif" size="2"><b>INSTANT&Aacute;NEAS</b></font><
/p>     ^cY#13.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704002200064002000700086#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\13.htm#S#p#6#2#text#11#<p>&nbsp;</p>     ^cY#13.htm##
00404000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704018700064002000700251#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\13.htm#S#p#7#3#text#11#<p><font face="Verdana, Arial, 
Helvetica, sans-serif" size="4"><b>Exposici&oacute;n    al cadmio e hipertensi&o
acute;n arterial en adultos fumadores y no fumadores</b></font></p>     ^cY#13.h
tm##
00239000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704002200064002000700086#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\13.htm#S#p#8#4#text#11#<p>&nbsp;</p>     ^cY#13.htm##
00239000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000500056708000300061704002200064002000700086#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\13.htm#S#p#9#5#text#11#<p>&nbsp;</p>     ^cY#13.htm##
00951000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000500057708000300062704073300065002000700798#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\13.htm#S#p#10#6#text#11#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2">El cadmio es un    metal t&oacute;xico y carcin
og&eacute;nico de amplia distribuci&oacute;n en    la naturaleza. Las principale
s fuentes de exposici&oacute;n al cadmio en la    poblaci&oacute;n general son e
l humo del cigarro, el consumo de algunos alimentos    y el aire ambiental, espe
cialmente en zonas urbanas y en las proximidades de    plantas industriales. La 
exposici&oacute;n al cadmio produce hipertensi&oacute;n    en modelos animales, 
sin embargo los estudios epidemiol&oacute;gicos para determinar    la asociaci&o
acute;n entre la exposici&oacute;n al cadmio ambiental y la tensi&oacute;n    ar
terial en las personas no son concluyentes.</font></p>     ^cY#13.htm##
00857000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000500057708000300062704063900065002000700704#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\13.htm#S#p#11#7#text#11#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2">En este trabajo    se investig&oacute; la asoci
aci&oacute;n entre los niveles de cadmio en la sangre    y la orina, por una par
te, y la tensi&oacute;n arterial y la prevalencia de    la hipertensi&oacute;n, 
por la otra, en una muestra representativa de los adultos    de los Estados Unid
os de Am&eacute;rica. El contenido de cadmio, tanto en la    orina como en la sa
ngre, es un marcador de la exposici&oacute;n prolongada o    actual a ese metal,
 aunque los niveles en la sangre reflejan mejor la exposici&oacute;n    reciente
 que los niveles en la orina.</font></p>     ^cY#13.htm##
00641000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000500057708000300062704042300065002000700488#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\13.htm#S#p#12#8#text#11#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2">Para este estudio    se analizaron las concentr
aciones de cadmio en la sangre de 10 991 personas    y de cadmio en la orina de 
3 496 personas, del total de 15 332 estadounidenses    no institucionalizados de
 20 a&ntilde;os de edad o m&aacute;s participantes    en la Encuesta Nacional de
 Salud y Nutrici&oacute;n (NHANES) de 1999&#150;2004.</font></p>     ^cY#13.htm#
#
00850000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000500057708000300062704063200065002000700697#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\13.htm#S#p#13#9#text#11#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2">Las medias geom&eacute;tricas    de la concentr
aci&oacute;n de cadmio en la sangre y en la orina fueron 3,77    nmol/L y 2,46 n
mol/L, respectivamente. Despu&eacute;s de ajustar por m&uacute;ltiples    variab
les, las diferencias promedio de la tensi&oacute;n arterial sist&oacute;lica    
entre el percentil 90 y el percentil 10 de la distribuci&oacute;n de las concent
raciones    de cadmio en la sangre fue de 1,36 mm Hg (intervalo de confianza de 
95% &#91;IC95%&#93;:    &#150;0,28 a 3,00) y de cadmio en la orina de 1,68 mm Hg
 (IC95%: 0,57 a 2,78).</font></p>     ^cY#13.htm##
01588000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704136900066002000701435#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\13.htm#S#p#14#10#text#11#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">La asociaci&oacute;n    de las concentraciones
 de cadmio en la sangre y la orina y la tensi&oacute;n    arterial fueron muy si
milares en hombres y mujeres, y no se observ&oacute; ning&uacute;n    tipo de in
teracci&oacute;n significativa. Seg&uacute;n su clasificaci&oacute;n    como fum
adores, las diferencias promedio entre la tensi&oacute;n arterial sist&oacute;li
ca    y diast&oacute;lica de los participantes ubicados en el percentil 90 por s
us    niveles de cadmio con respecto a los del percentil 10 fueron: 2,35 mm Hg y
 3,27    mm Hg, respectivamente, entre los que nunca fumaron; 1,69 mm Hg y 1,55 
mm Hg    entre los ex fumadores; y 0,02 mm Hg y 0,69 mm Hg entre los fumadores a
ctivos.    Las variaciones en la asociaci&oacute;n entre los niveles de cadmio e
n la sangre    y la tensi&oacute;n arterial sist&oacute;lica y diast&oacute;lica
 de los fumadores    activos en comparaci&oacute;n con los que nunca fumaron fue
ron significativas.    Para los niveles de cadmio en la orina, esta asociaci&oac
ute;n fue similar en    todos los subgrupos de fumadores y no fumadores. No se e
ncontr&oacute; asociaci&oacute;n    entre el nivel de cadmio en la orina y la te
nsi&oacute;n arterial, o entre los    niveles de cadmio en la sangre y la orina 
y la prevalencia de hipertensi&oacute;n.</font></p>     ^cY#13.htm##
01116000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000500058708000300063704089700066002000700963#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\13.htm#S#p#15#11#text#11#<p><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">A pesar del bajo    nivel de exposici&oacute;n
 al cadmio observado en esta muestra representativa    de la poblaci&oacute;n ad
ulta estadounidense, se encontr&oacute; una ligera    pero positiva asociaci&oac
ute;n entre los niveles de cadmio en la sangre y la    tensi&oacute;n arterial. 
Esta asociaci&oacute;n fue m&aacute;s fuerte en las    personas que nunca fumaro
n, intermedia en los ex fumadores y baja o nula en    los fumadores. Deben empre
nderse investigaciones similares en otros escenarios    de la Regi&oacute;n, don
de la contaminaci&oacute;n con cadmio puede ser mucho    mayor. (T&eacute;llez-P
laza M, Navas-Acien A, Crainiceanu CM, Guallar E. Cadmium    exposure and hypert
ension in the 1999&#150;2004 National Health and Nutrition    Examination Survey
 (NHANES). Environ Health Perspect. 2008;116(1).</font></p>     ^cY#13.htm##
00263000000000169000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640910009000660920007000750020007000827030
00400089#v23n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#o#1#1#article#1#20080
318#114754#14.htm#126##
03353000000000625000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000400084121000300088049000800091158000300099030002400102
03100030012603200020012906500090013101400110014003500100015101201270016101201260
02880100035004140100037004490100027004860100029005130100028005420100032005700100
02900602010003100631070011300662070010400775070007200879070005100951070010801002
07001280111008312970123808500080253508500200254308500250256308500220258808500300
2610085002602640085004502666117000602711072000302717002000702720#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#h#2#1#article#1#oa#es#br1.1#1#3.1#TAB#14#RPSP
050#nd#Rev Panam Salud Publica#23#2#20080200#^f129^l134#1020-4989#Red Regional d
e Laboratorios para la Vigilancia de las Infecciones Fúngicas Invasoras y Suscep
tibilidad a los Antifúngicos^les#Regional Laboratory Network for Surveillance of
 Invasive Fungal Infections and Antifungal Susceptibility in Latin America^len#^
rND^1A01^nManuel^sCuenca-Estrella#^rND^1A01^nJuan L.^sRodríguez-Tudela#^rND^1A02
^nSusana^sCórdoba#^rND^1A03^nMarcia C.^sMelhem#^rND^1A03^nMaría W.^sSzeszs#^rND^
1A04^nElizabeth^sCastañeda#^rND^1A05^nGerardo^sMartínez#^rND^1A06^nJean-Marc^sGa
bastou#Instituto de Salud Carlos III^iA01^1Centro Nacional de Microbiología^2Ser
vicio de Micología^cMajadahonda^pEspaña#Instituto Nacional de Enfermedades Infec
ciosas^iA02^1Departamento de Micología^cBuenos Aires^pArgentina#Instituto Adolfo
 Lutz^iA03^1Serviço de Parasitología^cSao Paulo^pBrasil#Instituto Nacional de Sa
lud^iA04^cBogotá^pColombia#Instituto de Medicina Tropical 'Pedro Kourí'^iA05^1De
partamento de Bacteriología/Micología^cLa Habana^pCuba#Organización Panamericana
 de la Salud^iA06^1Unidad de Medicamentos Esenciales, Vacunas y Tecnología de la
 Salud^cQuito^pEcuador#^len^aThis article describes the general objectives of th
e Regional Laboratory Network for Surveillance of Invasive Fungal Infections and
 Antifungal Susceptibility in Latin America. Formation of the Network was coordi
nated by the Essential Medicines, Vaccines, and Health Technologies Unit of the 
Pan American Health Organization, with the technical and financial support of th
e National Center for Microbiology of the Carlos III Health Institute (Spain), a
nd the technical support of the Microbiology Department of the Dr. C. Malbrán Na
tional Institute on Infectious Diseases (Argentina) and the Microbiology Unit of
 the Parasitology Service of the Adolfo Lutz Institute (Brazil). The Network's p
rinciple objectives are epidemiological surveillance of invasive fungal infectio
ns through detection of antifungal resistance and identification of emergent, in
vasive fungal infections; establishment of norms and common protocols for early 
diagnosis of mycoses; and strengthening coordination, communications, and transf
erence mechanisms among countries. The Network must be gradually implemented and
 must include staff training, a systematic process for sharing technology, evalu
ation of diagnostic techniques, identification of fungal species, and standardiz
ed tests for antifungal susceptibility.#^dnd^i1#^tm^len^kmycoses^i1#^tm^len^ksur
veillance^i1#^tm^len^kdiagnosis^i1#^tm^len^kantifungal agents^i1#^tm^len^kLatin 
America^i1#^tm^len^kPan American Health Organization^i1#other#32#14.htm##
03367000000000625000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000400084121000300088049000800091158000300099030002400102
03100030012603200020012906500090013101400110014003500100015101201340016101201330
02950100035004280100037004630100027005000100029005270100028005560100032005840100
02900616010003100645070011300676070010400789070007200893070005100965070010801016
07001280112408312970125208500080254908500200255708500250257708500220260208500300
2624085002602654085004502680117000602725072000302731002000702734#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#f#3#1#article#1#oa#es#br1.1#1#3.1#TAB#14#RPSP
050#nd#Rev Panam Salud Publica#23#2#20080200#^f129^l134#1020-4989#<B>Red Regiona
l de Laboratorios para la Vigilancia de las Infecciones Fúngicas Invasoras y Sus
ceptibilidad a los Antifúngicos</B>^les#<B>Regional Laboratory Network for Surve
illance of Invasive Fungal Infections and Antifungal Susceptibility in Latin Ame
rica</B>^len#^rND^1A01^nManuel^sCuenca-Estrella#^rND^1A01^nJuan L.^sRodríguez-Tu
dela#^rND^1A02^nSusana^sCórdoba#^rND^1A03^nMarcia C.^sMelhem#^rND^1A03^nMaría W.
^sSzeszs#^rND^1A04^nElizabeth^sCastañeda#^rND^1A05^nGerardo^sMartínez#^rND^1A06^
nJean-Marc^sGabastou#Instituto de Salud Carlos III^iA01^1Centro Nacional de Micr
obiología^2Servicio de Micología^cMajadahonda^pEspaña#Instituto Nacional de Enfe
rmedades Infecciosas^iA02^1Departamento de Micología^cBuenos Aires^pArgentina#In
stituto Adolfo Lutz^iA03^1Serviço de Parasitología^cSao Paulo^pBrasil#Instituto 
Nacional de Salud^iA04^cBogotá^pColombia#Instituto de Medicina Tropical 'Pedro K
ourí'^iA05^1Departamento de Bacteriología/Micología^cLa Habana^pCuba#Organizació
n Panamericana de la Salud^iA06^1Unidad de Medicamentos Esenciales, Vacunas y Te
cnología de la Salud^cQuito^pEcuador#^len^aThis article describes the general ob
jectives of the Regional Laboratory Network for Surveillance of Invasive Fungal 
Infections and Antifungal Susceptibility in Latin America. Formation of the Netw
ork was coordinated by the Essential Medicines, Vaccines, and Health Technologie
s Unit of the Pan American Health Organization, with the technical and financial
 support of the National Center for Microbiology of the Carlos III Health Instit
ute (Spain), and the technical support of the Microbiology Department of the Dr.
 C. Malbrán National Institute on Infectious Diseases (Argentina) and the Microb
iology Unit of the Parasitology Service of the Adolfo Lutz Institute (Brazil). T
he Network's principle objectives are epidemiological surveillance of invasive f
ungal infections through detection of antifungal resistance and identification o
f emergent, invasive fungal infections; establishment of norms and common protoc
ols for early diagnosis of mycoses; and strengthening coordination, communicatio
ns, and transference mechanisms among countries. The Network must be gradually i
mplemented and must include staff training, a systematic process for sharing tec
hnology, evaluation of diagnostic techniques, identification of fungal species, 
and standardized tests for antifungal susceptibility.#^dnd^i1#^tm^len^kmycoses^i
1#^tm^len^ksurveillance^i1#^tm^len^kdiagnosis^i1#^tm^len^kantifungal agents^i1#^
tm^len^kLatin America^i1#^tm^len^kPan American Health Organization^i1#other#32#1
4.htm##
03493000000000649000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640640013000660710003000790400003000820010
00600085042000200091120000400093038000400097121000300101049000800104158000300112
03000260011503100030014103200020014406500090014601400110015503500100016601201270
01760120126003030100035004290100036004640100027005000100028005270100027005550100
03200582010002900614010003100643070011500674070010600789070007400895070005300969
07001100102207001300113208312970126208500080255908500200256708500250258708500220
26120850030026340850026026640850045026901170006027350720003027410020007027440080
09202751#v23n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#l#4#1#article#1#^mfeb
.^a2008#oa#es#br1.1#1#3.1#tab#14#RPSP050#nd#Rev. panam. salud pública#23#2#20080
200#^f129^l134#1020-4989#Red Regional de Laboratorios para la Vigilancia de las 
Infecciones Fúngicas Invasoras y Susceptibilidad a los Antifúngicos^les#Regional
 Laboratory Network for Surveillance of Invasive Fungal Infections and Antifunga
l Susceptibility in Latin America^len#^rND^1A01^nManuel^sCuenca-Estrella#^rND^1A
01^nJuan L^sRodríguez-Tudela#^rND^1A02^nSusana^sCórdoba#^rND^1A03^nMarcia C^sMel
hem#^rND^1A03^nMaría W^sSzeszs#^rND^1A04^nElizabeth^sCastañeda#^rND^1A05^nGerard
o^sMartínez#^rND^1A06^nJean-Marc^sGabastou#^iA01^1Instituto de Salud Carlos III^
2Centro Nacional de Microbiología^3Servicio de Micología^cMajadahonda^pEspaña#^i
A02^1Instituto Nacional de Enfermedades Infecciosas^2Departamento de Micología^c
Buenos Aires^pArgentina#^iA03^1Instituto Adolfo Lutz^2Serviço de Parasitología^c
Sao Paulo^pBrasil#^iA04^1Instituto Nacional de Salud^cBogotá^pColombia#^iA05^1In
stituto de Medicina Tropical 'Pedro Kourí'^2Departamento de Bacteriología/Micolo
gía^cLa Habana^pCuba#^iA06^1Organización Panamericana de la Salud^2Unidad de Med
icamentos Esenciales, Vacunas y Tecnología de la Salud^cQuito^pEcuador#^len^aThi
s article describes the general objectives of the Regional Laboratory Network fo
r Surveillance of Invasive Fungal Infections and Antifungal Susceptibility in La
tin America. Formation of the Network was coordinated by the Essential Medicines
, Vaccines, and Health Technologies Unit of the Pan American Health Organization
, with the technical and financial support of the National Center for Microbiolo
gy of the Carlos III Health Institute (Spain), and the technical support of the 
Microbiology Department of the Dr. C. Malbrán National Institute on Infectious D
iseases (Argentina) and the Microbiology Unit of the Parasitology Service of the
 Adolfo Lutz Institute (Brazil). The Network's principle objectives are epidemio
logical surveillance of invasive fungal infections through detection of antifung
al resistance and identification of emergent, invasive fungal infections; establ
ishment of norms and common protocols for early diagnosis of mycoses; and streng
thening coordination, communications, and transference mechanisms among countrie
s. The Network must be gradually implemented and must include staff training, a 
systematic process for sharing technology, evaluation of diagnostic techniques, 
identification of fungal species, and standardized tests for antifungal suscepti
bility.#^dnd^i1#^tm^len^kmycoses^i1#^tm^len^ksurveillance^i1#^tm^len^kdiagnosis^
i1#^tm^len^kantifungal agents^i1#^tm^len^kLatin America^i1#^tm^len^kPan American
 Health Organization^i1#other#32#14.htm#Internet^ihttp://www.scielosp.org/scielo
.php?script=sci_arttext&pid=S1020-49892008000200014##
00361000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704014100067002000700208#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#5#1#article#90#<p align="right"><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>TEMAS    DE ACTUALIDAD</b> C
URRENT TOPICS</font></p>     ^cY#14.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704002200067002000700089#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#6#2#article#90#<p>&nbsp;</p>     ^cY#14.htm
##
00470000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704025000067002000700317#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#7#3#article#90#<p><a name="top"></a><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Red    Regional de Labor
atorios para la Vigilancia de las Infecciones F&uacute;ngicas    Invasoras y Sus
ceptibilidad a los Antif&uacute;ngicos</b></font></p>     ^cY#14.htm##
00242000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704002200067002000700089#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#8#4#article#90#<p>&nbsp;</p>     ^cY#14.htm
##
00437000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000300064704021700067002000700284#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#9#5#article#90#<p><font face="Verdana, Aria
l, Helvetica, sans-serif" size="3"><b>Regional Laboratory    Network for Surveil
lance of Invasive Fungal Infections and Antifungal Susceptibility    in Latin Am
erica</b></font></p>     ^cY#14.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704002200068002000700090#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#10#6#article#90#<p>&nbsp;</p>     ^cY#14.ht
m##
00243000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704002200068002000700090#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#11#7#article#90#<p>&nbsp;</p>     ^cY#14.ht
m##
00642000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704042100068002000700489#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#12#8#article#90#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><b>Manuel Cuenca-Estrella<sup>I,    <a href=
"#back">*</a></sup>; Juan L. Rodr&iacute;guez-Tudela<sup>I</sup>; Susana    C&oa
cute;rdoba<sup>II</sup>; Marcia C. Melhem<sup>III</sup>; Mar&iacute;a W.    Szes
zs<sup>III</sup>; Elizabeth Casta&ntilde;eda<sup>IV</sup>; Gerardo Mart&iacute;n
ez<sup>V</sup>;    Jean-Marc Gabastou<sup>VI</sup></b></font></p>     ^cY#14.htm
##
00438000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000300065704021700068002000700285#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#13#9#article#90#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><sup>I</sup>Servicio    de Micolog&iacute;a,
 Centro Nacional de Microbiolog&iacute;a, Instituto de Salud    Carlos III, Maja
dahonda, Espa&ntilde;a    ^cY#14.htm##
00381000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704015900069002000700228#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#14#10#article#90#<br>   <sup>II</sup>Depart
amento de Micolog&iacute;a, Instituto Nacional de Enfermedades    Infecciosas, A
NLIS, Malbr&aacute;n, Buenos Aires, Argentina    ^cY#14.htm##
00375000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704015300069002000700222#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#15#11#article#90#<br>   <sup>III</sup>Se&cc
edil;&atilde;o de Micolog&iacute;a. Servi&ccedil;o de Parasitolog&iacute;a,    I
nstituto Adolfo Lutz, Sao Paulo, Brasil    ^cY#14.htm##
00336000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704011400069002000700183#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#16#12#article#90#<br>   <sup>IV</sup>Grupo 
de Microbiolog&iacute;a, Instituto Nacional de Salud, Bogot&aacute;,    Colombia
    ^cY#14.htm##
00378000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704015600069002000700225#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#17#13#article#90#<br>   <sup>V</sup>Departa
mento de Bacteriolog&iacute;a/Micolog&iacute;a del Instituto    de Medicina Trop
ical "Pedro Kour&iacute;", La Habana, Cuba    ^cY#14.htm##
00401000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704017900069002000700248#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#18#14#article#90#<br>   <sup>VI</sup>Unidad
 de Medicamentos Esenciales, Vacunas y Tecnolog&iacute;a    de la Salud, Organiz
aci&oacute;n Panamericana de la Salud, Quito, Ecuador</font></p>     ^cY#14.htm#
#
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#19#15#article#90#<p>&nbsp;</p>     ^cY#14.h
tm##
00266000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704004400069002000700113#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#20#16#article#90#<p>&nbsp;</p> <hr size="1"
 noshade>     ^cY#14.htm##
00485000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704026300069002000700332#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#21#17#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Palabras clave:</b>    micosis, vigilanc
ia, diagn&oacute;stico, antif&uacute;ngicos, Latinoam&eacute;rica,    Organizaci
&oacute;n Panamericana de la Salud.</font></p> <hr size="1" noshade>     ^cY#14.
htm##
00319000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704009700069002000700166#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#22#18#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>SUMMARY</b></font></p>     ^cY#14.htm##
01002000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704078000069002000700849#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#23#19#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">This article describes    the general objec
tives of the Regional Laboratory Network for Surveillance of    Invasive Fungal 
Infections and Antifungal Susceptibility in Latin America. Formation    of the N
etwork was coordinated by the Essential Medicines, Vaccines, and Health    Techn
ologies Unit of the Pan American Health Organization, with the technical    and 
financial support of the National Center for Microbiology of the Carlos    III H
ealth Institute (Spain), and the technical support of the Microbiology    Depart
ment of the Dr. C. Malbr&aacute;n National Institute on Infectious Diseases    (
Argentina) and the Microbiology Unit of the Parasitology Service of the Adolfo  
  Lutz Institute (Brazil).    ^cY#14.htm##
00884000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704066200069002000700731#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#24#20#article#90#<br>   The Network's princ
iple objectives are epidemiological surveillance of invasive    fungal infection
s through detection of antifungal resistance and identification    of emergent, 
invasive fungal infections; establishment of norms and common protocols    for e
arly diagnosis of mycoses; and strengthening coordination, communications,    an
d transference mechanisms among countries. The Network must be gradually impleme
nted    and must include staff training, a systematic process for sharing techno
logy,    evaluation of diagnostic techniques, identification of fungal species, 
and standardized    tests for antifungal susceptibility.</font></p>     ^cY#14.h
tm##
00452000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704023000069002000700299#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#25#21#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Key words:</b>    mycoses, surveillance,
 diagnosis, antifungal agents, Latin America, Pan American    Health Organizatio
n.</font></p> <hr size="1" noshade>     ^cY#14.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#26#22#article#90#<p>&nbsp;</p>     ^cY#14.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#27#23#article#90#<p>&nbsp;</p>     ^cY#14.h
tm##
00334000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704011200069002000700181#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#28#24#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>OBJETIVOS DE    LA RED</b></font></p>   
  ^cY#14.htm##
01155000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704093300069002000701002#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#29#25#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Las infecciones    f&uacute;ngicas han aume
ntado en frecuencia e importancia en los &uacute;ltimos    a&ntilde;os (1&#150;3
). La introducci&oacute;n de los antibi&oacute;ticos en    1945, de la corticote
rapia en 1959 y del tratamiento con inmunosupresores en    1960, provoc&oacute; 
un aumento, sin precedentes, de la incidencia de las infecciones    f&uacute;ngi
cas en todo el mundo. Estos avances m&eacute;dicos han permitido    mejorar el p
ron&oacute;stico de muchas enfermedades aunque, paralelamente, han    dado lugar
 a un incremento de las complicaciones iatrog&eacute;nicas y de las    infeccion
es oportunistas, entre las que se encuentran las micosis. A partir    de1970, la
 incidencia anual de las infecciones f&uacute;ngicas ha aumentado    de 3 a 20 v
eces, dependiendo del tipo de infecci&oacute;n y del trabajo consultado    (4&#1
50;13).</font></p>     ^cY#14.htm##
01363000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704114100069002000701210#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#30#26#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Por otra parte,    con la aparici&oacute;n 
del VIH/SIDA al principio de la d&eacute;cada de 1980,    la poblaci&oacute;n su
sceptible de padecer infecciones oportunistas (IO) se    increment&oacute; de ma
nera considerable. En sus inicios, por s&oacute;lo citar    algunos ejemplos, ci
ertas micosis invasoras, como la neumocistosis, afectaron    de un 70% a un 80% 
de la poblaci&oacute;n con SIDA, con una mortalidad asociada    de 20% a 40%. Po
r otro lado, la criptococosis pas&oacute; de 5% a 8% en pa&iacute;ses    desarro
llados, y a m&aacute;s de 20 % en regiones de &Aacute;frica, con una    tasa de 
mortalidad superior a 30 %; por su parte, la histoplasmosis ascendi&oacute;    d
e 2% a 5% en regiones end&eacute;micas (14). En las dos &uacute;ltimas d&eacute;
cadas,    como resultado de los tratamientos profil&aacute;cticos y de la terapi
a antirretroviral    de gran efectividad, la incidencia de las IO ha disminuido;
 sin embargo, sus    tasas de morbilidad y mortalidad siguen siendo elevadas, en
 particular en pa&iacute;ses    de bajos recursos (15).</font></p>     ^cY#14.ht
m##
02048000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704182600069002000701895#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#31#27#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Adem&aacute;s,    otros estudios epidemiol&
oacute;gicos publicados en los &uacute;ltimos a&ntilde;os    han destacado que l
a elevada prevalencia de las infecciones f&uacute;ngicas    se acompa&ntilde;a d
e una mortalidad preocupante. De esta forma, la mortalidad    atribuible a la ca
ndidemia se sit&uacute;a entre 20% y 50% de los casos; la    correspondiente a l
a aspergilosis entre 40% y 80% de los casos y, en algunas    infecciones por hon
gos emergentes, la tasa de mortalidad puede ir m&aacute;s    all&aacute; de 90% 
(16&#150; 19). Las cifras de mortalidad dependen de muchos    factores concomita
ntes, como la enfermedad de base, la zona geogr&aacute;fica,    el tipo de infec
ci&oacute;n y el tratamiento aplicado; empero, en t&eacute;rminos    generales l
as infecciones f&uacute;ngicas oportunistas se est&aacute;n convirtiendo    en u
n problema sanitario de primer orden, en todo el mundo desarrollado (20).    Otr
os trabajos, quiz&aacute; m&aacute;s ilustrativos, han demostrado que <i>Candida
</i>    spp. causan 10% de las sepsis nosocomiales y que la candidemia prolonga 
en tres    semanas la estancia hospitalaria, duplicando el riesgo de muerte del 
enfermo    (11, 18, 19, 21). En todo el mundo se realizan m&aacute;s de 650 000 
trasplantes    al a&ntilde;o, con un incremento anual medio de 1,5%. La poblaci&
oacute;n de    enfermos trasplantados constituye uno de los principales grupos d
e riesgo de    micosis, ya que se calcula que de 10% a 15% de estos pacientes de
sarrollar&aacute;n    una infecci&oacute;n f&uacute;ngica. Esta cifra puede dupl
icarse en personas    trasplantadas de precursores hematopoy&eacute;ticos, para 
quienes se calcula    una tasa de mortalidad atribuible a las micosis de 20% a 2
5% (17, 22&#150;24).</font></p>     ^cY#14.htm##
01431000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704120900069002000701278#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#32#28#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Esta nueva situaci&oacute;n    epidemiol&oa
cute;gica ha causado un incremento en el consumo de antif&uacute;ngicos,    as&i
acute; como el desarrollo de nuevas t&eacute;cnicas diagn&oacute;sticas    y ter
ap&eacute;uticas. En la &uacute;ltima d&eacute;cada, el consumo de antif&uacute;
ngicos    ha aumentado alrededor de 12% de media cada a&ntilde;o, y seg&uacute;n
 datos    globales, el costo en antif&uacute;ngicos asciende a 3 600 millones de
 euros    anuales (25, 26). El uso masivo de antif&uacute;ngicos ha originado la
 aparici&oacute;n    de resistencias secundarias y, quiz&aacute;, el desplazamie
nto de especies sensibles    por otras m&aacute;s resistentes (27, 28), por lo q
ue se han desarrollado nuevas    mol&eacute;culas antif&uacute;ngicas que ya se 
emplean en muchos hospitales.    Ante esta nueva situaci&oacute;n, es necesario 
conocer el perfil de susceptibilidad    de las especies f&uacute;ngicas para ins
taurar el tratamiento m&aacute;s adecuado,    por lo que se han desarrollado m&e
acute;todos estandarizados para realizar estudios    de susceptibilidad <i>in vi
tro</i> a los antif&uacute;ngicos (26, 29).</font></p>     ^cY#14.htm##
00769000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704054700069002000700616#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#33#29#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Por tanto, el diagn&oacute;stico    precoz,
 la caracterizaci&oacute;n de las especies y la detecci&oacute;n de la    resist
encia a los antif&uacute;ngicos se han situado como herramientas b&aacute;sicas 
   para el control de las infecciones f&uacute;ngicas. Sin embargo, estas t&eacu
te;cnicas    no est&aacute;n a&uacute;n implantadas en muchos laboratorios ya qu
e son complejas    y costosas y, por tanto, deben ser manejadas e interpretadas 
por personal experto.</font></p>     ^cY#14.htm##
00859000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704063700069002000700706#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#34#30#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Los laboratorios    de referencia se han co
nvertido en centros imprescindibles en la formaci&oacute;n    de personal, en la
 estandarizaci&oacute;n de t&eacute;cnicas microbiol&oacute;gicas,    en la tran
sferencia de tecnolog&iacute;a y conocimiento a otros centros y en    el desarro
llo de programas de evaluaci&oacute;n externa del desempe&ntilde;o.    Asimismo,
 la interlocuci&oacute;n y el intercambio de informaci&oacute;n entre    estos c
entros son esenciales para conocer la aut&eacute;ntica realidad epidemiol&oacute
;gica    de las micosis (3, 1).</font></p>     ^cY#14.htm##
00968000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704074600069002000700815#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#35#31#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">La Organizaci&oacute;n    Panamericana de l
a Salud/ Organizaci&oacute;n Mundial de la Salud (OPS/OMS)    recomienda fortale
cer la capacidad de las redes de laboratorios e institutos    de salud p&uacute;
blica en Am&eacute;rica Latina y el Caribe, en una acci&oacute;n    fundamental 
del quehacer colectivo de la comunidad sanitaria de las Am&eacute;ricas,    para
 el diagn&oacute;stico, la vigilancia, la prevenci&oacute;n y el control    de l
as enfermedades prevalentes, respondiendo a los nuevos desaf&iacute;os epidemiol
&oacute;gicos    que se presentan en el hemisferio, dentro del marco de la aplic
aci&oacute;n    del Reglamento Sanitario Internacional 2005.</font></p>     ^cY#
14.htm##
01351000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704112900069002000701198#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#36#32#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">En este contexto,    en 2006, bajo la coord
inaci&oacute;n de la Unidad de Medicamentos Esenciales,    Vacunas y Tecnolog&ia
cute;as en Salud de la OPS/OMS, con el apoyo t&eacute;cnico    y financiero del 
Centro Nacional de Microbiolog&iacute;a del Instituto de Salud    Carlos III (IS
C III), y el soporte t&eacute;cnico del Departamento de Micolog&iacute;a    del 
Instituto Nacional de Enfermedades Infecciosas, ANLIS, Dr. C. Malbr&aacute;n,   
 de Buenos Aires, Argentina y de la Se&ccedil;&atilde;o de Micologia del Servi&c
cedil;o    de Parasitolog&iacute;a, Instituto Adolfo Lutz, de S&atilde;o Paulo, 
Brasil,    se cre&oacute; la Red Regional de Vigilancia de las Infecciones F&uac
ute;ngicas    Invasoras y Susceptibilidad a los Antif&uacute;ngicos. Esta &uacut
e;ltima se    organiz&oacute; a trav&eacute;s del Plan de Acci&oacute;n Conjunta
 entre la    Agencia Espa&ntilde;ola de Cooperaci&oacute;n Internacional (AECI) 
y la OPS,    por medio del financiamiento concedido por el ISC III del Ministeri
o de Sanidad    y Consumo de Espa&ntilde;a.</font></p>     ^cY#14.htm##
01384000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704116200069002000701231#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#37#33#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Los objetivos de    la Red recogen los aspe
ctos expuestos en los p&aacute;rrafos anteriores y pueden    enumerarse como: 1)
 la vigilancia epidemiol&oacute;gica de la infecci&oacute;n    f&uacute;ngica in
vasora mediante la detecci&oacute;n de resistencias a los antif&uacute;ngicos   
 y la caracterizaci&oacute;n de especies emergentes; 2) el establecimiento de   
 normas y protocolos comunes para el diagn&oacute;stico precoz de las micosis   
 y la detecci&oacute;n de resistencias a los antif&uacute;ngicos; 3) el fortalec
imiento    de los mecanismos de coordinaci&oacute;n, comunicaci&oacute;n y trans
ferencia    entre los pa&iacute;ses; 4) la diseminaci&oacute;n de informaci&oacu
te;n epidemiol&oacute;gica    veraz y confiable; 5) la capacitaci&oacute;n t&eac
ute;cnica de profesionales    mediante cursos, talleres y estad&iacute;as en los
 laboratorios de la red; 6)    el desarrollo de programas conjuntos de investiga
ci&oacute;n y de innovaci&oacute;n    tecnol&oacute;gica, y 7) la implementaci&o
acute;n de un programa de evaluaci&oacute;n    externa del desempe&ntilde;o.</fo
nt></p>     ^cY#14.htm##
01501000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704127900069002000701348#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#38#34#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">La Red est&aacute;    organizada en cuatro 
niveles de complejidad y se distribuye de la siguiente    manera: 1) el Servicio
 de Micolog&iacute;a del Centro Nacional de Microbiolog&iacute;a,    del Institu
to de Salud Carlos III en Majadahonda, Espa&ntilde;a, funge como    centro regio
nal de referencia para la Red Latinoamericana. 2) El Departamento    de Micolog&
iacute;a del Instituto Nacional de Enfermedades Infecciosas Dr. C.    Malbr&aacu
te;n, en Buenos Aires, Argentina, y el Departamento de Micolog&iacute;a    y Par
asitolog&iacute;a del Instituto Adolfo Lutz, en S&atilde;o Paulo, Brasil,    con
stituyen los dos centros de referencia sub-regionales. 3) Desde 2005, el    Grup
o de Microbiolog&iacute;a del Instituto Nacional de Salud, en Bogot&aacute;,    
Colombia, y desde finales de 2006, el Departamento de Bacteriolog&iacute;a/Micol
og&iacute;a    del Instituto de Medicina Tropical, Pedro Kour&iacute; (IPK) de L
a Habana, Cuba,    se constituyeron en los dos centros nacionales de referencia.
 4) En Argentina    existe un centro centinela, al igual que 11 en Brasil, tres 
en Colombia y dos    en Cuba, todos capacitados por los centros nacionales corre
spondientes entre    2002 y 2006.</font></p>     ^cY#14.htm##
01099000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704087700069002000700946#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#39#35#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">El plan de acci&oacute;n    de la Red consi
ste en la implantaci&oacute;n de las t&eacute;cnicas de vigilancia    en los lab
oratorios nacionales de referencia, para su posterior difusi&oacute;n    por los
 centros hospitalarios de cada pa&iacute;s. El desarrollo de las t&eacute;cnicas
    en los laboratorios de referencia se logra mediante un proceso gradual de tr
ansferencia    tecnol&oacute;gica <i>in situ</i>, as&iacute; como a trav&eacute;
s de la capacitaci&oacute;n    de los profesionales en cursos y talleres. Poster
iormente, cada centro de referencia    realiza un plan de acci&oacute;n similar 
en su zona de influencia, adem&aacute;s    de llevar a cabo la supervisi&oacute;
n de las actividades de los centros hospitalarios    en los que se implantan las
 t&eacute;cnicas de vigilancia.</font></p>     ^cY#14.htm##
00863000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704064100069002000700710#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#40#36#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">La evaluaci&oacute;n    externa del desempe
&ntilde;o de los centros de la Red Regional forma parte de    las actividades de
 supervisi&oacute;n, as&iacute; como de los programas para    garantizar la cali
dad que debe regir en la obtenci&oacute;n de informaci&oacute;n    precisa y con
fiable. En el segundo semestre de 2006 se llev&oacute; a cabo un    ejercicio de
 evaluaci&oacute;n de los centros de referencia de la Red, mediante    la realiz
aci&oacute;n de estudios de susceptibilidad a los antif&uacute;ngicos    con una
 colecci&oacute;n de cepas control.</font></p>     ^cY#14.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#41#37#article#90#<p>&nbsp;</p>     ^cY#14.h
tm##
00329000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704010700069002000700176#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#42#38#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>LOGROS ALCANZADOS</b></font></p>     ^cY
#14.htm##
00342000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704012000069002000700189#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#43#39#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Estudios de    susceptibilidad</b></font
></p>     ^cY#14.htm##
01247000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704102500069002000701094#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#44#40#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Los laboratorios    sub-regionales realizar
on los estudios de susceptibilidad siguiendo estrictamente    uno de los dos m&e
acute;todos de referencia recomendados para la Regi&oacute;n,    como el recogid
o en el documento M27-A2 del Clinical Laboratory Standards Institute    (CLSI) e
stadounidense o el m&eacute;todo del Antifungal Subcommittee of the    European 
Committee on Antifungal Susceptibility Testing (AFST-EUCAST, document    7.1) (2
9, 30). Algunos de los laboratorios tambi&eacute;n realizaron las pruebas    de 
susceptibilidad por un m&eacute;todo de difusi&oacute;n o por un m&eacute;todo  
  comercial como el Etest (AB Biodisk, Solna, Sweden). En esos casos, se siguier
on    las recomendaciones del fabricante y los protocolos estandarizados de las 
t&eacute;cnicas    de difusi&oacute;n (documento M44-A del CLSI), tanto en la re
alizaci&oacute;n    de las t&eacute;cnicas como en la interpretaci&oacute;n de l
os resultados (31).</font></p>     ^cY#14.htm##
00373000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704015100069002000700220#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#45#41#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Programa de    evaluaci&oacute;n externa
 del desempe&ntilde;o</b></font></p>     ^cY#14.htm##
01335000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704111300069002000701182#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#46#42#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">El centro de referencia    regional del Ins
tituto de Salud Carlos III, en su calidad de evaluador externo,    envi&oacute; 
una colecci&oacute;n de ocho cepas de referencia a cada uno de    los centros su
b-regionales y nacionales de referencia. Seis de las cepas estaban    codificada
s sin que se supiera su especie ni su perfil de susceptibilidad y    fueron eleg
idas por las caracter&iacute;sticas espec&iacute;ficas de sensibilidad    o resi
stencia a los antif&uacute;ngicos. Las otras dos cepas, <i>Candida krusei</i>   
 ATCC6258 y <i>Candida parapsilosis</i> ATCC22019 sirvieron de control interno  
  para que los laboratorios evaluados validaran sus propios resultados antes de 
   enviarlos al laboratorio evaluador externo. En los <a href="/img/revistas/rps
p/v23n2/14q1.gif">cuadros    1</a> y <a href="/img/revistas/rpsp/v23n2/14q2.gif"
>2</a> se incluyen las identificaciones    de las cepas analizadas y los interva
los de sensibilidad y resistencia a los    antif&uacute;ngicos por los m&eacute;
todos del EUCAST y de CLSI.</font></p>     ^cY#14.htm##
01209000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704098700069002000701056#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#47#43#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">La evaluaci&oacute;n    externa se realiz&o
acute; calculando el porcentaje de concentraciones m&iacute;nimas    inhibitoria
s (CMI) notificadas por cada laboratorio que se inclu&iacute;a dentro    del int
ervalo de control de calidad establecido para cada una de las cepas control    (
<a href="/img/revistas/rpsp/v23n2/14q1.gif">cuadros 1</a> y <a href="/img/revist
as/rpsp/v23n2/14q2.gif">2</a>)    (30, 32). Este intervalo es diferente seg&uacu
te;n el m&eacute;todo de referencia    (EUCAST y CLSI) utilizado. En el caso de 
los valores fuera del intervalo control,    se definieron <i>discrepancias susta
nciales o mayores</i> como aquellas CMI    mayores de dos diluciones dobles del 
intervalo de control. Los resultados de    cada laboratorio fueron validados cua
ndo se obtuvieron porcentajes de concordancia    por encina de 85% y porcentajes
 de discrepancias sustanciales o mayores por    debajo de 5%.</font></p>     ^cY
#14.htm##
00477000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704025500069002000700324#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#48#44#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Todos los c&aacute;lculos    se hicieron co
n el paquete inform&aacute;tico Statistical Package for the Social    Sciences (
version 14.0; SPSS, S.L., Madrid, Espa&ntilde;a).</font></p>     ^cY#14.htm##
00996000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704077400069002000700843#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#49#45#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">En el <a href="/img/revistas/rpsp/v23n2/14q
3.gif">cuadro    3</a> se presentan los porcentajes de CMI incluidos dentro de l
os intervalos    de control establecidos, as&iacute; como el n&uacute;mero de di
screpancias,    para cada uno de los laboratorios participantes. Los tres labora
torios obtuvieron    porcentajes de concordancia entre la CMI superiores a 85%, 
con un porcentaje    medio de 88,5%, as&iacute; como un porcentaje de discrepanc
ias mayores por debajo    de 5%. Adem&aacute;s, todos los laboratorios participa
ntes en el ejercicio fueron    capaces de detectar las cepas resistentes a fluco
nazol, as&iacute; como la cepa    multi-resistente <i>Candida tropicalis</i> ATC
C200956.</font></p>     ^cY#14.htm##
00668000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704044600069002000700515#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#50#46#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Al analizar los    resultados por antif&uac
ute;ngicos, se observaron porcentajes de concordancia    superiores a 90% con la
s CMI de anfotericina B y fluconazol. En el caso de itraconazol    y voriconazol
, esos porcentajes fueron de 85,2% y 86%, respectivamente. Las    discrepancias 
mayores fueron inferiores a 5% para todos los antif&uacute;ngicos    analizados.
</font></p>     ^cY#14.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#51#47#article#90#<p>&nbsp;</p>     ^cY#14.h
tm##
00324000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704010200069002000700171#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#52#48#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>PROYECCIONES</b></font></p>     ^cY#14.h
tm##
01084000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704086200069002000700931#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#53#49#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">La OPS se ha abocado    a la implementaci&o
acute;n de una iniciativa para reorientar las redes nacionales    de laboratorio
s de la Regi&oacute;n hacia un mayor entendimiento y cumplimiento    de su papel
 en la vigilancia de la salud. La Red Regional de Vigilancia de las    Infeccion
es F&uacute;ngicas Invasoras y Susceptibilidad a los Antif&uacute;ngicos    se c
re&oacute; en 2006, con los prop&oacute;sitos citados anteriormente. Toda    org
anizaci&oacute;n de este tipo debe contar con procedimientos que permitan    gar
antizar la calidad de sus resultados, y esa fue la raz&oacute;n que llev&oacute;
    a organizar el ejercicio de evaluaci&oacute;n externa del desempe&ntilde;o, 
   que adem&aacute;s se utiliz&oacute; como trabajo multic&eacute;ntrico inaugur
al    de la Red.</font></p>     ^cY#14.htm##
00623000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704040100069002000700470#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#54#50#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">El ejercicio se    efectu&oacute; para vali
dar los procedimientos de detecci&oacute;n de resistencia    a los antif&uacute;
ngicos de los laboratorios de la Red. Estos procedimientos    son esenciales par
a iniciar la vigilancia epidemiol&oacute;gica, ya que en sus    hallazgos deben 
basarse las estrategias de control.</font></p>     ^cY#14.htm##
00897000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704067500069002000700744#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#55#51#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Los resultados    del ejercicio pueden cons
iderarse excelentes. Todos los laboratorios superaron    los criterios de valida
ci&oacute;n elegidos y detectaron las resistencias a    anfotericina B y a los a
zoles. Estos datos permiten evaluar positivamente el    desempe&ntilde;o de todo
s los laboratorios de la Red que participaron en el    ejercicio, por lo que pue
de asegurarse que ha culminado el proceso de transferencia    tecnol&oacute;gica
 y que los resultados de la vigilancia epidemiol&oacute;gica    ser&aacute;n con
fiables para dise&ntilde;ar programas y estrategias de acci&oacute;n.</font></p>
     ^cY#14.htm##
01168000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704094600069002000701015#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#56#52#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">La Red debe ampliarse    paulatinamente y m
ejorar su funcionamiento para adecuarse a los objetivos planteados.    En 2007 s
e ha realizado un nuevo curso te&oacute;rico/pr&aacute;ctico que ha    permitido
 consolidar la capacidad t&eacute;cnica de los dos centros de referencia    sub-
regional en Argentina y Brasil, as&iacute; como ampliar la Red a nuevos    pa&ia
cute;ses como Venezuela. Adem&aacute;s, ya est&aacute;n en marcha nuevos    ejer
cicios de evaluaci&oacute;n, as&iacute; como de intercambio de informaci&oacute;
n    y de pasantes, que servir&aacute;n para analizar la capacidad de identifica
ci&oacute;n    y caracterizaci&oacute;n de las especies f&uacute;ngicas. Asimism
o, se continuar&aacute;    con las actividades formativas y de capacitaci&oacute
;n de profesionales y con    el desarrollo de proyectos de investigaci&oacute;n 
e innovaci&oacute;n.</font></p>     ^cY#14.htm##
00539000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704031700069002000700386#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#57#53#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">El objetivo de    largo plazo de la Red con
siste en transferir la tecnolog&iacute;a para fortalecer    la capacidad naciona
l y dar m&aacute;s autonom&iacute;a a los pa&iacute;ses    en la resoluci&oacute
;n concertada de los problemas.</font></p>     ^cY#14.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#58#54#article#90#<p>&nbsp;</p>     ^cY#14.h
tm##
00323000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704010100069002000700170#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#59#55#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>REFERENCIAS</b></font></p>     ^cY#14.ht
m##
00553000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704031700071002000700388#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#60#56#article#90#1#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">1.&nbsp;Cuenca-Estrella    M,
 Rodero L, Garcia-Effron G, Rodriguez-Tudela JL. Antifungal susceptibilities    
of Candida spp. isolated from blood in Spain and Argentina, 1996&#150;1999.    J
 Antimicrob Chemother. 2002;49(6):981&#150;7.</font></p>     ^cY#14.htm##
00616000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704038000071002000700451#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#61#57#article#90#2#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">2.&nbsp;Cuenca-Estrella    M,
 Gomez-Lopez A, Mellado E, Garcia-Effron G, Rodriguez-Tudela JL. In vitro    act
ivities of ravuconazole and four other antifungal agents against fluconazole-res
istant    or -susceptible clinical yeast isolates. Antimicrob Agents Chemother. 
2004;48(8):    3107&#150;11.</font></p>     ^cY#14.htm##
00474000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704023800071002000700309#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#62#58#article#90#3#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">3.&nbsp;Pfaller    MA, Diekem
a DJ. Epidemiology of invasive candidiasis: a persistent public health    proble
m. Clin Microbiol Rev. 2007;20(1):133&#150;63.</font></p>     ^cY#14.htm##
00417000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704018100071002000700252#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#63#59#article#90#4#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">4.&nbsp;Hazen KC.    New and 
emerging yeast pathogens. Clin Microbiol Rev. 1995; 8(4):462&#150;78.</font></p>
     ^cY#14.htm##
00443000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704020700071002000700278#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#64#60#article#90#5#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">5.&nbsp;Perfect    JR, Schell
 WA. The new fungal opportunists are coming. Clin Infect Dis. 1996;22    (suppl 
2):S112&#150;8.</font></p>     ^cY#14.htm##
00407000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704017100071002000700242#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#65#61#article#90#6#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">6.&nbsp;Denning    DW. Invasi
ve aspergillosis. Clin Infect Dis. 1998;26(4):781&#150;803.</font></p>     ^cY#1
4.htm##
00502000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704026600071002000700337#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#66#62#article#90#7#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">7.&nbsp;Walsh TJ,    Groll AH
. Emerging fungal pathogens: evolving challenges to immunocompromised    patient
s for the twenty-first century. Transpl Infect Dis. 1999;1(4):247&#150;61.</font
></p>     ^cY#14.htm##
00425000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704018900071002000700260#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#67#63#article#90#8#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">8.&nbsp;Latge JP.    Aspergil
lus fumigatus and aspergillosis. Clin Microbiol Rev. 1999; 12(2):310&#150;50.</f
ont></p>     ^cY#14.htm##
00514000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000200069704027800071002000700349#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#68#64#article#90#9#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">9.&nbsp;Singh N.    Trends in
 the epidemiology of opportunistic fungal infections: predisposing    factors an
d the impact of antimicrobial use practices. Clin Infect Dis. 2001;33(10):1692&#
150;6.</font></p>     ^cY#14.htm##
00522000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704028500072002000700357#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#69#65#article#90#10#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">10.&nbsp;Singh    N. Invasiv
e aspergillosis in organ transplant recipients: new issues in epidemiologic    c
haracteristics, diagnosis, and management. Medical Mycology. 2005;43(suppl    1)
:S267&#150;70.</font></p>     ^cY#14.htm##
00631000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704039400072002000700466#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#70#66#article#90#11#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">11.&nbsp;Almirante    B, Rod
riguez D, Park BJ, Cuenca-Estrella M, Planes AM, Almela M, et al. Epidemiology  
  and predictors of mortality in cases of Candida bloodstream infection: results
    from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J C
lin    Microbiol. 2005; 43(4):1829&#150;35.</font></p>     ^cY#14.htm##
00532000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704029500072002000700367#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#71#67#article#90#12#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">12.&nbsp;Munoz    P, Bouza E
, Cuenca-Estrella M, Eiros JM, Perez MJ, Sanchez-Somolinos M, et al.    Saccharo
myces cerevisiae fungemia: an emerging infectious disease. Clin Infect    Dis. 2
005;40(11):1625&#150;34.</font></p>     ^cY#14.htm##
00551000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704031400072002000700386#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#72#68#article#90#13#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">13.&nbsp;Guarro    J, Kantar
cioglu AS, Horre R, Rodriguez-Tudela JL, Cuenca EM, Berenguer J, et    al. Scedo
sporium apiospermum: changing clinical spectrum of a therapy-refractory    oppor
tunist. Med Mycol. 2006;44(4):295&#150;327.</font></p>     ^cY#14.htm##
00474000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704023700072002000700309#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#73#69#article#90#14#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">14.&nbsp;Gonz&aacute;lez    
A, Tob&oacute;n AM. Infecciones mic&oacute;ticas oportunistas en pacientes con  
  VIH/SIDA. Infectio. 2006;10(4): 279&#150;88.</font></p>     ^cY#14.htm##
00646000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704040900072002000700481#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#74#70#article#90#15#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">15.&nbsp;Benson    CA, Kapla
n JE, Masur H, Pau A, Holmes KK, CDC, et al. Treating opportunistic    infection
s among HIV-infected adults and adolescents: recommendations from CDC,    the Na
tional Institutes of Health, and the HIV Medicine Association/Infectious    Dise
ases Society of America. MMWR. 2004;53(RR-15): 1&#150;112.</font></p>     ^cY#14
.htm##
00487000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704025000072002000700322#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#75#71#article#90#16#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">16.&nbsp;Martin    GS, Manni
no DM, Eaton S, Moss M. The epidemiology of sepsis in the United States    from 
1979 through 2000. N Engl J Med. 2003;348(16):1546&#150;54.</font></p>     ^cY#1
4.htm##
00549000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704031200072002000700384#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#76#72#article#90#17#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">17.&nbsp;Gavalda    J, Len O
, San Juan R, Aguado JM, Fortun J, Lumbreras C, et al. Risk factors    for invas
ive aspergillosis in solid-organ transplant recipients: a case-control    study.
 Clin Infect Dis. 2005; 41(1): 52&#150;9.</font></p>     ^cY#14.htm##
00603000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704036600072002000700438#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#77#73#article#90#18#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">18.&nbsp;Arendrup    MC, Fuu
rsted K, Gahrn-Hansen B, Jensen IM, Knudsen JD, Lundgren B, et al. Seminational 
   surveillance of fungemia in Denmark: notably high rates of fungemia and numbe
rs    of isolates with reduced azole susceptibility. J Clin Microbiol. 2005;43(9
):4434&#150;40.</font></p>     ^cY#14.htm##
00612000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704037500072002000700447#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#78#74#article#90#19#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">19.&nbsp;Morgan    J, Meltze
r MI, Plikaytis BD, Sofair AN, Huie-White S, Wilcox S, et al. Excess    mortalit
y, hospital stay, and cost due to candidemia: a case-control study using    data
 from population-based candidemia surveillance. Infect Control Hosp Epidemiol.  
  2005;26(6):540&#150;7.</font></p>     ^cY#14.htm##
00501000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704026400072002000700336#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#79#75#article#90#20#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">20.&nbsp;Pinner    RW, Rebma
nn CA, Schuchat A, Hughes JM. Disease surveillance and the academic,    clinical
, and public health communities. Emerg Infect Dis. 2003; 9(7):781&#150;7.</font>
</p>     ^cY#14.htm##
00592000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704035500072002000700427#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#80#76#article#90#21#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">21.&nbsp;Shetty    SS, Harri
son LH, Hajjeh RA, Taylor T, Mirza SA, Schmidt AB, et al. Determining    risk fa
ctors for candidemia among newborn infants from population-based surveillance:  
  Baltimore, Maryland, 1998&#150; 2000. Pediatr Infect Dis J. 2005;24(7):601&#15
0;4.</font></p>     ^cY#14.htm##
00555000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704031800072002000700390#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#81#77#article#90#22#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">22.&nbsp;Grigull    L, Beier
 R, Schrauder A, Kirschner P, Loening L, Jack T, et al. Invasive fungal    infec
tions are responsible for one-fifth of the infectious deaths in children    with
 ALL. Mycoses. 2003;46 (11&#150;12):441&#150;6.</font></p>     ^cY#14.htm##
00525000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704028800072002000700360#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#82#78#article#90#23#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">23.&nbsp;Nucci    M, Marr KA
, Queiroz-Telles F, Martins CA, Trabasso P, Costa S, et al. Fusarium    infectio
n in hematopoietic stem cell transplant recipients. Clin Infect Dis.    2004; 38
(9):1237&#150;42.</font></p>     ^cY#14.htm##
00551000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704031400072002000700386#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#83#79#article#90#24#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">24.&nbsp;Castagnola    E, Ce
saro S, Giacchino M, Livadiotti S, Tucci F, Zanazzo G, et al. Fungal infections 
   in children with cancer: a prospective, multicenter surveillance study. Pedia
tr    Infect Dis J. 2006; 25(7):634&#150;9.</font></p>     ^cY#14.htm##
00664000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704042700072002000700499#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#84#80#article#90#25#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">25.&nbsp;Cuenca-Estrella    
M, Rodriguez D, Almirante B, Morgan J, Planes AM, Almela M, et al. In vitro    s
usceptibilities of bloodstream isolates of Candida species to six antifungal    
agents: results from a population-based active surveillance programme, Barcelona
,    Spain, 2002&#150; 2003. J Antimicrob Chemother. 2005; 55(2):194&#150;9.</fo
nt></p>     ^cY#14.htm##
00505000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704026800072002000700340#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#85#81#article#90#26#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">26.&nbsp;Cuenca-Estrella    
M, Rodriguez-Tudela JL. Should antifungal treatments be based upon results of   
 antifungal susceptibility testing? Rev Iberoam Micol. 2002;19(3):133&#150;8.</f
ont></p>     ^cY#14.htm##
00527000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704029000072002000700362#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#86#82#article#90#27#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">27.&nbsp;Mellado    E, Cuenc
a-Estrella M, Rodriguez-Tudela JL. Clinical relevance of mechanisms    of antifu
ngal drug resistance in filamentous fungi. Enferm Infecc Microbiol    Clin. 2002
;20(10):523&#150;9.</font></p>     ^cY#14.htm##
00490000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704025300072002000700325#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#87#83#article#90#28#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">28.&nbsp;White    TC. Mechan
ism of resistance to antifungal agents. En: Pfaller MA, ed. Manual    of Clinica
l Microbiology. Washington: ASM Press, 2003. Pp. 1869&#150;79.</font></p>     ^c
Y#14.htm##
00540000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704030300072002000700375#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#88#84#article#90#29#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">29.&nbsp;Clinical    Laborat
ory Standard Institute. Reference Method for Broth Dilution Antifungal    Suscep
tibility Testing of Yeast; Approved Standard-Second Edition. Document    M27-A2.
 Wayne, Pennsylvania, USA; 2002.</font></p>     ^cY#14.htm##
00737000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704050000072002000700572#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#89#85#article#90#30#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">30.&nbsp;Cuenca-Estrella    
M, Moore CB, Barchiesi F, Bille J, Chryssanthou E, Denning DW, et al. Multicente
r    evaluation of the reproducibility of the proposed antifungal susceptibility
    testing method for fermentative yeasts of the Antifungal Susceptibility Test
ing    Subcommittee of the European Committee on Antimicrobial Susceptibility Te
sting    (AFST-EUCAST). Clin Microbiol Infect. 2003;9(6):467&#150;74.</font></p>
     ^cY#14.htm##
00503000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704026600072002000700338#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#90#86#article#90#31#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">31.&nbsp;Clinical    Laborat
ory Standards Institute. Method for disk diffusion susceptibility testing    of 
yeasts. Approved guideline. Document M44-A. Wayne, Pennsylvania, USA; 2004.</fon
t></p>     ^cY#14.htm##
00553000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066888000300069704031600072002000700388#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#p#91#87#article#90#32#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">32.&nbsp;Barry    AL, Pfalle
r MA, Brown SD, Espinel-Ingroff A, Ghannoum MA, Knapp C, et al. Quality    contr
ol limits for broth microdilution susceptibility tests of ten antifungal    agen
ts. J Clin Microbiol. 2000;38(9):3457&#150;9.</font></p>     ^cY#14.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#92#88#article#90#<p>&nbsp;</p>     ^cY#14.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#93#89#article#90#<p>&nbsp;</p>     ^cY#14.h
tm##
00771000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000300066704054900069002000700618#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\14.htm#S#p#94#90#article#90#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#top">*</a>    
La correspondencia sedebe dirigir al Dr. Manuel Cuenca-Estrella. Director Adjunt
o,    Servi-cio de Micolog&iacute;a, Centro Nacional de Microbiolog&iacute;a, In
stituto    deSalud Carlos III. Carretera Majadahonda-Pozuelo Km 2. 28220 Maja-da
honda (Madrid),    Espa&ntilde;a. Tel.: + 34-91-5097961. Fax: + 34-91-5097966. C
orreo electr&oacute;nico:    <a href="mailto:mcuenca-estrella@isciii.es">mcuenca
-estrella@isciii.es</a></font></p>     ^cY#14.htm##
00674000000000313000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080003000651180002000680100025000700100016000950100
02300111010002700134012010200161030002300263065000900286064000500295031000300300
032000200303014000600305865000900311002000700320035001000327801002300337#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\14.htm#S#c#95#1#article#32#1#^rND^sCuenca-Estr
ella^nM#^rND^sRodero^nL#^rND^sGarcia-Effron^nG#^rND^sRodriguez-Tudela^nJL#Antifu
ngal susceptibilities of Candida spp. isolated from blood in Spain and Argentina
, 1996-1999^len#J Antimicrob Chemother#20020000#2002#49#6#981-7#20080200#14.htm#
0305-7453#J Antimicrob Chemother##
00761000000000325000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080003000651180002000680100025000700100021000950100
01700116010002300133010002700156012014300183030002800326065000900354064000500363
03100030036803200020037101400080037386500090038100200070039003500100039780100280
0407#v23n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#c#96#2#article#32#2#^rND^
sCuenca-Estrella^nM#^rND^sGomez-Lopez^nA#^rND^sMellado^nE#^rND^sGarcia-Effron^nG
#^rND^sRodriguez-Tudela^nJL#In vitro activities of ravuconazole and four other a
ntifungal agents against fluconazole-resistant or: susceptible clinical yeast is
olates^len#Antimicrob Agents Chemother#20040000#2004#48#8#3107-11#20080200#14.ht
m#0066-4804#Antimicrob Agents Chemother##
00563000000000289000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080003000651180002000680100018000700100018000880120
07700106030001900183065000900202064000500211031000300216032000200219014000700221
865000900228002000700237035001000244801001900254#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\14.htm#S#c#97#3#article#32#3#^rND^sPfaller^nMA#^rND^sDiekema^nDJ#Epide
miology of invasive candidiasis: a persistent public health problem^len#Clin Mic
robiol Rev#20070000#2007#20#1#133-63#20080200#14.htm#0893-8512#Clin Microbiol Re
v##
00490000000000277000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080003000651180002000680100016000700120037000860300
01900123065000900142064000500151031000200156032000200158014000700160865000900167
002000700176035001000183801001900193#v23n2#v:\scielo\serial\rpsp\v23n2\markup\14
.htm#S#c#98#4#article#32#4#^rND^sHazen^nKC#New and emerging yeast pathogens^len#
Clin Microbiol Rev#19950000#1995#8#4#462-78#20080200#14.htm#0893-8512#Clin Micro
biol Rev##
00522000000000289000450000400060000070200420000670500020004870600020005070000030
00527010002000557090008000577080003000651180002000680100018000700100017000880120
04300105030001600148065000900164064000500173031000300178032000200181014000700183
865000900190002000700199035001000206801001600216#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\14.htm#S#c#99#5#article#32#5#^rND^sPerfect^nJR#^rND^sSchell^nWA#The ne
w fungal opportunists are coming^len#Clin Infect Dis#19960000#1996#22#2#S112-8#2
0080200#14.htm#1058-4838#Clin Infect Dis##
00479000000000277000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100018000710120027000890300
01600116065000900132064000500141031000300146032000200149014000800151865000900159
002000700168035001000175801001600185#v23n2#v:\scielo\serial\rpsp\v23n2\markup\14
.htm#S#c#100#6#article#32#6#^rND^sDenning^nDW#Invasive aspergillosis^len#Clin In
fect Dis#19980000#1998#26#4#781-803#20080200#14.htm#1058-4838#Clin Infect Dis##
00553000000000277000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100016000710100016000870120
11000103030001900213710000200232065000900234064000500243031000200248032000200250
014000700252865000900259002000700268#v23n2#v:\scielo\serial\rpsp\v23n2\markup\14
.htm#S#c#101#7#article#32#7#^rND^sWalsh^nTJ#^rND^sGroll^nAH#Emerging fungal path
ogens: evolving challenges to immunocompromised patients for the twenty-first ce
ntury^len#Transpl Infect Dis#2#19990000#1999#1#4#247-61#20080200#14.htm##
00499000000000277000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100016000710120044000870300
01900131065000900150064000500159031000300164032000200167014000700169865000900176
002000700185035001000192801001900202#v23n2#v:\scielo\serial\rpsp\v23n2\markup\14
.htm#S#c#102#8#article#32#8#^rND^sLatge^nJP#Aspergillus fumigatus and aspergillo
sis^len#Clin Microbiol Rev#19990000#1999#12#2#310-50#20080200#14.htm#0893-8512#C
lin Microbiol Rev##
00583000000000277000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100015000710120134000860300
01600220065000900236064000500245031000300250032000300253014000700256865000900263
002000700272035001000279801001600289#v23n2#v:\scielo\serial\rpsp\v23n2\markup\14
.htm#S#c#103#9#article#32#9#^rND^sSingh^nN#Trends in the epidemiology of opportu
nistic fungal infections: predisposing factors and the impact of antimicrobial u
se practices^len#Clin Infect Dis#20010000#2001#33#10#1692-6#20080200#14.htm#1058
-4838#Clin Infect Dis##
00585000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730120130000880300
01700218065000900235064000500244031000300249032000400252014000800256865000900264
002000700273035001000280801001700290#v23n2#v:\scielo\serial\rpsp\v23n2\markup\14
.htm#S#c#104#10#article#32#10#^rND^sSingh^nN#Invasive aspergillosis in organ tra
nsplant recipients: new issues in epidemiologic characteristics, diagnosis, and 
management^len#Medical Mycology#20050000#2005#43#^s1#S267-70#20080200#14.htm#136
9-3786#Medical mycology##
00795000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100019000920100
01500111010002500126010001700151010001600168810000600184012016800190030001700358
06500090037506400050038403100030038903200020039201400080039486500090040200200070
0411035001000418801001700428#v23n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#c
#105#11#article#32#11#^rND^sAlmirante^nB#^rND^sRodriguez^nD#^rND^sPark^nBJ#^rND^
sCuenca-Estrella^nM#^rND^sPlanes^nAM#^rND^sAlmela^nM#et al#Epidemiology and pred
ictors of mortality in cases of Candida bloodstream infection: results from popu
lation-based surveillance, Barcelona, Spain, from 2002 to 2003^len#J Clin Microb
iol#20050000#2005#43#4#1829-35#20080200#14.htm#0095-1137#J Clin Microbiol##
00699000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100015000880100
02500103010001600128010001600144010002700160810000600187012007000193030001600263
06500090027906400050028803100030029303200030029601400080029986500090030700200070
0316035001000323801001600333#v23n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#c
#106#12#article#32#12#^rND^sMunoz^nP#^rND^sBouza^nE#^rND^sCuenca-Estrella^nM#^rN
D^sEiros^nJM#^rND^sPerez^nMJ#^rND^sSanchez-Somolinos^nM#et al#Saccharomyces cere
visiae fungemia: an emerging infectious disease^len#Clin Infect Dis#20050000#200
5#40#11#1625-34#20080200#14.htm#1058-4838#Clin Infect Dis##
00712000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100023000890100
01500112010002700127010001700154010001900171810000600190012009300196030001000289
06500090029906400050030803100030031303200020031601400080031886500090032600200070
0335035001000342801001000352#v23n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#c
#107#13#article#32#13#^rND^sGuarro^nJ#^rND^sKantarcioglu^nAS#^rND^sHorre^nR#^rND
^sRodriguez-Tudela^nJL#^rND^sCuenca^nEM#^rND^sBerenguer^nJ#et al#Scedosporium ap
iospermum: changing clinical spectrum of a therapy-refractory opportunist^len#Me
d Mycol#20060000#2006#44#4#295-327#20080200#14.htm#1369-3786#Med Mycol##
00503000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100016000910120
06500107030000900172710000200181065000900183064000500192031000300197032000200200
014000700202865000900209002000700218#v23n2#v:\scielo\serial\rpsp\v23n2\markup\14
.htm#S#c#108#14#article#32#14#^rND^sGonzález^nA#^rND^sTobón^nAM#Infecciones micó
ticas oportunistas en pacientes con VIH/SIDA^len#Infectio#2#20060000#2006#10#4#2
79-88#20080200#14.htm##
00791000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100017000900100
01500107010001300122010001700135011000400152810000600156012021400162030000500376
06500090038106400050039003100030039503200060039801400060040486500090041000200070
0419035001000426801000500436#v23n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#c
#109#15#article#32#15#^rND^sBenson^nCA#^rND^sKaplan^nJE#^rND^sMasur^nH#^rND^sPau
^nA#^rND^sHolmes^nKK#CDC#et al#Treating opportunistic infections among HIV-infec
ted adults and adolescents: recommendations from CDC, the National Institutes of
 Health, and the HIV Medicine Association/Infectious Diseases Society of America
^len#MMWR#20040000#2004#53#RR-15#1-112#20080200#14.htm#0149-2195#MMWR##
00607000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100018000900100
01500108010001400123012007500137030001300212065000900225064000500234031000400239
032000300243014000800246865000900254002000700263035001000270801001300280#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\14.htm#S#c#110#16#article#32#16#^rND^sMartin^n
GS#^rND^sMannino^nDM#^rND^sEaton^nS#^rND^sMoss^nM#The epidemiology of sepsis in 
the United States from 1979 through 2000^len#N Engl J Med#20030000#2003#348#16#1
546-54#20080200#14.htm#0028-4793#N Engl J Med##
00714000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100013000900100
01800103010001700121010001600138010001900154810000600173012010300179030001600282
06500090029806400050030703100030031203200020031501400050031786500090032200200070
0331035001000338801001600348#v23n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#c
#111#17#article#32#17#^rND^sGavalda^nJ#^rND^sLen^nO#^rND^sSan Juan^nR#^rND^sAgua
do^nJM#^rND^sFortun^nJ#^rND^sLumbreras^nC#et al#Risk factors for invasive asperg
illosis in solid-organ transplant recipients: a case-control study^len#Clin Infe
ct Dis#20050000#2005#41#1#52-9#20080200#14.htm#1058-4838#Clin Infect Dis##
00771000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100018000920100
02200110010001700132010001800149010001800167810000600185012014300191030001700334
06500090035106400050036003100030036503200020036801400080037086500090037800200070
0387035001000394801001700404#v23n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#c
#112#18#article#32#18#^rND^sArendrup^nMC#^rND^sFuursted^nK#^rND^sGahrn-Hansen^nB
#^rND^sJensen^nIM#^rND^sKnudsen^nJD#^rND^sLundgren^nB#et al#Seminational surveil
lance of fungemia in Denmark: notably high rates of fungemia and numbers of isol
ates with reduced azole susceptibility^len#J Clin Microbiol#20050000#2005#43#9#4
434-40#20080200#14.htm#0095-1137#J Clin Microbiol##
00790000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100018000890100
02000107010001700127010002000144010001600164810000600180012014300186030003000329
06500090035906400050036803100030037303200020037601400060037886500090038400200070
0393035001000400801003000410#v23n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#c
#113#19#article#32#19#^rND^sMorgan^nJ#^rND^sMeltzer^nMI#^rND^sPlikaytis^nBD#^rND
^sSofair^nAN#^rND^sHuie-White^nS#^rND^sWilcox^nS#et al#Excess mortality, hospita
l stay, and cost due to candidemia: a case-control study using data from populat
ion-based candidemia surveillance^len#Infect Control Hosp Epidemiol#20050000#200
5#26#6#540-7#20080200#14.htm#0899-823X#Infect Control Hosp Epidemiol##
00624000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100018000900100
01800108010001700126012008300143030001700226065000900243064000500252031000200257
032000200259014000600261865000900267002000700276035001000283801001700293#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\14.htm#S#c#114#20#article#32#20#^rND^sPinner^n
RW#^rND^sRebmann^nCA#^rND^sSchuchat^nA#^rND^sHughes^nJM#Disease surveillance and
 the academic, clinical, and public health communities^len#Emerg Infect Dis#2003
0000#2003#9#7#781-7#20080200#14.htm#1080-6040#Emerg Infect Dis##
00759000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100019000900100
01700109010001600126010001600142010001800158810000600176012013400182030002100316
06500090033706400050034603100030035103200020035401400060035686500090036200200070
0371035001000378801002100388#v23n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#c
#115#21#article#32#21#^rND^sShetty^nSS#^rND^sHarrison^nLH#^rND^sHajjeh^nRA#^rND^
sTaylor^nT#^rND^sMirza^nSA#^rND^sSchmidt^nAB#et al#Determining risk factors for 
candidemia among newborn infants from population-based surveillance: Baltimore, 
Maryland, 1998- 2000^len#Pediatr Infect Dis J#20050000#2005#24#7#601-4#20080200#
14.htm#0891-3668#Pediatr Infect Dis J##
00708000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100015000900100
01900105010001900124010001700143010001400160810000600174012010700180030000800287
06500090029506400050030403100030030903200060031201400060031886500090032400200070
0333035001000340801000800350#v23n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#c
#116#22#article#32#22#^rND^sGrigull^nL#^rND^sBeier^nR#^rND^sSchrauder^nA#^rND^sK
irschner^nP#^rND^sLoening^nL#^rND^sJack^nT#et al#Invasive fungal infections are 
responsible for one-fifth of the infectious deaths in children with ALL^len#Myco
ses#20030000#2003#46#11-12#441-6#20080200#14.htm#0933-7407#MYCOSES##
00691000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100015000730100015000880100
02400103010001800127010001800145010001500163810000600178012007200184030001600256
06500090027206400050028103100030028603200020028901400080029186500090029900200070
0308035001000315801001600325#v23n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#c
#117#23#article#32#23#^rND^sNucci^nM#^rND^sMarr^nKA#^rND^sQueiroz-Telles^nF#^rND
^sMartins^nCA#^rND^sTrabasso^nP#^rND^sCosta^nS#et al#Fusarium infection in hemat
opoietic stem cell transplant recipients^len#Clin Infect Dis#20040000#2004#38#9#
1237-42#20080200#14.htm#1058-4838#Clin Infect Dis##
00690000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100020000730100016000930100
01900109010002000128010001500148010001700163810000600180012009300186030002100279
06500090030006400050030903100030031486500090031700200070032603500100033380100210
0343#v23n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#c#118#24#article#32#24#^r
ND^sCastagnola^nE#^rND^sCesaro^nS#^rND^sGiacchino^nM#^rND^sLivadiotti^nS#^rND^sT
ucci^nF#^rND^sZanazzo^nG#et al#Fungal infections in children with cancer: a pros
pective, multicenter surveillance study^len#Pediatr Infect Dis J#20060000#2006#2
5#20080200#14.htm#0891-3668#Pediatr Infect Dis J##
00829000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100025000730100019000980100
01900117010001600136010001700152010001600169810000600185012019100191030002300382
06500090040506400050041403100030041903200020042201400060042486500090043000200070
0439035001000446801002300456#v23n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#c
#119#25#article#32#25#^rND^sCuenca-Estrella^nM#^rND^sRodriguez^nD#^rND^sAlmirant
e^nB#^rND^sMorgan^nJ#^rND^sPlanes^nAM#^rND^sAlmela^nM#et al#In vitro susceptibil
ities of bloodstream isolates of Candida species to six antifungal agents: resul
ts from a population-based active surveillance programme, Barcelona, Spain, 2002
- 2003^len#J Antimicrob Chemother#20050000#2005#55#2#194-9#20080200#14.htm#0305-
7453#J Antimicrob Chemother##
00557000000000277000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100025000730100027000980120
09300125030001800218710000200236065000900238064000500247031000300252032000200255
014000600257865000900263002000700272#v23n2#v:\scielo\serial\rpsp\v23n2\markup\14
.htm#S#c#120#26#article#32#26#^rND^sCuenca-Estrella^nM#^rND^sRodriguez-Tudela^nJ
L#Should antifungal treatments be based upon results of antifungal susceptibilit
y testing?^len#Rev Iberoam Micol#2#20020000#2002#19#3#133-8#20080200#14.htm##
00642000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100025000900100
02700115012008800142030002900230065000900259064000500268031000300273032000300276
014000600279865000900285002000700294035001000301801002900311#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\14.htm#S#c#121#27#article#32#27#^rND^sMellado^nE#^rND^sCue
nca-Estrella^nM#^rND^sRodriguez-Tudela^nJL#Clinical relevance of mechanisms of a
ntifungal drug resistance in filamentous fungi^len#Enferm Infecc Microbiol Clin#
20020000#2002#20#10#523-9#20080200#14.htm#0213-005X#Enferm Infecc Microbiol Clin
##
00517000000000265000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730120049000890160
01800138018003600156066001100192062001000203065000900213064000500222014000800227
865000900235002000700244#v23n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#c#122
#28#article#32#28#^rND^sWhite^nTC#Mechanism of resistance to antifungal agents^l
en#^rED^sPfaller^nMA#Manual of Clinical Microbiology^len#Washington#ASM Press#20
030000#2003#1869-79#20080200#14.htm##
00530000000000229000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700170039000730180134001120660
02000246067000400266065000900270064000500279865000900284002000700293#v23n2#v:\sc
ielo\serial\rpsp\v23n2\markup\14.htm#S#c#123#29#article#32#29#Clinical Laborator
y Standard Institute#Reference Method for Broth Dilution Antifungal Susceptibili
ty Testing of Yeast; Approved Standard-Second Edition: Document M27-A2^len#Wayne
^ePennsylvania#USA#20020000#2002#20080200#14.htm##
00862000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100025000730100016000980100
01900114010001500133010002200148010001800170810000600188012026500194030002200459
71000020048106500090048306400050049203100020049703200020049901400070050186500090
0508002000700517#v23n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#c#124#30#arti
cle#32#30#^rND^sCuenca-Estrella^nM#^rND^sMoore^nCB#^rND^sBarchiesi^nF#^rND^sBill
e^nJ#^rND^sChryssanthou^nE#^rND^sDenning^nDW#et al#Multicenter evaluation of the
 reproducibility of the proposed antifungal susceptibility testing method for fe
rmentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the E
uropean Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST)^len#Clin
 Microbiol Infect#2#20030000#2003#9#6#467-74#20080200#14.htm##
00496000000000229000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700170040000730180099001130660
02000212067000400232065000900236064000500245865000900250002000700259#v23n2#v:\sc
ielo\serial\rpsp\v23n2\markup\14.htm#S#c#125#31#article#32#31#Clinical Laborator
y Standards Institute#Method for disk diffusion susceptibility testing of yeasts
: Approved guideline. Document M44-A^len#Wayne^ePennsylvania#USA#20040000#2004#2
0080200#14.htm##
00721000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100018000890100
01600107010002500123010001900148010001500167810000600182012009700188030001700285
06500090030206400050031103100030031603200020031901400070032186500090032800200070
0337035001000344801001700354#v23n2#v:\scielo\serial\rpsp\v23n2\markup\14.htm#S#c
#126#32#article#32#32#^rND^sBarry^nAL#^rND^sPfaller^nMA#^rND^sBrown^nSD#^rND^sEs
pinel-Ingroff^nA#^rND^sGhannoum^nMA#^rND^sKnapp^nC#et al#Quality control limits 
for broth microdilution susceptibility tests of ten antifungal agents^len#J Clin
 Microbiol#20000000#2000#38#9#3457-9#20080200#14.htm#0095-1137#J Clin Microbiol#
#
00263000000000169000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640910009000660920007000750020007000827030
00400089#v23n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#o#1#1#article#1#20080
318#103158#15.htm#172##
03141000000000661000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000400084121000300088049000800091158000300099030002400102
03100030012603200020012906500090013101400110014003500100015101200890016101201160
02500100028003660100024003940100027004180100026004450100033004710700072005040700
05400576070005300630070004900683070004300732085000800775085004000783085002900823
08500270085208500260087908500190090508313150092408500080223908500510224708500280
22980850030023260850030023560850019023860580035024050600023024401170006024630720
00302469002000702472#v23n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#h#2#1#art
icle#1#oa#en#br1.1#1#3.1#TAB#15#RPSP050#nd#Rev Panam Salud Publica#23#2#20080200
#^f135^l143#1020-4989#Enhancement of underused cervical cancer prevention servic
es in rural Oaxaca, Mexico^len#Incremento en el uso de los servicios de prevenci
ón de cáncer cervicouterino en zonas rurales de Oaxaca, México^les#^rND^1A01^nMa
rtha^sGivaudan#^rND^1A02^nIwin^sLeenen#^rND^1A01 A03^nSusan^sPick#^rND^1A01^nAnd
rea^sAngulo#^rND^1A04 A05^nYpe H.^sPoortinga#Instituto Mexicano de Investigación
 de Familia y Población^iA01^pMexico#Universidad Complutense de Madrid^iA02^cMad
rid^pSpain#Universidad Nacional Autónoma de México^iA03^pMexico#University of Ti
lburg^iA04^cTilburg^pNetherlands#University of Leuven^iA05^cLeuven^pBelgium#^dnd
^i1#^tm^len^kcervix neoplasms prevention^i1#^tm^len^krural population^i1#^tm^len
^kwomen's health^i1#^tm^len^khealth policy^i1#^tm^len^kMexico^i1#^les^aEn este t
rabajo se analizan los resultados de la aplicación del programa educacional Porq
ue me quiero, me cuido, denominado actualmente Yo quiero, yo puedo. . . prevenir
 el cáncer, en poblaciones rurales e indígenas de Valles Centrales, estado de Oa
xaca, una de las regiones más pobres de México. Este programa está dirigido a pr
omover el uso de servicios de tamizaje y la prevención del cáncer cervicouterino
 mediante el cambio de conducta de las personas y la comunidad. Para ello se rea
lizaron talleres interactivos enfocados al desarrollo de habilidades y conocimie
ntos en las mujeres de 15 a 64 años de edad. Estos talleres se complementaron co
n campañas en la comunidad y talleres para hombres con el fin de conseguir su ap
oyo. Se cuantificaron las pruebas de Papanicolau realizadas en las 10 poblacione
s intervenidas y en 6 poblaciones con características similares empleadas como c
ontrol. Además se evaluó mediante un cuestionario los cambios en la conducta, lo
s conocimientos y las actitudes. Se observó un numero significativamente mayor d
e pruebas de Papanicolau realizadas en las poblaciones intervenidas con respecto
 a las de control (P = 0,02). Se comprobaron cambios positivos en el nivel de co
nocimientos de las mujeres respecto a las causas del cáncer cervical y las medid
as para prevenirlo.#^dnd^i2#^tm^les^kprevención de cáncer de cuello uterino^i2#^
tm^les^kpoblación rural^i2#^tm^les^ksalud de la mujer^i2#^tm^les^kpolítica de sa
lud^i2#^tm^les^kMéxico^i2#Commission of European Communities#MEX/B7-6310/IB/99/0
251#other#40#15.htm##
03218000000000661000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640710003000660400003000690010006000720420
00200078120000400080038000400084121000300088049000800091158000300099030002400102
03100030012603200020012906500090013101400110014003500100015101200960016101201230
02570100028003800100024004080100027004320100026004590100033004850700072005180700
05400590070005300644070004900697070004300746085000800789085004000797085002900837
08500270086608500260089308500190091908313360093808500080227408500510228208500280
23330850030023610850030023910850019024210580035024400600065024751170006025400720
00302546002000702549#v23n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#f#3#1#art
icle#1#oa#en#br1.1#1#3.1#TAB#15#RPSP050#nd#Rev Panam Salud Publica#23#2#20080200
#^f135^l143#1020-4989#<B>Enhancement of underused cervical cancer prevention ser
vices in rural Oaxaca, Mexico</B>^len#<B>Incremento en el uso de los servicios d
e prevención de cáncer cervicouterino en zonas rurales de Oaxaca, México</B>^les
#^rND^1A01^nMartha^sGivaudan#^rND^1A02^nIwin^sLeenen#^rND^1A01 A03^nSusan^sPick#
^rND^1A01^nAndrea^sAngulo#^rND^1A04 A05^nYpe H.^sPoortinga#Instituto Mexicano de
 Investigación de Familia y Población^iA01^pMexico#Universidad Complutense de Ma
drid^iA02^cMadrid^pSpain#Universidad Nacional Autónoma de México^iA03^pMexico#Un
iversity of Tilburg^iA04^cTilburg^pNetherlands#University of Leuven^iA05^cLeuven
^pBelgium#^dnd^i1#^tm^len^kcervix neoplasms prevention^i1#^tm^len^krural populat
ion^i1#^tm^len^kwomen's health^i1#^tm^len^khealth policy^i1#^tm^len^kMexico^i1#^
les^aEn este trabajo se analizan los resultados de la aplicación del programa ed
ucacional <I>Porque me quiero, me cuido,</I> denominado actualmente <I>Yo quiero
, yo puedo. . . prevenir el cáncer</I>, en poblaciones rurales e indígenas de Va
lles Centrales, estado de Oaxaca, una de las regiones más pobres de México. Este
 programa está dirigido a promover el uso de servicios de tamizaje y la prevenci
ón del cáncer cervicouterino mediante el cambio de conducta de las personas y la
 comunidad. Para ello se realizaron talleres interactivos enfocados al desarroll
o de habilidades y conocimientos en las mujeres de 15 a 64 años de edad. Estos t
alleres se complementaron con campañas en la comunidad y talleres para hombres c
on el fin de conseguir su apoyo. Se cuantificaron las pruebas de Papanicolau rea
lizadas en las 10 poblaciones intervenidas y en 6 poblaciones con característica
s similares empleadas como control. Además se evaluó mediante un cuestionario lo
s cambios en la conducta, los conocimientos y las actitudes. Se observó un numer
o significativamente mayor de pruebas de Papanicolau realizadas en las poblacion
es intervenidas con respecto a las de control (<I>P</I> = 0,02). Se comprobaron 
cambios positivos en el nivel de conocimientos de las mujeres respecto a las cau
sas del cáncer cervical y las medidas para prevenirlo.#^dnd^i2#^tm^les^kprevenci
ón de cáncer de cuello uterino^i2#^tm^les^kpoblación rural^i2#^tm^les^ksalud de 
la mujer^i2#^tm^les^kpolítica de salud^i2#^tm^les^kMéxico^i2#Commission of Europ
ean Communities#<FONT FACE="Verdana, Arial" SIZE=2>MEX/B7-6310/IB/99/0251</FONT>
#other#40#15.htm##
03281000000000685000450000400060000070200420000670500020004870600020005070000020
00527010002000547090008000567080002000640640013000660710003000790400003000820010
00600085042000200091120000400093038000400097121000300101049000800104158000300112
03000260011503100030014103200020014406500090014601400110015503500100016601200890
01760120116002650100028003810100024004090100027004330100026004600100032004860700
07400518070005600592070005500648070005100703070004500754085000800799085004000807
08500290084708500270087608500260090308500190092908313150094808500080226308500510
22710850028023220850030023500850030023800850019024100580035024290600023024641170
00602487072000302493002000702496008009202503#v23n2#v:\scielo\serial\rpsp\v23n2\m
arkup\15.htm#S#l#4#1#article#1#^mFeb.^a2008#oa#en#br1.1#1#3.1#tab#15#RPSP050#nd#
Rev. panam. salud pública#23#2#20080200#^f135^l143#1020-4989#Enhancement of unde
rused cervical cancer prevention services in rural Oaxaca, Mexico^len#Incremento
 en el uso de los servicios de prevención de cáncer cervicouterino en zonas rura
les de Oaxaca, México^les#^rND^1A01^nMartha^sGivaudan#^rND^1A02^nIwin^sLeenen#^r
ND^1A01 A03^nSusan^sPick#^rND^1A01^nAndrea^sAngulo#^rND^1A04 A05^nYpe H^sPoortin
ga#^iA01^1Instituto Mexicano de Investigación de Familia y Población^pMexico#^iA
02^1Universidad Complutense de Madrid^cMadrid^pSpain#^iA03^1Universidad Nacional
 Autónoma de México^pMexico#^iA04^1University of Tilburg^cTilburg^pNetherlands#^
iA05^1University of Leuven^cLeuven^pBelgium#^dnd^i1#^tm^len^kcervix neoplasms pr
evention^i1#^tm^len^krural population^i1#^tm^len^kwomen's health^i1#^tm^len^khea
lth policy^i1#^tm^len^kMexico^i1#^les^aEn este trabajo se analizan los resultado
s de la aplicación del programa educacional Porque me quiero, me cuido, denomina
do actualmente Yo quiero, yo puedo. . . prevenir el cáncer, en poblaciones rural
es e indígenas de Valles Centrales, estado de Oaxaca, una de las regiones más po
bres de México. Este programa está dirigido a promover el uso de servicios de ta
mizaje y la prevención del cáncer cervicouterino mediante el cambio de conducta 
de las personas y la comunidad. Para ello se realizaron talleres interactivos en
focados al desarrollo de habilidades y conocimientos en las mujeres de 15 a 64 a
ños de edad. Estos talleres se complementaron con campañas en la comunidad y tal
leres para hombres con el fin de conseguir su apoyo. Se cuantificaron las prueba
s de Papanicolau realizadas en las 10 poblaciones intervenidas y en 6 poblacione
s con características similares empleadas como control. Además se evaluó mediant
e un cuestionario los cambios en la conducta, los conocimientos y las actitudes.
 Se observó un numero significativamente mayor de pruebas de Papanicolau realiza
das en las poblaciones intervenidas con respecto a las de control (P = 0,02). Se
 comprobaron cambios positivos en el nivel de conocimientos de las mujeres respe
cto a las causas del cáncer cervical y las medidas para prevenirlo.#^dnd^i2#^tm^
les^kprevención de cáncer de cuello uterino^i2#^tm^les^kpoblación rural^i2#^tm^l
es^ksalud de la mujer^i2#^tm^les^kpolítica de salud^i2#^tm^les^kMéxico^i2#Commis
sion of European Communities#MEX/B7-6310/IB/99/0251#other#40#15.htm#Internet^iht
tp://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892008000200015#
#
00362000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704014100068002000700209#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#5#1#article#128#<p align="right"><font face
="Verdana, Arial, Helvetica, sans-serif" size="2"><b>TEMAS    DE ACTUALIDAD</b> 
CURRENT TOPICS</font></p>     ^cY#15.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704002200068002000700090#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#6#2#article#128#<p>&nbsp;</p>     ^cY#15.ht
m##
00416000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704019500068002000700263#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#7#3#article#128#<p><a name="top"></a><font 
face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Enhancement    of under
used cervical cancer prevention services in rural Oaxaca, Mexico</b></font></p> 
    ^cY#15.htm##
00243000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704002200068002000700090#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#8#4#article#128#<p>&nbsp;</p>     ^cY#15.ht
m##
00449000000000145000450000400060000070200420000670500020004870600020005070000020
0052701000200054709000800056708000400064704022800068002000700296#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#9#5#article#128#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="3"><b>Incremento en    el uso de los servicios 
de prevenci&oacute;n de c&aacute;ncer cervicouterino    en zonas rurales de Oaxa
ca, M&eacute;xico</b></font></p>     ^cY#15.htm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#10#6#article#128#<p>&nbsp;</p>     ^cY#15.h
tm##
00244000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704002200069002000700091#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#11#7#article#128#<p>&nbsp;</p>     ^cY#15.h
tm##
00484000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704026200069002000700331#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#12#8#article#128#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>Martha Givaudan<sup>I,    <a href="#back
">*</a></sup>; Iwin Leenen<sup>II</sup>; Susan Pick<sup>I, III</sup>;    Andrea 
Angulo<sup>I</sup>; Ype H. Poortinga<sup>IV, V</sup></b></font></p>     ^cY#15.h
tm##
00485000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000200055709000800057708000400065704026300069002000700332#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#13#9#article#128#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><sup>I</sup>Instituto    Mexicano de Invest
igaci&oacute;n de Familia y Poblaci&oacute;n, A.C., M&aacute;laga    Norte No. 2
5, Colonia Insurgentes Mixcoac, M&eacute;xico, D.F., CP 03920, Mexico    ^cY#15.
htm##
00299000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007600070002000700146#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#14#10#article#128#<br>   <sup>II</sup>Unive
rsidad Complutense de Madrid, Madrid, Spain    ^cY#15.htm##
00337000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704011400070002000700184#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#15#11#article#128#<br>   <sup>III</sup>Univ
ersidad Nacional Aut&oacute;noma de M&eacute;xico, M&eacute;xico,    D.F., Mexic
o    ^cY#15.htm##
00294000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007100070002000700141#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#16#12#article#128#<br>   <sup>IV</sup>Unive
rsity of Tilburg, Tilburg, Netherlands    ^cY#15.htm##
00299000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704007600070002000700146#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#17#13#article#128#<br>   <sup>V</sup>Univer
sity of Leuven, Leuven, Belgium</font></p>     ^cY#15.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#18#14#article#128#<p>&nbsp;</p>     ^cY#15.
htm##
00267000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704004400070002000700114#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#19#15#article#128#<p>&nbsp;</p> <hr size="1
" noshade>     ^cY#15.htm##
00437000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704021400070002000700284#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#20#16#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Key words:</b>    cervix neoplasms prev
ention, rural population, women's health, health policy,    Mexico.</font></p> <
hr size="1" noshade>     ^cY#15.htm##
00321000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009800070002000700168#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#21#17#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>SINOPSIS</b></font></p>     ^cY#15.htm#
#
01794000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704157100070002000701641#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#22#18#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">En este trabajo    se analizan los resulta
dos de la aplicaci&oacute;n del programa educacional    <i>Porque me quiero, me 
cuido,</i> denominado actualmente <i>Yo quiero, yo puedo.    . . prevenir el c&a
acute;ncer</i>, en poblaciones rurales e ind&iacute;genas    de Valles Centrales
, estado de Oaxaca, una de las regiones m&aacute;s pobres    de M&eacute;xico. E
ste programa est&aacute; dirigido a promover el uso de servicios    de tamizaje 
y la prevenci&oacute;n del c&aacute;ncer cervicouterino mediante    el cambio de
 conducta de las personas y la comunidad. Para ello se realizaron    talleres in
teractivos enfocados al desarrollo de habilidades y conocimientos    en las muje
res de 15 a 64 a&ntilde;os de edad. Estos talleres se complementaron    con camp
a&ntilde;as en la comunidad y talleres para hombres con el fin de conseguir    s
u apoyo. Se cuantificaron las pruebas de Papanicolau realizadas en las 10 poblac
iones    intervenidas y en 6 poblaciones con caracter&iacute;sticas similares em
pleadas    como control. Adem&aacute;s se evalu&oacute; mediante un cuestionario
 los cambios    en la conducta, los conocimientos y las actitudes. Se observ&oac
ute; un numero    significativamente mayor de pruebas de Papanicolau realizadas 
en las poblaciones    intervenidas con respecto a las de control (<i>P</i> = 0,0
2). Se comprobaron    cambios positivos en el nivel de conocimientos de las muje
res respecto a las    causas del c&aacute;ncer cervical y las medidas para preve
nirlo.</font></p>     ^cY#15.htm##
00494000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704027100070002000700341#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#23#19#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Palabras clave:</b>    prevenci&oacute;
n de c&aacute;ncer de cuello uterino, poblaci&oacute;n rural,    salud de la muj
er, pol&iacute;tica de salud, M&eacute;xico.</font></p> <hr size="1" noshade>   
  ^cY#15.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#24#20#article#128#<p>&nbsp;</p>     ^cY#15.
htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#25#21#article#128#<p>&nbsp;</p>     ^cY#15.
htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002400070002000700094#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#26#22#article#128#<blockquote>        ^cY#1
5.htm##
00637000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704041400070002000700484#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#27#23#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">"Whether it is      the two hour walk to t
he nearest clinic, <i>local myths or poor health services      millions of women
 worldwide never undergo cervical cancer screening and hundreds      of thousand
s die prematurely without ever knowing why they were ill."</i>      (Alliance fo
r Cervical Cancer Prevention, 2004)</font></p> </blockquote>     ^cY#15.htm##
01249000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704102600070002000701096#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#28#24#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Cervical cancer    is a global public heal
th issue. According to a recent report by the Alliance    for Cervical Cancer Pr
evention (1) an estimated 274 000 women fall victim to    cervical cancer each y
ear, 80% of whom live in low-income countries. The problem    has been associate
d with women's inadequate knowledge of the disease and its    prevention (2&#150
;4) and the low expertise of health professionals (5) as well    as their lack o
f cultural sensitivity (6, 7). In industrialized countries, the    incidence of 
and death rate from cervical cancer have significantly decreased    over the pas
t 50 years as a result of widespread implementation and use of Papanicolaou    o
r Pap smear testing (8, 9). The Pap smear test is an effective screening tool   
 for cervical neoplasia, a precursor of cervical cancer, which is mostly caused 
   by human papilloma virus. Treatment of cervical cancer precursors is usually 
   highly successful.</font></p>     ^cY#15.htm##
00974000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704075100070002000700821#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#29#25#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">In Mexico, as in    most developing countr
ies, rates of cervical cancer reflect prevalent high-risk    behavior, myths abo
ut prevention, and underuse of medical services. Cervical    cancer is the leadi
ng cause of death among women around 35 years of age (10)    and the second lead
ing cause of death among adult women aged 15&#150;64 years    (11). The mortalit
y rate from cervical cancer is estimated at 10.2 per 100 000    women (12). Ever
y day in Mexico, 12 women die from cervical cancer; the annual    growth in cerv
ical cancer deaths being 0.76%. Women in rural areas have a 3.07    times higher
 risk of dying from this illness than women in urban centers (13).</font></p>   
  ^cY#15.htm##
01040000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704081700070002000700887#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#30#26#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Although the Mexican    Health Ministry ha
s provided free or very low cost cancer-screening services    throughout the cou
ntry and prioritized the need for cervical cancer programming    (12), these ser
vices remain notoriously underutilized, most notably in low-income,    low-educa
tion, rural communities (14, 15). Some efforts are known to have failed    becau
se they focused on younger women and did not include the older at-risk    group 
(16). Social norms and a strong distrust in allopathic medicine contribute    to
 alienating women from institutional health care (17). Even though the costs    
of screening are favorable, the sociocultural context has not been conducive    
to widespread use of screening and diagnostic tests.</font></p>     ^cY#15.htm##
01034000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704081100070002000700881#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#31#27#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">In a study of women    in Mexico City and 
rural regions of the Mexican state of Oaxaca, the main predictors    of use of t
he Pap smear were knowledge of what the Pap test is meant for, socioeconomic    
and educational level, and access to social security (18). As recently as a    d
ecade ago, an evaluation of Mexico's national cervical cancer detection program 
   found that only 40% of women living in rural areas knew the purpose of the Pa
p    smear. Most women who used diagnostic programs did so only when they showed
    symptoms. Moreover, screening was found to be less common among older, less 
   educated, less parous women; nonusers of oral contraceptives; and women witho
ut    a history of venereal diseases (18, 19).</font></p>     ^cY#15.htm##
01136000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704091300070002000700983#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#32#28#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">In this article,    we discuss a health ed
ucation program, named <i>Porque me quiero, me cuido</i>    (Because I like myse
lf, I take care of myself) (20), that was implemented in    rural and indigenous
 populations in Valles Centrales in Oaxaca, one of Mexico's    poorest and most 
rural states. The Valles Centrales region occupies a third    of the state's ter
ritory. In Oaxaca, the mortality rate due to cervical cancer    is 12.4 per 100 
000 women (21). Hence, the goal of the program was to promote    the use of scre
ening services. The program is geared toward increasing knowledge    and skills,
 enabling women to take preventive measures against cervical cancer,    and prom
oting Pap smear tests. A first version of the program was implemented    with su
pport from the local health authorities in the state of Oaxaca (17).</font></p> 
    ^cY#15.htm##
00725000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704050200070002000700572#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#33#29#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The first question    to be answered in th
is article is whether the <i>Porque me quiero, me cuido</i>    program had a dem
onstrable impact on health behavior, especially in the form    of women seeking 
more Pap smear tests. A further question was to examine whether    there was a d
emonstrable increase in knowledge, attitudes, and behaviors related    to cervic
al cancer and prevention as a consequence of the program.</font></p>     ^cY#15.
htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#34#30#article#128#<p>&nbsp;</p>     ^cY#15.
htm##
00324000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010100070002000700171#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#35#31#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>THE PROGRAM</b></font></p>     ^cY#15.h
tm##
01153000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704093000070002000701000#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#36#32#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><i>Porque me quiero,    me cuido</i> was d
eveloped at the Instituto Mexicano de Investigaci&oacute;n    de Familia y Pobla
ci&oacute;n (IMIFAP), a Mexican nongovernmental organization    with a focus on 
health education and community development of groups in Latin    America with li
mited education. Since its development, the program has been    incorporated as 
part of an integral sustainable human development program called    <i>Yo quiero
, yo puedo</i> (I want to, I can) and the cancer module is known    as <i>Yo qui
ero, yo puedo . . . prevenir el cancer</i> (I want to, I can . .    . prevent ca
ncer). The conceptualization and implementation strategy adopted    in the progr
am, incorporating core issues discussed in the literature, have    been presente
d elsewhere (17, 22&#150;24). The guiding principles can be summarized    as fol
lows.</font></p>     ^cY#15.htm##
01121000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704089800070002000700968#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#37#33#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">First, a program    must be rooted in the 
needs of the target population (4, 7). Second, changes    in behavior have to be
 initiated at the level of specific situations (25) by    helping program client
s develop or acquire "tools" in the form of knowledge    and communication skill
s enabling them to change their behaviors. A third requirement    in building he
alth education programs is that the context, such as socioeconomic    variables,
 in which the target population lives should be taken into account    (7, 26). F
ourth, program advocacy and dissemination of results are an inherent    part of 
health promotion. The fifth and last principle underlying the IMIFAP    approach
 is an emphasis on evaluation at all stages of the program (25, 27);    there ha
s to be accountability to all important stakeholders.</font></p>     ^cY#15.htm#
#
01474000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704125100070002000701321#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#38#34#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Workshop sessions    and educational and p
romotional materials (training manual, flipchart, and a    video) for the progra
m <i>Porque me quiero, me cuido</i> were designed on the    basis of background 
research exploring the needs of the target population. The    workshops are cond
ucted by local women, called health promoters, who took part    in a 1-week trai
ning program in which they were program participants and in    addition were giv
en instructions on how to conduct workshops. Workshop sessions    are highly int
eractive and include discussions and role playing as well as the    presentation
 of factual information. Thus, the workshops foster the development    of knowle
dge and skills that empower women to make decisions about their own    sexual an
d reproductive health. They provide information to enhance women's    knowledge 
of their bodies, physical rights, and risks; information on how to    take care 
of their health; and information on skills to make choices for preventing    cer
vical cancer and how to realize these skills in an assertive manner. The    work
shops are composed of eight 2-hour weekly sessions with groups of 15&#150;25    
women.</font></p>     ^cY#15.htm##
01050000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704082700070002000700897#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#39#35#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">There was also    a workshop for men consi
sting of three 2-hour sessions: two for men only and    one for men and their pa
rtners. The workshop focused on sexual and reproductive    health, including the
 Pap test and skills such as communication and interaction    with one's partner
. Another module, directed at professional health care providers    (doctors and
 nurses), consisted of two 4-hour sessions during which participants    had the 
opportunity to exchange experiences and to reflect on their role and    the way 
they interacted with women. Finally, a dissemination promotion campaign    was c
onducted in communities as part of program advocacy. For further information    
on these additional activities, refer to Givaudan et al. (17).</font></p>     ^c
Y#15.htm##
00319000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009600070002000700166#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#40#36#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Method</b></font></p>     ^cY#15.htm##
01284000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704106100070002000701131#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#41#37#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Participants.</b>    Ten communities in
 Valles Centrales, Oaxaca, with low annual rates of screening    for cervical ca
ncer were selected on the basis of information provided by the    Ministry of He
alth.<a name="top1"></a><a href="#back1"><sup>1</sup></a> Women    taking part i
n the program ranged from 15 to 64 years old. For the purpose of    evaluation, 
six similar communities were selected in the same region from which    participa
nts were drawn to form the control group in a questionnaire study.    The sampli
ng technique amounted to selection with replacement; women participating    in t
he premeasurement might take part also in the postmeasurement, but there    was 
no attempt at matching. In accordance with common practice in Latin America,    
neither the women nor their communities were compensated for their cooperation. 
   However, they were often interested in being interviewed because of the oppor
tunity    to converse with someone about health matters.</font></p>     ^cY#15.h
tm##
01489000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704126600070002000701336#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#42#38#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">In each community    (village) where the p
rogram was administered, one to four rural health promoters    were recruited to
 implement the program. They were local women who had to be    able to read and 
write. The selection procedure included the recommendation    of a local health 
care provider (doctor or nurse) and an interview with each    candidate. Many wo
men in both the control and the experimental communities also    took part in a 
program called <i>Oportunidades</i> (Opportunities), formerly    called <i>Progr
esa</i> (Progress), a federally funded program that provides    financial and ec
onomic support for nutrition, education, and health to the poorest    communitie
s of Mexico. A condition for receiving benefits is to attend talks    about heal
th that are given periodically in the villages. The objectives overlap    with t
he program described here. The two main differences are that the <i>Oportunidade
s</i>    program provides information on a wide range of health issues and is ca
rried    out through public lectures to large groups, whereas <i>Porque me quier
o, me    cuido</i> focuses on cervical cancer and uses participatory techniques 
with    small groups.</font></p>     ^cY#15.htm##
00728000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704050500070002000700575#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#43#39#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">In each village,    local health promoters
 invited women to attend the workshops by using door-to-door    visits, by messa
ges through loudspeakers, by support of local authorities and    health provider
s, and by getting in touch with groups such as neighbors and    families. A tota
l of 2 177 women attended the workshops. More than half of them    attended all 
eight sessions, less than 10% attended three or fewer times.</font></p>     ^cY#
15.htm##
00642000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704041900070002000700489#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#44#40#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Evaluation procedures.</b>    The impac
t of the program was quantified by (1) comparing the numbers of Pap    smear tes
ts as recorded in local health clinics before and after program implementation, 
   and (2) a questionnaire that aimed at assessing knowledge, opinions, attitude
s,    and behavior of women regarding cervical cancer.</font></p>     ^cY#15.htm
##
00337000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704011400070002000700184#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#45#41#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Numbers of Pap    smears</b></font></p>
     ^cY#15.htm##
00709000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704048600070002000700556#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#46#42#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Records of local    clinics were examined 
to retrieve the numbers of Pap smears conducted in the    various villages for t
he year the program was implemented and for the preceding    year. It was imposs
ible to obtain a full set of data because in some clinics    the records of the 
previous year could not be found. We retrieved records for    both years in four
 control and eight experimental villages.</font></p>     ^cY#15.htm##
00699000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704047600070002000700546#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#47#43#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Participants    in the questionnaire st
udy.</b> The instrument was applied in a pretest-posttest    design with an expe
rimental and a control group. At least 20 women of reproductive    age were inte
rviewed in each of the 10 experimental and 6 control villages before    the prog
ram started and 10 months after its completion. Each round of data collection   
 was completed within 2 months.</font></p>     ^cY#15.htm##
00926000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704070300070002000700773#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#48#44#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Each interviewer    was told to start with
 a certain house. If a woman in the appropriate age range    was present, she wa
s asked for an interview. If an interview was conducted,    the interviewer woul
d skip a few houses (the number depended on the size of    the village) and go t
o another house. If no interview was administered (in the    case of no cooperat
ion or no woman present in the right age range), the interviewer    would go to 
the next house. The procedure was the same for control and experimental    villa
ges, implying that in the latter villages women were included who had not    att
ended the program.</font></p>     ^cY#15.htm##
00666000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704044300070002000700513#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#49#45#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Questionnaire.</b>    The questionnaire
 was based on an instrument used previously to assess a preliminary    version o
f the program (17). It begins with five questions asking for sociodemographic   
 data (age, educational level, participation in the <i>Oportunidades</i> program
,    civil status). The remainder of the questionnaire comprises seven scales:</
font></p>     ^cY#15.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002400070002000700094#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#50#46#article#128#<blockquote>        ^cY#1
5.htm##
00531000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704030800070002000700378#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#51#47#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">(1)&nbsp;Knowledge      about health, hygi
ene, and sexuality (20 items, such as, Do you think only      women who have sex
ual intercourse can get cervical cancer? Do you think too      much dust can cau
se cervical cancer?).</font></p>       ^cY#15.htm##
00522000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704029900070002000700369#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#52#48#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">(2)&nbsp;Attitudes      (12 items, such as
, Would you be concerned if other persons from your community      knew you had 
a Pap smear test? If cancer was detected from the test, would      you prefer to
 not know?).</font></p>       ^cY#15.htm##
00492000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704026900070002000700339#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#53#49#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">(3)&nbsp;Intentions      (16 items, such a
s, Would you have a Pap smear test performed by a male doctor?      Have you alr
eady thought about when you will go for your next Pap smear?).</font></p>       
^cY#15.htm##
00460000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704023700070002000700307#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#54#50#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">(4)&nbsp;Health-oriented      behaviors (1
2 items, such as, In the last month have you checked your sexual      organs? Ha
ve you ever had a Pap smear?).</font></p>       ^cY#15.htm##
00426000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704020300070002000700273#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#55#51#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">(5)&nbsp;Partner's      attitude (5 items,
 such as, Would it bother your partner that you have had      a Pap smear?).</fo
nt></p>       ^cY#15.htm##
00459000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704023600070002000700306#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#56#52#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">(6)&nbsp;Partner's      behavior (5 items,
 such as, In the last year, did your partner and you go      together to the hea
lth center to see a doctor?).</font></p>       ^cY#15.htm##
00560000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704033700070002000700407#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#57#53#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">(7)&nbsp;Social      desirability (10 item
s, such as, Does it make any difference to you whether      it is a male or fema
le doctor who performs your Pap smear? Do you wash your      hands every time be
fore and after you go to the toilet?).</font></p> </blockquote>     ^cY#15.htm##
00618000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704039500070002000700465#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#58#54#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Responses for most    items were limited t
o three options: agreement, disagreement, and an option    expressing uncertaint
y or unwillingness to answer. A few items were open questions    where a short r
esponse was expected (for example, naming some symptoms). The    questionnaire t
ook up to an hour to complete.</font></p>     ^cY#15.htm##
00700000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704047700070002000700547#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#59#55#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Questionnaire    administration.</b> Th
e data were collected by five interviewers (social science    students from a un
iversity in Oaxaca City), who were trained in a 5-hour session    where they pra
cticed by role playing among themselves. They worked in each community    in pai
rs. In view of the low educational level of most women, the instrument    was ap
plied as a structured interview.</font></p>     ^cY#15.htm##
00449000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704022600070002000700296#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#60#56#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The total number    of instruments was 679
 (200 pretest experimental, 120 pretest control, 239 posttest    experimental, 1
20 posttest control).</font></p>     ^cY#15.htm##
00348000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704012500070002000700195#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#61#57#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Analysis of    questionnaire scores</b>
</font></p>     ^cY#15.htm##
01098000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704087500070002000700945#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#62#58#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">For each respondent,    scores on items in
 the seven scales were obtained by assigning a 1 if the response    indicated ag
reement with the objectives of the program and 0 in the case of    disagreement 
or uncertainty/unwillingness to answer. About 3% of missing values    (due to it
ems without a response) were omitted from the analyses. To the obtained    item 
scores of each scale, except the two behavior scales, we applied the one-paramet
er    logistic model (OPLM) (28), which is a model from Item Response Theory sim
ilar    to Birnbaum's (29) two-parameter logistic model. This procedure yielded 
a score    for each respondent on each scale. To fix the origin and unit of the 
scale,    the score distributions were standardized (with a mean of 0.00 and a s
tandard    deviation of 1.00).</font></p>     ^cY#15.htm##
00736000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704051300070002000700583#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#63#59#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">As a next step,    the scale scores were e
ntered as dependent variables in a multilevel (or hierarchical)    model (30, 31
) with participation in the workshop and demographic information    as independe
nt variables. We opted for a multilevel analysis because the women    were neste
d in communities and women from the same community were expected to    be more h
omogeneous in their responses than women from different communities.</font></p> 
    ^cY#15.htm##
00835000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704061200070002000700682#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#64#60#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Because the behavioral    items (questions
 about the behavior of women and their partners) addressed quite    specific and
 heterogeneous situations (which implies a violation of the unidimensionality   
 assumption in OPLM), we did not try to construct a scale for these items. Inste
ad,    as in previous cases (32), we analyzed them separately using a logistic m
ultilevel    model with the dichotomous item score as the dependent variable and
 participation    in the workshop and demographic information as independent var
iables.</font></p>     ^cY#15.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#65#61#article#128#<p>&nbsp;</p>     ^cY#15.
htm##
00320000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704009700070002000700167#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#66#62#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>RESULTS</b></font></p>     ^cY#15.htm##
01032000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704080900070002000700879#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#67#63#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">For 8 of the 10    experimental communitie
s, we obtained records of Pap smears over 2 years. In    the year before the pro
gram was implemented, 1 074 Pap smears were taken. During    the year of impleme
ntation, there were 1 306 Pap smears, while the total number    of women in thes
e villages within the program's age range was calculated to    be 4 865. Under t
he assumption that there was no change in the size of the population,    this co
rresponds to an increase of 22% to 27%. A multilevel analysis (with women    nes
ted in villages) shows that the probability of women having a Pap smear signific
antly    increased in the experimental villages compared with the control villag
es, <i>t</i>(11)    = 2.66, <i>p</i> = 0.02.</font></p>     ^cY#15.htm##
01415000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704119200070002000701262#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#68#64#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><a href="/img/revistas/rpsp/v23n2/15t1.gif
">Table    1</a> presents descriptive statistics on the sociodemographic charact
eristics    of the women who were administered the questionnaire, separating con
trol and    experimental villages and pretest and posttest questionnaires. Stati
stically    significant differences among the four groups occur for all variable
s except    age. With respect to education level and civil state, the women in t
he posttest    control group differ from those in the other groups, with the for
mer group including    more women who initiated secondary school and who did not
 have a partner. Furthermore,    <a href="/img/revistas/rpsp/v23n2/15t1.gif">Tab
le 1</a> shows that in the experimental    groups more women participated in the
 state's <i>Oportunidades</i> program.    This program had already been running 
for a few years and is unlikely to account    for the increase in Pap smears in 
the experimental villages. In the multilevel    analyses presented next, the dif
ferences among these groups are accounted for    by including the sociodemograph
ic variables as covariates.</font></p>     ^cY#15.htm##
00814000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704059100070002000700661#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#69#65#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The main results    of the questionnaire a
re presented in <a href="/img/revistas/rpsp/v23n2/15t2.gif">Table    2</a>. The 
rows of the table refer to dependent variables and the columns refer    to indep
endent variables (or effects). There are three sets of dependent variables:    (
1) continuous scores based on five subscales in the questionnaire, (2) binary   
 scores based on self-reported health behavior items, and (3) binary scores on  
  items for which the women report the behavior of their partners.</font></p>   
  ^cY#15.htm##
02327000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704210400070002000702174#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#70#66#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The first column    in the body of <a href
="/img/revistas/rpsp/v23n2/15t2.gif">Table 2</a> gives    the value of the inter
cept. Because of the way the independent variables were    defined, the intercep
t value corresponds to the expected score on the pretest    of a woman of mean a
ge, with limited schooling, without a partner, who does    not take part in the 
<i>Oportunidades</i> program, and who has a mean score    for social desirabilit
y. The other columns on the left side of <a href="/img/revistas/rpsp/v23n2/15t2.
gif">Table    2</a> are control variables: "Age" refers to the difference in the
 dependent    variable associated with a difference of 1 year of age. This impli
es, for example,    that a woman 30 years old has an expected score on knowledge
 0.005 standard    deviation unit above the expected score of a 29-year-old, the
 values for all    other variables being equal. "Schooling" was treated as a dic
hotomous variable    with secondary school attendance or higher as one category,
 and education at    the primary school level or no school attendance as the oth
er category. The    table shows that the expected score for knowledge among more
 educated women    was 0.04 standard deviation higher than for the less educated
. "Has partner"    is a dichotomous variable with a positive score when an inter
viewee reported    having a partner. "<i>Oportunidades</i>" refers to participat
ion (versus nonparticipation)    in the <i>Oportunidades</i> program. The inclus
ion of "Social desirability"    (which represents the score on the social desira
bility scale obtained from the    OPLM analyses) as an independent variable stat
istically corrects the women's    responses on the attitude, intention, and beha
vior items for giving the socially    desirable answer. Theoretically, social de
sirability cannot affect knowledge;    therefore, this variable was not included
 as a control variable for knowledge    (the knowledge scale contained items wit
h negative responses and items with    positive responses).</font></p>     ^cY#1
5.htm##
01415000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704119200070002000701262#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#71#67#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">On the right side    of <a href="/img/revi
stas/rpsp/v23n2/15t2.gif">Table 2</a> are three variables    referring to progra
m-related effects. The first and second are binary variables.    The first refer
s to the moment of testing (pre and post) and the second refers    to treatment 
status (experimental versus control communities). The third variable    refers t
o the number of sessions the interviewee attended (based on the attendance    li
sts) and indicates the effect on the dependent variable of a unit change in    w
orkshop attendance (of eight workshops). For example, the increase in knowledge 
   for a woman from an experimental village who attended all sessions can be est
imated    at 0.49 standard deviation (moment effect + treatment effect: &#150;0.
17 + 0.66    = 0.49). For each session a woman missed, her knowledge can be esti
mated to    decrease by 0.056 standard deviation. For example, for a woman who a
ttended    four sessions instead of all eight, the effect of the program can be 
expected    to have been lower by 4 <font face="Symbol">&acute;</font> 0.056 = 0
.224 standard    deviation.</font></p>     ^cY#15.htm##
00686000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704046300070002000700533#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#72#68#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Of the continuous    variables, "knowledge
" shows a highly significant and substantial treatment    effect, which can be l
argely accounted for by attendance at the workshops. In    contrast, the effects
 of treatment on the subscales for attitude, perceived    attitude of partner, a
nd intention were small. The low estimates for session    effects are in line wi
th these findings.</font></p>     ^cY#15.htm##
01138000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704091500070002000700985#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#73#69#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">For reasons explained    previously, the i
tems on reported behaviors were entered as dependent variables    in separate (l
ogistic multilevel) analyses. As a consequence, the estimates    are less stable
 and tend to have a larger margin of error than scores based    on scales consis
ting of several items. <a href="/img/revistas/rpsp/v23n2/15t2.gif">Table    2</a
> shows the results of the 12 self-reported behaviors and 5 reported behaviors  
  of the partner. A statistically significant result (<i>p</i> &lt; 0.05) for   
 the treatment effect was obtained for only one item: women who attended the    
workshops talk more frequently about the importance of the Pap test (this was   
 an open item). As far as reported behavior of partners is concerned, the treatm
ent    effects varied over items, although four of five were positive.</font></p
>     ^cY#15.htm##
01006000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704078300070002000700853#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#74#70#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><a href="/img/revistas/rpsp/v23n2/15t2.gif
">Table    2</a> further presents estimates for the control variables. Older wom
en are    more likely to have had a Pap smear test, and younger women are more l
ikely    to report condom use. Generally, education turned out to be an importan
t variable,    with significant effects on attitudes, inspection of sexual organ
s, hygiene,    and asserting oneself vis-&agrave;-vis one's partner. In contrast
 to formal    education, the effects of having a partner were difficult to inter
pret. Participation    in the <i>Oportunidades</i> program had a positive effect
 on knowledge and on    Pap smear testing, both in its explanation and in report
ing a recent test.</font></p>     ^cY#15.htm##
00938000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704071500070002000700785#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#75#71#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">We would like to    draw attention to the 
considerable effect of social desirability on almost all    dependent variables.
 This suggests that social desirability is an important    variable that must be
 considered when relying on self-reports in evaluations    of program success. T
he multilevel analyses further imply the estimation of    (random) effects that 
model differences among the villages (beyond differences    already explained by
 the treatment variable). These estimates are not reported    here because no si
gnificant effects were found for any of the items and because    the results are
 of less substantive interest.</font></p>     ^cY#15.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#76#72#article#128#<p>&nbsp;</p>     ^cY#15.
htm##
00342000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704011900070002000700189#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#77#73#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>DISCUSSION AND    CONCLUSIONS</b></font
></p>     ^cY#15.htm##
01553000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704133000070002000701400#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#78#74#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The main finding    of this study is clear
. There was a significant increase in the number of rural    and indigenous wome
n who came to have a Pap smear in the communities where the    program was imple
mented compared with the control villages, where there was    no evidence of an 
increase. Further support for the success of the program comes    from the quest
ionnaire study, which also provides insight into how best to explain    the succ
ess of the program. The results in <a href="/img/revistas/rpsp/v23n2/15t2.gif">T
able    2</a> show that participation in the workshops contributed to an increas
e in    knowledge about cervical cancer and its prevention. Effects on behavior 
tended    to be smaller, and effects on underlying variables, such as intentions
 and attitudes,    were rather minimal. This pattern fits in with the idea, ment
ioned in the introduction,    that knowledge and skills to deal with specific si
tuations change before there    are changes in psychological variables that refl
ect more general characteristics    of a person, as is the case with personal at
titudes (21, 23) as well as the    fact that often in communities where there is
 little control over one's actions,    the concept of intention is not relevant 
(33).</font></p>     ^cY#15.htm##
01303000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704108000070002000701150#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#79#75#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Another finding    reflected in <a href="/
img/revistas/rpsp/v23n2/15t2.gif">Table 2</a> is the    importance of social des
irability when the effect of intervention is assessed    through self-reports. S
ocial desirability is a tendency to give an answer in    agreement with prevaili
ng norms and social expectations. The tendency to comply    with such expectatio
ns is higher among close-knit communities where following    social norms is mor
e closely controlled (34). This response style can strongly    affect self-repor
ts (35). However, such effects are rarely accounted for in    quantitative or qu
alitative program evaluations (36, 37). The estimated effect    size for this su
bscale sometimes exceeds the estimates for treatment effects    (see, for exampl
e, the attitude and intention subscales). This means not that    the treatment h
ad no effect but that the effects of the treatment would have    been seriously 
misrepresented if this response style effect had not been accounted    for.</fon
t></p>     ^cY#15.htm##
00666000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704044300070002000700513#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#80#76#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Attending the <i>Oportunidades</i>    prog
ram is mostly associated with positive outcomes and the present program    can p
robably be said to build on the more general <i>Oportunidades</i> lectures.    T
he focus of this program on cervical cancer and its prevention leads to higher  
  estimates for (specific) knowledge increase and Pap-smear-related behaviors.</
font></p>     ^cY#15.htm##
01040000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704081700070002000700887#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#81#77#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Apart from the    relevance for the target
 women of the program content, effectiveness, in our    view, has to be attribut
ed to two factors: the didactic mode and the attention    to context. The worksh
ops were designed to be highly interactive. Women were    encouraged to talk to 
each other and to ask questions. During the supervised    sessions, it was noted
 that this did happen and there was active participation    in simulations and o
ther group activities. In addition, there was a central    role for local health
 promoters who know the circumstances of the women in their    workshops. During
 their week-long training, the health promoters went through    the program, and
 they also learned how to conduct workshop sessions.</font></p>     ^cY#15.htm##
00957000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704073400070002000700804#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#82#78#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The second factor,    attention to context
, is reflected in an array of activities, including workshops    for men and hea
lth professionals, dissemination activities in the form of public    announcemen
ts and displays, and advocacy activities aimed at community officials    (17). I
t was difficult for any villager to <i>not</i> know about the program.    Testim
onials of the women indicated that such public visibility questioned restrictive
    social norms and opened up opportunities for change. The success of interven
tions    paying attention to context has also been reported in other countries s
uch as    Ghana (38), Peru (39), and Greece (40).</font></p>     ^cY#15.htm##
01485000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704126200070002000701332#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#83#79#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">Although we have    assessed the results o
f the program as positive, we realize that the design    and execution of the qu
estionnaire study was not optimal. The study would have    been stronger if the 
same women had participated in the pre- and posttest study,    but with bringing
 in a team of qualified interviewers from outside the communities    we did not 
have that choice. In the villages, it is impossible to make prior    arrangement
s for an interview. One has to work with whoever is available at    a given time
. Also, the number of villages was fairly small, allowing for a    larger margin
 of error than would have been the case with higher numbers. This    lack of pre
cision was compounded by the absence of demographic data for some    of the vill
ages needed to estimate the percentage increase in Pap smears. Finally,    some 
of the estimates in <a href="/img/revistas/rpsp/v23n2/15t2.gif">Table 2</a>    h
ave a substantial margin of error because of the unreliability of single-item   
 variables. Complex field studies cannot reach the level of precision and contro
l    of laboratory experiments, but they can help to provide insights not otherw
ise    available.</font></p>     ^cY#15.htm##
01040000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704081700070002000700887#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#84#80#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">The findings we    reported mainly concern
 the effectiveness of the program, but they also have    some relevance for an e
valuation of efficiency. The question of efficiency is    important for decision
s about future scaling up of the program to reach much    larger numbers of wome
n. To estimate the economic benefits, we would need to    make assumptions about
 the maintenance and further spread of individual health    care practices in co
mmunities as a consequence of the program, for which we    lack a sufficient fou
ndation. However, we would like to emphasize that the involvement    of local he
alth promoters as workshop facilitators is a cost-efficient way to    implement 
a highly interactive program at relatively low cost.</font></p>     ^cY#15.htm##
00970000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704074700070002000700817#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#85#81#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">In summary, the    findings show that the 
<i>Porque me quiero, me cuido</i> program has led to    a significant increase i
n the number of Pap smears among indigenous and rural    populations in the regi
on of Oaxaca, Mexico, where it was implemented and in    knowledge relevant for 
preventing cervical cancer. Several features of the program    can help explain 
these results, of which the two most important are the extension    of program a
ctivities to include the social environment and the highly participatory    meth
od of implementation through a closely accompanied cascade system in which    we
ll-trained and closely supervised local women play a key role.</font></p>     ^c
Y#15.htm##
00815000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704059200070002000700662#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#86#82#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2"><b>Acknowledgments.</b>    This project wa
s made possible by a grant from the Commission of European Communities,    MEX/B
7-6310/IB/99/0251. We acknowledge the support of Carmen Fuertes and Tere    Veng
uer in the fieldwork and program development. Completion of this article    was 
facilitated by a research fellowship at the Harvard Center for Population    and
 Development Studies, Cambridge, Massachusetts, awarded to Susan Pick. None    o
f the authors had any conflicts of interest in producing this work.</font></p>  
   ^cY#15.htm##
00245000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704002200070002000700092#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#87#83#article#128#<p>&nbsp;</p>     ^cY#15.
htm##
00323000000000145000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066704010000070002000700170#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#88#84#article#128#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>REFERENCES</b></font></p>     ^cY#15.ht
m##
00623000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704038600072002000700458#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#89#85#article#128#1#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">1.&nbsp;Alliance    for Cerv
ical Cancer Prevention. Women's stories, women's lives: experiences    with cerv
ical screening and treatment. Available from: <a href="http://www.phishare.org/d
ocuments/ACCP/2598/" target="_blank">http://www.phishare.org/documents/ACCP/2598
/</a>.    Accessed 7 December 2005.</font></p>     ^cY#15.htm##
00456000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704021900072002000700291#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#90#86#article#128#2#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">2.&nbsp;Adanu RM.    Cervica
l cancer knowledge and screening in Accra, Ghana. J Womens Health Gend    Based 
Med. 2002; 11(6):487&#150;8.</font></p>     ^cY#15.htm##
00481000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704024400072002000700316#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#91#87#article#128#3#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">3.&nbsp;Ajayi IO,    Adewole
 IF. Knowledge and attitudes of general outpatient attendants in Nigeria    to c
ervical cancer. Cent Afr J Med. 1998;44(2):41&#150;3.</font></p>     ^cY#15.htm#
#
00579000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704034200072002000700414#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#92#88#article#128#4#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">4.&nbsp;Masood    S. A plea 
for worldwide volunteer cervical cancer education and awareness program.    A pr
oposal from the International Academy of Cytology Committee on Cancer Detection 
   for Medically Underserved Women. Acta Cytol. 1999;43(4):539&#150;43.</font></
p>     ^cY#15.htm##
00473000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704023600072002000700308#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#93#89#article#128#5#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">5.&nbsp;Fylan F.    Screenin
g for cervical cancer: a review of women's attitudes, knowledge, and    behavior
. Br J Gen Pract. 1998; 48(433):1509&#150;14.</font></p>     ^cY#15.htm##
00475000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704023800072002000700310#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#94#90#article#128#6#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">6.&nbsp;Holroyd    E, Twinn 
S, Adab P. Socio-cultural influences on Chinese women's attendance    for cervic
al screening. J Adv Nurs. 2004;46(1):42&#150;5.</font></p>     ^cY#15.htm##
00565000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704032800072002000700400#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#95#91#article#128#7#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">7.&nbsp;Bingham    A, Bishop
 A, Coffey P, Winkler J, Bradley J, Dzuba I, et al. Factors affecting    utiliza
tion of cervical cancer prevention services in low-resource settings.    Salud P
&uacute;blica M&eacute;x. 2003;45(Suppl 3): S408&#150;16.</font></p>     ^cY#15.
htm##
00507000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704027000072002000700342#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#96#92#article#128#8#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">8.&nbsp;Franco    EL, Duarte
-Franco E, Ferenczy A. Prospects for controlling cervical cancer at    the turn 
of the century. Salud P&uacute;blica M&eacute;x. 2003;45(Suppl 3):S367&#150;75.<
/font></p>     ^cY#15.htm##
00477000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000200070704024000072002000700312#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#97#93#article#128#9#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">9.&nbsp;Pisani    P, Parkin 
DM, Bray F, Ferlay J. Erratum: estimates of the worldwide mortality    from 25 c
ancers in 1990. Int J Cancer. 1999;83:18&#150;29.</font></p>     ^cY#15.htm##
00495000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704025700073002000700330#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#98#94#article#128#10#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">10.&nbsp;Jimenez-Perez    M
, Thomas DB. Has the use of Pap smears reduced the risk of invasive cervical    
cancer in Guadalajara, Mexico? Int J Cancer. 1999;82(6):804&#150;9.</font></p>  
   ^cY#15.htm##
00591000000000157000450000400060000070200420000670500020004870600020005070000030
0052701000300055709000800058708000400066888000300070704035300073002000700426#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#99#95#article#128#11#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">11.&nbsp;Rangel    JI, P&ea
cute;rez Rend&oacute;n M, Rivera L, Velasco H, Hern&aacute;ndez Gir&oacute;n    
C. Prevalence of dysplasias and cervical cancer in women in the State of Quer&ea
cute;taro    (Mexico). Clinical and Translational Oncology. 2003;5(8):471&#150;4
75.</font></p>     ^cY#15.htm##
00494000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000300071704025500074002000700329#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#100#96#article#128#12#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">12.&nbsp;Secretaria    de 
Salud. Statistics of mortality related to reproductive health: Mexico, 1997    (
indicators). Salud P&uacute;blica M&eacute;x. 1999;41:138&#150;46.</font></p>   
  ^cY#15.htm##
00596000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000300071704035700074002000700431#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#101#97#article#128#13#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">13.&nbsp;Palacio-Mej&iacut
e;a    LS, Rangel-G&oacute;mez G, Hern&aacute;ndez-&Aacute;vila M, Lazcano-Ponce
 M.    Cervical cancer, a disease of poverty: mortality differences between urba
n and    rural areas in Mexico. Salud P&uacute;blica M&eacute;x. 2003;45(3):315&
#150;25.</font></p>     ^cY#15.htm##
00579000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000300071704034000074002000700414#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#102#98#article#128#14#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">14.&nbsp;Coughlin    SS, U
hler RJ, Richards T, Wilson KM. Breast and cervical cancer screening practices  
  among Hispanic and non-Hispanic women residing near the United States-Mexico  
  border, 1999&#150;2000. Fam Community Health. 2003;26(2): 130&#150;9.</font></
p>     ^cY#15.htm##
00601000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000300056709000800059708000400067888000300071704036200074002000700436#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#103#99#article#128#15#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">15.&nbsp;Escandon-Romero  
  C, Benitez-Martinez MG, Navarrete-Espinoza J, Vazquez-Martinez JL, Martinez-Mo
ntanez    OG, Escobedo-de la Pena J. Epidemiology of cervical cancer at the Mexi
can institute    of social security. Salud P&uacute;blica M&eacute;x. 1992;34(6)
:607&#150;14.</font></p>     ^cY#15.htm##
00596000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704035600075002000700431#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#104#100#article#128#16#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">16.&nbsp;Lazcano-Ponce   
 EC, Moss S, Cruz-Valdez A, Alonso de Ruiz P, Casares-Queralt S, Martinez-Leon  
  CJ, et al. The factors that determine participation in cervical cancer screeni
ng    in the state of Morelos. Salud P&uacute;blica M&eacute;x. 1999;41(4): 278&
#150;85.</font></p>     ^cY#15.htm##
00532000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704029200075002000700367#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#105#101#article#128#17#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">17.&nbsp;Givaudan    M, P
ick S, Poortinga YH, Fuertes C, Gold L. A cervical cancer prevention program    
in rural Mexico: addressing women and their context. J Commun Appl Soc Psychol. 
   2005;15: 338&#150;52.</font></p>     ^cY#15.htm##
00564000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704032400075002000700399#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#106#102#article#128#18#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">18.&nbsp;Lazcano-Ponce   
 EC, Najera-Aguilara P, Buiatti E, Alonso de Ruiz P, Kuri P, Cantoral L, et al. 
   The cervical cancer screening program in Mexico: problems with access and cov
erage.    Cancer Causes Control. 1997;8(5):698&#150;704.</font></p>     ^cY#15.h
tm##
00529000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704028900075002000700364#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#107#103#article#128#19#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">19.&nbsp;Herrero    R, Br
inton LA, Reeves WC, Brenes MM, de Britton RC, Gaintan E, et al. Screening    fo
r cervical cancer in Latin America: a case-control study. Int J Epidemiol.    19
92;21(6):1050&#150;6.</font></p>     ^cY#15.htm##
00607000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704036700075002000700442#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#108#104#article#128#20#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">20.&nbsp;Fuertes,    C. y
 Venguer, T. Porque me quiero, me cuido: un taller integral para la prevenci&oac
ute;n    y detecci&oacute;n temprana del c&aacute;ncer c&eacute;rvico uterino. (
Rotafolio).    M&eacute;xico: Uni&oacute;n Europea, IMIFAP-Educaci&oacute;n, sal
ud y vida;    2001.</font></p>     ^cY#15.htm##
00577000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704033700075002000700412#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#109#105#article#128#21#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">21.&nbsp;Deininger    K, 
Minten B. Poverty, policies, and deforestation: the case of Mexico, research    
project on social and environmental consequences of growth-oriented policies.   
 Working Paper, Policy Research Department. Geneva: World Bank; 1996.</font></p>
     ^cY#15.htm##
00484000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704024400075002000700319#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#110#106#article#128#22#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">22.&nbsp;Pick S,    Givau
dan M, Poortinga YH. Sexuality and life skills education: a multi-strategy    in
tervention in Mexico. Am Psychol. 2003;58(3):230&#150;4.</font></p>     ^cY#15.h
tm##
00584000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704034400075002000700419#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#111#107#article#128#23#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">23.&nbsp;Pick S,    Poort
inga Y. Marco conceptual y estrategia para el dise&ntilde;o e instrumentaci&oacu
te;n    de programas para el desarrollo: una visi&oacute;n cient&iacute;fica, po
l&iacute;tica    y psicosocial. Rev Latinoam Psicol. 2005;37(3): 445&#150;6.</fo
nt></p>     ^cY#15.htm##
00509000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704026900075002000700344#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#112#108#article#128#24#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">24.&nbsp;Pick S,    Poort
inga YH, Givaudan M. Integrating intervention theory and strategy in culture-sen
sitive    health promotion programs. Prof Psychol Res Pr. 2003; 34(4):422&#150;9
.</font></p>     ^cY#15.htm##
00486000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704024600075002000700321#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#113#109#article#128#25#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">25.&nbsp;Friedell    G, L
inville L, Rubio A, Wagner W, Tucker T. What providers should know about    comm
unity cancer control. Cancer Pract. 1997;5(6):367&#150;74.</font></p>     ^cY#15
.htm##
00517000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704027700075002000700352#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#114#110#article#128#26#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">26.&nbsp;Shanta    V, Kri
shnamurthi S, Gajalakshmi C, Swaminathan R, Ravichandran K. Epidemiology    of c
ancer of cervix: global and national perspective. J Indian Med Assoc. 2000;98:49
&#150;52.</font></p>     ^cY#15.htm##
00445000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704020500075002000700280#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#115#111#article#128#27#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">27.&nbsp;Rossi    PH, Fre
eman HE. Evaluation: a systematic approach, 5th ed. Newbury Park, CA:    Sage Pu
blications; 1993.</font></p>     ^cY#15.htm##
00540000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704030000075002000700375#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#116#112#article#128#28#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">28.&nbsp;Verhelst    ND, 
Glas CAW. The one parameter logistic model. In: Fisher GH, Molenaar IW,    eds. 
Rasch models: foundations, recent developments, and applications. New York:    S
pringer; 1995. Pp. 215&#150;237.</font></p>     ^cY#15.htm##
00553000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704031300075002000700388#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#117#113#article#128#29#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">29.&nbsp;Birnbaum    A. S
ome latent trait models and their use in inferring an examinee's ability.    In:
 Lord FM, Novick MR, eds. Statistical theories of mental test scores. Reading,  
  MA: Addison-Wesley; 1968. Pp. 396&#150;479.</font></p>     ^cY#15.htm##
00408000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704016800075002000700243#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#118#114#article#128#30#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">30.&nbsp;Goldstein    H. 
Multilevel statistical models. 3rd ed. London: Arnold; 2003.</font></p>     ^cY#
15.htm##
00470000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704023000075002000700305#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#119#115#article#128#31#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">31.&nbsp;Raudenbush    SW
, Bryk AS. Hierarchical linear models: applications and data analysis methods.  
  2nd ed. London: Sage Publications; 2002.</font></p>     ^cY#15.htm##
00539000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704029900075002000700374#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#120#116#article#128#32#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">32.&nbsp;Leenen    I, Giv
audan M, Pick S, Venguer T, Vera J, Poortinga Y. Effectiveness of an integral   
 health education program in a poverty stricken rural area of Guatemala. J Cross
-Cultural    Psychol. In press.</font></p>     ^cY#15.htm##
00664000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704042400075002000700499#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#121#117#article#128#33#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">33.&nbsp;Pick S.    Exten
sion of theory of reasoned action principles for health promotion programs    wi
th marginalized populations in Latin America. In: Ajzen I, Albarrac&iacute;n    
D, Hornik R, eds. Predic- tion and change of health behavior: applying a reasone
d    action approach. Mahwah, NJ.: Lawrence Erlbaum; 2007. Pp. 223&#150;241.</fo
nt></p>     ^cY#15.htm##
00431000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704019100075002000700266#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#122#118#article#128#34#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">34.&nbsp;Pelto    PJ. The
 differences between "tight" and "loose" societies. Transaction. 1968;5:37&#150;
40.</font></p>     ^cY#15.htm##
00551000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704031100075002000700386#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#123#119#article#128#35#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">35.&nbsp;Paulhus,    DL. 
Measurement and control of response bias. In: Robinson JP, Shaver PR, Wrightsman
    LS, eds. Measures of personality and social psychological attitudes. New Yor
k:    Academic Press; 1991. Pp. 17&#150;59.</font></p>     ^cY#15.htm##
00533000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704029300075002000700368#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#124#120#article#128#36#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">36.&nbsp;Gregson    S, Zh
uwau T, Ndlovu J, Nyamukapa C. Methods to reduce social desirability bias    in 
sex surveys in low-development settings: experience in Zimbabwe. Sex Transm    D
is. 2002;29: 568&#150;75.</font></p>     ^cY#15.htm##
00549000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704030900075002000700384#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#125#121#article#128#37#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">37.&nbsp;Wagner    GP, Mi
ller LG. Adherence in HIV: difficulties in evaluating: is the influence    of so
cial desirability on patients' self-reported adherence overrated? J Acquir    Im
mune Defic Syndr. 2004;35(2): 203&#150;4.</font></p>     ^cY#15.htm##
00568000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704032800075002000700403#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#126#122#article#128#38#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">38.&nbsp;Corneli    A, Kl
eine A, Salvador-Davila G, Gaffikin L, Lewis R, Amankwah A. A qualitative    eva
luation of the acceptability and feasibility of a single visit approach to    ce
rvical cancer prevention in Ghana. Baltimore: JHPIEGO; 2004.</font></p>     ^cY#
15.htm##
00643000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704040300075002000700478#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#127#123#article#128#39#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">39.&nbsp;Pan American    
Health Organization. Testing new technologies in the test-and-treat project,    
Peru: The TATI Intervention. Available from: <a href="http://www.paho.org/Englis
h/AD/DPC/NC/cctestingnewtech.pdf" target="_blank">www.paho.org/English/AD/DPC/NC
/cctestingnewtech.pdf</a>.    Accessed 12 October 2004.</font></p>     ^cY#15.ht
m##
00492000000000157000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068888000300072704025200075002000700327#v23
n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#p#128#124#article#128#40#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">40.&nbsp;Riza E,    Kyria
kogianni-Psaropolou P, Koumantakis E, Symiakaki H, Garas I, Linos A. Cervical   
 cancer screening in Greece. Eur J Cancer. 2002;36:2227&#150;32.</font></p>     
^cY#15.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#129#125#article#128#<p>&nbsp;</p>     ^cY#1
5.htm##
00247000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704002200072002000700094#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#130#126#article#128#<p>&nbsp;</p>     ^cY#1
5.htm##
00585000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704036000072002000700432#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#131#127#article#128#<p><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#top">*</a> 
   Send correspondence and reprint requests to: Martha Givaudan, Malaga Norte 25
,    Colonia Insurgentes Mixcoac, Mexico City, Mexico; telephone 52 555 6115876,
    ext. 252; e-mail: <a href="mailto:marthag@20imifap.org.mx">marthag@ imifap.o
rg.mx</a>    ^cY#15.htm##
01042000000000145000450000400060000070200420000670500020004870600020005070000040
0052701000400056709000800060708000400068704081700072002000700889#v23n2#v:\scielo
\serial\rpsp\v23n2\markup\15.htm#S#p#132#128#article#128#<br>   <a name="back1">
</a><a href="#top1">1</a> The State Department of Health assisted    in obtainin
g demographic data for each of the villages. We needed to know the    number of 
women between 15 and 50 years of age to assess the reach of the program.    Alth
ough municipalities are supposed to provide information to the department    abo
ut the composition of the population, this information was not available    for 
all villages. We estimated the number of women in the stipulated age range    in
 the case of two experimental villages on the basis of the total size of the    
population and the total number of women in the other eight villages, assuming  
  that age and gender distributions were the same in all villages. The two estim
ates    were close in value and the average was taken.</font></p>     ^cY#15.htm
##
00501000000000217000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690170040000710180086001110370
04500197110000900242109001600251865000900267002000700276#v23n2#v:\scielo\serial\
rpsp\v23n2\markup\15.htm#S#c#133#1#article#40#1#Alliance for Cervical Cancer Pre
vention#Women's stories, women's lives: experiences with cervical screening and 
treatment^len#http://www.phishare.org/documents/ACCP/2598/#20051207#7 December 2
005#20080200#15.htm##
00487000000000265000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100016000710120060000870300
03100147710000200178065000900180064000500189031000300194032000200197014000600199
865000900205002000700214#v23n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#c#134
#2#article#40#2#^rND^sAdanu^nRM#Cervical cancer knowledge and screening in Accra
, Ghana^len#J Womens Health Gend Based Med#2#20020000#2002#11#6#487-8#20080200#1
5.htm##
00566000000000289000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100016000710100018000870120
09100105030001500196065000900211064000500220031000300225032000200228014000500230
865000900235002000700244035001000251801001500261#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\15.htm#S#c#135#3#article#40#3#^rND^sAjayi^nIO#^rND^sAdewole^nIF#Knowle
dge and attitudes of general outpatient attendants in Nigeria to cervical cancer
^len#Cent Afr J Med#19980000#1998#44#2#41-3#20080200#15.htm#0008-9176#Cent Afr J
 Med##
00639000000000277000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100016000710120200000870300
01100287065000900298064000500307031000300312032000200315014000700317865000900324
002000700333035001000340801001100350#v23n2#v:\scielo\serial\rpsp\v23n2\markup\15
.htm#S#c#136#4#article#40#4#^rND^sMasood^nS#A plea for worldwide volunteer cervi
cal cancer education and awareness program: A proposal from the International Ac
ademy of Cytology Committee on Cancer Detection for Medically Underserved Women^
len#Acta Cytol#19990000#1999#43#4#539-43#20080200#15.htm#0001-5547#Acta cytol##
00539000000000277000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100015000710120090000860300
01500176065000900191064000500200031000300205032000400208014000800212865000900220
002000700229035001000236801001500246#v23n2#v:\scielo\serial\rpsp\v23n2\markup\15
.htm#S#c#137#5#article#40#5#^rND^sFylan^nF#Screening for cervical cancer: a revi
ew of women's attitudes, knowledge, and behavior^len#Br J Gen Pract#19980000#199
8#48#433#1509-14#20080200#15.htm#0960-1643#Br J Gen Pract##
00574000000000301000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100017000710100015000880100
01400103012008300117030001100200065000900211064000500220031000300225032000200228
014000500230865000900235002000700244035001000251801001100261#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\15.htm#S#c#138#6#article#40#6#^rND^sHolroyd^nE#^rND^sTwinn
^nS#^rND^sAdab^nP#Socio-cultural influences on Chinese women's attendance for ce
rvical screening^len#J Adv Nurs#20040000#2004#46#1#42-5#20080200#15.htm#0309-240
2#J Adv Nurs##
00714000000000349000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100017000710100016000880100
01600104010001700120010001700137010001500154810000600169012009800175030001800273
06500090029106400050030003100030030503200040030801400080031286500090032000200070
0329035001000336801001800346#v23n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#c
#139#7#article#40#7#^rND^sBingham^nA#^rND^sBishop^nA#^rND^sCoffey^nP#^rND^sWinkl
er^nJ#^rND^sBradley^nJ#^rND^sDzuba^nI#et al#Factors affecting utilization of cer
vical cancer prevention services in low-resource settings^len#Salud Pública Méx#
20030000#2003#45#^s3#S408-16#20080200#15.htm#0036-3634#Salud pública Méx##
00595000000000301000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100017000710100023000880100
01800111012007300129030001800202065000900220064000500229031000300234032000400237
014000800241865000900249002000700258035001000265801001800275#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\15.htm#S#c#140#8#article#40#8#^rND^sFranco^nEL#^rND^sDuart
e-Franco^nE#^rND^sFerenczy^nA#Prospects for controlling cervical cancer at the t
urn of the century^len#Salud Pública Méx#20030000#2003#45#^s3#S367-75#20080200#1
5.htm#0036-3634#Salud pública Méx##
00585000000000301000450000400060000070200420000670500020004870600020005070000040
00527010002000567090008000587080003000661180002000690100016000710100017000870100
01400104010001600118012007400134030001300208065000900221064000500230031000300235
014000600238865000900244002000700253035001000260801001300270#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\15.htm#S#c#141#9#article#40#9#^rND^sPisani^nP#^rND^sParkin
^nDM#^rND^sBray^nF#^rND^sFerlay^nJ#Erratum: estimates of the worldwide mortality
 from 25 cancers in 1990^len#Int J Cancer#19990000#1999#83#18-29#20080200#15.htm
#0020-7136#Int J Cancer##
00579000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100023000730100017000960120
09900113030001300212065000900225064000500234031000300239032000200242014000600244
865000900250002000700259035001000266801001300276#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\15.htm#S#c#142#10#article#40#10#^rND^sJimenez-Perez^nM#^rND^sThomas^nD
B#Has the use of Pap smears reduced the risk of invasive cervical cancer in Guad
alajara, Mexico?^len#Int J Cancer#19990000#1999#82#6#804-9#20080200#15.htm#0020-
7136#Int J Cancer##
00657000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100022000900100
01600112010001700128010002500145012009300170030003600263710000200299065000900301
064000500310031000200315032000200317014000800319865000900327002000700336#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\15.htm#S#c#143#11#article#40#11#^rND^sRangel^n
JI#^rND^sPérez Rendón^nM#^rND^sRivera^nL#^rND^sVelasco^nH#^rND^sHernández Girón^
nC#Prevalence of dysplasias and cervical cancer in women in the State of Queréta
ro (Mexico)^len#Clinical and Translational Oncology#2#20030000#2003#5#8#471-475#
20080200#15.htm##
00497000000000241000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700110020000730120086000930300
01800179065000900197064000500206865000900211002000700220035001000227801001800237
#v23n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#c#144#12#article#40#12#Secret
aria de Salud#Statistics of mortality related to reproductive health: Mexico, 19
97 (indicators)^len#Salud Pública Méx#19990000#1999#20080200#15.htm#0036-3634#Sa
lud pública Méx##
00674000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100024000730100022000970100
02500119010002300144012010500167030001800272065000900290064000500299031000300304
032000200307014000700309865000900316002000700325035001000332801001800342#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\15.htm#S#c#145#13#article#40#13#^rND^sPalacio-
Mejía^nLS#^rND^sRangel-Gómez^nG#^rND^sHernández-Ávila^nM#^rND^sLazcano-Ponce^nM#
Cervical cancer, a disease of poverty: mortality differences between urban and r
ural areas in Mexico^len#Salud Pública Méx#20030000#2003#45#3#315-25#20080200#15
.htm#0036-3634#Salud pública Méx##
00696000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100016000920100
01800108010001700126012014600143030002100289065000900310064000500319031000300324
032000200327014000600329865000900335002000700344035001000351801002100361#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\15.htm#S#c#146#14#article#40#14#^rND^sCoughlin
^nSS#^rND^sUhler^nRJ#^rND^sRichards^nT#^rND^sWilson^nKM#Breast and cervical canc
er screening practices among Hispanic and non-Hispanic women residing near the U
nited States-Mexico border, 1999-2000^len#Fam Community Health#20030000#2003#26#
2#130-9#20080200#15.htm#0160-6379#Fam Community Health##
00743000000000337000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100025000730100027000980100
02800125010002700153010002800180010002900208012008000237030001800317065000900335
06400050034403100030034903200020035201400070035486500090036100200070037003500100
0377801001800387#v23n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#c#147#15#arti
cle#40#15#^rND^sEscandon-Romero^nC#^rND^sBenitez-Martinez^nMG#^rND^sNavarrete-Es
pinoza^nJ#^rND^sVazquez-Martinez^nJL#^rND^sMartinez-Montanez^nOG#^rND^sEscobedo-
de la Pena^nJ#Epidemiology of cervical cancer at the Mexican institute of social
 security^len#Salud Pública Méx#19920000#1992#34#6#607-14#20080200#15.htm#0036-3
634#Salud pública Méx##
00747000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100024000730100014000970100
02100111010002400132010002500156010002400181810000600205012009800211030001800309
06500090032706400050033603100030034103200020034401400070034686500090035300200070
0362035001000369801001800379#v23n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#c
#148#16#article#40#16#^rND^sLazcano-Ponce^nEC#^rND^sMoss^nS#^rND^sCruz-Valdez^nA
#^rND^sAlonso de Ruiz^nP#^rND^sCasares-Queralt^nS#^rND^sMartinez-Leon^nCJ#et al#
The factors that determine participation in cervical cancer screening in the sta
te of Morelos^len#Salud Pública Méx#19990000#1999#41#4#278-85#20080200#15.htm#00
36-3634#Salud pública Méx##
00619000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100014000910100
02000105010001700125010001400142012009300156030002600249710000200275065000900277
064000500286031000300291014000700294865000900301002000700310#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\15.htm#S#c#149#17#article#40#17#^rND^sGivaudan^nM#^rND^sPi
ck^nS#^rND^sPoortinga^nYH#^rND^sFuertes^nC#^rND^sGold^nL#A cervical cancer preve
ntion program in rural Mexico: addressing women and their context^len#J Commun A
ppl Soc Psychol#2#20050000#2005#15#338-52#20080200#15.htm##
00734000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100024000730100025000970100
01700122010002400139010001400163010001800177810000600195012008700201030002200288
06500090031006400050031903100020032403200020032601400080032886500090033600200070
0345035001000352801002200362#v23n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#c
#150#18#article#40#18#^rND^sLazcano-Ponce^nEC#^rND^sNajera-Aguilara^nP#^rND^sBui
atti^nE#^rND^sAlonso de Ruiz^nP#^rND^sKuri^nP#^rND^sCantoral^nL#et al#The cervic
al cancer screening program in Mexico: problems with access and coverage^len#Can
cer Causes Control#19970000#1997#8#5#698-704#20080200#15.htm#0957-5243#Cancer Ca
uses Control##
00693000000000349000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100018000900100
01700108010001700125010002100142010001700163810000600180012007300186030001600259
06500090027506400050028403100030028903200020029201400070029486500090030100200070
0310035001000317801001600327#v23n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#c
#151#19#article#40#19#^rND^sHerrero^nR#^rND^sBrinton^nLA#^rND^sReeves^nWC#^rND^s
Brenes^nMM#^rND^sde Britton^nRC#^rND^sGaintan^nE#et al#Screening for cervical ca
ncer in Latin America: a case-control study^len#Int J Epidemiol#19920000#1992#21
#6#1050-6#20080200#15.htm#0300-5771#Int J Epidemiol##
00572000000000253000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700160017000730160017000900180
11800107025001000225066000700235062004600242065000900288064000500297865000900302
002000700311#v23n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#c#152#20#article#
40#20#^rND^sFuertes^nC#^rND^sVenguer^nT#Porque me quiero, me cuido: un taller in
tegral para la prevención y detección temprana del cáncer cérvico uterino^les#Ro
tafolio#México#Unión Europea, IMIFAP-Educación, salud y vida#20010000#2001#20080
200#15.htm##
00611000000000265000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700160019000730160016000920180
14800108025001400256062002700270066000700297062001100304065000900315064000500324
865000900329002000700338#v23n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#c#153
#21#article#40#21#^rND^sDeininger^nK#^rND^sMinten^nB#Poverty, policies, and defo
restation: the case of Mexico, research project on social and environmental cons
equences of growth-oriented policies^len#Working Paper#Policy Research Departmen
t#Geneva#World Bank#19960000#1996#20080200#15.htm##
00581000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100014000730100018000870100
02000105012008100125030001100206065000900217064000500226031000300231032000200234
014000600236865000900242002000700251035001000258801001100268#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\15.htm#S#c#154#22#article#40#22#^rND^sPick^nS#^rND^sGivaud
an^nM#^rND^sPoortinga^nYH#Sexuality and life skills education: a multi-strategy 
intervention in Mexico^len#Am Psychol#20030000#2003#58#3#230-4#20080200#15.htm#0
003-066X#Am Psychol##
00633000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100014000730100019000870120
14600106030002000252065000900272064000500281031000300286032000200289014000600291
865000900297002000700306035001000313801002000323#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\15.htm#S#c#155#23#article#40#23#^rND^sPick^nS#^rND^sPoortinga^nY#Marco
 conceptual y estrategia para el diseño e instrumentación de programas para el d
esarrollo: una visión científica, política y psicosocial^les#Rev Latinoam Psicol
#20050000#2005#37#3#445-6#20080200#15.htm#0120-0534#Rev Latinoam Psicol##
00614000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100014000730100020000870100
01800107012009600125030002000221065000900241064000500250031000300255032000200258
014000600260865000900266002000700275035001000282801002000292#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\15.htm#S#c#156#24#article#40#24#^rND^sPick^nS#^rND^sPoorti
nga^nYH#^rND^sGivaudan^nM#Integrating intervention theory and strategy in cultur
e-sensitive health promotion programs^len#Prof Psychol Res Pr#20030000#2003#34#4
#422-9#20080200#15.htm#0735-7028#Prof Psychol Res Pr##
00621000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730100018000910100
01500109010001600124010001600140012006200156030001300218065000900231064000500240
03100020024503200020024701400070024986500090025600200070026503500100027280100130
0282#v23n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#c#157#25#article#40#25#^r
ND^sFriedell^nG#^rND^sLinville^nL#^rND^sRubio^nA#^rND^sWagner^nW#^rND^sTucker^nT
#What providers should know about community cancer control^len#Cancer Pract#1997
0000#1997#5#6#367-74#20080200#15.htm#1065-4704#Cancer Pract##
00647000000000313000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730100023000890100
02100112010002100133010002200154012007000176030001900246065000900265064000500274
031000300279014000600282865000900288002000700297035001000304801001900314#v23n2#v
:\scielo\serial\rpsp\v23n2\markup\15.htm#S#c#158#26#article#40#26#^rND^sShanta^n
V#^rND^sKrishnamurthi^nS#^rND^sGajalakshmi^nC#^rND^sSwaminathan^nR#^rND^sRavicha
ndran^nK#Epidemiology of cancer of cervix: global and national perspective^len#J
 Indian Med Assoc#20000000#2000#98#49-52#20080200#15.htm#0019-5847#J Indian Med 
Assoc##
00466000000000253000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700160016000730160018000890180
03800107063000200145066001700147062001800164065000900182064000500191865000900196
002000700205#v23n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#c#159#27#article#
40#27#^rND^sRossi^nPH#^rND^sFreeman^nHE#Evaluation: a systematic approach^len#5#
Newbury Park^eCA#Sage Publications#19930000#1993#20080200#15.htm##
00596000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100019000730100016000920120
03700108016001700145016001900162018006900181066000900250062000900259065000900268
064000500277014000800282865000900290002000700299#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\15.htm#S#c#160#28#article#40#28#^rND^sVerhelst^nND#^rND^sGlas^nCAW#The
 one parameter logistic model^len#^rED^sFisher^nGH#^rED^sMolenaar^nIW#Rasch mode
ls: foundations, recent developments, and applications^len#New York#Springer#199
50000#1995#215-237#20080200#15.htm##
00604000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730120078000910160
01500169016001700184018004700201025000800248066000500256062001500261065000900276
064000500285014000800290865000900298002000700307#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\15.htm#S#c#161#29#article#40#29#^rND^sBirnbaum^nA#Some latent trait mo
dels and their use in inferring an examinee's ability^len#^rED^sLord^nFM#^rED^sN
ovick^nMR#Statistical theories of mental test scores^len#Reading#^eMA#Addison-We
sley#19680000#1968#396-479#20080200#15.htm##
00414000000000241000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700160019000730180034000920630
00200126066000700128062000700135065000900142064000500151865000900156002000700165
#v23n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#c#162#30#article#40#30#^rND^s
Goldstein^nH#Multilevel statistical models^len#3#London#Arnold#20030000#2003#200
80200#15.htm##
00491000000000253000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700160021000730160015000940180
07100109063000200180066000700182062001800189065000900207064000500216865000900221
002000700230#v23n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#c#163#31#article#
40#31#^rND^sRaudenbush^nSW#^rND^sBryk^nAS#Hierarchical linear models: applicatio
ns and data analysis methods^len#2#London#Sage Publications#20020000#2002#200802
00#15.htm##
00591000000000265000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700160016000730160018000890160
01400107016001700121016001400138016001900152018010400171025002500275061000900300
865000900309002000700318#v23n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#c#164
#32#article#40#32#^rND^sLeenen^nI#^rND^sGivaudan^nM#^rND^sPick^nS#^rND^sVenguer^
nT#^rND^sVera^nJ#^rND^sPoortinga^nY#Effectiveness of an integral health educatio
n program in a poverty stricken rural area of Guatemala^len#J Cross-Cultural Psy
chol#In press#20080200#15.htm##
00709000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100014000730120131000870160
01500218016002000233016001600253018008400269066001100353062001700364065000900381
064000500390014000800395865000900403002000700412#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\15.htm#S#c#165#33#article#40#33#^rND^sPick^nS#Extension of theory of r
easoned action principles for health promotion programs with marginalized popula
tions in Latin America^len#^rED^sAjzen^nI#^rED^sAlbarracín^nD#^rED^sHornik^nR#Pr
edic- tion and change of health behavior: applying a reasoned action approach^le
n#Mahwah^eNJ#Lawrence Erlbaum#20070000#2007#223-241#20080200#15.htm##
00453000000000253000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100016000730120058000890300
01200147710000200159065000900161064000500170031000200175014000600177865000900183
002000700192#v23n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#c#166#34#article#
40#34#^rND^sPelto^nPJ#The differences between "tight" and "loose" societies^len#
Transaction#2#19680000#1968#5#37-40#20080200#15.htm##
00606000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100018000730120045000910160
01900136016001700155016002100172018006300193066000900256062001500265065000900280
064000500289014000600294865000900300002000700309#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\15.htm#S#c#167#35#article#40#35#^rND^sPaulhus^nDL#Measurement and cont
rol of response bias^len#^rED^sRobinson^nJP#^rED^sShaver^nPR#^rED^sWrightsman^nL
S#Measures of personality and social psychological attitudes^len#New York#Academ
ic Press#19910000#1991#17-59#20080200#15.htm##
00637000000000301000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100016000900100
01600106010001900122012011400141030001500255065000900270064000500279031000300284
014000700287865000900294002000700303035001000310801001500320#v23n2#v:\scielo\ser
ial\rpsp\v23n2\markup\15.htm#S#c#168#36#article#40#36#^rND^sGregson^nS#^rND^sZhu
wau^nT#^rND^sNdlovu^nJ#^rND^sNyamukapa^nC#Methods to reduce social desirability 
bias in sex surveys in low-development settings: experience in Zimbabwe^len#Sex 
Transm Dis#20020000#2002#29#568-75#20080200#15.htm#0148-5717#Sex Transm Dis##
00642000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100017000730100017000900120
13800107030002800245065000900273064000500282031000300287032000200290014000600292
865000900298002000700307035001000314801002800324#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\15.htm#S#c#169#37#article#40#37#^rND^sWagner^nGP#^rND^sMiller^nLG#Adhe
rence in HIV: difficulties in evaluating: is the influence of social desirabilit
y on patients' self-reported adherence overrated?^len#J Acquir Immune Defic Synd
r#20040000#2004#35#2#203-4#20080200#15.htm#0894-9255#J Acquir Immune Defic Syndr
##
00652000000000289000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700160017000730160016000900160
02500106016001800131016001500149016001800164018013200182066001000314062000800324
065000900332064000500341865000900346002000700355#v23n2#v:\scielo\serial\rpsp\v23
n2\markup\15.htm#S#c#170#38#article#40#38#^rND^sCorneli^nA#^rND^sKleine^nA#^rND^
sSalvador-Davila^nG#^rND^sGaffikin^nL#^rND^sLewis^nR#^rND^sAmankwah^nA#A qualita
tive evaluation of the acceptability and feasibility of a single visit approach 
to cervical cancer prevention in Ghana^len#Baltimore#JHPIEGO#20040000#2004#20080
200#15.htm##
00505000000000217000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700170033000730180088001060370
05200194110000900246109001600255865000900271002000700280#v23n2#v:\scielo\serial\
rpsp\v23n2\markup\15.htm#S#c#171#39#article#40#39#Pan American Health Organizati
on#Testing new technologies in the test-and-treat project, Peru: The TATI Interv
ention^len#www.paho.org/English/AD/DPC/NC/cctestingnewtech.pdf#20041012#12 Octob
er 2004#20080200#15.htm##
00634000000000325000450000400060000070200420000670500020004870600020005070000040
00527010003000567090008000597080003000671180003000700100014000730100034000870100
02100121010001900142010001500161010001500176012004000191030001300231065000900244
06400050025303100030025801400080026186500090026900200070027803500100028580100130
0295#v23n2#v:\scielo\serial\rpsp\v23n2\markup\15.htm#S#c#172#40#article#40#40#^r
ND^sRiza^nE#^rND^sKyriakogianni-Psaropolou^nP#^rND^sKoumantakis^nE#^rND^sSymiaka
ki^nH#^rND^sGaras^nI#^rND^sLinos^nA#Cervical cancer screening in Greece^len#Eur 
J Cancer#20020000#2002#36#2227-32#20080200#15.htm#0014-2964#Eur J Cancer##
